{"trials": {"1": {"nct_id": "NCT02317263", "drug_name": "placebo gel", "intervention_type": "DRUG", "drug_description": null, "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "NIH did not fund the study so it never started", "title": "A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis", "start_date": null, "completion_date": "2099-01-31", "sponsor": "University of California, Los Angeles", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.534077", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:47:57.723358", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "placebo gel", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 1, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41192060", "title": "Evaluating Silicone Gel Efficacy in Reducing Scar Formation Following Microscopic Inguinal Varicocelectomy: A Double-Blind Prospective Controlled Trial.", "authors": [{"name": "Shamohammadi I", "authtype": "Author", "clusterid": ""}, {"name": "Jamzad S", "authtype": "Author", "clusterid": ""}, {"name": "Jamzad S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41123634", "title": "Topical lidocaine effectively mitigates radial pain, spasm, and sympathetic response following trans-radial coronary angiography: A randomized, double-blind, placebo-controlled clinical trial.", "authors": [{"name": "Dastani M", "authtype": "Author", "clusterid": ""}, {"name": "Askari VR", "authtype": "Author", "clusterid": ""}, {"name": "Shahri B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41122119", "title": "Addressing filamentous fungi-related onychomycosis in the era of antifungal resistance: assessment of Zataria multiflora nanostructured lipid carrier topical gel in a double-blinded clinical trial.", "authors": [{"name": "Moazeni M", "authtype": "Author", "clusterid": ""}, {"name": "Kelidari H", "authtype": "Author", "clusterid": ""}, {"name": "Kazeminejad A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41066380", "title": "Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.", "authors": [{"name": "Hohl A", "authtype": "Author", "clusterid": ""}, {"name": "Chavez MP", "authtype": "Author", "clusterid": ""}, {"name": "Pasqualotto E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41053831", "title": "Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.", "authors": [{"name": "Tian L", "authtype": "Author", "clusterid": ""}, {"name": "Han Z", "authtype": "Author", "clusterid": ""}, {"name": "Jiang M", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a multicenter, prospective, placebo-controlled, double-blind randomized Phase II clinical trial assessing the effect of testosterone treatment vs. placebo treatment for 96 weeks duration on whole brain atrophy in men with MS.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Testosterone gel", "type": "ACTIVE_COMPARATOR", "description": "Apply gel once a day for 96 weeks", "intervention_names": ["Drug: testosterone"]}, {"label": "Placebo gel", "type": "PLACEBO_COMPARATOR", "description": "Apply gel once a day for 96 weeks", "intervention_names": ["Drug: placebo gel"]}], "interventions": [{"type": "DRUG", "name": "testosterone", "description": null, "arm_group_labels": ["Testosterone gel"]}, {"type": "DRUG", "name": "placebo gel", "description": null, "arm_group_labels": ["Placebo gel"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of California, Los Angeles+NCT02317263+terminated", "https://www.google.com/search?q=University of California, Los Angeles+placebo gel+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for placebo gel by University of California, Los Angeles. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for placebo gel by University of California, Los Angeles (UCLA).\n\nFirst, I'll look for mentions of UCLA and placebo gel in the search results.\n\nFrom result [1]:\n|12/28/2017|University of California Los Angeles (UCLA)|Gallium 68 (68GA-PSMA) (Prostate Cancer Imaging webpage and brochure)|None|None|\n\nThis shows a mention of UCLA from December 28, 2017, but it's related to \"Gallium 68 (68GA-PSMA) (Prostate Cancer Imaging webpage and brochure)\" not a placebo gel. So this doesn't match our query.\n\nFrom result [2]:\nThis is about a \"universal placebo\" study, but it doesn't mention UCLA specifically. It's a general study about a universal placebo gel.\n\nFrom result [3]:\nThis discusses a Phase 1 trial of a rectally-applied, vaginally-formulated microbicide gel with UC781, but doesn't mention UCLA.\n\nFrom result [4]:\nThis is a warning letter to Namita A. Goyal, M.D., but it doesn't mention UCLA or placebo gel specifically.\n\nFrom result [5]:\nThis is just a general page about FDA warning letters, no specific mention of UCLA or placebo gel.\n\nFrom result [6]:\nThis appears to be a Freedom of Information Act request related to an inspection of a \"UNIVERSITY\" but doesn't specify UCLA or placebo gel.\n\nFrom result [7]:\nThis is about a study on PP405 for AGA (androgenetic alopecia), no mention of UCLA or placebo gel.\n\nFrom result [8]:\nThis is about skin substitute grafts, no mention of UCLA or placebo gel.\n\nFrom result [9]:\nGeneral information about warning letters for health fraud, no specific mention of UCLA or placebo gel.\n\nFrom result [10]:\nAbout oral health care drug products, no mention of UCLA or placebo gel.\n\nFrom result [11]:\nStudy of DHT-Gel to treat symptoms of low testosterone, but no mention of UCLA.\n\nFrom result [12]:\nAbout testosterone therapy, no mention of UCLA or placebo gel.\n\nLet me double-check if there's any other mention of UCLA or placebo gel that I might have missed:\n\nIn result [1], there's the UCLA mention I", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of California, Los Angeles"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of California, Los Angeles about clinical trial NCT02317263 for placebo gel. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the task and the information provided:\n\n1. I need to compile external safety evidence for a specific clinical trial (NCT02317263) that involves a placebo gel.\n2. I should focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n3. I need to look for company press releases, investor presentations, or public statements by UCLA about this specific trial.\n4. I need to respond with a JSON summary containing status, summary, relevance, and citations.\n\nFirst, I need to check if any of the search results mention the specific clinical trial NCT02317263.\n\nLet me go through each search result to see if NCT02317263 is mentioned:\n\n[1] UCLA physician-scientist receives $5 million grant to move wound healing gel clinical trial\n- Discusses Dr. Antoni Ribas and a wound healing gel called LUT017\n- Mentions preclinical testing in mice but not human trials\n- No mention of NCT02317263\n\n[2] ClinicalTrials.gov study NCT05639933\n- This is about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities\n- It's a Phase 2a dose-ranging study\n- No mention of NCT02317263\n\n[3] Open-Label Umbrella Study To Evaluate Safety And Efficacy Of...\n- This is about a Phase 1b/2 trial for ER+/HER2- advanced/metastatic breast cancer\n- No mention of NCT02317263\n\n[4] UCLA Cancer, General Clinical Trials for 2025\n- Lists various cancer clinical trials at UCLA\n- No specific mention of NCT02317263\n\n[5] A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel\u00ae)\n- This is about VivaGel, not NCT02317263\n- No mention of NCT02317263\n\n[6] Clinical Cancer Research Program Los Angeles\n- General information about Beverly Hills Cancer Center's clinical trials\n- No mention of NCT02317263\n\n", "citations": [], "search_params": {"company": "University of California, Los Angeles", "nct_id": "NCT02317263", "drug_name": "placebo gel"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "Based on the information provided, the trial was withdrawn due to lack of funding from the NIH, which is an administrative issue rather than a failure related to safety or efficacy. The official reason explicitly states that the study \"never started\" due to the NIH not funding it, indicating an administrative failure rather than any problems with the drug itself.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:47:57.722150", "claude_model": "claude-3-haiku-20240307", "tokens_used": 906}}, "2": {"nct_id": "NCT02317263", "drug_name": "testosterone", "intervention_type": "DRUG", "drug_description": null, "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "NIH did not fund the study so it never started", "title": "A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis", "start_date": null, "completion_date": "2099-01-31", "sponsor": "University of California, Los Angeles", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.535158", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:47:57.762739", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200335", "pref_name": "TESTOSTERONE ENANTHATE", "targets": [{"chembl_id": null, "uniprot_id": "P04278", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q96CJ1", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "C9JRZ8", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P15149", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P37058", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "testosterone", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "AMH", "protein_b": "IGF1", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "AMH", "protein_b": "PRL", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "AMH", "protein_b": "SHBG", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "AMH", "protein_b": "CYP19A1", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NRXN2", "protein_b": "SHBG", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "IGF1", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "ADIPOQ", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA6", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA7", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SHBG", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRL", "protein_b": "SHBG", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "PRL", "protein_b": "IGF1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "PRL", "protein_b": "INS", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "SERPINA7", "protein_b": "SHBG", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SERPINA6", "protein_b": "SHBG", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "SHBG", "protein_b": "CYP19A1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SHBG", "protein_b": "ADIPOQ", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SHBG", "protein_b": "IGF1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SHBG", "protein_b": "INS", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "ADIPOQ", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INS", "protein_b": "ADIPOQ", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "ICE2", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "EAF2", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "MLLT1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "AFF4", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "ELL3", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "EAF1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "ELL", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "ELL2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "TCEA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "SUPT4H1", "protein_b": "SUPT5H", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "TCEA2", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "ICE2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "ELL3", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "SUPT5H", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "ELL", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "EAF2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "EAF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "AFF4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ELL2", "protein_b": "MLLT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "ICE2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "TCEA2", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "EAF2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "SUPT5H", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "EAF1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "ELL3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "AFF4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MLLT1", "protein_b": "ELL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "SUPT5H", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "TCEA2", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "AFF4", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "EAF2", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "ELL3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "EAF1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ICE2", "protein_b": "ELL", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "TCEA2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "SUPT5H", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "ELL3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "EAF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "EAF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ELL", "protein_b": "AFF4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AFF4", "protein_b": "TCEA2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "AFF4", "protein_b": "SUPT5H", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "AFF4", "protein_b": "EAF2", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "AFF4", "protein_b": "EAF1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AFF4", "protein_b": "ELL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EAF2", "protein_b": "SUPT5H", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "EAF2", "protein_b": "TCEA2", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "EAF2", "protein_b": "EAF1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EAF2", "protein_b": "ELL3", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "ELL3", "protein_b": "TCEA2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ELL3", "protein_b": "SUPT5H", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ELL3", "protein_b": "EAF1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TCEA2", "protein_b": "EAF1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "TCEA2", "protein_b": "SUPT5H", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EAF1", "protein_b": "SUPT5H", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "CYP11B1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "SRD5A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "HSD3B1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "CYP19A1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "HSD3B2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "CYP17A1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "SRD5A1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "AKR1C3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "HSD17B3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HSD17B2", "protein_b": "HSD17B1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSD17B1", "protein_b": "CYP17A1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "HSD17B1", "protein_b": "HSD3B1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "HSD17B1", "protein_b": "AKR1C3", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "HSD17B1", "protein_b": "CYP19A1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "HSD17B1", "protein_b": "HSD17B3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "SRD5A2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "CYP11B1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "HSD3B1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "CYP19A1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "HSD17B3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "HSD3B2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "AKR1C3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SRD5A1", "protein_b": "CYP17A1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "AKR1C3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "CYP19A1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "SRD5A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "CYP17A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "HSD17B3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "HSD3B1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "CYP11B1", "protein_b": "HSD3B2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "SRD5A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "HSD3B2", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "AKR1C3", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "HSD17B3", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "CYP19A1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HSD3B1", "protein_b": "CYP17A1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP17A1", "protein_b": "CYP19A1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP17A1", "protein_b": "AKR1C3", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "CYP17A1", "protein_b": "SRD5A2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP17A1", "protein_b": "HSD17B3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CYP17A1", "protein_b": "HSD3B2", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HSD17B3", "protein_b": "CYP19A1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HSD17B3", "protein_b": "SRD5A2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "HSD17B3", "protein_b": "AKR1C3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "HSD17B3", "protein_b": "HSD3B2", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "AKR1C3", "protein_b": "CYP19A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "AKR1C3", "protein_b": "SRD5A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "AKR1C3", "protein_b": "HSD3B2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CYP19A1", "protein_b": "SRD5A2", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP19A1", "protein_b": "HSD3B2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "HSD3B2", "protein_b": "SRD5A2", "combined_score": 0.971, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.06, "clustering_coefficient": 4.03}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41225431", "title": "Association between estimated glucose disposal rate and testosterone deficiency in male patients with type 2 diabetes mellitus.", "authors": [{"name": "Pan W", "authtype": "Author", "clusterid": ""}, {"name": "Zhao J", "authtype": "Author", "clusterid": ""}, {"name": "Xu J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41225399", "title": "Impact of COVID-19 on pituitary function: a cross-sectional study in southern Iran.", "authors": [{"name": "Sheikhi S", "authtype": "Author", "clusterid": ""}, {"name": "Shirazi FKH", "authtype": "Author", "clusterid": ""}, {"name": "Zamani A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41216639", "title": "Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).", "authors": [{"name": "Morgans AK", "authtype": "Author", "clusterid": ""}, {"name": "Chehrazi-Raffle A", "authtype": "Author", "clusterid": ""}, {"name": "Niazi T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41214659", "title": "Gut microbiota dysbiosis and short-chain fatty acid depletion in phlegm-dampness polycystic ovary syndrome: a cross-sectional 16S rRNA sequencing analysis.", "authors": [{"name": "Xia XY", "authtype": "Author", "clusterid": ""}, {"name": "Chen Y", "authtype": "Author", "clusterid": ""}, {"name": "Zhang XJ", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41207813", "title": "Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial.", "authors": [{"name": "Agrawal R", "authtype": "Author", "clusterid": ""}, {"name": "Weiner AB", "authtype": "Author", "clusterid": ""}, {"name": "Livingstone J", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a multicenter, prospective, placebo-controlled, double-blind randomized Phase II clinical trial assessing the effect of testosterone treatment vs. placebo treatment for 96 weeks duration on whole brain atrophy in men with MS.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Testosterone gel", "type": "ACTIVE_COMPARATOR", "description": "Apply gel once a day for 96 weeks", "intervention_names": ["Drug: testosterone"]}, {"label": "Placebo gel", "type": "PLACEBO_COMPARATOR", "description": "Apply gel once a day for 96 weeks", "intervention_names": ["Drug: placebo gel"]}], "interventions": [{"type": "DRUG", "name": "testosterone", "description": null, "arm_group_labels": ["Testosterone gel"]}, {"type": "DRUG", "name": "placebo gel", "description": null, "arm_group_labels": ["Placebo gel"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of California, Los Angeles+NCT02317263+terminated", "https://www.google.com/search?q=University of California, Los Angeles+testosterone+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for testosterone by University of California, Los Angeles. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for testosterone by University of California, Los Angeles (UCLA).\n\nFirst, I'll scan through all the search results to identify any mentions of:\n1. UCLA (University of California, Los Angeles)\n2. FDA warning letters\n3. Clinical holds\n4. Testosterone products\n\nFrom the search results:\n\nResult [1]: Discusses FDA labeling changes for testosterone products based on TRAVERSE trial results. No mention of UCLA or warning letters/clinical holds.\n\nResult [2]: FDA Drug Safety Communication about testosterone products. No mention of UCLA or specific warning letters/clinical holds issued to UCLA.\n\nResult [3]: FDA issues class-wide labeling changes for testosterone products. No mention of UCLA or warning letters/clinical holds.\n\nResult [4]: Discusses FDA safety warnings and trends in testosterone marketing. No mention of UCLA or warning letters/clinical holds.\n\nResult [5]: Mentions UCLA Law Center on Reproductive Health, Law, and Policy (CRHLP) and Advancing New Standards in Reproductive Health (ANSIRH) at UCSF submitting a letter to FDA about mifepristone. This is about mifepristone (abortion pill), not testosterone. The date mentioned is August 27th, 2025, which is in the future relative to our current date of November 14, 2025.\n\nResult [6]: Discusses FDA labeling changes for testosterone products following TRAVERSE trial. No mention of UCLA or warning letters/clinical holds.\n\nResult [7]: \"UCLA Menopause Expert on FDA's Removal of Hormone Therapy Black Box Warning.\" This mentions UCLA but appears to be about hormone therapy (likely estrogen/progesterone for menopause), not testosterone. The release date is November 10, 2025.\n\nResult [8]: FDA approves new changes to testosterone labeling regarding abuse and dependence. No mention of UCLA or warning letters/clinical holds.\n\nResult [9]: Appears to be an FOIA request reference, no specific information about UCLA or testosterone warning letters.\n\nResult [10]: The Medical Letter about label changes for testosterone products. No mention of UCLA.\n\nResult [11]: \"News Archive 2024 - Urology - UCLA Health\" mentions \"Men's supplements contain 'hidden' prescription drugs, FDA warns - Dr. Jesse Mills, director of", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of California, Los Angeles"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of California, Los Angeles about clinical trial NCT02317263 for testosterone. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about University of California, Los Angeles (UCLA) press releases, investor presentations, or public statements regarding clinical trial NCT02317263 for testosterone, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT02317263 is from the search results:\n\nFrom result [1]:\n- NCT02317263 is titled \"A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis\"\n- It was launched by UCLA on December 10, 2014\n- Current status as of November 14, 2025: \"Withdrawn\"\n- It's a multicenter, prospective, placebo-controlled, double-blind randomized Phase II clinical trial\n- It was assessing the effect of testosterone treatment vs. placebo for 96 weeks on whole brain atrophy in men with MS\n- Inclusion criteria: Men, aged 18-60, with a diagnosis of multiple sclerosis by 2010 revised McDonald Criteria\n\nFrom result [2], we get similar information about the trial.\n\nNow, I need to look for any press releases, investor presentations, or public statements by UCLA specifically about this trial (NCT02317263), focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results:\n\nResult [1]: This is just a trial listing showing the trial was \"Withdrawn\" but doesn't provide any explanation for why it was withdrawn or any safety information.\n\nResult [2]: Another trial listing without any information about why it was withdrawn or safety issues.\n\nResult [3]: This is a PubMed article about testosterone therapy and cardiovascular disease risk in older men, but it doesn't specifically mention NCT02317263.\n\nResult [4]: This is a PubMed article about testosterone buciclate in hypogonadal men, but doesn't mention NCT02317263.\n\nResult [5]: Mentions NCT02317263 in relation to testosterone, but doesn't provide any details about the trial status or safety issues.\n\nResult [6]: This is about a different trial (28-day study of testosterone co-administered with dutasteride).\n\n", "citations": [], "search_params": {"company": "University of California, Los Angeles", "nct_id": "NCT02317263", "drug_name": "testosterone"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "Based on the information provided, the trial was withdrawn due to lack of funding from the NIH, which is an administrative issue rather than a failure related to safety or efficacy. The official reason explicitly states that the study \"never started\" due to the NIH not funding it, indicating an administrative failure rather than any problems with the drug itself.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:47:57.722150", "claude_model": "claude-3-haiku-20240307", "tokens_used": 906}}, "3": {"nct_id": "NCT05945147", "drug_name": "Ketamine", "intervention_type": "DRUG", "drug_description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.535412", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:00.282555", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL742", "pref_name": "KETAMINE", "targets": [{"chembl_id": "CHEMBL1907608", "ic50_values": [{"value": 860.0, "units": "nM"}, {"value": 8860.0, "units": "nM"}, {"value": 610.0, "units": "nM"}, {"value": 610.0, "units": "nM"}, {"value": 700.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}], "uniprot_id": "Q62646"}, {"chembl_id": "CHEMBL2072", "ic50_values": [{"value": 800000.0, "units": "nM"}, {"value": 2300000.0, "units": "nM"}], "uniprot_id": "P35499"}, {"chembl_id": "CHEMBL1907603", "ic50_values": [{"value": 3200.0, "units": "nM"}, {"value": 5011.87, "units": "nM"}], "uniprot_id": "A6NLK7"}, {"chembl_id": "CHEMBL1907604", "ic50_values": [{"value": 6100.0, "units": "nM"}, {"value": 1258.93, "units": "nM"}, {"value": 3310.0, "units": "nM"}], "uniprot_id": "A6NLK7"}, {"chembl_id": "CHEMBL4078", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "O42275"}, {"chembl_id": "CHEMBL5763", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "P81908"}, {"chembl_id": "CHEMBL368", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612348", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612851", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612849", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612884", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612888", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL613064", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL364", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL3879801", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612880", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612879", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612848", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL367", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612877", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612853", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL612855", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL220", "ic50_values": [], "uniprot_id": "A4D2E2"}, {"chembl_id": "CHEMBL226", "ic50_values": [], "uniprot_id": "A6NFY5"}, {"chembl_id": "CHEMBL251", "ic50_values": [], "uniprot_id": "B2R7E0"}, {"chembl_id": "CHEMBL256", "ic50_values": [], "uniprot_id": "A2A3P4"}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 1010.0, "units": "nM"}, {"value": 237000.0, "units": "nM"}, {"value": 83200.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL319", "ic50_values": [], "uniprot_id": "P43140"}, {"chembl_id": "CHEMBL315", "ic50_values": [], "uniprot_id": "P15823"}, {"chembl_id": "CHEMBL223", "ic50_values": [], "uniprot_id": "P25100"}, {"chembl_id": "CHEMBL1867", "ic50_values": [], "uniprot_id": "B0LPF6"}, {"chembl_id": "CHEMBL1942", "ic50_values": [], "uniprot_id": "A2RUS0"}, {"chembl_id": "CHEMBL1916", "ic50_values": [], "uniprot_id": "P18825"}, {"chembl_id": "CHEMBL213", "ic50_values": [], "uniprot_id": "B0LPE2"}, {"chembl_id": "CHEMBL210", "ic50_values": [], "uniprot_id": "B0LPE4"}, {"chembl_id": "CHEMBL246", "ic50_values": [], "uniprot_id": "P13945"}, {"chembl_id": "CHEMBL222", "ic50_values": [], "uniprot_id": "B2R707"}, {"chembl_id": "CHEMBL2622", "ic50_values": [], "uniprot_id": "P07943"}, {"chembl_id": "CHEMBL4607", "ic50_values": [], "uniprot_id": "B2R9V1"}, {"chembl_id": "CHEMBL3157", "ic50_values": [], "uniprot_id": "P30411"}, {"chembl_id": "CHEMBL1832", "ic50_values": [], "uniprot_id": "A0A0C4DG16"}, {"chembl_id": "CHEMBL218", "ic50_values": [], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL205", "ic50_values": [], "uniprot_id": "B2R7G8"}, {"chembl_id": "CHEMBL4015", "ic50_values": [], "uniprot_id": "A0AVQ3"}, {"chembl_id": "CHEMBL2414", "ic50_values": [], "uniprot_id": "P51679"}, {"chembl_id": "CHEMBL274", "ic50_values": [], "uniprot_id": "O14692"}, {"chembl_id": "CHEMBL4029", "ic50_values": [], "uniprot_id": "B2R6Q3"}, {"chembl_id": "CHEMBL2434", "ic50_values": [], "uniprot_id": "P25025"}, {"chembl_id": "CHEMBL1901", "ic50_values": [], "uniprot_id": "B2R9Z5"}, {"chembl_id": "CHEMBL221", "ic50_values": [], "uniprot_id": "A8K1V7"}, {"chembl_id": "CHEMBL230", "ic50_values": [], "uniprot_id": "A8K802"}, {"chembl_id": "CHEMBL3356", "ic50_values": [], "uniprot_id": "P05177"}, {"chembl_id": "CHEMBL5282", "ic50_values": [], "uniprot_id": "A7YAE5"}, {"chembl_id": "CHEMBL3622", "ic50_values": [], "uniprot_id": "P33259"}, {"chembl_id": "CHEMBL3397", "ic50_values": [], "uniprot_id": "P11712"}, {"chembl_id": "CHEMBL289", "ic50_values": [], "uniprot_id": "P10635"}, {"chembl_id": "CHEMBL5281", "ic50_values": [], "uniprot_id": "P05181"}, {"chembl_id": "CHEMBL340", "ic50_values": [], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL2056", "ic50_values": [], "uniprot_id": "B2RA44"}, {"chembl_id": "CHEMBL217", "ic50_values": [], "uniprot_id": "P14416"}, {"chembl_id": "CHEMBL234", "ic50_values": [], "uniprot_id": "A1A4V5"}, {"chembl_id": "CHEMBL219", "ic50_values": [], "uniprot_id": "B0M0J7"}, {"chembl_id": "CHEMBL238", "ic50_values": [], "uniprot_id": "A2RUN4"}, {"chembl_id": "CHEMBL252", "ic50_values": [], "uniprot_id": "B2R723"}, {"chembl_id": "CHEMBL206", "ic50_values": [], "uniprot_id": "Q13511"}, {"chembl_id": "CHEMBL242", "ic50_values": [], "uniprot_id": "A8K8K5"}, {"chembl_id": "CHEMBL2034", "ic50_values": [], "uniprot_id": "A0ZXF9"}, {"chembl_id": "CHEMBL3392921", "ic50_values": [], "uniprot_id": "Q91W28"}, {"chembl_id": "CHEMBL231", "ic50_values": [], "uniprot_id": "A8K047"}, {"chembl_id": "CHEMBL1941", "ic50_values": [], "uniprot_id": "B5BUP7"}, {"chembl_id": "CHEMBL402", "ic50_values": [], "uniprot_id": "B7Z3Y9"}, {"chembl_id": "CHEMBL5486", "ic50_values": [], "uniprot_id": "P15127"}, {"chembl_id": "CHEMBL1909043", "ic50_values": [], "uniprot_id": "A6XA80"}, {"chembl_id": "CHEMBL1798", "ic50_values": [], "uniprot_id": "B2R954"}, {"chembl_id": "CHEMBL4358", "ic50_values": [], "uniprot_id": "O19043"}, {"chembl_id": "CHEMBL4644", "ic50_values": [], "uniprot_id": "P41968"}, {"chembl_id": "CHEMBL259", "ic50_values": [], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4608", "ic50_values": [], "uniprot_id": "B0YJ34"}, {"chembl_id": "CHEMBL1951", "ic50_values": [], "uniprot_id": "B4DF46"}, {"chembl_id": "CHEMBL216", "ic50_values": [], "uniprot_id": "P11229"}, {"chembl_id": "CHEMBL211", "ic50_values": [], "uniprot_id": "P08172"}, {"chembl_id": "CHEMBL245", "ic50_values": [], "uniprot_id": "P20309"}, {"chembl_id": "CHEMBL1821", "ic50_values": [], "uniprot_id": "B2RPP4"}, {"chembl_id": "CHEMBL2035", "ic50_values": [], "uniprot_id": "P08912"}, {"chembl_id": "CHEMBL4777", "ic50_values": [], "uniprot_id": "B2R6H5"}, {"chembl_id": "CHEMBL4018", "ic50_values": [], "uniprot_id": "P49146"}, {"chembl_id": "CHEMBL3048", "ic50_values": [], "uniprot_id": "P70594"}, {"chembl_id": "CHEMBL3464", "ic50_values": [], "uniprot_id": "O70515"}, {"chembl_id": "CHEMBL236", "ic50_values": [], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL237", "ic50_values": [], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL233", "ic50_values": [], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL1827", "ic50_values": [], "uniprot_id": "A0AV69"}, {"chembl_id": "CHEMBL250", "ic50_values": [], "uniprot_id": "A3KMC8"}, {"chembl_id": "CHEMBL240", "ic50_values": [], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL1909044", "ic50_values": [], "uniprot_id": "Q690N0"}, {"chembl_id": "CHEMBL4074", "ic50_values": [], "uniprot_id": "O02852"}, {"chembl_id": "CHEMBL4801", "ic50_values": [], "uniprot_id": "B5MDZ1"}, {"chembl_id": "CHEMBL4071", "ic50_values": [], "uniprot_id": "P08311"}, {"chembl_id": "CHEMBL248", "ic50_values": [], "uniprot_id": "P08246"}, {"chembl_id": "CHEMBL332", "ic50_values": [], "uniprot_id": "P03956"}, {"chembl_id": "CHEMBL321", "ic50_values": [], "uniprot_id": "B2R7V9"}, {"chembl_id": "CHEMBL299", "ic50_values": [], "uniprot_id": "B5BU22"}, {"chembl_id": "CHEMBL3385", "ic50_values": [], "uniprot_id": "A8CZ58"}, {"chembl_id": "CHEMBL4040", "ic50_values": [], "uniprot_id": "A8CZ64"}, {"chembl_id": "CHEMBL260", "ic50_values": [], "uniprot_id": "A6ZJ92"}, {"chembl_id": "CHEMBL4445", "ic50_values": [], "uniprot_id": "A1A441"}, {"chembl_id": "CHEMBL203", "ic50_values": [], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL1841", "ic50_values": [], "uniprot_id": "B5BU57"}, {"chembl_id": "CHEMBL1824", "ic50_values": [], "uniprot_id": "B2RZG3"}, {"chembl_id": "CHEMBL258", "ic50_values": [], "uniprot_id": "D3DPP8"}, {"chembl_id": "CHEMBL3243", "ic50_values": [], "uniprot_id": "A0A0A0MT22"}, {"chembl_id": "CHEMBL273", "ic50_values": [], "uniprot_id": "P19327"}, {"chembl_id": "CHEMBL3459", "ic50_values": [], "uniprot_id": "P28564"}, {"chembl_id": "CHEMBL224", "ic50_values": [], "uniprot_id": "B2RAC5"}, {"chembl_id": "CHEMBL1833", "ic50_values": [], "uniprot_id": "B2R9D5"}, {"chembl_id": "CHEMBL225", "ic50_values": [], "uniprot_id": "B1AMW4"}, {"chembl_id": "CHEMBL5017", "ic50_values": [], "uniprot_id": "O70528"}, {"chembl_id": "CHEMBL3371", "ic50_values": [], "uniprot_id": "P50406"}, {"chembl_id": "CHEMBL228", "ic50_values": [], "uniprot_id": "P31645"}, {"chembl_id": "CHEMBL287", "ic50_values": [], "uniprot_id": "D3DRM7"}, {"chembl_id": "CHEMBL249", "ic50_values": [], "uniprot_id": "A8K150"}, {"chembl_id": "CHEMBL2327", "ic50_values": [], "uniprot_id": "A8K7I1"}, {"chembl_id": "CHEMBL3072", "ic50_values": [], "uniprot_id": "P15207"}, {"chembl_id": "CHEMBL1835", "ic50_values": [], "uniprot_id": "B4DJG6"}, {"chembl_id": "CHEMBL1868", "ic50_values": [], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL5144", "ic50_values": [], "uniprot_id": "A5JUT9"}, {"chembl_id": "CHEMBL1889", "ic50_values": [], "uniprot_id": "P37288"}, {"chembl_id": "CHEMBL3097", "ic50_values": [{"value": 1000000.0, "units": "nM"}, {"value": 4950.0, "units": "nM"}, {"value": 11100.0, "units": "nM"}], "uniprot_id": "P02710"}, {"chembl_id": "CHEMBL1940", "ic50_values": [{"value": 1800.0, "units": "nM"}], "uniprot_id": "B2RUT3"}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 135000.0, "units": "nM"}, {"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2096680", "ic50_values": [{"value": 1000.0, "units": "nM"}], "uniprot_id": "Q62646"}], "has_uniprot_targets": true, "search_name": "Ketamine"}, "ppi_enrichment": {"uniprot_count": 115, "interactions": [{"protein_a": "SCN2B", "protein_b": "SCNN1B", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCNN1A", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCN4B", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCN4A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCN3B", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCN2A", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SCN2B", "protein_b": "SCN1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALM2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "SCN4A", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "SCN2A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCNN1B", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCNN1A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCN2A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCN4A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCN3B", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "SCN4B", "protein_b": "SCN1B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CLCN1", "protein_b": "SCN4A", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SCNN1B", "protein_b": "SCN3B", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "SCNN1B", "protein_b": "SCN2A", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "SCNN1B", "protein_b": "SCN1B", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "SCNN1B", "protein_b": "SCN4A", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "SCNN1B", "protein_b": "SCNN1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SCNN1A", "protein_b": "SCN2A", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "SCNN1A", "protein_b": "SCN3B", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "SCNN1A", "protein_b": "SCN4A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SCNN1A", "protein_b": "SCN1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SCN3B", "protein_b": "SCN1B", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SCN3B", "protein_b": "SCN4A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SCN3B", "protein_b": "SCN2A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SCN4A", "protein_b": "CALM2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "SCN4A", "protein_b": "SCN2A", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SCN4A", "protein_b": "SCN1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SCN1B", "protein_b": "SCN2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "SCN2A", "protein_b": "CALM2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "DLG4", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN3A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN2C", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN2B", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN2D", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN3B", "protein_b": "GRIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "CALML4", "combined_score": 0.74, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "CALML3", "combined_score": 0.74, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "CALM3", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "DLG4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "GRIN3A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "GRIN2B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "GRIN2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "GRIN2C", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2D", "protein_b": "GRIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "GRIN2C", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "GRIN2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "GRIN2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "DLG4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "GRIN1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "CALML3", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "CALML4", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "DLG4", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "GRIN2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "GRIN2B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "GRIN3A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN2C", "protein_b": "GRIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "DLG4", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "GRIN2A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "GRIN2B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "GRIN1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GRIN2A", "protein_b": "CALML4", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "GRIN2A", "protein_b": "GRIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN2A", "protein_b": "GRIN2B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN2A", "protein_b": "GRIN3A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN2A", "protein_b": "DLG4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN3A", "protein_b": "DLG4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "GRIN3A", "protein_b": "GRIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN3A", "protein_b": "GRIN2B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRIN1", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "GRIN1", "protein_b": "DLG4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRIN1", "protein_b": "GRIN2B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "DLG4", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "GRIN2B", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GRIN2B", "protein_b": "DLG4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHKB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "PHOSPHO1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "ACHE", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "GPCPD1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "HSPG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "ACHE", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "DOK7", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "HSPG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "PHOSPHO1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHKB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "MAOB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "GPCPD1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHAT", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "COLQ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "PHOSPHO1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "CHKB", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "GPCPD1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DOK7", "protein_b": "COLQ", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HSPG2", "protein_b": "COLQ", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "PHOSPHO1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "CHKB", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "PHOSPHO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADORA2A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADA", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "SLC29A1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "SLC29A1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "ADORA2A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2A", "protein_b": "SLC29A1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "CNR1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "ADORA2A", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CNR1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2B", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2A", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAL", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "ADORA2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAS", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "GNAS", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "ADORA2A", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "ADORA2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADORA2A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADORA2A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1D", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1A", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "TBXA2R", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1D", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1B", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1D", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1A", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "TBXA2R", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "GNA13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1D", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "ADRA1D", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "SNTB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "UTRN", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "ADRA1D", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "SNTB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "TBXA2R", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "SNTB1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "ADRA1A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "GNA13", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ADRA1A", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TBXA2R", "protein_b": "GNA13", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNA13", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNAQ", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "ADRA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNG2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNG2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNG2", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNA13", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SEC24C", "protein_b": "ADRA2B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2C", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2C", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2C", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2C", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "ADRA2C", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2C", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ADRA2C", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "ADRA2C", "protein_b": "GNA13", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "DLG4", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "ADRB1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GCG", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "POMC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "NPPA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "DLG4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "GNAI1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ADRB2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SNX27", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GRK2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "AKAP12", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SAG", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "SAG", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "SAG", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB2", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "AKAP12", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SAG", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "UCP1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "ADRB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "FGF21", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "ADRB3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB3", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "SRC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "FGF21", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "SRC", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "ADRB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAS", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI3", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "SRC", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GNAI1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "YRDC", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "HTR1A", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SNCA", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SCRT1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC18A2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC5A2", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADCY7", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "STX1A", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC5A2", "protein_b": "ADCY7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MTUS1", "protein_b": "AGTR2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "AGTR2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "EDN1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "KNG1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "ACE2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ACE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "EDN1", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "KNG1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "ACE2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "AGTR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "KNG1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "AGTR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AGTR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "ACE", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "EDN1", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "BDKRB2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "AGT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNAQ", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "AGTR1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "BDKRB2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "BDKRB2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "BDKRB2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "BDKRB2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "BDKRB2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "BDKRB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "BDKRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "BDKRB2", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNG2", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNAS", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "ADM", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCB", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "RAMP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNAS", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "ADM", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNG2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNAS", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "ADM", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADM", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCR", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNB1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNAS", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "CALCB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "CALCB", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADM", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADM", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CALCB", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "SLC4A1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "CA2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "TCIRG1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA1", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "SLC4A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "CA2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CA2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CLCN7", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CLCN7", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBSL", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBS", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CA1", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "SLC4A4", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBS", "protein_b": "CBSL", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL13", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL7", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL8", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL5", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL8", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL7", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CXCL8", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL7", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL5", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL17", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL2", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL27", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL27", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCR4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CXCL12", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR4", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "CCR4", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "GRK3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GRK3", "protein_b": "CCR4", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL3", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CXCL12", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL5", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL3", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR1", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL2", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CXCL10", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL3", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL5", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ITIH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL3L1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL5", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CXCL10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3L1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3L1", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL3L1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL3L1", "protein_b": "CCL4", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL6", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL3", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL5", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CCL2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL8", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL12", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL12", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL12", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CCKAR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAI1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GAST", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCKAR", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNG2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNB1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAI1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAS", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCL28", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "PTK7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GAST", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCL28", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "GNB1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCK", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL28", "protein_b": "CCK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCK", "protein_b": "PTK7", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "HPGDS", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGDS", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX15", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGDS", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGDS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGDS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGS2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGDS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGES3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "ALOX5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGDS", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGES3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGDS", "protein_b": "PTGES3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "TP53", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGES", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CXCL8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "IL6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "IL6", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CXCL8", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PLA2G4A", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "PTGS2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "IL6", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "ALOX5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "PTGS2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "IL6", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2B6", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A8", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2B6", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP3A4", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2E1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A8", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2E1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP2E1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A8", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GAPDH", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "PPIG", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4A11", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "ALOX5", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C19", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C9", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4F2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP1A2", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "PPIG", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP4A11", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "ALOX5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C9", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "ALOX5", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP4A11", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "PPIG", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ALOX5", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2C19", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2C19", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ALOX5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2D6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B15", "protein_b": "CYP2D6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "CYP2D6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2D6", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "UGT1A3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A3", "protein_b": "CYP2D6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ADH1B", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "ADH1B", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A4", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A10", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTP1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTM1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "CYP2E1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "GSTP1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GSTP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP3A4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP2E1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "EPHX1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALY", "protein_b": "DRD1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "DRD1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "DRD1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "TMTC1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "DRD1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "DRD1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "DRD1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "TMTC1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "ADCYAP1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "POMC", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "NCS1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB2", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG7", "combined_score": 0.701, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG2", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "DRD3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD1", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD3", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "DRD3", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "DRD1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "BDNF", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "KLHL12", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD3", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "MAOA", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DRD2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "BDNF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TH", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SYNGR3", "protein_b": "SLC6A3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "FLOT1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "CAMK2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "TH", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SNCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "TH", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "SLC18A2", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "TH", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SNCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRB", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRB", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "KNG1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "GNA13", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "AGT", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDNRB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN2", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDNRB", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDN1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "KNG1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "GNA13", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NRIP1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SP1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SRC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA2", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA3", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "JUN", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "JUN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "MED1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SP1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "JUN", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "SRC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "FKBP5", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "STIP1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "PTGES3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "NR3C1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSPA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSPA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "STIP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "PTGES3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AB1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "PTGES3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "FKBP5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "FKBP5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FKBP5", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HRH1", "combined_score": 0.722, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "HRH1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "PLCB3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HRH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PLCB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HRH1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PLCB3", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PLCB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HRH1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "PLCB3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "TRPV1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "ATP4A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "GAST", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "GAST", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "GAST", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "HRH2", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HRH2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SQLE", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDFT1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDPS", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "INSIG1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "HMGCR", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "INSIG1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDPS", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCR", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDFT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDFT1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDPS", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "INSIG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "INSIG1", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "HMGCS2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDFT1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDPS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDPS", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDFT1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDPS", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDFT1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "HMGCS2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "SREBF2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "SREBF2", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "HMGCS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "FDFT1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "HMGCS2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "FDFT1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "HMGCS2", "protein_b": "FDFT1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "LTC4S", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "LTB4R2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR1", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "TBXA2R", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR2", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "TBXA2R", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "ALOX5AP", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTB4R2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "GNAQ", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTC4S", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "CYSLTR1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LTB4R2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CYSLTR1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5AP", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "LTB4R2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "CYSLTR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "LTB4R2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "TBXA2R", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5AP", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALOX5", "protein_b": "ALOX5AP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CTSZ", "protein_b": "MC3R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "LEP", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "POMC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "AGRP", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "MC3R", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "NPY", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "GHRL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ASIP", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "LEP", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "NPY", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "MRAP2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "GHRL", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ATP7A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "AGRP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "ASIP", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ATP7A", "protein_b": "POMC", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ASIP", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MRAP2", "protein_b": "MC5R", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "MC5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DBH", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DDC", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "COMT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "LRTOMT", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "AOC3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "ALDH2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC3", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOA", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "AOC3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DBH", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DDC", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DBH", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DDC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "COMT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOA", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOB", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "CYP2D6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "MAOB", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "AOC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DDC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DBH", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DBH", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DDC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "MAOB", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "CYP2D6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "AOC1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DBH", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DDC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "DBH", "protein_b": "DDC", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "DDC", "protein_b": "AOC1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR6", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "ARRB1", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR5", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR4", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "F2R", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "KNG1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR4", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR3", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "CHRM2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "ARRB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR4", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR5", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "CHRM2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "LPAR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "LPAR4", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "ARRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "AGTRAP", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNA15", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG12", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GRM5", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CHRM1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "NPY1R", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GHRL", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY1R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PPY", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY1R", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PYY", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY5R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNB1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY5R", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI3", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "NPY5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY5R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PRPH2", "protein_b": "NPY2R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY2R", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "POMC", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GLP1R", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "POMC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNG2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNB1", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PPY", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PYY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "POMC", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GLP1R", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "GLP1R", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "POMC", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "POMC", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "GNB1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PPY", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE6G", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE6G", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE2A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE5A", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUCY1B1", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE2A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "ITPA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "APRT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUK1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE5A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUCY1B1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUCY1B1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ALDH7A1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CCR1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PTAFR", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TLR4", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PTAFR", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ARRB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "TLR4", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "PTAFR", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "ARRB1", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "PTAFR", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TLR4", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "PTAFR", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "FPR2", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GPR135", "protein_b": "PTAFR", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "ARRB1", "protein_b": "PTAFR", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "TYK2", "protein_b": "PTAFR", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "PECAM1", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "FPR2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP8", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "GSDMD", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "IL1B", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "PYCARD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "GSDMD", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "IL1B", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP6", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP6", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "AIM2", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRC4", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "GSDMD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP8", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "GSDMD", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP8", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "GSDMD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRP1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "GSDMD", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRC4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "GSDMD", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "GSDMD", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "GSDMD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSDMD", "protein_b": "NLRP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINB4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "MMP9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "MMP9", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "MMP9", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "MMP9", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "ELANE", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPINA3", "protein_b": "ELANE", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SLPI", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "DEFA4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "SERPINA1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "DEFA4", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "DEFA4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "SLPI", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "DEFA4", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "DEFA4", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "SERPINA1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "DEFA4", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "DEFA4", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DEFA4", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLPI", "protein_b": "ELANE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPINA1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "STAT3", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "IL1B", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "IL1B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "STAT3", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP9", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP7", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "TIMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "IL1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP9", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "TIMP2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "STAT3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP9", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP9", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP3", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP9", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "MMP1", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "BSG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "MMP9", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "THBS1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "LCN2", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "CD44", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "MMP9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "TIMP3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "ELN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DMP1", "protein_b": "MMP9", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "CD44", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "MMP9", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "LCN2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCD", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCB", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PICK1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "NCF1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "MTOR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLD1", "protein_b": "PRKCA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCB", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "SDC4", "protein_b": "PRKCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PICK1", "protein_b": "PRKCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "RACK1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "RACK1", "protein_b": "PRKCB", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "FOS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "FOS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "MAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAPK3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "RPS6KA1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "PTPN7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "FOS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "FOS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "RPS6KA1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "STAT3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PEA15", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MKNK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "JUN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "JUN", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPKAPK2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ATF2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK14", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAPK14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "JUN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K6", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "DUSP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "ATF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "ATF2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "TP53", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MAP2K3", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAPKAPK3", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "JUN", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAP2K6", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAPKAPK3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "RCAN1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3R2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML6", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML5", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALM3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "NFATC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RCAN1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "RCAN1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3R2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3R2", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CB", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CB", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "CALML4", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CB", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "NFATC1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "CALML4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3CA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "CALML4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "NFATC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "CALML4", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "PPP3R2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "PPP3R2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "PTK2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LCK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SHC1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "FYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "LYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LCK", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LYN", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SHC1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "FYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SH2D1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SH2D1A", "protein_b": "LCK", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "DLG4", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LCK", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LYN", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "HSP90AA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SHC1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRG1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "HSP90AA1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SRC", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "CD44", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "ERBB4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SHC1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SRC", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "CD44", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ERBB4", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "GRB2", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "CD44", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SRC", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CD44", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "VAV1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCP2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD28", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD28", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "PTPRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD247", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "ZAP70", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "PTPRC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD28", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PTPRC", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "FYN", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "VAV1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD8A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD247", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "VAV1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD8A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SYK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD247", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "PTPRC", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "VAV1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "PTPRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "PTPRC", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "VAV1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VAV1", "protein_b": "LCK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LYN", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SPN", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "DPP4", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD22", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "SPN", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "PTPRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "SPN", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "PTPRC", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "LCK", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPP4", "protein_b": "PTPRC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD47", "protein_b": "PTPRC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LYN", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "SPN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GRM2", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GRM2", "protein_b": "HTR2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2C", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2B", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1F", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1S", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1F", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1S", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1F", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1S", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1S", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1F", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "HTR2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "CACNA1F", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CACNA1F", "protein_b": "HTR2A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNG2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNB1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "GNG2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNB1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR2A", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HTR2A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "FSHB", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "HTR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GIP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "NPPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "FSHB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GCG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "ADCYAP1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "VIP", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "POMC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "HTR7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GNAS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HTR7", "protein_b": "GNAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "VIP", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "FSHB", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "ADCYAP1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TPH1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A4", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOA", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "TPH2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "TPH2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "BDNF", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "MAOA", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR1B", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR2A", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR1B", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR1B", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR2A", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "HTR2A", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR2A", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "BDNF", "protein_b": "HTR2A", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SIGMAR1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "ERG28", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "MSMO1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SQLE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TMEM97", "protein_b": "SIGMAR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SQLE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SIGMAR1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "MSMO1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SIGMAR1", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SQLE", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SIGMAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNA4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR3", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNH6", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "HSPA5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "HSPA5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSPA5", "protein_b": "ITPR3", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "KCNA4", "protein_b": "KCNH6", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TAC1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "NTS", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TACR1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "UNC80", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC3", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "UNC80", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TACR1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "UNC80", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNAS", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "ARRB1", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "UNC80", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TACR2", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TACR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "CHKB", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TACR2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "CHKB", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "TAC3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "TBXAS1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "TBXAS1", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "TBXAS1", "protein_b": "MGAM2", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR2", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNB1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "ADCYAP1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIP", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "WASL", "protein_b": "VIPR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNB1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIPR1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNAS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNB1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ATG5", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADCYAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1B", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVP", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR2", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1B", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1B", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA14", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR1B", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "VIP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "GNA13", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVPR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AVP", "protein_b": "AVPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "AVPR2", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA2D4", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA2D1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALM3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CALML4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNB1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNB2", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNA2D4", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNB3", "protein_b": "CACNA2D1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNB1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNA2D4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CACNB2", "protein_b": "CACNA2D1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA2D1", "protein_b": "CACNA2D4", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CACNA2D1", "protein_b": "CACNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CACNA2D4", "protein_b": "CACNB1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 10.52, "clustering_coefficient": 5.26}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41221496", "title": "Efficacy and Safety of Esketamine-Lidocaine for Anesthesia Induction in Elderly Patients Undergoing Elective Surgery: A Randomized Controlled Trial.", "authors": [{"name": "Xu J", "authtype": "Author", "clusterid": ""}, {"name": "Yuan M", "authtype": "Author", "clusterid": ""}, {"name": "Zhou T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41217338", "title": "The hemodynamic effects of esketamine-based opioid-free anesthesia in laparoscopic hepatectomy: a randomized clinical trial.", "authors": [{"name": "Yao Y", "authtype": "Author", "clusterid": ""}, {"name": "Yang S", "authtype": "Author", "clusterid": ""}, {"name": "Xu Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209744", "title": "The Analgesic Effect of Low-Dose S(+)-Ketamine in Knee Joint Replacement: A Randomized Controlled Trial.", "authors": [{"name": "Deng SY", "authtype": "Author", "clusterid": ""}, {"name": "Song X", "authtype": "Author", "clusterid": ""}, {"name": "Chen LN", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209150", "title": "Low-Dose Esketamine Plus Dexmedetomidine in Patient-Controlled Intravenous Analgesia Improves Post-Cesarean Sleep Quality: A Double-Blind Randomized Trial.", "authors": [{"name": "Zhang L", "authtype": "Author", "clusterid": ""}, {"name": "He Y", "authtype": "Author", "clusterid": ""}, {"name": "Chen L", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41198736", "title": "Opioid-free anesthesia with quadratus lumborum block and Esketamine enhances postoperative recovery in laparoscopic colon cancer surgery: A randomized controlled trial.", "authors": [{"name": "Cheng CX", "authtype": "Author", "clusterid": ""}, {"name": "Wang K", "authtype": "Author", "clusterid": ""}, {"name": "Jiang YX", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Ketamine+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Ketamine by Stanford University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide an accurate response.\n\nQuery: \"FDA warning letters or clinical holds for Ketamine by Stanford University. Include specific dates, reasons, and safety issues cited.\"\n\nThe user is asking specifically about:\n1. FDA warning letters related to Ketamine\n2. Clinical holds for Ketamine\n3. Specifically from or involving Stanford University\n4. With specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this specific information:\n\nResult 1: FDA warning about compounded ketamine for psychiatric disorders (October 10, 2023)\n- This is a general FDA warning about compounded ketamine products\n- Mentions safety concerns: abuse/misuse, psychiatric events, increased blood pressure, respiratory depression, bladder symptoms\n- Does not mention Stanford University specifically\n- Does not mention warning letters or clinical holds\n\nResult 2: FDA Issues New Warning Regarding Compounded Ketamine (October 10, 2023)\n- Similar to Result 1, general FDA warning\n- Mentions lack of FDA approval for psychiatric indications\n- Does not mention Stanford University\n- Does not mention specific warning letters or clinical holds\n\nResult 3: FDA Issues Warning on Compounded Ketamine Products\n- Again, general FDA warning\n- Mentions Schedule III classification\n- Lists safety hazards: sedation, dissociation, psychiatric events, abuse, blood pressure issues, respiratory depression, bladder symptoms\n- Does not mention Stanford University specifically\n- Does not mention warning letters or clinical holds\n\nResult 4: Safety Concerns Prompt FDA Warning for Compounded Ketamine\n- Mentions an adverse event report from April 2023 involving respiratory depression\n- Notes ketamine is Schedule III controlled substance approved for anesthesia\n- Does not mention Stanford University\n- Does not mention specific warning letters or clinical holds\n\nResult 5: Doctors are prescribing ketamine for pain\n- Mentions FDA warnings about compounded ketamine\n- References research from Duke (not Stanford)\n- Mentions potential side effects: hallucinations, troubling thoughts, visual disturbances\n- Does not mention Stanford University specifically in relation to warning letters or clinical holds\n\nResult 6: Ketamine and Esketamine in Clinical Trials\n- Mentions FDA approval of esketamine for treatment-resistant depression in 2019\n- Does not mention warning letters, clinical holds, or Stanford University specifically", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Stanford University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Ketamine. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Ketamine\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me check the search results to see if they contain this information:\n\nResult [1]: Information about NCT01920555 (a different trial about ketamine for depression), not NCT05945147\n\nResult [2]: Information about a Phase 1 study of oral ketamine, not specifically about NCT05945147\n\nResult [3]: Information about a different ketamine study for extending antidepressant effects\n\nResult [4]: ClinicalTrials.gov page for NCT05945147 (Ketamine and Midazolam Infusions for CRPS: Feasibility Study)\n\nResult [5]: MedDataX page for NCT05945147 with some details about the study design but no safety data or termination reasons\n\nResult [6]: Stanford article about ketamine research, not specific to NCT05945147\n\nResult [7]: PubMed article about a different ketamine trial (NCT03861988)\n\nResult [8]: GlobeNewswire link with no available information\n\nResult [9]: Stanford Depression Research Clinic information about different ketamine studies\n\nResult [10]: Stanford Medicine news about ketamine research in rats, not specific to NCT05945147\n\nResult [11]: ClinicalTrials.gov page for NCT05945147, confirming it's a feasibility study for CRPS (Complex Regional Pain Syndrome)\n\nResult [12]: Stanford Medicine page about a different ketamine study for pain and mood\n\nResult [13]: Policy Lab information about ketamine treatments in California, mentioning a different Stanford study (NCT03475277)\n\nResult [14]: Stanford clinical trials page for NCT06317636, a different ketamine study\n\nFrom reviewing these results, I can see that:\n\n1. NCT05945147 is a feasibility study titled \"Ketamine and Midaz", "citations": [], "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Ketamine"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The official reason for the trial's withdrawal is \"Lack of funding,\" which is an administrative and operational issue rather than related to safety or efficacy concerns. The detailed description does not mention any safety or efficacy problems, but rather focuses on the feasibility objectives of the study. Therefore, the evidence suggests the trial was withdrawn due to administrative and funding-related reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:00.281739", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1200}}, "4": {"nct_id": "NCT05945147", "drug_name": "Midazolam", "intervention_type": "DRUG", "drug_description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.535606", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:00.318907", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL655", "pref_name": "MIDAZOLAM", "targets": [{"chembl_id": "CHEMBL340", "ic50_values": [{"value": 8100.0, "units": "nM"}, {"value": 33000.0, "units": "nM"}, {"value": 61.8, "units": "nM"}, {"value": 66.2, "units": "nM"}, {"value": 80.0, "units": "nM"}, {"value": 66.0, "units": "nM"}, {"value": 47.0, "units": "nM"}], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL4302", "ic50_values": [{"value": 50000.0, "units": "nM"}, {"value": 50000.0, "units": "nM"}, {"value": 50000.0, "units": "nM"}], "uniprot_id": "A8K294"}, {"chembl_id": "CHEMBL2573", "ic50_values": [{"value": 50000.0, "units": "nM"}, {"value": 50000.0, "units": "nM"}], "uniprot_id": "P21447"}, {"chembl_id": "CHEMBL3467", "ic50_values": [{"value": 33000.0, "units": "nM"}, {"value": 33000.0, "units": "nM"}], "uniprot_id": "P06795"}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 41700.0, "units": "nM"}, {"value": 41700.0, "units": "nM"}, {"value": 41740.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL613642", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL5748", "ic50_values": [], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [], "uniprot_id": "A9Z1Z7"}], "has_uniprot_targets": true, "search_name": "Midazolam"}, "ppi_enrichment": {"uniprot_count": 8, "interactions": [{"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "ABCF2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "SLCO1B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "NR1I2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "ABCB1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "PPIG", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP2C19", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP3A4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "NR1I2", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "ABCB1", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "CYP3A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB1", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "ABCF2-2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP2C19", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP3A4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ABCB1", "combined_score": 0.858, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "CYP3A4", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "IGKV2D-29", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 6.67, "clustering_coefficient": 3.33}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41222450", "title": "Characterization of Drug-Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS-CoV-2, in Healthy Participants.", "authors": [{"name": "Chang J", "authtype": "Author", "clusterid": ""}, {"name": "Kim A", "authtype": "Author", "clusterid": ""}, {"name": "Humeniuk R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41164404", "title": "Intranasal Dexmedetomidine with Propofol Provides Superior Sedation for Pediatric Contrast-Enhanced CT: A Randomized Controlled Trial.", "authors": [{"name": "Zhang SJ", "authtype": "Author", "clusterid": ""}, {"name": "Weng YJ", "authtype": "Author", "clusterid": ""}, {"name": "Lei Q", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41150706", "title": "Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.", "authors": [{"name": "Tachibana M", "authtype": "Author", "clusterid": ""}, {"name": "Horwitz S", "authtype": "Author", "clusterid": ""}, {"name": "Jacobsen E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41123905", "title": "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial.", "authors": [{"name": "Jelovac A", "authtype": "Author", "clusterid": ""}, {"name": "McCaffrey C", "authtype": "Author", "clusterid": ""}, {"name": "Terao M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41121399", "title": "Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial.", "authors": [{"name": "Li TT", "authtype": "Author", "clusterid": ""}, {"name": "He XL", "authtype": "Author", "clusterid": ""}, {"name": "Tang HL", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Midazolam+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Midazolam by Stanford University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Midazolam by Stanford University.\n\nFirst, I need to identify if there are any specific FDA warning letters or clinical holds related to Midazolam that involve Stanford University.\n\nLooking through the search results:\n\nResult [1]: Information about Midazolam side effects from recovered.org. No mention of Stanford University or FDA warning letters.\n\nResult [2]: FDA label for Midazolam Injection. Contains safety information but no specific warning letters or clinical holds related to Stanford.\n\nResult [3]: Another FDA label document for Midazolam. Contains safety information but no specific warning letters or clinical holds related to Stanford.\n\nResult [4]: Another FDA label document for Midazolam. Contains safety information but no specific warning letters or clinical holds related to Stanford.\n\nResult [5]: FDA.report information about Midazolam. Contains safety information but no specific warning letters or clinical holds related to Stanford.\n\nResult [6]: FDA document (211844Orig1s000SumR.pdf) which appears to be an NDA (New Drug Application) review. It mentions \"Stanford University\" in the context of a postdoctoral scholar, but this is from result [9], not result [6]. Result [6] discusses a review of safety data but doesn't mention Stanford University specifically in relation to warning letters.\n\nResult [7]: PMC article about a bioavailability study of Midazolam. No mention of FDA warning letters or clinical holds.\n\nResult [8]: FDA FOIA (Freedom of Information Act) case document. No specific information about Midazolam or Stanford.\n\nResult [9]: Mentions \"I am a postdoctoral scholar at Stanford University\" but this appears to be from an incoming request to the FDA, not a warning letter or clinical hold related to Midazolam.\n\nResult [10]: ClinicalTrials.gov entry for \"Safety and Efficacy of Oral Midazolam for Perioperative Anxiety\" but doesn't specify if this was conducted by Stanford University or if there were any warning letters or clinical holds.\n\nResult [11]: FDA announcement about requiring updated Boxed Warning for benzodiazepines, which includes Midazolam, but this is a general warning for the drug class, not specific to Stanford University.\n\nResult [12]: Information about FDA cancer drug safety warnings, not relevant", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Stanford University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Midazolam. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by Stanford University regarding clinical trial NCT05945147 for Midazolam, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results to see what information is available:\n\nResult [1] and [7] both refer to NCT05945147, which is titled \"Ketamine and Midazolam Infusions for CRPS: Feasibility Study\". From these results, I can see:\n- The study is listed as \"WITHDRAWN\" in result [1]\n- It's a Phase 2 interventional study\n- It was supposed to assess the feasibility of administering ketamine plus midazolam or midazolam alone over 5 days in an outpatient setting for CRPS (Complex Regional Pain Syndrome)\n- According to result [1], \"The study team has not published outcome measurements, participant flow, or safety data for this trial yet.\"\n- Result [7] mentions it was a small feasibility study with only 4 adults with CRPS who would be randomized to receive either ketamine and midazolam or midazolam-only\n\nResult [15] provides additional information:\n- It mentions \"Trial Updated: 11/20/2024\"\n- Locations include \"Stanford University, Stanford, California\"\n- Conditions: \"Complex Regional Pain\"\n\nNow, regarding the specific query about company press releases, investor presentations, or public statements by Stanford University about safety issues, adverse events, trial termination reasons, or regulatory actions:\n\nI don't see any explicit press releases, investor presentations, or public statements from Stanford University in the search results. The main information comes from clinical trial registries (clinicaltrials.gov and meddatax.com).\n\nFrom result [1], I can see that the trial status is listed as \"WITHDRAWN\", but there's no explanation for why it was withdrawn. This is relevant to the query as it relates to trial termination.\n\nThe search results don't provide specific information about:\n1. Safety issues or adverse events related to this specific trial (NCT05945147)\n2. Any public statements from Stanford University explaining the withdrawal\n3. Regulatory actions related to this trial\n\nResults [2], [3], [4", "citations": [], "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Midazolam"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The official reason for the trial's withdrawal is \"Lack of funding,\" which is an administrative and operational issue rather than related to safety or efficacy concerns. The detailed description does not mention any safety or efficacy problems, but rather focuses on the feasibility objectives of the study. Therefore, the evidence suggests the trial was withdrawn due to administrative and funding-related reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:00.281739", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1200}}, "5": {"nct_id": "NCT05945147", "drug_name": "Normal Saline", "intervention_type": "DRUG", "drug_description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.535819", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:00.355688", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q940H6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q0JNS6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q6ZI01", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q40359", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Normal Saline", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 4, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "aact_documents": [], "pubmed_results": [{"pmid": "41221568", "title": "Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial.", "authors": [{"name": "Agrawal A", "authtype": "Author", "clusterid": ""}, {"name": "Dhibar DP", "authtype": "Author", "clusterid": ""}, {"name": "Prakash A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41221567", "title": "Effect of dexmedetomidine combined with ropivacaine in ultrasound-guided paravertebral nerve block for acute herpes zoster neuralgia patients.", "authors": [{"name": "Liu C", "authtype": "Author", "clusterid": ""}, {"name": "Wang Y", "authtype": "Author", "clusterid": ""}, {"name": "Wang P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41214223", "title": "Nasal allergen challenge with dissolved birch tree pollen tablets.", "authors": [{"name": "Paziou E", "authtype": "Author", "clusterid": ""}, {"name": "Ali KJ", "authtype": "Author", "clusterid": ""}, {"name": "Geor\u00e9n SK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41200477", "title": "Efficacy of Intravenous Butorphanol for Preventing Epidural-Related Maternal Fever (ERMF) During Epidural Labor Analgesia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.", "authors": [{"name": "Zhang Y", "authtype": "Author", "clusterid": ""}, {"name": "Chen X", "authtype": "Author", "clusterid": ""}, {"name": "Xu S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41198897", "title": "Effects of chlorhexidine and a polyherbal mouthwash on the oral microbiome and user satisfaction: a randomized controlled trial.", "authors": [{"name": "Wattanawongwan W", "authtype": "Author", "clusterid": ""}, {"name": "Krasaesin A", "authtype": "Author", "clusterid": ""}, {"name": "Khieota T", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).", "detailed_description": "Subanesthetic ketamine infusions are a potentially impactful treatment for chronic refractory pain, but the acute psychoactive effects of ketamine complicate successful masking in randomized trials. Multi-day ketamine infusions have produced long-lasting, but not permanent, remission of symptoms in complex regional pain syndrome (CRPS), a chronic and often debilitating neuropathic pain condition that can affect one or more limbs. In this feasibility study, 4 adults with CRPS will be randomized to receive either ketamine and midazolam or midazolam-only, infused over 5 days in an outpatient setting. The objectives of this feasibility study are:\n\n1. Assess whether the recruitment and retention rate observed in this feasibility study can support a larger clinical trial.\n2. Evaluate whether participants can adhere to study procedures.\n3. Determine whether midazolam, when given alone as an intravenous (IV) infusion, can be used as an active placebo that is well-tolerated, practical, and believable compared to a ketamine plus midazolam infusion.\n4. Gather preliminary data on clinically-relevant outcomes for CRPS.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Ketamine and Midazolam", "type": "EXPERIMENTAL", "description": "Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Ketamine", "Drug: Midazolam"]}, {"label": "Midazolam and Saline", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.", "intervention_names": ["Drug: Midazolam", "Drug: Normal Saline"]}], "interventions": [{"type": "DRUG", "name": "Ketamine", "description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam"]}, {"type": "DRUG", "name": "Midazolam", "description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Ketamine and Midazolam", "Midazolam and Saline"]}, {"type": "DRUG", "name": "Normal Saline", "description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "arm_group_labels": ["Midazolam and Saline"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Stanford University+NCT05945147+terminated", "https://www.google.com/search?q=Stanford University+Normal Saline+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Normal Saline by Stanford University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Normal Saline by Stanford University.\n\nFirst, I need to identify if there are any specific mentions of:\n1. FDA warning letters related to Normal Saline\n2. Clinical holds related to Normal Saline\n3. Any connection to Stanford University\n4. Specific dates, reasons, and safety issues\n\nLet's go through the search results one by one:\n\nResult [1]: Discusses FDA's investigation about patients being injected with simulated IV fluids (Wallcur's products), which are not sterile and should not be injected. This is about simulated training products being mistakenly used on patients, not about Stanford University or clinical trials.\n\nResult [2]: Mentions an FDA recall alert for saline and sterile water products, but doesn't specify Stanford University.\n\nResult [3]: Discusses a recall of simulated saline solution after erroneous patient infusion. Again, this is about Wallcur's training products being mistakenly used, not about Stanford University.\n\nResult [4]: Announces resolution of the IV saline solutions shortage. No mention of Stanford University.\n\nResult [5]: Discusses a recall of certain saline and sterile water medical products by Nurse Assist, LLC. No mention of Stanford University.\n\nResult [6]: A study about warning letters issued to clinical investigators by the FDA, but it's a general study from 2004 and doesn't specifically mention Stanford University or Normal Saline.\n\nResult [7]: A warning letter to ivsupplyclinic.com, but not related to Stanford University.\n\nResult [8]: A PDF about KDIGO Clinical Practice Guideline for Acute Kidney Injury, not related to FDA warning letters for Normal Saline at Stanford.\n\nResult [9]: A warning letter to Medline Industries, LP, but not related to Stanford University.\n\nResult [10]: Profile of Russ B. Altman from Stanford, mentioning \"Failure to demonstrate efficacy and safety issues are important reasons that drugs do not reach the market.\" But this is just a general statement in his profile, not specific to Normal Saline or FDA warning letters.\n\nResult [11]: General information about FDA warning letters, no specific mention of Stanford or Normal Saline.\n\nResult [12]: Profile of John P.A. Ioannidis from Stanford, but no mention of Normal Saline or FDA warning letters.\n\nResult [13]: Profile of Brian T. Bateman from Stanford, mentioning an FDA black-box warning about co-prescription", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Stanford University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Stanford University about clinical trial NCT05945147 for Normal Saline. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about external safety evidence for clinical trial NCT05945147 for Normal Saline.\n\nThe query is asking specifically for:\n- Company press releases\n- Investor presentations\n- Public statements by Stanford University \n- About clinical trial NCT05945147 for Normal Saline\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me examine the search results to see what information is available about NCT05945147:\n\nFrom result [3] and [5], I can see that NCT05945147 is titled \"Ketamine and Midazolam Infusions for CRPS: Feasibility Study\". It involves:\n- Participants receiving intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting\n- According to result [5], the study status is listed as \"WITHDRAWN\" with Phase 2\n- Result [5] states: \"The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.\"\n\nFrom result [5], I can see:\n- The study is titled \"Ketamine and Midazolam Infusions for CRPS: Feasibility Study\"\n- NCT ID: NCT05945147\n- Status: WITHDRAWN\n- Phase: PHASE2\n- Basic timeline: 2099-01-01 to 2099-05-31 (which seems odd as these are future dates)\n- One location listed: Stanford University in Stanford, California\n\nResult [5] also provides intervention details:\n- Midazolam and Saline: Participants receive intravenous infusions of midazolam and normal saline\n- Midazolam: A constant dose of midazolam (0.04 mg/kg/hr) administered as 4-hour infusions over 5 consecutive days\n- Normal Saline: An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) administered as 4-hour infusions over 5 consecutive days\n\nResult [6] mentions another trial (NCT03861988) about", "citations": [], "search_params": {"company": "Stanford University", "nct_id": "NCT05945147", "drug_name": "Normal Saline"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The official reason for the trial's withdrawal is \"Lack of funding,\" which is an administrative and operational issue rather than related to safety or efficacy concerns. The detailed description does not mention any safety or efficacy problems, but rather focuses on the feasibility objectives of the study. Therefore, the evidence suggests the trial was withdrawn due to administrative and funding-related reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:00.281739", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1200}}, "6": {"nct_id": "NCT03883360", "drug_name": "Cannabidiol (CBD)", "intervention_type": "DRUG", "drug_description": "Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "not funded", "title": "Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis", "start_date": "2050-01-31", "completion_date": "2050-03-31", "sponsor": "University of Maryland, Baltimore", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.536028", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:03.254522", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL190461", "pref_name": "CANNABIDIOL", "targets": [{"chembl_id": "CHEMBL613710", "ic50_values": [{"value": 0.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL3762", "ic50_values": [{"value": 100.0, "units": "nM"}], "uniprot_id": "P22002"}, {"chembl_id": "CHEMBL614910", "ic50_values": [{"value": 48000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL395", "ic50_values": [{"value": 42800.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 12000.0, "units": "nM"}, {"value": 2900.0, "units": "nM"}, {"value": 10500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 55000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL392", "ic50_values": [{"value": 40000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614212", "ic50_values": [{"value": 50000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL394", "ic50_values": [{"value": 18000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL3229", "ic50_values": [{"value": 53200.0, "units": "nM"}], "uniprot_id": "P97612"}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5545", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": "A0A024R517"}, {"chembl_id": "CHEMBL4349", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": "Q02083"}, {"chembl_id": "CHEMBL614632", "ic50_values": [{"value": 25300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}, {"value": 72780.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5011", "ic50_values": [{"value": 2800.0, "units": "nM"}], "uniprot_id": "Q8R455"}, {"chembl_id": "CHEMBL5160", "ic50_values": [{"value": 450.0, "units": "nM"}], "uniprot_id": "F1LRH9"}, {"chembl_id": "CHEMBL2775", "ic50_values": [{"value": 5900.0, "units": "nM"}], "uniprot_id": "Q9ERZ8"}, {"chembl_id": "CHEMBL3879847", "ic50_values": [{"value": 750.0, "units": "nM"}], "uniprot_id": "Q4QYD9"}, {"chembl_id": "CHEMBL2863", "ic50_values": [{"value": 1100.0, "units": "nM"}], "uniprot_id": "Q5FWT3"}, {"chembl_id": "CHEMBL4794", "ic50_values": [{"value": 3700.0, "units": "nM"}], "uniprot_id": "A2RUA9"}, {"chembl_id": "CHEMBL614781", "ic50_values": [{"value": 10300.0, "units": "nM"}, {"value": 8000.0, "units": "nM"}, {"value": 12300.0, "units": "nM"}, {"value": 8500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5763", "ic50_values": [{"value": 670.0, "units": "nM"}], "uniprot_id": "P81908"}, {"chembl_id": "CHEMBL4078", "ic50_values": [{"value": 17070.0, "units": "nM"}], "uniprot_id": "O42275"}, {"chembl_id": "CHEMBL364", "ic50_values": [{"value": 4100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613898", "ic50_values": [{"value": 51100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL400", "ic50_values": [{"value": 6000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612589", "ic50_values": [{"value": 1800.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614058", "ic50_values": [{"value": 3730.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613508", "ic50_values": [{"value": 5400.0, "units": "nM"}, {"value": 1500.0, "units": "nM"}, {"value": 12300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075319", "ic50_values": [{"value": 60.0, "units": "nM"}], "uniprot_id": "A0AVG2"}, {"chembl_id": "CHEMBL233", "ic50_values": [{"value": 311.0, "units": "nM"}, {"value": 1800.0, "units": "nM"}], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL612518", "ic50_values": [{"value": 2600.0, "units": "nM"}, {"value": 18000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296492", "ic50_values": [{"value": 1100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296487", "ic50_values": [{"value": 900.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL218", "ic50_values": [{"value": 3800.0, "units": "nM"}], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL5871", "ic50_values": [{"value": 2700.0, "units": "nM"}], "uniprot_id": "A8K0J6"}, {"chembl_id": "CHEMBL1920", "ic50_values": [{"value": 130.0, "units": "nM"}], "uniprot_id": "A8K115"}, {"chembl_id": "CHEMBL3736", "ic50_values": [{"value": 30000.0, "units": "nM"}], "uniprot_id": "A0A7D6JAD5"}, {"chembl_id": "CHEMBL3535", "ic50_values": [{"value": 110.0, "units": "nM"}], "uniprot_id": "B2RBI5"}, {"chembl_id": "CHEMBL2362975", "ic50_values": [{"value": 33300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4304", "ic50_values": [{"value": 280.0, "units": "nM"}], "uniprot_id": "F8WA96"}], "has_uniprot_targets": true, "search_name": "Cannabidiol (CBD)"}, "ppi_enrichment": {"uniprot_count": 20, "interactions": [{"protein_a": "FAAH", "protein_b": "ABHD4", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "ABHD12", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "DAGLB", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "ABHD6", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "DAGLA", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "NAPEPLD", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "GPR55", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "ABHD4", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "ABHD12", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "GRM5", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "CNR1", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "ABHD6", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "MGLL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "NAPEPLD", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "DAGLA", "protein_b": "DAGLB", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "ABHD4", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "DAGLB", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "ABHD12", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "ABHD6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "NAPEPLD", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ABHD6", "protein_b": "GPR55", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "ABHD6", "protein_b": "ABHD4", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "ABHD6", "protein_b": "DAGLB", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "ABHD6", "protein_b": "NAPEPLD", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "ABHD6", "protein_b": "ABHD12", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "DAGLB", "protein_b": "CNR1", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "DAGLB", "protein_b": "ABHD12", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "DAGLB", "protein_b": "NAPEPLD", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "NAPEPLD", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ABHD12", "protein_b": "ABHD4", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "ABHD12", "protein_b": "NAPEPLD", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NAPEPLD", "protein_b": "GPR55", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "NAPEPLD", "protein_b": "ABHD4", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "FIG4", "protein_b": "LAMP2", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "FIG4", "protein_b": "NAAA", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "FIG4", "protein_b": "VAC14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "NAAA", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "NAPEPLD", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "VAC14", "protein_b": "NAAA", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "VAC14", "protein_b": "LAMP2", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "NAAA", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "NAPEPLD", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NAAA", "protein_b": "PPARA", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "NAAA", "protein_b": "FAAH2", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "NAAA", "protein_b": "LAMP2", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "NAAA", "protein_b": "NAPEPLD", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "FAAH2", "protein_b": "NAPEPLD", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "CALML4", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "CALML6", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "CALM3", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "CALML3", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "CALML5", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPM8", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPV1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PRKACB", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PRKACA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PRKACG", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "TRPV1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PRKACA", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PRKACB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "TRPV1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PRKACG", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "TRPV1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "PRKACG", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "PRKACB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "CALML4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "CALML5", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "CALML3", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PRKACB", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "TRPV1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PRKACG", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "TRPV1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PRKACB", "protein_b": "TRPV1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKACB", "protein_b": "PRKACG", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "PRKACB", "protein_b": "CALML4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PRKACB", "protein_b": "CALML5", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PRKACG", "protein_b": "TRPV1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKACG", "protein_b": "CALML5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PRKACG", "protein_b": "CALML4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "TRPV1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "TRPV1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPV4", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPV3", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPV2", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPM8", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "TRPA1", "protein_b": "TRPV1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "PPP1CB", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "TRPV4", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "TRPV2", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "TRPM8", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "TRPV3", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "ANK1", "protein_b": "TRPV1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "TRPV3", "protein_b": "TRPM8", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NUDT9", "protein_b": "TRPM8", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "TRPV4", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "PPP1CC", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "PPP1CB", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "PPP1CA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "TRPV2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "TRPM8", "protein_b": "TRPV1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP1CA", "protein_b": "PPP1CB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP1CA", "protein_b": "PPP1CC", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP1CC", "protein_b": "PPP1CB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRPV4", "protein_b": "TRPV1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GLRA2", "protein_b": "GRPR", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "GLRA2", "protein_b": "NOVA1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRG1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "ALDH5A1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "NSF", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "PLCL1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "HAP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "TRAK2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRB3", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRG2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "GABRB2", "protein_b": "GABRA1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRB3", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRA1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRG2", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "GABRB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "HAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "TRAK2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "NSF", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GABRG1", "protein_b": "PLCL1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRG2", "combined_score": 0.87, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "PLCL1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "TRAK2", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "NSF", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "HAP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRB3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GABRB1", "protein_b": "GABRA1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "PLCL1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "TRAK2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "HAP1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "NSF", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "GABRG2", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GABRB3", "protein_b": "GABRA1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TRAK2", "protein_b": "GABRA1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HAP1", "protein_b": "GABRA1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NSF", "protein_b": "GABRA1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "PLCL1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GABRA1", "protein_b": "GABRG2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE9A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GUCY1A2", "protein_b": "PDE9A", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "GUCY1A2", "protein_b": "ITPA", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GUCY1A2", "protein_b": "GUCY1B1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "GUCY1B1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "NPR1", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "ALDH7A1", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "GUK1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "HPRT1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "ITPA", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "PDE9A", "protein_b": "APRT", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "NPR1", "protein_b": "ITPA", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "PRKACA", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNMB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNMB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNN1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNMB1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNN2", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNN4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNN3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "KCNMB4", "protein_b": "KCNMA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNMB2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNN4", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNMB3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNN3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNN1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNMB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "KCNN2", "protein_b": "KCNMA1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "PRKACA", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNMB3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNMB2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNN3", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNN4", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNN1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "LRRC26", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "KCNMB1", "protein_b": "KCNMA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "PRKACA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "KCNN3", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "LRRC26", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "KCNMB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "KCNN1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "KCNN4", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "KCNMA1", "protein_b": "KCNMB3", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "KCNMB2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "KCNMB3", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "KCNMB3", "protein_b": "KCNMB2", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "KCNMB3", "protein_b": "KCNN3", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "KCNMB3", "protein_b": "KCNN4", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "KCNMB3", "protein_b": "KCNN1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "KCNMB2", "protein_b": "KCNN4", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "KCNMB2", "protein_b": "KCNN3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "KCNMB2", "protein_b": "KCNN1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "KCNN1", "protein_b": "KCNN3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "KCNN1", "protein_b": "KCNN4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "KCNN3", "protein_b": "KCNN4", "combined_score": 0.923, "interaction_type": "physical"}], "network_features": {"avg_degree": 6.55, "clustering_coefficient": 3.27}}, "failure_enrichment": {"aact_description": "This is a double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis. The study will be conducted at the Maryland Psychiatric Research Center (University of Maryland School of Medicine) and associated Early Intervention Programs in Baltimore, at the Sheppard Pratt Health System in Baltimore, and at the Psychosis Clinic of the University of California Los Angeles.\n\nThe daily dose of CBD is 600 mg (p.o.), administered as adjunct medication. Any non-exclusionary antipsychotic, antidepressant, anxiolytic, or other medication prescribed prior to the trial will be continued. Participants may, but do not have to be taking conventional antipsychotic medication.\n\nThe study will include 84 regular cannabis users with a schizophrenia-spectrum disorder who experienced their first psychotic episode within the last 5 years (90). Participants will be randomized 1:1 to either the CBD or the placebo group.\n\nOutcome measures include psychiatric symptoms, cognition, global functioning, and drug use, and will be assessed at baseline, and every 3 or 6 weeks thereafter (depending on the measure), until the end of treatment at 12 weeks. Outcome will be assessed again at a 3-month follow-up.", "aact_documents": [], "pubmed_results": [{"pmid": "41103807", "title": "Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study.", "authors": [{"name": "Sannar EM", "authtype": "Author", "clusterid": ""}, {"name": "Winter J", "authtype": "Author", "clusterid": ""}, {"name": "Franke RK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41094745", "title": "Field safety and efficacy study with a cannabidiol/cannabidiol acid-rich hemp paste in cats with osteoarthritic pain.", "authors": [{"name": "Mulder LM", "authtype": "Author", "clusterid": ""}, {"name": "Deterd Oude Weme J", "authtype": "Author", "clusterid": ""}, {"name": "Blees NR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41090077", "title": "Efficacy of a 20:1 CBD:THC cannabis herbal extract for pain and inflammation in dogs following tibial plateau leveling osteotomy.", "authors": [{"name": "Lyons C", "authtype": "Author", "clusterid": ""}, {"name": "Pinto KR", "authtype": "Author", "clusterid": ""}, {"name": "Penney K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41071032", "title": "Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial.", "authors": [{"name": "Martino F", "authtype": "Author", "clusterid": ""}, {"name": "Ortiz-Peregrina S", "authtype": "Author", "clusterid": ""}, {"name": "Casares-L\u00f3pez M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40962814", "title": "Effect of caffeine and cannabidiol (CBD) co-administration on \u03949-tetrahydrocannabinol (\u03949-THC) subjective effects, performance impairment, and pharmacokinetics.", "authors": [{"name": "Strickland JC", "authtype": "Author", "clusterid": ""}, {"name": "Tilton HE", "authtype": "Author", "clusterid": ""}, {"name": "Patton NM", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of \u03949-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.", "detailed_description": "This is a double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis. The study will be conducted at the Maryland Psychiatric Research Center (University of Maryland School of Medicine) and associated Early Intervention Programs in Baltimore, at the Sheppard Pratt Health System in Baltimore, and at the Psychosis Clinic of the University of California Los Angeles.\n\nThe daily dose of CBD is 600 mg (p.o.), administered as adjunct medication. Any non-exclusionary antipsychotic, antidepressant, anxiolytic, or other medication prescribed prior to the trial will be continued. Participants may, but do not have to be taking conventional antipsychotic medication.\n\nThe study will include 84 regular cannabis users with a schizophrenia-spectrum disorder who experienced their first psychotic episode within the last 5 years (90). Participants will be randomized 1:1 to either the CBD or the placebo group.\n\nOutcome measures include psychiatric symptoms, cognition, global functioning, and drug use, and will be assessed at baseline, and every 3 or 6 weeks thereafter (depending on the measure), until the end of treatment at 12 weeks. Outcome will be assessed again at a 3-month follow-up.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Cannabidiol (CBD)", "type": "EXPERIMENTAL", "description": "Participants receive CBD daily for 12 weeks.", "intervention_names": ["Drug: Cannabidiol (CBD)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive vehicle not containing any drug daily for 12 weeks.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Cannabidiol (CBD)", "description": "Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.", "arm_group_labels": ["Cannabidiol (CBD)"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.", "arm_group_labels": ["Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of Maryland, Baltimore+NCT03883360+terminated", "https://www.google.com/search?q=University of Maryland, Baltimore+Cannabidiol (CBD)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Cannabidiol (CBD) by University of Maryland, Baltimore. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking for:\n1. FDA warning letters or clinical holds for Cannabidiol (CBD) by University of Maryland, Baltimore\n2. Specific dates, reasons, and safety issues cited\n\nFirst, I need to determine if there are any FDA warning letters or clinical holds specifically issued to the University of Maryland, Baltimore related to CBD.\n\nLet me go through the search results to find relevant information:\n\nResult 1: FDA warning letters to companies selling delta-8 THC and CBD products, but no mention of University of Maryland, Baltimore.\n\nResult 2: FDA warning letters to two companies concerning marketing and sale of OTC CBD products, but no mention of University of Maryland, Baltimore.\n\nResult 3: Information about FDA warning letters for CBD products in general, but no specific mention of University of Maryland, Baltimore.\n\nResult 4: FDA warning letters to five companies marketing food and beverage products containing CBD, but no mention of University of Maryland, Baltimore.\n\nResult 5: FDA warning letter regarding delta-8 and CBD gummies, but no mention of University of Maryland, Baltimore.\n\nResult 6: FDA warnings about illegally selling food and beverage products containing CBD, but no mention of University of Maryland, Baltimore.\n\nResult 7: FDA warning letters to four companies selling CBD products for food-producing animals, but no mention of University of Maryland, Baltimore.\n\nResult 8: FDA warning letters to companies selling unapproved CBD products for animals, but no mention of University of Maryland, Baltimore.\n\nResult 9: Mentions \"Cannabis - Maryland Carey Law\" which is part of University of Maryland, but this appears to be just a collection of FDA warning letters, not warning letters issued TO the university.\n\nResult 10: FDA warning letters related to CBD, but no mention of University of Maryland, Baltimore.\n\nResult 11: Lists FDA warning letters for cannabis-derived products, but no specific mention of University of Maryland, Baltimore.\n\nResult 12: Regulatory snapshot about CBD, but no specific mention of University of Maryland, Baltimore.\n\nResult 13: Contains \"[PDF] Letter of Information House Bill 12 Cannabis - Maryland\" which mentions \"archived warning letters\" but doesn't indicate that University of Maryland, Baltimore received any warning letters.\n\nResult 14: Mentions \"Hemp-Derived Non-Delta-9-Tetrahydrocannabinol Products", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of Maryland, Baltimore"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of Maryland, Baltimore about clinical trial NCT03883360 for Cannabidiol (CBD). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by University of Maryland, Baltimore\n- Specifically about clinical trial NCT03883360 for Cannabidiol (CBD)\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see if they contain this specific information:\n\nResult [1]: This is a ClinicalTrials.gov entry for NCT03883360, which describes the study details but doesn't contain any press releases, investor presentations, or public statements from University of Maryland about safety issues or trial termination.\n\nResult [2]: This is a PMC article reviewing CBD clinical trials and adverse effects, but it doesn't specifically address NCT03883360 or contain University of Maryland press releases.\n\nResult [3]: This is about a different clinical trial (NCT05753007) for GBM patients, not NCT03883360.\n\nResult [4]: This is an FDA article about CBD safety in a randomized trial, but it doesn't mention NCT03883360 or University of Maryland specifically.\n\nResult [5]: This appears to be a generic trial listing without specific information about NCT03883360 or University of Maryland press releases.\n\nResult [6]: This is a systematic review of CBD adverse effects, but doesn't specifically address NCT03883360.\n\nResult [7]: This is about a different CBD trial for opioid use disorder at Mount Sinai, not NCT03883360.\n\nResult [8]: This is a press release from cbdMD about their own clinical trial, not about NCT03883360.\n\nResult [9]: This is another listing of NCT03883360 but doesn't contain press releases or safety information from University of Maryland.\n\nResult [10]: This is a PR Newswire article about FDA work on CBD products, but doesn't mention NCT03883360 specifically.\n\nResult [11]: This is a University of Maryland news article, but it's about a different clinical trial for dementia-related agitation, not NCT0388", "citations": [], "search_params": {"company": "University of Maryland, Baltimore", "nct_id": "NCT03883360", "drug_name": "Cannabidiol (CBD)"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial's withdrawal is \"not funded,\" which indicates an administrative issue rather than concerns about safety or efficacy. The detailed description does not mention any safety concerns or lack of efficacy that led to the termination of the trial. Therefore, the most likely reason for the trial's failure is administrative, such as a lack of funding or other operational problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:03.253359", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1260}}, "7": {"nct_id": "NCT03883360", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "not funded", "title": "Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis", "start_date": "2050-01-31", "completion_date": "2050-03-31", "sponsor": "University of Maryland, Baltimore", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.536320", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:03.292661", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": "This is a double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis. The study will be conducted at the Maryland Psychiatric Research Center (University of Maryland School of Medicine) and associated Early Intervention Programs in Baltimore, at the Sheppard Pratt Health System in Baltimore, and at the Psychosis Clinic of the University of California Los Angeles.\n\nThe daily dose of CBD is 600 mg (p.o.), administered as adjunct medication. Any non-exclusionary antipsychotic, antidepressant, anxiolytic, or other medication prescribed prior to the trial will be continued. Participants may, but do not have to be taking conventional antipsychotic medication.\n\nThe study will include 84 regular cannabis users with a schizophrenia-spectrum disorder who experienced their first psychotic episode within the last 5 years (90). Participants will be randomized 1:1 to either the CBD or the placebo group.\n\nOutcome measures include psychiatric symptoms, cognition, global functioning, and drug use, and will be assessed at baseline, and every 3 or 6 weeks thereafter (depending on the measure), until the end of treatment at 12 weeks. Outcome will be assessed again at a 3-month follow-up.", "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of \u03949-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.", "detailed_description": "This is a double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis. The study will be conducted at the Maryland Psychiatric Research Center (University of Maryland School of Medicine) and associated Early Intervention Programs in Baltimore, at the Sheppard Pratt Health System in Baltimore, and at the Psychosis Clinic of the University of California Los Angeles.\n\nThe daily dose of CBD is 600 mg (p.o.), administered as adjunct medication. Any non-exclusionary antipsychotic, antidepressant, anxiolytic, or other medication prescribed prior to the trial will be continued. Participants may, but do not have to be taking conventional antipsychotic medication.\n\nThe study will include 84 regular cannabis users with a schizophrenia-spectrum disorder who experienced their first psychotic episode within the last 5 years (90). Participants will be randomized 1:1 to either the CBD or the placebo group.\n\nOutcome measures include psychiatric symptoms, cognition, global functioning, and drug use, and will be assessed at baseline, and every 3 or 6 weeks thereafter (depending on the measure), until the end of treatment at 12 weeks. Outcome will be assessed again at a 3-month follow-up.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Cannabidiol (CBD)", "type": "EXPERIMENTAL", "description": "Participants receive CBD daily for 12 weeks.", "intervention_names": ["Drug: Cannabidiol (CBD)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive vehicle not containing any drug daily for 12 weeks.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Cannabidiol (CBD)", "description": "Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.", "arm_group_labels": ["Cannabidiol (CBD)"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.", "arm_group_labels": ["Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of Maryland, Baltimore+NCT03883360+terminated", "https://www.google.com/search?q=University of Maryland, Baltimore+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by University of Maryland, Baltimore. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a JSON summary about FDA warning letters or clinical holds for Placebo by University of Maryland, Baltimore.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds related to \"Placebo\" by University of Maryland, Baltimore\n2. Specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is about a warning letter to Angela M. Stupi, M.D. dated 08/08/2023. It mentions issues with study drug administration (injecting in forearms instead of required locations), but doesn't specifically mention University of Maryland, Baltimore or placebo issues.\n\nResult [2]: This is about a warning letter to AB Science, a pharmaceutical company, not related to University of Maryland or placebo.\n\nResult [3]: Mentions University of Maryland, Baltimore in relation to \"placebo effects and expectations in pain treatment\" but doesn't indicate any FDA warning letter or clinical hold related to placebo. It's just mentioning research on placebo effects.\n\nResult [4]: General FDA history document, no specific mention of University of Maryland or placebo warnings.\n\nResult [5]: About rosiglitazone's black box warning, not related to University of Maryland or placebo.\n\nResult [6]: About FDA drug risk communications, not specifically about University of Maryland or placebo warnings.\n\nResult [7]: General FDA warning letters page, no specific mention of University of Maryland or placebo.\n\nResult [8]: Some FDA document references, but nothing specific to University of Maryland or placebo.\n\nResult [9]: Mentions a warning letter to Inova Medical Group, not University of Maryland.\n\nResult [10]: Warning letter to Melanie M. Hoppers, M.D., not related to University of Maryland.\n\nResult [11]: Mentions NCT01858896 which is a study related to GLP-1 and Hypoglycemia, but doesn't show any warning letter for University of Maryland regarding placebo.\n\nResult [12]: About Botulinum Toxins coverage, not relevant.\n\nResult [13]: Warning letter to ReConserve of Maryland, Inc. dated 04/11/2025, but this is not University of Maryland, Baltimore and not about placebo.\n\nResult [14]: Medicare program document, not relevant.\n\nResult [15]: Article about a", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of Maryland, Baltimore"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of Maryland, Baltimore about clinical trial NCT03883360 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by University of Maryland, Baltimore about clinical trial NCT03883360 for Placebo\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me examine the search results to see if they contain this information:\n\nResult [1] and [7] both refer to NCT03883360, which is a \"double-blind, randomized, placebo-controlled trial, evaluating the effects of a 12-week treatment course with CBD on psychiatric symptoms, cognition, and cannabis consumption in regular cannabis users with recent-onset psychosis.\" This matches the trial ID mentioned in the query. However, these results only provide basic study details and inclusion/exclusion criteria, not safety issues, adverse events, termination reasons, or regulatory actions.\n\nResult [2] is about radiation oncology clinical trials at University of Maryland, but doesn't mention NCT03883360.\n\nResult [3] is about a phase 1/1b/2 study from NYU, not related to NCT03883360.\n\nResult [4] is general information about mental health diseases from MalaCards, not specific to the trial.\n\nResult [5] is about clinical trials at University of Maryland School of Medicine, but doesn't mention NCT03883360 specifically.\n\nResult [6] is a general page about research and clinical trials at University of Maryland Medical Center, without specific information about NCT03883360.\n\nResult [8] is about the University of Maryland Greenebaum Cancer Center clinical trials search, not specific to NCT03883360.\n\nResult [9] is about an NIH project related to HIV, not related to NCT03883360.\n\nResult [10] is about Sodium oxamate, not related to the trial.\n\nAfter reviewing all the search results, I don't see any:\n1. Press releases from University of Maryland, Baltimore about NCT03883360\n2. Investor presentations mentioning this trial\n3. Public statements about safety issues, adverse events, trial termination, or regulatory actions for this specific trial\n\nThe search results only provide basic information about", "citations": [], "search_params": {"company": "University of Maryland, Baltimore", "nct_id": "NCT03883360", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial's withdrawal is \"not funded,\" which indicates an administrative issue rather than concerns about safety or efficacy. The detailed description does not mention any safety concerns or lack of efficacy that led to the termination of the trial. Therefore, the most likely reason for the trial's failure is administrative, such as a lack of funding or other operational problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:03.253359", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1260}}, "8": {"nct_id": "NCT04516603", "drug_name": "Fampridine SR", "intervention_type": "DRUG", "drug_description": "Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Changement of study design. Restart spring 2021. See new registration number: NCT04652557 (FamH)", "title": "Influence of Fampridine on Working Memory in Healthy Subjects", "start_date": "2040-01-01", "completion_date": "2041-12-31", "sponsor": "Prof. Dominique de Quervain, MD", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.536604", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:05.967245", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Fampridine SR"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "40126943", "title": "Combinatorial approaches increasing neuronal activity accelerate recovery after spinal cord injury.", "authors": [{"name": "Chen B", "authtype": "Author", "clusterid": ""}, {"name": "Gaikwad S", "authtype": "Author", "clusterid": ""}, {"name": "Powell RH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40043557", "title": "Efficacy of pharmacologic treatments for fatigue in multiple sclerosis: A systematic review and meta-analysis.", "authors": [{"name": "Toljan K", "authtype": "Author", "clusterid": ""}, {"name": "Aboseif A", "authtype": "Author", "clusterid": ""}, {"name": "Amin M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39954116", "title": "Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy.", "authors": [{"name": "Jones AA", "authtype": "Author", "clusterid": ""}, {"name": "Purohit R", "authtype": "Author", "clusterid": ""}, {"name": "Bhatt T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "38773595", "title": "4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study.", "authors": [{"name": "Ghazi A", "authtype": "Author", "clusterid": ""}, {"name": "Osinski TL", "authtype": "Author", "clusterid": ""}, {"name": "Feng C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "38582798", "title": "Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail.", "authors": [{"name": "Mavandadi S", "authtype": "Author", "clusterid": ""}, {"name": "Paybast S", "authtype": "Author", "clusterid": ""}, {"name": "Mirzadeh M", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.\n\nThe hypotheses is that fampridine improves working memory performance.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Fampridine SR", "type": "EXPERIMENTAL", "description": "Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.\n\nThe single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t\u00bd = 3.61 h) between experimental and control intervention.", "intervention_names": ["Drug: Fampridine SR"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Identically looking placebo tablets consisting of the identical additives formulated for oral administration.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fampridine SR", "description": "Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).", "arm_group_labels": ["Fampridine SR"]}, {"type": "DRUG", "name": "Placebo", "description": "no active component", "arm_group_labels": ["Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Prof. Dominique de Quervain, MD+NCT04516603+terminated", "https://www.google.com/search?q=Prof. Dominique de Quervain, MD+Fampridine SR+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Fampridine SR by Prof. Dominique de Quervain, MD. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Fampridine SR specifically related to Prof. Dominique de Quervain, MD.\n\nFirst, I need to check if any of the search results mention:\n1. FDA warning letters related to Fampridine SR\n2. Clinical holds for Fampridine SR\n3. Any connection to Prof. Dominique de Quervain, MD\n\nLooking through the search results:\n\nResult [1] discusses FDA reports about seizure risk with dalfampridine (which is the same as fampridine), but doesn't mention any warning letters or clinical holds, nor does it mention Prof. de Quervain.\n\nResult [2] is a PubMed article about Fampridine-SR in multiple sclerosis showing some convulsions as adverse events, but no mention of warning letters, clinical holds, or Prof. de Quervain.\n\nResult [3] mentions FDA staffers expressing concern over MS drug fampridine SR, but it's about a panel meeting and concerns about efficacy rather than a warning letter or clinical hold. No mention of Prof. de Quervain.\n\nResult [4] is about a clinical trial (NCT04652557) on fampridine and working memory, but doesn't mention warning letters or Prof. de Quervain.\n\nResult [5] appears to be an FDA clinical review document for Fampridine Extended Release (NDA 22-250). It mentions:\n- The reviewer recommended a \"complete response\" (not approval)\n- Concerns about \"potential risks and apparently little clinical benefit\"\n- \"It is associated with a known risk of seizures\"\n- Recommendation for REMS strategy if approved\n- Recommendation for postmarket studies on seizures\nBut no specific warning letter to Prof. de Quervain.\n\nResult [6] is another clinical trial (NCT04516603) on fampridine, but no warning letters mentioned.\n\nResult [7] is a PMC article about safety of fampridine, mentioning adverse effects like seizures, but no warning letters or Prof. de Quervain.\n\nResult [8] is a Nature article stating fampridine is \"generally a safe drug\" but no warning letters mentioned.\n\nResult [9] is about post-marketing safety surveillance of dalfampridine, mentioning adverse events but no warning letters to Prof. de Quervain", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD mentioning clinical trial NCT04516603 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to determine if I can provide a JSON summary about SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD related to clinical trial NCT04516603.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD\n- Specifically mentioning clinical trial NCT04516603 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nLet me examine the search results to see if they contain this information:\n\nResult [1]: Australian Official Journal of Patents - This appears to be a patent document with various patent numbers and dates, but doesn't seem to contain SEC filings or information about Prof. de Quervain or clinical trial NCT04516603.\n\nResult [2]: SEC filing detail (https://www.sec.gov/Archives/edgar/data/1403708/000156459021036500/0001564590-21-036500-index.htm) - This is an SEC filing, but I don't see any indication that it's related to Prof. de Quervain or clinical trial NCT04516603. The URL shows a CIK number 1403708, but without seeing the actual content, I can't confirm if it's relevant.\n\nResult [3]: A word list from Northwestern University - Contains various words and terms but doesn't appear to have SEC filings information.\n\nResult [4]: American College of Surgeons bulletin index - Contains medical journal references but doesn't seem to relate to SEC filings or the specific clinical trial.\n\nResult [5]: Behavioral Finance book - Mentions \"de Quervain, Dominique J.-F\" in what appears to be a citation, but this is about a book on behavioral finance, not SEC filings or clinical trials. It does mention \"SEC filings\" in a general context about data analysis, but not specific to Prof. de Quervain.\n\nResult [6]: \"Making up the mind\" book chapter - Contains information about Chris Frith, not Dominique de Quervain, and doesn't relate to SEC filings.\n\nResult [7]:", "citations": [], "search_params": {"company": "Prof. Dominique de Quervain, MD", "nct_id": "NCT04516603", "start_date": "2040-01-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Prof. Dominique de Quervain, MD about clinical trial NCT04516603 for Fampridine SR. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Prof. Dominique de Quervain, MD\n- About clinical trial NCT04516603 for Fampridine SR\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT04516603 is from the search results:\n\nFrom result [7]:\nhttps://www.clinicaltrials.gov/study/NCT04516603\n\"Influence of Fampridine on Working Memory in Healthy Subjects\nProof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants. The hypotheses is that fampridine...\"\n\nSo NCT04516603 is a study titled \"Influence of Fampridine on Working Memory in Healthy Subjects\" which is a proof-of-concept study examining the effects of 10 mg fampridine on working memory in healthy participants.\n\nNow, I need to check if any of the search results contain:\n1. Company press releases\n2. Investor presentations\n3. Public statements by Prof. Dominique de Quervain, MD\n4. Specifically about NCT04516603\n5. Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through each search result:\n\n[1] PubMed article about PR-fampridine in MS (NCT02219932) - Phase III trial\n[2] PubMed article about fampridine-SR in spinal cord injury\n[3] PubMed article about dose comparison of fampridine in MS (Phase II)\n[4] PubMed article about Fampridine-SR in MS (adverse events mentioned)\n[5] Patlynk.com page about NCT00053417 (safety and efficacy study of Fampridine-SR in MS)\n[6] Network of Care page about NCT00127530 (study of Oral Fampridine-SR in MS)\n[7] ClinicalTrials.gov page about NCT04516603 (Influence of Fampridine on Working Memory in Healthy Subjects", "citations": [], "search_params": {"company": "Prof. Dominique de Quervain, MD", "nct_id": "NCT04516603", "drug_name": "Fampridine SR"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states \"Changement of study design. Restart spring 2021.\" This indicates that the trial was withdrawn due to administrative reasons, such as changes in the study design, rather than safety or efficacy concerns. The fact that the study is being restarted under a new registration number (NCT04652557) further supports the conclusion that this was an administrative decision rather than a failure due to safety or lack of efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:05.966028", "claude_model": "claude-3-haiku-20240307", "tokens_used": 961}}, "9": {"nct_id": "NCT04516603", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "no active component", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Changement of study design. Restart spring 2021. See new registration number: NCT04652557 (FamH)", "title": "Influence of Fampridine on Working Memory in Healthy Subjects", "start_date": "2040-01-01", "completion_date": "2041-12-31", "sponsor": "Prof. Dominique de Quervain, MD", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.536936", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:06.006095", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.\n\nThe hypotheses is that fampridine improves working memory performance.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Fampridine SR", "type": "EXPERIMENTAL", "description": "Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.\n\nThe single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t\u00bd = 3.61 h) between experimental and control intervention.", "intervention_names": ["Drug: Fampridine SR"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Identically looking placebo tablets consisting of the identical additives formulated for oral administration.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fampridine SR", "description": "Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).", "arm_group_labels": ["Fampridine SR"]}, {"type": "DRUG", "name": "Placebo", "description": "no active component", "arm_group_labels": ["Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Prof. Dominique de Quervain, MD+NCT04516603+terminated", "https://www.google.com/search?q=Prof. Dominique de Quervain, MD+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by Prof. Dominique de Quervain, MD. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about FDA warning letters or clinical holds for Placebo by Prof. Dominique de Quervain, MD.\n\nThe query is asking specifically about:\n1. FDA warning letters or clinical holds\n2. Related to \"Placebo\" \n3. By Prof. Dominique de Quervain, MD\n4. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is about an FDA warning letter to Novo Nordisk Inc. regarding their promotion of Wegovy, Ozempic, and Victoza. It mentions misleading risk presentation but doesn't relate to Prof. Dominique de Quervain or placebo studies.\n\nResult [2]: This is about FDA cancer drug safety warnings and updates. It doesn't mention Prof. Dominique de Quervain or placebo studies.\n\nResult [3]: This discusses FDA's approach to placebo-controlled trials in the context of vaccines, but doesn't mention Prof. Dominique de Quervain specifically.\n\nResult [4]: This is a retrospective analysis of FDA warning letters to pharmaceutical companies. It discusses general patterns of violations but doesn't mention Prof. Dominique de Quervain.\n\nResult [5]: This is about a clinical trial \"Influence of Luteolin for Two Weeks on Memory in Healthy Subjects\" but doesn't mention Prof. Dominique de Quervain or FDA warning letters related to placebo.\n\nResult [6]: This is a study of warning letters issued to clinical investigators by the FDA, but doesn't specifically mention Prof. Dominique de Quervain.\n\nResult [7]: This mentions \"Dominique de Quervain, MD, Prof. Dr. med.\" in the context of registered ongoing studies related to cannabis evidence, but doesn't mention FDA warning letters or clinical holds related to placebo.\n\nResult [8]: This is general information about FDA warning letters but doesn't mention Prof. Dominique de Quervain.\n\nResult [9]: This is about fampridine and working memory but doesn't mention FDA warning letters or clinical holds.\n\nResult [10]: This mentions \"Dr Dominique de Quervain is a full professor at the Faculty of Medicine and Faculty of Psychology\" but doesn't mention FDA warning letters or clinical holds related to placebo.\n\nResult [11]: This mentions \"Dominique de Quervain, MD, University of Basel\" in relation", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD mentioning clinical trial NCT04516603 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to determine if I can provide a JSON summary about SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD mentioning clinical trial NCT04516603 or related drug safety issues.\n\nThe query is asking for:\n1. SEC EDGAR 8-K filings by Prof. Dominique de Quervain, MD\n2. That mention clinical trial NCT04516603 or related drug safety issues\n3. Including filing dates, CIK number, and specific material events disclosed\n\nLet me examine the search results to see if they contain this information:\n\nResult [1]: Australian Official Journal of Patents - This appears to be patent information from Australia, not SEC filings. No relevant information about the query.\n\nResult [2]: SEC EDGAR filing for \"COGNITION THERAPEUTICS, INC.\" - This is an SEC filing (10-K form), but it's for a company called Cognition Therapeutics, not for Prof. Dominique de Quervain. The filing date appears to be for the fiscal year ended December 31, 2024. There's no mention of clinical trial NCT04516603 or Prof. de Quervain in the visible excerpt.\n\nResult [3]: A word list file from Northwestern University - Contains various words and terms but no SEC filings information.\n\nResult [4]: American College of Surgeons bulletin index - Contains medical journal index information, but no SEC filings.\n\nResult [5]: A book on behavioral finance - Mentions \"de Quervain, Dominique J.-F\" as an author along with others, but this appears to be referencing academic work, not SEC filings. It also mentions \"SEC filings\" in a general context about archival data analysis, but doesn't contain actual SEC filings by de Quervain.\n\nResult [6]: A PDF about \"Making up the mind\" - Contains information about Chris Frith and mentions \"de O Sacks\" but not Dominique de Quervain in the context of SEC filings.\n\nResult [7]: A book titled \"Norms and the Law\" - No relevant information about SEC filings.\n\nResult [8]: A Scribd document with what appears to be a token list - No relevant SEC filing information.\n\nResult [9]: University of Munich dissertation listings - No relevant SEC filing information", "citations": [], "search_params": {"company": "Prof. Dominique de Quervain, MD", "nct_id": "NCT04516603", "start_date": "2040-01-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Prof. Dominique de Quervain, MD about clinical trial NCT04516603 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Prof. Dominique de Quervain, MD\n- Specifically about clinical trial NCT04516603 for Placebo\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT04516603 is from the search results:\n\nFrom result [5] and [7], I can see that NCT04516603 is titled \"Influence of Fampridine on Working Memory in Healthy Subjects\" or \"Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.\"\n\nHowever, the query mentions \"for Placebo\" which suggests it might be a placebo-controlled trial, which makes sense for a study testing the effects of fampridine.\n\nNow, let me check if there are any mentions of Prof. Dominique de Quervain, MD in relation to this specific trial (NCT04516603):\n\nLooking through the search results:\n- Result [1] mentions Dominique de Quervain, MD, University of Basel as the Responsible Party, but it's for a different study (NCT02904109)\n- Result [3] mentions \"Influence of Triflusal on Cognitive Functions in Healthy Subjects (Tribunal-Basel). ClinicalTrials.gov ID NCT02321852. Sponsor Prof. Dominique de Quervain\"\n- Result [9] mentions \"Dominique de Quervain, MD, University of Basel (Responsible Party)\" for NCT01718964\n\nI don't see any direct connection between Prof. Dominique de Quervain and NCT04516603 in the search results. Results [5] and [7] describe NCT04516603 as a \"Proof-of-concept study on the effects of 10 mg fampridine\" but don't mention Prof. de Quervain as being involved.\n\nLet me double-check all results for any mention of NCT04516603 and Prof. de Quervain together:\n- Result", "citations": [], "search_params": {"company": "Prof. Dominique de Quervain, MD", "nct_id": "NCT04516603", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states \"Changement of study design. Restart spring 2021.\" This indicates that the trial was withdrawn due to administrative reasons, such as changes in the study design, rather than safety or efficacy concerns. The fact that the study is being restarted under a new registration number (NCT04652557) further supports the conclusion that this was an administrative decision rather than a failure due to safety or lack of efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:05.966028", "claude_model": "claude-3-haiku-20240307", "tokens_used": 961}}, "10": {"nct_id": "NCT04832438", "drug_name": "9-ING-41", "intervention_type": "DRUG", "drug_description": "15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Replaced by NCT05010629", "title": "9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma", "start_date": "2030-12-18", "completion_date": "2034-06-18", "sponsor": "Actuate Therapeutics Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.537232", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:08.729919", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q9UNL4", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "9-ING-41", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 1, "interactions": [{"protein_a": "JADE1", "protein_b": "H3C12", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "JADE1", "protein_b": "MEAF6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "JADE1", "protein_b": "KAT7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "JADE1", "protein_b": "ING4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "TP53", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3-4", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C12", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C13", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "ING4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "KAT7", "protein_b": "H3C12", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "KAT7", "protein_b": "JADE2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KAT7", "protein_b": "MEAF6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KAT7", "protein_b": "ING4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "H3C1", "combined_score": 0.858, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "H3C13", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "H3-4", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "H3C12", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "ING4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "JADE2", "protein_b": "MEAF6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "JADE2", "protein_b": "ING4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3-4", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "ING4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C12", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H3-4", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H3C1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "ING4", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "H3-4", "protein_b": "H3C1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "H3-4", "protein_b": "ING4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MEAF6", "protein_b": "ING4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ING4", "protein_b": "H3C1", "combined_score": 0.976, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.82, "clustering_coefficient": 2.91}}, "failure_enrichment": {"aact_description": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. It acts through downregulation of NF-\u03baB and decreases the expression NF-\u03baB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.\n\nThe primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3\u03b2 inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.", "aact_documents": [], "pubmed_results": [{"pmid": "40403387", "title": "Phase II study of elraglusib (9-ING-41), a GSK-3\u03b2 inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.", "authors": [{"name": "Mahalingam D", "authtype": "Author", "clusterid": ""}, {"name": "Saeed A", "authtype": "Author", "clusterid": ""}, {"name": "Powell SF", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37982822", "title": "Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3\u03b2 Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.", "authors": [{"name": "Carneiro BA", "authtype": "Author", "clusterid": ""}, {"name": "Cavalcante L", "authtype": "Author", "clusterid": ""}, {"name": "Mahalingam D", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37446056", "title": "GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.", "authors": [{"name": "Huntington KE", "authtype": "Author", "clusterid": ""}, {"name": "Louie AD", "authtype": "Author", "clusterid": ""}, {"name": "Srinivasan PR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "35815408", "title": "Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor, in refractory adult T-Cell leukemia/lymphoma.", "authors": [{"name": "Hsu A", "authtype": "Author", "clusterid": ""}, {"name": "Huntington KE", "authtype": "Author", "clusterid": ""}, {"name": "De Souza A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.", "detailed_description": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. It acts through downregulation of NF-\u03baB and decreases the expression NF-\u03baB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.\n\nThe primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3\u03b2 inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "9-ING-41 plus carboplatin", "type": "EXPERIMENTAL", "description": "Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle", "intervention_names": ["Drug: 9-ING-41", "Drug: Carboplatin"]}], "interventions": [{"type": "DRUG", "name": "9-ING-41", "description": "15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle", "arm_group_labels": ["9-ING-41 plus carboplatin"]}, {"type": "DRUG", "name": "Carboplatin", "description": "Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle", "arm_group_labels": ["9-ING-41 plus carboplatin"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Actuate Therapeutics Inc.+NCT04832438+terminated", "https://www.google.com/search?q=Actuate Therapeutics Inc.+9-ING-41+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for 9-ING-41 by Actuate Therapeutics Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to identify any FDA warning letters or clinical holds specifically for 9-ING-41 by Actuate Therapeutics Inc.\n\nFirst, I need to carefully examine each search result to find information about FDA warning letters or clinical holds related to 9-ING-41.\n\nFrom the search results:\n\n1. Results [1], [3], [5], [6], [10], [12], and [15] mention FDA designations (Fast Track and Orphan Drug Designation) for 9-ING-41/elraglusib for pancreatic cancer treatment. These are positive regulatory actions, not warning letters or clinical holds.\n\n2. Result [2] and [8] mention clinical activity and safety data for 9-ING-41 in specific cancer types, but don't mention any FDA warning letters or clinical holds.\n\n3. Result [4] and [14] describe clinical trials for 9-ING-41 in pediatric patients and advanced cancers, respectively, but don't mention any FDA warning letters or clinical holds.\n\n4. Result [7] and [9] discuss an FDA warning letter, but it appears to be for Applied Therapeutics, not Actuate Therapeutics. Let me examine these more carefully:\n\nResult [7] states: \"In an SEC filing, Applied Therapeutics disclosed that the warning letter addresses issues previously encountered during a study involving 47 children.\" It goes on to describe dosing errors in a study where \"the medication concentration was lower than labeled, resulting in at least 19 subjects receiving only 80% of the protocol-required dose.\"\n\nResult [9] states: \"The Warning Letter to Applied Therapeutics identified critical issues, specifically regarding dosing error, data integrity and protocol adherence issues.\"\n\nThese results are clearly about Applied Therapeutics, not Actuate Therapeutics. The names are similar but they are different companies.\n\n5. Result [11] is Actuate Therapeutics' Form 10-K, which discusses their development of elraglusib (formerly 9-ING-41), but doesn't mention any FDA warning letters or clinical holds.\n\n6. Result [13] mentions FDA Rare Pediatric Disease Designation for elraglusib for Ewing sarcoma, which is another positive regulatory action.\n\nAfter reviewing all the search results, I don't see any FDA warning letters or clinical holds specifically for 9-ING-", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Actuate Therapeutics Inc. mentioning clinical trial NCT04832438 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Actuate Therapeutics Inc. that mention clinical trial NCT04832438 or related drug safety issues.\n\nFirst, I need to identify:\n1. The CIK number for Actuate Therapeutics Inc.\n2. Any 8-K filings that mention NCT04832438\n3. Any drug safety issues mentioned in these filings\n4. Filing dates and specific material events disclosed\n\nFrom the search results, I can see:\n\nCIK number:\n- Result [4] shows: \"ACTUATE THERAPEUTICS, INC. (Filer) CIK : 0001652935 (see all company filings)\"\n- Result [6] also confirms: \"ACTUATE THERAPEUTICS, INC. (Filer) CIK : 0001652935\"\n- Result [8] confirms again: \"ACTUATE THERAPEUTICS, INC. (Filer) CIK : 0001652935\"\n\nSo the CIK number is 0001652935.\n\nNow, let's check if any filings mention NCT04832438:\n\nLooking through all the results, I don't see any specific mention of NCT04832438. Instead, I see references to:\n- Result [1]: \"The Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib in combination with GnP\"\n- Result [1] also mentions: \"topline Phase 2 (Actuate-1801 Part 3B) trial... in first-line treatment of mPDAC\"\n\nSo they're discussing NCT03678883, not NCT04832438.\n\nLet me check if there are any drug safety issues mentioned:\n\nFrom Result [1]:\n- \"that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern\"\n\nFrom Result [2]:\n- \"that elraglusib could be associated", "citations": [], "search_params": {"company": "Actuate Therapeutics Inc.", "nct_id": "NCT04832438", "start_date": "2030-12-18"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Actuate Therapeutics Inc. about clinical trial NCT04832438 for 9-ING-41. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT04832438 for 9-ING-41 (elraglusib) from Actuate Therapeutics Inc., with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results mention NCT04832438:\n\n- Result [9]: https://www.clinicaltrials.gov/study/NCT04832438 - This is about \"9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic...\" for salivary gland carcinomas (SGC)\n- Result [11]: https://ckb-core.genomenon.com/clinicalTrial/show?nctId=NCT04832438 - This shows details about NCT04832438, indicating it's for salivary gland carcinoma with therapies Carboplatin + Elraglusib\n- Result [15]: https://aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials/Detail/NCT04832438 - This describes it as a phase 2, open-label, non-randomized, single institution study investigating 9-ING-41\n- Result [17]: https://trial.medpath.com/drug/548641a0f353f8be/elraglusib - Mentions Actuate Therapeutics presenting Phase II clinical trial data on elraglusib for advanced salivary gland carcinoma at AACR\n- Result [18]: https://www.withpower.com/trial/phase-3-carcinoma-9-2021-0bd30 - Describes the trial as testing 9-ING-41 + Carboplatin for salivary gland cancer\n\nNow, let me check if there are any press releases, investor presentations, or public statements from Actuate Therapeutics specifically about this trial (NCT04832438) that discuss safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLooking through the results:\n\nResult [1]: This is about a Phase 2 study in pancreatic cancer, not NCT04832438 (which is for salivary gland cancer).\n\nResult [", "citations": [], "search_params": {"company": "Actuate Therapeutics Inc.", "nct_id": "NCT04832438", "drug_name": "9-ING-41"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The provided information indicates that the trial was \"WITHDRAWN\" and replaced by a new trial with the ID NCT05010629. The official reason given for the withdrawal is that it was \"Replaced by NCT05010629\". This suggests that the trial was terminated due to administrative or operational reasons, rather than specific safety or efficacy concerns. The trial was likely replaced by a new, updated protocol, leading to the withdrawal of the original trial.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:08.729246", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1399}}, "11": {"nct_id": "NCT04832438", "drug_name": "Carboplatin", "intervention_type": "DRUG", "drug_description": "Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Replaced by NCT05010629", "title": "9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma", "start_date": "2030-12-18", "completion_date": "2034-06-18", "sponsor": "Actuate Therapeutics Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.537525", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:08.767398", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1351", "pref_name": "CARBOPLATIN", "targets": [{"chembl_id": "CHEMBL614931", "ic50_values": [{"value": 37.78, "units": "ug.mL-1"}, {"value": 20110.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614934", "ic50_values": [{"value": 10.75, "units": "ug.mL-1"}, {"value": 9160.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613529", "ic50_values": [{"value": 34.02, "units": "ug.mL-1"}, {"value": 13650.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614197", "ic50_values": [{"value": 153.38, "units": "ug.mL-1"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612700", "ic50_values": [{"value": 10.5, "units": "ug.mL-1"}, {"value": 49700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614354", "ic50_values": [{"value": 6.4, "units": "ug.mL-1"}, {"value": 32400.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614102", "ic50_values": [{"value": 19.0, "units": "ug.mL-1"}, {"value": 60500.0, "units": "nM"}, {"value": 21820.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614140", "ic50_values": [{"value": 5.8, "units": "ug.mL-1"}, {"value": 9700.0, "units": "nM"}, {"value": 15620.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612279", "ic50_values": [{"value": 3000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL386", "ic50_values": [{"value": 2000.0, "units": "nM"}, {"value": 45300.0, "units": "nM"}, {"value": 1830.0, "units": "nM"}, {"value": 44200.0, "units": "nM"}, {"value": 9920.0, "units": "nM"}, {"value": 9700.0, "units": "nM"}, {"value": 10140.0, "units": "nM"}, {"value": 17780.0, "units": "nM"}, {"value": 138000.0, "units": "nM"}, {"value": 9700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL392", "ic50_values": [{"value": 37700.0, "units": "nM"}, {"value": 42300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614925", "ic50_values": [{"value": 13900.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 148730.0, "units": "nM"}, {"value": 28500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613533", "ic50_values": [{"value": 13600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614455", "ic50_values": [{"value": 2500.0, "units": "nM"}, {"value": 6200.0, "units": "nM"}, {"value": 14000.0, "units": "nM"}, {"value": 6000.0, "units": "nM"}, {"value": 52000000.0, "units": "nM"}, {"value": 185000000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614004", "ic50_values": [{"value": 35000.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 6000.0, "units": "nM"}, {"value": 8200.0, "units": "nM"}, {"value": 41600.0, "units": "nM"}, {"value": 18000000.0, "units": "nM"}, {"value": 178000000.0, "units": "nM"}, {"value": 7660.0, "units": "nM"}, {"value": 123270.0, "units": "nM"}, {"value": 16100.0, "units": "nM"}, {"value": 5220.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL383", "ic50_values": [{"value": 2900.0, "units": "nM"}, {"value": 2860.0, "units": "nM"}, {"value": 2900.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614231", "ic50_values": [{"value": 200000000.0, "units": "nM"}, {"value": 200000000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614562", "ic50_values": [{"value": 188030.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614912", "ic50_values": [{"value": 500560.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL400", "ic50_values": [{"value": 1082660.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL396", "ic50_values": [{"value": 60260.0, "units": "nM"}, {"value": 17780.0, "units": "nM"}, {"value": 54600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614206", "ic50_values": [{"value": 2750.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL3879801", "ic50_values": [{"value": 2400.0, "units": "nM"}, {"value": 29100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614279", "ic50_values": [{"value": 36100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614187", "ic50_values": [{"value": 700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL220", "ic50_values": [], "uniprot_id": "A4D2E2"}, {"chembl_id": "CHEMBL226", "ic50_values": [], "uniprot_id": "A6NFY5"}, {"chembl_id": "CHEMBL251", "ic50_values": [], "uniprot_id": "B2R7E0"}, {"chembl_id": "CHEMBL256", "ic50_values": [], "uniprot_id": "A2A3P4"}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL319", "ic50_values": [], "uniprot_id": "P43140"}, {"chembl_id": "CHEMBL315", "ic50_values": [], "uniprot_id": "P15823"}, {"chembl_id": "CHEMBL223", "ic50_values": [], "uniprot_id": "P25100"}, {"chembl_id": "CHEMBL1867", "ic50_values": [], "uniprot_id": "B0LPF6"}, {"chembl_id": "CHEMBL1942", "ic50_values": [], "uniprot_id": "A2RUS0"}, {"chembl_id": "CHEMBL1916", "ic50_values": [], "uniprot_id": "P18825"}, {"chembl_id": "CHEMBL213", "ic50_values": [], "uniprot_id": "B0LPE2"}, {"chembl_id": "CHEMBL210", "ic50_values": [], "uniprot_id": "B0LPE4"}, {"chembl_id": "CHEMBL246", "ic50_values": [], "uniprot_id": "P13945"}, {"chembl_id": "CHEMBL222", "ic50_values": [], "uniprot_id": "B2R707"}, {"chembl_id": "CHEMBL2622", "ic50_values": [], "uniprot_id": "P07943"}, {"chembl_id": "CHEMBL4607", "ic50_values": [], "uniprot_id": "B2R9V1"}, {"chembl_id": "CHEMBL3157", "ic50_values": [], "uniprot_id": "P30411"}, {"chembl_id": "CHEMBL1832", "ic50_values": [], "uniprot_id": "A0A0C4DG16"}, {"chembl_id": "CHEMBL218", "ic50_values": [], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL205", "ic50_values": [], "uniprot_id": "B2R7G8"}, {"chembl_id": "CHEMBL4015", "ic50_values": [], "uniprot_id": "A0AVQ3"}, {"chembl_id": "CHEMBL2414", "ic50_values": [], "uniprot_id": "P51679"}, {"chembl_id": "CHEMBL274", "ic50_values": [], "uniprot_id": "O14692"}, {"chembl_id": "CHEMBL4029", "ic50_values": [], "uniprot_id": "B2R6Q3"}, {"chembl_id": "CHEMBL2434", "ic50_values": [], "uniprot_id": "P25025"}, {"chembl_id": "CHEMBL1901", "ic50_values": [], "uniprot_id": "B2R9Z5"}, {"chembl_id": "CHEMBL221", "ic50_values": [], "uniprot_id": "A8K1V7"}, {"chembl_id": "CHEMBL230", "ic50_values": [], "uniprot_id": "A8K802"}, {"chembl_id": "CHEMBL3356", "ic50_values": [], "uniprot_id": "P05177"}, {"chembl_id": "CHEMBL5282", "ic50_values": [], "uniprot_id": "A7YAE5"}, {"chembl_id": "CHEMBL3622", "ic50_values": [], "uniprot_id": "P33259"}, {"chembl_id": "CHEMBL3397", "ic50_values": [], "uniprot_id": "P11712"}, {"chembl_id": "CHEMBL289", "ic50_values": [], "uniprot_id": "P10635"}, {"chembl_id": "CHEMBL5281", "ic50_values": [], "uniprot_id": "P05181"}, {"chembl_id": "CHEMBL340", "ic50_values": [], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL2056", "ic50_values": [], "uniprot_id": "B2RA44"}, {"chembl_id": "CHEMBL217", "ic50_values": [], "uniprot_id": "P14416"}, {"chembl_id": "CHEMBL234", "ic50_values": [], "uniprot_id": "A1A4V5"}, {"chembl_id": "CHEMBL219", "ic50_values": [], "uniprot_id": "B0M0J7"}, {"chembl_id": "CHEMBL238", "ic50_values": [], "uniprot_id": "A2RUN4"}, {"chembl_id": "CHEMBL252", "ic50_values": [], "uniprot_id": "B2R723"}, {"chembl_id": "CHEMBL206", "ic50_values": [], "uniprot_id": "Q13511"}, {"chembl_id": "CHEMBL242", "ic50_values": [], "uniprot_id": "A8K8K5"}, {"chembl_id": "CHEMBL2034", "ic50_values": [], "uniprot_id": "A0ZXF9"}, {"chembl_id": "CHEMBL3392921", "ic50_values": [], "uniprot_id": "Q91W28"}, {"chembl_id": "CHEMBL231", "ic50_values": [], "uniprot_id": "A8K047"}, {"chembl_id": "CHEMBL1941", "ic50_values": [], "uniprot_id": "B5BUP7"}, {"chembl_id": "CHEMBL402", "ic50_values": [], "uniprot_id": "B7Z3Y9"}, {"chembl_id": "CHEMBL5486", "ic50_values": [], "uniprot_id": "P15127"}, {"chembl_id": "CHEMBL1909043", "ic50_values": [], "uniprot_id": "A6XA80"}, {"chembl_id": "CHEMBL1798", "ic50_values": [], "uniprot_id": "B2R954"}, {"chembl_id": "CHEMBL4358", "ic50_values": [], "uniprot_id": "O19043"}, {"chembl_id": "CHEMBL4644", "ic50_values": [], "uniprot_id": "P41968"}, {"chembl_id": "CHEMBL259", "ic50_values": [], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4608", "ic50_values": [], "uniprot_id": "B0YJ34"}, {"chembl_id": "CHEMBL1951", "ic50_values": [], "uniprot_id": "B4DF46"}, {"chembl_id": "CHEMBL216", "ic50_values": [], "uniprot_id": "P11229"}, {"chembl_id": "CHEMBL211", "ic50_values": [], "uniprot_id": "P08172"}, {"chembl_id": "CHEMBL245", "ic50_values": [], "uniprot_id": "P20309"}, {"chembl_id": "CHEMBL1821", "ic50_values": [], "uniprot_id": "B2RPP4"}, {"chembl_id": "CHEMBL2035", "ic50_values": [], "uniprot_id": "P08912"}, {"chembl_id": "CHEMBL4777", "ic50_values": [], "uniprot_id": "B2R6H5"}, {"chembl_id": "CHEMBL4018", "ic50_values": [], "uniprot_id": "P49146"}, {"chembl_id": "CHEMBL3048", "ic50_values": [], "uniprot_id": "P70594"}, {"chembl_id": "CHEMBL3464", "ic50_values": [], "uniprot_id": "O70515"}, {"chembl_id": "CHEMBL236", "ic50_values": [], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL237", "ic50_values": [], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL233", "ic50_values": [], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL1827", "ic50_values": [], "uniprot_id": "A0AV69"}, {"chembl_id": "CHEMBL250", "ic50_values": [], "uniprot_id": "A3KMC8"}, {"chembl_id": "CHEMBL240", "ic50_values": [], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL1909044", "ic50_values": [], "uniprot_id": "Q690N0"}, {"chembl_id": "CHEMBL4074", "ic50_values": [], "uniprot_id": "O02852"}, {"chembl_id": "CHEMBL4801", "ic50_values": [], "uniprot_id": "B5MDZ1"}, {"chembl_id": "CHEMBL4071", "ic50_values": [], "uniprot_id": "P08311"}, {"chembl_id": "CHEMBL248", "ic50_values": [], "uniprot_id": "P08246"}, {"chembl_id": "CHEMBL332", "ic50_values": [], "uniprot_id": "P03956"}, {"chembl_id": "CHEMBL321", "ic50_values": [], "uniprot_id": "B2R7V9"}, {"chembl_id": "CHEMBL299", "ic50_values": [], "uniprot_id": "B5BU22"}, {"chembl_id": "CHEMBL3385", "ic50_values": [], "uniprot_id": "A8CZ58"}, {"chembl_id": "CHEMBL4040", "ic50_values": [], "uniprot_id": "A8CZ64"}, {"chembl_id": "CHEMBL260", "ic50_values": [], "uniprot_id": "A6ZJ92"}, {"chembl_id": "CHEMBL4445", "ic50_values": [], "uniprot_id": "A1A441"}, {"chembl_id": "CHEMBL203", "ic50_values": [], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL1841", "ic50_values": [], "uniprot_id": "B5BU57"}, {"chembl_id": "CHEMBL1824", "ic50_values": [], "uniprot_id": "B2RZG3"}, {"chembl_id": "CHEMBL258", "ic50_values": [], "uniprot_id": "D3DPP8"}, {"chembl_id": "CHEMBL3243", "ic50_values": [], "uniprot_id": "A0A0A0MT22"}, {"chembl_id": "CHEMBL273", "ic50_values": [], "uniprot_id": "P19327"}, {"chembl_id": "CHEMBL3459", "ic50_values": [], "uniprot_id": "P28564"}, {"chembl_id": "CHEMBL224", "ic50_values": [], "uniprot_id": "B2RAC5"}, {"chembl_id": "CHEMBL1833", "ic50_values": [], "uniprot_id": "B2R9D5"}, {"chembl_id": "CHEMBL225", "ic50_values": [], "uniprot_id": "B1AMW4"}, {"chembl_id": "CHEMBL5017", "ic50_values": [], "uniprot_id": "O70528"}, {"chembl_id": "CHEMBL3371", "ic50_values": [], "uniprot_id": "P50406"}, {"chembl_id": "CHEMBL228", "ic50_values": [], "uniprot_id": "P31645"}, {"chembl_id": "CHEMBL287", "ic50_values": [], "uniprot_id": "D3DRM7"}, {"chembl_id": "CHEMBL249", "ic50_values": [], "uniprot_id": "A8K150"}, {"chembl_id": "CHEMBL2327", "ic50_values": [], "uniprot_id": "A8K7I1"}, {"chembl_id": "CHEMBL3072", "ic50_values": [], "uniprot_id": "P15207"}, {"chembl_id": "CHEMBL1835", "ic50_values": [], "uniprot_id": "B4DJG6"}, {"chembl_id": "CHEMBL1868", "ic50_values": [], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL5144", "ic50_values": [], "uniprot_id": "A5JUT9"}, {"chembl_id": "CHEMBL1889", "ic50_values": [], "uniprot_id": "P37288"}], "has_uniprot_targets": true, "search_name": "Carboplatin"}, "ppi_enrichment": {"uniprot_count": 104, "interactions": [{"protein_a": "CHKA", "protein_b": "CHKB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "PHOSPHO1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "ACHE", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "GPCPD1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "HSPG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "ACHE", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "DOK7", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "HSPG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "PHOSPHO1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHKB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "MAOB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "GPCPD1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHAT", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "COLQ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "PHOSPHO1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "CHKB", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "GPCPD1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DOK7", "protein_b": "COLQ", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HSPG2", "protein_b": "COLQ", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "PHOSPHO1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "CHKB", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "PHOSPHO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADORA2A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADA", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "SLC29A1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "SLC29A1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "ADORA2A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2A", "protein_b": "SLC29A1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "CNR1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "ADORA2A", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CNR1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2B", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2A", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAL", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "ADORA2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAS", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "GNAS", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "ADORA2A", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "ADORA2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADORA2A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADORA2A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1D", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1A", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "TBXA2R", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1D", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1B", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1D", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1A", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "TBXA2R", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "GNA13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1D", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "ADRA1D", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "SNTB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "UTRN", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "ADRA1D", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "SNTB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "TBXA2R", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "SNTB1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "ADRA1A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "GNA13", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ADRA1A", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TBXA2R", "protein_b": "GNA13", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNA13", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNAQ", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "ADRA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNG2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNG2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNG2", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNA13", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SEC24C", "protein_b": "ADRA2B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2C", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2C", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2C", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2C", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "ADRA2C", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2C", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ADRA2C", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "ADRA2C", "protein_b": "GNA13", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "DLG4", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "ADRB1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GCG", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "POMC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "NPPA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "DLG4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "GNAI1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ADRB2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SNX27", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GRK2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "AKAP12", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SAG", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "SAG", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "SAG", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB2", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "AKAP12", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SAG", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "UCP1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "ADRB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "FGF21", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "ADRB3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB3", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "SRC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "FGF21", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "SRC", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "ADRB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAS", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI3", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "SRC", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GNAI1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "YRDC", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "HTR1A", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SNCA", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SCRT1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC18A2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC5A2", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADCY7", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "STX1A", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC5A2", "protein_b": "ADCY7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MTUS1", "protein_b": "AGTR2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "AGTR2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "EDN1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "KNG1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "ACE2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ACE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "EDN1", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "KNG1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "ACE2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "AGTR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "KNG1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "AGTR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AGTR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "ACE", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "EDN1", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "BDKRB2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "AGT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNAQ", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "AGTR1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "BDKRB2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "BDKRB2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "BDKRB2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "BDKRB2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "BDKRB2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "BDKRB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "BDKRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "BDKRB2", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNG2", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNAS", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "ADM", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCB", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "RAMP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNAS", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "ADM", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNG2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNAS", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "ADM", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADM", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCR", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNB1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNAS", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "CALCB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "CALCB", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADM", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADM", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CALCB", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "SLC4A1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "CA2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "TCIRG1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA1", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "SLC4A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "CA2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CA2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CLCN7", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CLCN7", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBSL", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBS", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CA1", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "SLC4A4", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBS", "protein_b": "CBSL", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL13", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL7", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL8", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL5", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL8", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL7", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CXCL8", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL7", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL5", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL17", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL2", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL27", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL27", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCR4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CXCL12", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR4", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "CCR4", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "GRK3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GRK3", "protein_b": "CCR4", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL3", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CXCL12", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL5", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL3", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR1", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL2", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CXCL10", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL3", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL5", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ITIH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL3L1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL5", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CXCL10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3L1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3L1", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL3L1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL3L1", "protein_b": "CCL4", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL6", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL3", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL5", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CCL2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL8", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL12", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL12", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL12", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CCKAR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAI1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GAST", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCKAR", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNG2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNB1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAI1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAS", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCL28", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "PTK7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GAST", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCL28", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "GNB1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCK", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL28", "protein_b": "CCK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCK", "protein_b": "PTK7", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "HPGDS", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGDS", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX15", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGDS", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGDS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGDS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGS2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGDS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGES3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "ALOX5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGDS", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGES3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGDS", "protein_b": "PTGES3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "TP53", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGES", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CXCL8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "IL6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "IL6", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CXCL8", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PLA2G4A", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "PTGS2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "IL6", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "ALOX5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "PTGS2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "IL6", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2B6", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A8", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2B6", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP3A4", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2E1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A8", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2E1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP2E1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A8", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GAPDH", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "PPIG", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4A11", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "ALOX5", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C19", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C9", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4F2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP1A2", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "PPIG", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP4A11", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "ALOX5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C9", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "ALOX5", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP4A11", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "PPIG", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ALOX5", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2C19", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2C19", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ALOX5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2D6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B15", "protein_b": "CYP2D6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "CYP2D6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2D6", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "UGT1A3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A3", "protein_b": "CYP2D6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ADH1B", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "ADH1B", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A4", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A10", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTP1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTM1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "CYP2E1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "GSTP1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GSTP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP3A4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP2E1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "EPHX1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALY", "protein_b": "DRD1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "DRD1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "DRD1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "TMTC1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "DRD1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "DRD1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "DRD1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "TMTC1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "ADCYAP1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "POMC", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "NCS1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB2", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG7", "combined_score": 0.701, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG2", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "DRD3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD1", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD3", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "DRD3", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "DRD1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "BDNF", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "KLHL12", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD3", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "MAOA", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DRD2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "BDNF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TH", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SYNGR3", "protein_b": "SLC6A3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "FLOT1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "CAMK2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "TH", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SNCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "TH", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "SLC18A2", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "TH", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SNCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRB", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRB", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "KNG1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "GNA13", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "AGT", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDNRB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN2", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDNRB", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDN1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "KNG1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "GNA13", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NRIP1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SP1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SRC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA2", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA3", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "JUN", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "JUN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "MED1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SP1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "JUN", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "SRC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "FKBP5", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "STIP1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "PTGES3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "NR3C1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSPA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSPA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "STIP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "PTGES3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AB1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "PTGES3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "FKBP5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "FKBP5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FKBP5", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HRH1", "combined_score": 0.722, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "HRH1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "PLCB3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HRH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PLCB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HRH1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PLCB3", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PLCB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HRH1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "PLCB3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "TRPV1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "ATP4A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "GAST", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "GAST", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "GAST", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "HRH2", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HRH2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SQLE", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDFT1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDPS", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "INSIG1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "HMGCR", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "INSIG1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDPS", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCR", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDFT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDFT1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDPS", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "INSIG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "INSIG1", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "HMGCS2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDFT1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDPS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDPS", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDFT1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDPS", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDFT1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "HMGCS2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "SREBF2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "SREBF2", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "HMGCS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "FDFT1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "HMGCS2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "FDFT1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "HMGCS2", "protein_b": "FDFT1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "LTC4S", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "LTB4R2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR1", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "TBXA2R", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR2", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "TBXA2R", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "ALOX5AP", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTB4R2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "GNAQ", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTC4S", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "CYSLTR1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LTB4R2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CYSLTR1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5AP", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "LTB4R2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "CYSLTR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "LTB4R2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "TBXA2R", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5AP", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALOX5", "protein_b": "ALOX5AP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CTSZ", "protein_b": "MC3R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "LEP", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "POMC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "AGRP", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "MC3R", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "NPY", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "GHRL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ASIP", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "LEP", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "NPY", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "MRAP2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "GHRL", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ATP7A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "AGRP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "ASIP", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ATP7A", "protein_b": "POMC", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ASIP", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MRAP2", "protein_b": "MC5R", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "MC5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DBH", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DDC", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "COMT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "LRTOMT", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "AOC3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "ALDH2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC3", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOA", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "AOC3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DBH", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DDC", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DBH", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DDC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "COMT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOA", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOB", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "CYP2D6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "MAOB", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "AOC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DDC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DBH", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DBH", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DDC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "MAOB", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "CYP2D6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "AOC1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DBH", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DDC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "DBH", "protein_b": "DDC", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "DDC", "protein_b": "AOC1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR6", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "ARRB1", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR5", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR4", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "F2R", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "KNG1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR4", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR3", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "CHRM2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "ARRB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR4", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR5", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "CHRM2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "LPAR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "LPAR4", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "ARRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "AGTRAP", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNA15", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG12", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GRM5", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CHRM1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "NPY1R", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GHRL", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY1R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PPY", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY1R", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PYY", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY5R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNB1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY5R", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI3", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "NPY5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY5R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PRPH2", "protein_b": "NPY2R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY2R", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "POMC", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GLP1R", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "POMC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNG2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNB1", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PPY", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PYY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "POMC", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GLP1R", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "GLP1R", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "POMC", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "POMC", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "GNB1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PPY", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE6G", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE6G", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE2A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE5A", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUCY1B1", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE2A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "ITPA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "APRT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUK1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE5A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUCY1B1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUCY1B1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ALDH7A1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CCR1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PTAFR", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TLR4", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PTAFR", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ARRB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "TLR4", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "PTAFR", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "ARRB1", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "PTAFR", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TLR4", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "PTAFR", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "FPR2", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GPR135", "protein_b": "PTAFR", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "ARRB1", "protein_b": "PTAFR", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "TYK2", "protein_b": "PTAFR", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "PECAM1", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "FPR2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP8", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "GSDMD", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "IL1B", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "PYCARD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "GSDMD", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "IL1B", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP6", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP6", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "AIM2", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRC4", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "GSDMD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP8", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "GSDMD", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP8", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "GSDMD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRP1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "GSDMD", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRC4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "GSDMD", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "GSDMD", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "GSDMD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSDMD", "protein_b": "NLRP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINB4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "MMP9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "MMP9", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "MMP9", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "MMP9", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "ELANE", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPINA3", "protein_b": "ELANE", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SLPI", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "DEFA4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "SERPINA1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "DEFA4", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "DEFA4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "SLPI", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "DEFA4", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "DEFA4", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "SERPINA1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "DEFA4", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "DEFA4", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DEFA4", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLPI", "protein_b": "ELANE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPINA1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "STAT3", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "IL1B", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "IL1B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "STAT3", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP9", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP7", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "TIMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "IL1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP9", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "TIMP2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "STAT3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP9", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP9", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP3", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP9", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "MMP1", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "BSG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "MMP9", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "THBS1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "LCN2", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "CD44", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "MMP9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "TIMP3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "ELN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DMP1", "protein_b": "MMP9", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "CD44", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "MMP9", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "LCN2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCD", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCB", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PICK1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "NCF1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "MTOR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLD1", "protein_b": "PRKCA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCB", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "SDC4", "protein_b": "PRKCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PICK1", "protein_b": "PRKCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "RACK1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "RACK1", "protein_b": "PRKCB", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "FOS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "FOS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "MAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAPK3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "RPS6KA1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "PTPN7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "FOS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "FOS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "RPS6KA1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "STAT3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PEA15", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MKNK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "JUN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "JUN", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPKAPK2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ATF2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK14", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAPK14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "JUN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K6", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "DUSP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "ATF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "ATF2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "TP53", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MAP2K3", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAPKAPK3", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "JUN", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAP2K6", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAPKAPK3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "RCAN1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3R2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML6", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML5", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALM3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "NFATC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RCAN1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "RCAN1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3R2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3R2", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CB", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CB", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "CALML4", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CB", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "NFATC1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "CALML4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3CA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "CALML4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "NFATC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "CALML4", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "PPP3R2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "PPP3R2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "PTK2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LCK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SHC1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "FYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "LYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LCK", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LYN", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SHC1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "FYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SH2D1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SH2D1A", "protein_b": "LCK", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "DLG4", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LCK", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LYN", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "HSP90AA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SHC1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRG1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "HSP90AA1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SRC", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "CD44", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "ERBB4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SHC1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SRC", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "CD44", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ERBB4", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "GRB2", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "CD44", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SRC", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CD44", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "VAV1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCP2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD28", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD28", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "PTPRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD247", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "ZAP70", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "PTPRC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD28", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PTPRC", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "FYN", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "VAV1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD8A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD247", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "VAV1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD8A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SYK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD247", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "PTPRC", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "VAV1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "PTPRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "PTPRC", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "VAV1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VAV1", "protein_b": "LCK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LYN", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SPN", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "DPP4", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD22", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "SPN", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "PTPRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "SPN", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "PTPRC", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "LCK", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPP4", "protein_b": "PTPRC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD47", "protein_b": "PTPRC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LYN", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "SPN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GRM2", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GRM2", "protein_b": "HTR2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2C", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2B", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1F", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1S", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1F", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1S", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1F", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1S", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1S", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1F", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "HTR2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "CACNA1F", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CACNA1F", "protein_b": "HTR2A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNG2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNB1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "GNG2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNB1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR2A", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HTR2A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "FSHB", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "HTR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GIP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "NPPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "FSHB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GCG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "ADCYAP1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "VIP", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "POMC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "HTR7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GNAS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HTR7", "protein_b": "GNAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "VIP", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "FSHB", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "ADCYAP1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TPH1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A4", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOA", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "TPH2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "TPH2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "BDNF", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "MAOA", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR1B", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR2A", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR1B", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR1B", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR2A", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "HTR2A", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR2A", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "BDNF", "protein_b": "HTR2A", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SIGMAR1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "ERG28", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "MSMO1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SQLE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TMEM97", "protein_b": "SIGMAR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SQLE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SIGMAR1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "MSMO1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SIGMAR1", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SQLE", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SIGMAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNA4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR3", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNH6", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "HSPA5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "HSPA5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSPA5", "protein_b": "ITPR3", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "KCNA4", "protein_b": "KCNH6", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TAC1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "NTS", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TACR1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "UNC80", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC3", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "UNC80", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TACR1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "UNC80", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNAS", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "ARRB1", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "UNC80", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TACR2", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TACR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "CHKB", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TACR2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "CHKB", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "TAC3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "TBXAS1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "TBXAS1", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "TBXAS1", "protein_b": "MGAM2", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR2", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNB1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "ADCYAP1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIP", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "WASL", "protein_b": "VIPR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNB1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIPR1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNAS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNB1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ATG5", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADCYAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1B", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVP", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR2", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1B", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1B", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA14", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR1B", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "VIP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "GNA13", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVPR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AVP", "protein_b": "AVPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "AVPR2", "combined_score": 0.742, "interaction_type": "physical"}], "network_features": {"avg_degree": 10.73, "clustering_coefficient": 5.36}}, "failure_enrichment": {"aact_description": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. It acts through downregulation of NF-\u03baB and decreases the expression NF-\u03baB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.\n\nThe primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3\u03b2 inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.", "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41228347", "title": "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.", "authors": [{"name": "Fedele P", "authtype": "Author", "clusterid": ""}, {"name": "Stucci SL", "authtype": "Author", "clusterid": ""}, {"name": "Landriscina M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41225446", "title": "Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021).", "authors": [{"name": "Damato A", "authtype": "Author", "clusterid": ""}, {"name": "Maglietta G", "authtype": "Author", "clusterid": ""}, {"name": "Antonuzzo L", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41213670", "title": "NEOadjuvant Dendritic cell therapy added to first line standard of care in advanced epithelial Ovarian Cancer (NEODOC): protocol of a first-in-human, exploratory, single-centre phase I/II trial in the Netherlands.", "authors": [{"name": "Koeneman B", "authtype": "Author", "clusterid": ""}, {"name": "Schreibelt G", "authtype": "Author", "clusterid": ""}, {"name": "Duiveman-de Boer T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209621", "title": "Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.", "authors": [{"name": "Skoulidis F", "authtype": "Author", "clusterid": ""}, {"name": "Borghaei H", "authtype": "Author", "clusterid": ""}, {"name": "Garon EB", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.", "detailed_description": "9-ING-41 is a small molecule potent selective GSK-3\u03b2 inhibitor with antitumor activity. It acts through downregulation of NF-\u03baB and decreases the expression NF-\u03baB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \\[ACC\\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.\n\nThe primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3\u03b2 inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "9-ING-41 plus carboplatin", "type": "EXPERIMENTAL", "description": "Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle", "intervention_names": ["Drug: 9-ING-41", "Drug: Carboplatin"]}], "interventions": [{"type": "DRUG", "name": "9-ING-41", "description": "15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle", "arm_group_labels": ["9-ING-41 plus carboplatin"]}, {"type": "DRUG", "name": "Carboplatin", "description": "Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle", "arm_group_labels": ["9-ING-41 plus carboplatin"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Actuate Therapeutics Inc.+NCT04832438+terminated", "https://www.google.com/search?q=Actuate Therapeutics Inc.+Carboplatin+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Carboplatin by Actuate Therapeutics Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a JSON summary about FDA warning letters or clinical holds for Carboplatin by Actuate Therapeutics Inc.\n\nThe query is asking specifically about:\n1. FDA warning letters or clinical holds for Carboplatin\n2. By Actuate Therapeutics Inc.\n3. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult 1: About Actuate Therapeutics providing FDA with updated clinical data for elraglusib (not Carboplatin) for pancreatic cancer.\n\nResult 2: About recent FDA cancer drug safety warnings, but doesn't mention Actuate Therapeutics or Carboplatin specifically.\n\nResult 3: Actuate Therapeutics Form 10-K, mentions elraglusib but not Carboplatin.\n\nResult 4: General FDA warning letters page, no specific information about Actuate or Carboplatin.\n\nResult 5: Actuate Therapeutics announcement about FDA Fast Track Designation for 9-ING-41 (not Carboplatin) for pancreatic cancer.\n\nResult 6: PDF about drug-drug interactions with anticancer drugs, mentions carboplatin briefly but not in relation to Actuate Therapeutics.\n\nResult 7: Pfizer's carboplatin injection boxed warning information, but this is from Pfizer, not Actuate Therapeutics.\n\nResult 8: SEC filing for Actuate Therapeutics, mentions \"warning letters\" in general but doesn't specify anything about Carboplatin.\n\nResult 9: ClinicalTrials.gov entry for \"9-ING-41 Plus Carboplatin in Salivary Gland...\" - this shows Actuate is using carboplatin in combination with their drug 9-ING-41, but doesn't mention any warning letters or clinical holds.\n\nResult 10: About gene- and immune-targeted therapy combinations, not relevant to the query.\n\nResult 11: SEC filing mentioning Actuate, but not about Carboplatin warning letters.\n\nResult 12: About antibody-drug conjugates, not relevant.\n\nResult 13: FDA untitled letters page, no specific information about Actuate or Carboplatin.\n\nResult 14: About PEGylated lipid nanoparticle formulations, not relevant.\n\nResult 15: Same as result 1, about Actuate providing FDA with updated clinical data for elraglusib.\n\nResult 16: FDA grants elrag", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Actuate Therapeutics Inc. mentioning clinical trial NCT04832438 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Actuate Therapeutics Inc. that mention clinical trial NCT04832438 or related drug safety issues.\n\nFirst, let me identify the key information requested:\n1. SEC EDGAR 8-K filings by Actuate Therapeutics Inc.\n2. That mention clinical trial NCT04832438 or related drug safety issues\n3. Include filing dates, CIK number, and specific material events disclosed\n\nLet me go through the search results to find relevant information:\n\nFrom result [1]:\n- This is a Form 8-K filed by Actuate Therapeutics, Inc.\n- Date of report: May 31, 2025\n- CIK: 0001652935 (implied from the EDGAR data path)\n- Mentions the Actuate-1801 Part 3B study (NCT03678883), which is a Phase 2 trial of elraglusib in combination with GnP\n- The trial is for first-line treatment of metastatic pancreatic cancer\n- The trial met primary endpoints and achieved statistical significance\n- However, this mentions NCT03678883, not NCT04832438\n\nFrom result [2]:\n- Another Form 8-K filed by Actuate Therapeutics, Inc.\n- Date of report: May 31, 2025\n- Mentions the same Actuate-1801 Part 3B trial (NCT03678883)\n- Discusses topline Phase 2 data of elraglusib\n- Contains forward-looking statements about clinical trials\n- Mentions risks related to \"elraglusib could be associated with side effects, adverse events or other properties or safety risks\"\n- But again, this refers to NCT03678883, not NCT04832438\n\nFrom result [3]:\n- Form 8-K filed on September 10, 2025\n- This appears to be about a stock offering, not clinical trial data\n- No mention of clinical trials or safety issues\n\nFrom result [4]:\n- Form 8-K filed on December 17, 202", "citations": [], "search_params": {"company": "Actuate Therapeutics Inc.", "nct_id": "NCT04832438", "start_date": "2030-12-18"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Actuate Therapeutics Inc. about clinical trial NCT04832438 for Carboplatin. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT04832438 for Carboplatin, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results mention NCT04832438:\n\n- Result [9]: CKB (Cancer Knowledgebase) entry for NCT04832438, which states it's a Phase II trial for \"9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma\" with status \"Withdrawn\"\n- Result [11]: ClinicalTrials.gov entry for NCT04832438, describing it as \"a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3\u03b2) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC)\"\n- Result [13]: Another entry for NCT04832438 from Aging.NetworkofCare.org, describing it as \"a phase 2, open-label, non-randomized, single institution study\"\n- Result [14]: Biotech Hunter entry showing NCT04832438 as \"Withdrawn\" with start date Dec 18, 2030 (which seems like a future date and likely an error) and completion date Jun 18, 2034\n- Result [16]: WithPower entry describing the trial as testing \"9-ING-41 + Carboplatin for Salivary Gland Cancer\"\n\nNow, let me check if there are any press releases, investor presentations, or public statements from Actuate Therapeutics specifically about this trial:\n\nLooking through the other search results:\n- Results [1], [3], [4], [5], [6], [7], [10], [12] are about other trials (mainly pancreatic cancer trials with elraglusib/GnP combinations)\n- Results [2] and [8] are corporate presentations, but the snippets don't specifically mention NCT04832438\n\nI don't see any specific press releases, investor presentations, or", "citations": [], "search_params": {"company": "Actuate Therapeutics Inc.", "nct_id": "NCT04832438", "drug_name": "Carboplatin"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The provided information indicates that the trial was \"WITHDRAWN\" and replaced by a new trial with the ID NCT05010629. The official reason given for the withdrawal is that it was \"Replaced by NCT05010629\". This suggests that the trial was terminated due to administrative or operational reasons, rather than specific safety or efficacy concerns. The trial was likely replaced by a new, updated protocol, leading to the withdrawal of the original trial.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:08.729246", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1399}}, "12": {"nct_id": "NCT01796795", "drug_name": "SR-T100 gel with 1.0% of SM", "intervention_type": "DRUG", "drug_description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Budget issue.", "title": "Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients", "start_date": "2030-09-30", "completion_date": "2033-08-31", "sponsor": "G&E Herbal Biotechnology Co., LTD", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.537919", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:11.826538", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "SR-T100 gel with 1.0% of SM"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "vehicle gel", "type": "PLACEBO_COMPARATOR", "description": "The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: Vehicle gel"]}, {"label": "SR-T100 gel with 1.0% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 1.0% of SM"]}, {"label": "SR-T100 gel with 2.3% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 2.3% of SM"]}], "interventions": [{"type": "DRUG", "name": "Vehicle gel", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["vehicle gel"]}, {"type": "DRUG", "name": "SR-T100 gel with 1.0% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 1.0% of SM"]}, {"type": "DRUG", "name": "SR-T100 gel with 2.3% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 2.3% of SM"]}]}}, "company_search_urls": ["https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+NCT01796795+terminated", "https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+SR-T100 gel with 1.0% of SM+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for SR-T100 gel with 1.0% of SM by G&E Herbal Biotechnology Co., LTD. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for SR-T100 gel with 1.0% of SM by G&E Herbal Biotechnology Co., LTD.\n\nFirst, I need to identify which search results might contain relevant information about FDA warning letters or clinical holds related to SR-T100.\n\nResult [1]: This is about a clinical trial (NCT01493921) for SR-T100 Gel in Actinic Keratosis. It mentions \"Violation: Shown when the FDA issues a Notice of Noncompliance and posts the Notice of Noncompliance on its designated webpage.\" However, this appears to be a standard template text that's part of the clinicaltrials.gov display format, not an actual indication that a violation occurred for this specific trial. There's no specific mention of a warning letter or clinical hold.\n\nResult [2]: This is about a clinical trial (NCT01796821) for SR-T100 Gel on External Genital Warts. There's no mention of FDA warning letters or clinical holds.\n\nResult [3]: This is about intellectual property patents for SR-T100 being approved in the USA, South Africa, and New Zealand. No mention of FDA warning letters or clinical holds.\n\nResult [4]: This is about a Phase II study (NCT01516515) of SR-T100 to treat Actinic Keratosis. No mention of FDA warning letters or clinical holds.\n\nResult [5]: This is the FDA Warning Letters page. It shows a table of warning letters, but I don't see any specific warning letter addressed to \"G&E Herbal Biotechnology Co., LTD\" or related to \"SR-T100\" in the excerpt provided. The companies listed include \"Taizhou Kangping Medical Science and Technology Co., Ltd.\", \"Compass Group USA\", \"Miers Laboratories, Ltd\", etc., but not G&E Herbal Biotechnology.\n\nResult [6]: This is an article about FDA posting more than 100 warning and untitled letters, but it specifically mentions these are related to an \"ad crackdown\" and GLP-1 drugs. No specific mention of SR-T100 or G&E Herbal Biotechnology.\n\nResult [7]: This is about a clinical trial (NCT01796795) for SR-T", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD mentioning clinical trial NCT01796795 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD that mention clinical trial NCT01796795 or related drug safety issues.\n\nFirst, let me understand what I'm looking for:\n1. SEC EDGAR Form 8-K filings by G&E Herbal Biotechnology Co., LTD\n2. That mention clinical trial NCT01796795\n3. Or related drug safety issues\n4. I need to extract filing dates, CIK number, and specific material events disclosed\n\nLet me go through the search results to see if they contain this information:\n\nResult [1]: This is from G&E Herbal Biotechnology's website, describing the company as a biopharmaceutical company focused on botanical extraction. It mentions they do clinical trials but doesn't provide specific SEC filings or the NCT01796795 trial.\n\nResult [2]: This shows an SEC Form 8-K filing, but it's for RIGEL PHARMACEUTICALS INC (CIK: 0001034842), not G&E Herbal Biotechnology. The filing date is 2005-12-02. This isn't relevant to our query.\n\nResult [3]: This is from G&E Herbal Biotechnology's website about their profile. It mentions they have conducted Phase III clinical trials for actinic keratosis treatment & Bowen's disease, and Phase II clinical trials in the USA for actinic keratosis treatment & Bowen's disease and for Genital Wart. However, it doesn't mention NCT01796795 specifically or provide SEC filing information.\n\nResult [4]: This appears to be a SEC filing for Benitec Biopharma Inc., not G&E Herbal Biotechnology. It discusses their clinical trials for BB-301 for Oculopharyngeal Muscular Dystrophy, but doesn't mention NCT01796795.\n\nResult [5]: This mentions Solamargine, which was \"Initially developed by G&E Herbal Biotechnology Co., Ltd.\" It states \"Now, its global highest R&D status is...\" but doesn't complete the information. It doesn't mention NCT01796795 or provide SEC filing details.\n\nResult [6]: This appears to be a", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "start_date": "2030-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by G&E Herbal Biotechnology Co., LTD about clinical trial NCT01796795 for SR-T100 gel with 1.0% of SM. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by G&E Herbal Biotechnology Co., LTD regarding clinical trial NCT01796795 for SR-T100 gel with 1.0% of SM, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT01796795 is from the search results:\n\nFrom result [1]:\n\"NCT01796795 - Suspended - Phase 2 - A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.\"\n\nFrom result [2]:\n\"Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients - This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in...\"\n\nFrom result [6] and [9]:\nSimilar descriptions of the trial.\n\nSo NCT01796795 is a Phase 2 clinical trial evaluating SR-T100 gel (with 1.0% and 2.3% of SM - Solamargine) for the treatment of common warts.\n\nNow, let me check if there are any company press releases, investor presentations, or public statements about this specific trial, particularly focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFrom result [1]:\n- The trial is listed as \"Suspended\"\n- No specific reason for suspension is mentioned\n\nFrom result [2]:\n- The trial status is listed as \"Suspended\"\n- No specific reason for suspension is mentioned\n- There are some inclusion/exclusion criteria mentioned, including:\n  * \"Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests.\"\n  * \"Patient in good general health condition (performance status \u2264 2 Eastern Cooperative Oncology Group (ECOG)).\"\n  * \"Patient has a history of allergy or sensitivity to Solanum undatum plant extract, SM, or SR-T100 gel excipients including carbomer, propylene glycol, and", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "drug_name": "SR-T100 gel with 1.0% of SM"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The provided information indicates that the trial was suspended due to a \"budget issue,\" which suggests an administrative or operational problem rather than issues related to safety or efficacy. The lack of detailed description and published results further supports the conclusion that this was an administrative failure rather than a failure due to safety concerns or lack of efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:11.825190", "claude_model": "claude-3-haiku-20240307", "tokens_used": 859}}, "13": {"nct_id": "NCT01796795", "drug_name": "SR-T100 gel with 2.3% of SM", "intervention_type": "DRUG", "drug_description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Budget issue.", "title": "Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients", "start_date": "2030-09-30", "completion_date": "2033-08-31", "sponsor": "G&E Herbal Biotechnology Co., LTD", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.538243", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:11.865858", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "SR-T100 gel with 2.3% of SM"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "vehicle gel", "type": "PLACEBO_COMPARATOR", "description": "The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: Vehicle gel"]}, {"label": "SR-T100 gel with 1.0% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 1.0% of SM"]}, {"label": "SR-T100 gel with 2.3% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 2.3% of SM"]}], "interventions": [{"type": "DRUG", "name": "Vehicle gel", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["vehicle gel"]}, {"type": "DRUG", "name": "SR-T100 gel with 1.0% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 1.0% of SM"]}, {"type": "DRUG", "name": "SR-T100 gel with 2.3% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 2.3% of SM"]}]}}, "company_search_urls": ["https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+NCT01796795+terminated", "https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+SR-T100 gel with 2.3% of SM+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for SR-T100 gel with 2.3% of SM by G&E Herbal Biotechnology Co., LTD. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for SR-T100 gel with 2.3% of SM by G&E Herbal Biotechnology Co., LTD.\n\nFirst, let's identify all the relevant information about SR-T100 gel from the search results:\n\n1. From result [2]: There's a clinical trial NCT01796821 about \"Efficacy and Safety Profiles of SR-T100 Gel on External Genital...\" which mentions SR-T100 gel containing 1.0% and 2.3% SM (Solanum undatum plant extract).\n\n2. From result [3]: There's a clinical trial NCT01493921 about \"Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic...\" which mentions SR-T100 gel.\n\n3. From result [5]: There's a clinical trial NCT01516515 about \"Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic...\" which specifically mentions \"SR-T100 gel with 2.3% of SM in Solanum undatum plant extract\".\n\n4. From result [6]: There's a news article about \"G&E Herbal Biotech achievement for the New Drug Development of SR-T100 Gel at the National pharmaceutical Technology & Research Development Award.\"\n\n5. From result [7]: There's a clinical trial NCT01796795 about \"Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients\" which mentions \"SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM\".\n\n6. From result [9]: There's a clinical trial NCT02085395 about \"Assessment of SR-T100 Topical Gel...\"\n\nNow, let's look for any FDA warning letters or clinical holds related to SR-T100 gel:\n\n1. Result [1] is an FDA warning letter, but it's for \"Health and Natural Beauty USA Corp.\" regarding violations of CGMP regulations for finished pharmaceuticals. It mentions issues with testing for diethylene glycol (DEG) or ethylene glycol (EG) contamination in components like glycerin and", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD mentioning clinical trial NCT01796795 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD that mention clinical trial NCT01796795 or related drug safety issues.\n\nLet me go through the search results systematically:\n\n1. Result [1] - This is from G&E Herbal Biotechnology's website (en.geherbs.com). It describes the company as a biopharmaceutical company focused on botanical extraction. It mentions they do clinical trials but doesn't specifically reference NCT01796795 or any SEC filings.\n\n2. Result [2] - This is about Generex Biotechnology Corp SEC filings, not G&E Herbal Biotechnology. The CIK is 0001059784.\n\n3. Result [3] - Another page from G&E Herbal Biotechnology's website (en.geherbs.com) describing their company profile. It mentions they conduct clinical trials including Phase III trials for actinic keratosis treatment & Bowen's disease, and Phase II trials in the USA for actinic keratosis treatment & Bowen's disease and for Genital Wart. However, it doesn't mention NCT01796795 specifically or any SEC filings.\n\n4. Result [4] - This is an EDGAR filing for RIGEL PHARMACEUTICALS INC, not G&E Herbal Biotechnology.\n\n5. Result [5] - This is about Solamargine, mentioning G&E Herbal Biotechnology Co., Ltd as the initial developer, but doesn't reference NCT01796795 or SEC filings.\n\n6. Result [6] - This is about Benitec Biopharma Inc, not G&E Herbal Biotechnology.\n\n7. Result [7] - Another page from G&E Herbal Biotechnology's website (en.geherbs.com) about investor information, but doesn't mention specific SEC filings or NCT01796795.\n\n8. Result [8] - This appears to be a 10-K filing but doesn't clearly identify the company. It contains general risk factors related to biopharmaceutical development but doesn't specifically mention G&E Herbal Biotechnology or NCT01796795.\n\n9. Result [9] - This is a Form 8-K for Generex Biotechnology, not G&E Herbal Biotechnology.\n\n", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "start_date": "2030-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by G&E Herbal Biotechnology Co., LTD about clinical trial NCT01796795 for SR-T100 gel with 2.3% of SM. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about the safety evidence for clinical trial NCT01796795 for SR-T100 gel with 2.3% of SM (Solamargine).\n\nFirst, let me identify what NCT01796795 is about:\n- From result [1], it's \"A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients\"\n- From result [2], it's described as \"This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.\"\n- From result [6] and [9], similar descriptions are provided.\n\nNow, let's look for information about the status of this trial:\n- From result [1], it shows NCT01796795 as \"Suspended\" with \"Phase 2\"\n- From result [2], it states \"Suspended\" with \"Current as of October 02, 2025\"\n\nI need to find information about why it was suspended, any safety issues, adverse events, or regulatory actions.\n\nLooking through the results:\n\nResult [1] shows:\n- NCT01796795 is listed as \"Suspended\" (Phase 2)\n- Other trials by the same company:\n  - NCT02559934: \"Completed\" (Phase 1) - An Open-label, Multiple-dose, Pharmacokinetic Study of SR-T100 Gel\n  - NCT01796821: \"Completed\" (Phase 2) - A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts\n\nResult [2] provides more details about NCT01796795:\n- It mentions inclusion criteria including \"Patient is judged to be in good health based upon the results of physical examinations (PEs), medical history, and safety laboratory tests\"\n- Exclusion criteria: \"Patient has a history of allergy or sensitivity to Solanum", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "drug_name": "SR-T100 gel with 2.3% of SM"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The provided information indicates that the trial was suspended due to a \"budget issue,\" which suggests an administrative or operational problem rather than issues related to safety or efficacy. The lack of detailed description and published results further supports the conclusion that this was an administrative failure rather than a failure due to safety concerns or lack of efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:11.825190", "claude_model": "claude-3-haiku-20240307", "tokens_used": 859}}, "14": {"nct_id": "NCT01796795", "drug_name": "Vehicle gel", "intervention_type": "DRUG", "drug_description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Budget issue.", "title": "Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients", "start_date": "2030-09-30", "completion_date": "2033-08-31", "sponsor": "G&E Herbal Biotechnology Co., LTD", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.538598", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:11.906338", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL2108661", "pref_name": "VEHICLE", "targets": [], "has_uniprot_targets": false, "search_name": "Vehicle gel"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "40906626", "title": "Efficacy and safety of a medical device based on hyaluronic acid and amino acids for the topical treatment of hard-to-heal skin ulcers: a pilot clinical trial.", "authors": [{"name": "Romanelli M", "authtype": "Author", "clusterid": ""}, {"name": "Michelucci A", "authtype": "Author", "clusterid": ""}, {"name": "Reggiardo G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40846240", "title": "Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study.", "authors": [{"name": "Schlesinger T", "authtype": "Author", "clusterid": ""}, {"name": "Chapman MS", "authtype": "Author", "clusterid": ""}, {"name": "Tu JH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40843233", "title": "Impact of Microencapsulated Benzoyl Peroxide on the Skin Microbiome and Clinical Outcomes in Rosacea: An Update on a Randomized, Double-blind, Crossover, Vehicle-controlled Clinical Trial.", "authors": [{"name": "Nong Y", "authtype": "Author", "clusterid": ""}, {"name": "Sugarman J", "authtype": "Author", "clusterid": ""}, {"name": "York JP", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40773616", "title": "Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne.", "authors": [{"name": "Kircik LH", "authtype": "Author", "clusterid": ""}, {"name": "Harper JC", "authtype": "Author", "clusterid": ""}, {"name": "Gold M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40377868", "title": "Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity.", "authors": [{"name": "Gold M", "authtype": "Author", "clusterid": ""}, {"name": "Lain T", "authtype": "Author", "clusterid": ""}, {"name": "Harper JC", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "vehicle gel", "type": "PLACEBO_COMPARATOR", "description": "The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: Vehicle gel"]}, {"label": "SR-T100 gel with 1.0% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 1.0% of SM"]}, {"label": "SR-T100 gel with 2.3% of SM", "type": "ACTIVE_COMPARATOR", "description": "SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.", "intervention_names": ["Drug: SR-T100 gel with 2.3% of SM"]}], "interventions": [{"type": "DRUG", "name": "Vehicle gel", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["vehicle gel"]}, {"type": "DRUG", "name": "SR-T100 gel with 1.0% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 1.0% of SM"]}, {"type": "DRUG", "name": "SR-T100 gel with 2.3% of SM", "description": "Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.", "arm_group_labels": ["SR-T100 gel with 2.3% of SM"]}]}}, "company_search_urls": ["https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+NCT01796795+terminated", "https://www.google.com/search?q=G&E Herbal Biotechnology Co., LTD+Vehicle gel+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Vehicle gel by G&E Herbal Biotechnology Co., LTD. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Vehicle gel by G&E Herbal Biotechnology Co., LTD.\n\nFirst, I need to identify if there's any mention of \"G&E Herbal Biotechnology Co., LTD\" or \"Vehicle gel\" in the search results.\n\nGoing through the search results:\n\n1. Result [1] contains FDA-related information, including Form 483s and Warning Letters, but I don't see any specific mention of \"G&E Herbal Biotechnology\" or \"Vehicle gel\".\n\n2. Result [2] is about bacterial mutagenicity assay - not relevant to our query.\n\n3. Result [3] is a list of FDA Warning Letters, but scanning through the company names (Taizhou Kangping Medical Science and Technology Co., Ltd., Compass Group USA, Miers Laboratories, Ltd, etc.), I don't see \"G&E Herbal Biotechnology Co., LTD\".\n\n4. Result [4] is about Warning & Notice of Violation Letters to Pharmaceutical Companies, but doesn't provide specific company names that match our query.\n\n5. Result [5] is about antiviral activity of natural products - not relevant.\n\n6. Result [6] is about Aclaris Therapeutics, Inc. - not relevant.\n\n7. Result [7] is about a clinical trial (NCT02473289) but doesn't mention our company or product.\n\n8. Result [8] is a Financial Times archive from 1992 - not relevant.\n\n9. Result [9] contains FOIA requests for FDA information, but I don't see any mention of \"G&E Herbal Biotechnology\" or \"Vehicle gel\".\n\n10. Result [10] is a warning letter to Drivergent, Inc. - not relevant to our query.\n\n11. Result [11] is about GMP news - no specific company mentioned.\n\n12. Result [12] is about ethical issues in research - not relevant.\n\n13. Result [13] is about a medical research conference - not relevant.\n\nAfter reviewing all the search results, I don't see any specific information about FDA warning letters or clinical holds for Vehicle gel by G&E Herbal Biotechnology Co., LTD. There's no mention of this company or product in any of the provided search results.\n\nThis could mean:\n1. There are no FDA warning letters or clinical holds for this specific product/company", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD mentioning clinical trial NCT01796795 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find SEC EDGAR 8-K filings by G&E Herbal Biotechnology Co., LTD that mention clinical trial NCT01796795 or related drug safety issues.\n\nLet me go through the search results systematically:\n\nResult [1] - This is from G&E Herbal Biotechnology's website (en.geherbs.com). It provides general information about the company as a biopharmaceutical company focused on botanical extraction. It mentions they conduct clinical trials but doesn't specifically reference NCT01796795 or any specific SEC filings.\n\nResult [2] - This is an SEC EDGAR filing document (Form 8-K) but it's for a company with SEC Accession No. 0001104659-05-058782, filed on 2005-12-02. The filer is identified as \"RIGEL PHARMACEUTICALS INC\" with CIK: 0001034842. This is not G&E Herbal Biotechnology.\n\nResult [3] - This is another page from G&E Herbal Biotechnology's website (en.geherbs.com) with their company profile. It mentions they conduct clinical trials including Phase III clinical trials for actinic keratosis treatment & Bowen's disease, and Phase II clinical trials for actinic keratosis treatment & Bowen's disease in the USA and for Genital Wart. However, it doesn't mention NCT01796795 specifically or any SEC filings.\n\nResult [4] - This appears to be a SEC filing for Benitec Biopharma Inc., not G&E Herbal Biotechnology. It discusses their product candidates including BB-301 for Oculopharyngeal Muscular Dystrophy.\n\nResult [5] - This is from Patsnap Synapse about Solamargine, which is noted as being \"Initially developed by G&E Herbal Biotechnology Co., Ltd.\" It mentions that Solamargine is a drug but doesn't provide specific information about clinical trial NCT01796795 or SEC filings.\n\nResult [6] - This appears to be a 10-K filing but doesn't clearly identify the company. It contains risk factors related to clinical trials, product development, etc., but doesn't seem to", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "start_date": "2030-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by G&E Herbal Biotechnology Co., LTD about clinical trial NCT01796795 for Vehicle gel. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by G&E Herbal Biotechnology Co., LTD specifically about clinical trial NCT01796795 for Vehicle gel. I should focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results to find relevant information:\n\nResult [1] - This appears to be from Synapse.patsnap.com and provides information about G&E Herbal Biotechnology Co., Ltd. It mentions NCT01796795 as a \"Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.\" It states the status is \"Suspended\" and it's a Phase 2 trial. This gives me the basic status of the trial but doesn't provide details about why it was suspended or any safety issues.\n\nResult [2] - This is from clinconnect.io and provides more details about the NCT01796795 trial titled \"Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.\" It mentions the trial was launched by G&E HERBAL BIOTECHNOLOGY CO., LTD on Feb 20, 2013, and is currently \"Suspended.\" It provides some inclusion criteria (patients must be in good health, have ECOG performance status \u2264 2) and exclusion criteria (history of allergy to Solanum undatum plant extract, SM, or SR-T100 gel excipients). However, it doesn't provide information about why the trial was suspended or any safety issues.\n\nResult [3] - This appears to be the company's website (en.geherbs.com). It mentions that \"The phase III clinical trials on human subjects (under the code name SR-T100) have been completed and have published multiple papers in international dermatology journals.\" This is confusing because result [1] indicates NCT01796795 is suspended at Phase 2. The website also lists some publications related to solamargine, but doesn't specifically address the suspension of NCT01796795 or any safety issues.\n\nResult [4] - This appears to be from trial.medpath.com and", "citations": [], "search_params": {"company": "G&E Herbal Biotechnology Co., LTD", "nct_id": "NCT01796795", "drug_name": "Vehicle gel"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The provided information indicates that the trial was suspended due to a \"budget issue,\" which suggests an administrative or operational problem rather than issues related to safety or efficacy. The lack of detailed description and published results further supports the conclusion that this was an administrative failure rather than a failure due to safety concerns or lack of efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:11.825190", "claude_model": "claude-3-haiku-20240307", "tokens_used": 859}}, "15": {"nct_id": "NCT06592664", "drug_name": "certepetide", "intervention_type": "DRUG", "drug_description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.539056", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.395370", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5315026", "pref_name": "CERTEPETIDE", "targets": [], "has_uniprot_targets": false, "search_name": "certepetide"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+certepetide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for certepetide by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds specifically related to certepetide by Lisata Therapeutics, Inc. I'll go through each result carefully.\n\nResult [1]: This is about Lisata announcing positive preclinical ADC data for certepetide. It mentions that the data is preclinical only, with no human safety data reported. There's no mention of FDA warning letters or clinical holds.\n\nResult [2]: This is about certepetide being granted FDA Orphan Drug Designation for cholangiocarcinoma. It mentions that \"certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials.\" No warning letters or clinical holds are mentioned.\n\nResult [3]: This is an FDA warning letter, but it's for \"www.nomida.biz\" regarding unapproved semaglutide and tirzepatide products. This is not related to Lisata Therapeutics or certepetide.\n\nResult [4]: This is another article about certepetide receiving FDA Orphan Drug Designation for cholangiocarcinoma. It mentions the BOLSTER trial (Phase 2a study) but no warning letters or clinical holds.\n\nResult [5]: Another article about certepetide receiving FDA Orphan Drug Designation for cholangiocarcinoma. No warning letters or clinical holds mentioned.\n\nResult [6]: This mentions \"encouraging preliminary cohort A data from the AGITG-led Phase 2 ASCEND trial evaluating certepetide with standard of care chemotherapy in metastatic pancreatic ductal adenocarcinoma.\" It states that \"certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials.\" No warning letters or clinical holds mentioned.\n\nResult [7]: Another article about FDA granting orphan drug designation to certepetide for cholangiocarcinoma. No warning letters or clinical holds.\n\nResult [8]: This is just a general page about FDA warning letters, not specific to Lisata or certepetide.\n\nResult [9]: This appears to be from the FDA's orphan drug designation database, showing information about certepetide's orphan drug designation. It states \"FDA Orphan Approval Status: Not FDA Approved for Orphan Indication.\" No warning letters or clinical holds mentioned.\n\nResult [10]: This is about FDA issuing warning letters to GLP", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nThe query specifically asks for:\n1. SEC EDGAR 8-K filings by Lisata Therapeutics, Inc.\n2. That mention clinical trial NCT06592664 or related drug safety issues\n3. Include filing dates, CIK number, and specific material events disclosed\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is about the clinical trial NCT06592664 (FORTIFIDE trial) testing certepetide for metastatic pancreatic cancer. It provides details about the trial design, objectives, and status.\n\nResult [2]: Shows SEC EDGAR filings for LISATA THERAPEUTICS, INC. with CIK 320017. It mentions an 8-K filing dated 10/14/2025.\n\nResult [3]: Provides additional details about the FORTIFIDE trial (NCT06592664), confirming it's a Phase 1b/2a clinical trial testing certepetide. It states the status is \"Enrollment pending\".\n\nResult [4]: Shows EDGAR filing documents but doesn't provide specific content about 8-K filings related to the clinical trial.\n\nResult [5]: This appears to be a Form 8-K Current Event Report for LISATA THERAPEUTICS, INC. It mentions \"Requisite clinical development steps completed in preparation for Phase 3 trial\" and \"Full NDA-ready preclinical toxicology package \u2667 no DLTs\". This seems relevant to drug safety.\n\nResult [6] and [7]: These provide general information about Lisata Therapeutics and certepetide but don't seem to contain specific SEC filing information.\n\nNow, let me extract the specific information requested:\n\n1. CIK number: From result [2], we can see the CIK is 320017 for LISATA THERAPEUTICS, INC.\n\n2. Filing dates: Result [2] mentions an 8-K filing dated 10/14/2025. Result [5] appears to be an 8-K", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for certepetide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. regarding clinical trial NCT06592664 for certepetide, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results are relevant to the query:\n\n1. Result [1] is from clinicaltrials.gov with details about NCT06592664 (Certepetide Phase 1b/2a trial)\n2. Result [2] is a GlobeNewswire press release from Lisata Therapeutics dated September 29, 2025\n3. Result [3] is from Lisata's website about the FORTIFIDE trial (which is NCT06592664)\n4. Result [4] is a GlobeNewswire press release from November 4, 2025\n5. Result [5] is from MedPath about Lisata Therapeutics\n6. Result [6] is from ADC Review about Lisata and Catalent\n7. Result [7] is from MedPath about Certepetide\n8. Result [8] is from MedChemExpress about Certepetide\n9. Result [9] is from Synapse about Certepetide\n10. Result [10] is from Sigma Larvol about Marshfield Clinic trials\n\nNow, let me focus on the results that contain company press releases or public statements specifically about NCT06592664 with safety information:\n\nResult [2] (GlobeNewswire Sept 29, 2025):\n- Mentions \"Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial\"\n- However, this appears to be about the CENDIFOX trial, not NCT06592664 (which is the FORTIFIDE trial based on other results)\n- Contains forward-looking statements language but no specific safety data for NCT06592664\n\nResult [3] (Lisata website):\n- Clearly identifies NCT06592664 as the FORTIFIDE trial\n- States \"Status: Enrollment pending\"\n- Describes the trial", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "certepetide"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "16": {"nct_id": "NCT06592664", "drug_name": "certepetide", "intervention_type": "DRUG", "drug_description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.539341", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.432953", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5315026", "pref_name": "CERTEPETIDE", "targets": [], "has_uniprot_targets": false, "search_name": "certepetide"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+certepetide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for certepetide by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds for certepetide by Lisata Therapeutics, Inc. I'll go through each result carefully to identify relevant information.\n\nResult [1]: This discusses positive preclinical data for certepetide as part of antibody-drug conjugate combinations. It mentions that the data is preclinical only and no human safety data was reported. There's no mention of FDA warning letters or clinical holds.\n\nResult [2]: This discusses recent FDA cancer drug safety warnings and updates, but none specifically related to certepetide or Lisata Therapeutics. It mentions warnings for pexidartinib, capecitabine, duvelisib, denosumab-bnht, and ciltacabtagene autoleucel, but not certepetide.\n\nResult [3]: This reports that certepetide has been granted FDA orphan drug designation for the treatment of patients with cholangiocarcinoma. There's no mention of warning letters or clinical holds.\n\nResult [4]: This discusses a Complete Response Letter and Warning Letter to Applied Therapeutics regarding govorestat for galactosemia, not certepetide or Lisata Therapeutics.\n\nResult [5]: This appears to be about FDA granting orphan drug designation to certepetide for cholangiocarcinoma, but shows an error message (403: Forbidden).\n\nResult [6]: This is a general FDA page about warning letters, but doesn't contain specific information about Lisata Therapeutics or certepetide.\n\nResult [7]: This is an SEC filing for Lisata Therapeutics. It mentions that \"certepetide is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types,\" but doesn't mention any FDA warning letters or clinical holds.\n\nResult [8]: This Nasdaq press release states that \"certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials.\" This suggests there are no major safety issues that would have triggered warning letters or clinical holds, but doesn't explicitly state this.\n\nResult [9]: This is an FDA orphan drug designation search result showing that certepetide was designated for treatment of pancreatic cancer on 01/29/2019.\n\nResult [10]: This is a Nasdaq press release about certepetide being granted", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nFirst, let's identify what we're looking for:\n- SEC EDGAR Form 8-K filings by Lisata Therapeutics, Inc.\n- Filings that mention clinical trial NCT06592664 (FORTIFIDE trial)\n- Filings that discuss drug safety issues related to certepetide (the drug in the trial)\n- We need to extract filing dates, CIK number, and specific material events disclosed\n\nLet's go through the search results:\n\nResult [1]: This is about the clinical trial NCT06592664 (FORTIFIDE trial) from clinicaltrials.gov. It describes the trial design, which is testing certepetide in combination with standard treatment for metastatic pancreatic ductal adenocarcinoma. It mentions the trial is in Phase 1b/2a.\n\nResult [2]: This shows SEC EDGAR filings for LISATA THERAPEUTICS, INC. with CIK 320017. It mentions an 8-K filing dated 10/14/2025.\n\nResult [3]: This is from Lisata's website describing the FORTIFIDE trial (NCT06592664). It states the trial status is \"Enrollment pending\" and provides details about the trial design.\n\nResult [4]: This appears to be an EDGAR filing document index for Lisata Therapeutics, Inc. with CIK 0000320017.\n\nResult [5]: This shows a Form 8-K filing by Lisata Therapeutics, Inc. dated January 22, 2025, announcing \"preliminary cohort A data from the.\" It seems to be cut off, but likely refers to a clinical trial.\n\nResult [6]: This shows another Form 8-K filing by Lisata Therapeutics, Inc. It mentions \"Requisite clinical development steps completed in preparation for Phase 3 trial\" and \"Full NDA-ready preclinical toxicology package \u2667 no DLTs\" (DLTs likely refers to Dose Limiting Toxicities).\n\nResult [7] and [8]: These appear to", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for certepetide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. regarding clinical trial NCT06592664 for certepetide, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results are relevant to the query:\n\n1. Result [1] - ClinicalTrials.gov entry for NCT06592664 (FORTIFIDE trial)\n2. Result [2] - GlobeNewswire press release from Lisata Therapeutics (Sept 2025)\n3. Result [3] - Lisata Therapeutics website about the FORTIFIDE trial\n4. Result [4] - GlobeNewswire press release from Lisata Therapeutics (Nov 2025)\n5. Result [5] - MedPath page about Lisata Therapeutics\n6. Result [6] - ADC Review article about Lisata and Catalent\n7. Result [7] - Synapse drug information page\n8. Result [8] - MedChemExpress product page\n9. Result [9] - MedPath drug information page\n\nNow, let me go through each relevant result to find information about safety issues, adverse events, trial termination reasons, or regulatory actions related to NCT06592664:\n\nResult [1] - ClinicalTrials.gov entry:\n- This is the study details for NCT06592664 (FORTIFIDE trial)\n- It's a Phase 1b/2a trial testing certepetide plus standard treatment vs standard treatment alone in metastatic pancreatic cancer\n- One of the main questions is \"is the new drug plus standard treatment safe and tolerable\"\n- Outcome measure includes \"Incidence of adverse events\" using NCI CTCAE v5.0\n- However, this is just the study protocol, not a press release or results announcement\n\nResult [2] - GlobeNewswire press release (Sept 2025):\n- Mentions \"certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials\"\n- This is a general statement about certepetide, not specific to NCT06592664\n- It's a forward-looking statement section with typical disclaimer language", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "certepetide"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "17": {"nct_id": "NCT06592664", "drug_name": "gemcitabine", "intervention_type": "DRUG", "drug_description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.539577", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.469796", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3039516", "pref_name": "GEMCITABINE ELAIDATE", "targets": [{"chembl_id": null, "uniprot_id": "P27707", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NR71", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P21524", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q29550", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P31350", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "gemcitabine", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "NT5C", "protein_b": "AMPD2", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "AMPD1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "APRT", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "CMPK2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "CDA", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "DCTD", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "ADA", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "DCK", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "NT5C2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "NT5C", "protein_b": "PNP", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "CDA", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "NT5C2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "DCTD", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "DCK", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "AMPD1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "ADA", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "AMPD2", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "APRT", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "PNP", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "NT5C2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "DCTD", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "CDA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "AMPD1", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "AMPD2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "APRT", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "CDA", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "ADA", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "DCTD", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NT5C2", "protein_b": "PNP", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "DCTD", "protein_b": "CDA", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PNP", "protein_b": "AMPD1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "PNP", "protein_b": "AMPD2", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "PNP", "protein_b": "CDA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "PNP", "protein_b": "APRT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PNP", "protein_b": "ADA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "AMPD1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "AMPD2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "APRT", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "AMPD1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "AMPD2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AMPD1", "protein_b": "AMPD2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "CERS4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "SGMS1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "CERS6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "ACER1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "ACER2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "ASAH2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CERK", "protein_b": "ASAH1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "CERS6", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "ACER3", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SPHK2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SPHK1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SGMS1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "ASAH2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "ASAH1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "ACER2", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "ACER1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "ACER2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "SGMS1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "CERS6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "SPHK1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "SPHK2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "ASAH1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "ACER1", "protein_b": "ASAH2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "SPHK2", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "ACER3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "CERS6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "ACER2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "ASAH2", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "ASAH1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ACER2", "protein_b": "SGMS1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ACER2", "protein_b": "CERS6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ACER2", "protein_b": "SPHK2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ACER2", "protein_b": "ASAH1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "ACER2", "protein_b": "ASAH2", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SGMS1", "protein_b": "CERS6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SGMS1", "protein_b": "ASAH1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "SGMS1", "protein_b": "ASAH2", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "ASAH1", "protein_b": "CERS6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "ASAH1", "protein_b": "ACER3", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ASAH1", "protein_b": "SPHK2", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "ASAH1", "protein_b": "ASAH2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CERS6", "protein_b": "SPHK2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CERS6", "protein_b": "ACER3", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CERS6", "protein_b": "ASAH2", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "ASAH2", "protein_b": "SPHK2", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "ASAH2", "protein_b": "ACER3", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "ACER3", "protein_b": "SPHK2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "MKI67", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "RRM2", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "CDK1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "NUSAP1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "TOP2A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "KIF11", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DLGAP5", "protein_b": "CEP55", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "DTYMK", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "RRM2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "RRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "RRM1", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "MKI67", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "RRM2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "NUSAP1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "TOP2A", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "CDK1", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "KIF11", "protein_b": "CEP55", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "CDK1", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "TOP2A", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "DTYMK", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "RRM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DTYMK", "protein_b": "RRM2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "MKI67", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "CEP55", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "NUSAP1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "TOP2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "CDK1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MKI67", "protein_b": "CEP55", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "MKI67", "protein_b": "CDK1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "MKI67", "protein_b": "NUSAP1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "MKI67", "protein_b": "TOP2A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CEP55", "protein_b": "TOP2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CEP55", "protein_b": "NUSAP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CEP55", "protein_b": "CDK1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CDK1", "protein_b": "NUSAP1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CDK1", "protein_b": "TOP2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TOP2A", "protein_b": "NUSAP1", "combined_score": 0.999, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.58, "clustering_coefficient": 3.79}}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41224817", "title": "Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma.", "authors": [{"name": "Yamada D", "authtype": "Author", "clusterid": ""}, {"name": "Kobayashi S", "authtype": "Author", "clusterid": ""}, {"name": "Takahashi H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41220738", "title": "Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study.", "authors": [{"name": "Zeng J", "authtype": "Author", "clusterid": ""}, {"name": "Liu J", "authtype": "Author", "clusterid": ""}, {"name": "Ma F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206673", "title": "Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).", "authors": [{"name": "Villaruz LC", "authtype": "Author", "clusterid": ""}, {"name": "Schluger B", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41197185", "title": "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.", "authors": [{"name": "Jameson GS", "authtype": "Author", "clusterid": ""}, {"name": "LeGrand SD", "authtype": "Author", "clusterid": ""}, {"name": "Gordon MS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41168707", "title": "Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO).", "authors": [{"name": "Stas D", "authtype": "Author", "clusterid": ""}, {"name": "Vandamme T", "authtype": "Author", "clusterid": ""}, {"name": "Roeyen G", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+gemcitabine+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for gemcitabine by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for gemcitabine by Lisata Therapeutics, Inc.\n\nFirst, I need to understand what the query is asking for:\n- FDA warning letters related to gemcitabine\n- Clinical holds related to gemcitabine\n- Specifically from or involving Lisata Therapeutics, Inc.\n- With specific dates, reasons, and safety issues cited\n\nLet me go through the search results one by one:\n\nResult [1]: This is an FDA label for gemcitabine injection. It contains safety information about gemcitabine, including warnings about pulmonary toxicity, hemolytic uremic syndrome, hepatic toxicity, capillary leak syndrome, and posterior reversible encephalopathy syndrome. However, this is just the standard drug label and doesn't mention any warning letters or clinical holds from the FDA to Lisata Therapeutics.\n\nResult [2]: Another FDA label for gemcitabine injection. Similar to result [1], it contains safety information about gemcitabine but doesn't mention any warning letters or clinical holds to Lisata Therapeutics.\n\nResult [3]: This is about recent FDA cancer drug safety warnings and updates, but it mentions capecitabine, duvelisib, denosumab, ciltacabtagene autoleucel, and pexidartinib - not gemcitabine or Lisata Therapeutics.\n\nResult [4]: This is about FDA warning letters in general, but the examples given are for Compass Group USA (food safety), Miers Laboratories (CGMP issues), and IBSPOT.com (unapproved drugs). None of these are related to gemcitabine or Lisata Therapeutics.\n\nResult [5]: This discusses FDA granting orphan drug designation to LSTA1 (which appears to be a drug developed by Lisata Therapeutics) for advanced solid tumor treatment. It mentions a phase 1 study that assessed CEND-1 (which seems to be the same as LSTA1) in combination with nab-paclitaxel and gemcitabine for pancreatic cancer. It notes that the combination showed an \"acceptable safety profile\" with adverse events consistent with nab-paclitaxel and gemcitabine. This doesn't mention any warning letters or clinical holds.\n\nResult [6]: This is the NIOSH List of Hazardous Drugs in Healthcare Settings, 2020. It lists gem", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nThe query asks for:\n1. SEC EDGAR 8-K filings by Lisata Therapeutics, Inc.\n2. That mention clinical trial NCT06592664 or related drug safety issues\n3. Include filing dates, CIK number, and specific material events disclosed\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is about the clinical trial NCT06592664 (FORTIFIDE trial) for certepetide in metastatic pancreatic cancer. It provides details about the trial design, objectives, and status but doesn't mention any SEC filings.\n\nResult [2]: This shows SEC EDGAR filings for LISATA THERAPEUTICS, INC. with CIK 320017. It mentions an 8-K filing dated 10/14/2025 (which is in the future relative to the current date of November 14, 2025). However, it doesn't provide details about what was disclosed in the filing.\n\nResult [3]: This is the company's webpage about the FORTIFIDE trial (NCT06592664). It confirms the trial status as \"Enrollment pending\" and provides details about the trial design, but doesn't mention SEC filings.\n\nResult [4]: This shows an EDGAR filing document with CIK 0000320017 (which matches Lisata Therapeutics' CIK), but doesn't provide details about the content of the filing.\n\nResult [5]: This appears to be a Form 8-K Current Event Report for LISATA THERAPEUTICS, INC. It mentions \"Requisite clinical development steps completed in preparation for Phase 3 trial\" and \"Full NDA-ready preclinical toxicology package \u2667 no DLTs\". This seems relevant as it discusses clinical development and safety (no DLTs = no dose-limiting toxicities).\n\nResult [6] and [7]: These provide general information about Lisata Therapeutics and certepetide but don't mention SEC filings.\n\nNow, let me extract the specific information", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for gemcitabine. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT06592664 for gemcitabine, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions as mentioned in company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc.\n\nFirst, let me identify which search results are relevant to NCT06592664:\n\nResult 1: Mentions NCT06592664 but doesn't provide specific details about this trial. It mainly discusses other trials like NCT04614467.\n\nResult 3: This is from clinicaltrials.gov and provides details about NCT06592664, which is titled \"Certepetide Phase 1b/2a...\" It describes the study as testing a new drug (certepetide) plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma. It mentions safety as one of the main questions the trial aims to answer.\n\nResult 5: This is from Lisata's website and describes the FORTIFIDE trial, which is identified as NCT06592664. It states the trial status is \"Enrollment pending\" and describes it as a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating certepetide (LSTA1) when added to standard of care in patients with second-line metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX.\n\nResult 7: This is from MedPath and lists NCT06592664 as \"Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC\" with status \"Withdrawn\" sponsored by Lisata Therapeutics, Inc.\n\nResult 8: Mentions FORTIFIDE, NCT06592664 at Marshfield Clinic.\n\nNow, let me look for specific information about safety issues, adverse events, trial termination reasons, or regulatory actions:\n\nFrom Result 2 (earnings call transcript):\n- Mentions \"certepetide's benign safety profile\" and that it \"does not potentiate further adverse events\"\n- This is in the context of discussing the ASCEND trial, not specifically N", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "gemcitabine"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "18": {"nct_id": "NCT06592664", "drug_name": "nab-paclitaxel", "intervention_type": "DRUG", "drug_description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.539784", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.506603", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "nab-paclitaxel"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41224817", "title": "Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma.", "authors": [{"name": "Yamada D", "authtype": "Author", "clusterid": ""}, {"name": "Kobayashi S", "authtype": "Author", "clusterid": ""}, {"name": "Takahashi H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41197185", "title": "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.", "authors": [{"name": "Jameson GS", "authtype": "Author", "clusterid": ""}, {"name": "LeGrand SD", "authtype": "Author", "clusterid": ""}, {"name": "Gordon MS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41184224", "title": "Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).", "authors": [{"name": "Wang P", "authtype": "Author", "clusterid": ""}, {"name": "Chen Y", "authtype": "Author", "clusterid": ""}, {"name": "Wang F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41168707", "title": "Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO).", "authors": [{"name": "Stas D", "authtype": "Author", "clusterid": ""}, {"name": "Vandamme T", "authtype": "Author", "clusterid": ""}, {"name": "Roeyen G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41167638", "title": "Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial.", "authors": [{"name": "Qu W", "authtype": "Author", "clusterid": ""}, {"name": "Gao J", "authtype": "Author", "clusterid": ""}, {"name": "Zhang B", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+nab-paclitaxel+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for nab-paclitaxel by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for nab-paclitaxel by Lisata Therapeutics, Inc.\n- Specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1]: Discusses FDA removing a red flag for paclitaxel-coated devices (for peripheral arterial disease) in July 2023. This is about paclitaxel-coated medical devices, not nab-paclitaxel (which is a cancer drug formulation), and not related to Lisata Therapeutics.\n\nResult [2]: Discusses adverse event profile for nanoparticle albumin-bound paclitaxel (nab-paclitaxel), but doesn't mention Lisata Therapeutics or any FDA warning letters/clinical holds.\n\nResult [3]: Contains information about Abraxane (paclitaxel protein-bound particles), but doesn't mention Lisata Therapeutics or any FDA warning letters/clinical holds.\n\nResult [4]: Discusses recent FDA cancer drug safety warnings and updates, but doesn't mention nab-paclitaxel or Lisata Therapeutics specifically.\n\nResult [5]: Discusses an FDA alert about not combining Tecentriq with paclitaxel (not nab-paclitaxel) for triple-negative breast cancer. Not related to Lisata Therapeutics.\n\nResult [6]: Contains the label for ABRAXANE (paclitaxel), but doesn't mention Lisata Therapeutics or any FDA warning letters/clinical holds.\n\nResult [7]: Discusses an FDA alert about atezolizumab in combination with paclitaxel, not nab-paclitaxel, and not related to Lisata Therapeutics.\n\nResult [8]: SEC filing for \"lsta-20241231\" which appears to be related to Lisata Therapeutics (based on the filename), but the snippet doesn't provide specific information about FDA warning letters or clinical holds for nab-paclitaxel.\n\nResult [9]: Mentions FDA granting orphan drug designation to LSTA1 for advanced solid tumor treatment. It states: \"All 31 patients were evaluable for safety. Overall, there were no CEND-1 dose-limiting toxicities observed during the dose-escalation phase of the study. The most", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nFirst, I need to identify which of the search results are relevant SEC EDGAR 8-K filings:\n\nResult [2] appears to be a Form 8-K filing: \"LISATA THERAPEUTICS, INC. Form 8-K Current Event Report...\" with a date mentioned: \"On January 22, 2025, Lisata Therapeutics, Inc. (the \"Company\") issued a press release announcing preliminary cohort A data from the.\"\n\nResult [5] also appears to be a Form 8-K filing: \"LISATA THERAPEUTICS, INC. Form 8-K Current Event Report...\" with content mentioning \"Requisite clinical development steps completed in preparation for Phase 3 trial Full NDA-ready preclinical toxicology package \u2667 no DLTs...\"\n\nResult [4] appears to be an EDGAR filing document index but doesn't seem to contain specific content about the clinical trial.\n\nLet me check if these filings mention NCT06592664 or related drug safety issues:\n\nFrom result [1], I can see that NCT06592664 is the \"Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE)\" which is testing certepetide (also called LSTA1) in combination with standard treatment for metastatic pancreatic ductal adenocarcinoma.\n\nFrom result [3], I see that FORTIFIDE is the name of the Phase 1b/2a clinical trial testing certepetide in combination with standard treatment for pancreatic cancer.\n\nNow, let's see if the 8-K filings mention this specific trial or drug safety issues:\n\nResult [2] mentions \"preliminary cohort A data from the\" but doesn't explicitly state which trial. Given the context of the other results, this is likely referring to the FORTIFIDE trial (NCT06592664).\n\nResult [5] mentions \"Requisite clinical development steps completed in preparation for Phase 3 trial\" and \"Full NDA-ready preclinical toxicology package \u2667 no DLTs...\" This suggests positive safety", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for nab-paclitaxel. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. regarding clinical trial NCT06592664, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT06592664 is from the search results:\n\nFrom result [3], I can see that NCT06592664 is titled \"Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE)\". It's a clinical trial testing certepetide in combination with standard treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nFrom result [5], I see that FORTIFIDE is described as \"a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a 4-hour infusion of certepetide (LSTA1) when added to standard of care (SoC) in patients with second-line metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX.\"\n\nFrom result [7], I see that the status of NCT06592664 is listed as \"Withdrawn\".\n\nNow, let me look for any press releases, investor presentations, or public statements specifically about this trial, focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nResult [1] mentions Lisata Therapeutics and various trials, but doesn't specifically mention NCT06592664 or provide details about safety issues or trial termination for this specific trial.\n\nResult [2] is a Form 8-K Current Event Report from June 26, 2025, but it only mentions \"preliminary cohort B data\" without specifying which trial or providing safety information.\n\nResult [3] provides details about the FORTIFIDE trial (NCT06592664) but doesn't mention any safety issues, adverse events, or reasons for termination.\n\nResult [4] mentions Lisata Therapeutics reporting Second Quarter 2025 results and stopping enrollment in a CCA cohort, but it doesn't specifically address NCT06592664.\n\nResult [5] provides details about the", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "nab-paclitaxel"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "19": {"nct_id": "NCT06592664", "drug_name": "placebo matching certepetide", "intervention_type": "DRUG", "drug_description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.539990", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.542981", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5315026", "pref_name": "CERTEPETIDE", "targets": [], "has_uniprot_targets": false, "search_name": "placebo matching certepetide"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+placebo matching certepetide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for placebo matching certepetide by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds related to certepetide by Lisata Therapeutics, Inc. Specifically, I'm looking for information about placebo matching certepetide.\n\nLet me go through each search result:\n\nResult 1: This is about Lisata Therapeutics highlighting positive preclinical data for Certepetide as part of Antibody-Drug Conjugate combinations. It mentions:\n- Preclinical data showed improved tumor-selective penetration using certepetide\n- Preclinical data showed enhanced ADC efficacy when certepetide was incorporated\n- Licensing partnership with Catalent confirmed on Nov 4, 2025\n- Data are preclinical only; human safety and efficacy not demonstrated\n- No clinical or human safety data were reported\n- Certepetide has received various designations (Fast Track, Orphan Drug Designation for pancreatic cancer, glioma, osteosarcoma, etc.)\n\nResult 2: This is about Lisata Therapeutics announcing encouraging preliminary results from the pancreatic cancer cohort of the CENDIFOX trial. It mentions:\n- Certepetide has demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials\n- The trial evaluated certepetide in combination with FOLFIRINOX-based therapies\n- The combination was safe and feasible with no serious adverse events attributed to certepetide\n- 35 patients enrolled in the PDAC cohort\n- Certepetide has received various designations similar to Result 1\n\nResult 3: This is an FDA warning letter to Nomida.biz about unapproved and misbranded semaglutide and tirzepatide drug products. This is not related to certepetide or Lisata Therapeutics.\n\nResult 4: This is about certepetide winning FDA Orphan Drug Designation for cholangiocarcinoma. It mentions:\n- The FDA granted orphan drug designation to certepetide for cholangiocarcinoma\n- Certepetide is an investigational agent that assists co-administered anticancer drugs to more effectively penetrate tumors\n- The agent is being investigated in the phase 2a BOLSTER study (NCT05712356)\n- Orphan drug designation details\n\nResult 5: This is about FDA issuing warning letters to GLP-1 drug sellers for misbranding. It", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nWe are given search results about SEC EDGAR filings for Lisata Therapeutics, Inc. (CIK: 320017) and we are to look for 8-K filings that mention clinical trial NCT06592664 or related drug safety issues.\n\nLet's analyze each search result:\n\n[1] \n- URL: http://pdf.secdatabase.com/1603/0000320017-25-000004.pdf\n- Content: Form 8-K Current Event Report. On January 22, 2025, the company issued a press release announcing preliminary cohort A data from the [trial?]. \n- Note: The trial identifier (NCT06592664) is not mentioned in the snippet, but it says \"preliminary cohort A data\". We don't know if this is for NCT06592664.\n\n[2]\n- URL: https://research.secdatabase.com/CIK/320017/Company-Name/LISATA-THERAPEUTICS-INC.\n- Content: Lists SEC filings. One entry: Filing Date 10/14/2025, Period Ending 10/14/2025, Form 8-K, Company Name LISATA THERAPEUTICS, INC.\n- Note: This is a future date (10/14/2025) but the current date is November 14, 2025. However, the query is about filings that mention NCT06592664. We don't have the content of the filing, only the date and form.\n\n[3]\n- URL: http://pdf.secdatabase.com/1642/0000320017-25-000043.pdf\n- Content: Form 8-K Current Event Report. On June 26, 2025, the company issued a press release announcing preliminary cohort B data from the [trial?].\n- Note: Again, no explicit mention of NCT06592664.\n\n[4]\n- URL: https://www.sec.gov/Archives/edgar/data/320017", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for placebo matching certepetide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. regarding clinical trial NCT06592664 (the FORTIFIDE trial) with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results might contain relevant information:\n\n1. Result [1]: ClinicalTrials.gov entry for NCT06592664 - This provides basic trial information but doesn't contain press releases or safety data\n2. Result [2]: GlobeNewswire article from Nov 4, 2025 about preclinical data - This is a press release but about preclinical data, not specifically about NCT06592664 safety\n3. Result [3]: Lisata's website about the FORTIFIDE trial - Describes the trial design but doesn't mention safety issues or termination\n4. Result [4]: WebDisclosure article - Mentions \"promising preliminary results\" but doesn't specify safety data\n5. Result [5]: MedPath page about Lisata - Contains multiple trial references but seems to have some potentially outdated or conflicting information\n6. Result [6]: SEC Form 8-K - Might contain financial information but not clear if it has safety data\n7. Result [7]: ADC Review article about licensing agreement - Not directly about safety of NCT06592664\n8. Result [8]: MedPath page about Certepetide - Shows the trial as \"Withdrawn\" which is important\n9. Result [9]: Synapse/PatSnap - Mentions iLSTA trial but not clear about NCT06592664\n10. Result [10]: MedChemExpress product page - Not relevant for safety data\n\nKey findings from the search results:\n\n1. From result [8], I see that the trial NCT06592664 is listed as \"Withdrawn\" in the MedPath database. This is significant because the ClinicalTrials.gov entry (result [1]) doesn't indicate this status.\n\n2. Result [3] states \"Status: Enrollment pending\" which suggests the trial was not yet actively recruiting.\n\n3. Result [5] contains several potentially conflicting statements:\n   - \"Lisata Therapeutics Reports Promising Results", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "placebo matching certepetide"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "20": {"nct_id": "NCT06592664", "drug_name": "placebo matching certepetide", "intervention_type": "DRUG", "drug_description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.540198", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.578851", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5315026", "pref_name": "CERTEPETIDE", "targets": [], "has_uniprot_targets": false, "search_name": "placebo matching certepetide"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+placebo matching certepetide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for placebo matching certepetide by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to determine if there are any FDA warning letters or clinical holds related to certepetide by Lisata Therapeutics, Inc. The query specifically asks for:\n1. FDA warning letters\n2. Clinical holds\n3. For placebo matching certepetide\n4. Including specific dates, reasons, and safety issues cited\n\nLet me go through each search result to see if they contain this information:\n\nResult [1]: This is about positive preclinical data for Certepetide as part of Antibody-Drug Conjugate combinations. It mentions:\n- Preclinical data showed improved tumor-selective penetration using certepetide\n- Preclinical data showed enhanced ADC efficacy when certepetide was incorporated\n- Licensing partnership with Catalent confirmed on Nov 4, 2025\n- Data are preclinical only; human safety and efficacy not demonstrated\n- No clinical or human safety data were reported\n- Certepetide has received various designations (Fast Track, Orphan Drug for pancreatic cancer, glioma, osteosarcoma)\n- Mentions risks in preclinical-to-clinical translation\n\nResult [2]: This is about Certepetide being granted FDA Orphan Drug Designation for cholangiocarcinoma. It mentions:\n- Certepetide has demonstrated \"favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials\"\n- Lisata is evaluating certepetide in its BOLSTER trial (Phase 2a)\n- Certepetide has received various designations (Fast Track, Orphan Drug for pancreatic cancer, glioma, osteosarcoma, cholangiocarcinoma)\n- Mentions risks that product candidates may not demonstrate safety/efficacy in larger trials\n\nResult [3]: This is another article about Certepetide winning FDA Orphan Drug Designation for cholangiocarcinoma. It mentions:\n- Certepetide is an investigational agent that assists co-administered anticancer drugs to penetrate tumors\n- It's being investigated in the phase 2a BOLSTER study (NCT05712356)\n- Certepetide has been granted FDA orphan drug designation for cholangiocarcinoma\n\nResult [4]: This appears to be a Nasdaq press release about positive preclinical data of Certepetide. It mentions:\n- \"To date", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nFirst, let me identify which search results are SEC EDGAR 8-K filings:\n\nResult [2]: http://pdf.secdatabase.com/1603/0000320017-25-000004.pdf - This appears to be a Form 8-K Current Event Report by Lisata Therapeutics, Inc. dated January 22, 2025. It mentions \"preliminary cohort A data from the\" but doesn't explicitly mention NCT06592664.\n\nResult [4]: https://www.sec.gov/Archives/edgar/data/320017/0000320017-22-000085-index.htm - This is an EDGAR filing document, but it doesn't seem to be a specific 8-K filing related to the clinical trial in question. It just shows the company information.\n\nResult [6]: http://pdf.secdatabase.com/1642/0000320017-25-000043.pdf - This appears to be another Form 8-K Current Event Report by Lisata Therapeutics, Inc. It mentions \"Requisite clinical development steps completed in preparation for Phase 3 trial\" and \"Full NDA-ready preclinical toxicology package \u2667 no DLTs\" (DLTs likely refers to Dose Limiting Toxicities).\n\nNow, let me check if any of these filings specifically mention NCT06592664 or related drug safety issues:\n\nFrom result [1], I can see that NCT06592664 is the \"Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE)\" which is testing certepetide (also called LSTA1) in combination with standard treatment for metastatic pancreatic ductal adenocarcinoma.\n\nFrom result [3], I can see that FORTIFIDE is the name of the trial associated with NCT06592664, and it's described as \"Phase ", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for placebo matching certepetide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. regarding clinical trial NCT06592664 (the FORTIFIDE trial) with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results are relevant to the query:\n\n1. Result [1]: ClinicalTrials.gov entry for NCT06592664 - This provides basic trial information but doesn't contain press releases or safety data\n2. Result [2]: GlobeNewswire press release from Nov 4, 2025 about preclinical data of certepetide\n3. Result [3]: Lisata's website about the FORTIFIDE trial\n4. Result [4]: WebDisclosure article about Lisata Therapeutics\n5. Result [5]: MedPath information about Lisata Therapeutics\n6. Result [6]: SEC Form 8-K filing\n7. Result [7]: ADC Review article about Lisata and Catalent agreement\n8. Result [8]: MedPath information about Certepetide\n9. Result [9]: Synapse/PatSnap information about Certepetide\n10. Result [10]: MedChemExpress product page for Certepetide\n\nNow, let me examine each relevant result for information about safety issues, adverse events, trial termination reasons, or regulatory actions related to NCT06592664:\n\nResult [1]: ClinicalTrials.gov entry for NCT06592664\n- This describes the FORTIFIDE trial as a Phase 1b/2a study testing certepetide plus standard treatment vs standard treatment alone in metastatic pancreatic cancer\n- It mentions the trial will assess safety and tolerability as one of its main questions\n- No specific safety data or adverse events are reported here\n- No indication of trial termination\n\nResult [2]: GlobeNewswire press release from Nov 4, 2025\n- This is a forward-looking statement about preclinical data of certepetide as part of ADC combinations\n- Mentions \"positive preclinical data\" but doesn't provide specific safety information\n- Contains standard forward-looking statement language about risks including \"the safety and efficacy of Lisata's product candidates\"\n- No specific safety issues", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "placebo matching certepetide"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "21": {"nct_id": "NCT06592664", "drug_name": "placebo matching certepetide", "intervention_type": "DRUG", "drug_description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Management Decision", "title": "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC", "start_date": "2030-01-31", "completion_date": "2040-01-31", "sponsor": "Lisata Therapeutics, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.540409", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:15.614545", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL5315026", "pref_name": "CERTEPETIDE", "targets": [], "has_uniprot_targets": false, "search_name": "placebo matching certepetide"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n* is the new drug plus standard treatment safe and tolerable\n* is the new drug plus standard treatment more effective than standard treatment\n\nParticipants will:\n\n* Visit the clinic three times every 28 days for treatment and tests\n* Have CT or MRI scans every 8 weeks while on treatment", "detailed_description": "This is a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a single intravenous push of certepetide followed by a continuous infusion of certepetide over 4 hours when added to standard of care (SoC) versus two intravenous pushes of certepetide given 4 hours apart when added to SoC, versus SoC alone in people with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).\n\nThe study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.\n\nParticipants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the three treatment groups.\n\nDuring the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days \u00b1 7 days) while on treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: certepetide", "Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: certepetide", "Drug: placebo matching certepetide"]}, {"label": "SoC chemotherapy plus two placebo IV pushes and placebo infusion", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: nab-paclitaxel", "Drug: gemcitabine", "Drug: placebo matching certepetide"]}], "interventions": [{"type": "DRUG", "name": "certepetide", "description": "certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}, {"type": "DRUG", "name": "nab-paclitaxel", "description": "nab-paclitaxel 125 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "gemcitabine", "description": "gemcitabine 1000 mg/m\\^2 IV administered on Day 1, 8, and 15 every 28 days", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion", "SoC chemotherapy plus two certepetide IV pushes and placebo infusion", "SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two placebo IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "certepetide", "description": "certepetide given as two IV pushes over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "placebo given as an IV infusion over 4 hours when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus two certepetide IV pushes and placebo infusion"]}, {"type": "DRUG", "name": "placebo matching certepetide", "description": "certepetide given as a slow IV push over 1 minute when standard treatment(s) are given", "arm_group_labels": ["SoC chemotherapy plus one certepetide IV push, one placebo IV push, and certepetide infusion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Lisata Therapeutics, Inc.+NCT06592664+terminated", "https://www.google.com/search?q=Lisata Therapeutics, Inc.+placebo matching certepetide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for placebo matching certepetide by Lisata Therapeutics, Inc.. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for placebo matching certepetide by Lisata Therapeutics, Inc.\n\nFirst, I need to understand what the query is asking for:\n- FDA warning letters related to \"placebo matching certepetide\" by Lisata Therapeutics\n- Clinical holds for the same\n- Specific dates, reasons, and safety issues cited\n\nLet me go through each search result to see if they contain relevant information:\n\nResult [1]: This is about Lisata announcing positive preclinical ADC data for Certepetide. It mentions:\n- Preclinical data showing improved tumor-selective penetration and enhanced ADC efficacy\n- A licensing partnership with Catalent\n- The data is preclinical only; no human safety data reported\n- Certepetide has received various designations (Fast Track, Orphan Drug for pancreatic cancer, glioma, osteosarcoma)\n- No mention of FDA warning letters or clinical holds\n\nResult [2]: This is about Lisata announcing preliminary results from a pancreatic cancer trial. It mentions:\n- Certepetide demonstrated favorable safety, tolerability, and clinical activity in clinical trials\n- The combination with FOLFIRINOX was safe and feasible with no serious adverse events attributed to certepetide\n- Certepetide has received various designations\n- No mention of FDA warning letters or clinical holds\n\nResult [3]: This is about Certepetide receiving FDA orphan drug designation for cholangiocarcinoma. It mentions:\n- FDA granted orphan drug designation to certepetide for cholangiocarcinoma\n- Certepetide is an investigational agent that assists co-administered anticancer drugs\n- It's being investigated in phase 2a BOLSTER study\n- No mention of FDA warning letters or clinical holds\n\nResult [4]: This is about FDA issuing warning letters to GLP-1 drug sellers, not related to certepetide or Lisata Therapeutics. It mentions:\n- FDA sent Warning Letters to five companies selling GLP-1 products\n- This is about misbranding and unapproved therapeutic claims for GLP-1 products like Semaglutide and Tirzepatide\n- Not related to certepetide or Lisata Therapeutics\n\nResult [5]: This appears to be about Certepetide receiving FDA orphan drug designation, but the content is truncated. No", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. mentioning clinical trial NCT06592664 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Lisata Therapeutics, Inc. that mention clinical trial NCT06592664 or related drug safety issues.\n\nFirst, let me identify the relevant information from each search result:\n\nResult [1]:\n- Shows SEC EDGAR filings for LISATA THERAPEUTICS, INC.\n- Mentions an 8-K filing dated 10/14/2025 (which is in the future from our current date of November 14, 2025)\n- CIK appears to be 320017 (from the URL)\n\nResult [2]:\n- This is the company website for Lisata Therapeutics\n- Describes them as a clinical-stage pharmaceutical company\n- Mentions their CendR Platform\u00ae technology for tumor-targeted drug delivery\n- References \"preliminary Phase 2b results in metastatic pancreatic cancer\" for a drug called \"certepetide\"\n- No specific mention of NCT06592664 or safety issues\n\nResult [3]:\n- Shows SEC EDGAR filings but the URL mentions \"NeoStem,-Inc.\" which seems inconsistent\n- Shows 8-K filings dated 07/15/2025 and 06/26/2025\n- CIK appears to be 320017 (from the URL)\n\nResult [4]:\n- PDF of a Form 8-K Current Event Report for LISATA THERAPEUTICS, INC.\n- Mentions \"On June 26, 2025, Lisata Therapeutics, Inc. (the \"Company\") issued a press release announcing preliminary cohort B data from the...\"\n- This appears to correspond to the 8-K filing mentioned in result [3] dated 06/26/2025\n\nResult [5]:\n- Shows EDGAR filing documents\n- Confirms CIK: 0000320017 for LISATA THERAPEUTICS, INC.\n- Shows a filing type 8-K\n\nNow, I need to specifically look for mentions of clinical trial NCT06592664 or drug safety issues:\n\nFrom the search results, I don't see any explicit mention of clinical trial NCT06592", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "start_date": "2030-01-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Lisata Therapeutics, Inc. about clinical trial NCT06592664 for placebo matching certepetide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about safety issues, adverse events, trial termination reasons, or regulatory actions related to clinical trial NCT06592664 for certepetide (which appears to be the drug being tested, with \"placebo matching certepetide\" being the placebo).\n\nFirst, let me identify what NCT06592664 is about:\n\nFrom result [1]:\n- NCT06592664 is a Phase 1b/2a clinical trial\n- It's testing \"certepetide\" plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma\n- The main questions are about safety/tolerability and effectiveness\n- It's a three-arm study with randomization\n- There's a 3-day run-in period where participants receive only LSTA1 (which appears to be certepetide) or placebo\n- The drugs involved are: certepetide, nab-paclitaxel, gemcitabine, and placebo matching certepetide\n\nFrom result [5]:\n- This trial is called \"FORTIFIDE\"\n- It's a Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study\n- It's evaluating a 4-hour infusion of certepetide (LSTA1) when added to standard of care in patients with second-line metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX\n- Status: \"Enrollment pending\" (as of when this page was published)\n\nFrom result [9]:\n- It lists \"Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC\" with Study ID NCT06592664\n- Status: \"Withdrawn\"\n\nThis is important - result [9] indicates the trial status is \"Withdrawn\", which is relevant to the query about \"trial termination reasons\".\n\nNow, let me look for information about safety issues, adverse events, trial termination reasons, or regulatory actions:\n\nFrom result [1]:\n- The study aims to answer \"is the new drug plus standard treatment safe and tolerable\"\n- But it doesn't provide any specific safety data or adverse events\n\nFrom result [2]:\n- This is a press release about preclinical data of cert", "citations": [], "search_params": {"company": "Lisata Therapeutics, Inc.", "nct_id": "NCT06592664", "drug_name": "placebo matching certepetide"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was \"WITHDRAWN\" according to the status, and the official reason given is \"Management Decision.\" This suggests that the trial was terminated due to administrative or operational reasons, rather than due to safety concerns or lack of efficacy. The detailed description does not mention any safety issues or poor efficacy results that led to the termination. Therefore, the most likely reason for the trial failure appears to be an administrative or managerial decision, rather than scientific or clinical concerns.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:15.394132", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1366}}, "22": {"nct_id": "NCT06131502", "drug_name": "ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy", "intervention_type": "DEVICE", "drug_description": "The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "The IRB for this project lapsed, the IDE transfer to Dr. Joseph Taylor is underway, and there may be a possible change in funding source. Pending IRB re-submission in 2026.", "title": "Sonication-based OCD Neurosurgical Intervention Via Capsulotomy", "start_date": "2026-04-30", "completion_date": "2032-06-30", "sponsor": "Brigham and Women's Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.540627", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:18.259823", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The proposed study aims to establish the safety and efficacy of ExAblate MR-guided Focused Ultrasound (MRgFUS) for patients with treatment-refractory obsessive-compulsive disorder (OCD). Bilateral anterior thermo-capsulotomy and gamma-knife capsulotomy are well-known and effective treatments for treatment-refractory OCD patients. In this study, the investigators will use the ExAblate MRgFUS technology (Insightec Ltd) as a new method for capsulotomy for OCD patients. The ExAblate MRgFUS technology for neuro-related clinical applications has received FDA approval for Essential Tremor. In addition, the FDA approved an expansion of the ExAblate Neuro to include the treatment of tremor-dominant Parkinson's Disease. The study is designed to demonstrate safety and effectiveness and intended as a primary clinical support for a future marketing application.\n\nThe investigators propose a two-stage research protocol to establish the safety and efficacy of ExAblate MRgFUS for patients with treatment-resistant OCD. The first stage will be designed as a 'patient as own control' paradigm. Severe, treatment resistant OCD patients (n=10) will be recruited in two centers (Harvard and Stanford) and treated for 6 months by a best medical treatment (BMT) protocol followed by the ExAblate MRgFUS procedure plus BMT for another 12 months. The second stage will be designed as a 'double blind randomized control trial' paradigm. Moderate to severe, partially treatment resistant OCD patients (n=56) will be recruited in a multi-centered study and randomized into the ExAblate MRgFUS or sham procedures. They will be treated by BMT plus MRgFUS or BMT plus sham for 12 months followed by BMT plus the Exablate MRgFUS for the non-responding sham group for another 12 months.\n\nThis study is the first to evaluate ExAblate MRgFUS for OCD in the USA. This protocol was developed by two collaborating centers at Harvard and Stanford Universities, with two experienced and dedicated multidisciplinary teams of psychiatrists, neurosurgeons, psychologists, radiologists and neurologists. The suggested technical protocol using the ExAblate MRgFUS system for OCD is derived from a reported Korean study and an on-going Canadian clinical study.\n\nThe study is funded by the Focused Ultrasound Foundation and Insightec Ltd.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical trial is to determine if ExAblate MR-guided Focused Ultrasound (MRgFUS) bilateral anterior capsulotomy can be used safely and effectively to relieve symptoms of moderate to severe obsessive compulsive disorder (OCD) in individuals who have not benefited from psychotherapy and medications.\n\nThe main questions it aims to answer are:\n\n1. Can ExAblate MRgFUS capsulotomy be safely delivered to individuals suffering from treatment-refractory OCD through an intact skull with a risk and side-effect profile that is comparable to other neurosurgical approaches for capsulotomy?\n2. Will ExAblate MRgFUS capsulotomy result in improvement in clinical symptoms and quality of life metrics that are similar to those seen with other surgical approaches for capsulotomy?\n\nIn the first stage of the study, participants with severe, treatment resistant OCD (n=10) will be recruited in two centers (Harvard and Stanford) and treated with best medical care (BMT) for 6 months. Thereafter, they will receive the ExAblate MRgFUS procedure and then another BMT for 12 months. In the second stage of the study, participants with moderate to severe OCD (n=56) will be recruited in a multi-center study and treated with BMT plus real or sham MRgFUS for 12 months. Thereafter, those who received sham MRgFUS and did not improve will receive real MRgFUS and then treated with BMT for another 12 months.", "detailed_description": "The proposed study aims to establish the safety and efficacy of ExAblate MR-guided Focused Ultrasound (MRgFUS) for patients with treatment-refractory obsessive-compulsive disorder (OCD). Bilateral anterior thermo-capsulotomy and gamma-knife capsulotomy are well-known and effective treatments for treatment-refractory OCD patients. In this study, the investigators will use the ExAblate MRgFUS technology (Insightec Ltd) as a new method for capsulotomy for OCD patients. The ExAblate MRgFUS technology for neuro-related clinical applications has received FDA approval for Essential Tremor. In addition, the FDA approved an expansion of the ExAblate Neuro to include the treatment of tremor-dominant Parkinson's Disease. The study is designed to demonstrate safety and effectiveness and intended as a primary clinical support for a future marketing application.\n\nThe investigators propose a two-stage research protocol to establish the safety and efficacy of ExAblate MRgFUS for patients with treatment-resistant OCD. The first stage will be designed as a 'patient as own control' paradigm. Severe, treatment resistant OCD patients (n=10) will be recruited in two centers (Harvard and Stanford) and treated for 6 months by a best medical treatment (BMT) protocol followed by the ExAblate MRgFUS procedure plus BMT for another 12 months. The second stage will be designed as a 'double blind randomized control trial' paradigm. Moderate to severe, partially treatment resistant OCD patients (n=56) will be recruited in a multi-centered study and randomized into the ExAblate MRgFUS or sham procedures. They will be treated by BMT plus MRgFUS or BMT plus sham for 12 months followed by BMT plus the Exablate MRgFUS for the non-responding sham group for another 12 months.\n\nThis study is the first to evaluate ExAblate MRgFUS for OCD in the USA. This protocol was developed by two collaborating centers at Harvard and Stanford Universities, with two experienced and dedicated multidisciplinary teams of psychiatrists, neurosurgeons, psychologists, radiologists and neurologists. The suggested technical protocol using the ExAblate MRgFUS system for OCD is derived from a reported Korean study and an on-going Canadian clinical study.\n\nThe study is funded by the Focused Ultrasound Foundation and Insightec Ltd.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Real FUS", "type": "ACTIVE_COMPARATOR", "description": "The treatment volume and plan will be defined by the neurosurgeon. The ExAblate MRgFUS system will automatically compute the number of sonications, and the (per sonication spot) phase and amplitude corrections necessary for the system to produce a focal spot at each of the desired locations. The target selected for this study is the anterior limb of the internal capsule (ALIC). The target will be approximately 7-10mm rostral to the anterior edge of the anterior commissure, in the ventral part of the ALIC. A central point in the targeted area will be targeted with a low dose, sub-lethal energy level sonication to confirm the targeting accuracy on the MR images. Focal point position and/or transducer location will be adjusted as necessary.", "intervention_names": ["Device: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy"]}, {"label": "Sham FUS", "type": "SHAM_COMPARATOR", "description": "The sham procedure will be identical in planning and execution to the ExAblate procedure with the only exception being that the energy output will be 0 for the sham-treated subjects. To perform the sham treatment, the sonication will be performed with energy output disabled. For sham subjects, the physician will interact with a subject in a similar manner and for a similar duration to simulate an actual procedure. When possible, the treating physician may determine a sonication (treatment) time for sham subjects to be similar to that which is occurring in the ExAblate procedure to maintain consistency between treatment arms. It should be noted that all treatment times of both treatment arms will be captured in the study CRF.", "intervention_names": ["Device: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy"]}], "interventions": [{"type": "DEVICE", "name": "ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy", "description": "The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.", "arm_group_labels": ["Real FUS", "Sham FUS"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Brigham and Women's Hospital+NCT06131502+terminated", "https://www.google.com/search?q=Brigham and Women's Hospital+ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy by Brigham and Women's Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking about:\n1. FDA warning letters or clinical holds for \"ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy\" \n2. Specifically conducted by Brigham and Women's Hospital\n3. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this specific information:\n\nResult [1]: ClinicalTrials.gov entry for NCT01304758 about ExAblate Transcranial MR Guided Focused Ultrasound. This appears to be about tumor treatment, not specifically about bilateral anterior capsulotomy or Brigham and Women's Hospital.\n\nResult [2]: FDA Summary of Safety and Effectiveness Data (SSED) for P150038. This discusses the Exablate Neuro device approval for thalamotomy treatment of essential tremor, but doesn't mention warning letters or clinical holds from Brigham and Women's Hospital.\n\nResult [3]: Article about Exablate Neuro gaining FDA approval for staged bilateral focused ultrasound for Parkinson's disease. No mention of warning letters or Brigham and Women's Hospital.\n\nResult [4]: Article about FDA approval of Exablate Neuro for essential tremor. No mention of warning letters.\n\nResult [5]: Another FDA SSED document for P150038. Contains information about contraindications and adverse events but no warning letters.\n\nResult [6]: This is interesting - it's an FDA warning letter to \"Brigham and Women's Hospital Inc.\" dated 04/11/2022 (April 11, 2022). The title is \"Brigham and Women's Hospital Inc. - 623476 - 04/11/2022 - FDA\". However, the description says: \"This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography...\" This appears to be about PET (positron emission tomography), not about ExAblate or focused ultrasound. So this is not relevant to our query.\n\nResult [7]: FDA PMA information for P150038, which is about ExAblate Neuro approval for essential tremor. No warning letters mentioned.\n\nResult [8]: Article about FDA approving bilateral focused ultrasound for Parkinson's disease", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Brigham and Women's Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Brigham and Women's Hospital about clinical trial NCT06131502 for ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about clinical trial NCT06131502 for ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions. I'll go through each search result to see what relevant information I can find.\n\nLet me first identify which search results are about NCT06131502:\n\nResult [4]: https://ctv.veeva.com/study/sonication-based-ocd-neurosurgical-intervention-via-capsulotomy\nThis appears to be about the clinical trial \"Sonication-based OCD Neurosurgical Intervention Via Capsulotomy\" which matches the description of NCT06131502.\n\nResult [6]: https://ichgcp.net/clinical-trials-registry/NCT06131502\nThis is directly about NCT06131502, titled \"Sonication-based OCD Neurosurgical Intervention Via Capsulotomy\".\n\nResult [7]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12148002/\nThis article mentions \"Brigham and Women's Hospital. Sonication-based OCD neurosurgical intervention via capsulotomy (SONIC). ClinicalTrials.gov identifier: NCT06131502.\"\n\nSo results [4], [6], and [7] are directly related to NCT06131502. Let me examine these in detail.\n\nFrom result [4] and [6], I see:\n\"The goal of this clinical trial is to determine if ExAblate MR-guided Focused Ultrasound (MRgFUS) bilateral anterior capsulotomy can be used safely and...\"\n\nThis indicates the trial is focused on safety, but doesn't provide specific safety data or adverse events.\n\nFrom result [7], I get more detailed information:\n- The trial is called \"Sonication-based OCD neurosurgical intervention via capsulotomy (SONIC)\"\n- It's associated with Brigham and Women's Hospital\n- The Exablate Neuro is being used off-label for OCD treatment in Canada (though this trial is likely in the US)\n- In Canada, \"OCD is not an approved intended use for the Exablate Neuro; the Exablate Neuro is currently intended for", "citations": [], "search_params": {"company": "Brigham and Women's Hospital", "nct_id": "NCT06131502", "drug_name": "ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial suspension states that the IRB for the project lapsed, the IDE transfer to a new investigator is underway, and there may be a change in the funding source. These administrative issues, rather than safety or efficacy concerns, appear to be the primary reasons for the trial suspension. The detailed description does not mention any safety or efficacy problems, further supporting an administrative failure.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:18.258678", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1403}}, "23": {"nct_id": "NCT05563948", "drug_name": "Cannabis", "intervention_type": "DRUG", "drug_description": "Vaporized cannabis will be administered 3x/day for 15 days.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023.", "title": "Repeated Administration of Cannabis Varying in THC and CBD", "start_date": "2026-02-01", "completion_date": "2034-09-30", "sponsor": "New York State Psychiatric Institute", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.540881", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:20.823588", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "A0A1V0QSH2", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "I6WU39", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "H9A1V3", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GTB6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "A6P6V9", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Cannabis", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41218202", "title": "Solution-Focused Brief Intervention for Substance Use: Protocol for a Multisite Randomized Controlled Trial.", "authors": [{"name": "Gonz\u00e1lez-Suitt K", "authtype": "Author", "clusterid": ""}, {"name": "Verg\u00e9s A", "authtype": "Author", "clusterid": ""}, {"name": "Portilla Huidobro R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206802", "title": "Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.", "authors": [{"name": "Wong CX", "authtype": "Author", "clusterid": ""}, {"name": "Cheung CC", "authtype": "Author", "clusterid": ""}, {"name": "Montenegro G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41191341", "title": "Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use.", "authors": [{"name": "Hutchison KE", "authtype": "Author", "clusterid": ""}, {"name": "Hooper JF", "authtype": "Author", "clusterid": ""}, {"name": "Karoly HC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41187669", "title": "Brief mindfulness intervention for adults with cannabis use disorder: A randomised clinical trial.", "authors": [{"name": "Lorenzetti V", "authtype": "Author", "clusterid": ""}, {"name": "McTavish E", "authtype": "Author", "clusterid": ""}, {"name": "Thomson H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41177894", "title": "Dual abstinence from nicotine vaping and cannabis use among young people: secondary analyses from two U.S.-based randomized controlled trials of vaping cessation.", "authors": [{"name": "Graham AL", "authtype": "Author", "clusterid": ""}, {"name": "Cha S", "authtype": "Author", "clusterid": ""}, {"name": "Do EK", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The majority of the \\>3 million medical cannabis patients in the U.S. use cannabis products to manage pain but many questions remain. This project is designed to answer three questions that will fill important voids in the field's understanding of sustained cannabis use: 1) is abrupt cessation of cannabis associated with increased pain sensitivity; 2) does tolerance develop to the analgesic and abuse-related effects of repeatedly administered cannabis with varying ratios of THC and CBD, and is this tolerance reversible following a period of abstinence; 3) how does repeated cannabis use affect levels of endocannabinoids, and are these changes associated with changes in pain sensitivity and abuse liability? In this study, the investigators will enroll participants (N=100 healthy, cannabis-using men and non-pregnant women, ages 21-65) inpatient for 15 days. They will be randomized to one of four cannabis conditions (n=25/group). Following a day of standardization on which participants will receive their assigned cannabis condition (Day 1), cannabis will be administered repeatedly for 14 days (Day 2-15). The investigators will measure abuse-related effects (\"Good Drug Effect\"), endocannabinoid levels and two distinct types of experimental pain: The Cold Pressor Test and Quantitative Sensory Testing Thermal Temporal Summation. Given the widespread use of cannabis for pain, understanding the consequences of daily repeated administration of cannabis with THC:CBD ratios that are representative of most medical cannabis products on pain, abuse liability, and endocannabinoids is imperative.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "High THC : High CBD", "type": "EXPERIMENTAL", "description": "Cannabis that is high in THC and high in CBD will be administered.", "intervention_names": ["Drug: Cannabis"]}, {"label": "High THC : Low CBD", "type": "EXPERIMENTAL", "description": "Cannabis that is high in THC and low in CBD will be administered.", "intervention_names": ["Drug: Cannabis"]}, {"label": "Low THC : High CBD", "type": "EXPERIMENTAL", "description": "Cannabis that is low in THC and high in CBD will be administered.", "intervention_names": ["Drug: Cannabis"]}, {"label": "Low THC : Low CBD", "type": "PLACEBO_COMPARATOR", "description": "Cannabis that is low in THC and low in CBD will be administered.", "intervention_names": ["Drug: Cannabis"]}], "interventions": [{"type": "DRUG", "name": "Cannabis", "description": "Vaporized cannabis will be administered 3x/day for 15 days.", "arm_group_labels": ["High THC : High CBD", "High THC : Low CBD", "Low THC : High CBD", "Low THC : Low CBD"]}]}}, "company_search_urls": ["https://www.google.com/search?q=New York State Psychiatric Institute+NCT05563948+terminated", "https://www.google.com/search?q=New York State Psychiatric Institute+Cannabis+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Cannabis by New York State Psychiatric Institute. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Cannabis by New York State Psychiatric Institute.\n\nFirst, I need to identify which results are relevant to the query:\n\n1. Result [1] - This is about a warning letter to New York State Psychiatric Institute (NYSPI) IRB, but it doesn't specifically mention cannabis. It's about objectionable conditions observed during an FDA inspection in January-February 2023.\n\n2. Result [2] - This is about therapeutic use of medical cannabis in New York State, but it doesn't mention any warning letters or clinical holds related to NYSPI.\n\n3. Result [3] - This discusses an FDA warning letter to NYSPI, but it appears to be about a clinical trial where a participant died by suicide. It doesn't specifically mention cannabis.\n\n4. Result [4] - This is about FDA Warning Letters for CBD products in general (2015-2019), but not specific to NYSPI.\n\n5. Result [5] - This confirms the warning letter to NYSPI IRB issued on March 21, 2024, related to failure to report a serious adverse event (participant death).\n\n6. Result [6] - This is about cannabis product recalls in New York, but not related to NYSPI or FDA warning letters.\n\n7. Result [7] - This is about FDA enforcement in general, not specific to NYSPI or cannabis.\n\n8. Result [8] - This mentions FDA warning letters for cannabis-derived products, but doesn't specify any related to NYSPI.\n\nNow, let me look for specific information about cannabis-related warning letters or clinical holds for NYSPI:\n\nFrom result [1], [3], and [5], I can see that there was a warning letter issued to NYSPI IRB on March 21, 2024, related to a clinical trial where a participant died by suicide. However, none of these results explicitly state that this was a cannabis-related trial.\n\nResult [3] states: \"According to a 21 March warning letter posted on the FDA's website last week, the institute's IRB, which is led by Corinne Rogers, did not report to the agency that a participant died by suicide during a 2021 clinical trial.\"\n\nResult [5] confirms: \"On March 2", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "New York State Psychiatric Institute"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by New York State Psychiatric Institute about clinical trial NCT05563948 for Cannabis. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about the external safety evidence for clinical trial NCT05563948, which is titled \"Repeated Administration of Cannabis Varying in THC and CBD\" conducted by the New York State Psychiatric Institute.\n\nFirst, I need to identify what information is available about:\n1. Status of the trial\n2. Safety issues, adverse events\n3. Trial termination reasons (if applicable)\n4. Regulatory actions\n5. Relevance to the current investigation\n6. Citations\n\nFrom the search results:\n\nResult [1] indicates:\n- Trial status: \"Suspended\" (as of November 14, 2025, which is today's date according to the prompt)\n- Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE on Sep 30, 2022\n- No description provided in the ClinConnect Summary\n- Inclusion/Exclusion criteria provided\n\nResult [2] provides more details about the study:\n- It's measuring \"abuse-related effects ('Good Drug Effect'), endocannabinoid levels and two distinct types of experimental pain: The Cold Pressor...\"\n- It has different arms: \"Cannabis that is low in THC and high in CBD will be administered\" and \"Cannabis that is low in THC and low in CBD will be administered\"\n- Provides inclusion/exclusion criteria\n\nResult [3] discusses research on cannabis use disorder treatment but doesn't specifically mention NCT05563948. It talks about a different study involving AEF0117 for cannabis use disorder.\n\nResult [4] is about cannabis dependence in general and lists various medications being studied, but doesn't specifically address NCT05563948.\n\nResult [5] mentions a study about \"Smoked Cannabis Effects in Cannabis Users\" but doesn't specifically reference NCT05563948.\n\nResult [6] is about registered ongoing studies related to cannabis but doesn't provide specific information about NCT05563948.\n\nResult [7] provides a brief description: \"Given the widespread use of cannabis for pain, understanding the consequences of daily repeated administration of cannabis with THC:CBD ratios that are...\" but doesn't give specific safety information about NCT05563948.\n\nResult [8] confirms it's an interventional study", "citations": [], "search_params": {"company": "New York State Psychiatric Institute", "nct_id": "NCT05563948", "drug_name": "Cannabis"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the suspension of this clinical trial is not related to safety or efficacy concerns, but rather due to \"quality assurance and compliance concerns\" that led to an FWA (Federal-Wide Assurance) restriction on the research being conducted at the New York State Psychiatric Institute. This indicates that the trial was suspended for administrative reasons, rather than issues with the safety or efficacy of the investigational cannabis product.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:20.822608", "claude_model": "claude-3-haiku-20240307", "tokens_used": 908}}, "24": {"nct_id": "NCT05375708", "drug_name": "Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)", "intervention_type": "DRUG", "drug_description": "CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \\<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.\n\n5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\n5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\nWhen S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Pilot study findings pointed to a overhaul in study design", "title": "Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites", "start_date": "2025-12-01", "completion_date": "2034-06-01", "sponsor": "UMC Utrecht", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.541132", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:25.080421", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1201583", "pref_name": "BEVACIZUMAB", "targets": [], "has_uniprot_targets": false, "search_name": "Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The addition of stereotactic body radiation therapy (SBRT) to metastases in a limited unresectable metastatic setting might improve progression-free survival (PFS). The success of the addition of local treatments in mCRC patients depends largely on: control of microscopic disease, diagnostic accuracy of macroscopic disease and effective treatment of all detected metastases with limited additional toxicity to surrounding tissues. Until shortly, the use of SBRT was possible to a limited number of locations due to target movement or toxicity to surrounding radiosensitive structures. With the introduction of MRI-guided radiotherapy these limitations have been largely reduced due to the possibility to make a daily new treatment plan based on MRI-visualized anatomy. This allows the use of smaller margins for uncertainty with less healthy tissues in the radiation field. Thereby, a broader application of SBRT to add local control to metastases became possible.\n\nThis study is an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases with no option of local treatment with curative intent and with stable disease or partial response after treatment of CAPOX-B, FOLFOX-B or FOLFOXIRI-B.", "aact_documents": [], "pubmed_results": [{"pmid": "39885896", "title": "Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with\u00a0\u2264\u00a010 metastases: A multicenter pilot study (NCT05375708).", "authors": [{"name": "Zwart K", "authtype": "Author", "clusterid": ""}, {"name": "Braat MNGJA", "authtype": "Author", "clusterid": ""}, {"name": "van der Baan FH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36921494", "title": "Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.", "authors": [{"name": "Ducreux M", "authtype": "Author", "clusterid": ""}, {"name": "Tabernero J", "authtype": "Author", "clusterid": ""}, {"name": "Grothey A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "31850687", "title": "Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.", "authors": [{"name": "Kurk SA", "authtype": "Author", "clusterid": ""}, {"name": "Peeters PHM", "authtype": "Author", "clusterid": ""}, {"name": "Dorresteijn B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "30614531", "title": "Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.", "authors": [{"name": "Modest DP", "authtype": "Author", "clusterid": ""}, {"name": "Rivera F", "authtype": "Author", "clusterid": ""}, {"name": "Bachet JB", "authtype": "Author", "clusterid": ""}]}, {"pmid": "28911067", "title": "Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.", "authors": [{"name": "Goey KKH", "authtype": "Author", "clusterid": ""}, {"name": "Elias SG", "authtype": "Author", "clusterid": ""}, {"name": "van Tinteren H", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation). However, it is unclear if patients with more extensive metastatic disease benefit from local therapies to control visible metastasis.\n\nThe purpose of this study is to assess the impact of stereotactic body radiation therapy (SBRT) in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with metastatic colorectal cancer (mCRC) and \u226410 metastases.", "detailed_description": "The addition of stereotactic body radiation therapy (SBRT) to metastases in a limited unresectable metastatic setting might improve progression-free survival (PFS). The success of the addition of local treatments in mCRC patients depends largely on: control of microscopic disease, diagnostic accuracy of macroscopic disease and effective treatment of all detected metastases with limited additional toxicity to surrounding tissues. Until shortly, the use of SBRT was possible to a limited number of locations due to target movement or toxicity to surrounding radiosensitive structures. With the introduction of MRI-guided radiotherapy these limitations have been largely reduced due to the possibility to make a daily new treatment plan based on MRI-visualized anatomy. This allows the use of smaller margins for uncertainty with less healthy tissues in the radiation field. Thereby, a broader application of SBRT to add local control to metastases became possible.\n\nThis study is an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases with no option of local treatment with curative intent and with stable disease or partial response after treatment of CAPOX-B, FOLFOX-B or FOLFOXIRI-B.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Systemic maintenance therapy", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"]}, {"label": "Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Radiation: Stereotactic body radiation therapy (SBRT)", "Drug: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"]}], "interventions": [{"type": "RADIATION", "name": "Stereotactic body radiation therapy (SBRT)", "description": "Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.", "arm_group_labels": ["Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)"]}, {"type": "DRUG", "name": "Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)", "description": "CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \\<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.\n\n5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\n5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\nWhen S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.", "arm_group_labels": ["Systemic maintenance therapy", "Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=UMC Utrecht+NCT05375708+terminated", "https://www.google.com/search?q=UMC Utrecht+Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) by UMC Utrecht. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about FDA warning letters or clinical holds for Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab) by UMC Utrecht.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds\n2. Related to Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab)\n3. From UMC Utrecht\n4. Including specific dates, reasons, and safety issues cited\n\nLet me go through each search result to see if it contains relevant information:\n\nResult [1]: This is about a study analyzing FDA warning letters from 2012-2019. It discusses general categories of violations but doesn't mention UMC Utrecht or the specific maintenance therapy in question.\n\nResult [2]: This describes the BEVAMAINT trial, which is a phase III trial comparing fluoropyrimidine alone or plus bevacizumab as maintenance treatment for metastatic colorectal cancer. It mentions the trial started in January 2020 but doesn't mention UMC Utrecht specifically or any FDA warning letters/clinical holds.\n\nResult [3]: This is a warning letter to the University of Kentucky from March 26, 2020, but it's not related to UMC Utrecht or the maintenance therapy in question.\n\nResult [4]: This discusses recent FDA cancer drug safety warnings but doesn't mention UMC Utrecht or the specific maintenance therapy.\n\nResult [5]: This is about FDA warning letters in general and their costs to the medical device industry, but doesn't mention UMC Utrecht or the specific maintenance therapy.\n\nResult [6]: This is about a fake bevacizumab warning from 2013, but doesn't mention UMC Utrecht.\n\nResult [7]: This appears to be about incoming requests to the FDA, but doesn't seem to contain relevant information about UMC Utrecht.\n\nResult [8]: This is about infliximab trough levels, not related to the query.\n\nResult [9]: This is about dabrafenib plus trametinib, not related to the query.\n\nResult [10]: This is about long-acting insulin analogues, not related to the query.\n\nResult [11]: This mentions UMC Utrecht in the context of gender dysphoria treatment, but not related to the maintenance therapy in", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by UMC Utrecht mentioning clinical trial NCT05375708 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by UMC Utrecht\n- Specifically mentioning clinical trial NCT05375708 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to identify what \"UMC Utrecht\" refers to. Utrecht is a city in the Netherlands, so this likely refers to a company based in Utrecht, Netherlands.\n\nLet me go through the search results to see if any of them contain relevant information:\n\nResult [1]: This appears to be a generic EDGAR search page with no specific company information. It shows \"No Filings for this company\" for various categories.\n\nResult [2]: This is a Form 8-K for uniQure N.V. filed on 2025-02-27. uniQure appears to be a biotech company (mentions clinical trials, FDA meetings, etc.). It discusses:\n- A Type B meeting with FDA in Q1 2025\n- Completion of enrollment of 12 patients in the third cohort of a study\n- Expectation to provide safety update in Q2 2025\n- Mentions \"AMT-130\" which appears to be a drug candidate\n- Mentions \"neurofilament light chain (NfL) in the cerebrospinal fluid (CSF)\"\n- Mentions \"Phase I/II EPISODE1 study\"\n\nResult [3]: This is a 10-K annual report, but it doesn't seem to be from UMC Utrecht. It contains general risk factors related to biotech/pharma companies but no specific mention of UMC Utrecht or NCT05375708.\n\nResult [4]: This shows information about Merus N.V. (MRUS on Nasdaq), which is incorporated in the Netherlands. It has CIK 0001651311. It shows some 8-K filings from 2025, but no specific content details that mention clinical trial NCT05375708.\n\nResult [5]: This is about United Microelectronics Corporation (UMC), which is a semiconductor company based in Taiwan. It filed a Form 20-F for ", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT05375708", "start_date": "2025-12-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by UMC Utrecht about clinical trial NCT05375708 for Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by UMC Utrecht regarding clinical trial NCT05375708, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what trial NCT05375708 is about based on the search results:\n\nFrom result [1], I can see that NCT05375708 is titled \"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites\" and is launched by UMC UTRECHT.\n\nFrom result [3], I can see more details: \"This study is an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases.\"\n\nFrom result [6], I see that the target recruit count is 93.\n\nNow, let me look for any press releases, investor presentations, or public statements by UMC Utrecht specifically about this trial, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nResult [1] provides general information about the trial but doesn't mention any press releases or safety issues.\n\nResult [2] is about a study titled \"Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with \u2264 10 metastases: A multicenter pilot study (SIRIUS)\". This seems related to the trial in question, as it discusses feasibility and safety of a similar treatment approach. The abstract states: \"Results indicate that radiotherapy combined with systemic therapy is feasible and safe in this population.\" It also mentions: \"In summary, we demonstrate that the concept of single-fraction sub-ablative radiotherapy in combination with systemic therapy in patients with limited polymetastatic (\u226410) CRC is feasible and safe.\" However, this appears to be a separate pilot study (SIRIUS) rather than the NCT05375708 trial itself.\n\nResult [3] provides more details about the trial design but doesn't mention any press releases or safety issues.\n\nResult [4] just lists the trial with brief information.\n\nResult [", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT05375708", "drug_name": "Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"}}}}, "llm_analysis": {"classification": "FAILURE_DESIGN", "confidence": "high", "reasoning": "The official reason for trial suspension states \"Pilot study findings pointed to a overhaul in study design.\" This suggests the trial was suspended due to administrative or operational issues, rather than safety or efficacy concerns. The detailed description does not mention any safety or efficacy issues that led to the suspension. Therefore, the most likely reason for the trial failure is administrative problems that required a redesign of the study.", "verification_passed": false, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:25.079190", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1355}}, "25": {"nct_id": "NCT05375708", "drug_name": "Stereotactic body radiation therapy (SBRT)", "intervention_type": "RADIATION", "drug_description": "Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Pilot study findings pointed to a overhaul in study design", "title": "Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites", "start_date": "2025-12-01", "completion_date": "2034-06-01", "sponsor": "UMC Utrecht", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.541346", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:25.118563", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Stereotactic body radiation therapy (SBRT)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The addition of stereotactic body radiation therapy (SBRT) to metastases in a limited unresectable metastatic setting might improve progression-free survival (PFS). The success of the addition of local treatments in mCRC patients depends largely on: control of microscopic disease, diagnostic accuracy of macroscopic disease and effective treatment of all detected metastases with limited additional toxicity to surrounding tissues. Until shortly, the use of SBRT was possible to a limited number of locations due to target movement or toxicity to surrounding radiosensitive structures. With the introduction of MRI-guided radiotherapy these limitations have been largely reduced due to the possibility to make a daily new treatment plan based on MRI-visualized anatomy. This allows the use of smaller margins for uncertainty with less healthy tissues in the radiation field. Thereby, a broader application of SBRT to add local control to metastases became possible.\n\nThis study is an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases with no option of local treatment with curative intent and with stable disease or partial response after treatment of CAPOX-B, FOLFOX-B or FOLFOXIRI-B.", "aact_documents": [], "pubmed_results": [{"pmid": "41175290", "title": "Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.", "authors": [{"name": "Laurent PA", "authtype": "Author", "clusterid": ""}, {"name": "Ka K", "authtype": "Author", "clusterid": ""}, {"name": "Roulleaux Dugage M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41173140", "title": "Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality of Life Outcomes from a Prospective Clinical Trial.", "authors": [{"name": "Patel KR", "authtype": "Author", "clusterid": ""}, {"name": "Schott E", "authtype": "Author", "clusterid": ""}, {"name": "Huang EP", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41168707", "title": "Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO).", "authors": [{"name": "Stas D", "authtype": "Author", "clusterid": ""}, {"name": "Vandamme T", "authtype": "Author", "clusterid": ""}, {"name": "Roeyen G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41160161", "title": "Ethical considerations of prospective data collection for stereotactic arrhythmia radioablation (STAR): an overview from the STOPSTORM.eu consortium.", "authors": [{"name": "Crico C", "authtype": "Author", "clusterid": ""}, {"name": "Blanck O", "authtype": "Author", "clusterid": ""}, {"name": "Miszczyk M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41145979", "title": "Experimental investigation of real-time 3D beam's eye view image-guided radiotherapy for prostate SBRT.", "authors": [{"name": "Chrystall D", "authtype": "Author", "clusterid": ""}, {"name": "Stewart M", "authtype": "Author", "clusterid": ""}, {"name": "Jin F", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation). However, it is unclear if patients with more extensive metastatic disease benefit from local therapies to control visible metastasis.\n\nThe purpose of this study is to assess the impact of stereotactic body radiation therapy (SBRT) in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with metastatic colorectal cancer (mCRC) and \u226410 metastases.", "detailed_description": "The addition of stereotactic body radiation therapy (SBRT) to metastases in a limited unresectable metastatic setting might improve progression-free survival (PFS). The success of the addition of local treatments in mCRC patients depends largely on: control of microscopic disease, diagnostic accuracy of macroscopic disease and effective treatment of all detected metastases with limited additional toxicity to surrounding tissues. Until shortly, the use of SBRT was possible to a limited number of locations due to target movement or toxicity to surrounding radiosensitive structures. With the introduction of MRI-guided radiotherapy these limitations have been largely reduced due to the possibility to make a daily new treatment plan based on MRI-visualized anatomy. This allows the use of smaller margins for uncertainty with less healthy tissues in the radiation field. Thereby, a broader application of SBRT to add local control to metastases became possible.\n\nThis study is an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases with no option of local treatment with curative intent and with stable disease or partial response after treatment of CAPOX-B, FOLFOX-B or FOLFOXIRI-B.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Systemic maintenance therapy", "type": "ACTIVE_COMPARATOR", "description": null, "intervention_names": ["Drug: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"]}, {"label": "Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Radiation: Stereotactic body radiation therapy (SBRT)", "Drug: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)"]}], "interventions": [{"type": "RADIATION", "name": "Stereotactic body radiation therapy (SBRT)", "description": "Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.", "arm_group_labels": ["Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)"]}, {"type": "DRUG", "name": "Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)", "description": "CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \\<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.\n\n5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\n5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.\n\nWhen S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.", "arm_group_labels": ["Systemic maintenance therapy", "Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=UMC Utrecht+NCT05375708+terminated", "https://www.google.com/search?q=UMC Utrecht+Stereotactic body radiation therapy (SBRT)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Stereotactic body radiation therapy (SBRT) by UMC Utrecht. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically for Stereotactic Body Radiation Therapy (SBRT) by UMC Utrecht.\n\nFirst, I need to identify which results might contain relevant information:\n\n1. Result [1]: Discusses FDA clinical holds related to investigator misconduct, but doesn't mention SBRT or UMC Utrecht specifically.\n\n2. Result [2]: Discusses safety and efficacy of moderate-intensity SBRT for treating tumors, but doesn't mention FDA warning letters or clinical holds related to UMC Utrecht.\n\n3. Result [3]: Contains FDA guidance on clinical holds, but doesn't mention SBRT or UMC Utrecht.\n\n4. Result [4]: Discusses use of SBRT but doesn't mention FDA warning letters or clinical holds for UMC Utrecht.\n\n5. Result [5]: Discusses FDA warning letters in general for clinical trials, but doesn't specifically mention SBRT or UMC Utrecht.\n\n6. Result [6]: Discusses safety considerations in SBRT, but doesn't mention FDA warning letters or clinical holds for UMC Utrecht.\n\n7. Result [7]: Contains FDA guidance on clinical holds, but doesn't mention SBRT or UMC Utrecht.\n\n8. Result [8]: Discusses safety and efficacy of SBRT for ultra-central thoracic tumors, but doesn't mention FDA warning letters or clinical holds for UMC Utrecht.\n\n9. Result [9]: General information about FDA warning letters, but doesn't mention SBRT or UMC Utrecht.\n\n10. Result [10]: Discusses quality and safety in stereotactic radiosurgery and SBRT, but doesn't mention FDA warning letters or clinical holds for UMC Utrecht.\n\n11. Result [11]: Information about a Phase II trial evaluating SBRT, but doesn't mention FDA warning letters or clinical holds for UMC Utrecht.\n\n12. Result [12]: Record history for a clinical trial, but doesn't mention SBRT or UMC Utrecht specifically in the snippet.\n\n13. Result [13]: Mentions an FDA partial hold on a BioNTech-OncoC4 phase 3 trial, but this is for a different trial (non-small cell lung cancer) and not related to SBRT or UMC Utrecht.\n\n14. Result [14]: Information about an SBRT study, but doesn't mention FDA warning letters or clinical holds", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by UMC Utrecht mentioning clinical trial NCT05375708 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by \"UMC Utrecht\" \n- Specifically mentioning clinical trial NCT05375708 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to understand what \"UMC Utrecht\" refers to. Utrecht is a city in the Netherlands, and there might be a medical center or university there. However, in the search results, I see several different entities:\n\n1. Result [1] - General EDGAR search page (no specific company)\n2. Result [2] - uniQure N.V. Form 8-K (filed 2025-02-27)\n3. Result [3] - Merus N.V. (CIK: 0001651311)\n4. Result [4] - United Microelectronics Corporation (UMC) filing Form 20-F\n5. Results [5]-[10] - Various other filings\n\nLooking at these results, I need to determine if any of them match \"UMC Utrecht\" and contain information about clinical trial NCT05375708 or drug safety issues.\n\nLet's examine each relevant result:\n\nResult [2]: This is a Form 8-K from uniQure N.V. filed on 2025-02-27. It mentions:\n- A Type B meeting with the FDA in Q1 2025 to discuss CMC requirements\n- Completion of enrollment of 12 patients in the third cohort (investigating an optimized immunosuppression regimen)\n- Expectation to provide an initial safety update on the third cohort in Q2 2025\n- Plans to present data from ongoing Phase I/II studies in Q3 2025\n- A favorable recommendation from the IDMC based on 28-day safety data from the first study cohort in the Phase I/II EPISODE1 study\n\nHowever, this is from uniQure N.V., not \"UMC Utrecht\". The document mentions \"AMT-130\" which appears to be a gene therapy product, but there's no mention of NCT0537570", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT05375708", "start_date": "2025-12-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by UMC Utrecht about clinical trial NCT05375708 for Stereotactic body radiation therapy (SBRT). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by UMC Utrecht regarding clinical trial NCT05375708 (SIRIUS trial) that focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each search result to see what information is available:\n\nResult [1]: This is just a link to the clinical trial details for NCT05375708 at clin.larvol.com. It mentions it's a multicenter pilot study called SIRIUS at UMC Utrecht about \"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10...\" but doesn't provide specific safety information or press releases.\n\nResult [2]: This is about a different study on stereotactic body radiotherapy with pembrolizumab for lung cancer, not the NCT05375708 trial for colorectal cancer.\n\nResult [3]: This provides detailed information about the NCT05375708 trial (SIRIUS). It describes it as \"an open-label, multicenter, randomized phase II screening trial assessing the impact of SBRT in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with mCRC and \u226410 metastases.\" It mentions the trial aims to assess safety and efficacy, but doesn't provide specific safety results, adverse events, or information about press releases or trial termination.\n\nResult [4]: This is another summary of the NCT05375708 trial, mentioning it's about \"Systemic Therapy in Combination with Stereotactic\" radiation for colorectal cancer. It provides some details about eligibility criteria but no specific safety information or press releases.\n\nResult [5]: This is a PMC article titled \"Feasibility and safety of single-fraction sub-ablative radiotherapy combined with systemic therapy is feasible and safe in colorectal cancer patients.\" It describes the SIRIUS pilot study (which appears to be NCT05375708) as \"a single-arm, open-label, multicenter, pilot study (SIRIUS) to assess feasibility and safety.\" The abstract states: \"Results indicate that radiotherapy combined with systemic therapy is feasible and safe in this population.\" It also mentions:", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT05375708", "drug_name": "Stereotactic body radiation therapy (SBRT)"}}}}, "llm_analysis": {"classification": "FAILURE_DESIGN", "confidence": "high", "reasoning": "The official reason for trial suspension states \"Pilot study findings pointed to a overhaul in study design.\" This suggests the trial was suspended due to administrative or operational issues, rather than safety or efficacy concerns. The detailed description does not mention any safety or efficacy issues that led to the suspension. Therefore, the most likely reason for the trial failure is administrative problems that required a redesign of the study.", "verification_passed": false, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:25.079190", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1355}}, "26": {"nct_id": "NCT05642195", "drug_name": "H1299 Cell Lysates", "intervention_type": "BIOLOGICAL", "drug_description": "H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Revisions to eligibility/design being made prior to enrollment of first participants.", "title": "Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer", "start_date": "2025-11-18", "completion_date": "2035-12-30", "sponsor": "National Cancer Institute (NCI)", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.541611", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:27.887141", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "H1299 Cell Lysates"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Background:\n\nSurgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back.\n\nObjective:\n\nTo test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803) in people who received surgery for NSCLC.\n\nEligibility:\n\nAdults aged 18 years or older with no sign of disease after surgery for NSCLC.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and lung function. They will have imaging scans.\n\nStudy treatment will be given in 28-day cycles. Participants will visit the clinic on the first day of each cycle. They will receive 2 treatments at each visit:\n\nThe study vaccine is given as 2-4 small shots under the skin of the thigh or arm.\n\nN-803 is given as a shot under the skin of the abdomen.\n\nTreatment will continue for 6 cycles. Blood tests and imaging scans will be repeated throughout the study.\n\nParticipants will have a blood test 1 month after receiving the 6th vaccine. Some participants may then resume taking N-803; they may also receive 2 more vaccinations at 3 and 6 months after their previous treatment.\n\nFollow-up visits will continue for up to 5 years.", "detailed_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "1/ Vaccine with Montanide Adjuvant", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}, {"label": "2/ Vaccine with Montanide Adjuvant and N-803", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "description": "H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "BIOLOGICAL", "name": "H1299 Cell Lysates", "description": "H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DRUG", "name": "N-803", "description": "N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DEVICE", "name": "Ventana PD-L1 (SP263 or SP142) assay", "description": "FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}]}}, "company_search_urls": ["https://www.google.com/search?q=National Cancer Institute (NCI)+NCT05642195+terminated", "https://www.google.com/search?q=National Cancer Institute (NCI)+H1299 Cell Lysates+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for H1299 Cell Lysates by National Cancer Institute (NCI). Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- FDA warning letters or clinical holds specifically for H1299 Cell Lysates by National Cancer Institute (NCI)\n- Specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if there's any information that matches this query:\n\nResult [1]: This is about a randomized phase II trial of a cancer cell lysate vaccine using H1299 lung cancer line. It describes how the H1299 cells were used to create a vaccine, but there's no mention of FDA warning letters or clinical holds related to this.\n\nResult [2]: This discusses oncolytic CV-B5/F treatment for NSCLCs using NCI-H1299 cells in xenograft models, but no FDA warning letters or clinical holds are mentioned.\n\nResult [3]: This contains information about various FDA cancer drug safety warnings and updates, including:\n- REMS safety update for pexidartinib (Turalio)\n- Boxed warning for capecitabine\n- Safety updates for duvelisib and denosumab-bnht\n- Boxed warning for ciltacabtagene autoleucel (Carvykti)\nHowever, none of these specifically mention H1299 Cell Lysates by NCI.\n\nResult [4]: This is about glutaminase inhibition in cancer therapy, with no mention of H1299 Cell Lysates or FDA warnings related to them.\n\nResult [5]: This discusses hederagenin and its effects on NCI-H1299 cells, but no FDA warning letters or clinical holds are mentioned.\n\nResult [6]: This is a 10-K SEC filing that mentions NCI-H1299 tumor model in relation to a viral strain ONCR-021, but no FDA warning letters or clinical holds related to H1299 Cell Lysates are mentioned.\n\nResult [7]: This discusses benzethonium chloride effects on H1299 cells, but no FDA warning letters or clinical holds are mentioned.\n\nResult [8]: This is about a small molecule NLOC-015A for NSCLC treatment, with no specific mention of H1299 Cell Lysates or FDA warnings related to them.\n\nResult [9]: This is an", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "National Cancer Institute (NCI)"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for H1299 Cell Lysates. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary of external safety evidence for clinical trial NCT05642195.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for H1299 Cell Lysates\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available about this specific trial (NCT05642195) and whether there are any safety concerns mentioned.\n\nFrom search result [1], I can see that this is about the clinical trial NCT05642195:\n- It's a Phase I/II Evaluation of a Cancer treatment\n- It's testing \"H1299 lung cancer cell vaccine combined with the drug N-803\" in people who received surgery for NSCLC (Non-Small Cell Lung Cancer)\n- The eligibility criteria include adults aged 18+ with no sign of disease after surgery for NSCLC\n- It mentions inclusion and exclusion criteria but doesn't specifically mention any safety issues, adverse events, or trial termination\n\nFrom search result [3], I see information about N-803 (which is part of the treatment in trial NCT05642195):\n- N-803 is related to IL-15 (an interleukin)\n- It mentions that \"while toxicity related to IL-15 is less likely than with IL-2, some patients still develop toxicity such as weight loss, rash, and hypotension (though capillary leak syndrome has not been observed)\"\n- This provides some general safety information about N-803, which is part of the treatment being tested in NCT05642195\n\nLet me check if there are any other results that mention NCT05642195 specifically or provide safety information about this trial:\n\nResult [2] discusses general clinical trial methodology and regulatory considerations but doesn't mention NCT05642195 specifically.\n\nResult [4] is about a Clinical Trials and Translational Research Advisory Committee meeting but doesn't mention NCT05642195.\n\nResult [5] discusses cancer", "citations": [], "search_params": {"company": "National Cancer Institute (NCI)", "nct_id": "NCT05642195", "drug_name": "H1299 Cell Lysates"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the trial suspension is \"Revisions to eligibility/design being made prior to enrollment of first participants.\" This indicates that the trial was suspended due to administrative or operational issues, rather than safety concerns or lack of efficacy. The detailed description also does not mention any safety issues or poor results, further supporting that this was an administrative failure rather than a failure due to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:27.885654", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1326}}, "27": {"nct_id": "NCT05642195", "drug_name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "intervention_type": "BIOLOGICAL", "drug_description": "H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Revisions to eligibility/design being made prior to enrollment of first participants.", "title": "Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer", "start_date": "2025-11-18", "completion_date": "2035-12-30", "sponsor": "National Cancer Institute (NCI)", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.541924", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:27.925363", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Background:\n\nSurgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back.\n\nObjective:\n\nTo test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803) in people who received surgery for NSCLC.\n\nEligibility:\n\nAdults aged 18 years or older with no sign of disease after surgery for NSCLC.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and lung function. They will have imaging scans.\n\nStudy treatment will be given in 28-day cycles. Participants will visit the clinic on the first day of each cycle. They will receive 2 treatments at each visit:\n\nThe study vaccine is given as 2-4 small shots under the skin of the thigh or arm.\n\nN-803 is given as a shot under the skin of the abdomen.\n\nTreatment will continue for 6 cycles. Blood tests and imaging scans will be repeated throughout the study.\n\nParticipants will have a blood test 1 month after receiving the 6th vaccine. Some participants may then resume taking N-803; they may also receive 2 more vaccinations at 3 and 6 months after their previous treatment.\n\nFollow-up visits will continue for up to 5 years.", "detailed_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "1/ Vaccine with Montanide Adjuvant", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}, {"label": "2/ Vaccine with Montanide Adjuvant and N-803", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "description": "H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "BIOLOGICAL", "name": "H1299 Cell Lysates", "description": "H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DRUG", "name": "N-803", "description": "N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DEVICE", "name": "Ventana PD-L1 (SP263 or SP142) assay", "description": "FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}]}}, "company_search_urls": ["https://www.google.com/search?q=National Cancer Institute (NCI)+NCT05642195+terminated", "https://www.google.com/search?q=National Cancer Institute (NCI)+Montanide (Registered Trademark) ISA-51 VG Adjuvant+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Montanide (Registered Trademark) ISA-51 VG Adjuvant by National Cancer Institute (NCI). Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds specifically related to Montanide ISA-51 VG Adjuvant by the National Cancer Institute (NCI).\n\nLet me go through each search result to identify relevant information:\n\nResult 1: This is a safety review of Montanide ISA 51 VG and Montanide ISA 720 VG. It discusses safety data from clinical trials but doesn't mention any FDA warning letters or clinical holds.\n\nResult 2: This discusses safety and tolerability of Montanide ISA 51. It mentions \"Reports on SAEs and premature termination of 2 trials advise caution when using ISA 51\" but doesn't specifically mention FDA warning letters or clinical holds.\n\nResult 3: This is a clinical trial (NCT01176474) using Montanide ISA-51. It lists exclusion criteria including \"Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component\" but doesn't mention FDA warning letters or clinical holds.\n\nResult 4: This is another safety review of Montanide ISA 51. It mentions \"Reports on SAEs and premature termination of 2 trials advise caution when using ISA 51\" and \"Notably, 2 other trials conducted with healthy subjects were stopped due to unacceptable AEs.\" However, it doesn't specifically mention FDA warning letters or clinical holds.\n\nResult 5: This discusses the sustained release properties of Montanide ISA 51 VG and ISA 720 VG but doesn't mention FDA warning letters or clinical holds.\n\nResult 6: This is about FDA cancer drug safety warnings but doesn't specifically mention Montanide ISA-51.\n\nResult 7: This mentions FDA untitled letters but doesn't specify any related to Montanide ISA-51.\n\nResult 8: This is the same clinical trial as result 3 (NCT01176474) and doesn't mention FDA warning letters.\n\nResult 9: This mentions \"A Notice of Noncompliance indicates that the FDA has determined the...\" but doesn't specify what the noncompliance was related to Montanide ISA-51.\n\nResult 10: This is a review of Montanide ISA-51 as a cancer vaccine adjuvant but doesn't mention FDA warning letters.\n\nResult 11: This discusses Mont", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "National Cancer Institute (NCI)"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for Montanide (Registered Trademark) ISA-51 VG Adjuvant. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for Montanide ISA-51 VG Adjuvant\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me review the search results to see what information is available:\n\nResult [1]: This is a PubMed article about Montanide ISA-51 as a promising adjuvant in cancer vaccines. It's a review article discussing the mechanisms and applications of Montanide ISA-51 in cancer vaccines. It doesn't contain specific information about NCT05642195 or safety issues related to this specific trial.\n\nResult [2] and [3]: These appear to be clinical trial listings for \"Evaluation of a Cancer Lysate Vaccine and Montanide ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1...\" This is indeed the NCT05642195 trial mentioned in the query. However, these are just trial descriptions and don't contain press releases, investor presentations, or public statements by NCI about safety issues.\n\nResult [4]: This shows the trial NCT05642195 as \"Suspendu\" (which means \"Suspended\" in French), indicating the trial has been suspended. This is relevant information about the trial status.\n\nResult [5]: This provides some details about the trial, listing the components: \"Montanide ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 assay\" and identifies the National Cancer Institute (NCI) as the sponsor.\n\nResult [6]: This provides more detailed protocol information about the trial, including treatment schedule, eligibility criteria, and study design. It mentions it's a Phase I/II trial. However, it doesn't provide any information about safety issues, adverse events, or why the trial might have been suspended.\n\nResult [7]: This is a product page for Montanide ISA-51 VG Range from a manufacturer (SEPPIC), providing general information about the product but not specific to the clinical trial", "citations": [], "search_params": {"company": "National Cancer Institute (NCI)", "nct_id": "NCT05642195", "drug_name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the trial suspension is \"Revisions to eligibility/design being made prior to enrollment of first participants.\" This indicates that the trial was suspended due to administrative or operational issues, rather than safety concerns or lack of efficacy. The detailed description also does not mention any safety issues or poor results, further supporting that this was an administrative failure rather than a failure due to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:27.885654", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1326}}, "28": {"nct_id": "NCT05642195", "drug_name": "N-803", "intervention_type": "DRUG", "drug_description": "N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Revisions to eligibility/design being made prior to enrollment of first participants.", "title": "Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer", "start_date": "2025-11-18", "completion_date": "2035-12-30", "sponsor": "National Cancer Institute (NCI)", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.542196", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:27.961219", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "P11245", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q00722", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8TDW0", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q07157", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8R502", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "N-803", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "MPO", "protein_b": "NAT1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "NAT2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CES1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AADAC", "protein_b": "NAT1", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "AADAC", "protein_b": "NAT2", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "GSTM1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2D6", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "NAT1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CES1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "XDH", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "NAT1", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "XDH", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "GSTM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2D6", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "NAT1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "XDH", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CES1", "protein_b": "NAT1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CES1", "protein_b": "CYP2E1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "XDH", "protein_b": "NAT1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "NAT1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG13", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TRPM5", "protein_b": "GNAT3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "TRPM5", "protein_b": "PLCB2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA15", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA14", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAT3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "PLCB2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG13", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG13", "protein_b": "GNAQ", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "GNG13", "protein_b": "GNA14", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "GNG13", "protein_b": "PLCB2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "GNG13", "protein_b": "GNAT3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "ITPR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "GNA14", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "ITPR3", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "GNA15", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "GNAQ", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PLCB2", "protein_b": "GNAT3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNA14", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ITPR1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ITPR3", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRRC8A", "protein_b": "LRRC8B", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LRRC8A", "protein_b": "LRRC8C", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LRRC8C", "protein_b": "LRRC8B", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "CLDN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "AFDN", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "MARVELD2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "F11R", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "OCLN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "TJP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CGN", "protein_b": "TJP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GJA1", "protein_b": "OCLN", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GJA1", "protein_b": "CLDN5", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "GJA1", "protein_b": "TJP2", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "GJA1", "protein_b": "TJP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "CLDN5", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "MARVELD2", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "F11R", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "TJP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "OCLN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLDN1", "protein_b": "TJP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "CLDN5", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "AFDN", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "F11R", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "CLDN7", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "OCLN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "TJP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MARVELD2", "protein_b": "TJP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "AFDN", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "F11R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "CLDN5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "TJP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "TJP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OCLN", "protein_b": "CLDN7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TJP1", "protein_b": "AFDN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TJP1", "protein_b": "CLDN5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TJP1", "protein_b": "TJP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TJP1", "protein_b": "CLDN7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TJP1", "protein_b": "F11R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLDN7", "protein_b": "CLDN5", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "CLDN7", "protein_b": "F11R", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CLDN7", "protein_b": "TJP2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AFDN", "protein_b": "F11R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AFDN", "protein_b": "TJP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F11R", "protein_b": "CLDN5", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "F11R", "protein_b": "TJP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CLDN5", "protein_b": "TJP2", "combined_score": 0.989, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.78, "clustering_coefficient": 2.89}}, "failure_enrichment": {"aact_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "aact_documents": [], "pubmed_results": [{"pmid": "40471871", "title": "Impact of the IL-15 superagonist N-803 on lymphatic reservoirs of HIV.", "authors": [{"name": "Rhein J", "authtype": "Author", "clusterid": ""}, {"name": "Chipman JG", "authtype": "Author", "clusterid": ""}, {"name": "Beilman GJ", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39948608", "title": "First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.", "authors": [{"name": "Shapiro RM", "authtype": "Author", "clusterid": ""}, {"name": "Sheffer M", "authtype": "Author", "clusterid": ""}, {"name": "Booker MA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39362494", "title": "N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial.", "authors": [{"name": "Merino A", "authtype": "Author", "clusterid": ""}, {"name": "Brunstein CC", "authtype": "Author", "clusterid": ""}, {"name": "Shanley R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39236729", "title": "Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.", "authors": [{"name": "Hong SJ", "authtype": "Author", "clusterid": ""}, {"name": "Lee SJ", "authtype": "Author", "clusterid": ""}, {"name": "Lee SH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "38953850", "title": "N-803 Plus BCG Treatment for BCG-Na\u00efve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.", "authors": [{"name": "Chamie K", "authtype": "Author", "clusterid": ""}, {"name": "Chang SS", "authtype": "Author", "clusterid": ""}, {"name": "Rosser CJ", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Background:\n\nSurgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back.\n\nObjective:\n\nTo test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803) in people who received surgery for NSCLC.\n\nEligibility:\n\nAdults aged 18 years or older with no sign of disease after surgery for NSCLC.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and lung function. They will have imaging scans.\n\nStudy treatment will be given in 28-day cycles. Participants will visit the clinic on the first day of each cycle. They will receive 2 treatments at each visit:\n\nThe study vaccine is given as 2-4 small shots under the skin of the thigh or arm.\n\nN-803 is given as a shot under the skin of the abdomen.\n\nTreatment will continue for 6 cycles. Blood tests and imaging scans will be repeated throughout the study.\n\nParticipants will have a blood test 1 month after receiving the 6th vaccine. Some participants may then resume taking N-803; they may also receive 2 more vaccinations at 3 and 6 months after their previous treatment.\n\nFollow-up visits will continue for up to 5 years.", "detailed_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "1/ Vaccine with Montanide Adjuvant", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}, {"label": "2/ Vaccine with Montanide Adjuvant and N-803", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "description": "H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "BIOLOGICAL", "name": "H1299 Cell Lysates", "description": "H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DRUG", "name": "N-803", "description": "N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DEVICE", "name": "Ventana PD-L1 (SP263 or SP142) assay", "description": "FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}]}}, "company_search_urls": ["https://www.google.com/search?q=National Cancer Institute (NCI)+NCT05642195+terminated", "https://www.google.com/search?q=National Cancer Institute (NCI)+N-803+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for N-803 by National Cancer Institute (NCI). Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for N-803 by the National Cancer Institute (NCI).\n\nFirst, I need to identify which search results contain relevant information about N-803, FDA actions, warning letters, or clinical holds.\n\nFrom the search results:\n\n1. Result [1] mentions that the FDA declined to approve N-803 (Anktiva) plus BCG for non-muscle invasive bladder cancer. It states: \"The FDA has declined to approve a biologics license application (BLA) for N-803 (Anktiva) plus Bacillus Calmette-Gu\u00e9rin (BCG) as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.\" It also mentions: \"the agency noted that it could not approve the application in its current form due to deficiencies observed during a pre-license inspection of the manufacturer's third-party contract firms.\" However, it states: \"Although the agency did not require any additional preclinical or late-stage clinical trials to supplement the BLA, it requested manufacturers to provide more data and a safety update in their resubmission.\"\n\n2. Result [2] mentions that the FDA accepted a BLA resubmission for N-803 and BCG for NMIBC with a PDUFA date of April 23, 2024.\n\n3. Result [3] states: \"FDA approval has not been granted to N-803 for the treatment of Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.... In the CRL, the FDA cited insufficient inspection of a third-party manufacturer. The regulatory body stated that ImmunityBio must resolve the observations process in their SEC filing before the BLA can be reviewed. No efficacy or safety issues related to N-803 were mentioned in the CRL.\"\n\n4. Result [9] has a title \"FDA Issues Complete Response Letter to BLA for N-803 in BCG-Unresponsive NIMBC In Situ\" which suggests there was a Complete Response Letter (CRL) issued for N-803.\n\nLet me check if there are any specific warning letters or clinical holds mentioned:\n\nFrom result [1], [3], and [9], it appears that the FDA issued a Complete Response Letter (CRL) for the", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "National Cancer Institute (NCI)"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for N-803. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about clinical trial NCT05642195 for N-803, focusing specifically on safety issues, adverse events, trial termination reasons, or regulatory actions. I'll go through each result to see what relevant information I can find.\n\nFirst, let me identify what NCT05642195 is about. From result [13], I can see:\n\"San Mateo Clinical Trial Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for...\"\n\nFrom result [3], I can see more details:\n\"Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative ...\"\n\nFrom result [9], I see:\n\"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for ...\"\n\nFrom result [15], I see:\n\"H1299 cell lysate vaccine adjuvanted with ISA-51 VG(National Cancer Institute) Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 ...\"\n\nSo NCT05642195 appears to be a Phase I/II trial evaluating a cancer lysate vaccine (specifically H1299 lung cancer cell vaccine) with or without N-803 as adjuvant therapy for PD-L1 negative patients who have had surgery for NSCLC (non-small cell lung cancer).\n\nNow, let me go through all the results to find information specifically about safety issues, adverse events, trial termination reasons, or regulatory actions related to this trial:\n\nResult [1]: This is about FDA accepting a BLA for N-803 plus BCG in NMIBC (non-muscle invasive bladder cancer), related to trials QUILT-2.005 and QUILT-3", "citations": [], "search_params": {"company": "National Cancer Institute (NCI)", "nct_id": "NCT05642195", "drug_name": "N-803"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the trial suspension is \"Revisions to eligibility/design being made prior to enrollment of first participants.\" This indicates that the trial was suspended due to administrative or operational issues, rather than safety concerns or lack of efficacy. The detailed description also does not mention any safety issues or poor results, further supporting that this was an administrative failure rather than a failure due to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:27.885654", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1326}}, "29": {"nct_id": "NCT05642195", "drug_name": "Ventana PD-L1 (SP263 or SP142) assay", "intervention_type": "DEVICE", "drug_description": "FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Revisions to eligibility/design being made prior to enrollment of first participants.", "title": "Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer", "start_date": "2025-11-18", "completion_date": "2035-12-30", "sponsor": "National Cancer Institute (NCI)", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.542477", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:27.996488", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Ventana PD-L1 (SP263 or SP142) assay"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "aact_documents": [], "pubmed_results": [{"pmid": "40991883", "title": "Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.", "authors": [{"name": "Perez J", "authtype": "Author", "clusterid": ""}, {"name": "Kerr KM", "authtype": "Author", "clusterid": ""}, {"name": "Baker B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40373876", "title": "Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab.", "authors": [{"name": "Moehler M", "authtype": "Author", "clusterid": ""}, {"name": "Yoon HH", "authtype": "Author", "clusterid": ""}, {"name": "Wagner DC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "38102374", "title": "Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.", "authors": [{"name": "Climent M\u00c1", "authtype": "Author", "clusterid": ""}, {"name": "\u00c1lvarez C", "authtype": "Author", "clusterid": ""}, {"name": "Morales R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37903590", "title": "Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.", "authors": [{"name": "Zhou C", "authtype": "Author", "clusterid": ""}, {"name": "Srivastava MK", "authtype": "Author", "clusterid": ""}, {"name": "Xu H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37019764", "title": "Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.", "authors": [{"name": "Lee JL", "authtype": "Author", "clusterid": ""}, {"name": "Desai C", "authtype": "Author", "clusterid": ""}, {"name": "Park SH", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Background:\n\nSurgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back.\n\nObjective:\n\nTo test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803) in people who received surgery for NSCLC.\n\nEligibility:\n\nAdults aged 18 years or older with no sign of disease after surgery for NSCLC.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and lung function. They will have imaging scans.\n\nStudy treatment will be given in 28-day cycles. Participants will visit the clinic on the first day of each cycle. They will receive 2 treatments at each visit:\n\nThe study vaccine is given as 2-4 small shots under the skin of the thigh or arm.\n\nN-803 is given as a shot under the skin of the abdomen.\n\nTreatment will continue for 6 cycles. Blood tests and imaging scans will be repeated throughout the study.\n\nParticipants will have a blood test 1 month after receiving the 6th vaccine. Some participants may then resume taking N-803; they may also receive 2 more vaccinations at 3 and 6 months after their previous treatment.\n\nFollow-up visits will continue for up to 5 years.", "detailed_description": "Background:\n\n* Cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X antigens) have emerged as attractive targets for cancer immunotherapy.\n* Recent studies suggest that CT-X antigens which are up regulated by epigenetic mechanisms may be preferentially expressed in pluripotent stem/tumor initiating cells that mediate treatment resistance and metastasis of human cancers.\n* Whereas pulmonary malignancies express a variety of CT-X antigens, immune responses to these proteins are uncommon in lung cancer patients due to low-level, heterogeneous antigen expression, epigenetic repression of genes regulating antigen processing/presentation, and local as well as systemic immunosuppression in these individuals.\n* Conceivably, vaccination of lung cancer patients with tumor cells expressing high levels of CT-X antigens in combination with regimens that inhibit immunosuppressive functions of T regulatory cells and enhance activity of natural killer (NK) cells will induce broad immunity to these antigens.\n\nPrimary Objectives:\n\n* Phase I Component: To determine the safety of H1299 lung cancer cell lysate vaccines administered with Montanide (Registered Trademark) ISA-51 VG adjuvant and N-803.\n* Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide (Registered Trademark) ISA-51 VG adjuvant in combination with N-803.\n\nEligibility:\n\n* Participants with pathologically confirmed Stage IB-IIIA (T2a-T4/N0, T1-T3N1, T1-T2/N2) NSCLC per 8th edition TNM Staging System non-small cell lung cancer (NSCLC) who have no clinical evidence of active disease (NED) following standard therapy completed within the past 12 weeks.\n* Participants must be 18 years or older with an ECOG performance status of 0-2.\n* Participants must have adequate bone marrow, kidney, liver, lung, and cardiac function.\n* Participants receiving systemic immunosuppressive medications will be excluded.\n* Participants with HIV will be excluded.\n\nDesign:\n\n* Following recovery from surgery, and adjuvant therapy if indicated, eligible participants will be vaccinated via deep subcutaneous (SQ) injection with H1299 cell lysate and Montanide (Registered Trademark) ISA-51 VG (Trademark) adjuvant with or without subcutaneous N-803 monthly until six vaccinations have been given.\n* Imaging studies will be performed at baseline, one month following the 3rd and 6th vaccinations, and at post-treatment follow-up (every 3 months for 3 years and then every 6 months for another 2 years, for 5 years total follow-up).\n* Leukapheresis will be performed at baseline and at treatment evaluation one month following completion of the six vaccinations.\n* Systemic toxicities and immunologic responses to therapy will be recorded.\n* Pre- and post-vaccination serologic and cell mediated responses to a panel of CT-X antigens will be assessed before and one month following completion of the six vaccinations.\n* Individuals deemed to have responded to vaccine treatment and exhibit no evidence of disease recurrence or secondary malignancy will be eligible for 2 additional vaccinations at 3 months after receiving the sixth vaccine and 6 months after receiving the 6th vaccine with N-803.\n* Numbers and percentages of immune subsets, soluble factors, and cytokines in peripheral blood will be assessed before and after the six vaccinations.\n* Immunologic responses to autologous tumor cells (if available) as well as pooled lung cancer stem cell vs. normal lung-induced pluripotent stem cell (Lu-iPSC) lysates will be evaluated in an exploratory manner.\n* Up to 28 participants may receive study intervention on this protocol.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "1/ Vaccine with Montanide Adjuvant", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}, {"label": "2/ Vaccine with Montanide Adjuvant and N-803", "type": "EXPERIMENTAL", "description": "H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)", "intervention_names": ["Biological: Montanide (Registered Trademark) ISA-51 VG Adjuvant", "Biological: H1299 Cell Lysates", "Drug: N-803", "Device: Ventana PD-L1 (SP263 or SP142) assay"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Montanide (Registered Trademark) ISA-51 VG Adjuvant", "description": "H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "BIOLOGICAL", "name": "H1299 Cell Lysates", "description": "H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DRUG", "name": "N-803", "description": "N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}, {"type": "DEVICE", "name": "Ventana PD-L1 (SP263 or SP142) assay", "description": "FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.", "arm_group_labels": ["1/ Vaccine with Montanide Adjuvant", "2/ Vaccine with Montanide Adjuvant and N-803"]}]}}, "company_search_urls": ["https://www.google.com/search?q=National Cancer Institute (NCI)+NCT05642195+terminated", "https://www.google.com/search?q=National Cancer Institute (NCI)+Ventana PD-L1 (SP263 or SP142) assay+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Ventana PD-L1 (SP263 or SP142) assay by National Cancer Institute (NCI). Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds specifically related to Ventana PD-L1 (SP263 or SP142) assays that were issued by the National Cancer Institute (NCI). Let me go through each search result carefully.\n\nFirst, let me clarify what I'm looking for:\n1. FDA warning letters OR clinical holds\n2. Specifically for Ventana PD-L1 (SP263 or SP142) assays\n3. Issued by the National Cancer Institute (NCI)\n4. With specific dates, reasons, and safety issues cited\n\nLet's examine each search result:\n\nResult [1]: This is a Roche Diagnostics product page for the VENTANA PD-L1 (SP142) Assay. It describes the product as an FDA-approved test for TECENTRIQ in urothelial carcinoma and NSCLC. No warning letters or clinical holds mentioned.\n\nResult [2]: This appears to be an FDA PDF document about the VENTANA PD-L1 (SP142) Assay. It describes the assay as an immunohistochemical assay but doesn't mention any warning letters or clinical holds.\n\nResult [3]: This is an FDA page about the VENTANA PD-L1 (SP263) Assay. It states \"When should it not be used? There are no known reasons not to use this test.\" This suggests no warnings or restrictions, but doesn't specifically address warning letters or clinical holds.\n\nResult [4]: This is a Roche press release about FDA approval of the VENTANA PD-L1 (SP263) Assay. It's positive news about approval, not about warnings or holds.\n\nResult [5]: This is an FDA Premarket Approval page for what appears to be the VENTANA PD-L1 (SP142) Assay. It discusses approval, not warnings or holds.\n\nResult [6]: This is an FDA PDF about the VENTANA PD-L1 (SP263) Assay. It discusses indications but doesn't mention warning letters or clinical holds.\n\nResult [7]: This is another FDA Premarket Approval page, this time for the VENTANA PD-L1 (SP263) Assay. Again, it discusses approval, not warnings.\n\nResult [8]: This is a scientific article about the role of PD-L1 SP263", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "National Cancer Institute (NCI)"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by National Cancer Institute (NCI) about clinical trial NCT05642195 for Ventana PD-L1 (SP263 or SP142) assay. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT05642195 for Ventana PD-L1 (SP263 or SP142) assay, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, I need to check if any of the search results mention the specific clinical trial NCT05642195.\n\nLooking through the search results:\n\n1. Result [1] discusses FDA approval of VENTANA PD-L1 (SP263) Assay as a CDx for NSCLC subtype for Libtayo (cemiplimab), but doesn't mention NCT05642195.\n\n2. Result [2] discusses Roche's VENTANA PD-L1 (SP263) Assay receiving FDA approval as a companion diagnostic for Tecentriq, but doesn't mention NCT05642195.\n\n3. Result [3] is similar to [2], discussing the FDA approval of VENTANA PD-L1 (SP263) Assay for Tecentriq, but no mention of NCT05642195.\n\n4. Result [4] discusses Roche securing CE mark for Ventana PD-L1 for NSCLC patients, but doesn't mention NCT05642195.\n\n5. Result [5] appears to be a PDF of the VENTANA PD-L1 (SP263) Assay Interpretation Guide for Non-Small Cell Lung Cancer, but doesn't mention NCT05642195.\n\n6. Result [6] mentions \"Ventana PD-L1 (SP263 or SP142) assay\" and \"National Cancer Institute\" but the URL shows \"id=000520-C&query=Residual+Stage\" which doesn't match NCT05642195. It appears to be a different trial. The text shows:\n   \"Biological/Vaccine: Montanide (Registered Trademark) ISA-51 VG Adjuvant Biological/Vaccine: H1299 Cell Lysates Drug: N-803 Device: Ventana PD-L1 (SP263 or SP142) assay\n   Supporting Site\n   National Cancer", "citations": [], "search_params": {"company": "National Cancer Institute (NCI)", "nct_id": "NCT05642195", "drug_name": "Ventana PD-L1 (SP263 or SP142) assay"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the trial suspension is \"Revisions to eligibility/design being made prior to enrollment of first participants.\" This indicates that the trial was suspended due to administrative or operational issues, rather than safety concerns or lack of efficacy. The detailed description also does not mention any safety issues or poor results, further supporting that this was an administrative failure rather than a failure due to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:27.885654", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1326}}, "30": {"nct_id": "NCT06361810", "drug_name": "177Lu-PNT2002", "intervention_type": "DRUG", "drug_description": "177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.\n\n177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "funding withdrawn", "title": "PSMA Therapy and Immunotherapy in Kidney Cancer", "start_date": "2025-10-01", "completion_date": "2032-01-31", "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.542749", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:30.555424", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "177Lu-PNT2002"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "aact_documents": [], "pubmed_results": [{"pmid": "36797449", "title": "LUNAR: a randomized Phase 2 study of (177) Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).", "authors": [{"name": "Ma TM", "authtype": "Author", "clusterid": ""}, {"name": "Czernin J", "authtype": "Author", "clusterid": ""}, {"name": "Felix C", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.", "detailed_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "177Lu-PNT2002 3.4 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 3.4 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 megabecquerel (MBq) (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 5.1 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 5.1 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 6.8 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 6.8 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "Dose Expansion", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at the maximum tolerated dose (determined by the 3 dose levels in the dose escalation phase of the study) intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab", "description": "Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.\n\nPembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "177Lu-PNT2002", "description": "177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.\n\n177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "(F-18)-DCFPyL", "description": "Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+NCT06361810+terminated", "https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+177Lu-PNT2002+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for 177Lu-PNT2002 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there are any FDA warning letters or clinical holds for 177Lu-PNT2002 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.\n\nThe query specifically asks for:\n1. FDA warning letters or clinical holds for 177Lu-PNT2002\n2. Issued by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n3. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this information:\n\nResult [1]: Discusses FDA Fast Track designation for 177Lu-PNT2002 for mCRPC treatment. Mentions the SPLASH Phase 3 study (NCT04647526) sponsored by POINT Biopharma. No mention of warning letters or clinical holds.\n\nResult [2]: A pharmacovigilance study of FDA adverse events related to 177Lu-PSMA-617 (not PNT2002 specifically). It discusses safety concerns like anemia, platelet count decreased, pancytopenia, dry mouth, etc. But this is about PSMA-617 (Pluvicto), not PNT2002, and doesn't mention any warning letters or clinical holds.\n\nResult [3]: Lantheus presents results from SPLASH trial showing 177Lu-PNT2002 demonstrated improvement compared to ARPI. Mentions safety profile but no warning letters or clinical holds.\n\nResult [4]: Discusses recent FDA cancer drug safety warnings for various drugs (duvelisib, capecitabine, ciltacabtagene autoleucel, pexidartinib) but doesn't mention 177Lu-PNT2002.\n\nResult [5]: Discusses the LUNAR trial adding 177Lu-PNT2002 to SBRT for oligorecurrent prostate cancer. Mentions safety data but no warning letters or clinical holds.\n\nResult [6]: Mentions FDA granted Fast Track designation for 177Lu-PNT2002 for mCRPC. No warning letters.\n\nResult [7]: Initial clinical experience with [177Lu]Lu-PNT2002 showing favorable dosimetry and safety profile. No warning letters.\n\nResult [8]: Mentions", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins about clinical trial NCT06361810 for 177Lu-PNT2002. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n- About clinical trial NCT06361810 for 177Lu-PNT2002\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me check if any of the search results contain information specifically from:\n1. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n2. About trial NCT06361810\n3. With focus on safety issues, adverse events, trial termination, or regulatory actions\n\nLooking at the search results:\n\nResult [1]: About the SPLASH trial (NCT04647526) for 177Lu-PNT2002 in mCRPC. Mentions safety outcomes but not specifically about NCT06361810 or Sidney Kimmel.\n\nResult [2]: About the SPLASH trial (NCT04647526) lead-in portion. Mentions safety profile but not about NCT06361810 or Sidney Kimmel.\n\nResult [3]: General information about 177Lu-PNT2002, mentions it's being studied for various cancers including renal cell carcinoma, but doesn't specifically mention NCT06361810 or Sidney Kimmel.\n\nResult [4]: This is about NCT06361810 - \"PSMA Therapy and Immunotherapy in Kidney Cancer\". It describes the trial design but doesn't contain any press releases, investor presentations, or statements from Sidney Kimmel Comprehensive Cancer Center. It also doesn't mention any safety issues, adverse events, trial termination, or regulatory actions - just the trial design.\n\nResult [5]: About ESMO 2024 results for 177Lu-PNT2002 in mCRPC, comparing it to Pluvicto. Mentions safety profile but not about NCT06361810 or Sidney Kimmel.\n\nResult [6]: About ESMO 22 results of the SPLASH trial. Mentions safety profile but not about NCT06361810 or Sidney Kimmel.\n\nResult", "citations": [], "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "nct_id": "NCT06361810", "drug_name": "177Lu-PNT2002"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed description of the trial does not mention any safety concerns or lack of efficacy as the reason for termination. Instead, the official reason provided is that the trial was \"withdrawn\" due to \"funding withdrawn.\" This indicates that the trial was terminated due to administrative or operational problems, specifically the withdrawal of funding, rather than issues related to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:30.554615", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1333}}, "31": {"nct_id": "NCT06361810", "drug_name": "(F-18)-DCFPyL", "intervention_type": "DRUG", "drug_description": "Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "funding withdrawn", "title": "PSMA Therapy and Immunotherapy in Kidney Cancer", "start_date": "2025-10-01", "completion_date": "2032-01-31", "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.543028", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:30.593475", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q9NYZ1", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q96GS6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q5QNW6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8NFZ0", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8K2I9", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "(F-18)-DCFPyL", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "TVP23B", "protein_b": "CDRT15", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "ABHD17A", "protein_b": "LYPLA1", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "CENPN", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC7", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC13", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2BC18", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2BC17", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C13", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC18", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "CENPA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC13", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2BC18", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C12", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2BC17", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC18", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2AC7", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H3C12", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2AC13", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2AC6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2BC18", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2BC17", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "H2AC18", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "CENPN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H2AC7", "protein_b": "H2AC13", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "H2AC7", "protein_b": "H2BC18", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "H2AC7", "protein_b": "H3C12", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "H2AC7", "protein_b": "H2BC17", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H3C12", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC18", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC6", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2BC18", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2BC17", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H2AC6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H2BC18", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H2BC17", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H2AC18", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H2AC18", "protein_b": "H2BC18", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "H2AC18", "protein_b": "H2AC6", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "H2AC18", "protein_b": "H2BC17", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "H2AC6", "protein_b": "CENPN", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "H2AC6", "protein_b": "H2BC18", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "H2AC6", "protein_b": "H2BC17", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CENPN", "protein_b": "H2BC17", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CENPN", "protein_b": "H2BC18", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "H2BC18", "protein_b": "H2BC17", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "RBX1", "protein_b": "FBH1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "RBX1", "protein_b": "SKP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RBX1", "protein_b": "CUL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SKP1", "protein_b": "CUL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SKP1", "protein_b": "FBH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "XRCC3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "PCNA", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "RAD51", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "FBH1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "RAD52", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "RECQL5", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FANCM", "protein_b": "WRN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "PCNA", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "FBH1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "XRCC3", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "RAD51", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "RAD52", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "RECQL5", "protein_b": "XRCC3", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "RECQL5", "protein_b": "RAD52", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "RECQL5", "protein_b": "FBH1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "RECQL5", "protein_b": "RAD51", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CUL1", "protein_b": "FBH1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "RAD52", "protein_b": "FBH1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "RAD52", "protein_b": "XRCC3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "RAD52", "protein_b": "RAD51", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PCNA", "protein_b": "FBH1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PCNA", "protein_b": "RAD51", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "FBH1", "protein_b": "XRCC3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "FBH1", "protein_b": "RAD51", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "XRCC3", "protein_b": "RAD51", "combined_score": 0.998, "interaction_type": "physical"}], "network_features": {"avg_degree": 6.0, "clustering_coefficient": 3.0}}, "failure_enrichment": {"aact_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "aact_documents": [], "pubmed_results": [{"pmid": "40379702", "title": "A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma.", "authors": [{"name": "Voter AF", "authtype": "Author", "clusterid": ""}, {"name": "Amindarolzarbi A", "authtype": "Author", "clusterid": ""}, {"name": "Shen CJ", "authtype": "Author", "clusterid": ""}]}, {"pmid": "33568190", "title": "Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.", "authors": [{"name": "Rowe LS", "authtype": "Author", "clusterid": ""}, {"name": "Harmon S", "authtype": "Author", "clusterid": ""}, {"name": "Horn A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "27889802", "title": "F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.", "authors": [{"name": "Giesel FL", "authtype": "Author", "clusterid": ""}, {"name": "Hadaschik B", "authtype": "Author", "clusterid": ""}, {"name": "Cardinale J", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.", "detailed_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "177Lu-PNT2002 3.4 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 3.4 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 megabecquerel (MBq) (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 5.1 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 5.1 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 6.8 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 6.8 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "Dose Expansion", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at the maximum tolerated dose (determined by the 3 dose levels in the dose escalation phase of the study) intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab", "description": "Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.\n\nPembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "177Lu-PNT2002", "description": "177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.\n\n177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "(F-18)-DCFPyL", "description": "Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+NCT06361810+terminated", "https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+(F-18)-DCFPyL+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for (F-18)-DCFPyL by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically for (F-18)-DCFPyL (also known as piflufolastat F-18) related to Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.\n\nLet me go through the search results systematically:\n\nResult 1: This is about the initial evaluation of [18F]DCFPyL. It mentions that the radiotracer is safe with no major adverse events observed in the study (only three NCI CTCAE grade I adverse events in nine patients). This is a positive safety profile, not a warning or clinical hold.\n\nResult 2: This discusses FDA safety warnings for various cancer drugs (duvelisib, capecitabine, ciltacabtagene autoleucel, pexidartinib), but none specifically for DCFPyL.\n\nResult 3: This is about FDA accepting an NDA for a new formulation of piflufolastat F-18 (which is DCFPyL F-18). It mentions that adverse events were observed in less than 2% of patients (headache, dysgeusia, fatigue, and one delayed hypersensitivity reaction). This is about approval, not warnings or holds.\n\nResult 4: This discusses the diagnostic accuracy of DCFPyL PET/CT but doesn't mention any FDA warnings or clinical holds.\n\nResult 5: This is general information about piflufolastat F-18 (DCFPyL F-18) including its approval status and mechanism of action. No warnings or holds mentioned.\n\nResult 6: This is a review article about piflufolastat F-18 for PSMA PET imaging in prostate cancer. It mentions it's FDA-approved but doesn't discuss any warnings or holds.\n\nResult 7: Similar to result 6, this is about piflufolastat F-18 as an FDA-approved agent, no warnings mentioned.\n\nResult 8: This discusses [18F]DCFPyL PET/CT for imaging prostate cancer, noting it's superior to conventional imaging. No FDA warnings mentioned.\n\nResult 9: This is a clinical trial registration (NCT02523924) for a pilot study of 18F-DCFPyL PET/CT, but", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins about clinical trial NCT06361810 for (F-18)-DCFPyL. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins regarding clinical trial NCT06361810 for (F-18)-DCFPyL, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each search result to see if it contains relevant information:\n\n1. Result [1]: This is about NCI-2020-03606, which appears to be related to 18F-DCFPyL PET/CT imaging for prostate cancer, but it's not about NCT06361810. It doesn't mention Sidney Kimmel Comprehensive Cancer Center or safety issues for the specific trial we're looking for.\n\n2. Result [2]: This is a PubMed article about the diagnostic performance of 18F-DCFPyL-PET/CT in men, but it doesn't appear to be related to NCT06361810 or Sidney Kimmel Comprehensive Cancer Center's statements.\n\n3. Result [3]: This is about ClinicalTrials.gov study NCT03800784, which is a different trial (about 18F-DCFPyL PET/CT imaging in patients with prostate cancer), not NCT06361810. It mentions Mark Markowski from Johns Hopkins University as the Principal Investigator, but doesn't provide press releases or statements about safety issues for NCT06361810.\n\n4. Result [4]: This is about ClinicalTrials.gov study NCT06361810, which is exactly the trial we're looking for. It describes a study of PSMA Therapy and Immunotherapy in Kidney Cancer using (F-18)-DCFPyL. It mentions that (F-18)-DCFPyL was FDA approved in 2021 for prostate cancer detection. However, it doesn't contain any press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center about safety issues, adverse events, trial termination, or regulatory actions. It does show the trial status as \"Recruiting\" (though I need to check if this is current information).\n\n5. Result [5]: This is a PubMed article about P", "citations": [], "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "nct_id": "NCT06361810", "drug_name": "(F-18)-DCFPyL"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed description of the trial does not mention any safety concerns or lack of efficacy as the reason for termination. Instead, the official reason provided is that the trial was \"withdrawn\" due to \"funding withdrawn.\" This indicates that the trial was terminated due to administrative or operational problems, specifically the withdrawal of funding, rather than issues related to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:30.554615", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1333}}, "32": {"nct_id": "NCT06361810", "drug_name": "Pembrolizumab", "intervention_type": "DRUG", "drug_description": "Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.\n\nPembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "funding withdrawn", "title": "PSMA Therapy and Immunotherapy in Kidney Cancer", "start_date": "2025-10-01", "completion_date": "2032-01-31", "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.543300", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:30.629078", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O95243", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Pembrolizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "MBD4", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "SMUG1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MLH1", "protein_b": "MBD4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "UHRF1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "MBD2", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TRDMT1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "SMUG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TDG", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3B", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TRDMT1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TDG", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "UHRF1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT3B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TRDMT1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "UHRF1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "TDG", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "UHRF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TDG", "protein_b": "SMUG1", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.74, "clustering_coefficient": 4.37}}, "failure_enrichment": {"aact_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "aact_documents": [], "pubmed_results": [{"pmid": "41228347", "title": "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.", "authors": [{"name": "Fedele P", "authtype": "Author", "clusterid": ""}, {"name": "Stucci SL", "authtype": "Author", "clusterid": ""}, {"name": "Landriscina M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41219635", "title": "Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis.", "authors": [{"name": "Lala M", "authtype": "Author", "clusterid": ""}, {"name": "Bardia A", "authtype": "Author", "clusterid": ""}, {"name": "Calles A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209621", "title": "Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.", "authors": [{"name": "Skoulidis F", "authtype": "Author", "clusterid": ""}, {"name": "Borghaei H", "authtype": "Author", "clusterid": ""}, {"name": "Garon EB", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206673", "title": "Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).", "authors": [{"name": "Villaruz LC", "authtype": "Author", "clusterid": ""}, {"name": "Schluger B", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41177680", "title": "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.", "authors": [{"name": "Jain P", "authtype": "Author", "clusterid": ""}, {"name": "Naqvi SAA", "authtype": "Author", "clusterid": ""}, {"name": "Tripathi N", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.", "detailed_description": "In the dose escalation phase, three dose levels of 177Lu-PNT2002 given intravenously every 8 weeks, starting from 3.4 gigabequerel (GBq) in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks. After determining the maximum tolerated dose (MTD) or the recommended Phase 2 Dose (RP2D), the study will proceed to the dose expansion phase and in this portion of the study, patients will receive 177Lu-PNT-2002 intravenously every 8 weeks at the MTD/RP2D for a maximum of 4 cycles in combination pembrolizumab 400 mg intravenously every 6 weeks for a maximum of 17 cycles.\n\nThe primary objective of the phase 1b portion of the study is to determine the MTD or RP2D of 177Lu-PNT2002 radiopharmaceutical therapy in combination with pembrolizumab in patients with metastatic clear cell RCC. The primary objective of the phase 2 portion of the study is to evaluate the efficacy of 177Lu-PNT2002 in combination with pembrolizumab in patients with metastatic clear cell RCC who progressed on prior anti PD-1/PDL1 therapy based on objective response rate (ORR) by RECIST 1.1 criteria.\n\nPatients in both phases will receive PSMA-PET with (F-18)-DCFPyl at screening, 12 weeks, and 24 weeks. (F-18)-DCFPyl was developed as a diagnostic radiotracer for the detection of prostate cancer and was FDA approved in 2021 for the detection of PSMA positive lesions in men with prostate cancer. However, PSMA is not entirely prostate-specific, as it has been shown to be present on neovascular endothelium of numerous solid tumors, including RCC. Prior studies have demonstrated high sensitivity and specificity of the detection of metastatic clear cell RCC lesions using PET imaging with various PSMA radiotracers, such as (F-18)-DCFPyl. Based on this, the high expression of PSMA in RCC and the synergy of PSMA radiopharmaceuticals with ICIs, such as pembrolizumab, provide a novel treatment strategy in RCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "177Lu-PNT2002 3.4 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 3.4 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 megabecquerel (MBq) (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 5.1 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 5.1 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "177Lu-PNT2002 6.8 GBq", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at 6.8 GBq intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}, {"label": "Dose Expansion", "type": "EXPERIMENTAL", "description": "177Lu-PNT2002 administered at the maximum tolerated dose (determined by the 3 dose levels in the dose escalation phase of the study) intravenously (IV) every 8 weeks combined with the standard dose of pembrolizumab 400 mg IV every 6 weeks. 18F-DCFPyL administered as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "intervention_names": ["Drug: Pembrolizumab", "Drug: 177Lu-PNT2002", "Drug: (F-18)-DCFPyL"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab", "description": "Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.\n\nPembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "177Lu-PNT2002", "description": "177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.\n\n177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}, {"type": "DRUG", "name": "(F-18)-DCFPyL", "description": "Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.", "arm_group_labels": ["177Lu-PNT2002 3.4 GBq", "177Lu-PNT2002 5.1 GBq", "177Lu-PNT2002 6.8 GBq", "Dose Expansion"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+NCT06361810+terminated", "https://www.google.com/search?q=Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+Pembrolizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Pembrolizumab specifically related to the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.\n\nFirst, I need to identify if there are any specific mentions of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in relation to FDA warning letters or clinical holds for Pembrolizumab.\n\nLooking through the search results:\n\nResult [3] mentions a legal case \"Merck-v-Johns-Hopkins-Complaint.pdf\" and describes a \"phase 2 trial\" that used \"pembrolizumab (Merck)\" to treat three cohorts. It also mentions Johns Hopkins University (JHU) in relation to a database issue.\n\nResult [5] mentions PTAB (Patent Trial and Appeal Board) instituting IPRs (Inter Partes Reviews) challenging Johns Hopkins University's pembrolizumab patents. It mentions a \"MSI-H Study Record\" which is \"the study record of a clinical trial sponsored by Merck and JHU using Keytruda in MSI positive cancer patients.\"\n\nResult [9] discusses a dispute between Merck and Johns Hopkins concerning patents related to pembrolizumab.\n\nResult [11] mentions \"issues with the Johns Hopkins University (JHU) database\" in relation to FDA granting breakthrough therapy designation to pembrolizumab.\n\nResult [17] mentions \"Update on John Hopkins and Merck Pembrolizumab Litigation\" and notes that Merck filed petitions for IPR on eight patents owned by Johns Hopkins.\n\nResult [18] states \"PTAB Invalidates Johns Hopkins' US Pembrolizumab MOT Patent\" and mentions a decision issued on June 9, 2025.\n\nHowever, I don't see specific mentions of:\n1. Sidney Kimmel Comprehensive Cancer Center (though Johns Hopkins is mentioned)\n2. FDA warning letters specifically to Sidney Kimmel Comprehensive Cancer Center\n3. Clinical holds specifically at Sidney Kimmel Comprehensive Cancer Center\n\nWhat I do see are several mentions of clinical holds related to pembrolizumab trials, but these appear to be broader FDA actions rather than specific to Johns Hopkins:\n\nResult [2] mentions \"Two Halted Pembrolizumab Trials in Myeloma\" - KEYNOTE-183 and KEYNOTE-185 were placed on hold in July 2017.\n\nResult [4] states: \"On", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins about clinical trial NCT06361810 for Pembrolizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\n- Specifically about clinical trial NCT06361810 for Pembrolizumab\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me examine the search results to see if they contain this information:\n\nResult [1]: This is about NCT05633602, which is a different trial (Ramucirumab Plus Pembrolizumab for lung cancer). Not relevant to NCT06361810.\n\nResult [2]: This is about NCT06361810, which is \"PSMA Therapy and Immunotherapy in Kidney Cancer\". It describes a phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 for kidney cancer. It mentions:\n- It's a multi-center study\n- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is involved (Principal Investigator: Yasser Ged, MD)\n- It's sponsored by Merck Sharp & Dohme LLC and Lantheus Medical Imaging\n- The primary objective is to determine the MTD/RP2D of 177Lu-PNT2002 with pembrolizumab\n- However, it doesn't contain any press releases, investor presentations, or public statements from Sidney Kimmel about safety issues, adverse events, etc.\n\nResult [3]: This is about a phase II study of pembrolizumab in colorectal cancer (KEYNOTE-164), not related to NCT06361810.\n\nResult [4]: This appears to be about determinants of 5-year survival in NSCLC patients treated with pembrolizumab, not related to NCT06361810.\n\nResult [5]: This seems to be a duplicate of result [3], about the phase II study of pembrolizumab in colorectal cancer.\n\nResult [6]: This is general information about pembrolizumab as a drug, not specific to NCT06361810.\n\nResult [7]: This mentions Sidney Kimmel Comprehensive Cancer Center at Johns", "citations": [], "search_params": {"company": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "nct_id": "NCT06361810", "drug_name": "Pembrolizumab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed description of the trial does not mention any safety concerns or lack of efficacy as the reason for termination. Instead, the official reason provided is that the trial was \"withdrawn\" due to \"funding withdrawn.\" This indicates that the trial was terminated due to administrative or operational problems, specifically the withdrawal of funding, rather than issues related to safety or efficacy.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:30.554615", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1333}}, "33": {"nct_id": "NCT05617625", "drug_name": "Busulfan", "intervention_type": "DRUG", "drug_description": "0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "The study has been put on hold while pending CMS approval", "title": "CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome", "start_date": "2025-09-30", "completion_date": "2032-09-30", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.543600", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:33.260707", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL820", "pref_name": "BUSULFAN", "targets": [{"chembl_id": "CHEMBL614004", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614573", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614088", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614647", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614466", "ic50_values": [{"value": 92500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612798", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL220", "ic50_values": [], "uniprot_id": "A4D2E2"}, {"chembl_id": "CHEMBL226", "ic50_values": [], "uniprot_id": "A6NFY5"}, {"chembl_id": "CHEMBL251", "ic50_values": [], "uniprot_id": "B2R7E0"}, {"chembl_id": "CHEMBL256", "ic50_values": [], "uniprot_id": "A2A3P4"}, {"chembl_id": "CHEMBL612545", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL319", "ic50_values": [], "uniprot_id": "P43140"}, {"chembl_id": "CHEMBL315", "ic50_values": [], "uniprot_id": "P15823"}, {"chembl_id": "CHEMBL223", "ic50_values": [], "uniprot_id": "P25100"}, {"chembl_id": "CHEMBL1867", "ic50_values": [], "uniprot_id": "B0LPF6"}, {"chembl_id": "CHEMBL1942", "ic50_values": [], "uniprot_id": "A2RUS0"}, {"chembl_id": "CHEMBL1916", "ic50_values": [], "uniprot_id": "P18825"}, {"chembl_id": "CHEMBL213", "ic50_values": [], "uniprot_id": "B0LPE2"}, {"chembl_id": "CHEMBL210", "ic50_values": [], "uniprot_id": "B0LPE4"}, {"chembl_id": "CHEMBL246", "ic50_values": [], "uniprot_id": "P13945"}, {"chembl_id": "CHEMBL222", "ic50_values": [], "uniprot_id": "B2R707"}, {"chembl_id": "CHEMBL2622", "ic50_values": [], "uniprot_id": "P07943"}, {"chembl_id": "CHEMBL4607", "ic50_values": [], "uniprot_id": "B2R9V1"}, {"chembl_id": "CHEMBL3157", "ic50_values": [], "uniprot_id": "P30411"}, {"chembl_id": "CHEMBL1832", "ic50_values": [], "uniprot_id": "A0A0C4DG16"}, {"chembl_id": "CHEMBL218", "ic50_values": [], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL205", "ic50_values": [], "uniprot_id": "B2R7G8"}, {"chembl_id": "CHEMBL4015", "ic50_values": [], "uniprot_id": "A0AVQ3"}, {"chembl_id": "CHEMBL2414", "ic50_values": [], "uniprot_id": "P51679"}, {"chembl_id": "CHEMBL274", "ic50_values": [], "uniprot_id": "O14692"}, {"chembl_id": "CHEMBL4029", "ic50_values": [], "uniprot_id": "B2R6Q3"}, {"chembl_id": "CHEMBL2434", "ic50_values": [], "uniprot_id": "P25025"}, {"chembl_id": "CHEMBL1901", "ic50_values": [], "uniprot_id": "B2R9Z5"}, {"chembl_id": "CHEMBL221", "ic50_values": [], "uniprot_id": "A8K1V7"}, {"chembl_id": "CHEMBL230", "ic50_values": [], "uniprot_id": "A8K802"}, {"chembl_id": "CHEMBL3356", "ic50_values": [], "uniprot_id": "P05177"}, {"chembl_id": "CHEMBL5282", "ic50_values": [], "uniprot_id": "A7YAE5"}, {"chembl_id": "CHEMBL3622", "ic50_values": [], "uniprot_id": "P33259"}, {"chembl_id": "CHEMBL3397", "ic50_values": [], "uniprot_id": "P11712"}, {"chembl_id": "CHEMBL289", "ic50_values": [], "uniprot_id": "P10635"}, {"chembl_id": "CHEMBL5281", "ic50_values": [], "uniprot_id": "P05181"}, {"chembl_id": "CHEMBL340", "ic50_values": [], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL2056", "ic50_values": [], "uniprot_id": "B2RA44"}, {"chembl_id": "CHEMBL217", "ic50_values": [], "uniprot_id": "P14416"}, {"chembl_id": "CHEMBL234", "ic50_values": [], "uniprot_id": "A1A4V5"}, {"chembl_id": "CHEMBL219", "ic50_values": [], "uniprot_id": "B0M0J7"}, {"chembl_id": "CHEMBL238", "ic50_values": [], "uniprot_id": "A2RUN4"}, {"chembl_id": "CHEMBL252", "ic50_values": [], "uniprot_id": "B2R723"}, {"chembl_id": "CHEMBL206", "ic50_values": [], "uniprot_id": "Q13511"}, {"chembl_id": "CHEMBL242", "ic50_values": [], "uniprot_id": "A8K8K5"}, {"chembl_id": "CHEMBL2034", "ic50_values": [], "uniprot_id": "A0ZXF9"}, {"chembl_id": "CHEMBL3392921", "ic50_values": [], "uniprot_id": "Q91W28"}, {"chembl_id": "CHEMBL231", "ic50_values": [], "uniprot_id": "A8K047"}, {"chembl_id": "CHEMBL1941", "ic50_values": [], "uniprot_id": "B5BUP7"}, {"chembl_id": "CHEMBL402", "ic50_values": [], "uniprot_id": "B7Z3Y9"}, {"chembl_id": "CHEMBL5486", "ic50_values": [], "uniprot_id": "P15127"}, {"chembl_id": "CHEMBL1909043", "ic50_values": [], "uniprot_id": "A6XA80"}, {"chembl_id": "CHEMBL1798", "ic50_values": [], "uniprot_id": "B2R954"}, {"chembl_id": "CHEMBL4358", "ic50_values": [], "uniprot_id": "O19043"}, {"chembl_id": "CHEMBL4644", "ic50_values": [], "uniprot_id": "P41968"}, {"chembl_id": "CHEMBL259", "ic50_values": [], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4608", "ic50_values": [], "uniprot_id": "B0YJ34"}, {"chembl_id": "CHEMBL1951", "ic50_values": [], "uniprot_id": "B4DF46"}, {"chembl_id": "CHEMBL216", "ic50_values": [], "uniprot_id": "P11229"}, {"chembl_id": "CHEMBL211", "ic50_values": [], "uniprot_id": "P08172"}, {"chembl_id": "CHEMBL245", "ic50_values": [], "uniprot_id": "P20309"}, {"chembl_id": "CHEMBL1821", "ic50_values": [], "uniprot_id": "B2RPP4"}, {"chembl_id": "CHEMBL2035", "ic50_values": [], "uniprot_id": "P08912"}, {"chembl_id": "CHEMBL4777", "ic50_values": [], "uniprot_id": "B2R6H5"}, {"chembl_id": "CHEMBL4018", "ic50_values": [], "uniprot_id": "P49146"}, {"chembl_id": "CHEMBL3048", "ic50_values": [], "uniprot_id": "P70594"}, {"chembl_id": "CHEMBL3464", "ic50_values": [], "uniprot_id": "O70515"}, {"chembl_id": "CHEMBL236", "ic50_values": [], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL237", "ic50_values": [], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL233", "ic50_values": [], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL1827", "ic50_values": [], "uniprot_id": "A0AV69"}, {"chembl_id": "CHEMBL250", "ic50_values": [], "uniprot_id": "A3KMC8"}, {"chembl_id": "CHEMBL240", "ic50_values": [], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL1909044", "ic50_values": [], "uniprot_id": "Q690N0"}, {"chembl_id": "CHEMBL4074", "ic50_values": [], "uniprot_id": "O02852"}, {"chembl_id": "CHEMBL4801", "ic50_values": [], "uniprot_id": "B5MDZ1"}, {"chembl_id": "CHEMBL4071", "ic50_values": [], "uniprot_id": "P08311"}, {"chembl_id": "CHEMBL248", "ic50_values": [], "uniprot_id": "P08246"}, {"chembl_id": "CHEMBL332", "ic50_values": [], "uniprot_id": "P03956"}, {"chembl_id": "CHEMBL321", "ic50_values": [{"value": 5215.0, "units": "nM"}], "uniprot_id": "B2R7V9"}, {"chembl_id": "CHEMBL299", "ic50_values": [], "uniprot_id": "B5BU22"}, {"chembl_id": "CHEMBL3385", "ic50_values": [], "uniprot_id": "A8CZ58"}, {"chembl_id": "CHEMBL4040", "ic50_values": [], "uniprot_id": "A8CZ64"}, {"chembl_id": "CHEMBL260", "ic50_values": [], "uniprot_id": "A6ZJ92"}, {"chembl_id": "CHEMBL4445", "ic50_values": [], "uniprot_id": "A1A441"}, {"chembl_id": "CHEMBL203", "ic50_values": [], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL1841", "ic50_values": [], "uniprot_id": "B5BU57"}, {"chembl_id": "CHEMBL1824", "ic50_values": [], "uniprot_id": "B2RZG3"}, {"chembl_id": "CHEMBL258", "ic50_values": [], "uniprot_id": "D3DPP8"}, {"chembl_id": "CHEMBL3243", "ic50_values": [], "uniprot_id": "A0A0A0MT22"}, {"chembl_id": "CHEMBL273", "ic50_values": [], "uniprot_id": "P19327"}, {"chembl_id": "CHEMBL3459", "ic50_values": [], "uniprot_id": "P28564"}, {"chembl_id": "CHEMBL224", "ic50_values": [], "uniprot_id": "B2RAC5"}, {"chembl_id": "CHEMBL1833", "ic50_values": [], "uniprot_id": "B2R9D5"}, {"chembl_id": "CHEMBL225", "ic50_values": [], "uniprot_id": "B1AMW4"}, {"chembl_id": "CHEMBL5017", "ic50_values": [], "uniprot_id": "O70528"}, {"chembl_id": "CHEMBL3371", "ic50_values": [], "uniprot_id": "P50406"}, {"chembl_id": "CHEMBL228", "ic50_values": [], "uniprot_id": "P31645"}, {"chembl_id": "CHEMBL287", "ic50_values": [], "uniprot_id": "D3DRM7"}, {"chembl_id": "CHEMBL249", "ic50_values": [], "uniprot_id": "A8K150"}, {"chembl_id": "CHEMBL2327", "ic50_values": [], "uniprot_id": "A8K7I1"}, {"chembl_id": "CHEMBL3072", "ic50_values": [], "uniprot_id": "P15207"}, {"chembl_id": "CHEMBL1835", "ic50_values": [], "uniprot_id": "B4DJG6"}, {"chembl_id": "CHEMBL1868", "ic50_values": [], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL5144", "ic50_values": [], "uniprot_id": "A5JUT9"}, {"chembl_id": "CHEMBL1889", "ic50_values": [], "uniprot_id": "P37288"}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 135000.0, "units": "nM"}, {"value": 1000000.0, "units": "nM"}, {"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL613508", "ic50_values": [{"value": 25800.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612657", "ic50_values": [{"value": 24300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 36200.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Busulfan"}, "ppi_enrichment": {"uniprot_count": 108, "interactions": [{"protein_a": "CHKA", "protein_b": "CHKB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "PHOSPHO1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "ACHE", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "GPCPD1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "HSPG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "ACHE", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "DOK7", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "HSPG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "PHOSPHO1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHKB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "MAOB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "GPCPD1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHAT", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "COLQ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "PHOSPHO1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "CHKB", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "GPCPD1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DOK7", "protein_b": "COLQ", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HSPG2", "protein_b": "COLQ", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "PHOSPHO1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "CHKB", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "PHOSPHO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADORA2A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADA", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "SLC29A1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "SLC29A1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "ADORA2A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2A", "protein_b": "SLC29A1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "CNR1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "ADORA2A", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CNR1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2B", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2A", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAL", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "ADORA2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAS", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "GNAS", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "ADORA2A", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "ADORA2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADORA2A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADORA2A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1D", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1A", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "TBXA2R", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1D", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1B", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1D", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1A", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "TBXA2R", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "GNA13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1D", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "ADRA1D", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "SNTB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "UTRN", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "ADRA1D", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "SNTB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "TBXA2R", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "SNTB1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "ADRA1A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "GNA13", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ADRA1A", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TBXA2R", "protein_b": "GNA13", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNA13", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNAQ", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "ADRA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNG2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNG2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNG2", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNA13", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SEC24C", "protein_b": "ADRA2B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2C", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2C", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2C", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2C", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "ADRA2C", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2C", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ADRA2C", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "ADRA2C", "protein_b": "GNA13", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "DLG4", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "ADRB1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GCG", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "POMC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "NPPA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "DLG4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "GNAI1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ADRB2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SNX27", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GRK2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "AKAP12", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SAG", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "SAG", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "SAG", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB2", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "AKAP12", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SAG", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "UCP1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "ADRB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "FGF21", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "ADRB3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB3", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "SRC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "FGF21", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "SRC", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "ADRB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAS", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI3", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "SRC", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GNAI1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "YRDC", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "HTR1A", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SNCA", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SCRT1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC18A2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC5A2", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADCY7", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "STX1A", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC5A2", "protein_b": "ADCY7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MTUS1", "protein_b": "AGTR2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "AGTR2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "EDN1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "KNG1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "ACE2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ACE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "EDN1", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "KNG1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "ACE2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "AGTR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "KNG1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "AGTR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AGTR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "ACE", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "EDN1", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "BDKRB2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "AGT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNAQ", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "AGTR1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "BDKRB2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "BDKRB2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "BDKRB2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "BDKRB2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "BDKRB2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "BDKRB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "BDKRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "BDKRB2", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNG2", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNAS", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "ADM", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCB", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "RAMP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNAS", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "ADM", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNG2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNAS", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "ADM", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADM", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCR", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNB1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNAS", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "CALCB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "CALCB", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADM", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADM", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CALCB", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "SLC4A1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "CA2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "TCIRG1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA1", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "SLC4A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "CA2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CA2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CLCN7", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CLCN7", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBSL", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBS", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CA1", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "SLC4A4", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBS", "protein_b": "CBSL", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL13", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL7", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL8", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL5", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL8", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL7", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CXCL8", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL7", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL5", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL17", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL2", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL27", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL27", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCR4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CXCL12", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR4", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "CCR4", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "GRK3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GRK3", "protein_b": "CCR4", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL3", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CXCL12", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL5", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL3", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR1", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL2", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CXCL10", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL3", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL5", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ITIH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL3L1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL5", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CXCL10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3L1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3L1", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL3L1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL3L1", "protein_b": "CCL4", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL6", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL3", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL5", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CCL2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL8", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL12", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL12", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL12", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CCKAR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAI1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GAST", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCKAR", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNG2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNB1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAI1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAS", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCL28", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "PTK7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GAST", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCL28", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "GNB1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCK", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL28", "protein_b": "CCK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCK", "protein_b": "PTK7", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "HPGDS", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGDS", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX15", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGDS", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGDS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGDS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGS2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGDS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGES3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "ALOX5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGDS", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGES3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGDS", "protein_b": "PTGES3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "TP53", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGES", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CXCL8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "IL6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "IL6", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CXCL8", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PLA2G4A", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "PTGS2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "IL6", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "ALOX5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "PTGS2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "IL6", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2B6", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A8", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2B6", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP3A4", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2E1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A8", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2E1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP2E1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A8", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GAPDH", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "PPIG", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4A11", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "ALOX5", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C19", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C9", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4F2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP1A2", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "PPIG", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP4A11", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "ALOX5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C9", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "ALOX5", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP4A11", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "PPIG", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ALOX5", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2C19", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2C19", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ALOX5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2D6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B15", "protein_b": "CYP2D6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "CYP2D6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2D6", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "UGT1A3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A3", "protein_b": "CYP2D6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ADH1B", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "ADH1B", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A4", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A10", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTP1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTM1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "CYP2E1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "GSTP1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GSTP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP3A4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP2E1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "EPHX1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALY", "protein_b": "DRD1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "DRD1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "DRD1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "TMTC1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "DRD1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "DRD1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "DRD1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "TMTC1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "ADCYAP1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "POMC", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "NCS1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB2", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG7", "combined_score": 0.701, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG2", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "DRD3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD1", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD3", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "DRD3", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "DRD1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "BDNF", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "KLHL12", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD3", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "MAOA", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DRD2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "BDNF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TH", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SYNGR3", "protein_b": "SLC6A3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "FLOT1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "CAMK2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "TH", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SNCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "TH", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "SLC18A2", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "TH", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SNCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRB", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRB", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "KNG1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "GNA13", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "AGT", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDNRB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN2", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDNRB", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDN1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "KNG1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "GNA13", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NRIP1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SP1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SRC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA2", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA3", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "JUN", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "JUN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "MED1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SP1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "JUN", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "SRC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "FKBP5", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "STIP1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "PTGES3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "NR3C1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSPA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSPA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "STIP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "PTGES3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AB1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "PTGES3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "FKBP5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "FKBP5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FKBP5", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HRH1", "combined_score": 0.722, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "HRH1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "PLCB3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HRH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PLCB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HRH1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PLCB3", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PLCB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HRH1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "PLCB3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "TRPV1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "ATP4A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "GAST", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "GAST", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "GAST", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "HRH2", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HRH2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SQLE", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDFT1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDPS", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "INSIG1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "HMGCR", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "INSIG1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDPS", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCR", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDFT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDFT1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDPS", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "INSIG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "INSIG1", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "HMGCS2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDFT1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDPS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDPS", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDFT1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDPS", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDFT1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "HMGCS2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "SREBF2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "SREBF2", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "HMGCS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "FDFT1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "HMGCS2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "FDFT1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "HMGCS2", "protein_b": "FDFT1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "LTC4S", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "LTB4R2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR1", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "TBXA2R", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR2", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "TBXA2R", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "ALOX5AP", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTB4R2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "GNAQ", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTC4S", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "CYSLTR1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LTB4R2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CYSLTR1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5AP", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "LTB4R2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "CYSLTR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "LTB4R2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "TBXA2R", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5AP", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALOX5", "protein_b": "ALOX5AP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CTSZ", "protein_b": "MC3R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "LEP", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "POMC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "AGRP", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "MC3R", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "NPY", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "GHRL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ASIP", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "LEP", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "NPY", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "MRAP2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "GHRL", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ATP7A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "AGRP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "ASIP", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ATP7A", "protein_b": "POMC", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ASIP", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MRAP2", "protein_b": "MC5R", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "MC5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DBH", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DDC", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "COMT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "LRTOMT", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "AOC3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "ALDH2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC3", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOA", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "AOC3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DBH", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DDC", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DBH", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DDC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "COMT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOA", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOB", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "CYP2D6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "MAOB", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "AOC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DDC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DBH", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DBH", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DDC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "MAOB", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "CYP2D6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "AOC1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DBH", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DDC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "DBH", "protein_b": "DDC", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "DDC", "protein_b": "AOC1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR6", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "ARRB1", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR5", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR4", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "F2R", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "KNG1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR4", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR3", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "CHRM2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "ARRB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR4", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR5", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "CHRM2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "LPAR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "LPAR4", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "ARRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "AGTRAP", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNA15", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG12", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GRM5", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CHRM1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "NPY1R", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GHRL", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY1R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PPY", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY1R", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PYY", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY5R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNB1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY5R", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI3", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "NPY5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY5R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PRPH2", "protein_b": "NPY2R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY2R", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "POMC", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GLP1R", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "POMC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNG2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNB1", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PPY", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PYY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "POMC", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GLP1R", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "GLP1R", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "POMC", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "POMC", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "GNB1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PPY", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE6G", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE6G", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE2A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE5A", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUCY1B1", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE2A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "ITPA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "APRT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUK1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE5A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUCY1B1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUCY1B1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ALDH7A1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CCR1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PTAFR", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TLR4", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PTAFR", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ARRB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "TLR4", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "PTAFR", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "ARRB1", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "PTAFR", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TLR4", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "PTAFR", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "FPR2", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GPR135", "protein_b": "PTAFR", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "ARRB1", "protein_b": "PTAFR", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "TYK2", "protein_b": "PTAFR", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "PECAM1", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "FPR2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP8", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "GSDMD", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "IL1B", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "PYCARD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "GSDMD", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "IL1B", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP6", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP6", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "AIM2", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRC4", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "GSDMD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP8", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "GSDMD", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP8", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "GSDMD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRP1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "GSDMD", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRC4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "GSDMD", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "GSDMD", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "GSDMD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSDMD", "protein_b": "NLRP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINB4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "MMP9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "MMP9", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "MMP9", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "MMP9", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "ELANE", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPINA3", "protein_b": "ELANE", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SLPI", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "DEFA4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "SERPINA1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "DEFA4", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "DEFA4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "SLPI", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "DEFA4", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "DEFA4", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "SERPINA1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "DEFA4", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "DEFA4", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DEFA4", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLPI", "protein_b": "ELANE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPINA1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "STAT3", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "IL1B", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "IL1B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "STAT3", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP9", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP7", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "TIMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "IL1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP9", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "TIMP2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "STAT3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP9", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP9", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP3", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP9", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "MMP1", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "BSG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "MMP9", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "THBS1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "LCN2", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "CD44", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "MMP9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "TIMP3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "ELN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DMP1", "protein_b": "MMP9", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "CD44", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "MMP9", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "LCN2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCD", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCB", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PICK1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "NCF1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "MTOR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLD1", "protein_b": "PRKCA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCB", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "SDC4", "protein_b": "PRKCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PICK1", "protein_b": "PRKCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "RACK1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "RACK1", "protein_b": "PRKCB", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "FOS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "FOS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "MAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAPK3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "RPS6KA1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "PTPN7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "FOS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "FOS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "RPS6KA1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "STAT3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PEA15", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MKNK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "JUN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "JUN", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPKAPK2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ATF2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK14", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAPK14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "JUN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K6", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "DUSP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "ATF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "ATF2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "TP53", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MAP2K3", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAPKAPK3", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "JUN", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAP2K6", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAPKAPK3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "RCAN1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3R2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML6", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML5", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALM3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "NFATC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RCAN1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "RCAN1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3R2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3R2", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CB", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CB", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "CALML4", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CB", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "NFATC1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "CALML4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3CA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "CALML4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "NFATC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "CALML4", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "PPP3R2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "PPP3R2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "PTK2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LCK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SHC1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "FYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "LYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LCK", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LYN", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SHC1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "FYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SH2D1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SH2D1A", "protein_b": "LCK", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "DLG4", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LCK", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LYN", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "HSP90AA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SHC1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRG1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "HSP90AA1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SRC", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "CD44", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "ERBB4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SHC1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SRC", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "CD44", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ERBB4", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "GRB2", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "CD44", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SRC", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CD44", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "VAV1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCP2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD28", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD28", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "PTPRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD247", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "ZAP70", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "PTPRC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD28", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PTPRC", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "FYN", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "VAV1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD8A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD247", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "VAV1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD8A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SYK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD247", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "PTPRC", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "VAV1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "PTPRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "PTPRC", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "VAV1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VAV1", "protein_b": "LCK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LYN", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SPN", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "DPP4", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD22", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "SPN", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "PTPRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "SPN", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "PTPRC", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "LCK", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPP4", "protein_b": "PTPRC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD47", "protein_b": "PTPRC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LYN", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "SPN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GRM2", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GRM2", "protein_b": "HTR2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2C", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2B", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1F", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1S", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1F", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1S", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1F", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1S", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1S", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1F", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "HTR2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "CACNA1F", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CACNA1F", "protein_b": "HTR2A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNG2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNB1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "GNG2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNB1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR2A", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HTR2A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "FSHB", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "HTR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GIP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "NPPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "FSHB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GCG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "ADCYAP1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "VIP", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "POMC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "HTR7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GNAS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HTR7", "protein_b": "GNAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "VIP", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "FSHB", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "ADCYAP1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TPH1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A4", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOA", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "TPH2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "TPH2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "BDNF", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "MAOA", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR1B", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR2A", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR1B", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR1B", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR2A", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "HTR2A", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR2A", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "BDNF", "protein_b": "HTR2A", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SIGMAR1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "ERG28", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "MSMO1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SQLE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TMEM97", "protein_b": "SIGMAR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SQLE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SIGMAR1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "MSMO1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SIGMAR1", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SQLE", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SIGMAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNA4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR3", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNH6", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "HSPA5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "HSPA5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSPA5", "protein_b": "ITPR3", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "KCNA4", "protein_b": "KCNH6", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TAC1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "NTS", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TACR1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "UNC80", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC3", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "UNC80", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TACR1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "UNC80", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNAS", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "ARRB1", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "UNC80", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TACR2", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TACR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "CHKB", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TACR2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "CHKB", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "TAC3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "TBXAS1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "TBXAS1", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "TBXAS1", "protein_b": "MGAM2", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR2", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNB1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "ADCYAP1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIP", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "WASL", "protein_b": "VIPR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNB1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIPR1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNAS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNB1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ATG5", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADCYAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1B", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVP", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR2", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1B", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1B", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA14", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR1B", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "VIP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "GNA13", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVPR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AVP", "protein_b": "AVPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "AVPR2", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 10.53, "clustering_coefficient": 5.26}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41152998", "title": "Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study.", "authors": [{"name": "Alomari N", "authtype": "Author", "clusterid": ""}, {"name": "Kurdi A", "authtype": "Author", "clusterid": ""}, {"name": "Alghamdi M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41016399", "title": "Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.", "authors": [{"name": "Henderson TO", "authtype": "Author", "clusterid": ""}, {"name": "Bardwell JK", "authtype": "Author", "clusterid": ""}, {"name": "Kao PC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40949119", "title": "Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation.", "authors": [{"name": "Cao D", "authtype": "Author", "clusterid": ""}, {"name": "Qian X", "authtype": "Author", "clusterid": ""}, {"name": "Wang P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40901473", "title": "Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.", "authors": [{"name": "Wei Y", "authtype": "Author", "clusterid": ""}, {"name": "Luan S", "authtype": "Author", "clusterid": ""}, {"name": "Wang L", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.\n\nThe CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen", "type": "EXPERIMENTAL", "description": "1. Cytoreduction therapy:\n\n   1. 0.8 mg/kg q6h x 12 doses busulfan via IV injection\n   2. 70 mg/m\\^2/day x 2 days melphalan via IV infusion over 30 minutes\n   3. 25 mg/m\\^2/day x 5 days fludarabine vis IV infusion over 30 minutes\n2. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells", "intervention_names": ["Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"]}], "interventions": [{"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m\\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m\\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DEVICE", "name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)", "description": "CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT05617625+terminated", "https://www.google.com/search?q=Guenther Koehne+Busulfan+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Busulfan by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about FDA warning letters or clinical holds for Busulfan by Guenther Koehne.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds for Busulfan\n2. Related to Guenther Koehne\n3. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this information:\n\nResult [1]: Discusses dose escalation trials but doesn't mention Guenther Koehne or FDA warning letters/clinical holds for Busulfan specifically.\n\nResult [2]: Discusses cell transplantation but doesn't mention Guenther Koehne or FDA warning letters/clinical holds for Busulfan.\n\nResult [3]: This is an MSKCC annual report that mentions Guenther Koehne (listed as \"Guenther Koehne, Susan Prockop\" in what appears to be an author list). It also mentions FDA approvals for PD-1 inhibitors and brentuximab vedotin, but doesn't mention any warning letters or clinical holds for Busulfan.\n\nResult [4]: This appears to be a document about Waldenstr\u00f6m's Award that mentions \"Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation\" but doesn't mention Guenther Koehne or FDA warning letters/clinical holds.\n\nResult [5]: This is an abstract book from the 14th International Myeloma Workshop that mentions FDA approvals but doesn't specifically discuss warning letters or clinical holds for Busulfan or mention Guenther Koehne.\n\nResult [6]: This is a ClinicalTrials.gov entry for \"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic...\" It mentions FDA \"Violation\" and \"Notice of Noncompliance\" but doesn't specifically link this to Guenther Koehne or provide details about warning letters for Busulfan.\n\nResult [7]: This is a press release about Miami Cancer Institute launching FDA-approved clinical trials, mentioning \"led by Dr. Koehne's...\" This suggests Dr. Guenther Koehne is involved in clinical trials at Miami Cancer Institute, but doesn't mention any warning letters or clinical holds for Busulfan.\n\nAfter reviewing all the search results, I don't", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT05617625 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT05617625 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to check if any of the search results contain information about:\n1. SEC EDGAR 8-K filings\n2. By someone named Guenther Koehne\n3. Related to clinical trial NCT05617625\n4. With drug safety issues\n\nLet me go through each search result:\n\nResult [1]: \n- URL: https://www.clinicaltrials.gov/ct2/keydates/NCT05617625\n- Content: Describes a study evaluating CD34+ Enriched Transplants to Treat Myelodysplastic... using the CliniMACS system\n- This is a clinical trial registration page for NCT05617625, but it's not an SEC filing\n\nResult [2]:\n- URL: http://pdf.secdatabase.com/1263/0001776985-24-000066.pdf\n- Content: BioNTech SE Form 6-K Current Event Report Filed 2024-08-05\n- Mentions several clinical trials (NCT04486378, NCT05918445, NCT05438329) but not NCT05617625\n- Contains safety data for some trials (e.g., \"52/61) with \u2265Grade 3 TRAEs in 19.7% (12/61), serious adverse events were observed in 24.6% (15/61) of patients\")\n- No mention of Guenther Koehne\n\nResult [3]:\n- URL: https://www.sec.gov/Archives/edgar/data/1034842/000110465905058782/0001104659-05-", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "start_date": "2025-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT05617625 for Busulfan. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive JSON summary.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Guenther Koehne\n- Specifically about clinical trial NCT05617625 for Busulfan\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT05617625 is from the search results:\n\nFrom results [9] and [11], I can see that NCT05617625 is titled \"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome\". The study evaluates \"whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer...\"\n\nFrom result [17], I see that NCT05617625 is associated with Guenther Koehne and relates to \"Myelodysplastic Syndromes|Graft Vs Host Disease|Graft-versus-host-disease\" and is a PHASE2 trial with an expected completion date of 2025-09.\n\nNow, let me check if there are any press releases, investor presentations, or public statements by Guenther Koehne specifically about this trial (NCT05617625) that discuss safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLooking through the search results:\n\nResult [1] and [3] mention Dr. Guenther Koehne as the Chief of Blood & Marrow Transplant at Miami Cancer Institute and discuss clinical trials related to blood cancers and stem cell transplants, but they don't specifically mention NCT05617625.\n\nResult [7] mentions Dr. Guenther Koehne as the Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute, but doesn't provide specific information about NCT05617625.\n\nResult [15] mentions \"Guenther Koehne\" and \"NCT05617625\" together, but it appears to be a Korean document (based on the URL) and I don't have the content to analyze.\n\nResult [17] also mentions \"NCT056176", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "drug_name": "Busulfan"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the suspension of the trial is \"The study has been put on hold while pending CMS approval.\" This indicates an administrative issue, likely related to regulatory approval or oversight, that led to the suspension of the trial. There is no mention of safety concerns or lack of efficacy as the reason for the trial termination.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:33.259360", "claude_model": "claude-3-haiku-20240307", "tokens_used": 917}}, "34": {"nct_id": "NCT05617625", "drug_name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)", "intervention_type": "DEVICE", "drug_description": "CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "The study has been put on hold while pending CMS approval", "title": "CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome", "start_date": "2025-09-30", "completion_date": "2032-09-30", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.543893", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:33.297951", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.\n\nThe CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen", "type": "EXPERIMENTAL", "description": "1. Cytoreduction therapy:\n\n   1. 0.8 mg/kg q6h x 12 doses busulfan via IV injection\n   2. 70 mg/m\\^2/day x 2 days melphalan via IV infusion over 30 minutes\n   3. 25 mg/m\\^2/day x 5 days fludarabine vis IV infusion over 30 minutes\n2. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells", "intervention_names": ["Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"]}], "interventions": [{"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m\\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m\\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DEVICE", "name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)", "description": "CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT05617625+terminated", "https://www.google.com/search?q=Guenther Koehne+CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC) by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there is any information about FDA warning letters or clinical holds for CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC) by Guenther Koehne.\n\nThe query is asking specifically for:\n1. FDA warning letters\n2. Clinical holds\n3. For CliniMACS CD34+ enriched, T-cell depleted PBSC\n4. Related to Guenther Koehne\n5. Including specific dates, reasons, and safety issues cited\n\nLet me go through each search result to see if it contains this information:\n\nResult [1]: This is a PDF about a Phase I Dose Escalation Trial of T-cell Receptor \u03b1/\u03b2 Depleted cells. It mentions the CliniMACS device and refers to \"the BMT Clinical Trials Network\" and FDA approval. Specifically, it states: \"The highly favorable results of the BMT CTN trial published formed the basis for an application to the FDA for licensure as a device to prevent GvHD in patients transplanted for AML. Approval for use of the CliniMACS CD34 reagent system for processing of hematopoietic progenitor cells...\"\n\nThis suggests FDA approval was granted, not a warning letter or clinical hold. There's no mention of Guenther Koehne specifically in the excerpt provided.\n\nResult [2]: This is a PDF about a Phase II Trial of Transplants from HLA-Compatible donors. It mentions the CliniMACS system and states: \"have now been submitted for publication and form the basis for an application to the FDA for licensure as a device to prevent GVHD in patients transplanted for AML. As we are waiting for approval, trials of T-cell depleted CD34+ PBSC transplants fractionated on the CliniMACS...\"\n\nThis suggests they were awaiting FDA approval at the time of writing, but doesn't mention any warning letters or clinical holds. No specific mention of Guenther Koehne.\n\nResult [3]: This is an article about gene and cell therapy for children. It mentions CD34+ cells and the CliniMACS system in passing but doesn't discuss FDA warnings or clinical holds. No mention of Guenther Koehne.\n\nResult [4]: This appears to be a PhD thesis about Epstein-Barr Virus-Specific T cells. There's a mention of", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT05617625 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT05617625 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, let me check if any of the search results contain information about:\n1. Guenther Koehne\n2. Clinical trial NCT05617625\n3. SEC EDGAR 8-K filings related to these\n\nLooking at the search results:\n\nResult [1] is about clinical trial NCT05617625 from clinicaltrials.gov. It describes a study evaluating CD34+ Enriched Transplants to Treat Myelodysplastic using the CliniMACS system.\n\nResult [2] is a BioNTech SEC Form 6-K filed on 2024-08-05. It contains information about various clinical trials (NCT04486378, NCT05918445, NCT05438329) but doesn't mention NCT05617625 or Guenther Koehne.\n\nResult [3] is a 10-K annual report filing. It contains general information about clinical trials, risks, and development but doesn't specifically mention NCT05617625 or Guenther Koehne.\n\nResults [4], [5], [6], and [7] appear to be SEC filing indexes or Form 8-K filings for other companies (Zynerba Pharmaceuticals, Audentes Therapeutics), but don't seem to contain specific information about NCT05617625 or Guenther Koehne based on the limited information provided.\n\nLet me check if there's any mention of Guenther Koehne in the results:\n\nI don't see any explicit mention of \"Guenther Koehne\" in the provided search results. Result [3] has some information about clinical trials and risks but doesn't name Guenther Koehne.\n\nLet me check if there's any mention of NCT05617625 in the SEC filings:\n\nResult [1] confirms N", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "start_date": "2025-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT05617625 for CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about external safety evidence for clinical trial NCT05617625 for CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC) transplants.\n\nFirst, I need to identify which search results contain information about NCT05617625 and specifically about safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFrom the search results:\n\n1. Result [1] and [2] are about Miami Cancer Institute launching two FDA-approved clinical trials for blood cancers using stem cell transplants, led by Dr. Guenther Koehne. These mention his work on manipulating donor cells to reduce graft-versus-host disease (GVHD), but they don't specifically mention NCT05617625.\n\n2. Result [3] is about a phase 2 trial of elranatamab for multiple myeloma, not related to NCT05617625.\n\n3. Result [4] is about a Miami Cancer Institute BMT Cellular Therapy educational program where Dr. Guenther Koehne is the Chief of Blood & Marrow Transplant, but doesn't provide specific information about NCT05617625.\n\n4. Result [5] and [6] mention Guenther Koehne in relation to clinical trials involving Fludarabine and Busulfan, with NCT05617625 listed as a phase 2 trial for \"Myelodysplastic Syndromes|Graft Vs Host Disease|Graft-versus-host-disease\" with a completion date of 2025-09.\n\n5. Result [7] and [8] are from clinicaltrials.gov and describe NCT05617625 as \"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome\" which will \"evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer...\" (the text is cut off).\n\n6. Result [9] appears to be a PDF in Korean about overseas biopharmaceutical clinical status.\n\nNow, focusing specifically on NCT05617625:\n\n- From results [5], [6], [7], and [8],", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "drug_name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the suspension of the trial is \"The study has been put on hold while pending CMS approval.\" This indicates an administrative issue, likely related to regulatory approval or oversight, that led to the suspension of the trial. There is no mention of safety concerns or lack of efficacy as the reason for the trial termination.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:33.259360", "claude_model": "claude-3-haiku-20240307", "tokens_used": 917}}, "35": {"nct_id": "NCT05617625", "drug_name": "Fludarabine", "intervention_type": "DRUG", "drug_description": "25 mg/m\\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "The study has been put on hold while pending CMS approval", "title": "CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome", "start_date": "2025-09-30", "completion_date": "2032-09-30", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.544187", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:33.333298", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1096882", "pref_name": "FLUDARABINE PHOSPHATE", "targets": [{"chembl_id": "CHEMBL3879801", "ic50_values": [{"value": 2000.0, "units": "nM"}, {"value": 950.0, "units": "nM"}, {"value": 150.0, "units": "nM"}, {"value": 6000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614628", "ic50_values": [{"value": 400.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL383", "ic50_values": [{"value": 90.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL385", "ic50_values": [{"value": 400.0, "units": "nM"}, {"value": 150.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614393", "ic50_values": [{"value": 600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 130.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614735", "ic50_values": [{"value": 9000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL382", "ic50_values": [{"value": 400.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL386", "ic50_values": [{"value": 3000.0, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Fludarabine"}, "ppi_enrichment": {"uniprot_count": 4, "interactions": [{"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.69, "clustering_coefficient": 2.84}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41146244", "title": "Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups.", "authors": [{"name": "Mikhaylenko N", "authtype": "Author", "clusterid": ""}, {"name": "Braun T", "authtype": "Author", "clusterid": ""}, {"name": "Timonen S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41110448", "title": "IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.", "authors": [{"name": "Xu Q", "authtype": "Author", "clusterid": ""}, {"name": "Guo Y", "authtype": "Author", "clusterid": ""}, {"name": "Gao M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41037957", "title": "Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.", "authors": [{"name": "Wang Y", "authtype": "Author", "clusterid": ""}, {"name": "Yang S", "authtype": "Author", "clusterid": ""}, {"name": "Yu Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40960310", "title": "Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.", "authors": [{"name": "Liu W", "authtype": "Author", "clusterid": ""}, {"name": "Xie T", "authtype": "Author", "clusterid": ""}, {"name": "Zhang Z", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40859744", "title": "Randomization in phase II trials: No exemption based on sample size.", "authors": [{"name": "Framke T", "authtype": "Author", "clusterid": ""}, {"name": "Beutel G", "authtype": "Author", "clusterid": ""}, {"name": "Ganser A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.\n\nThe CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen", "type": "EXPERIMENTAL", "description": "1. Cytoreduction therapy:\n\n   1. 0.8 mg/kg q6h x 12 doses busulfan via IV injection\n   2. 70 mg/m\\^2/day x 2 days melphalan via IV infusion over 30 minutes\n   3. 25 mg/m\\^2/day x 5 days fludarabine vis IV infusion over 30 minutes\n2. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells", "intervention_names": ["Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"]}], "interventions": [{"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m\\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m\\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DEVICE", "name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)", "description": "CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT05617625+terminated", "https://www.google.com/search?q=Guenther Koehne+Fludarabine+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Fludarabine by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Fludarabine by Guenther Koehne.\n\nFirst, I need to identify if there are any mentions of:\n1. FDA warning letters related to Fludarabine\n2. Clinical holds related to Fludarabine\n3. Any involvement of Guenther Koehne in these matters\n4. Specific dates, reasons, and safety issues cited\n\nLet me go through each search result:\n\nResult [1]: This discusses dose escalation trials but doesn't mention Fludarabine specifically or Guenther Koehne. It talks about a grass pollen allergoid trial, lenalidomide, and some other drugs, but not Fludarabine.\n\nResult [2]: This appears to be a PDF about Waldenstr\u00f6m's Award, but the content isn't fully visible in the snippet. It mentions Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R, and a reference to \"2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine.\" This mentions fludarabine but not in the context of FDA warning letters or clinical holds, and doesn't mention Guenther Koehne specifically.\n\nResult [3]: This is an FDA query result listing various FOIA requests, including requests for adverse event reports for several drugs (ELEVIDYS, Wegovy, Ozempic, Zepbound, Mounjaro), but doesn't mention Fludarabine or Guenther Koehne.\n\nResult [4]: This discusses immunotherapy for multiple myeloma, mentioning various drugs including daratumumab, isatuximab, and elotuzumab. It mentions \"Infusion reactions, which include rash, headache, cough, nausea, vomiting, nasal congestion, and dyspnea, represent an adverse but usually low-grade reaction to daratumumab...\" but doesn't mention Fludarabine or Guenther Koehne.\n\nResult [5]: This is another FDA query result listing various FOIA requests, including some related to warning letters, but none specifically about Fludarabine or Guenther Koehne.\n\nResult [6]: This appears to be from the 14th International Myeloma Workshop. It mentions \"fl", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT05617625 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT05617625 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to check if any of the search results contain information about:\n1. SEC EDGAR 8-K filings\n2. By someone named Guenther Koehne\n3. Related to clinical trial NCT05617625\n4. With drug safety issues\n\nLet me go through each search result:\n\nResult [1]: \n- URL: https://www.clinicaltrials.gov/ct2/keydates/NCT05617625\n- Content: Describes a study evaluating CD34+ Enriched Transplants to Treat Myelodysplastic... using the CliniMACS system\n- This is a clinical trial registration page for NCT05617625, but it's not an SEC filing\n\nResult [2]:\n- URL: http://pdf.secdatabase.com/1263/0001776985-24-000066.pdf\n- Content: BioNTech SE Form 6-K Current Event Report Filed 2024-08-05\n- This is an SEC filing (Form 6-K) by BioNTech SE\n- Mentions several clinical trials including NCT04486378, NCT05918445, NCT05438329\n- But does not mention NCT05617625 or Guenther Koehne\n\nResult [3]:\n- URL: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm\n- Content: 10-K Annual Report\n- This appears to be a generic 10-K form template with risk factors related to clinical trials and drug development\n- Does not mention NCT05617625", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "start_date": "2025-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT05617625 for Fludarabine. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Guenther Koehne regarding clinical trial NCT05617625 for Fludarabine, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results are relevant to NCT05617625 and Guenther Koehne:\n\n1. Result [1] mentions NCT05617625 at Karmanos Cancer Institute, with Guenther Koehne and Jazz Pharmaceuticals. It describes the trial as involving \"Fludarabine, Fludara, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor.\"\n\n2. Result [3] mentions NCT05617625 at Baptist Health South Florida/Miami Cancer Institute, with Guenther Koehne studying \"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute\" with the title \"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome.\"\n\n3. Result [9] provides key dates for NCT05617625, describing it as \"CD34+ Enriched Transplants to Treat Myelodysplastic...\" with a regimen of \"25 mg/m^2/day x 5 days fludarabine vis IV infusion over 30 minutes. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system.\"\n\n4. Result [11] is the ClinicalTrials.gov page for NCT05617625, describing it as a study \"to evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer...\"\n\n5. Result [13] mentions Fludarabine with \"DEVICE: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)\" with Guenther Koehne and indicates it's a Phase 2 trial.\n\nNow, let me look for any press releases, investor presentations, or public statements by Guenther Koehne about this specific trial:\n\nResult [14] mentions \"Kura Oncology to present", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "drug_name": "Fludarabine"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the suspension of the trial is \"The study has been put on hold while pending CMS approval.\" This indicates an administrative issue, likely related to regulatory approval or oversight, that led to the suspension of the trial. There is no mention of safety concerns or lack of efficacy as the reason for the trial termination.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:33.259360", "claude_model": "claude-3-haiku-20240307", "tokens_used": 917}}, "36": {"nct_id": "NCT05617625", "drug_name": "Melphalan", "intervention_type": "DRUG", "drug_description": "70 mg/m\\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "The study has been put on hold while pending CMS approval", "title": "CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome", "start_date": "2025-09-30", "completion_date": "2032-09-30", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.544473", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:33.369920", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200863", "pref_name": "MELPHALAN HYDROCHLORIDE", "targets": [{"chembl_id": null, "uniprot_id": "P02763", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NS82", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q01650", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P15144", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O75751", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Melphalan", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "ORM1", "protein_b": "SPTLC3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA3", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AMBP", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "CP", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AHSG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SPTLC1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "HP", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ALB", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ORM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SPTLC1", "protein_b": "SPTLC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "AHSG", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA3", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ALB", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "HP", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "SERPINA1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "HP", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ORM2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "AHSG", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ALB", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "HP", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ALB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "HP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "ORM2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA3", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "ORM2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SLC7A10", "protein_b": "SLC3A1", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "SLC7A10", "protein_b": "SLC3A2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC3A2", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC3A2", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC7A5", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC1A5", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC38A1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC3A2", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC7A8", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC7A5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC38A1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC43A2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "ASNS", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC7A8", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "LLGL2", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC1A5", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC43A1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC3A2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC43A1", "protein_b": "SLC3A2", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "SLC43A1", "protein_b": "SLC7A8", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC7A8", "protein_b": "SLC43A2", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC7A8", "protein_b": "SLC3A2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "ASNS", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "SLC43A2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "SLC1A5", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SLC1A5", "protein_b": "SLC38A1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "RTN4R", "protein_b": "ANPEP", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT7", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT5", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "ANPEP", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT5", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT7", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "ANPEP", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT6", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "CD7", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "ANPEP", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "FCGR3A", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT7", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "FCGR3A", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT6", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "SFN", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "CD7", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CD7", "protein_b": "FCGR3A", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GGT7", "protein_b": "GGT5", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GGT7", "protein_b": "GGT6", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GGT6", "protein_b": "GGT5", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "SLC22A3", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "SLC47A1", "protein_b": "SLC22A3", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "SLC47A1", "protein_b": "SLC29A4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "SLC29A4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "EHMT2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "IGF2R", "combined_score": 0.906, "interaction_type": "physical"}], "network_features": {"avg_degree": 4.49, "clustering_coefficient": 2.24}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41136366", "title": "35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du My\u00e9lome (IFM) experience.", "authors": [{"name": "Moreau P", "authtype": "Author", "clusterid": ""}, {"name": "Hulin C", "authtype": "Author", "clusterid": ""}, {"name": "Talbot A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41117344", "title": "Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.", "authors": [{"name": "Rausch C", "authtype": "Author", "clusterid": ""}, {"name": "Bacher U", "authtype": "Author", "clusterid": ""}, {"name": "Rabaglio M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41065854", "title": "Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?", "authors": [{"name": "Talarico M", "authtype": "Author", "clusterid": ""}, {"name": "Barbato S", "authtype": "Author", "clusterid": ""}, {"name": "Maisnar V", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41016399", "title": "Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.", "authors": [{"name": "Henderson TO", "authtype": "Author", "clusterid": ""}, {"name": "Bardwell JK", "authtype": "Author", "clusterid": ""}, {"name": "Kao PC", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder.\n\nThe CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen", "type": "EXPERIMENTAL", "description": "1. Cytoreduction therapy:\n\n   1. 0.8 mg/kg q6h x 12 doses busulfan via IV injection\n   2. 70 mg/m\\^2/day x 2 days melphalan via IV infusion over 30 minutes\n   3. 25 mg/m\\^2/day x 5 days fludarabine vis IV infusion over 30 minutes\n2. CD34+ selected, T-cell depleted, allogeneic PBSC transplant using CliniMACS system to select CD34+ cells", "intervention_names": ["Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)"]}], "interventions": [{"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m\\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m\\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}, {"type": "DEVICE", "name": "CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)", "description": "CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.", "arm_group_labels": ["CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant with Busulfan/Melphalan/Fludarabine Regimen"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT05617625+terminated", "https://www.google.com/search?q=Guenther Koehne+Melphalan+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Melphalan by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for Melphalan by Guenther Koehne\n- Specific dates, reasons, and safety issues cited\n\nFirst, let me check if there's any information about FDA warning letters or clinical holds specifically for Melphalan associated with Guenther Koehne in the search results.\n\nLooking through the search results:\n\nResult [1] discusses dose escalation trials but doesn't mention Melphalan specifically or Guenther Koehne.\n\nResult [2] mentions \"High-dose melphalan and autologous stem cell transplantation\" but doesn't mention FDA warning letters, clinical holds, or Guenther Koehne.\n\nResult [3] discusses immunotherapy for multiple myeloma but doesn't mention Melphalan specifically in the context of FDA warnings or Guenther Koehne.\n\nResult [4] discusses cell transplantation but doesn't mention Melphalan specifically or FDA warnings.\n\nResult [5] is a PDF about the International Myeloma Workshop but doesn't seem to contain specific information about FDA warnings for Melphalan by Guenther Koehne.\n\nResult [6] mentions FDA orphan drug designations for LP-284 but not for Melphalan or related to Guenther Koehne.\n\nResult [7] mentions \"Dr Koehne on the Evolution of the Multiple Myeloma Treatment Paradigm\" but shows an error message (403: Forbidden), so I can't access the content.\n\nResult [8] mentions \"autologous stem cell transplant with high-dose melphalan\" but doesn't mention FDA warning letters, clinical holds, or Guenther Koehne specifically.\n\nResult [9] appears to be about drug repositioning but doesn't seem relevant to the query.\n\nI don't see any specific information about FDA warning letters or clinical holds for Melphalan by Guenther Koehne in the search results. There are mentions of melphalan in results [2] and [8], but they don't discuss FDA warnings or clinical holds. There's a mention of Dr. Guenther Koehne in result [7], but the content is inaccessible due to a 403 error.\n\nLet me double-check if there's any indirect information that might be relevant:\n\n- Result [2] mentions \"High-dose mel", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT05617625 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- That mention clinical trial NCT05617625 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nFirst, let me check the search results to see if they contain relevant information:\n\nResult [1] is about clinical trial NCT05617625, which is titled \"CD34+ Enriched Transplants to Treat Myelodysplastic...\" It mentions evaluating processing blood stem cell transplants using an investigational device (the CliniMACS system).\n\nResults [2] through [6] appear to be SEC filings:\n- [2] is a 10-K annual report\n- [3] is an EDGAR filing detail\n- [4] is another EDGAR filing\n- [5] is a Form 8-K for Zynerba Pharmaceuticals\n- [6] is a Form 8-K for Audentes Therapeutics\n\nNow, I need to check if any of these filings:\n1. Are by Guenther Koehne\n2. Mention clinical trial NCT05617625\n3. Discuss related drug safety issues\n\nLet me analyze each result more carefully:\n\nResult [1]: This is about the clinical trial NCT05617625, but it's from clinicaltrials.gov, not an SEC filing. It doesn't mention Guenther Koehne.\n\nResult [2]: This is a 10-K annual report (not a Form 8-K as requested in the query). It contains general risk factors and business information but doesn't specifically mention:\n- Guenther Koehne\n- Clinical trial NCT05617625\n- Specific drug safety issues related to this trial\n\nResult [3]: This is just an EDGAR filing detail index with no specific content shown.\n\nResult [4]: Another EDGAR filing index with no specific content shown.\n\nResult [5]: This is a Form 8-K for Zynerba Pharmaceuticals dated April 10, but there's no content shown to determine if it mentions Guenther Koehne or NCT05617625.\n\n", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "start_date": "2025-09-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT05617625 for Melphalan. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Guenther Koehne\n- About clinical trial NCT05617625 for Melphalan\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available:\n\nResult [1]: About clinical trials at Miami Cancer Institute led by Guenther Koehne, but it's about blood cancers including AML, multiple myeloma, and ALL. It mentions Dr. Koehne and his work with CRISPR technology for AML (NCT04849910), but not NCT05617625 or Melphalan specifically.\n\nResult [2]: About FDA withdrawing approval for melphalan flufenamide (Pepaxto) for multiple myeloma based on the OCEAN trial. This is about melphalan flufenamide, which is a derivative of melphalan, but it's not about NCT05617625.\n\nResult [3]: This is about NCT05617625, which is titled \"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome\". It mentions evaluating processing blood stem cell transplants using the CliniMACS system. There's no mention of melphalan in this brief description.\n\nResult [4]: About Kezar halting a lupus drug trial after patient deaths, not related to NCT05617625 or melphalan.\n\nResult [5]: Appears to be a Korean document about clinical trials, but access is denied.\n\nResult [6]: About FDA alerts regarding PD1/PD-L1 oncology drugs in combination with immunomodulatory agents, specifically mentioning KEYNOTE-183 and KEYNOTE-185 trials for multiple myeloma. Not about NCT05617625.\n\nResult [7]: Another reference to NCT05617625, same as result [3], about CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome.\n\nResult [8]: Mentions \"Safety and Efficacy Study of High Dose Melph", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT05617625", "drug_name": "Melphalan"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the suspension of the trial is \"The study has been put on hold while pending CMS approval.\" This indicates an administrative issue, likely related to regulatory approval or oversight, that led to the suspension of the trial. There is no mention of safety concerns or lack of efficacy as the reason for the trial termination.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:33.259360", "claude_model": "claude-3-haiku-20240307", "tokens_used": 917}}, "37": {"nct_id": "NCT06940804", "drug_name": "CLDN6 CAR-T", "intervention_type": "BIOLOGICAL", "drug_description": "Intravenous (IV) infusion", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Sponsor decision", "title": "A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm", "start_date": "2025-07-31", "completion_date": "2042-06-30", "sponsor": "BioNTech SE", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.544762", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:36.125461", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CLDN6 CAR-T"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T \u00b1 CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.\n\nTo increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.\n\nIt is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.\n\nParticipants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.", "aact_documents": [], "pubmed_results": [{"pmid": "37872225", "title": "CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.", "authors": [{"name": "Mackensen A", "authtype": "Author", "clusterid": ""}, {"name": "Haanen JBAG", "authtype": "Author", "clusterid": ""}, {"name": "Koenecke C", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) \u00b1 CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.", "detailed_description": "The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T \u00b1 CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.\n\nTo increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.\n\nIt is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.\n\nParticipants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}, {"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 2)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T"]}, {"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}, {"label": "Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": "Doses as selected from the Safety Lead-in Part", "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}], "interventions": [{"type": "BIOLOGICAL", "name": "CLDN6 CAR-T", "description": "Intravenous (IV) infusion", "arm_group_labels": ["Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2)", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX"]}, {"type": "BIOLOGICAL", "name": "CLDN6 RNA-LPX", "description": "IV injection", "arm_group_labels": ["Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX"]}]}}, "company_search_urls": ["https://www.google.com/search?q=BioNTech SE+NCT06940804+terminated", "https://www.google.com/search?q=BioNTech SE+CLDN6 CAR-T+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CLDN6 CAR-T by BioNTech SE. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically for CLDN6 CAR-T by BioNTech SE.\n\nFirst, I need to identify which search results are relevant to CLDN6 CAR-T:\n\nResult [2] appears to be about CLDN6-specific CAR-T cells plus amplifying RNA vaccine, which seems directly relevant. It's from Nature and discusses a study with CLDN6 CAR-T cells.\n\nResult [12] is a ClinicalTrials.gov entry for study NCT04503278, which appears to be related to CLDN6 CAR-T or CLDN6 RNA-LPX cancer vaccine.\n\nLet me examine these results in detail:\n\nFrom Result [2] (Nature article):\n- This discusses a study of CLDN6-specific CAR-T cells plus amplifying RNA vaccine\n- It mentions safety data: 46% of patients experienced cytokine release syndrome (CRS), including one grade 3 event\n- 19 of 22 patients had treatment-emergent adverse events (TEAEs) grade 3 or higher\n- Most frequent TEAEs were hematologic toxicities\n- One patient had grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS)\n- Dose-limiting toxicities (DLTs) emerged in two patients at DL2 (dose level 2)\n- One event was grade 4 hemophagocytic lymphohistiocytosis (HLH)\n- All eight deaths in the study were classified as disease progression and not attributed to CAR-T cell toxicity\n- The Safety Review Committee determined that the MTD (maximum tolerated dose) was not reached\n\nHowever, this article does not mention any FDA warning letters or clinical holds specifically for this CLDN6 CAR-T therapy.\n\nResult [12] is just a ClinicalTrials.gov entry reference but doesn't provide specific details about FDA actions.\n\nNow, let me check if any other results mention CLDN6 CAR-T specifically:\n\nResults [1], [3], [5], [11], and [13] all discuss FDA actions related to BioNTech, but they're about an ADC (antibody-drug conjugate) called BNT326/YL202, not CLDN6 CAR-T.\n\nResults [4], [6], [7], [8], [9], [14], [15],", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by BioNTech SE mentioning clinical trial NCT06940804 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by BioNTech SE\n- Specifically mentioning clinical trial NCT06940804 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nLet me go through each search result to see if it contains the requested information:\n\nResult [1]: This is just a Nasdaq page showing SEC filings for BioNTech SE (BNTX). It doesn't provide specific content of any filings, just indicates that SEC filings are available.\n\nResult [2]: This appears to be a SECDatabase page showing some filings for BioNTech SE with CIK 1776985. It shows some 6-K forms dated 11/03/2025, but this date is in the future (current date in the prompt is November 14, 2025), which seems suspicious. Also, there's no mention of NCT06940804 or specific safety issues.\n\nResult [3]: This is a Fintel page showing SEC filings for BioNTech SE, but it doesn't provide specific content of the filings, just indicates that filings exist.\n\nResult [4]: This shows an F-1 form from BioNTech, but the SEC site blocked access due to exceeding traffic limits. It does mention that BioNTech converted to a European stock corporation (SE) on March 8, 2019. No mention of the specific clinical trial or safety issues.\n\nResult [5]: This shows an EDGAR filing index for BioNTech SE with CIK 0001776985. It's a 6-K form, but doesn't provide the content of the filing. No mention of NCT06940804.\n\nResult [6]: This is about a drug called BNT-211, which is a CLDN6 modulator developed by BioNTech SE. It mentions the drug is in Phase 1, but doesn't provide any SEC filing information or mention NCT06940804 specifically.\n\nAfter reviewing all the search results, I don't see any specific information about:\n1. SEC EDGAR 8-K filings by BioNTech SE mentioning clinical", "citations": [], "search_params": {"company": "BioNTech SE", "nct_id": "NCT06940804", "start_date": "2025-07-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by BioNTech SE about clinical trial NCT06940804 for CLDN6 CAR-T. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about BioNTech's press releases, investor presentations, or public statements regarding clinical trial NCT06940804 for CLDN6 CAR-T, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, I need to identify what NCT06940804 is. From search result [3], I can see that this is the BNT211-02 trial, which is described as:\n\"This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) \u00b1 CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.\"\n\nFrom search result [8], I can confirm this is the same trial (NCT06940804).\n\nNow, let me look for press releases, investor presentations, or public statements by BioNTech about this specific trial.\n\nFrom search result [2], I see that BioNTech is winding down cell therapy manufacturing in Maryland and laying off 63 employees. The article states:\n\"The move, expected to impact members of the Gaithersburg site's cell therapy technical operations team, was influenced by BioNTech's decision to stop development of its CLDN6-directed CAR-T asset BNT211 in testicular cancer with germ cell tumors, the spokesperson explained.\"\n\nAnd further:\n\"Following a thorough assessment of data from a signal-seeking Phase 1 clinical trial on BNT211 in testicular cancer/germ cell tumors, BioNTech has decided to discontinue future investigation of this candidate in this indication,\" she said.\n\nThe discontinuation in testicular cancer won't affect BioNTech's ongoing phase 1 BNT211-01 study of the CAR-T prospect in patients with CLDN6-positive relapsed or refractory solid tumors, the spokesperson said.\n\nThis seems directly relevant to NCT06940804 (BNT211-02), which is focused on testicular or extragonadal germ cell tumors.\n\nFrom search result [4], I see:\n\"A phase 2 trial", "citations": [], "search_params": {"company": "BioNTech SE", "nct_id": "NCT06940804", "drug_name": "CLDN6 CAR-T"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was officially withdrawn due to a \"sponsor decision,\" which suggests administrative or strategic reasons rather than safety or efficacy concerns. The detailed description does not mention any specific safety or efficacy issues that led to the termination. Therefore, the available information indicates that the trial was withdrawn for administrative or operational reasons by the sponsor, BioNTech SE.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:36.124147", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1336}}, "38": {"nct_id": "NCT06940804", "drug_name": "CLDN6 RNA-LPX", "intervention_type": "BIOLOGICAL", "drug_description": "IV injection", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Sponsor decision", "title": "A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm", "start_date": "2025-07-31", "completion_date": "2042-06-30", "sponsor": "BioNTech SE", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.545096", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:36.162908", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CLDN6 RNA-LPX"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T \u00b1 CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.\n\nTo increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.\n\nIt is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.\n\nParticipants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) \u00b1 CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.", "detailed_description": "The study will consist of two parts. The Safety Lead-in Part will evaluate safety and tolerability of CLDN6 CAR T \u00b1 CLDN6 RNA-LPX therapy in three arms with different dosing regimens. In the Safety Lead-in Part, participants will be randomized in a 1:1:1 ratio. Data from the Safety Lead-in Part up to the cut off will be used to select the dose for the single-arm Main Part of the study.\n\nTo increase the potency of the transferred CAR-T cells, a lymphodepleting chemotherapy regimen (comprising fludarabine and cyclophosphamide) will be administered in participants prior to infusion of CLDN6 CAR-T.\n\nIt is expected that it will take approximately 28 months for each participant to complete screening, apheresis, pre-treatment, treatment, and primary follow-up.\n\nParticipants who receive a CLDN6 CAR-T infusion will complete the long-term follow-up (LTFU) to assess safety and efficacy of the CLDN6 CAR-T treatment for a total of 15 years after CLDN6 CAR-T infusion. No investigational medicinal product (IMP) will be administered during the LTFU.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}, {"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 2)", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T"]}, {"label": "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}, {"label": "Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "type": "EXPERIMENTAL", "description": "Doses as selected from the Safety Lead-in Part", "intervention_names": ["Biological: CLDN6 CAR-T", "Biological: CLDN6 RNA-LPX"]}], "interventions": [{"type": "BIOLOGICAL", "name": "CLDN6 CAR-T", "description": "Intravenous (IV) infusion", "arm_group_labels": ["Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2)", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX"]}, {"type": "BIOLOGICAL", "name": "CLDN6 RNA-LPX", "description": "IV injection", "arm_group_labels": ["Main Part - Selected dose of CLDN6 CAR-T + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 1) + CLDN6 RNA-LPX", "Safety Lead-in Part - CLDN6 CAR-T (dose level 2) + CLDN6 RNA-LPX"]}]}}, "company_search_urls": ["https://www.google.com/search?q=BioNTech SE+NCT06940804+terminated", "https://www.google.com/search?q=BioNTech SE+CLDN6 RNA-LPX+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CLDN6 RNA-LPX by BioNTech SE. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically for CLDN6 RNA-LPX by BioNTech SE.\n\nFirst, I need to identify which search results might contain relevant information about CLDN6 RNA-LPX:\n\nResult [4] discusses \"CLDN6-specific CAR-T cells plus amplifying RNA vaccine\" from Nature. This seems most relevant to CLDN6 RNA-LPX, as it mentions a CAR-T cell therapy with an RNA vaccine component. The study is identified as \"BNT211-01 trial\". However, this result doesn't mention any FDA warning letters or clinical holds - it's just reporting on the trial results.\n\nLet me check the other results to see if they mention CLDN6 RNA-LPX specifically:\n\nResults [1], [2], [3], [9], [10] all discuss a partial clinical hold on a BioNTech-MediLink ADC trial for BNT326/YL202, which is an antibody-drug conjugate (ADC) for non-small cell lung cancer and breast cancer. This is not CLDN6 RNA-LPX.\n\nResult [5] discusses a partial hold on a phase 3 trial for gotistobart (BNT316/ONC-392), a CTLA-4 inhibitor, not CLDN6 RNA-LPX.\n\nResult [6] is just a general page about FDA warning letters, with no specific information about BioNTech.\n\nResult [7] appears to be about lifting a clinical hold for YL202 (which we already know from other results is the ADC mentioned in results [1], [2], [3]), but shows a 403 Forbidden error.\n\nResult [8] is a general article about clinical holds for cell and gene therapy trials, but doesn't mention BioNTech or CLDN6 specifically.\n\nResult [11] appears to be a general SEC document mentioning clinical holds but doesn't seem specific to BioNTech's CLDN6 RNA-LPX.\n\nResult [12] is about recent FDA cancer drug safety warnings but doesn't appear to mention BioNTech's CLDN6 specifically.\n\nBased on my analysis, none of the search results specifically mention FDA warning letters or clinical holds for CLDN6 RNA-LPX by BioNTech SE. Result [4] does discuss a CLDN6-related therapy (BNT211-0", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by BioNTech SE mentioning clinical trial NCT06940804 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find information about SEC EDGAR 8-K filings by BioNTech SE that mention clinical trial NCT06940804 or related drug safety issues.\n\nLet me go through each search result:\n\n1. Result [1]: This is from MarketBeat showing SEC filings for BioNTech (BNTX). It lists various Form 6-K filings (which are reports of foreign private issuers) dated from 2024-2025, but doesn't specifically mention clinical trial NCT06940804 or drug safety issues. It shows filings from dates like 09/08/2025, 08/27/2025, 08/15/2025, etc., but no specific content about the requested clinical trial.\n\n2. Result [2]: This is from Nasdaq.com showing SEC filings for BioNTech, but it's just a general listing page without specific content about the requested clinical trial.\n\n3. Result [3]: This appears to be a PDF link to BioNTech's Annual Report 2024. It mentions \"Trial ongoing in China only\" and \"Part of a Phase 2/3 clinical trial\" but doesn't specifically reference NCT06940804.\n\n4. Result [4]: This is from ShareSEER, which provides SEC filings for BioNTech SE, but it's just a general listing page without specific content about the requested clinical trial.\n\n5. Result [5]: This is from Fintel.io showing SEC filings for BioNTech, but it's just a general listing of filings without specific content about NCT06940804.\n\n6. Result [6]: This is from SECDatabase showing all SEC EDGAR filings for BioNTech SE (CIK 1776985). It lists Form 6-K filings dated 11/03/2025, but doesn't provide specific content about the requested clinical trial.\n\n7. Result [7]: This is an SEC.gov link to an F-1 form, but it shows an error message about exceeding the SEC's traffic limit, so no useful content is available.\n\nAfter reviewing all the search results, I don't see any specific mention of clinical trial NCT06940", "citations": [], "search_params": {"company": "BioNTech SE", "nct_id": "NCT06940804", "start_date": "2025-07-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by BioNTech SE about clinical trial NCT06940804 for CLDN6 RNA-LPX. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about BioNTech's clinical trial NCT06940804 for CLDN6 RNA-LPX, specifically focusing on company press releases, investor presentations, or public statements about safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results are relevant to NCT06940804:\n\n- Result [1] mentions BNT211-02, which appears to be related to NCT06940804 based on the description of evaluating CLDN6 CAR-T \u00b1 CLDN6 RNA-LPX in participants with germ cell tumors.\n- Result [2] mentions a withdrawn BioNTech cancer therapy study but doesn't specifically mention NCT06940804.\n- Result [3] and [5] discuss the BNT211-01 trial (NCT04503278), not NCT06940804.\n- Result [4] and [7] discuss the BNT211-01 trial (NCT04503278).\n- Result [8] directly mentions NCT06940804, describing it as a study evaluating CLDN6 CAR-T safety, efficacy, etc.\n- Results [9] and [10] mention NCT06940804 as \"BNT211 / BioNTech ; AVENTURINE\".\n\nNow, let me look for any specific information about press releases, investor presentations, or public statements by BioNTech regarding safety issues, adverse events, trial termination, or regulatory actions for NCT06940804:\n\nFrom result [2], there's a mention of \"BioNTech's Cancer Therapy Study Withdrawn: Implications for Investors\" which suggests a study was withdrawn, but it doesn't specifically identify if this refers to NCT06940804 or another trial. The title mentions \"Open-label Phase II Trial to Evaluate Anti-tumor Activity and Safety of CLDN6 CAR-T \u00b1 CLDN6 RNA-LPX\" which is similar to what's described for NCT06940804, so this might be relevant.\n\nFrom result [1], we see that BNT211-02 is evaluating", "citations": [], "search_params": {"company": "BioNTech SE", "nct_id": "NCT06940804", "drug_name": "CLDN6 RNA-LPX"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "The trial was officially withdrawn due to a \"sponsor decision,\" which suggests administrative or strategic reasons rather than safety or efficacy concerns. The detailed description does not mention any specific safety or efficacy issues that led to the termination. Therefore, the available information indicates that the trial was withdrawn for administrative or operational reasons by the sponsor, BioNTech SE.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:36.124147", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1336}}, "39": {"nct_id": "NCT06670105", "drug_name": "Glofitamab", "intervention_type": "DRUG", "drug_description": "Given by vein", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "PI Request", "title": "A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma", "start_date": "2025-06-06", "completion_date": "2032-01-06", "sponsor": "M.D. Anderson Cancer Center", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.545417", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:38.402685", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL4298092", "pref_name": "GLOFITAMAB", "targets": [{"chembl_id": null, "uniprot_id": "P04234", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P09693", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P11836", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P07766", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P20963", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Glofitamab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "CD4", "protein_b": "TRAT1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8B", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3D", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3G", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3E", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "TRAT1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8B", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3G", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3D", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3E", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "LCK", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8B", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8A", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3G", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3E", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3D", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD247", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "LCK", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8B", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD247", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3G", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3E", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "LCK", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD8A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD2", "protein_b": "CD3G", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CD2", "protein_b": "LCK", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CD2", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3G", "protein_b": "LCK", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "B2M", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "TRAT1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8B", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3D", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3G", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3E", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "B2M", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "TRAT1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8B", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3G", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3D", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3E", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "SYK", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8B", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8A", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3G", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3E", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3D", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD247", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "B2M", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "SYK", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8B", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "B2M", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "SYK", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD247", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3G", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3E", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "B2M", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD8A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "B2M", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "B2M", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD3G", "protein_b": "B2M", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "MS4A1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD79B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD79A", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD19", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "TCL1A", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "POU2AF1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "MS4A1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "CD19", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "CD79B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MS4A3", "protein_b": "MS4A1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "POU2AF1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "TCL1A", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "MS4A1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "CD79B", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BANK1", "protein_b": "MS4A1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "CD79B", "protein_b": "POU2AF1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CD79B", "protein_b": "MS4A1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "POU2AF1", "protein_b": "MS4A1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "TCL1A", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "IGHV3-43D", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "IGKV2D-29", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "IGHV3-43D", "protein_b": "IGKV2D-29", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "TRAT1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8B", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3D", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3G", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD3E", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "TRAT1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8B", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3G", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3D", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3E", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "LCK", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "SYK", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8B", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD8A", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3G", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3E", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD3D", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "TRAT1", "protein_b": "CD247", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "SYK", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "LCK", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8B", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "SYK", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD247", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3G", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD3E", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD8B", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "LCK", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD8A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3G", "protein_b": "LCK", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FCGR3B", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FCGR3A", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3G", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3D", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD3E", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "CD3E", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "CD8A", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "FCGR3B", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "FCGR3A", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "NCR3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NCR1", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "SYK", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD8A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3D", "protein_b": "CD3E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCR3", "protein_b": "FCGR3B", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "NCR3", "protein_b": "FCGR3A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NCR3", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "FCGR3A", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "FCGR3B", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD8A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD3E", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "FCGR3A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "FCGR3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD3G", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "CD3G", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "CD8A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "FCGR3B", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "SYK", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "FCGR3B", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "FCGR3B", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "CD3G", "combined_score": 0.989, "interaction_type": "physical"}], "network_features": {"avg_degree": 16.0, "clustering_coefficient": 8.0}}, "failure_enrichment": {"aact_description": "Primary Objective:\n\nTo determine the rate of undetectable MRD following treatment with glofitamab in patients with LBCL who were MRD positive at the end of standard first line treatment\n\nSecondary Objective:\n\nTo determine progression-free survival (PFS), overall survival (OS), and evaluate safety of glofitamab as treatment for patients with LBCL who are MRD positive at end of standard first line treatment\n\nExploratory Objective:\n\nTo determine the biomarkers of response and mechanisms of resistance to glofitamab in LBCL\n\nTo determine the kinetics of T-cell activation and exhaustion in patients treated with gofitamab to eliminate MRD", "aact_documents": [], "pubmed_results": [{"pmid": "40532125", "title": "Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.", "authors": [{"name": "Minson A", "authtype": "Author", "clusterid": ""}, {"name": "Verner E", "authtype": "Author", "clusterid": ""}, {"name": "Giri P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40202060", "title": "Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis(\u2021).", "authors": [{"name": "Mahmoudjafari Z", "authtype": "Author", "clusterid": ""}, {"name": "Di Maio D", "authtype": "Author", "clusterid": ""}, {"name": "Li J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40181090", "title": "Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.", "authors": [{"name": "Cartron G", "authtype": "Author", "clusterid": ""}, {"name": "Houot R", "authtype": "Author", "clusterid": ""}, {"name": "Al Tabaa Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39820375", "title": "The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.", "authors": [{"name": "Lutfi FG", "authtype": "Author", "clusterid": ""}, {"name": "Ahmed N", "authtype": "Author", "clusterid": ""}, {"name": "Hoffmann MS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "39661985", "title": "Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.", "authors": [{"name": "Shumilov E", "authtype": "Author", "clusterid": ""}, {"name": "Wurm-Kuczera R", "authtype": "Author", "clusterid": ""}, {"name": "Kerkhoff A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The goal of this clinical research study is to learn if glofitamab can help to prevent recurrence of LBCL in patients who have achieved CR after standard first-line therapy but have tested positive for MRD. The safety of glofitamab will also be studied.", "detailed_description": "Primary Objective:\n\nTo determine the rate of undetectable MRD following treatment with glofitamab in patients with LBCL who were MRD positive at the end of standard first line treatment\n\nSecondary Objective:\n\nTo determine progression-free survival (PFS), overall survival (OS), and evaluate safety of glofitamab as treatment for patients with LBCL who are MRD positive at end of standard first line treatment\n\nExploratory Objective:\n\nTo determine the biomarkers of response and mechanisms of resistance to glofitamab in LBCL\n\nTo determine the kinetics of T-cell activation and exhaustion in patients treated with gofitamab to eliminate MRD", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Glofitamab", "type": "EXPERIMENTAL", "description": "Participants will enter a screening period to determine eligibility for the study", "intervention_names": ["Drug: Glofitamab"]}], "interventions": [{"type": "DRUG", "name": "Glofitamab", "description": "Given by vein", "arm_group_labels": ["Glofitamab"]}]}}, "company_search_urls": ["https://www.google.com/search?q=M.D. Anderson Cancer Center+NCT06670105+terminated", "https://www.google.com/search?q=M.D. Anderson Cancer Center+Glofitamab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Glofitamab by M.D. Anderson Cancer Center. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there's information about FDA warning letters or clinical holds for Glofitamab by M.D. Anderson Cancer Center.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds for Glofitamab\n2. Issued by M.D. Anderson Cancer Center\n3. With specific dates, reasons, and safety issues cited\n\nFirst, I need to clarify that M.D. Anderson Cancer Center is a research institution and hospital, not a regulatory body. FDA warning letters and clinical holds are issued by the FDA (Food and Drug Administration), not by M.D. Anderson Cancer Center. This seems to be a misunderstanding in the query.\n\nLet me check the search results to see if there's any information about:\n- FDA warning letters for Glofitamab\n- Clinical holds for Glofitamab\n- Any involvement of M.D. Anderson Cancer Center in these matters\n\nFrom the search results:\n\nResult [1] discusses FDA granting accelerated approval to glofitamab-gxbm, with a Boxed Warning for serious or fatal cytokine release syndrome (CRS). It mentions other warnings and precautions including neurologic toxicity, serious infections, and tumor flare. This is about approval with safety warnings, not a warning letter or clinical hold.\n\nResult [2] mentions FDA issuing a Complete Response Letter (CRL) for Glofit-GemOx in relapsed/refractory DLBCL, citing insufficient evidence from the STARGLO trial. This is not a warning letter or clinical hold.\n\nResults [3], [4], [5], [6], [7], [8], [9], [10] all discuss the FDA issuing a Complete Response Letter (CRL) for glofitamab in combination with GemOx for relapsed/refractory DLBCL, citing insufficient evidence from the STARGLO trial, particularly regarding the representativeness of the US patient population (only 9% of the intent-to-treat population enrolled from the US compared with 48% from Asia). None of these mention warning letters or clinical holds.\n\nResult [11] appears to be a Genentech press release about Columvi (glofitamab-gxbm).\n\nResult [12] mentions a Phase 2 trial of Glofitamab for Minimal Residual Disease.\n\nNone of the search results mention:\n1. FDA warning letters specifically for Glofitam", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "M.D. Anderson Cancer Center"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by M.D. Anderson Cancer Center about clinical trial NCT06670105 for Glofitamab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find any company press releases, investor presentations, or public statements by M.D. Anderson Cancer Center about clinical trial NCT06670105 for Glofitamab, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results one by one:\n\nResult [1]: This is just a basic description of the clinical trial NCT06670105 from Cancer Knowledgebase (CKB). It shows it's a Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients with Large B-cell Lymphoma. No safety information or statements from M.D. Anderson.\n\nResult [2]: This is an NIH article about adverse event profiles for glofitamab based on FDA Adverse Event Reporting System database. It discusses safety concerns with glofitamab, noting that 35% of serious outcomes were \"Death\" (n=208), 32% \"Other Serious\" (n=193), 29% \"Hospitalization\" (n=173), and 4% \"Life-Threatening\" (n=26). However, this is not specifically about trial NCT06670105, and it's not a press release or statement from M.D. Anderson.\n\nResult [3]: This is the ClinicalTrials.gov page for NCT06670105. It describes the study objectives (primary, secondary, exploratory), mentions safety as a secondary objective, and indicates that safety and adverse events will be monitored using NCI CTCAE Version 5.0. But there's no information about trial termination or safety issues specific to this trial.\n\nResult [4]: This is an article about FDA issuing a Complete Response Letter (CRL) to glofitamab plus GemOx in ASCT-ineligible relapsed/refractory DLBCL. It discusses issues with the STARGLO trial, including inconsistent treatment effects between regional subgroups and applicability to US patient population. However, this is not about NCT06670105 specifically, and it's not a statement from M.D. Anderson.\n\nResult [5]: This is another description of the NCT06670105 trial from PatLynk, describing the study's focus on", "citations": [], "search_params": {"company": "M.D. Anderson Cancer Center", "nct_id": "NCT06670105", "drug_name": "Glofitamab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed description does not mention any safety concerns, lack of efficacy, or inability to meet endpoints. The official reason for the trial withdrawal is \"PI Request,\" which suggests an administrative or operational problem, such as the principal investigator requesting the withdrawal of the trial. There is no evidence provided that the trial was terminated due to safety or efficacy issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:38.401243", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1112}}, "40": {"nct_id": "NCT05006599", "drug_name": "Aptar Pharma CPS Intranasal Delivery Device", "intervention_type": "DEVICE", "drug_description": "Participants will be assigned to receive Humulin\u00ae insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "protocol being rewritten and submitted as new study", "title": "SNIFF - 3-Week Aptar CPS Device", "start_date": "2025-05-31", "completion_date": "2031-05-31", "sponsor": "Wake Forest University Health Sciences", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.545736", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:40.901705", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Aptar Pharma CPS Intranasal Delivery Device"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).", "detailed_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Humulin\u00ae R U-100", "type": "EXPERIMENTAL", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin\u00ae R U-100 (40 IU) four times daily for 3 weeks.", "intervention_names": ["Drug: Insulin (Humulin\u00ae R U-100)", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.", "intervention_names": ["Drug: Placebo", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}], "interventions": [{"type": "DRUG", "name": "Insulin (Humulin\u00ae R U-100)", "description": "Participants will administer 40 IU of Humulin\u00ae U-100 insulin four times per day with an intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Aptar Pharma CPS Intranasal Delivery Device", "description": "Participants will be assigned to receive Humulin\u00ae insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Wake Forest University Health Sciences+NCT05006599+terminated", "https://www.google.com/search?q=Wake Forest University Health Sciences+Aptar Pharma CPS Intranasal Delivery Device+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Aptar Pharma CPS Intranasal Delivery Device by Wake Forest University Health Sciences. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds specifically related to Aptar Pharma CPS Intranasal Delivery Device by Wake Forest University Health Sciences.\n\nLet me go through each search result:\n\n1. Result [1]: This appears to be a legal document about a patent infringement case involving Aptar's Unidose Powder System and BAQSIMI. It doesn't mention any FDA warning letters or clinical holds.\n\n2. Result [2]: This is about a clinical trial called \"SNIFF - 3-Week Aptar CPS Device\" which involves using a device to administer insulin or placebo through the nose for patients with dementia, mild cognitive impairment, and learning disorders. It doesn't mention any FDA warning letters or clinical holds.\n\n3. Result [3]: This is a press release about Aptar's CPS Technology being reviewed by the FDA for Oyster Point Pharma's therapy for dry eye disease. It mentions FDA approval but no warning letters or clinical holds.\n\n4. Result [4]: This is about Aptar announcing a clinical validation study to accelerate US FDA approval of SmartTrack for pressurized metered dose inhalers. It doesn't mention any warning letters or clinical holds.\n\n5. Result [5]: This is about Aptar Pharma's Nasal Unidose Device being approved by the US FDA. It doesn't mention any warning letters or clinical holds.\n\n6. Result [6]: This is a general page about FDA warning letters, but doesn't specifically mention Aptar Pharma CPS Intranasal Delivery Device.\n\n7. Result [7]: This is about Aptar's Nasal Unidose System delivering FDA-approved neffy (epinephrine nasal spray). It doesn't mention any warning letters or clinical holds.\n\n8. Result [8]: This is a business wire article about a study using Aptar's nasal drug delivery system to validate insulin nasal spray for Alzheimer's treatment. It mentions a study by Wake Forest but doesn't indicate any FDA warning letters or clinical holds. It states: \"The Wake Forest study involved 16 older adults (average age 72), including seven who were cognitively normal and nine with mild cognitive impairment (MCI). Using a novel radiotracer, [68Ga]Ga-NOTA-insulin, delivered with a specialized six-spray nasal system, participants underwent a 40-minute brain PET scan followed by whole-body imaging. Participants described the nasal spray as 'sur", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Wake Forest University Health Sciences"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Wake Forest University Health Sciences about clinical trial NCT05006599 for Aptar Pharma CPS Intranasal Delivery Device. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Wake Forest University Health Sciences\n- About clinical trial NCT05006599 for Aptar Pharma CPS Intranasal Delivery Device\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me review the search results to see if they contain this information:\n\nResult [1]: This appears to be from PMC (PubMed Central) about Alzheimer's disease drug development pipeline in 2024. It mentions NCT05006599 as \"Insulin + Empagliflozin\" trial by Wake Forest University Health Sciences with dates May 2025 to May 2029. However, it doesn't seem to contain press releases or safety information.\n\nResult [2]: This is from CenterWatch about the \"SNIFF - 3-Week Aptar CPS Device\" trial. It provides details about the study design, conditions (Dementia, Mild Cognitive Impairment, Learning Disorders), treatments (Insulin, Aptar Pharma CPS Intranasal Delivery Device, Placebo), and study summary. It mentions it's a Phase 2 study examining intranasal delivery of insulin. However, it doesn't contain press releases or specific safety issues/adverse events.\n\nResult [3]: This appears to be from Alzheimer's & Dementia journal about the 2023 drug development pipeline. It mentions NCT05006599 as \"Insulin + empagliflozin\" trial by Wake Forest University Health Sciences with dates May 2025 to May 2029. Again, no press releases or safety information.\n\nResult [4]: This is from LARVOL Sigma about Wake Forest Baptist Health Trials. It mentions NCT05006599: SNIFF - 3-Week Aptar CPS Device at Wake Forest University Health Sciences. No press releases or safety information.\n\nResult [5]: This is from LARVOL Sigma about University of Washington/VA Puget Sound Health Care System Trials. It mentions NCT05006599: SNIFF - 3-Week but doesn't provide press releases or safety information.\n\nResult [6]: This is from clinicaltrials", "citations": [], "search_params": {"company": "Wake Forest University Health Sciences", "nct_id": "NCT05006599", "drug_name": "Aptar Pharma CPS Intranasal Delivery Device"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states that the \"protocol [was] being rewritten and submitted as new study.\" This indicates that the trial was withdrawn due to administrative reasons, such as the need to revise the study protocol, rather than due to safety or efficacy concerns. The detailed description also does not mention any issues with safety or lack of efficacy, further supporting the conclusion that the trial was withdrawn for administrative reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:40.900224", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1134}}, "41": {"nct_id": "NCT05006599", "drug_name": "Insulin (Humulin\u00ae R U-100)", "intervention_type": "DRUG", "drug_description": "Participants will administer 40 IU of Humulin\u00ae U-100 insulin four times per day with an intranasal delivery device.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "protocol being rewritten and submitted as new study", "title": "SNIFF - 3-Week Aptar CPS Device", "start_date": "2025-05-31", "completion_date": "2031-05-31", "sponsor": "Wake Forest University Health Sciences", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.546057", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:40.939336", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "P01308", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Insulin (Humulin\u00ae R U-100)", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 1, "interactions": [{"protein_a": "EGF", "protein_b": "ALB", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "INSR", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "IGF1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "INS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NTRK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "IGF1R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IDE", "protein_b": "GCG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "IDE", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "IGF1", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "GCG", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSR", "protein_b": "IGF1R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSR", "protein_b": "IRS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSR", "protein_b": "IRS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSR", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSR", "protein_b": "IGF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IRS1", "protein_b": "NTRK1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "IRS1", "protein_b": "IRS2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IRS1", "protein_b": "IGF1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IRS1", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IRS1", "protein_b": "IGF1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IRS2", "protein_b": "NTRK1", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "IRS2", "protein_b": "IGF1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "IRS2", "protein_b": "INS", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IRS2", "protein_b": "IGF1R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "GCG", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "NTRK1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "IGF1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "INS", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INS", "protein_b": "NTRK1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "INS", "protein_b": "GCG", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "INS", "protein_b": "IGF1R", "combined_score": 0.999, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.82, "clustering_coefficient": 2.91}}, "failure_enrichment": {"aact_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "aact_documents": [], "pubmed_results": [{"pmid": "37756542", "title": "The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness\u00a0Study\u00a0(GRADE).", "authors": [{"name": "Hollander PA", "authtype": "Author", "clusterid": ""}, {"name": "Krause-Steinrauf H", "authtype": "Author", "clusterid": ""}, {"name": "Butera NM", "authtype": "Author", "clusterid": ""}]}, {"pmid": "34101779", "title": "Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.", "authors": [{"name": "Kellar D", "authtype": "Author", "clusterid": ""}, {"name": "Lockhart SN", "authtype": "Author", "clusterid": ""}, {"name": "Aisen P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "27716283", "title": "Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.", "authors": [{"name": "Kabul S", "authtype": "Author", "clusterid": ""}, {"name": "Hood RC", "authtype": "Author", "clusterid": ""}, {"name": "Duan R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "26307903", "title": "OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES \u03b2-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.", "authors": [{"name": "Mari A", "authtype": "Author", "clusterid": ""}, {"name": "Rosenstock J", "authtype": "Author", "clusterid": ""}, {"name": "Ma X", "authtype": "Author", "clusterid": ""}]}, {"pmid": "25813411", "title": "TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.", "authors": [{"name": "Hood RC", "authtype": "Author", "clusterid": ""}, {"name": "Arakaki RF", "authtype": "Author", "clusterid": ""}, {"name": "Wysham C", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).", "detailed_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Humulin\u00ae R U-100", "type": "EXPERIMENTAL", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin\u00ae R U-100 (40 IU) four times daily for 3 weeks.", "intervention_names": ["Drug: Insulin (Humulin\u00ae R U-100)", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.", "intervention_names": ["Drug: Placebo", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}], "interventions": [{"type": "DRUG", "name": "Insulin (Humulin\u00ae R U-100)", "description": "Participants will administer 40 IU of Humulin\u00ae U-100 insulin four times per day with an intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Aptar Pharma CPS Intranasal Delivery Device", "description": "Participants will be assigned to receive Humulin\u00ae insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Wake Forest University Health Sciences+NCT05006599+terminated", "https://www.google.com/search?q=Wake Forest University Health Sciences+Insulin (Humulin\u00ae R U-100)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Insulin (Humulin\u00ae R U-100) by Wake Forest University Health Sciences. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Insulin (Humulin\u00ae R U-100) by Wake Forest University Health Sciences.\n\nFirst, I need to identify if there are any specific warning letters or clinical holds related to Humulin R U-100 from Wake Forest University Health Sciences.\n\nLooking through the search results:\n\nResult [1] mentions FDA FOIA requests related to Praluent and REPATHA, and also mentions Ukoniq withdrawal, but nothing about Humulin R U-100 or Wake Forest University.\n\nResult [2] is the label for Humulin R U-100, which contains safety information about the drug, but doesn't mention any warning letters or clinical holds from the FDA specifically for Wake Forest University.\n\nResult [3] shows some FDA Warning Letter references, including \"Warning Letter 320-25-28 dated on December 19th, 2024\" but doesn't specifically connect it to Humulin R U-100 or Wake Forest University.\n\nResult [4] is another label document for Humulin R U-100 with safety information, but again no specific warning letters for Wake Forest.\n\nResult [5] mentions FDA sending warning letters to GLP-1 compounders in September 2025, but this is about GLP-1 drugs, not insulin/Humulin R.\n\nResult [6] is another Humulin R label document with safety information.\n\nResult [7] is just a general page about FDA Warning Letters without specific content.\n\nResult [8] appears to be another FOIA request document but doesn't seem to contain relevant information for our query.\n\nResult [9] mentions a case where a 67-year-old male confused Humalog insulin with Humulin insulin, leading to hypoglycemia, but this is just an example case study, not a warning letter to Wake Forest.\n\nResult [10] appears to be about peer reviews and public comments, not relevant to our query.\n\nResult [11] is just the Purple Book database entry for Humulin R products.\n\nResults [12]-[17] don't appear to contain relevant information about FDA warning letters to Wake Forest University regarding Humulin R.\n\nI don't see any specific mention of:\n1. Wake Forest University Health Sciences in relation to Humulin R U-100\n2. Any", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Wake Forest University Health Sciences"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Wake Forest University Health Sciences about clinical trial NCT05006599 for Insulin (Humulin\u00ae R U-100). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about safety issues, adverse events, trial termination reasons, or regulatory actions related to clinical trial NCT05006599 (SNIFF - 3-Week Aptar CPS Device) for Insulin (Humulin\u00ae R U-100) from Wake Forest University Health Sciences.\n\nFirst, let me identify what NCT05006599 is about based on the search results:\n\nFrom result [2], [5], and others, I can see that NCT05006599 is the \"SNIFF - 3-Week Aptar CPS Device\" study. It's a clinical trial that involves using a device to administer insulin or placebo through participants' noses (intranasally). The study is focused on examining whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease to reliably deliver insulin or placebo four times daily over a 4 week period. It also examines effects of treatment on cognition, CSF biomarkers, and cerebral perfusion.\n\nFrom result [9], I see that this trial is listed as \"Withdrawn\" with 2 sites and 40 participants.\n\nNow, let me look for specific information about:\n1. Safety issues\n2. Adverse events\n3. Trial termination reasons\n4. Regulatory actions\n5. Company press releases, investor presentations, or public statements by Wake Forest University Health Sciences\n\nLooking through the search results:\n\nResult [1] and [3] mention NCT05006599 as \"Insulin + Empagliflozin\" or \"Insulin + empagliflozin\" with dates May 2025 to May 2029, but this seems inconsistent with other results that describe it as an intranasal insulin study without empagliflozin. This might be an error or confusion with another trial.\n\nResult [2] provides details about the study design, inclusion criteria, and purpose, but doesn't mention safety issues, adverse events, or why it might have been withdrawn.\n\nResult [4] and [9] both list the trial as associated with Wake Forest University Health Sciences, and result [9] specifically notes it as \"Withdrawn.\"\n\nResult [5] is from clinicaltrials.gov but only provides the basic description without safety information or termination reasons.\n\nResult [6] is", "citations": [], "search_params": {"company": "Wake Forest University Health Sciences", "nct_id": "NCT05006599", "drug_name": "Insulin (Humulin\u00ae R U-100)"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states that the \"protocol [was] being rewritten and submitted as new study.\" This indicates that the trial was withdrawn due to administrative reasons, such as the need to revise the study protocol, rather than due to safety or efficacy concerns. The detailed description also does not mention any issues with safety or lack of efficacy, further supporting the conclusion that the trial was withdrawn for administrative reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:40.900224", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1134}}, "42": {"nct_id": "NCT05006599", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "protocol being rewritten and submitted as new study", "title": "SNIFF - 3-Week Aptar CPS Device", "start_date": "2025-05-31", "completion_date": "2031-05-31", "sponsor": "Wake Forest University Health Sciences", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.546381", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:40.975465", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).", "detailed_description": "The proposed study will examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease (cognitively normal but with abnormal brain levels of the hallmark peptide A\u03b2) to reliably deliver insulin or placebo four times daily over a 4 week period. We will also examine effects of treatment on cognition, CSF biomarkers, and cerebral perfusion. If successful, information gained from the study will inform the design of future Phase III trials of intranasal insulin.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Humulin\u00ae R U-100", "type": "EXPERIMENTAL", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin\u00ae R U-100 (40 IU) four times daily for 3 weeks.", "intervention_names": ["Drug: Insulin (Humulin\u00ae R U-100)", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.", "intervention_names": ["Drug: Placebo", "Device: Aptar Pharma CPS Intranasal Delivery Device"]}], "interventions": [{"type": "DRUG", "name": "Insulin (Humulin\u00ae R U-100)", "description": "Participants will administer 40 IU of Humulin\u00ae U-100 insulin four times per day with an intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Aptar Pharma CPS Intranasal Delivery Device", "description": "Participants will be assigned to receive Humulin\u00ae insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.", "arm_group_labels": ["Humulin\u00ae R U-100", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Wake Forest University Health Sciences+NCT05006599+terminated", "https://www.google.com/search?q=Wake Forest University Health Sciences+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by Wake Forest University Health Sciences. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to compile a JSON summary about FDA warning letters or clinical holds for Placebo by Wake Forest University Health Sciences.\n\nThe query is asking specifically for:\n- FDA warning letters or clinical holds\n- Related to Placebo\n- By Wake Forest University Health Sciences\n- Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if there's any relevant information:\n\nResult 1: This is a PDF from Wake Forest University about a clinical trial involving Metformin vs. placebo. It describes a study where participants receive either Metformin or placebo. It mentions the IRB approval (IRB00034977) dated 9/26/2018. However, this is just an informed consent form for a study, not an FDA warning letter or clinical hold.\n\nResult 2: This is about thiazolidinedione drugs and cardiovascular risks, specifically rosiglitazone. No mention of Wake Forest University or placebo-related FDA warnings.\n\nResult 3: This is about health claims regarding CBD products and FDA warning letters issued for CBD products making unapproved health claims. No specific connection to Wake Forest University or placebo.\n\nResult 4: This appears to be a government document discussing FDA's adequacy in assuring drug safety, mentioning Wake Forest University School of Medicine but not in relation to placebo or warning letters specifically for Wake Forest.\n\nResult 5: This is about unauthorized claims for CBD products in North Carolina, mentioning FDA regulations but not specific warning letters to Wake Forest University regarding placebo.\n\nResult 6: This is about strategies for addressing the opioid epidemic - not relevant to the query.\n\nResult 7: Another Wake Forest University clinical trial document, this time about Atorvastatin. It mentions placebo but is just an informed consent form, not an FDA warning letter.\n\nResults 8-17: These are various FDA documents, warning letter information, and other regulatory materials, but I don't see specific mentions of FDA warning letters or clinical holds issued to Wake Forest University specifically regarding placebo.\n\nAfter reviewing all the search results, I don't see any evidence of FDA warning letters or clinical holds specifically for \"Placebo\" by Wake Forest University Health Sciences. \n\nImportant clarification: Placebo itself is not a product that would receive FDA warning letters or clinical holds. Placebos are inactive substances used as controls in clinical trials. The FDA regulates the conduct of", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Wake Forest University Health Sciences"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Wake Forest University Health Sciences about clinical trial NCT05006599 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT05006599 (SNIFF - 3-Week Aptar CPS Device) specifically looking for:\n\n1. Company press releases\n2. Investor presentations \n3. Public statements by Wake Forest University Health Sciences\n4. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT05006599 is about based on the search results:\n\nFrom result [5]:\n- Title: \"SNIFF - 3-Week Aptar CPS Device\"\n- Phase: 2\n- Condition: Dementia, Mild Cognitive Impairment, Learning Disorders\n- Treatment: Insulin (Humulin\u00ae R U-100), Aptar Pharma CPS Intranasal Delivery Device, Placebo\n- Ages: 55-85, All Genders\n- Study Summary: The study involves using a device to administer insulin or placebo through the nose. It's measuring how much insulin the device delivers and looking at effects on memory, blood, and cerebrospinal fluid (CSF).\n- Primary goal: Examine whether an intranasal delivery device can be used by adults with preclinical Alzheimer's disease to reliably deliver insulin or placebo four times daily over a 4 week period.\n\nFrom result [11]:\n- Confirms it's the \"SNIFF - 3-Week Aptar Device study\" involving intranasal administration of insulin or placebo.\n\nFrom results [1], [3], and [7]:\n- NCT05006599 is listed as \"Intranasal insulin + Empagliflozin\" or \"Insulin + Empagliflozin\" for Alzheimer's disease treatment, with Wake Forest University as the sponsor.\n- Original dates: Oct 2021-Oct 2025 (from [1]), but updated to May 2025-May 2029 (from [3] and [7])\n\nFrom result [15]:\n- It states \"NCT05006599: SNIFF - 3-Week Aptar CPS Device. Withdrawn. 2. 40. NA\"\n\nThis is important - it indicates the trial was withdrawn. Let me look for more information about why it was withdrawn.\n\nFrom result [9]:\n", "citations": [], "search_params": {"company": "Wake Forest University Health Sciences", "nct_id": "NCT05006599", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states that the \"protocol [was] being rewritten and submitted as new study.\" This indicates that the trial was withdrawn due to administrative reasons, such as the need to revise the study protocol, rather than due to safety or efficacy concerns. The detailed description also does not mention any issues with safety or lack of efficacy, further supporting the conclusion that the trial was withdrawn for administrative reasons.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:40.900224", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1134}}, "43": {"nct_id": "NCT02503280", "drug_name": "Autologous hMSCs", "intervention_type": "DRUG", "drug_description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study has never enrolled any subjects", "title": "The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.", "start_date": "2025-03-01", "completion_date": "2032-03-31", "sponsor": "Joshua M Hare", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.546729", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:44.072531", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Autologous hMSCs"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "aact_documents": [], "pubmed_results": [{"pmid": "36464628", "title": "Volume and location of bone regeneration after autologous expanded mesenchymal stromal cells in hip osteonecrosis : a pilot study.", "authors": [{"name": "G\u00f3mez-Barrena E", "authtype": "Author", "clusterid": ""}, {"name": "Padilla-Eguiluz NG", "authtype": "Author", "clusterid": ""}, {"name": "L\u00f3pez-Marfil M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "33673388", "title": "Implantation of autologous Expanded Mesenchymal Stromal Cells in Hip Osteonecrosis through Percutaneous Forage: Evaluation of the Operative Technique.", "authors": [{"name": "G\u00f3mez-Barrena E", "authtype": "Author", "clusterid": ""}, {"name": "Padilla-Eguiluz NG", "authtype": "Author", "clusterid": ""}, {"name": "Consortium R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "29188680", "title": "Biomaterials as bone graft substitutes for spine surgery: from preclinical results to clinical study.", "authors": [{"name": "Barbanti Br\u00f2dano G", "authtype": "Author", "clusterid": ""}, {"name": "Griffoni C", "authtype": "Author", "clusterid": ""}, {"name": "Nataloni A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "27856208", "title": "Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem\u00a0Cells for Nonischemic Dilated\u00a0Cardiomyopathy: POSEIDON-DCM Trial.", "authors": [{"name": "Hare JM", "authtype": "Author", "clusterid": ""}, {"name": "DiFede DL", "authtype": "Author", "clusterid": ""}, {"name": "Rieger AC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "25354998", "title": "Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.", "authors": [{"name": "Mushtaq M", "authtype": "Author", "clusterid": ""}, {"name": "DiFede DL", "authtype": "Author", "clusterid": ""}, {"name": "Golpanian S", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board.\n\nFollowing the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline.\n\nPatients will be randomized in a 2:2:1 ratio to one of three Treatment Strategies.", "detailed_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A - Autologous hMSCs", "type": "EXPERIMENTAL", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous hMSCs", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Group B - Autologous Human C-Kit CSCs II", "type": "EXPERIMENTAL", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous Human C-Kit CSCs II", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Placebo", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}], "interventions": [{"type": "DRUG", "name": "Autologous hMSCs", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs.", "arm_group_labels": ["Group A - Autologous hMSCs"]}, {"type": "DRUG", "name": "Autologous Human C-Kit CSCs II", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.", "arm_group_labels": ["Group B - Autologous Human C-Kit CSCs II"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Biosense Webster MyoStar NOGA Injection Catheter System", "description": "Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug", "arm_group_labels": ["Group A - Autologous hMSCs", "Group B - Autologous Human C-Kit CSCs II", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Joshua M Hare+NCT02503280+terminated", "https://www.google.com/search?q=Joshua M Hare+Autologous hMSCs+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Autologous hMSCs by Joshua M Hare. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically for Autologous hMSCs (human Mesenchymal Stem Cells) by Joshua M Hare.\n\nFirst, I need to identify:\n1. Any FDA warning letters related to Joshua M Hare\n2. Any clinical holds related to his work with autologous hMSCs\n3. Specific dates, reasons, and safety issues cited\n\nLet's go through the search results:\n\nResult 1: This is about Bone Marrow Concentrate (BMC) therapy and FDA regulations regarding homologous use. It mentions that if FDA doesn't accept BMC as homologous, it would require IND classification. But it doesn't mention Joshua M Hare specifically or any warning letters to him.\n\nResult 2: This is about a study by Joshua M Hare on allogeneic Mesenchymal Stem Cells for aging frailty. It discusses safety data showing the treatment was safe, with no procedure-related hospitalizations. No mention of FDA warning letters or clinical holds.\n\nResult 3: Wikipedia article on stem cell therapy. Mentions FDA sent a warning letter to StemGenex Biologic Laboratories in 2018, but not to Joshua M Hare. Also mentions safety issues with stem cell treatments generally, but not specific to Hare's work.\n\nResult 4: Another document about BMC therapy. Mentions Joshua M Hare in a citation but doesn't discuss any warning letters to him.\n\nResult 5: Mentions \"Joshua M. Hare, MD, FACC, FAHA\" but doesn't provide specific information about warning letters to him. It does mention FDA issuing \"hundreds of warning letters to stem cell marketers, clinics, and health care\" generally.\n\nResult 6: About efficacy and safety of MSC cell therapies, but no specific mention of Joshua M Hare or warning letters to him.\n\nResult 7: \"Mesenchymal Stem Cells as a Biological Drug for Heart Disease\" mentions Joshua M Hare but discusses FDA approval for testing MSC-therapy in early phase trials that established safety. No warning letters mentioned.\n\nResult 8: Study protocol for a Phase I study involving allo-MSCs (allogeneic, not autologous) for anthracycline-induced cardiomyopathy. Joshua M Hare is listed as an author but no warning letters mentioned.\n\nResult 9: General information about MSCs but", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Joshua M Hare mentioning clinical trial NCT02503280 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Joshua M Hare that mention clinical trial NCT02503280 or related drug safety issues.\n\nFirst, I need to identify:\n1. 8-K filings (current reports on Form 8-K)\n2. Filed by or mentioning Joshua M Hare\n3. That reference clinical trial NCT02503280 or drug safety issues\n\nLet me go through each search result:\n\nResult [1]:\n- Shows a Form 4 filing (Statement of changes in beneficial ownership)\n- Filing date: 2025-05-16\n- References Joshua Hare (Reporting) with CIK: 0001449392\n- Issuer is Longeveron Inc. (CIK: 0001721484)\n- This is not an 8-K filing, it's a Form 4\n\nResult [2]:\n- Shows information about clinical trial NCT02503280\n- Indicates it was \"reported late by Joshua M Hare\"\n- The trial is titled \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells...\"\n- It states the trial was previously reported as an Applicable Clinical Trial but is no longer\n- Start date: March 1, 2025\n- Completion date: March 31, 2030\n- Required reporting date: March 31, 2031\n- Actual reporting date: None\n- This is not an SEC filing but information from ClinicalTrials.gov\n\nResult [3]:\n- Shows a document related to filings by Joshua M. Hare, M.D. on February 17, 2021 and April 9, 2021\n- Relates to ownership of shares of Class\n- This appears to be related to Form 13D/A filings (amendments to beneficial ownership)\n- Not an 8-K filing\n\nResult [4]:\n- Shows a Longeveron Inc. Form 8-K\n- Mentions Joshua M. Hare, M.D. but doesn't appear to be filed by him\n- The filing is about the appointment of a new CEO", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "start_date": "2025-03-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Joshua M Hare about clinical trial NCT02503280 for Autologous hMSCs. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to compile external safety evidence for a specific clinical trial. The user has provided search results and wants me to respond with a JSON summary containing status, summary, relevance, and citations.\n\nLet me analyze the search results to understand what clinical trial we're focusing on and what safety evidence is available:\n\nFrom the search results, I can see that the main clinical trial being referenced is NCT02503280, which is titled \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\"\n\nKey information about this trial:\n\n1. Principal Investigator: Joshua M. Hare\n2. Status: According to result [1], it's listed as \"no-longer-act\" (no longer active) on ClinicalTrials.gov\n3. Start date: March 1, 2025 (this seems odd as it's in the future relative to the current date of November 14, 2025)\n4. Completion date: March 31, 2030\n5. Required reporting date: March 31, 2031\n6. Actual reporting date: None\n7. Date last checked: Oct. 23, 2020\n8. Enrollment: 55 patients (5 in pilot phase, 50 in randomized phase)\n\nFrom result [4], I see more details about the study design:\n- It's a Phase 1/2 trial\n- It's studying transendocardial injection of autologous human cells (Mesenchymal or combination of MSC and Cardiac Stem Cells)\n- Condition: Heart Failure\n- There was a Pilot Safety Phase with 5 patients before the randomized portion with 50 patients\n- Randomization ratio: 2:2:1 to three treatment strategies\n\nFrom result [8], I see:\n- Contact: Darcy L DiFede (DDIFEDE@MED.MIAMI.EDU)\n- Planned enrollment: 55\n- Estimated completion date: March 2030\n\nNow, regarding safety evidence specifically:\n\nResult [1] indicates this trial was \"", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "drug_name": "Autologous hMSCs"}}}}, "llm_analysis": {"classification": "FAILURE_INITIATION", "confidence": "medium", "reasoning": "The official reason for the trial withdrawal states that \"the study has never enrolled any subjects.\" This indicates that the trial was terminated due to administrative or operational issues, rather than safety or efficacy concerns. The lack of any enrolled participants suggests that the trial failed to progress beyond the planning or initiation stage, which is consistent with an administrative failure.", "verification_passed": false, "contradictions_found": ["The information provided indicates that the trial was planned to have a total of 55 subjects, with 5 in the pilot phase and 50 in the randomized phase. This contradicts the previous statement that \"the study has never enrolled any subjects.\""], "analysis_timestamp": "2025-11-14T17:48:44.071080", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1246}}, "44": {"nct_id": "NCT02503280", "drug_name": "Autologous Human C-Kit CSCs II", "intervention_type": "DRUG", "drug_description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study has never enrolled any subjects", "title": "The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.", "start_date": "2025-03-01", "completion_date": "2032-03-31", "sponsor": "Joshua M Hare", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.547074", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:44.108917", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Autologous Human C-Kit CSCs II"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board.\n\nFollowing the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline.\n\nPatients will be randomized in a 2:2:1 ratio to one of three Treatment Strategies.", "detailed_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A - Autologous hMSCs", "type": "EXPERIMENTAL", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous hMSCs", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Group B - Autologous Human C-Kit CSCs II", "type": "EXPERIMENTAL", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous Human C-Kit CSCs II", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Placebo", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}], "interventions": [{"type": "DRUG", "name": "Autologous hMSCs", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs.", "arm_group_labels": ["Group A - Autologous hMSCs"]}, {"type": "DRUG", "name": "Autologous Human C-Kit CSCs II", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.", "arm_group_labels": ["Group B - Autologous Human C-Kit CSCs II"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Biosense Webster MyoStar NOGA Injection Catheter System", "description": "Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug", "arm_group_labels": ["Group A - Autologous hMSCs", "Group B - Autologous Human C-Kit CSCs II", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Joshua M Hare+NCT02503280+terminated", "https://www.google.com/search?q=Joshua M Hare+Autologous Human C-Kit CSCs II+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Autologous Human C-Kit CSCs II by Joshua M Hare. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically for \"Autologous Human C-Kit CSCs II\" by Joshua M Hare. Let me go through each search result to see if there's relevant information.\n\nFirst, let me understand what I'm looking for:\n- FDA warning letters\n- Clinical holds\n- Specifically for \"Autologous Human C-Kit CSCs II\" \n- Related to Joshua M Hare\n- With specific dates, reasons, and safety issues cited\n\nLet's examine each search result:\n\n[1] This appears to be about cardiotoxicity (CTX) related to cancer treatments, discussing Type II CTX associated with biologics and targeted drugs. It mentions c-Kit in relation to some drugs (sunitinib), but not specifically about C-Kit CSCs (Cardiac Stem Cells) therapy by Joshua M Hare. No FDA warning letters or clinical holds mentioned.\n\n[2] This is about eribulin mesylate, a cancer drug. It discusses peripheral neuropathy as a side effect but nothing related to C-Kit CSCs or Joshua M Hare.\n\n[3] This discusses cardiac repair and regeneration, including cell therapy and cardiac stem cells. It mentions c-Kit+ cardiac stem cells but there's no specific information about FDA warning letters or clinical holds for Joshua M Hare's work. It does note \"controversy over the existence of cardiac resident c-KIT+ cardiac stem cells in vivo\" and mentions \"many notable trials\" but doesn't specify any FDA actions.\n\n[4] This discusses cell therapy and extracellular vesicles, mentioning EVs derived from human cardiac c-Kit+ cells, but no FDA warning letters or clinical holds.\n\n[5] This is about bioengineering of scaffolds for cell-based therapy in heart disease, mentioning c-kit (CD117) as a surface marker for endogenous CSCs, but no FDA actions mentioned.\n\n[6] This appears to be just the description of the World Journal of Stem Cells, no relevant information.\n\n[7] This discusses NHLBI-funded production of cardiac C-Kit+ stem cells. It mentions \"Cardiac C-Kit+ stem cells (CSCs) are a cell type currently under investigation for regenerative therapies\" and notes \"a phase IIb trial jointly supported by the Department of Defense and PACT 3/NHLBI is underway.\" However, it", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Joshua M Hare mentioning clinical trial NCT02503280 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Joshua M Hare that mention clinical trial NCT02503280 or related drug safety issues.\n\nFirst, let me identify what I'm looking for:\n1. SEC Form 8-K filings\n2. Filed by or mentioning Joshua M Hare\n3. Related to clinical trial NCT02503280 or drug safety issues\n4. Need filing dates, CIK numbers, and specific material events\n\nLet me go through each search result:\n\nResult [1]:\n- Shows an SEC filing with Accession No. 0001214659-25-008011\n- Filing Date: 2025-05-16\n- Form 4 (Statement of changes in beneficial ownership)\n- Reporting person: Hare Joshua (CIK: 0001449392)\n- Issuer: Longeveron Inc. (CIK: 0001721484)\n- This is a Form 4, not a Form 8-K, so it's not what we're looking for\n\nResult [2]:\n- About clinical trial NCT02503280\n- Described as \"A trial that was reported late by Joshua M Hare\"\n- Trial title: \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells...\"\n- Results Status: no-longer-act\n- Start date: March 1, 2025\n- Completion date: March 31, 2030\n- Required reporting date: March 31, 2031\n- Actual reporting date: None\n- This provides information about the clinical trial but doesn't appear to be an SEC 8-K filing\n\nResult [3]:\n- SEC document with reference to filings by Joshua M. Hare, M.D. on February 17, 2021 and April 9, 2021\n- Related to ownership of shares\n- Not specifically an 8-K filing or related to NCT02503280\n\nResult [4]:\n- Form 8-K for Longeveron Inc", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "start_date": "2025-03-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Joshua M Hare about clinical trial NCT02503280 for Autologous Human C-Kit CSCs II. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about external safety evidence for clinical trial NCT02503280, which appears to be related to stem cell therapy for heart failure.\n\nFirst, let me identify what NCT02503280 is about:\n\nFrom results [1], [4], and [10], I can see that NCT02503280 is titled \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\"\n\nKey details about the trial:\n- Principal Investigator: Joshua M Hare\n- Phase: I/II\n- Status: According to result [1], it's listed as \"no-longer-act\" (no longer active)\n- Result [1] also mentions it was \"previously reported as an Applicable Clinical Trial, but is no longer\"\n- Start date: March 1, 2025 (this seems odd as it's in the future from our current date of November 14, 2025)\n- Completion date: March 31, 2030\n- Required reporting date: March 31, 2031\n- Actual reporting date: None\n\nThis start date being in the future (March 1, 2025) is confusing since our current date is November 14, 2025. This might be an error in the data.\n\nFrom result [4], I see more details:\n- Overall Status: \"Trial Not Available\"\n- It had a Pilot Safety Phase with 5 patients\n- Then a randomized portion with 50 patients (total 55)\n- Patients were randomized in a 2:2:1 ratio to one of three Treatment Strategies\n- It involved transendocardial injection of autologous human cells (Mesenchymal or combination of MSC and Cardiac Stem Cells)\n\nResult [7] describes CONCERT-HF, which appears to be related but might be a different trial:\n- NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial\n- Assessed treatment with autolog", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "drug_name": "Autologous Human C-Kit CSCs II"}}}}, "llm_analysis": {"classification": "FAILURE_INITIATION", "confidence": "medium", "reasoning": "The official reason for the trial withdrawal states that \"the study has never enrolled any subjects.\" This indicates that the trial was terminated due to administrative or operational issues, rather than safety or efficacy concerns. The lack of any enrolled participants suggests that the trial failed to progress beyond the planning or initiation stage, which is consistent with an administrative failure.", "verification_passed": false, "contradictions_found": ["The information provided indicates that the trial was planned to have a total of 55 subjects, with 5 in the pilot phase and 50 in the randomized phase. This contradicts the previous statement that \"the study has never enrolled any subjects.\""], "analysis_timestamp": "2025-11-14T17:48:44.071080", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1246}}, "45": {"nct_id": "NCT02503280", "drug_name": "Biosense Webster MyoStar NOGA Injection Catheter System", "intervention_type": "DEVICE", "drug_description": "Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study has never enrolled any subjects", "title": "The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.", "start_date": "2025-03-01", "completion_date": "2032-03-31", "sponsor": "Joshua M Hare", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.547430", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:44.144692", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Biosense Webster MyoStar NOGA Injection Catheter System"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board.\n\nFollowing the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline.\n\nPatients will be randomized in a 2:2:1 ratio to one of three Treatment Strategies.", "detailed_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A - Autologous hMSCs", "type": "EXPERIMENTAL", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous hMSCs", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Group B - Autologous Human C-Kit CSCs II", "type": "EXPERIMENTAL", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous Human C-Kit CSCs II", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Placebo", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}], "interventions": [{"type": "DRUG", "name": "Autologous hMSCs", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs.", "arm_group_labels": ["Group A - Autologous hMSCs"]}, {"type": "DRUG", "name": "Autologous Human C-Kit CSCs II", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.", "arm_group_labels": ["Group B - Autologous Human C-Kit CSCs II"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Biosense Webster MyoStar NOGA Injection Catheter System", "description": "Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug", "arm_group_labels": ["Group A - Autologous hMSCs", "Group B - Autologous Human C-Kit CSCs II", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Joshua M Hare+NCT02503280+terminated", "https://www.google.com/search?q=Joshua M Hare+Biosense Webster MyoStar NOGA Injection Catheter System+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Biosense Webster MyoStar NOGA Injection Catheter System by Joshua M Hare. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically for the Biosense Webster MyoStar NOGA Injection Catheter System related to Joshua M Hare.\n\nLet me go through the search results systematically:\n\nResult [1]: This is about a recall for the Varipulse Bi-Directional Ablation Catheter, not the MyoStar NOGA Injection Catheter System.\n\nResult [2]: This is a PDF about quarterly medical device warning letters from January-March 2024, but it doesn't specifically mention Biosense Webster or the MyoStar NOGA system.\n\nResult [3]: This is a MAUDE adverse event report for NGEN RF Generator, not specifically about the MyoStar NOGA system.\n\nResult [4]: This is a MAUDE report for VIZIGO catheter, not the MyoStar NOGA system.\n\nResult [5]: This is a Material Supply Agreement between Biosense Webster and Bioheart. It mentions the Myostar catheter and states \"The Company agrees that the Myostar catheter can only be used with the approved Noga XP cardiac mapping system.\" This is relevant as it confirms the connection between Myostar and Noga XP system. It also mentions that the study shall be conducted under supervision of a Principal Investigator determined by the Company, but doesn't specifically name Joshua M Hare.\n\nResult [6]: This appears to be a table of contents for FDA documents, but doesn't contain specific information about the MyoStar NOGA system.\n\nResult [7]: This is a MAUDE report for NOGA XP CARDIAC NAVIGATION SYSTEM, which is relevant as it's part of the system in question. It mentions \"Adverse event(s) and provided interventions: there were two serious adverse events in relation to the noga procedure: one patient with a history of ventricular...\" but doesn't provide complete details.\n\nResult [8]: This appears to be a medical device recalls page but doesn't show specific content.\n\nResult [9]: This is a MAUDE report for NAVISTAR, not the MyoStar NOGA system.\n\nResult [10]: This is a Substack article about medical device news from August 2023, but no specific content is shown.\n\nResult [11]: This mentions \"The MyoCath is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemic", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Joshua M Hare mentioning clinical trial NCT02503280 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Joshua M Hare that mention clinical trial NCT02503280 or related drug safety issues.\n\nFirst, let me identify what I'm looking for:\n1. SEC EDGAR Form 8-K filings\n2. Related to Joshua M Hare\n3. Mentioning clinical trial NCT02503280 or drug safety issues\n4. Need filing dates, CIK numbers, and specific material events\n\nLet me go through each search result:\n\nResult [1]: This is a Form 4 filing (Statement of changes in beneficial ownership) for Joshua Hare (CIK: 0001449392) related to Longeveron Inc. (CIK: 0001721484). It's dated May 16, 2025. This is not an 8-K filing and doesn't mention NCT02503280.\n\nResult [2]: This is about clinical trial NCT02503280, which was reported late by Joshua M Hare. It's from fdaaa.trialstracker.net, not an SEC filing. It mentions that this was a Phase I/II trial studying the safety and efficacy of transendocardial injection of autologous human cells in patients with chronic ischemic left ventricular dysfunction. The trial was previously reported as an Applicable Clinical Trial but is no longer. However, this is not an SEC 8-K filing.\n\nResult [3]: This appears to be a document related to Joshua M. Hare's ownership of shares, but it's not clear if it's an 8-K filing. It mentions filings from February 17, 2021 and April 9, 2021.\n\nResult [4]: This is an 8-K filing for Longeveron Inc. It mentions Joshua M. Hare, M.D. as someone whose \"leadership and commitment to developing new therapeutic strategies will be invaluable to Longeveron.\" However, it doesn't specifically mention NCT02503280 or drug safety issues related to that trial. It's dated March 1, 2023.\n\nResult [5]: This appears to be a 2023 Annual Report (Form ", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "start_date": "2025-03-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Joshua M Hare about clinical trial NCT02503280 for Biosense Webster MyoStar NOGA Injection Catheter System. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to compile a JSON summary containing status, summary, relevance, and citations for a specific clinical trial based on the search results provided. The query is asking for information about clinical trial NCT02503280, specifically focusing on safety evidence.\n\nLet me analyze the search results to extract the relevant information:\n\n1. Result [1] - FDA trial tracker information about NCT02503280:\n   - Title: \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\"\n   - Status: \"no-longer-act\" (no longer active)\n   - Principal Investigator: Joshua M Hare\n   - Start date: March 1, 2025 (this seems odd as it's in the future relative to current date of Nov 14, 2025)\n   - Completion date: March 31, 2030\n   - Required reporting date: March 31, 2031\n   - Actual reporting date: None\n   - Date last checked: Oct. 23, 2020\n   - Note: \"This trial was previously reported as an Applicable Clinical Trial, but is no longer.\"\n\n2. Result [4] - CenterWatch information about the same trial:\n   - Overall Status: \"Trial Not Available\"\n   - Phase: 1/2\n   - Condition: Heart Failure\n   - Sponsor: Joshua M Hare\n   - Study design: Pilot Safety Phase with 5 patients, then randomized portion with 50 patients (total 55)\n   - Intervention: Transendocardial injection of autologous human cells (Mesenchymal or combination of MSC and Cardiac Stem Cells)\n   - Exclusion criteria include life-threatening arrhythmia, unstable angina, non-cardiac conditions limiting lifespan to <1 year, history of drug/alcohol abuse, immunosuppressant medication use, HIV/hepatitis positivity\n\n3. Result [9] - ClinicalTrials.gov entry for NCT02503280:\n   - Confirms it", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "drug_name": "Biosense Webster MyoStar NOGA Injection Catheter System"}}}}, "llm_analysis": {"classification": "FAILURE_INITIATION", "confidence": "medium", "reasoning": "The official reason for the trial withdrawal states that \"the study has never enrolled any subjects.\" This indicates that the trial was terminated due to administrative or operational issues, rather than safety or efficacy concerns. The lack of any enrolled participants suggests that the trial failed to progress beyond the planning or initiation stage, which is consistent with an administrative failure.", "verification_passed": false, "contradictions_found": ["The information provided indicates that the trial was planned to have a total of 55 subjects, with 5 in the pilot phase and 50 in the randomized phase. This contradicts the previous statement that \"the study has never enrolled any subjects.\""], "analysis_timestamp": "2025-11-14T17:48:44.071080", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1246}}, "46": {"nct_id": "NCT02503280", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study has never enrolled any subjects", "title": "The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.", "start_date": "2025-03-01", "completion_date": "2032-03-31", "sponsor": "Joshua M Hare", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.547786", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:44.180115", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board.\n\nFollowing the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline.\n\nPatients will be randomized in a 2:2:1 ratio to one of three Treatment Strategies.", "detailed_description": "A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\n\nA total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized phase.\n\nPatients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI scheduled to undergo cardiac catheterization.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Group A - Autologous hMSCs", "type": "EXPERIMENTAL", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous hMSCs", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Group B - Autologous Human C-Kit CSCs II", "type": "EXPERIMENTAL", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Autologous Human C-Kit CSCs II", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.", "intervention_names": ["Drug: Placebo", "Device: Biosense Webster MyoStar NOGA Injection Catheter System"]}], "interventions": [{"type": "DRUG", "name": "Autologous hMSCs", "description": "Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\\^8 (200 million) hMSCs.", "arm_group_labels": ["Group A - Autologous hMSCs"]}, {"type": "DRUG", "name": "Autologous Human C-Kit CSCs II", "description": "Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.", "arm_group_labels": ["Group B - Autologous Human C-Kit CSCs II"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo (ten 0.5 ml injections of phosphate-buffered saline \\[PBS\\] and 1% human serum albumin \\[HSA\\]).", "arm_group_labels": ["Placebo"]}, {"type": "DEVICE", "name": "Biosense Webster MyoStar NOGA Injection Catheter System", "description": "Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug", "arm_group_labels": ["Group A - Autologous hMSCs", "Group B - Autologous Human C-Kit CSCs II", "Placebo"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Joshua M Hare+NCT02503280+terminated", "https://www.google.com/search?q=Joshua M Hare+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by Joshua M Hare. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about FDA warning letters or clinical holds for Placebo by Joshua M Hare.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for Placebo by Joshua M Hare\n- Specific dates, reasons, and safety issues cited\n\nFirst, I need to clarify what's being asked. It seems there might be some confusion in the query. \"Placebo\" is not a company or drug name - it's a control treatment used in clinical trials. The query appears to be asking about FDA warning letters or clinical holds related to placebo treatments in clinical trials led by Joshua M Hare.\n\nLet me go through the search results to find relevant information:\n\nResult 1: This is about Longeveron's 2024 Annual Report. It mentions:\n- Joshua M Hare, M.D. is listed as part of the team\n- Lomecel-B\u2122 received FDA designations (Rare Pediatric Disease, Orphan Drug, Fast Track)\n- Positive results from a study against placebo\n- Safety profile showing \"no incidence of hypersensitivity or infusion-related reactions\" and \"no cases of amyloid-related imaging abnormalities (ARIA)\"\n- No mention of FDA warning letters or clinical holds\n\nResult 2: This is about cognitive function assessment in patients on statins. It mentions:\n- FDA warnings about statins and cognitive impairment\n- No connection to Joshua M Hare or placebo clinical holds\n\nResult 3: This is about stem cell clinics for heart failure. It mentions:\n- Joshua M. Hare and colleagues conducted a trial on stem cell therapy for heart failure\n- Mentions FDA taking steps to curtail unregulated stem cell practices\n- No specific warning letters or clinical holds for Hare's work\n\nResult 4: This appears to be a clinical trial protocol document. It mentions:\n- \"In a multi-center, randomized, double-blinded, placebo-controlled clinical study by Hare et al.\"\n- Details about adverse event reporting procedures\n- No mention of warning letters or clinical holds\n\nResult 5: This discusses FDA's expanded access to investigational new drugs. It mentions:\n- A case where a patient received allogeneic MSCs\n- No connection to Joshua M Hare or placebo clinical holds\n\nResult 6: This appears to be a program book mentioning:\n- \"Hare was Professor of Medicine and Biomedical Engineering and Director of the Cardiac", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Joshua M Hare mentioning clinical trial NCT02503280 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Joshua M Hare that mention clinical trial NCT02503280 or related drug safety issues.\n\nFirst, let's identify what we're looking for:\n1. SEC EDGAR 8-K filings\n2. Related to Joshua M Hare\n3. Mentioning clinical trial NCT02503280 or related drug safety issues\n4. Need filing dates, CIK numbers, and specific material events disclosed\n\nLet me go through each search result:\n\nResult [1]:\n- This appears to be a Form 4 filing (Statement of changes in beneficial ownership)\n- Filing date: 2025-05-16\n- Involves Joshua Hare (CIK: 0001449392) and Longeveron Inc. (CIK: 0001721484)\n- This is not an 8-K filing, it's a Form 4\n- No mention of NCT02503280 or clinical trial safety issues\n\nResult [2]:\n- This is about clinical trial NCT02503280\n- It mentions \"A trial that was reported late by Joshua M Hare\"\n- The trial is \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\"\n- However, this is not an SEC filing, it's from ClinicalTrials.gov\n- It states the trial was \"previously reported as an Applicable Clinical Trial, but is no longer\"\n- It shows a start date of March 1, 2025 and completion date of March 31, 2030\n- No actual SEC filing details here\n\nResult [3]:\n- This appears to be related to Form 13D/A filings by Joshua M. Hare\n- Mentions filings on February 17, 2021 and April 9, 2021\n- Relates to ownership of shares\n- Not an 8-K filing", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "start_date": "2025-03-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Joshua M Hare about clinical trial NCT02503280 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about external safety evidence for clinical trial NCT02503280, focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT02503280 is about:\n\nFrom results [1], [4], and [9], I can see that NCT02503280 is titled \"A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.\"\n\nKey details about the trial:\n- Principal Investigator: Joshua M. Hare\n- Status: According to result [1], it's listed as \"no-longer-act\" (no longer active)\n- Planned enrollment: 55 participants (5 in pilot phase, 50 in randomized phase) [4], [8]\n- Start date: March 1, 2025 (this seems odd as it's in the future relative to the current date of November 14, 2025) [1]\n- Completion date: March 31, 2030 [1]\n- Required reporting date: March 31, 2031 [1]\n- Actual reporting date: None [1]\n\nNow, let me look for information about safety issues, adverse events, trial termination reasons, or regulatory actions:\n\nResult [1] indicates that this trial was \"previously reported as an Applicable Clinical Trial, but is no longer.\" It also says it was \"reported late by Joshua M Hare\" but then says \"Days late: None\" which is confusing.\n\nResult [4] provides details about the study design, including exclusion criteria that mention safety concerns:\n- \"Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia \u2265 20 consecutive beats or complete heart block) or QTc interval > 550 ms on screening ECG.\"\n- \"AICD firing in the past 60 days prior to the procedure.\"\n- \"Have unstable angina within 2 weeks of the planned procedure.\"\n\nHowever, this", "citations": [], "search_params": {"company": "Joshua M Hare", "nct_id": "NCT02503280", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_INITIATION", "confidence": "medium", "reasoning": "The official reason for the trial withdrawal states that \"the study has never enrolled any subjects.\" This indicates that the trial was terminated due to administrative or operational issues, rather than safety or efficacy concerns. The lack of any enrolled participants suggests that the trial failed to progress beyond the planning or initiation stage, which is consistent with an administrative failure.", "verification_passed": false, "contradictions_found": ["The information provided indicates that the trial was planned to have a total of 55 subjects, with 5 in the pilot phase and 50 in the randomized phase. This contradicts the previous statement that \"the study has never enrolled any subjects.\""], "analysis_timestamp": "2025-11-14T17:48:44.071080", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1246}}, "47": {"nct_id": "NCT06513884", "drug_name": "HB-202/HB-201 alternating 2-vector therapy", "intervention_type": "DRUG", "drug_description": "Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "phase": "PHASE2/PHASE3", "overall_status": "WITHDRAWN", "why_stopped": "Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "start_date": "2024-12-31", "completion_date": "2032-04-30", "sponsor": "Hookipa Biotech GmbH", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.548149", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:47.238708", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL6068582", "pref_name": "HB-202", "targets": [], "has_uniprot_targets": false, "search_name": "HB-202/HB-201 alternating 2-vector therapy"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda\u00ae) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the throat, who have not yet received systemic treatment after their cancer spread (metastatic) and/or returned (recurrent) and who are eligible to receive pembrolizumab.\n\nDoctors already use pembrolizumab therapy (with or without chemotherapy) to treat head and neck cancer. However, the treatment does not work well in most people with this type of cancer. HB-202/HB-201 alternating 2-vector therapy with pembrolizumab, which is designated to stimulate a stronger immune attack against HPV16+ tumors, was shown to be safe and suggested to work better than pembrolizumab-only in a small number of participants with HPV16+ head and neck cancer (see H-200-001, NCT04180215).\n\nThis trial studies HB-202/HB-201 alternating 2-vector therapy with pembrolizumab in a much larger number of participants from different countries to confirm its benefits for people with HPV16+ head and neck cancer that started in the middle part of the throat compared with pembrolizumab-only therapy. This trial studies whether administering HB-202/HB-201 alternating 2-vector therapy with pembrolizumab works better in more participants by shrinking their tumors and makes them live longer than pembrolizumab-only therapy.\n\nParticipants will receive the study treatments by injection into a vein every 3 weeks during the first 3 months and then every 6 weeks until up to about 2 years, which will be followed by a long observation period to continue looking at the safety and clinical benefits after the last dose of study treatment.", "detailed_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "type": "EXPERIMENTAL", "description": "Intravenous injection of HB-202 followed by pembrolizumab alternating with HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: HB-202/HB-201 alternating 2-vector therapy", "Drug: Pembrolizumab"]}, {"label": "Matched placebo with pembrolizumab", "type": "PLACEBO_COMPARATOR", "description": "Intravenous injection of matched placebo for HB-202 followed by pembrolizumab alternating with matched placebo for HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "HB-202/HB-201 alternating 2-vector therapy", "description": "Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["Matched placebo with pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "Matched placebo with pembrolizumab"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Hookipa Biotech GmbH+NCT06513884+terminated", "https://www.google.com/search?q=Hookipa Biotech GmbH+HB-202/HB-201 alternating 2-vector therapy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for HB-202/HB-201 alternating 2-vector therapy by Hookipa Biotech GmbH. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for HB-202/HB-201 alternating 2-vector therapy by Hookipa Biotech GmbH.\n\nFirst, I need to identify which search results might contain relevant information about FDA warning letters or clinical holds specifically for HB-202/HB-201.\n\nLooking at the search results:\n\n1. Result [1] is about FDA cancer drug safety warnings, but doesn't mention HB-202/HB-201 specifically.\n\n2. Result [2] mentions HOOKIPA announcing first patient enrolled in a Phase 2 trial and FDA Fast Track Designation for HB-201 and HB-202, but doesn't mention any warning letters or clinical holds.\n\n3. Result [3] describes Hookipa's immuno-oncology programs, including HB-200 (which alternates HB-201 and HB-202). It mentions that as of November 2024, HB-200 clinical development is paused due to a restructuring plan at the company. This is important - it indicates a pause in development, but it's due to company restructuring, not necessarily an FDA clinical hold.\n\n4. Result [4] is about ClinicalTrials.gov entry NCT04180215, which is a Phase 1/2 study of HB-201 and HB-202, but doesn't mention any FDA warning letters or clinical holds.\n\n5. Result [5] is about ClinicalTrials.gov entry NCT06513884, which is a study of HB-202/HB-201 with pembrolizumab, but doesn't mention any FDA warning letters or clinical holds.\n\n6. Result [6] mentions HOOKIPA announcing first patient dosed in Phase 1/2 clinical trial for HB-202/HB-201, but doesn't mention any warning letters or clinical holds.\n\n7. Result [7] is an SEC filing from HOOKIPA PHARMA INC. for December 31, 2024. It mentions HB-201 and HB-202 as components of their product candidate, and that they received FDA clearance of their IND application for HB-700 in April 2024. It also mentions", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Hookipa Biotech GmbH mentioning clinical trial NCT06513884 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Hookipa Biotech GmbH that mention clinical trial NCT06513884 or related drug safety issues.\n\nFirst, I need to understand what I'm looking for:\n1. SEC EDGAR 8-K filings\n2. By Hookipa Biotech GmbH (not Hookipa Pharma Inc., which appears to be the parent company)\n3. Mentioning clinical trial NCT06513884 or related drug safety issues\n4. Need to include filing dates, CIK number, and specific material events disclosed\n\nLet me go through each search result:\n\nResult [1]:\n- This is a Form 8-K filing by HOOKIPA Pharma Inc. (not Hookipa Biotech GmbH)\n- Filing date: 2024-05-23\n- CIK: 0001760542\n- Items disclosed: Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item 9.01 (Financial Statements and Exhibits)\n- No specific mention of clinical trial NCT06513884 or drug safety issues\n\nResult [2]:\n- This is a Form 8-K filing by HOOKIPA Pharma Inc.\n- Filing date: 2023-03-15\n- CIK: 0001760542\n- Items disclosed: Item 2.02 (Results of Operations and Financial Condition), Item 9.01 (Financial Statements and Exhibits)\n- No specific mention of clinical trial NCT06513884 or drug safety issues\n\nResult [3]:\n- This appears to be a Form 8-K filing related to an Employment Agreement between Malte Peters and Hookipa Biotech GmbH dated July 22, 2024\n- This is the first mention of Hookipa Biotech GmbH specifically\n- However, it doesn't mention clinical trial NCT06513884 or drug safety issues\n\nResult [4]:\n- This is an index page for a Form 8-K filing with accession number 0001104659-25-000020\n- No specific details about content provided\n- Doesn't mention", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "start_date": "2024-12-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Hookipa Biotech GmbH about clinical trial NCT06513884 for HB-202/HB-201 alternating 2-vector therapy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about Hookipa Biotech GmbH's press releases, investor presentations, or public statements regarding clinical trial NCT06513884 for HB-202/HB-201 alternating 2-vector therapy, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let's identify what we know about the trial from the search results:\n\n1. From result [1]: NCT06513884 is titled \"A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer\" and is marked as \"Withdrawn\". It's a Phase 2/3 trial.\n\n2. From result [2]: Confirms the same trial information, showing it's a Phase 2/3 study in the US.\n\n3. From result [4]: Provides more details that this is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (Keytruda) in people with HPV16+ cancer.\n\n4. From result [1] again: It specifically states the trial is \"Withdrawn\".\n\nNow, I need to find company press releases, investor presentations, or public statements by Hookipa Biotech GmbH about this specific trial, focusing on:\n- Safety issues\n- Adverse events\n- Trial termination reasons\n- Regulatory actions\n\nLet me check if any of the search results contain this specific information:\n\nResult [1]: Only states the trial is \"Withdrawn\" but doesn't provide any reason or details about safety issues.\n\nResult [2]: Just confirms the trial details without any information about why it was withdrawn or safety concerns.\n\nResult [3]: Shows that HOOKIPA Biotech GmbH has conducted 15 trials, with 73.3% being Phase 1 trials, but doesn't provide specific information about NCT06513884.\n\nResult [4]: Provides basic information about the trial but doesn't mention why it was withdrawn or any safety concerns.\n\nResult [5]: Mentions \"There were no Grade 4 AEs reported. All patients completed neoadjuvant HB-200/chemotherapy and response-stratified locoregional treatment. Deep responses...\" This seems relevant as", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "drug_name": "HB-202/HB-201 alternating 2-vector therapy"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states \"Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.\" This indicates that the trial was terminated due to a strategic decision by the sponsor, Hookipa Biotech GmbH, and not due to safety or efficacy concerns. The lack of any publications or safety issues mentioned also suggests an administrative or business-related reason for the trial withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:47.237052", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1474}}, "48": {"nct_id": "NCT06513884", "drug_name": "Pembrolizumab", "intervention_type": "DRUG", "drug_description": "Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.", "phase": "PHASE2/PHASE3", "overall_status": "WITHDRAWN", "why_stopped": "Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "start_date": "2024-12-31", "completion_date": "2032-04-30", "sponsor": "Hookipa Biotech GmbH", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.548536", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:47.277499", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O95243", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Pembrolizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "MBD4", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "SMUG1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MLH1", "protein_b": "MBD4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "UHRF1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "MBD2", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TRDMT1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "SMUG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TDG", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3B", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TRDMT1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TDG", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "UHRF1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT3B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TRDMT1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "UHRF1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "TDG", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "UHRF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TDG", "protein_b": "SMUG1", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.74, "clustering_coefficient": 4.37}}, "failure_enrichment": {"aact_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "aact_documents": [], "pubmed_results": [{"pmid": "41228347", "title": "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.", "authors": [{"name": "Fedele P", "authtype": "Author", "clusterid": ""}, {"name": "Stucci SL", "authtype": "Author", "clusterid": ""}, {"name": "Landriscina M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41219635", "title": "Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis.", "authors": [{"name": "Lala M", "authtype": "Author", "clusterid": ""}, {"name": "Bardia A", "authtype": "Author", "clusterid": ""}, {"name": "Calles A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209621", "title": "Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.", "authors": [{"name": "Skoulidis F", "authtype": "Author", "clusterid": ""}, {"name": "Borghaei H", "authtype": "Author", "clusterid": ""}, {"name": "Garon EB", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206673", "title": "Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).", "authors": [{"name": "Villaruz LC", "authtype": "Author", "clusterid": ""}, {"name": "Schluger B", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41177680", "title": "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.", "authors": [{"name": "Jain P", "authtype": "Author", "clusterid": ""}, {"name": "Naqvi SAA", "authtype": "Author", "clusterid": ""}, {"name": "Tripathi N", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda\u00ae) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the throat, who have not yet received systemic treatment after their cancer spread (metastatic) and/or returned (recurrent) and who are eligible to receive pembrolizumab.\n\nDoctors already use pembrolizumab therapy (with or without chemotherapy) to treat head and neck cancer. However, the treatment does not work well in most people with this type of cancer. HB-202/HB-201 alternating 2-vector therapy with pembrolizumab, which is designated to stimulate a stronger immune attack against HPV16+ tumors, was shown to be safe and suggested to work better than pembrolizumab-only in a small number of participants with HPV16+ head and neck cancer (see H-200-001, NCT04180215).\n\nThis trial studies HB-202/HB-201 alternating 2-vector therapy with pembrolizumab in a much larger number of participants from different countries to confirm its benefits for people with HPV16+ head and neck cancer that started in the middle part of the throat compared with pembrolizumab-only therapy. This trial studies whether administering HB-202/HB-201 alternating 2-vector therapy with pembrolizumab works better in more participants by shrinking their tumors and makes them live longer than pembrolizumab-only therapy.\n\nParticipants will receive the study treatments by injection into a vein every 3 weeks during the first 3 months and then every 6 weeks until up to about 2 years, which will be followed by a long observation period to continue looking at the safety and clinical benefits after the last dose of study treatment.", "detailed_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "type": "EXPERIMENTAL", "description": "Intravenous injection of HB-202 followed by pembrolizumab alternating with HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: HB-202/HB-201 alternating 2-vector therapy", "Drug: Pembrolizumab"]}, {"label": "Matched placebo with pembrolizumab", "type": "PLACEBO_COMPARATOR", "description": "Intravenous injection of matched placebo for HB-202 followed by pembrolizumab alternating with matched placebo for HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "HB-202/HB-201 alternating 2-vector therapy", "description": "Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["Matched placebo with pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "Matched placebo with pembrolizumab"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Hookipa Biotech GmbH+NCT06513884+terminated", "https://www.google.com/search?q=Hookipa Biotech GmbH+Pembrolizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab by Hookipa Biotech GmbH. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Pembrolizumab by Hookipa Biotech GmbH.\n\nFirst, I need to identify if there are any mentions of Hookipa Biotech GmbH in relation to Pembrolizumab (Keytruda) and FDA warning letters or clinical holds.\n\nLooking through the search results:\n\n1. Result [1] discusses FDA converting to full approval for KEYTRUDA (pembrolizumab) for certain patients with MSI-H or dMMR solid tumors. It mentions immune-mediated adverse reactions but doesn't mention Hookipa Biotech or any warning letters/clinical holds.\n\n2. Result [2] discusses FDA alerts about two clinical trials (KEYNOTE-183 and KEYNOTE-185) evaluating KEYTRUDA combined with other treatments in multiple myeloma patients. It mentions increased risk of death and toxicity, but doesn't mention Hookipa Biotech.\n\n3. Result [3] discusses FDA alerts about decreased survival associated with Keytruda as monotherapy in clinical trials for metastatic urothelial cancer, but doesn't mention Hookipa Biotech.\n\n4. Result [4] is about FDA converting to full approval for KEYTRUDA, similar to result [1], but doesn't mention Hookipa Biotech.\n\n5. Result [5] discusses FDA approval of Keytruda for advanced lung cancer, but doesn't mention Hookipa Biotech.\n\n6. Result [6] mentions FDA issuing a complete response letter for updated pembrolizumab dosing schedule, but it's for Merck (the developer of pembrolizumab), not Hookipa Biotech.\n\n7. Result [7] discusses patent issues related to pembrolizumab, mentioning Merck as the seller of Keytruda, but not Hookipa Biotech.\n\n8. Result [8] discusses FDA halting some pembrolizumab trials for multiple myeloma due to patient deaths, but it's for Keytruda (Merck's product), not Hookipa Biotech.\n\n9. Result [9] is about FDA approval of pembrolizumab for esophageal or GEJ carcinoma, not related to Hookipa.\n\n10. Result [10] discusses FDA placing clinical hold on 3 pembrolizumab myeloma trials, but again, this is for Merck's Keytruda.\n\n11. Result [11", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Hookipa Biotech GmbH mentioning clinical trial NCT06513884 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Hookipa Biotech GmbH that mention clinical trial NCT06513884 or related drug safety issues.\n\nFirst, let me identify the relevant information from the search results:\n\n1. The company in question appears to be \"HOOKIPA Pharma Inc.\" (not Hookipa Biotech GmbH specifically, though result [6] mentions \"Hookipa Biotech\" as a clinical stage company)\n2. CIK number is 0001760542 (mentioned in multiple results)\n3. I need to find 8-K filings that mention clinical trial NCT06513884 or drug safety issues\n\nLet's go through each result:\n\nResult [1]: This is a Form 4 filing (Statement of changes in beneficial ownership of securities) from July 23, 2025. It doesn't appear to be an 8-K filing and doesn't mention any clinical trials.\n\nResult [2]: This is a Form 8-K filing from March 15, 2023. It mentions \"Item 2.02: Results of Operations and Financial Condition\" and \"Item 9.01: Financial Statements and Exhibits\". However, there's no specific mention of clinical trial NCT06513884 or drug safety issues in the excerpt provided.\n\nResult [3]: This shows a listing of SEC filings for HOOKIPA PHARMA INC., including an 8-K filing from July 29, 2025. But there's no detail about the content of this filing.\n\nResult [4]: This is the EDGAR Entity Landing Page for HOOKIPA Pharma Inc., which notes \"This company's Exchange Act registration has been revoked.\" No specific filing details are provided.\n\nResult [5]: This appears to be a document for \"hookipa pharma inc.\" but shows an error message about \"Your Request Originates from an Undeclared Automated Tool\". No useful content about clinical trials is visible.\n\nResult [6]: This is from Synapse and mentions \"Hookipa Biotech is a clinical stage company that specializes in creating innovative immunotherapies for infectious diseases and cancer...\" This confirms the company's focus but doesn't provide specific SEC filing information about the clinical trial in question.\n\nResult [7]: This shows an EDGAR filing document", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "start_date": "2024-12-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Hookipa Biotech GmbH about clinical trial NCT06513884 for Pembrolizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Hookipa Biotech GmbH regarding clinical trial NCT06513884 for Pembrolizumab, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let's understand what NCT06513884 is about based on the search results:\n\nFrom result [1]:\n- Trial ID: H-200-004, NCT06513884\n- Title: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer\n- Status: Withdrawn\n- Phase: 2/3\n- Year: 2019- (appears to be the start year)\n\nFrom result [2]:\n- US trial NCT06513884\n- Date: 2024-11-24 (likely the registration date)\n- Title: A Phase 2/3 Study Of Hb-202/Hb-201 With Pembrolizumab In Patients With Hpv16+ Recurrent/Metastatic Oropharyngeal Cancer\n\nFrom result [3]:\n- Title: A Study of HB-202/HB-201 With Pembrolizumab in...\n- Description: This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda\u00ae) in people with human papillomavirus subtype 16...\n\nFrom result [5]:\n- NCT06513884 is listed as \"Withdrawn Phase 2/3\"\n- Title: A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201...\n\nFrom result [6]:\n- Mentions \"Eseba-Vec\" which appears to be related to HB-202/HB-201\n- HOOKIPA's pipeline includes biological therapies for oncology, targeting HPV16+ cancers\n\nNow, regarding the specific query about company press releases, investor presentations, or public statements by Hookipa Biotech GmbH about this", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "drug_name": "Pembrolizumab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states \"Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.\" This indicates that the trial was terminated due to a strategic decision by the sponsor, Hookipa Biotech GmbH, and not due to safety or efficacy concerns. The lack of any publications or safety issues mentioned also suggests an administrative or business-related reason for the trial withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:47.237052", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1474}}, "49": {"nct_id": "NCT06513884", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "phase": "PHASE2/PHASE3", "overall_status": "WITHDRAWN", "why_stopped": "Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.", "title": "A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer", "start_date": "2024-12-31", "completion_date": "2032-04-30", "sponsor": "Hookipa Biotech GmbH", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.548907", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:47.313904", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda\u00ae) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the throat, who have not yet received systemic treatment after their cancer spread (metastatic) and/or returned (recurrent) and who are eligible to receive pembrolizumab.\n\nDoctors already use pembrolizumab therapy (with or without chemotherapy) to treat head and neck cancer. However, the treatment does not work well in most people with this type of cancer. HB-202/HB-201 alternating 2-vector therapy with pembrolizumab, which is designated to stimulate a stronger immune attack against HPV16+ tumors, was shown to be safe and suggested to work better than pembrolizumab-only in a small number of participants with HPV16+ head and neck cancer (see H-200-001, NCT04180215).\n\nThis trial studies HB-202/HB-201 alternating 2-vector therapy with pembrolizumab in a much larger number of participants from different countries to confirm its benefits for people with HPV16+ head and neck cancer that started in the middle part of the throat compared with pembrolizumab-only therapy. This trial studies whether administering HB-202/HB-201 alternating 2-vector therapy with pembrolizumab works better in more participants by shrinking their tumors and makes them live longer than pembrolizumab-only therapy.\n\nParticipants will receive the study treatments by injection into a vein every 3 weeks during the first 3 months and then every 6 weeks until up to about 2 years, which will be followed by a long observation period to continue looking at the safety and clinical benefits after the last dose of study treatment.", "detailed_description": "This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.\n\nPembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.\n\nHB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.\n\nHB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.\n\nParticipants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.\n\nUp to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "type": "EXPERIMENTAL", "description": "Intravenous injection of HB-202 followed by pembrolizumab alternating with HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: HB-202/HB-201 alternating 2-vector therapy", "Drug: Pembrolizumab"]}, {"label": "Matched placebo with pembrolizumab", "type": "PLACEBO_COMPARATOR", "description": "Intravenous injection of matched placebo for HB-202 followed by pembrolizumab alternating with matched placebo for HB-201 followed by pembrolizumab.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "HB-202/HB-201 alternating 2-vector therapy", "description": "Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.", "arm_group_labels": ["Matched placebo with pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.", "arm_group_labels": ["HB-202/HB-201 alternating 2-vector therapy with pembrolizumab", "Matched placebo with pembrolizumab"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Hookipa Biotech GmbH+NCT06513884+terminated", "https://www.google.com/search?q=Hookipa Biotech GmbH+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by Hookipa Biotech GmbH. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for \"Placebo\" by Hookipa Biotech GmbH\n- Specific dates, reasons, and safety issues cited\n\nFirst, I need to understand what \"Placebo\" refers to in this context. In clinical trials, a placebo is an inactive substance used as a control in testing new treatments. However, it's unusual to have FDA warning letters specifically for \"Placebo\" as a product, since placebos aren't marketed products but rather control substances in clinical trials.\n\nLet me search through the provided results to find any mentions of:\n1. Hookipa Biotech GmbH\n2. FDA warning letters related to Hookipa\n3. Clinical holds related to Hookipa\n4. Any mention of \"placebo\" in relation to Hookipa\n\nFrom the search results:\n\nResult [5] mentions HOOKIPA PHARMA INC. and states:\n\"In June 2018, Hookipa Biotech, Inc. changed its name to HOOKIPA Pharma Inc. and acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH.\"\n\nResult [7] is an Annual Report 2021 that mentions:\n\"In June 2018, Hookipa Biotech, Inc. changed its name to HOOKIPA Pharma Inc. and acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH.\"\n\nResult [9] and [12] also mention the same name change information.\n\nResult [10] mentions a clinical trial: \"NCT06430905 | ClinicalTrials.gov - Clinical Trials. This is a first-in-human Phase 1b, randomized, double-blind, placebo-controlled, multicenter study of HB-502 and HB-501 alternating 2-vector therapy...\"\n\nResult [11] mentions \"Hookipa Biotech GmbH\" in relation to Monkeypox and smallpox vaccines.\n\nResult [4] mentions \"Achilles Therapeutics PLC\" and has some general information about FDA clinical holds, but doesn't specifically mention Hookipa.\n\nResults [1], [2], [3], [6], and [8] contain information about FDA warning letters and advisory letters, but I don't see specific mentions of Hookipa Biotech GmbH in these results.\n\nLet me look more carefully for any", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Hookipa Biotech GmbH mentioning clinical trial NCT06513884 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Hookipa Biotech GmbH that mention clinical trial NCT06513884 or related drug safety issues.\n\nFirst, let me identify the relevant information from the search results:\n\n1. The company in question appears to be \"HOOKIPA Pharma Inc.\" (not Hookipa Biotech GmbH specifically, though result [6] mentions \"Hookipa Biotech\" as a clinical stage company)\n2. CIK number is consistently 0001760542 across multiple filings\n3. I need to look for 8-K filings that mention clinical trial NCT06513884 or drug safety issues\n\nLet's examine each result:\n\nResult [1]: This is a Form 4 filing (Statement of changes in beneficial ownership of securities) from July 23, 2025. It doesn't appear to be an 8-K filing and doesn't mention any clinical trials.\n\nResult [2]: This is a Form 8-K filing from March 15, 2023. The items listed are:\n- Item 2.02: Results of Operations and Financial Condition\n- Item 9.01: Financial Statements and Exhibits\nThere's no mention of clinical trial NCT06513884 or drug safety issues in the visible portion.\n\nResult [3]: This appears to be a listing of SEC filings for HOOKIPA PHARMA INC., showing an 8-K filing from July 29, 2025, but no details about the content.\n\nResult [4]: This is an EDGAR Entity Landing Page for HOOKIPA Pharma Inc., noting that \"This company's Exchange Act registration has been revoked.\" No specific filing details.\n\nResult [5]: This appears to be a document for \"hookipa pharma inc.\" but shows an error message about \"Your Request Originates from an Undeclared Automated Tool\" and doesn't provide content about clinical trials.\n\nResult [6]: This is from Synapse and mentions \"Hookipa Biotech is a clinical stage company that specializes in creating innovative immunotherapies for infectious diseases and cancer...\" but doesn't provide specific SEC filing information or mention the clinical trial NCT06513884.\n\nResult [7]: This is another Form 8-K filing but the details are", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "start_date": "2024-12-31"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Hookipa Biotech GmbH about clinical trial NCT06513884 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Hookipa Biotech GmbH regarding clinical trial NCT06513884, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let's understand what NCT06513884 is about based on the search results:\n\nFrom result [1]:\n- Trial ID: H-200-004, NCT06513884\n- Title: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer\n- Status: Withdrawn\n- Phase: 2/3\n- Year: 2019- (appears to be the start year)\n\nFrom result [2]:\n- US \u00b7 NCT06513884 \u00b7 2024-11-24 \u00b7 1932-04-01 \u00b7 A Phase 2/3 Study Of Hb-202/Hb-201 With Pembrolizumab In Patients With Hpv16+ Recurrent/Metastatic Oropharyngeal Cancer.\n\nFrom result [4]:\n- NCT06513884 | A Study of HB-202/HB-201 With Pembrolizumab in ...\n- This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda\u00ae) in people with human papillomavirus subtype 16 ...\n\nFrom result [5]:\n- Clinical Trials associated with HOOKIPA Pharma, Inc. NCT06513884. / WithdrawnPhase 2/3. A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 ...\n\nSo we have a clear picture of the trial: It's a Phase 2/3 study of HB-202/HB-201 (which appears to be Eseba-Vec based on result [6]) with pembrolizumab in patients with HPV16+ recurrent/metastatic oropharyngeal cancer", "citations": [], "search_params": {"company": "Hookipa Biotech GmbH", "nct_id": "NCT06513884", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal states \"Due to the decision by the company not to pursue the development of HB-202 and HB-201 in this indication.\" This indicates that the trial was terminated due to a strategic decision by the sponsor, Hookipa Biotech GmbH, and not due to safety or efficacy concerns. The lack of any publications or safety issues mentioned also suggests an administrative or business-related reason for the trial withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:47.237052", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1474}}, "50": {"nct_id": "NCT05545969", "drug_name": "Lenvatinib", "intervention_type": "DRUG", "drug_description": "Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFR\u03b1), stem cell factor receptor (KIT), and rearranged during transfection (RET)", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Insufficient funding", "title": "Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma", "start_date": "2024-03-31", "completion_date": "2036-05-31", "sponsor": "Melanoma Institute Australia", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.549281", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:50.153870", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1289601", "pref_name": "LENVATINIB", "targets": [{"chembl_id": "CHEMBL279", "ic50_values": [{"value": 4.0, "units": "nM"}, {"value": 4.0, "units": "nM"}, {"value": 4.0, "units": "nM"}, {"value": 4.0, "units": "nM"}, {"value": 0.7, "units": "nM"}, {"value": 4.0, "units": "nM"}, {"value": 4.0, "units": "nM"}, {"value": 4.0, "units": "nM"}], "uniprot_id": "A2RRS0"}, {"chembl_id": "CHEMBL1955", "ic50_values": [{"value": 5.2, "units": "nM"}, {"value": 5.2, "units": "nM"}, {"value": 5.2, "units": "nM"}, {"value": 5.2, "units": "nM"}], "uniprot_id": "A8K6L4"}, {"chembl_id": "CHEMBL3430888", "ic50_values": [{"value": 10.0, "units": "nM"}], "uniprot_id": "A8K6Z2"}, {"chembl_id": "CHEMBL3430904", "ic50_values": [{"value": 10.0, "units": "nM"}], "uniprot_id": "A8K6Z2"}, {"chembl_id": "CHEMBL3430877", "ic50_values": [{"value": 10.0, "units": "nM"}], "uniprot_id": "A8K6Z2"}, {"chembl_id": "CHEMBL1868", "ic50_values": [{"value": 22.0, "units": "nM"}, {"value": 22.0, "units": "nM"}, {"value": 22.0, "units": "nM"}], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL613979", "ic50_values": [{"value": 3.0, "units": "nM"}, {"value": 3.47, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2041", "ic50_values": [{"value": 35.0, "units": "nM"}], "uniprot_id": "A8K6Z2"}, {"chembl_id": "CHEMBL1913", "ic50_values": [{"value": 39.0, "units": "nM"}], "uniprot_id": "B5A957"}, {"chembl_id": "CHEMBL2007", "ic50_values": [{"value": 51.0, "units": "nM"}], "uniprot_id": "B2RE69"}, {"chembl_id": "CHEMBL614524", "ic50_values": [{"value": 3.23, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4142", "ic50_values": [{"value": 11.0, "units": "nM"}], "uniprot_id": "B4DFC2"}, {"chembl_id": "CHEMBL3650", "ic50_values": [{"value": 66.0, "units": "nM"}], "uniprot_id": "A8K6T9"}, {"chembl_id": "CHEMBL3973", "ic50_values": [{"value": 311.0, "units": "nM"}, {"value": 1.9, "units": "nM"}], "uniprot_id": "G3JVM2"}, {"chembl_id": "CHEMBL614039", "ic50_values": [{"value": 850.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296437", "ic50_values": [{"value": 696.2, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296470", "ic50_values": [{"value": 80000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5465453", "ic50_values": [{"value": 27810.0, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Lenvatinib"}, "ppi_enrichment": {"uniprot_count": 9, "interactions": [{"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "SRC", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PECAM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PECAM1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CDH5", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "PECAM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PECAM1", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "SHC1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "GRB2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "ANGPT2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "PDGFC", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "NRP2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "KDR", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "PGF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT4", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "GRB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "NRP2", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "NRP2", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "NRP2", "protein_b": "PGF", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "NRP2", "protein_b": "VEGFC", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "ARTN", "combined_score": 0.796, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "GFRAL", "combined_score": 0.796, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "NRTN", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "GDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "RET", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "GFRA2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "GFRA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PSPN", "protein_b": "GFRA3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCDC6", "protein_b": "NCOA4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CCDC6", "protein_b": "RET", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "GFRA3", "protein_b": "GFRA1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GFRA3", "protein_b": "GDNF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GFRA3", "protein_b": "NRTN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GFRA3", "protein_b": "ARTN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GFRA3", "protein_b": "RET", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRTN", "protein_b": "ARTN", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NRTN", "protein_b": "GDNF", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NRTN", "protein_b": "GFRA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRTN", "protein_b": "RET", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRTN", "protein_b": "GFRA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GFRAL", "protein_b": "GDNF", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GFRAL", "protein_b": "RET", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GFRA1", "protein_b": "ARTN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GFRA1", "protein_b": "RET", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GFRA1", "protein_b": "GDNF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RET", "protein_b": "NCOA4", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RET", "protein_b": "GFRA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RET", "protein_b": "ARTN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RET", "protein_b": "GDNF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARTN", "protein_b": "GDNF", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "ARTN", "protein_b": "GFRA2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GDNF", "protein_b": "GFRA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PTPN11", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "SRC", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PIK3R1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "EGFR", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PDGFRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "EGFR", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PTPN11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PIK3R1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PDGFD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PDGFC", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PDGFA", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PDGFB", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PIK3R1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PTPN11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFC", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDGFA", "protein_b": "PDGFD", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDGFA", "protein_b": "PDGFC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "PIK3R1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "PIK3R1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "PTPN11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFD", "protein_b": "PDGFC", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "PIK3R1", "protein_b": "PTPN11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "EGF", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PTPN11", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PIK3R1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PIK3CA", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PDGFRA", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PDGFRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "EGF", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PDGFRB", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PIK3CA", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PTPN11", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PIK3R1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PDGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PDGFA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PDGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRA", "protein_b": "PDGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PIK3CA", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "EGF", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PTPN11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PIK3R1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDGFRB", "protein_b": "PDGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PDGFA", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PTPN11", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PIK3R1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PTPN11", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PIK3R1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PDGFC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PDGFD", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PDGFA", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PDGFB", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFC", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PDGFB", "protein_b": "PDGFA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDGFA", "protein_b": "PDGFD", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDGFA", "protein_b": "PDGFC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PDGFD", "protein_b": "PDGFC", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "PIK3R1", "protein_b": "PTPN11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF22", "protein_b": "FGF3", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "FGF22", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF18", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF7", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF17", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF10", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF7", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGF3", "combined_score": 0.727, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF3", "protein_b": "FGF17", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGF3", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF17", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF9", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGF23", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "KLB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF20", "protein_b": "FGF23", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "FGF20", "protein_b": "KLB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "FGF20", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF22", "protein_b": "KLB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "FGF22", "protein_b": "FGF23", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "FGF22", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "FGF23", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "KLB", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF23", "protein_b": "FGF10", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "FGF23", "protein_b": "FGF7", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "FGF23", "protein_b": "KLB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FGF23", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF10", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF7", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF10", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF7", "protein_b": "FGFR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGF1", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGF19", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "KLB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "FGF4", "protein_b": "FGFR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "FGF1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "KLB", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "FGF6", "protein_b": "FGFR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF8", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF9", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF18", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGFR4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KLB", "protein_b": "FGF19", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF18", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGFR4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGF1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGF19", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGFR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FGFR4", "protein_b": "FGF9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FGFR4", "protein_b": "FGF8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FGFR4", "protein_b": "FGF5", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FGFR4", "protein_b": "FGF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGFR4", "protein_b": "FGF19", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF19", "protein_b": "FGF9", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "FGF19", "protein_b": "FGF8", "combined_score": 0.851, "interaction_type": "physical"}, {"protein_a": "FGF5", "protein_b": "FGF1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGF1", "combined_score": 0.704, "interaction_type": "physical"}], "network_features": {"avg_degree": 9.76, "clustering_coefficient": 4.88}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41213213", "title": "Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer.", "authors": [{"name": "Doerfler R", "authtype": "Author", "clusterid": ""}, {"name": "Chen J", "authtype": "Author", "clusterid": ""}, {"name": "Kim C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41186842", "title": "DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/\u03b2-catenin signaling pathway.", "authors": [{"name": "Huang S", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}, {"name": "Fu S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41169385", "title": "First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.", "authors": [{"name": "Lin Y", "authtype": "Author", "clusterid": ""}, {"name": "Liao Y", "authtype": "Author", "clusterid": ""}, {"name": "Luo B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41126100", "title": "Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.", "authors": [{"name": "Nong X", "authtype": "Author", "clusterid": ""}, {"name": "Yao Y", "authtype": "Author", "clusterid": ""}, {"name": "Xie J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41121202", "title": "Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.", "authors": [{"name": "Huang XY", "authtype": "Author", "clusterid": ""}, {"name": "Shi GM", "authtype": "Author", "clusterid": ""}, {"name": "Zheng ZT", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival. Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before surgical resection in high-risk resectable disease, such as mucosal melanoma. In resectable cancers, immune checkpoint inhibitors can enhance anti-tumour immunity by exploiting a competent immune system prior to surgery. Activating antigen-specific T cells found in the primary or baseline tumour continue to exert anti-tumour effects on remaining neoplastic cells after the resection of the original tumour, potentially preventing recurrences from occurring.\n\nIn resectable mucosal melanoma, an opportunity exists to improve clinical outcomes with the addition of neoadjuvant and adjuvant systemic therapy with nivolumab and lenvatinib as an adjunct to surgery.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Neoadjuvant and Adjuvant Therapy", "type": "EXPERIMENTAL", "description": "Neoadjuvant pembrolizumab \\& lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks", "intervention_names": ["Drug: Pembrolizumab", "Drug: Lenvatinib"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab", "description": "Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.", "arm_group_labels": ["Neoadjuvant and Adjuvant Therapy"]}, {"type": "DRUG", "name": "Lenvatinib", "description": "Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFR\u03b1), stem cell factor receptor (KIT), and rearranged during transfection (RET)", "arm_group_labels": ["Neoadjuvant and Adjuvant Therapy"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Melanoma Institute Australia+NCT05545969+terminated", "https://www.google.com/search?q=Melanoma Institute Australia+Lenvatinib+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Lenvatinib by Melanoma Institute Australia. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a comprehensive response.\n\nThe query asks for:\n- FDA warning letters or clinical holds for Lenvatinib\n- Specifically related to Melanoma Institute Australia\n- Including specific dates, reasons, and safety issues cited\n\nFirst, I need to check if there are any FDA warning letters or clinical holds mentioned in the search results that are:\n1. Related to Lenvatinib\n2. Specifically connected to Melanoma Institute Australia\n3. With specific dates, reasons, and safety issues\n\nLet me go through the search results:\n\nResult 1: Discusses Merck and Eisai discontinuing Phase 3 LEAP-003 trial for KEYTRUDA plus LENVIMA for advanced melanoma. It mentions safety monitoring for immune-mediated adverse reactions but doesn't mention any FDA warning letters or clinical holds specifically for Lenvatinib related to Melanoma Institute Australia.\n\nResult 2: Discusses various FDA cancer drug safety warnings, but doesn't mention Lenvatinib or Melanoma Institute Australia specifically.\n\nResult 3: Clinical trial information for NCT03776136 about lenvatinib and pembrolizumab, but no mention of FDA warning letters or clinical holds.\n\nResult 4: Discusses the LEAP-003 study showing lenvatinib plus pembrolizumab didn't provide additional benefit for advanced melanoma. It mentions adverse events but no FDA warning letters or clinical holds.\n\nResult 5: FDA supplemental approval for lenvatinib for hepatocellular carcinoma, but no warning letters.\n\nResult 6: FDA document about Lenvima (lenvatinib) but doesn't mention warning letters or clinical holds related to Melanoma Institute Australia.\n\nResult 7: Information about FDA approval of pembrolizumab plus lenvatinib, but no warning letters.\n\nResult 8: Merck and Eisai update on Phase 3 LEAP-012 trial, mentions adverse reactions but no FDA warning letters.\n\nResult 9: Australian document (TGA) about lenvatinib, but this is not FDA and not specifically about Melanoma Institute Australia.\n\nResult 10: FDA document about LENVIMA but doesn't mention warning letters related to Melanoma Institute Australia.\n\nResult 11: Phase II LEAP-004 study of lenvatinib plus pembrolizum", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Melanoma Institute Australia"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Melanoma Institute Australia about clinical trial NCT05545969 for Lenvatinib. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Melanoma Institute Australia regarding clinical trial NCT05545969 for Lenvatinib, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT05545969 is from the search results:\n\nFrom results [1], [3], [4], [6], [10], and [11], I can see that NCT05545969 is a clinical trial titled \"Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma\" (also called \"Neo PeLeMM\"). It's a Phase II trial sponsored by Melanoma Institute Australia.\n\nKey information about the trial:\n- It's a multicenter, open-label, phase II study\n- It's investigating neoadjuvant pembrolizumab and lenvatinib followed by adjuvant treatment\n- It's focused on mucosal melanoma\n- The status is listed as \"Withdrawn\" in results [1] and [3]\n\nNow, I need to look for any press releases, investor presentations, or public statements by Melanoma Institute Australia specifically about this trial, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each result:\n\n[1] This is from Cancer Knowledgebase (CKB) and provides basic trial information but doesn't contain any press releases or statements about safety issues or trial termination reasons.\n\n[2] This is about a Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), not related to NCT05545969 or mucosal melanoma.\n\n[3] This is from ClinConnect and provides trial information, including that the trial status is \"Withdrawn\". It lists some exclusion criteria that relate to safety (e.g., active infection, HIV, hepatitis, TB, gastrointestinal conditions), but these are standard trial criteria, not statements about safety issues discovered during the trial.\n\n[4] This appears to be from clinicaltrials.gov and provides a brief description of the trial as \"A multicentre, open label, phase II study to determine the response to neoadjuvant pembrolizumab and lenvatinib followed by ad", "citations": [], "search_params": {"company": "Melanoma Institute Australia", "nct_id": "NCT05545969", "drug_name": "Lenvatinib"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial being withdrawn is \"Insufficient funding,\" which indicates an administrative issue rather than safety or efficacy concerns. The lack of detailed description and the relatively small number of 5 PubMed publications suggest that the trial was likely terminated early due to lack of resources or funding, rather than any specific safety or efficacy issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:50.153280", "claude_model": "claude-3-haiku-20240307", "tokens_used": 866}}, "51": {"nct_id": "NCT05545969", "drug_name": "Pembrolizumab", "intervention_type": "DRUG", "drug_description": "Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Insufficient funding", "title": "Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma", "start_date": "2024-03-31", "completion_date": "2036-05-31", "sponsor": "Melanoma Institute Australia", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.549664", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:50.191238", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O95243", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Pembrolizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "MBD4", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "SMUG1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MLH1", "protein_b": "MBD4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "UHRF1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "MBD2", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TRDMT1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "SMUG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TDG", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3B", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TRDMT1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TDG", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "UHRF1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT3B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TRDMT1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "UHRF1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "TDG", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "UHRF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TDG", "protein_b": "SMUG1", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.74, "clustering_coefficient": 4.37}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41228347", "title": "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.", "authors": [{"name": "Fedele P", "authtype": "Author", "clusterid": ""}, {"name": "Stucci SL", "authtype": "Author", "clusterid": ""}, {"name": "Landriscina M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41219635", "title": "Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis.", "authors": [{"name": "Lala M", "authtype": "Author", "clusterid": ""}, {"name": "Bardia A", "authtype": "Author", "clusterid": ""}, {"name": "Calles A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209621", "title": "Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.", "authors": [{"name": "Skoulidis F", "authtype": "Author", "clusterid": ""}, {"name": "Borghaei H", "authtype": "Author", "clusterid": ""}, {"name": "Garon EB", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206673", "title": "Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).", "authors": [{"name": "Villaruz LC", "authtype": "Author", "clusterid": ""}, {"name": "Schluger B", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41177680", "title": "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.", "authors": [{"name": "Jain P", "authtype": "Author", "clusterid": ""}, {"name": "Naqvi SAA", "authtype": "Author", "clusterid": ""}, {"name": "Tripathi N", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "In many cancers, early stage diagnosis and early treatment offers the best chance of a prolonged recurrence free- and overall survival. Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before surgical resection in high-risk resectable disease, such as mucosal melanoma. In resectable cancers, immune checkpoint inhibitors can enhance anti-tumour immunity by exploiting a competent immune system prior to surgery. Activating antigen-specific T cells found in the primary or baseline tumour continue to exert anti-tumour effects on remaining neoplastic cells after the resection of the original tumour, potentially preventing recurrences from occurring.\n\nIn resectable mucosal melanoma, an opportunity exists to improve clinical outcomes with the addition of neoadjuvant and adjuvant systemic therapy with nivolumab and lenvatinib as an adjunct to surgery.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Neoadjuvant and Adjuvant Therapy", "type": "EXPERIMENTAL", "description": "Neoadjuvant pembrolizumab \\& lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks", "intervention_names": ["Drug: Pembrolizumab", "Drug: Lenvatinib"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab", "description": "Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.", "arm_group_labels": ["Neoadjuvant and Adjuvant Therapy"]}, {"type": "DRUG", "name": "Lenvatinib", "description": "Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFR\u03b1), stem cell factor receptor (KIT), and rearranged during transfection (RET)", "arm_group_labels": ["Neoadjuvant and Adjuvant Therapy"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Melanoma Institute Australia+NCT05545969+terminated", "https://www.google.com/search?q=Melanoma Institute Australia+Pembrolizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab by Melanoma Institute Australia. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a JSON summary about FDA warning letters or clinical holds for Pembrolizumab by Melanoma Institute Australia.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds for Pembrolizumab\n2. Related to Melanoma Institute Australia\n3. Including specific dates, reasons, and safety issues cited\n\nFirst, I need to check if there are any FDA warning letters or clinical holds specifically related to Pembrolizumab in the context of Melanoma Institute Australia.\n\nLet me go through the search results:\n\nResult [1]: Discusses FDA advising against a BLA (Biologics License Application) for a novel vaccine combo with pembrolizumab in melanoma. This is about a different drug (adjuvanted imsapepimut and etimupepimut) combined with pembrolizumab, not pembrolizumab alone. The FDA advised against submitting a BLA because the phase 3 trial failed to meet statistical significance for PFS. This is not a warning letter or clinical hold for pembrolizumab itself.\n\nResult [2]: Discusses FDA safety concerns and clinical hold for pembrolizumab combinations in myeloma (not melanoma). This is specifically for multiple myeloma, not melanoma. The FDA put a clinical hold on trials combining pembrolizumab with pomalidomide or lenalidomide for multiple myeloma due to safety concerns (more deaths in the pembrolizumab arms).\n\nResult [3]: Australian Public Assessment Report for Pembrolizumab. This is from the TGA (Therapeutic Goods Administration) in Australia, not FDA warning letters.\n\nResult [4]: Discusses adverse event data for pembrolizumab in melanoma treatment, but doesn't mention FDA warning letters or clinical holds.\n\nResult [5]: FDA approval of pembrolizumab for advanced melanoma. This is about approval, not warnings or holds.\n\nResult [6]: Clinical review of pembrolizumab from NCBI Bookshelf. Discusses side effects but no FDA warning letters or holds specific to melanoma.\n\nResult [7]: FDA document about an application, but doesn't appear to be a warning letter or clinical hold for pembrolizumab in melanoma.\n\nResult [8]: FDA alert about decreased survival with Keytruda (pemb", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Melanoma Institute Australia"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Melanoma Institute Australia about clinical trial NCT05545969 for Pembrolizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Melanoma Institute Australia about clinical trial NCT05545969 for Pembrolizumab, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT05545969 is about based on the search results:\n\nFrom result [1]:\n- NCT05545969 is titled \"Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)\"\n- It's a Phase II trial\n- Sponsors: Melanoma Institute Australia\n- Indications: mucosal melanoma\n- Therapies: Lenvatinib + Pembrolizumab\n- Recruitment status: Withdrawn\n- Age Groups: adult | senior\n- Covered Countries: Australia (AUS)\n\nFrom result [2]:\n- Trial launched by Melanoma Institute Australia on Sep 15, 2022\n- Current status as of November 14, 2025: Withdrawn\n- Includes eligibility criteria but no specific safety information or reasons for withdrawal\n\nFrom result [3]:\n- This discusses a different trial (NADINA) about neoadjuvant immunotherapy for high-risk Stage III melanoma\n- It mentions Melanoma Institute Australia but not specifically about NCT05545969\n- No information about safety issues or trial termination for NCT05545969\n\nFrom result [4]:\n- Just confirms the trial name and sponsor but no additional details\n\nFrom result [5]:\n- General information about mucosal melanoma treatment\n- Mentions immunotherapy efficacy but not specific to NCT05545969\n\nFrom result [6]:\n- Describes it as \"A multicentre, open label, phase II study to determine the response to neoadjuvant pembrolizumab and lenvatinib followed by adjuvant treatment\"\n\nFrom result [7]:\n- Mentions a poster about \"Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III...\"\n- References the phase II SWOG S1801 study showing improved event-free survival with anti-PD-1 neoadjuvant", "citations": [], "search_params": {"company": "Melanoma Institute Australia", "nct_id": "NCT05545969", "drug_name": "Pembrolizumab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial being withdrawn is \"Insufficient funding,\" which indicates an administrative issue rather than safety or efficacy concerns. The lack of detailed description and the relatively small number of 5 PubMed publications suggest that the trial was likely terminated early due to lack of resources or funding, rather than any specific safety or efficacy issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:50.153280", "claude_model": "claude-3-haiku-20240307", "tokens_used": 866}}, "52": {"nct_id": "NCT06247540", "drug_name": "Biopsy", "intervention_type": "PROCEDURE", "drug_description": "Undergo tissue biopsy", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.550074", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.550732", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q8IZH2", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9P2X0", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P05976", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q6PCB0", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q13326", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Biopsy", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "XRN1", "protein_b": "LSM3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "DCP1B", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "DDX6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "EDC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "PATL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "DCP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "DCP1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "PATL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "XRN1", "protein_b": "LSM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "LSM1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "PATL1", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "DCP1A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "EDC4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "DDX6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "EDC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DCP1B", "protein_b": "DCP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "LSM3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "DDX6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "LSM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "EDC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "DCP1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL1", "protein_b": "DCP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LSM3", "protein_b": "DDX6", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "LSM3", "protein_b": "DCP2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "LSM3", "protein_b": "PATL2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LSM3", "protein_b": "EDC3", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LSM3", "protein_b": "LSM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "DCP1A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "EDC4", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "DCP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "EDC3", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "DDX6", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "LSM1", "protein_b": "PATL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDC4", "protein_b": "DDX6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDC4", "protein_b": "DCP1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDC4", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDC4", "protein_b": "DCP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DCP2", "protein_b": "PATL2", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "DCP2", "protein_b": "DCP1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DCP2", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DCP2", "protein_b": "DDX6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PATL2", "protein_b": "DDX6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DCP1A", "protein_b": "DDX6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DCP1A", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DDX6", "protein_b": "EDC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "ALG1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "DOLK", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "DPM2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "DPM3", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "DOLPP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "DPAGT1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALG5", "protein_b": "ALG3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "DOLK", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "DPM1", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "DPAGT1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "ALG3", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "DPM2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "ALG1", "protein_b": "DPM3", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGM", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGV", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "DOLPP1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "DPAGT1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "ALG3", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "DOLK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "DPM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "DPM3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGM", "protein_b": "DPM3", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "PIGM", "protein_b": "ALG3", "combined_score": 0.899, "interaction_type": "physical"}, {"protein_a": "PIGM", "protein_b": "PIGV", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "PIGV", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "DPAGT1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "ALG3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "DOLPP1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "DOLK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DPM3", "protein_b": "DPM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DPM1", "protein_b": "DPAGT1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "DPM1", "protein_b": "PIGV", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "DPM1", "protein_b": "DOLK", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DPM1", "protein_b": "ALG3", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "DOLPP1", "protein_b": "DPAGT1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "DOLPP1", "protein_b": "DOLK", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DOLK", "protein_b": "DPAGT1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PIGV", "protein_b": "ALG3", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "ALG3", "protein_b": "DPAGT1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "TNNI1", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYL12B", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "TNNI2", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "TNNT3", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYH13", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYH7", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYLPF", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYL1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MYH1", "protein_b": "MYH2", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "MYH13", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "NEB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "TNNI2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "TNNI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "TNNT3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "MYL12B", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "MYH2", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "MYLPF", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MYL1", "protein_b": "MYH7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "MYH13", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "TNNI1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "TNNI2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "TNNT3", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "MYH2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MYLPF", "protein_b": "MYH7", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "NEB", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "TNNI2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "TNNT3", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "MYL12B", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "MYH13", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "MYH2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MYH7", "protein_b": "TNNI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "TNNI1", "protein_b": "NEB", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "TNNI1", "protein_b": "MYH2", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "TNNI1", "protein_b": "TNNT3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "TNNT3", "protein_b": "NEB", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "TNNT3", "protein_b": "MYH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "TNNT3", "protein_b": "TNNI2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TNNI2", "protein_b": "NEB", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "TNNI2", "protein_b": "MYH2", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "MYH2", "protein_b": "NEB", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "MYH2", "protein_b": "MYL12B", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "MYH2", "protein_b": "MYH13", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "MYH13", "protein_b": "MYL12B", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "VWA1", "protein_b": "COL19A1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SNTB1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SGCB", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SGCE", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SGCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SSPN", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SGCD", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "SGCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "DAG1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "SNTA1", "protein_b": "DMD", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SGCE", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SNTB1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "FLNC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SGCB", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SGCD", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "DMD", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SSPN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "DAG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SGCG", "protein_b": "SGCA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "SNTB1", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "SGCB", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "SGCE", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "SGCD", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "SGCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "DMD", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SSPN", "protein_b": "DAG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "SGCE", "combined_score": 0.74, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "SNTB1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "DMD", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "SGCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "SGCD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SGCA", "protein_b": "DAG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLNC", "protein_b": "DMD", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "FLNC", "protein_b": "SGCD", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SGCD", "protein_b": "SNTB1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SGCD", "protein_b": "SGCE", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SGCD", "protein_b": "DMD", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SGCD", "protein_b": "SGCB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SGCD", "protein_b": "DAG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DMD", "protein_b": "SGCE", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "DMD", "protein_b": "SGCB", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "DMD", "protein_b": "SNTB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "DMD", "protein_b": "DAG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SGCB", "protein_b": "SNTB1", "combined_score": 0.899, "interaction_type": "physical"}, {"protein_a": "SGCB", "protein_b": "DAG1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SGCB", "protein_b": "SGCE", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "SNTB1", "protein_b": "SGCE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SNTB1", "protein_b": "DAG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "DAG1", "protein_b": "SGCE", "combined_score": 0.981, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.74, "clustering_coefficient": 3.87}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233759", "title": "CDK5 regulates PPAR\u03b3/NF-\u03baB signaling to exacerbate obesity-related osteoarthritis via modulating macrophage polarization and chondrocyte apoptosis.", "authors": [{"name": "Li Y", "authtype": "Author", "clusterid": ""}, {"name": "Li H", "authtype": "Author", "clusterid": ""}, {"name": "Chen X", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233468", "title": "Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study).", "authors": [{"name": "Kobayashi N", "authtype": "Author", "clusterid": ""}, {"name": "Yabushita Y", "authtype": "Author", "clusterid": ""}, {"name": "Mori R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233047", "title": "Unexpected Findings in the Head and Neck: When to Raise Concern for Possible Malignancy.", "authors": [{"name": "Malouf WT", "authtype": "Author", "clusterid": ""}, {"name": "Hiatt KD", "authtype": "Author", "clusterid": ""}, {"name": "Kelly HR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41232982", "title": "[The role of lymph node surgery in the treatment of breast cancer].", "authors": [{"name": "Fitoussi A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Biopsy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Biopsy by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about FDA warning letters or clinical holds for Biopsy by Northwestern University.\n\nThe query is asking specifically for:\n1. FDA warning letters or clinical holds related to \"Biopsy\" by Northwestern University\n2. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1] discusses an FDA warning letter to Northwestern University regarding Dr. Richard Burt's stem cell trial. This was issued in November 2016 (mid-November 2016 as mentioned). The issues were related to failure to report patient deaths and other problems with clinical trial practices. However, this doesn't specifically mention \"biopsy\" procedures.\n\nResult [5] appears to be the actual PDF of the FDA Warning Letter to Richard K. Burt, M.D. dated 2016-11-15. It mentions adverse events including \"elevated transaminases\" and \"liver function test elevation\" but doesn't specifically mention biopsy procedures.\n\nResult [11] mentions \"FDA Inspection of Northwestern IRB\" but doesn't provide specific details about biopsy-related issues.\n\nResult [7] is from Northwestern's IRB office about FDA site inspections in general, but doesn't mention any specific warning letter related to biopsies.\n\nResult [6] is about FDA draft guidance on including tissue biopsies in clinical trials, but it's general guidance and not specific to Northwestern University.\n\nLet me check if any other results mention Northwestern University and biopsies specifically:\n\nResults [2], [3], [4], [8], [9], [10], [12], [13], and [14] don't appear to be specifically about Northwestern University and biopsies.\n\nAfter reviewing all the search results, I don't see any specific FDA warning letters or clinical holds that are:\n1. Specifically about \"biopsy\" procedures\n2. Issued to Northwestern University\n\nThe main warning letter mentioned in the results is the one to Dr. Richard Burt at Northwestern University in November 2016 (2016-11-15), but it was related to stem cell trials and issues with reporting patient deaths and adverse events, not specifically about biopsy procedures.\n\nResult [5] appears to be the actual warning letter document to Dr. Burt, which mentions adverse events like", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Biopsy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about Northwestern University's clinical trial NCT06247540 specifically related to biopsy procedures, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me first identify what NCT06247540 is from the search results:\n\nFrom result [3], I can see that NCT06247540 is a clinical trial titled \"Venetoclax, Rituximab and Nivolumab in Combination for the...\" which is a phase II trial testing venetoclax, rituximab and nivolumab for treating patients with chronic lymphocytic leukemia/small lymphocytic leukemia.\n\nFrom result [17], I see that this trial is associated with Northwestern University and the National Cancer Institute.\n\nFrom result [18], I see the primary objective is \"To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\"\n\nNow, I need to check if there are any company press releases, investor presentations, or public statements by Northwestern University about this specific trial that mention biopsy procedures and safety issues.\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is a Northwestern University clinical trials page that lists various trials, but I don't see specific mention of NCT06247540 or biopsy safety issues for this trial.\n\nResult [2]: This is an article about mandatory research biopsy requirements delaying clinical trials, but it doesn't specifically mention NCT06247540.\n\nResult [3]: This provides details about NCT06247540, but it's from clinicaltrials.gov and doesn't contain press releases or public statements from Northwestern University. It does mention exploratory objectives related to biopsies: \"Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\" So this trial does involve biopsies, but there's no information about safety issues or adverse events specifically related to biopsies.\n\nResult [4]: This is an article about ethical concerns with biopsies in clinical trials, but doesn't", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Biopsy"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "53": {"nct_id": "NCT06247540", "drug_name": "Biospecimen Collection", "intervention_type": "PROCEDURE", "drug_description": "Undergo blood sample collection", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.550471", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.589643", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Biospecimen Collection"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41208421", "title": "The global impact of the General Data Protection Regulation: implications, challenges, and future outlook in oncology clinical research sponsors.", "authors": [{"name": "Liu X", "authtype": "Author", "clusterid": ""}, {"name": "Lacombe D", "authtype": "Author", "clusterid": ""}, {"name": "Lejeune S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41146285", "title": "Efficacy of Diet on Quality of life in Multiple Sclerosis (EDQ-MS): a study protocol for a randomized controlled clinical trial.", "authors": [{"name": "Shemirani F", "authtype": "Author", "clusterid": ""}, {"name": "Klein AM", "authtype": "Author", "clusterid": ""}, {"name": "Groux AR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41074189", "title": "Operational determinants of recruitment and biospecimen collection in translational observational studies: a multi-site comparative analysis.", "authors": [{"name": "Devoy C", "authtype": "Author", "clusterid": ""}, {"name": "McLaughlin RA", "authtype": "Author", "clusterid": ""}, {"name": "Cronin C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41021581", "title": "The Founders' 400 and Chicago Perinatal Origins of Disease study protocol: Following a prospective, longitudinal cohort from early pregnancy through two years of postnatal life.", "authors": [{"name": "Fisher SA", "authtype": "Author", "clusterid": ""}, {"name": "Branche TN", "authtype": "Author", "clusterid": ""}, {"name": "Akel MJ", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40966617", "title": "Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial.", "authors": [{"name": "Li S", "authtype": "Author", "clusterid": ""}, {"name": "Hamaya R", "authtype": "Author", "clusterid": ""}, {"name": "Zhu H", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Biospecimen Collection+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Biospecimen Collection by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically related to biospecimen collection by Northwestern University.\n\nFirst, I'll look for any direct mentions of Northwestern University in connection with FDA warning letters or clinical holds related to biospecimen collection.\n\nFrom the search results:\n\nResult [1] - This is about NIH's new biospecimen security policy, not related to FDA warning letters for Northwestern.\n\nResult [2] - This is an FDA warning letter to Adarsh Daswani, M.D., but it doesn't mention Northwestern University specifically.\n\nResult [3] - This is about governing secondary research use of health data and specimens, but doesn't mention Northwestern or FDA warning letters.\n\nResult [4] - This is about pharmacogenomic panel testing, not specifically about Northwestern or FDA warning letters.\n\nResult [5] - This is about Certificates of Confidentiality from Northwestern's IRB Office, but not about FDA warning letters.\n\nResult [6] - This is a CDC ALS meeting summary, not relevant.\n\nResult [7] - This is about public comments on biospecimen informed consent, not specific to Northwestern or FDA warning letters.\n\nResult [8] - This is about RNA medicine, not relevant.\n\nResult [9] - This is Northwestern University's Investigator Manual, but doesn't mention FDA warning letters.\n\nResult [10] - This is about NCI Best Practices for Biospecimen Resources, not specific to Northwestern or FDA warning letters.\n\nResult [11] - This is a general page about FDA Warning Letters, but doesn't mention Northwestern specifically.\n\nResult [12] - This is about NCAB meeting minutes, not relevant.\n\nResult [13] - This mentions \"collected from patients at Northwestern University\" in a feasibility study, but doesn't indicate any warning letter or clinical hold.\n\nResult [14] - This is about a warning letter to Melanie M. Hoppers, M.D., but doesn't mention Northwestern.\n\nResult [15] - This is titled \"FDA Inspection of Northwestern IRB\" from Scribd. This seems most relevant. Let me examine this more closely.\n\nFrom result [15]:\n\"FDA Inspection of Northwestern IRB | PDF - Scribd\nThe FDA letter suggests Northwestern contact Edwards to determine if study data was used in an FDA application. No response is required but the FDA appreciates...\"\n\nThis indicates there was an FDA inspection of Northwestern's IRB, but the", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Biospecimen Collection. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Northwestern University\n- Specifically about clinical trial NCT06247540\n- Focusing on Biospecimen Collection\n- With emphasis on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT06247540 is from the search results:\n\nFrom result [1]:\nhttps://clinicaltrials.gov/study/NCT06247540\nThis is a phase II trial testing \"venetoclax, rituximab and nivolumab\" for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter's transformation.\n\nThe primary objective is to determine the preliminary efficacy in terms of overall response rate with this combination treatment.\n\nFrom result [9], we see the same information:\nSan Mateo Clinical Trial Venetoclax, Rituximab and Nivolumab in ...\nPRIMARY OBJECTIVE: I. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab...\n\nNow, the query specifically asks about \"Biospecimen Collection\" related to this trial. Let me check if there's any mention of biospecimen collection in NCT06247540.\n\nLooking at result [1], I don't see explicit mention of \"Biospecimen Collection\" as a primary focus of NCT06247540. The trial is focused on testing the efficacy and safety of the drug combination.\n\nHowever, result [2] and [8] mention:\n\"Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects\" with ClinicalTrials.gov ID NCT04242095\n\nThis study is specifically about biospecimen collection from patients experiencing immunotherapy side effects. It's a different trial (NCT04242095, not NCT06247540).\n\nLet me check if there's any connection between NCT06247540 and biospecimen collection:\n\nFrom result [1], under EXPLORATORY OBJECTIVES:\n\"I. The study team will study various prognostic markers and biomarkers", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Biospecimen Collection"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "54": {"nct_id": "NCT06247540", "drug_name": "Bone Marrow Biopsy", "intervention_type": "PROCEDURE", "drug_description": "Undergo bone marrow biopsy", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.550876", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.625078", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q9Y219", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P23921", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q13642", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P51530", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P09651", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Bone Marrow Biopsy", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "JAG1", "protein_b": "SRRT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "RBPJ", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "JAG2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "NOTCH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "NOTCH2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "NOTCH3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JAG1", "protein_b": "NOTCH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "NOTCH3", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "SRRT", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "NOTCH4", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "NOTCH1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "RBPJ", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NOTCH2", "protein_b": "JAG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NOTCH3", "protein_b": "SRRT", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "NOTCH3", "protein_b": "NOTCH1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NOTCH3", "protein_b": "NOTCH4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NOTCH3", "protein_b": "RBPJ", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NOTCH3", "protein_b": "JAG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SUPT6H", "protein_b": "JAG2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "MIB2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "SRRT", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "RBPJ", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "PYCR1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "NOTCH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JAG2", "protein_b": "NOTCH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RBPJ", "protein_b": "SRRT", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RBPJ", "protein_b": "NOTCH4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "RBPJ", "protein_b": "NOTCH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NOTCH4", "protein_b": "SRRT", "combined_score": 0.785, "interaction_type": "physical"}, {"protein_a": "NOTCH4", "protein_b": "NOTCH1", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SRRT", "protein_b": "NOTCH1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "MCM5", "protein_b": "RRM2B", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "MCM5", "protein_b": "TYMS", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "MCM5", "protein_b": "RRM2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MCM5", "protein_b": "RRM1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "MCM5", "protein_b": "MCM6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "MCM6", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "TYMS", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "GLRX", "combined_score": 0.858, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "NTPCR", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "CMPK2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "GUK1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "DTYMK", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "RRM2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RRM2B", "protein_b": "RRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "TYMS", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "DTYMK", "combined_score": 0.899, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "RRM2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CMPK2", "protein_b": "RRM1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "MCM6", "protein_b": "RRM2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MCM6", "protein_b": "TYMS", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MCM6", "protein_b": "RRM1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "GUK1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "DTYMK", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "TYMS", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "GLRX", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "NTPCR", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RRM1", "protein_b": "RRM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DTYMK", "protein_b": "RRM2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "DTYMK", "protein_b": "TYMS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TYMS", "protein_b": "RRM2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "GLRX", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "NTPCR", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "RRM2", "protein_b": "GUK1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT6", "combined_score": 0.899, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT5A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT5B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT4", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT2", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "FHL1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT6", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT5A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "STAT6", "protein_b": "STAT1", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "STAT6", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "STAT6", "protein_b": "STAT4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "STAT6", "protein_b": "STAT5A", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "STAT6", "protein_b": "STAT2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "STAT2", "protein_b": "STAT5A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "STAT2", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "STAT2", "protein_b": "STAT4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "STAT2", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "STAT4", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "STAT1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "RBPJ", "protein_b": "FHL1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "STAT4", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "STAT4", "protein_b": "STAT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "FHL1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "INPP5A", "protein_b": "FHL1", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TTN", "protein_b": "FHL1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "FEN1", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "RBBP8", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "EXO1", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "RAD51", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "DNA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "TOP3A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "BLM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "RMI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RPA1", "protein_b": "WRN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "BLM", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "RBBP8", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "RMI1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "RAD51", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "TOP3A", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "FEN1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "EXO1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "WRN", "protein_b": "DNA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "TOP3A", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "RBBP8", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "WDHD1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "EXO1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "BLM", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "RAD51", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FEN1", "protein_b": "DNA2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "RBBP8", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "EXO1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "RAD51", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "DNA2", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "BLM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RMI1", "protein_b": "TOP3A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TOP3A", "protein_b": "RBBP8", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TOP3A", "protein_b": "EXO1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "TOP3A", "protein_b": "RAD51", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TOP3A", "protein_b": "DNA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TOP3A", "protein_b": "BLM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BLM", "protein_b": "RBBP8", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "BLM", "protein_b": "DNA2", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BLM", "protein_b": "RAD51", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BLM", "protein_b": "EXO1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DNA2", "protein_b": "RBBP8", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DNA2", "protein_b": "RAD51", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "DNA2", "protein_b": "WDHD1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DNA2", "protein_b": "EXO1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "WDHD1", "protein_b": "RBBP8", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "WDHD1", "protein_b": "RAD51", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "WDHD1", "protein_b": "EXO1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "EXO1", "protein_b": "RBBP8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EXO1", "protein_b": "RAD51", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RBBP8", "protein_b": "RAD51", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "TARDBP", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "SRSF1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPM", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPH1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPK", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "PTBP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPA1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "HNRNPL", "protein_b": "HNRNPA2B1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPM", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "SRSF1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPH1", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPK", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "PTBP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TARDBP", "protein_b": "HNRNPA2B1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPM", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPK", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPA2B1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "PTBP1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPH1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "HNRNPA1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "TNPO1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "PTBP1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "HNRNPK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "HNRNPA2B1", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "HNRNPC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "HNRNPH1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "HNRNPM", "protein_b": "HNRNPA1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TNPO1", "protein_b": "HNRNPH1", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "TNPO1", "protein_b": "HNRNPA2B1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "TNPO1", "protein_b": "HNRNPA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HNRNPA1", "protein_b": "HNRNPK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "HNRNPA1", "protein_b": "HNRNPH1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HNRNPA1", "protein_b": "HNRNPA2B1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HNRNPA1", "protein_b": "PTBP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HNRNPA1", "protein_b": "HNRNPC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HNRNPA2B1", "protein_b": "HNRNPK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "HNRNPA2B1", "protein_b": "HNRNPH1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HNRNPA2B1", "protein_b": "PTBP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "HNRNPA2B1", "protein_b": "HNRNPC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HNRNPH1", "protein_b": "HNRNPK", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "HNRNPH1", "protein_b": "PTBP1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "HNRNPH1", "protein_b": "HNRNPC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTBP1", "protein_b": "HNRNPC", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTBP1", "protein_b": "HNRNPK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HNRNPK", "protein_b": "HNRNPC", "combined_score": 0.982, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.15, "clustering_coefficient": 3.57}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41207974", "title": "Bone Marrow Mesenchymal Stromal Cell Osteogenesis is driven by Paracrine signals from Regulatory T Cell.", "authors": [{"name": "Baysal E", "authtype": "Author", "clusterid": ""}, {"name": "Al-Sharabi N", "authtype": "Author", "clusterid": ""}, {"name": "Mustafa K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41194261", "title": "Therapeutic application of EUS-guided intraportal autologous bone marrow transplantation for decompensated liver cirrhosis.", "authors": [{"name": "Cai T", "authtype": "Author", "clusterid": ""}, {"name": "Chen B", "authtype": "Author", "clusterid": ""}, {"name": "Li XM", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41193540", "title": "Virtual reality and hypnosis for symptom alleviation before bone marrow procedure.", "authors": [{"name": "Levy Yurkovski I", "authtype": "Author", "clusterid": ""}, {"name": "Libes D", "authtype": "Author", "clusterid": ""}, {"name": "Meiseles M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41163019", "title": "Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial.", "authors": [{"name": "Qu W", "authtype": "Author", "clusterid": ""}, {"name": "Yan D", "authtype": "Author", "clusterid": ""}, {"name": "Durand NC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41136913", "title": "Iptacopan in C5 blockade refractory atypical hemolytic uremic syndrome with associated Castleman's disease: case report.", "authors": [{"name": "Nguyen MD", "authtype": "Author", "clusterid": ""}, {"name": "Ciurea S", "authtype": "Author", "clusterid": ""}, {"name": "Desai S", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Bone Marrow Biopsy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Bone Marrow Biopsy by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically related to Bone Marrow Biopsy by Northwestern University.\n\nFirst, I need to identify which search results are relevant to:\n1. FDA warning letters\n2. Clinical holds\n3. Bone Marrow Biopsy\n4. Northwestern University\n\nLooking through the search results:\n\nResult [1] discusses an FDA warning letter to Northwestern University regarding Dr. Richard Burt's stem cell trial practices. It mentions failure to report patient deaths to the FDA. This seems relevant.\n\nResult [5] also mentions the FDA warning letter to Northwestern University's stem cell therapy program, specifically noting \"failure to timely report adverse events and patient deaths to the FDA.\"\n\nResult [7] appears to be the actual FDA Warning Letter to Richard K. Burt, M.D. from November 15, 2016. This seems highly relevant.\n\nResult [11] mentions \"Northwestern abruptly ending Burt HSCT autoimmune trials\" and notes that \"Burt received an FDA warning letter regarding some issues including delayed reporting of patient deaths.\"\n\nResult [15] states: \"A prominent physician at Northwestern University failed to promptly report deaths in a stem cell study\"\n\nLet me examine these results more closely to find specific information about bone marrow biopsy:\n\nFrom Result [1]:\n- FDA issued a warning letter to Northwestern University regarding Dr. Richard Burt's clinical trial practices\n- Issues included \"failure to promptly report patient deaths to the FDA\"\n- The letter was issued late in 2016 (as it says \"late last year\" and the article is dated March 2017)\n- It mentions concerns about whether trial participants were properly consented regarding risks\n\nFrom Result [5]:\n- Mentions \"FDA warning letter setting out a list of violations\" for Northwestern's stem cell therapy\n- Specifically notes \"failure to timely report adverse events and patient deaths to the FDA\"\n- Dr. Burt claimed to have received a \"follow-up letter\" from FDA indicating his response was adequate\n\nFrom Result [7] (the actual warning letter):\n- Dated November 15, 2016\n- From FDA to Richard K. Burt, M.D.\n- Mentions \"July 7, 2016, during the inspection\"\n- References \"Subject (b)(6) underwent a Human Stem Cell Transplant (HSCT)\"\n- Mentions issues with", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Bone Marrow Biopsy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Northwestern University\n- About clinical trial NCT06247540 for Bone Marrow Biopsy\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT06247540 is from the search results:\n\nFrom result [1]:\nhttps://clinicaltrials.gov/study/NCT06247540\n\"Venetoclax, Rituximab and Nivolumab in Combination for the ...\"\nThis is a phase II trial testing venetoclax, rituximab and nivolumab for treating patients with chronic lymphocytic leukemia/small lymphocytic leukemia with Richter's transformation.\n\nFrom result [7]:\nhttps://aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials/Detail/NCT06247540\n\"San Mateo Clinical Trial Venetoclax, Rituximab and Nivolumab in ...\"\nThis confirms it's the same trial.\n\nFrom result [15]:\nhttps://sigma.larvol.com/facility.php?e1=2484394&e2=&FacilityId=2484394&tab=FacilityOTT&sr=now&er=1+month&itype=0%2C1&ipwnd=on&rlink=%2CFacilityId%3D2484394%2Citype%3D0%2C1&rflag=1&page=2\n\"NorthShore University HealthSystem-Glenbrook Hospital Trials ...\"\n\"NCI-2023-08755, NCT06247540 ... Northwestern University, National Cancer ...\"\n\nSo NCT06247540 is a clinical trial titled \"Venetoclax, Rituximab and Nivolumab in Combination\" for Richter's transformation (a complication of chronic lymphocytic leukemia), and it appears to be associated with Northwestern University.\n\nNow, the query specifically asks for:\n1. Company press releases\n2. Investor presentations \n3. Public statements by Northwestern University\nabout this trial, focusing on safety", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Bone Marrow Biopsy"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "55": {"nct_id": "NCT06247540", "drug_name": "Computed Tomography", "intervention_type": "PROCEDURE", "drug_description": "Undergo PET/CT, CT", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.551282", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.661051", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q9P2K8", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q13873", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P22607", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Computed Tomography", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "EIF2S1", "protein_b": "GCN1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "EIF2S1", "protein_b": "ATF4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "EIF2S1", "protein_b": "EIF2AK4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EIF2S1", "protein_b": "EIF2B5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "EIF2B5", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "IFIT1B", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "CHUK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "IKBKG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "IKBKB", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "IFIT1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "ATF4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "NFE2L2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "EIF2AK4", "protein_b": "GCN1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ATF4", "protein_b": "NFE2L2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CHUK", "protein_b": "IKBKB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHUK", "protein_b": "IKBKG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFIT1", "protein_b": "IFIT1B", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "IKBKB", "protein_b": "IKBKG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMP6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMP2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMP7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "ACVR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMPR1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP4", "protein_b": "BMPR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP6", "protein_b": "BMP2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "BMP6", "protein_b": "BMPR1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP6", "protein_b": "ACVR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP6", "protein_b": "BMPR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP6", "protein_b": "BMPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP10", "protein_b": "BMPR1B", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "BMP10", "protein_b": "BMPR1A", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "BMP10", "protein_b": "ACVR1", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "BMP10", "protein_b": "GDF2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "BMP10", "protein_b": "BMPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "GDF9", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "GDF2", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "BMPR1B", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "ACVR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "BMP7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "BMPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR1A", "protein_b": "BMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "GDF9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "BMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "BMPR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "ACVR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "BMP7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR2", "protein_b": "GDF2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GDF9", "protein_b": "BMPR1B", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "BMP2", "protein_b": "BMP7", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "BMP2", "protein_b": "ACVR1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "BMP2", "protein_b": "BMPR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP7", "protein_b": "BMPR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMP7", "protein_b": "ACVR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMPR1B", "protein_b": "GDF2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "BMPR1B", "protein_b": "ACVR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACVR1", "protein_b": "GDF2", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF18", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF17", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGF1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FGFR3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGF1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGFR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FGF18", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGF1", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "GRB2", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGFR3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF8", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "HRAS", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "GRB2", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "FGF17", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "FGFR2", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "FGF13", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "FGF9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGFR3", "protein_b": "FGF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF17", "protein_b": "GRB2", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "FGF17", "protein_b": "FGF13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "FGF17", "protein_b": "FGF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "FGF17", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF9", "protein_b": "GRB2", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "FGF9", "protein_b": "FGFR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "HRAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "FGFR2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FGF13", "protein_b": "FGF1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "FGF13", "protein_b": "FGFR2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "HRAS", "protein_b": "FGFR2", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "FGFR2", "protein_b": "FGF1", "combined_score": 0.999, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.39, "clustering_coefficient": 2.7}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41233762", "title": "Impact of abdominal adipose tissue segmentation on radiomics-based prognostic evaluation using CT enterography in Crohn's disease.", "authors": [{"name": "Zhou F", "authtype": "Author", "clusterid": ""}, {"name": "You J", "authtype": "Author", "clusterid": ""}, {"name": "Guo Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233698", "title": "Validation of a deep learning approach for epicardial adipose tissue segmentation in computed tomography.", "authors": [{"name": "Baeza R", "authtype": "Author", "clusterid": ""}, {"name": "Nunes F", "authtype": "Author", "clusterid": ""}, {"name": "Santos C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41228532", "title": "Sex Differences in Associations Between Diet and Metabolic Health in Older Adults: The Roles of Vegetable Protein and Alcohol Intake.", "authors": [{"name": "Anderson KR", "authtype": "Author", "clusterid": ""}, {"name": "Kern PA", "authtype": "Author", "clusterid": ""}, {"name": "Steele AL", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41225163", "title": "Microvascular dysfunction assessed by dynamic spect has a prognostic value in patients with a first acute myocardial infarction in a 3-year follow-up study.", "authors": [{"name": "Mochula AV", "authtype": "Author", "clusterid": ""}, {"name": "Nalesnik EO", "authtype": "Author", "clusterid": ""}, {"name": "Vorobyeva DA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41222615", "title": "Development and multi-institutional validation of the Swin transformer model for prediction of spontaneous passage of ureteral calculi: A retrospective multicentric study.", "authors": [{"name": "Lin Y", "authtype": "Author", "clusterid": ""}, {"name": "Li Z", "authtype": "Author", "clusterid": ""}, {"name": "Li Z", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Computed Tomography+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Computed Tomography by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Computed Tomography by Northwestern University.\n\nFirst, I need to identify which search results might contain relevant information:\n\n1. Result [1] discusses an FDA warning letter to Northwestern University regarding Dr. Richard Burt's stem cell trials. This is about stem cell trials, not computed tomography.\n\n2. Result [2] is about Non-Contrast MR Angiography, which is MRI-related, not CT.\n\n3. Result [3] appears to be the actual FDA Warning Letter to Richard K. Burt, M.D. from 2016-11-15, which is about stem cell trials, not CT.\n\n4. Result [4] is a retrospective analysis of FDA warning letters to pharmaceutical companies, not specific to Northwestern or CT.\n\n5. Result [5] is about Abbott/St. Jude Medical and EP devices, not Northwestern or CT.\n\n6. Result [6] appears to be an FDA query result spreadsheet, but the snippet doesn't show specific information about Northwestern and CT.\n\n7. Result [7] is general information about FDA warning letters.\n\n8. Result [8] is about McGaw Medical Center of Northwestern University's health care plan, not relevant.\n\n9. Result [9] is a warning letter to Xoran Technologies, LLC from 2024-12-09, but this is not about Northwestern University.\n\n10. Result [10] appears to be another FDA query result spreadsheet.\n\n11. Result [11] is guidance from Northwestern University IRB about FDA site inspections, but doesn't mention specific warning letters for CT.\n\n12. Result [12] appears to be unrelated data from NITRD.gov.\n\n13. Result [13] is about a 510(k) Premarket Notification, not specific to Northwestern.\n\n14. Result [14] is about a medical guideline, not relevant.\n\n15. Result [15] mentions \"FDA Inspection of Northwestern IRB\" but the snippet doesn't provide details about CT.\n\n16. Result [16] is Northwestern University's IRB information about FDA site inspections, but doesn't mention specific warning letters for CT.\n\n17. Result [17] is an FDA Clinical Investigator Inspection List, but only shows the range L-P, not specific to Northwestern or CT.\n\nAfter reviewing all", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Computed Tomography. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Northwestern University\n- Specifically about clinical trial NCT06247540\n- Focusing on Computed Tomography\n- Looking for information about safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT06247540 is from the search results:\n\nFrom result [1]:\nhttps://clinicaltrials.gov/study/NCT06247540\n\"Venetoclax, Rituximab and Nivolumab in Combination for the ...\"\nThis is a phase II trial testing venetoclax, rituximab and nivolumab for treating patients with chronic lymphocytic leukemia/small lymphocytic leukemia with Richter's transformation.\n\nFrom result [9]:\nhttps://aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials/Detail/NCT06247540\n\"San Mateo Clinical Trial Venetoclax, Rituximab and Nivolumab in ...\"\nThis confirms it's the same trial.\n\nNow, the query specifically mentions \"for Computed Tomography\" but the trial NCT06247540 is about venetoclax, rituximab and nivolumab for Richter's transformation (a complication of chronic lymphocytic leukemia), not Computed Tomography. This seems to be a mismatch.\n\nLet me check if there's any connection to Computed Tomography in this trial:\n\nFrom result [1], the study overview mentions:\n\"Measurable disease assessed by PET/CT\" - this appears in result [5] under eligibility criteria for a different trial (JCAR017-FOL-001), not for NCT06247540.\n\nLooking through all the search results, I don't see any specific mention of Computed Tomography being a focus of NCT06247540. The trial is clearly about a drug combination for Richter's transformation.\n\nThe query also asks for \"Company press releases, investor presentations, or public statements by Northwestern University\" about this trial. Let me check if any of the search results contain such information:\n\nResult [1] shows that the trial has", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Computed Tomography"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "56": {"nct_id": "NCT06247540", "drug_name": "Magnetic Resonance Imaging", "intervention_type": "PROCEDURE", "drug_description": "Undergo MRI", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.551699", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.696982", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q96I23", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q14CZ8", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q96Q05", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q921L3", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q6PI48", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Magnetic Resonance Imaging", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "PIGQ", "protein_b": "PYURF", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "PIGP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "PIGH", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "PIGC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "DPM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "PIGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGQ", "protein_b": "PIGY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "PYURF", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "PIGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "PIGY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "DPM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "PIGP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGH", "protein_b": "PIGC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYURF", "protein_b": "DPM2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "PYURF", "protein_b": "PIGA", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYURF", "protein_b": "PIGC", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "PYURF", "protein_b": "PIGP", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "PYURF", "protein_b": "PIGY", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGY", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DPM2", "protein_b": "PIGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGC", "protein_b": "PIGP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGC", "protein_b": "PIGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGC", "protein_b": "PIGY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGA", "protein_b": "PIGY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGA", "protein_b": "PIGP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIGP", "protein_b": "PIGY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HEPACAM", "protein_b": "KCNJ10", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC6B", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC10", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC2L", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6A", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC9", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC10", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC2L", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC6B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC8", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC6B", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC10", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC6B", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC1", "protein_b": "TRAPPC2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC5", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC6B", "protein_b": "TRAPPC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC9", "protein_b": "TRAPPC4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC9", "protein_b": "TRAPPC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRAPPC9", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC9", "protein_b": "TRAPPC2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC9", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2", "protein_b": "TRAPPC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC4", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC4", "protein_b": "TRAPPC2L", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC4", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2L", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC2L", "protein_b": "TRAPPC5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRAPPC5", "protein_b": "TRAPPC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "EPRS1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "AARS1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "VARS1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "EARS2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "VARS2", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "AARS2", "protein_b": "DARS2", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "DARS1", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "GATB", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "EARS2", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "DARS2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "VARS2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "VARS1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "AARS1", "protein_b": "EPRS1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "VARS2", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "GMPS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "EARS2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "EPRS1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "DARS1", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "QRSL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GATB", "protein_b": "DARS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DARS1", "protein_b": "QRSL1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "DARS1", "protein_b": "DARS2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DARS1", "protein_b": "EPRS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "GMPS", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "VARS2", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "QRSL1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "EARS2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "VARS1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "EPRS1", "protein_b": "DARS2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "QRSL1", "protein_b": "GMPS", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "QRSL1", "protein_b": "EARS2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "QRSL1", "protein_b": "DARS2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "VARS1", "protein_b": "GMPS", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "VARS1", "protein_b": "EARS2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "VARS1", "protein_b": "VARS2", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "VARS1", "protein_b": "DARS2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GMPS", "protein_b": "VARS2", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "GMPS", "protein_b": "DARS2", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "VARS2", "protein_b": "EARS2", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "VARS2", "protein_b": "DARS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "EARS2", "protein_b": "DARS2", "combined_score": 0.929, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.81, "clustering_coefficient": 3.91}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41231127", "title": "Rapid Late Gadolinium Enhancement Cardiac MRI in Real-World Clinical Practice: A Prospective Clinical Trial.", "authors": [{"name": "Kong H", "authtype": "Author", "clusterid": ""}, {"name": "Zhou J", "authtype": "Author", "clusterid": ""}, {"name": "Li J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41230611", "title": "Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.", "authors": [{"name": "Bonatto MG", "authtype": "Author", "clusterid": ""}, {"name": "Avila MS", "authtype": "Author", "clusterid": ""}, {"name": "Ayub Ferreira SM", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41230400", "title": "Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial.", "authors": [{"name": "Solis-Jimenez F", "authtype": "Author", "clusterid": ""}, {"name": "Araiza-Garaygordobil D", "authtype": "Author", "clusterid": ""}, {"name": "Masso-Bueso JS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41225416", "title": "Sex-specific associations of episode type in bipolar I disorder with neuro-metabolic lateralization of the cortico-striatal-cerebellar (CSC) circuit.", "authors": [{"name": "Wang RC", "authtype": "Author", "clusterid": ""}, {"name": "Wang JX", "authtype": "Author", "clusterid": ""}, {"name": "Li Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41225352", "title": "Radiomic imaging models for predicting breast cancer prognosis based on Interleukin-18 (IL18).", "authors": [{"name": "Zhou Q", "authtype": "Author", "clusterid": ""}, {"name": "Chen M", "authtype": "Author", "clusterid": ""}, {"name": "Ye X", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Magnetic Resonance Imaging+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Magnetic Resonance Imaging by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds specifically related to Magnetic Resonance Imaging (MRI) at Northwestern University.\n\nFirst, I'll identify which search results might contain relevant information:\n\n1. Result [1]: About FDA warnings for MRI contrast agents (gadolinium-based), but not specific to Northwestern University\n2. Result [2]: About ethical oversight of portable MRI research, but not specific to Northwestern or warning letters\n3. Result [3]: Northwestern Memorial Hospital MRI Safety Manual - this is relevant to Northwestern's MRI practices but doesn't mention warning letters\n4. Result [4]: General FDA Warning Letters page, not specific to Northwestern or MRI\n5. Result [5]: FDA warning letter to Northwestern's Richard Burt regarding stem cell trials - this is relevant but about stem cell trials, not MRI\n6. Result [6]: FDA inspection data query, not specific to Northwestern or MRI\n7. Result [7]: FDA Drug Safety Podcast about gadolinium-based contrast agents - relevant to MRI safety but not specific to Northwestern\n8. Result [8]: FDA Class 1 recall affecting Siemens MRI units - not specific to Northwestern\n9. Result [9]: FDA Warning Letter to Richard K. Burt, M.D. - this appears to be the actual warning letter mentioned in result [5], but about stem cell trials\n10. Result [10]: About infective endocarditis, not relevant\n11. Result [11]: FDA warning letter to a thermography clinic - not about MRI or Northwestern\n12. Result [12]: Clinical practice guideline, not relevant\n13. Result [13]: Information about FDA site inspections for IRBs at Northwestern - mentions warning letters generally but not specific to MRI\n14. Result [14]: Transplant team information, not relevant\n15. Result [15]: Northwestern University Center for Translational Imaging policies - mentions MRI safety but not warning letters\n16. Result [16]: SEC filing mentioning potential FDA warning letters generally\n\nLet me focus on the results that might contain information about FDA warning letters related to MRI at Northwestern:\n\nResult [3] is Northwestern Memorial Hospital's MRI Safety Manual, which shows they have MRI safety protocols, but doesn't mention any warning letters.\n\nResult [15] mentions Northwestern University's Center for Translational Imaging policies related to MRI safety, but again, no", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Magnetic Resonance Imaging. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Magnetic Resonance Imaging\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT06247540 is from the search results:\n\nFrom result [3]:\nhttps://clinicaltrials.gov/study/NCT06247540\n\"Venetoclax, Rituximab and Nivolumab in Combination for ...\"\nThis is a phase II trial testing venetoclax, rituximab and nivolumab for treating patients with chronic lymphocytic leukemia/small lymphocytic leukemia with Richter's transformation.\n\nFrom result [7]:\nhttps://aging.networkofcare.org/sanmateo/CommunityResources/ClinicalTrials/Detail/NCT06247540\n\"Venetoclax, Rituximab and Nivolumab in Combination for the ...\"\n\nSo NCT06247540 is a cancer trial involving venetoclax, rituximab and nivolumab for Richter's transformation, not an MRI trial.\n\nNow, let me check if there are any press releases, investor presentations, or public statements by Northwestern University about this specific trial (NCT06247540) that mention safety issues, adverse events, trial termination, or regulatory actions.\n\nLooking through all the search results:\n\n1. Result [1] - Northwestern Medicine clinical trials page - mentions various MRI trials but not NCT06247540\n2. Result [2] - Feinberg Labs clinical trials - mentions various trials but not NCT06247540\n3. Result [3] - ClinicalTrials.gov for NCT06247540 - describes the trial but doesn't mention any Northwestern University press releases or safety issues\n4. Result [4] - ClinConnect for NCT01130545 - an MRI trial but not NCT06247540\n5. Result [5] - ALS Center clinical trials - mentions an MRI trial (NCT06735", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Magnetic Resonance Imaging"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "57": {"nct_id": "NCT06247540", "drug_name": "Nivolumab", "intervention_type": "BIOLOGICAL", "drug_description": "Receive IV", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.552115", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.733735", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL2108738", "pref_name": "NIVOLUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Nivolumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 2, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.38, "clustering_coefficient": 5.69}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41231502", "title": "Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.", "authors": [{"name": "Carlino MS", "authtype": "Author", "clusterid": ""}, {"name": "Gao B", "authtype": "Author", "clusterid": ""}, {"name": "Michael M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41188808", "title": "Effects of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol levels in patients with metastatic renal cell carcinoma: a retrospective study.", "authors": [{"name": "Hataya Y", "authtype": "Author", "clusterid": ""}, {"name": "Kurata M", "authtype": "Author", "clusterid": ""}, {"name": "Murabe K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41176489", "title": "Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab.", "authors": [{"name": "Jespersen MS", "authtype": "Author", "clusterid": ""}, {"name": "Palshof JAE", "authtype": "Author", "clusterid": ""}, {"name": "Fristrup N", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41163864", "title": "Adherence to CheckMate 577 Within a Community Health Care System in the First 2 Years After Approval.", "authors": [{"name": "Campbell JM", "authtype": "Author", "clusterid": ""}, {"name": "Louie BE", "authtype": "Author", "clusterid": ""}, {"name": "White PT", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41138165", "title": "Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.", "authors": [{"name": "Nguyen MK", "authtype": "Author", "clusterid": ""}, {"name": "Jelinek M", "authtype": "Author", "clusterid": ""}, {"name": "Singh A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Nivolumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Nivolumab by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds for Nivolumab (Opdivo) specifically related to Northwestern University. Let me go through each result carefully.\n\nResult 1: About FDA rejecting rivoceranib plus camrelizumab for liver cancer - not relevant to Nivolumab or Northwestern University.\n\nResult 2: About nivolumab safety from FDA Adverse Event Analysis - discusses safety signals but doesn't mention Northwestern University or specific warning letters/clinical holds.\n\nResult 3: FDA untitled letters - lists various letters but doesn't specifically mention Nivolumab or Northwestern University.\n\nResult 4: Another nivolumab safety analysis from FAERS - discusses safety profile but doesn't mention Northwestern University or specific warning letters/clinical holds.\n\nResult 5: Mentions a FOIA request about Jeffrey Sosman, MD at Northwestern University and FDA audits. It says: \"The inquiry is about Jeffrey Sosman, MD at Northwestern University. We are requesting information on FDA audits for Dr. Sosman and outcomes from the audit...\" and also mentions \"2022-6965,Scot Middlebrook,11/01/2022,\"In August 2015, a drug trial NCT00045968 for DCVAX-L from Northwest Biotherapeutics was put on halt for \"regulatory review\", per the companies statements. Halt lasted 18 months.\" This mentions Northwestern University but seems to be about a different drug (DCVAX-L) not Nivolumab.\n\nResult 6: About FDA lifting a partial clinical hold on Opdivo (nivolumab) based combination study in Multiple Myeloma. This is relevant! It states: \"The US Food and Drug Administration (FDA) lifted a partial clinical hold placed on CA209-602 (CheckMate -602), a randomized, open-label Phase 3 study.\" This mentions a clinical hold on a nivolumab study, but doesn't specifically connect it to Northwestern University.\n\nResult 7: About nivolumab and ipilimumab in microsatellite instability - mentions a clinical trial NCT04088500 but doesn't connect it to Northwestern University or mention warning letters/clinical holds.\n\nResult 8: About combination immunotherapy showing no additional", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Nivolumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about external safety evidence for clinical trial NCT06247540.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Northwestern University\n- Specifically about clinical trial NCT06247540 for Nivolumab\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT06247540 is from the search results:\n\nFrom results [3] and [5], I can see that NCT06247540 is a phase II trial titled \"Venetoclax, Rituximab and Nivolumab in Combination for the...\" which tests how well venetoclax, rituximab and nivolumab work in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter's transformation.\n\nKey details about NCT06247540:\n- It's a phase II trial\n- Testing combination of venetoclax, rituximab and nivolumab\n- For patients with Richter's transformation\n- Primary objective: determine preliminary efficacy in terms of overall response rate\n- Secondary objective: determine safety and tolerability of the combination\n\nNow, I need to check if there are any company press releases, investor presentations, or public statements by Northwestern University about this specific trial (NCT06247540) that mention safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results:\n\nResult [1]: About NCT02595944 (ALCHEMIST trial), not relevant to NCT06247540\n\nResult [2]: About FDA placing partial clinical holds on 3 nivolumab myeloma trials (CheckMate-602, CheckMate-039, and CA204142), but these are different trials than NCT06247540\n\nResult [3]: Describes NCT06247540 but doesn't contain any safety issues, adverse events, trial termination reasons, or regulatory actions specific to this trial\n\nResult [4]: About NCT03668119 (CheckMate ", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Nivolumab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "58": {"nct_id": "NCT06247540", "drug_name": "Positron Emission Tomography", "intervention_type": "PROCEDURE", "drug_description": "Undergo PET/CT", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.552561", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.771468", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "P16257", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q5S007", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Positron Emission Tomography", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 2, "interactions": [{"protein_a": "LRRK2", "protein_b": "DNM1L", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "MSN", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "PINK1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "HSP90AA1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "SFN", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "GAK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "SNCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "PRKN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "PARK7", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "LRRK2", "protein_b": "RAB29", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GAK", "protein_b": "RAB29", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SNCA", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PARK7", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PRKN", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PINK1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "PARK7", "protein_b": "DNM1L", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "PARK7", "protein_b": "SNCA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PARK7", "protein_b": "PINK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PARK7", "protein_b": "PRKN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRKN", "protein_b": "DNM1L", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "PRKN", "protein_b": "SNCA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRKN", "protein_b": "PINK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAB29", "protein_b": "SNCA", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "PINK1", "protein_b": "DNM1L", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "PINK1", "protein_b": "SNCA", "combined_score": 0.975, "interaction_type": "physical"}], "network_features": {"avg_degree": 4.55, "clustering_coefficient": 2.27}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41216639", "title": "Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).", "authors": [{"name": "Morgans AK", "authtype": "Author", "clusterid": ""}, {"name": "Chehrazi-Raffle A", "authtype": "Author", "clusterid": ""}, {"name": "Niazi T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41207531", "title": "Association between aortic calcification and primary intimal tear in type B aortic dissection.", "authors": [{"name": "Lu W", "authtype": "Author", "clusterid": ""}, {"name": "Cao L", "authtype": "Author", "clusterid": ""}, {"name": "Luan S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41197684", "title": "IV IL-1 receptor antagonist reduces pain sensitivity and enhances brain endorphin release during a standardized, experimental, acute pain challenge: A BESH clinical trial.", "authors": [{"name": "Prossin AR", "authtype": "Author", "clusterid": ""}, {"name": "Holihan J", "authtype": "Author", "clusterid": ""}, {"name": "Cox CS Jr", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41196333", "title": "Preclinical development of [(18)F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy.", "authors": [{"name": "Haider A", "authtype": "Author", "clusterid": ""}, {"name": "Xiao Z", "authtype": "Author", "clusterid": ""}, {"name": "Chen J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41193908", "title": "ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.", "authors": [{"name": "Woo S", "authtype": "Author", "clusterid": ""}, {"name": "Russo L", "authtype": "Author", "clusterid": ""}, {"name": "Withey SJ", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Positron Emission Tomography+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Positron Emission Tomography by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Positron Emission Tomography (PET) by Northwestern University.\n\nFirst, I need to identify which search results are relevant to the query:\n- The query is specifically about FDA warning letters or clinical holds related to Positron Emission Tomography (PET) at Northwestern University\n- I need to find specific dates, reasons, and safety issues cited\n\nLet me go through each search result:\n\n[1] This is about an FDA warning letter to Northwestern University regarding Dr. Richard Burt's stem cell trials. It mentions failure to report patient deaths and other issues, but it's not related to PET imaging. This is about stem cell trials, not PET.\n\n[2] This appears to be about Medicare coverage for PET for solid tumors, mentioning Northwestern University Feinberg School of Medicine, but it doesn't discuss any FDA warning letters or clinical holds.\n\n[3] This is a PDF of the FDA Warning Letter to Richard K. Burt, M.D. dated 2016-11-15. It discusses issues with adverse event reporting in what appears to be a stem cell trial, not PET imaging.\n\n[4] This is about Society for Immunotherapy of Cancer clinical practice guidelines, mentioning PET/CT but not in relation to Northwestern University or FDA warning letters.\n\n[5] This is an FDA warning letter to PETNET Solutions Inc. regarding CGMP violations for PET drugs, but it's not related to Northwestern University.\n\n[6] This appears to be a health care plan booklet from McGaw Medical Center of Northwestern University, but doesn't mention FDA warning letters.\n\n[7] This is a spreadsheet request for firms that received FDA Warning Letters, but doesn't specifically mention Northwestern University in relation to PET.\n\n[8] This is a general page about FDA Warning Letters, but doesn't provide specific information about Northwestern University and PET.\n\n[9] This is a Northwestern University Single Audit Report that mentions \"MALDI/PET Early Warning Imaging System for Lethal Prostate Cancer\" but doesn't discuss FDA warning letters.\n\n[10] This is about an FDA warning letter to Columbia University Medical Center regarding radiopharma drugs, not Northwestern University.\n\n[11] This is about policies for the Center for Translational Imaging at Northwestern University, but doesn't mention FDA warning letters.\n\n[12] This is about diagnostic performance of a PSMA-target", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Positron Emission Tomography. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about clinical trial NCT06247540 for Positron Emission Tomography, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions. I'll go through each search result to see if it contains relevant information.\n\nFirst, let me identify which search results mention NCT06247540:\n\nResult [9] mentions: \"San Mateo Clinical Trial Venetoclax, Rituximab and Nivolumab in ... Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic ...\"\n\nResult [13] mentions: \"Venetoclax, Rituximab and Nivolumab in Combination for the ... Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic ...\"\n\nThese appear to be referring to the same trial NCT06247540, which involves Venetoclax, Rituximab and Nivolumab, and includes PET/CT imaging as part of the procedure. However, these results don't provide specific information about safety issues, adverse events, trial termination reasons, or regulatory actions related to the PET imaging component.\n\nLet me check if any other results provide relevant information about this specific trial or PET imaging safety:\n\nResult [1] is about PET/CT imaging services at Northwestern Medicine, but doesn't mention NCT06247540 specifically.\n\nResult [2] is about a different clinical trial (Safety and Efficacy of Positron Emission Tomography with MNI-558), which is completed but not NCT06247540.\n\nResult [3] is about PET scans at Northwestern Medicine, general information.\n\nResult [4] is about 68Ga-Dotatoc PET for NETs, which is a different trial (NCT02359500).\n\nResult [5] is about Nuclear Medicine at Northwestern Radiology, general information.\n\nResult [6] appears to be about 68Ga-PSMA PET/CT but doesn't provide specific details.\n\nResult [7] is a PubMed article about PET/CT technology and applications.\n\nResult [8] appears to be about a PET", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Positron Emission Tomography"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "59": {"nct_id": "NCT06247540", "drug_name": "Rituximab", "intervention_type": "BIOLOGICAL", "drug_description": "Receive IV", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.552996", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.808308", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1201576", "pref_name": "RITUXIMAB", "targets": [{"chembl_id": null, "uniprot_id": "P11836", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Rituximab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 1, "interactions": [{"protein_a": "CD22", "protein_b": "MS4A1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD79B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD79A", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "CD19", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "TCL1A", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "POU2AF1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "MS4A1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "CD19", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD79A", "protein_b": "CD79B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MS4A3", "protein_b": "MS4A1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "POU2AF1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "TCL1A", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "MS4A1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD19", "protein_b": "CD79B", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BANK1", "protein_b": "MS4A1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "CD79B", "protein_b": "POU2AF1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CD79B", "protein_b": "MS4A1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "POU2AF1", "protein_b": "MS4A1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "TCL1A", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "IGHV3-43D", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MS4A1", "protein_b": "IGKV2D-29", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "IGHV3-43D", "protein_b": "IGKV2D-29", "combined_score": 0.972, "interaction_type": "physical"}], "network_features": {"avg_degree": 4.0, "clustering_coefficient": 2.0}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41225396", "title": "Spectrum and outcomes of thrombotic microangiopathies in nephrology: a 17-year cohort from a North African center.", "authors": [{"name": "Mrabet S", "authtype": "Author", "clusterid": ""}, {"name": "Dardour G", "authtype": "Author", "clusterid": ""}, {"name": "Boukadida R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41223495", "title": "Chemotherapy-Free Salvage Therapy with Rituximab, Lenalidomide, and Poseltinib in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Multi-Center, Phase II Study.", "authors": [{"name": "Kim DH", "authtype": "Author", "clusterid": ""}, {"name": "An S", "authtype": "Author", "clusterid": ""}, {"name": "Ahn H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41217554", "title": "Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies.", "authors": [{"name": "Mirza W", "authtype": "Author", "clusterid": ""}, {"name": "Dadan S", "authtype": "Author", "clusterid": ""}, {"name": "Ahmad E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41210898", "title": "Warm Autoimmune Haemolytic Anaemia Management in Asia-Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review.", "authors": [{"name": "Choi P", "authtype": "Author", "clusterid": ""}, {"name": "Hoi A", "authtype": "Author", "clusterid": ""}, {"name": "Fu R", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41210897", "title": "Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman Disease: A Retrospective Analysis of an Italian Cohort.", "authors": [{"name": "Cristinelli C", "authtype": "Author", "clusterid": ""}, {"name": "Merli M", "authtype": "Author", "clusterid": ""}, {"name": "Lucioni M", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Rituximab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Rituximab by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Rituximab by Northwestern University.\n\nFirst, let me identify which results might be relevant to the query:\n\n1. The query is specifically about:\n   - FDA warning letters or clinical holds\n   - Related to Rituximab (a specific drug)\n   - From Northwestern University\n   - Need specific dates, reasons, and safety issues cited\n\nLet me go through the search results:\n\nResult [1]: This discusses an FDA warning letter to Northwestern University regarding Dr. Richard Burt's stem cell trials. It mentions a warning letter from November 2016, but it's about stem cell trials, not Rituximab specifically.\n\nResult [2]: This is about recent FDA cancer drug safety warnings, mentioning duvelisib, denosumab, and ciltacabtagene autoleucel, but not Rituximab or Northwestern University specifically.\n\nResult [3]: This discusses progressive multifocal leukoencephalopathy (PML) after rituximab therapy. It mentions FDA actions regarding rituximab safety, but not specifically related to Northwestern University.\n\nResult [4]: This appears to be a PDF of a drug label for what seems to be Rituxan (rituximab), with information about PML and other safety concerns.\n\nResult [5]: This mentions Burt's Northwestern stem cell MS trial and references an FDA warning letter, but again, it's about stem cell trials, not Rituximab.\n\nResult [6]: This discusses an FDA black box warning for CD20-directed monoclonal antibodies, specifically rituximab and ofatumumab, regarding hepatitis B reactivation.\n\nResult [7]: This appears to be an FDA query about Jeffrey Sosman, MD at Northwestern University, but doesn't provide specific information about warning letters or clinical holds.\n\nResult [8]: This is a Wikipedia page about Rituximab, mentioning various adverse events including PML and hepatitis B reactivation.\n\nResult [9]: This appears to be a technology assessment document from CMS, but the snippet doesn't provide specific information about FDA warning letters.\n\nResult [10]: This appears to be a drug label for Rituxan (rituximab), with warnings about infusion reactions, mucocutaneous reactions, hepatitis B virus reactivation, and PML.\n\nResult [11]: This mentions a boxed", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Rituximab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to compile a JSON summary about external safety evidence for clinical trial NCT06247540, which is testing \"Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia.\"\n\nFirst, I need to understand what information I have about this trial:\n\n1. From result [1], I can see this is a phase II trial (NU 23H01) with the identifier NCT06247540. The primary objective is to determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with the combination of venetoclax, nivolumab, and rituximab in patients with Richter's transformation. A secondary objective is to determine the safety and tolerability of this combination.\n\n2. Results [2], [3], [4], [5], [6], and [7] all reference the same trial (NCT06247540 or NCI-2023-08755) but don't provide additional specific safety information.\n\n3. Result [8] appears to be about a different trial (NU 12H09) involving Brentuximab Vedotin Plus Rituximab.\n\n4. Result [9] is general information about Rituximab as a drug, not specific to this trial.\n\n5. Result [10] is about a different trial (NCT03267433) involving rituximab.\n\nThe user is asking me to search for \"Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Rituximab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\"\n\nLooking at the search results provided, I don't see any press releases, investor presentations, or public statements from Northwestern University specifically addressing safety issues, adverse events, trial termination, or regulatory actions for this trial. The results mainly contain registration information about the trial from clinicaltrials.gov and NIH RePORTER.\n\nFrom result [1], I can see some exclusion criteria related to safety:\n- \"Patients who have adverse events due to agents administered \u2265 30 days", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Rituximab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "60": {"nct_id": "NCT06247540", "drug_name": "Venetoclax", "intervention_type": "DRUG", "drug_description": "Receive PO", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "start_date": "2024-03-29", "completion_date": "2031-12-29", "sponsor": "Northwestern University", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.553441", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:52.844240", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137309", "pref_name": "VENETOCLAX", "targets": [{"chembl_id": "CHEMBL4860", "ic50_values": [{"value": 1.0, "units": "nM"}, {"value": 7.39, "units": "nM"}, {"value": 7.4, "units": "nM"}, {"value": 230.0, "units": "nM"}, {"value": 1.0, "units": "nM"}, {"value": 100.0, "units": "nM"}, {"value": 23.0, "units": "nM"}, {"value": 0.24, "units": "nM"}, {"value": 25.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 0.34, "units": "nM"}, {"value": 28.0, "units": "nM"}, {"value": 1.2, "units": "nM"}, {"value": 2.3, "units": "nM"}], "uniprot_id": "C9JHD5"}, {"chembl_id": "CHEMBL4361", "ic50_values": [{"value": 4000.0, "units": "nM"}], "uniprot_id": "B2R6B2"}, {"chembl_id": "CHEMBL2366159", "ic50_values": [{"value": 1.5, "units": "nM"}, {"value": 330.0, "units": "nM"}, {"value": 6.0, "units": "nM"}, {"value": 1.8, "units": "nM"}, {"value": 4.3, "units": "nM"}, {"value": 4.3, "units": "nM"}, {"value": 110.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 10000.0, "units": "nM"}, {"value": 5500.0, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 26.67, "units": "nM"}, {"value": 3180.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296391", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL4625", "ic50_values": [{"value": 52.7, "units": "nM"}, {"value": 52.7, "units": "nM"}, {"value": 157.0, "units": "nM"}, {"value": 65.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 55.0, "units": "nM"}, {"value": 190.0, "units": "nM"}], "uniprot_id": "E1P5L6"}, {"chembl_id": "CHEMBL4296505", "ic50_values": [{"value": 11.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614882", "ic50_values": [{"value": 2700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366315", "ic50_values": [{"value": 94000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4680030", "ic50_values": [{"value": 1400.0, "units": "nM"}, {"value": 1520.0, "units": "nM"}, {"value": 1290.0, "units": "nM"}, {"value": 1570.0, "units": "nM"}], "uniprot_id": "A0A0A0MSK8"}, {"chembl_id": "CHEMBL399", "ic50_values": [{"value": 20000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL383", "ic50_values": [{"value": 77.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL3706568", "ic50_values": [{"value": 20000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL3108645", "ic50_values": [{"value": 1700.0, "units": "nM"}], "uniprot_id": "A2A2T2"}, {"chembl_id": "CHEMBL3588738", "ic50_values": [{"value": 2400.0, "units": "nM"}], "uniprot_id": "Q96L73"}, {"chembl_id": "CHEMBL3108646", "ic50_values": [{"value": 1300.0, "units": "nM"}], "uniprot_id": "B7ZL11"}, {"chembl_id": "CHEMBL613835", "ic50_values": [{"value": 440.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296489", "ic50_values": [{"value": 6260.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614177", "ic50_values": [{"value": 2823.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL392", "ic50_values": [{"value": 1500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL6044", "ic50_values": [], "uniprot_id": "Q16548"}, {"chembl_id": "CHEMBL3817", "ic50_values": [{"value": 55.0, "units": "nM"}], "uniprot_id": "O14803"}, {"chembl_id": "CHEMBL3397", "ic50_values": [{"value": 1770.0, "units": "nM"}], "uniprot_id": "P11712"}], "has_uniprot_targets": true, "search_name": "Venetoclax"}, "ppi_enrichment": {"uniprot_count": 10, "interactions": [{"protein_a": "BIK", "protein_b": "BAX", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BAK1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "PMAIP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2L11", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BCL2L11", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BECN1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PMAIP1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BAX", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BAK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BECN1", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BAD", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "PMAIP1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BAK1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BAK1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BAK1", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BNIP3", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L11", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BNIP3", "protein_b": "BCL2L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BNIP3", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BAD", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BAD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L11", "protein_b": "BAD", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "BCL2L11", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAD", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BAX", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BID", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BCL2L1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BAK1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BBC3", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BECN1", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "MCL1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "PMAIP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BCL2L2", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BECN1", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "PMAIP1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BBC3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BAK1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BID", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "MCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "PMAIP1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BBC3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BCL2L11", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "MCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BAK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BAK1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BBC3", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "MCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HUWE1", "protein_b": "MCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BAK1", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L11", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "MCL1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MCL1", "protein_b": "BCL2L1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MCL1", "protein_b": "BBC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MCL1", "protein_b": "BAK1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MCL1", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BBC3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BBC3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L11", "protein_b": "BBC3", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BAX", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BAK1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "PMAIP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "HRK", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2L11", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "BCL2L11", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "PMAIP1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BID", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BCL2L11", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BECN1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PMAIP1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BAX", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BAK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BECN1", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BAD", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "PMAIP1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BAK1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BID", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAX", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BAD", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "PMAIP1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BCL2L11", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BAK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BAK1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BAK1", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L11", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BECN1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BAD", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BAD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L11", "protein_b": "BAD", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "CALM3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "FKBP1B", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "CASQ1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "TRDN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "ASPH", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "TRDN", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "FKBP1B", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR3", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "JPH1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "FKBP1B", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "CASQ1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "ASPH", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "CASQ1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "ASPH", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "RYR1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "ASPH", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "RYR3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "RYR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "CASQ1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "FKBP1B", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "CASQ1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "RYR3", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "FKBP1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASQ1", "protein_b": "RYR3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CASQ1", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "ASPH", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ASPH", "protein_b": "RYR3", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "ASPH", "protein_b": "FKBP1B", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "FKBP1B", "protein_b": "RYR3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC11", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC15", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "NSD2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC17", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC13", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H2AC6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3-4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "BRD4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C13", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "NSD2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3-4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3C13", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NKX2-5", "protein_b": "NSD2", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3-4", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC11", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC15", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC17", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H2AC13", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "NSD2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "NSD2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC15", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC6", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC11", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "H2AC13", "protein_b": "H2AC17", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "H2AC11", "protein_b": "H2AC15", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "H2AC11", "protein_b": "NSD2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "H2AC11", "protein_b": "H2AC6", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "H2AC11", "protein_b": "H2AC17", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "H2AC17", "protein_b": "NSD2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "H2AC17", "protein_b": "H2AC15", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "H2AC17", "protein_b": "H2AC6", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "H3-4", "protein_b": "NSD2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "H2AC6", "protein_b": "H2AC15", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "H2AC6", "protein_b": "NSD2", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "NSD2", "protein_b": "H2AC15", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PLOD1", "protein_b": "NSD1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "PLOD1", "protein_b": "CAMKMT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "NSD1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C13", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZNF496", "protein_b": "NSD1", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "DDX10", "protein_b": "NSD1", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "DDX10", "protein_b": "NUP98", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "NUP98", "protein_b": "KDM5A", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NUP98", "protein_b": "PHF23", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NUP98", "protein_b": "NSD1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "PHF23", "protein_b": "NSD1", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "PHF23", "protein_b": "KDM5A", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "NSD1", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "KDM5A", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C12", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "NSD1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "KDM5A", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CAMKMT", "protein_b": "NSD1", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "KDM5A", "protein_b": "NSD1", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "NSD3", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "BRD3", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3-2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3-4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3-3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "BRD4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C13", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3C12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H4C6", "protein_b": "H3-5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "BRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3-5", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3-2", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3-4", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C12", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "H3C13", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "NSD3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "H3-3B", "protein_b": "BRD4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3C1", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "BRD3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3-5", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3-2", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3-4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3C12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "H3C13", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "BRD4", "protein_b": "NSD3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BRD3", "protein_b": "H3C12", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "BRD3", "protein_b": "NSD3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3C1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3-2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3-5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3C13", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3C12", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "NSD3", "protein_b": "H3-4", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3-5", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3-2", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3-4", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "H3C13", "protein_b": "H3C12", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "H3-5", "protein_b": "H3C1", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "H3-5", "protein_b": "H3-4", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "H3-5", "protein_b": "H3C12", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "H3-5", "protein_b": "H3-2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H3-4", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H3-2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "H3C12", "protein_b": "H3C1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "H3-4", "protein_b": "H3-2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "H3-4", "protein_b": "H3C1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "H3C1", "protein_b": "H3-2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BAK1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "PMAIP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2A1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BMF", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "HRK", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "BIK", "protein_b": "BCL2L11", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "BCL2L11", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "BMF", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "PMAIP1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "HRK", "protein_b": "BCL2A1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "FKBP5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "HSP90AB1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "HSP90AA1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "BMF", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "BID", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "BAK1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "PMAIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2A1", "protein_b": "BCL2L11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "PMAIP1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BCL2L11", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "BID", "protein_b": "BAK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BAK1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BMF", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "PMAIP1", "protein_b": "BCL2L11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BMF", "protein_b": "BCL2L11", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BAK1", "protein_b": "BCL2L11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "YWHAQ", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "YWHAE", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "YWHAB", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "YWHAZ", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "BAD", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "YWHAH", "protein_b": "RAF1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "YWHAE", "protein_b": "YWHAB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "YWHAE", "protein_b": "BAD", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "YWHAE", "protein_b": "YWHAQ", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "YWHAE", "protein_b": "RAF1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "YWHAE", "protein_b": "YWHAZ", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "BCL2", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "RAF1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PRKACA", "protein_b": "BAD", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "YWHAB", "protein_b": "YWHAQ", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "YWHAB", "protein_b": "BAD", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "YWHAB", "protein_b": "YWHAZ", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "YWHAB", "protein_b": "RAF1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "RAF1", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "AKT1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2L1", "protein_b": "BAD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "YWHAQ", "protein_b": "BAD", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "YWHAQ", "protein_b": "YWHAZ", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "YWHAQ", "protein_b": "RAF1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "BAD", "protein_b": "RAF1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "BAD", "protein_b": "YWHAZ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "BAD", "protein_b": "AKT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "BAD", "protein_b": "BCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "YWHAZ", "protein_b": "AKT1", "combined_score": 0.851, "interaction_type": "physical"}, {"protein_a": "YWHAZ", "protein_b": "RAF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCL2", "protein_b": "RAF1", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "BCL2", "protein_b": "AKT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAF1", "protein_b": "AKT1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}], "network_features": {"avg_degree": 9.31, "clustering_coefficient": 4.65}}, "failure_enrichment": {"aact_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "aact_documents": [], "pubmed_results": [{"pmid": "41212498", "title": "Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.", "authors": [{"name": "Izutsu K", "authtype": "Author", "clusterid": ""}, {"name": "Watanabe M", "authtype": "Author", "clusterid": ""}, {"name": "Toubai T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41193417", "title": "Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.", "authors": [{"name": "Lee CK", "authtype": "Author", "clusterid": ""}, {"name": "Kartikasari AER", "authtype": "Author", "clusterid": ""}, {"name": "Bound NT", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41192867", "title": "[Treatment of unfit acute myeloid leukemia].", "authors": [{"name": "Wakita S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41175112", "title": "Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.", "authors": [{"name": "Munir T", "authtype": "Author", "clusterid": ""}, {"name": "Le\u00e3o D", "authtype": "Author", "clusterid": ""}, {"name": "Messahel B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41151983", "title": "Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.", "authors": [{"name": "Tan Y", "authtype": "Author", "clusterid": ""}, {"name": "Zhao X", "authtype": "Author", "clusterid": ""}, {"name": "Suo X", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.", "detailed_description": "PRIMARY OBJECTIVE:\n\nI. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).\n\nII. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIII. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nIV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nV. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.\n\nEXPLORATORY OBJECTIVES:\n\nI. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:\n\nIa. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.\n\nEXPLORATORY STUDIES OBJECTIVES:\n\nI. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.\n\nII. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.\n\nOUTLINE: This is a dose-escalation study of venetoclax.\n\nPatients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment (venetoclax, rituximab, nivolumab)", "type": "EXPERIMENTAL", "description": "Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.", "intervention_names": ["Procedure: Biopsy", "Procedure: Biospecimen Collection", "Procedure: Bone Marrow Biopsy", "Procedure: Computed Tomography", "Procedure: Magnetic Resonance Imaging", "Biological: Nivolumab", "Procedure: Positron Emission Tomography", "Biological: Rituximab", "Drug: Venetoclax"]}], "interventions": [{"type": "PROCEDURE", "name": "Biopsy", "description": "Undergo tissue biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Biospecimen Collection", "description": "Undergo blood sample collection", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Bone Marrow Biopsy", "description": "Undergo bone marrow biopsy", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Computed Tomography", "description": "Undergo PET/CT, CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Magnetic Resonance Imaging", "description": "Undergo MRI", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Nivolumab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "PROCEDURE", "name": "Positron Emission Tomography", "description": "Undergo PET/CT", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "BIOLOGICAL", "name": "Rituximab", "description": "Receive IV", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}, {"type": "DRUG", "name": "Venetoclax", "description": "Receive PO", "arm_group_labels": ["Treatment (venetoclax, rituximab, nivolumab)"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Northwestern University+NCT06247540+terminated", "https://www.google.com/search?q=Northwestern University+Venetoclax+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Venetoclax by Northwestern University. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a comprehensive response.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for Venetoclax by Northwestern University\n- Specific dates, reasons, and safety issues cited\n\nFirst, I need to check if there are any mentions of Northwestern University in the search results related to FDA warning letters or clinical holds for Venetoclax.\n\nLet me go through the search results:\n\nResult [1]: FDA warning about safety concerns related to investigational use of Venclexta (venetoclax) for multiple myeloma. Date: March 21, 2019. It mentions the FDA requiring discontinuation of patients in a clinical trial due to increased risk of death when Venclexta was combined with bortezomib compared to the control group. However, there's no mention of Northwestern University.\n\nResult [2]: FDA approval of venetoclax for CLL or SLL. No mention of Northwestern University or clinical holds.\n\nResult [3]: FDA warning about risks associated with investigational use of Venclexta in Multiple Myeloma. Date: March 21, 2019. It references the BELLINI clinical trial (NCT02755597, Study M14-031) and mentions an increased risk of death (hazard ratio of 2.03). No mention of Northwestern University.\n\nResult [4]: AbbVie announcement that FDA lifted partial clinical hold on Phase 3 study of Venetoclax in patients with multiple myeloma. Mentions that in March 2019, FDA placed a partial clinical hold on all trials evaluating venetoclax for multiple myeloma following review of BELLINI trial data. No mention of Northwestern University.\n\nResult [5]: FDA grants regular approval to venetoclax for untreated acute myeloid leukemia. No mention of clinical holds or Northwestern University.\n\nResult [6]: FDA places partial clinical hold on trials involving venetoclax in multiple myeloma. Date: March 19, 2019. References the BELLINI trial showing higher death rate (21% vs 11%) in the venetoclax arm. No mention of Northwestern University.\n\nResult [7]: AbbVie receives FDA accelerated approval of Venclexta. No mention of clinical holds or Northwestern", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Northwestern University"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Northwestern University about clinical trial NCT06247540 for Venetoclax. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by Northwestern University regarding clinical trial NCT06247540 for Venetoclax, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each search result to see what information is available:\n\nResult [1]: This is from clinicaltrials.gov for study NCT06247540 titled \"Venetoclax, Rituximab and Nivolumab in Combination for the...\" It's a phase II trial for chronic lymphocytic leukemia/small lymphocytic lymphoma. It provides some inclusion/exclusion criteria but doesn't mention any safety issues, adverse events, trial termination, or regulatory actions. It does mention that patients must have recovered from adverse events due to agents administered \u2265 30 days prior to registration to \u2264 grade 2, but this is part of the eligibility criteria, not a report of actual safety issues in the trial.\n\nResult [2]: This is from Larvol Sigma showing the same trial NCT06247540 but for Richter's Transformation Arising From Chronic Lymphocytic Leukemia. No safety information is provided.\n\nResult [3]: This is from NIH RePORTER showing funding information for Northwestern University related to NCT06247540. No safety information is provided.\n\nResult [4]: This is about a different trial (NCT07012447) for Venetoclax + Azacytidine for newly diagnosed ETP-like ALL and T-ALL. Not relevant to our specific query about NCT06247540.\n\nResult [5]: This is from NIH RePORTER about the Robert H. Lurie Comprehensive Cancer Center at Northwestern University mentioning the Venetoclax, Rituximab and Nivolumab trial. No safety information is provided.\n\nResult [6]: This is an ASH conference paper about Venetoclax in combination with decitabine or azacitidine in AML, but it's not about the specific trial NCT06247540. It does discuss safety outcomes like infections, neutropenia, anemia, thrombocytopenia, and tumor lysis syndrome, but these are for a different study.\n\nResult [7]:", "citations": [], "search_params": {"company": "Northwestern University", "nct_id": "NCT06247540", "drug_name": "Venetoclax"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed trial information states the official reason for the trial's withdrawal as \"Funding,\" indicating that the trial was terminated due to administrative issues related to a lack of funding, rather than safety or efficacy concerns. The trial was not terminated due to any reported adverse events or lack of efficacy, but rather due to operational and financial problems.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:52.549135", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1212}}, "61": {"nct_id": "NCT06050954", "drug_name": "Monitoring", "intervention_type": "DIAGNOSTIC_TEST", "drug_description": "active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Change in standard of care.", "title": "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)", "start_date": "2023-09-30", "completion_date": "2032-01-31", "sponsor": "Fox Chase Cancer Center", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.553886", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:55.328527", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q8WXI7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q86VB7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9FIR9", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "F4KG58", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O00408", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Monitoring", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "LGALS3", "protein_b": "MUC16", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "MUC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC3A", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC4", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC5AC", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC16", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC12", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC15", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "MUC17", "protein_b": "MUC13", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC4", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC12", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC5AC", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC1", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC15", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MUC3A", "protein_b": "MUC16", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "MSLN", "protein_b": "MUC1", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "MSLN", "protein_b": "MUC16", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC15", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC5AC", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC12", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MUC16", "protein_b": "MUC4", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MUC4", "protein_b": "MUC5AC", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MUC4", "protein_b": "MUC12", "combined_score": 0.851, "interaction_type": "physical"}, {"protein_a": "MUC4", "protein_b": "MUC15", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MUC4", "protein_b": "MUC13", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MUC4", "protein_b": "MUC1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MUC15", "protein_b": "MUC5AC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "MUC15", "protein_b": "MUC13", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "MUC15", "protein_b": "MUC12", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MUC15", "protein_b": "MUC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MUC12", "protein_b": "MUC5AC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "MUC12", "protein_b": "MUC1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MUC12", "protein_b": "MUC13", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "MUC1", "protein_b": "MUC13", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "MUC1", "protein_b": "MUC5AC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MUC13", "protein_b": "MUC5AC", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "MYH9", "protein_b": "CD163", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "HPX", "protein_b": "CD163", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "HPX", "protein_b": "HP", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "MRC1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "IL6", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "VSIG4", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "CD163", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "IL6", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "CD163", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "MRC1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "VSIG4", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "IL10", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "IL6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "GP2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD163", "protein_b": "CD36", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GP2", "protein_b": "CD36", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL6", "protein_b": "CD36", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "IL6", "protein_b": "MRC1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IL6", "protein_b": "IL10", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL10", "protein_b": "MRC1", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ENPP3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ENPP1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "ENPP3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "PDE2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "ENPP1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "AK3", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "DCK", "protein_b": "APRT", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "AK3", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ENPP3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ADK", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ENPP1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ENPP3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ENPP1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "AK3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ADK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "ENPP1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "ENPP3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "AK3", "protein_b": "ENPP3", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AK3", "protein_b": "ENPP1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AK3", "protein_b": "ADK", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ENPP3", "protein_b": "ENPP1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ENPP3", "protein_b": "ADK", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADK", "protein_b": "ENPP1", "combined_score": 0.933, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.94, "clustering_coefficient": 2.97}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those that achieved disease control could prolong progression-free survival (overall survival benefit in JAVELIN may have been related to the lack of guaranteed crossover at time of progression). Of note, both of these studies showed consistency with regards to the magnitude of the PFS benefit which was \\~40% vs \\~20% at 6-months with maintenance ICI compared to BSC/placebo. Maintenance avelumab is now category 1 on the NCCN guidelines.\n\nHowever, some patients prefer prolonged chemotherapy responses and literature supports a treatment break without effecting longevity. The underlying risk resides in the selection of patients with some (currently difficult to diagnose) progressing rapidly. This trial proposes to use ctDNA to stratify chemo-responsive patients to active surveillance (i.e. a ctDNA responder referred to here as \"ctDNA-\") vs SOC maintenance pembrolizumab (ctDNA+). All patients will be treated with SOC chemotherapy and only patients with an objective (RECIST) response will be stratified.\n\nThis is a non-randomized phase 2 study with two arms based on ctDNA\n\n1. Pembrolizumab (ctDNA non-responder) maintenance therapy arm (SOC)\n2. Active surveillance arm (ctDNA responders) with serial ctDNA and crossover 1st line chemotherapy is based on physician discretion choice as described in the protocol. Patients with metastatic Urothelial Cancer are enrolled prior to initiation of SOC chemotherapy. Based on ORR (CR + PR), it is estimated that 75 patients will need to enroll onto the protocol to find 25 responders for the two arms.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Maintenance Therapy 200mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 200mg Pembrolizumab every six weeks via IV infusion.", "intervention_names": ["Drug: Pembrolizumab (200mg)"]}, {"label": "Maintenance Therapy 400mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 400mg Pembrolizumab every six weeks via IV infusion..", "intervention_names": ["Drug: Pembrolizumab (400mg)"]}, {"label": "Active Surveillance", "type": "OTHER", "description": "Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.", "intervention_names": ["Diagnostic Test: Monitoring"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab (200mg)", "description": "200mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 200mg Pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab (400mg)", "description": "400mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 400mg Pembrolizumab"]}, {"type": "DIAGNOSTIC_TEST", "name": "Monitoring", "description": "active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.", "arm_group_labels": ["Active Surveillance"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Fox Chase Cancer Center+NCT06050954+terminated", "https://www.google.com/search?q=Fox Chase Cancer Center+Monitoring+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Monitoring by Fox Chase Cancer Center. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically related to monitoring by Fox Chase Cancer Center. I'll go through each result to see if it contains relevant information.\n\nResult [1]: This is a PDF from Fox Chase Cancer Center about their cancer research and treatments. It mentions they conduct phase 1 clinical trials and have a bone marrow transplant department, but I don't see any specific FDA warning letters or clinical holds mentioned for Fox Chase Cancer Center.\n\nResult [2]: This is about FDA cancer drug safety warnings in general, but doesn't mention Fox Chase Cancer Center specifically.\n\nResult [3]: This is about safety and tolerability concepts in clinical trials, but doesn't mention Fox Chase Cancer Center or specific warning letters for them.\n\nResult [4]: This discusses FDA Warning Letters in general and how they reveal clinical trial oversight issues, but doesn't specifically mention Fox Chase Cancer Center.\n\nResult [5]: This is about FDA warning letters for companies marketing antibody tests during COVID-19, not related to Fox Chase Cancer Center.\n\nResult [6]: This is just the FDA's warning letters page, a general listing without specific information about Fox Chase.\n\nResult [7]: This appears to be a \"Notice of Non-Compliance Letter\" from the FDA to someone named Mantia-Smaldone, Gina M. It mentions \"Fox Chase Cancer Center is listed as the responsible party for this applicable clinical trial in the ClinicalTrials.gov data...\" This is the first direct reference to Fox Chase Cancer Center in relation to an FDA compliance issue. However, the document seems to be cut off and I don't have the full details of the non-compliance issue, dates, or specific safety concerns.\n\nResult [8]: This is a closed FDA FOIA log from July 2025, but doesn't appear to contain specific information about Fox Chase Cancer Center warning letters.\n\nResult [9]: This is an SEC filing that mentions \"fines, warning letters or holds on post-approval clinical studies\" and \"Fox Chase Cancer Center\" but doesn't provide specific details about any warning letters to Fox Chase.\n\nResult [10]: This appears to be a request for marketing materials related to a warning letter to Quincy Bioscience, not Fox Chase Cancer Center.\n\nResult [11]: This is an FDA list of clinical investigator inspections for names beginning with A-D, but I don't see Fox Chase Cancer Center specifically mentioned.\n\nResult [12", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Fox Chase Cancer Center"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Fox Chase Cancer Center about clinical trial NCT06050954 for Monitoring. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a comprehensive response.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Fox Chase Cancer Center\n- Specifically about clinical trial NCT06050954\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available about NCT06050954 and whether there are any press releases or public statements about safety issues for this specific trial.\n\nFrom search result [1], I can see that NCT06050954 is titled \"A Pilot Study of Circulating Tumor...\" and is related to transitional cell carcinoma of the urothelium (bladder cancer). It's a study at Fox Chase Cancer Center with Principal Investigator Benjamin Miron. The study involves patients with unresectable locally advanced or metastatic transitional cell carcinoma who are eligible for standard first-line platinum-based chemotherapy.\n\nFrom search result [9], I see more details about NCT06050954, which is titled \"A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)\" or \"CARMA\" for short. It was updated on November 8, 2023.\n\nNow, let me check if there are any press releases or public statements about safety issues, adverse events, trial termination, or regulatory actions specifically for NCT06050954:\n\nSearch result [2] mentions a Fox Chase trial related to chemotherapy for bladder cancer that was halted due to serious side effects. However, this appears to be from 2014 (based on the date \"May 30, 2014\" in the text) and involves Dr. Elizabeth R. Plimack. The trial described was halted when patients experienced serious side effects like heart attacks and blood clots. But this doesn't seem to be about NCT06050954 specifically, as NCT06050954 appears to be a more recent trial (updated November 2023 according to result [9]).\n\nLet me check the other results:\n\nResults [3], [4], [5], [6], [7], [8], and [10] don't appear to contain specific information about", "citations": [], "search_params": {"company": "Fox Chase Cancer Center", "nct_id": "NCT06050954", "drug_name": "Monitoring"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Change in standard of care,\" which indicates an administrative or operational issue rather than safety or efficacy concerns. The lack of detailed description and published results also suggests administrative or strategic reasons for the trial termination, rather than any specific safety or efficacy problems with the intervention.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:55.326947", "claude_model": "claude-3-haiku-20240307", "tokens_used": 836}}, "62": {"nct_id": "NCT06050954", "drug_name": "Pembrolizumab (200mg)", "intervention_type": "DRUG", "drug_description": "200mg Pembrolizumab every six weeks via IV infusion.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Change in standard of care.", "title": "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)", "start_date": "2023-09-30", "completion_date": "2032-01-31", "sponsor": "Fox Chase Cancer Center", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.554337", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:55.365035", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [], "has_uniprot_targets": false, "search_name": "Pembrolizumab (200mg)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "39115419", "title": "T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.", "authors": [{"name": "Gainor JF", "authtype": "Author", "clusterid": ""}, {"name": "Patel MR", "authtype": "Author", "clusterid": ""}, {"name": "Weber JS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36388466", "title": "Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.", "authors": [{"name": "Barber EL", "authtype": "Author", "clusterid": ""}, {"name": "Chen S", "authtype": "Author", "clusterid": ""}, {"name": "Pineda MJ", "authtype": "Author", "clusterid": ""}]}, {"pmid": "32847746", "title": "Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?", "authors": [{"name": "Pederzoli F", "authtype": "Author", "clusterid": ""}, {"name": "Bandini M", "authtype": "Author", "clusterid": ""}, {"name": "Marandino L", "authtype": "Author", "clusterid": ""}]}, {"pmid": "32423837", "title": "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.", "authors": [{"name": "Grivas P", "authtype": "Author", "clusterid": ""}, {"name": "Plimack ER", "authtype": "Author", "clusterid": ""}, {"name": "Balar AV", "authtype": "Author", "clusterid": ""}]}, {"pmid": "32278621", "title": "Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.", "authors": [{"name": "Schmid P", "authtype": "Author", "clusterid": ""}, {"name": "Salgado R", "authtype": "Author", "clusterid": ""}, {"name": "Park YH", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those that achieved disease control could prolong progression-free survival (overall survival benefit in JAVELIN may have been related to the lack of guaranteed crossover at time of progression). Of note, both of these studies showed consistency with regards to the magnitude of the PFS benefit which was \\~40% vs \\~20% at 6-months with maintenance ICI compared to BSC/placebo. Maintenance avelumab is now category 1 on the NCCN guidelines.\n\nHowever, some patients prefer prolonged chemotherapy responses and literature supports a treatment break without effecting longevity. The underlying risk resides in the selection of patients with some (currently difficult to diagnose) progressing rapidly. This trial proposes to use ctDNA to stratify chemo-responsive patients to active surveillance (i.e. a ctDNA responder referred to here as \"ctDNA-\") vs SOC maintenance pembrolizumab (ctDNA+). All patients will be treated with SOC chemotherapy and only patients with an objective (RECIST) response will be stratified.\n\nThis is a non-randomized phase 2 study with two arms based on ctDNA\n\n1. Pembrolizumab (ctDNA non-responder) maintenance therapy arm (SOC)\n2. Active surveillance arm (ctDNA responders) with serial ctDNA and crossover 1st line chemotherapy is based on physician discretion choice as described in the protocol. Patients with metastatic Urothelial Cancer are enrolled prior to initiation of SOC chemotherapy. Based on ORR (CR + PR), it is estimated that 75 patients will need to enroll onto the protocol to find 25 responders for the two arms.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Maintenance Therapy 200mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 200mg Pembrolizumab every six weeks via IV infusion.", "intervention_names": ["Drug: Pembrolizumab (200mg)"]}, {"label": "Maintenance Therapy 400mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 400mg Pembrolizumab every six weeks via IV infusion..", "intervention_names": ["Drug: Pembrolizumab (400mg)"]}, {"label": "Active Surveillance", "type": "OTHER", "description": "Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.", "intervention_names": ["Diagnostic Test: Monitoring"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab (200mg)", "description": "200mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 200mg Pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab (400mg)", "description": "400mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 400mg Pembrolizumab"]}, {"type": "DIAGNOSTIC_TEST", "name": "Monitoring", "description": "active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.", "arm_group_labels": ["Active Surveillance"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Fox Chase Cancer Center+NCT06050954+terminated", "https://www.google.com/search?q=Fox Chase Cancer Center+Pembrolizumab (200mg)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab (200mg) by Fox Chase Cancer Center. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds for Pembrolizumab (200mg) specifically related to Fox Chase Cancer Center. I'll go through each result to see if it contains relevant information.\n\nResult [1]: This discusses FDA alerts about safety issues with Keytruda (pembrolizumab) and Tecentriq for urothelial cancer patients with low PD-L1 expression. It mentions decreased survival associated with these drugs compared to platinum-based chemotherapy. However, it doesn't specifically mention Fox Chase Cancer Center or any warning letters or clinical holds related to them.\n\nResult [2]: This is about various FDA cancer drug safety warnings, but doesn't specifically mention pembrolizumab in relation to Fox Chase Cancer Center.\n\nResult [3]: This discusses FDA expanding pembrolizumab indication for first-line treatment of NSCLC. It doesn't mention any warning letters or clinical holds related to Fox Chase Cancer Center.\n\nResult [4]: This provides information about pembrolizumab for advanced or metastatic urothelial carcinoma, including adverse reactions, but doesn't mention Fox Chase Cancer Center specifically in relation to warning letters or clinical holds.\n\nResult [5]: Mentions Fox Chase Cancer Center in relation to new targeted therapies for cervical cancer, but doesn't discuss any warning letters or clinical holds for pembrolizumab.\n\nResult [6]: This is an FDA approval summary for pembrolizumab but doesn't mention Fox Chase Cancer Center in relation to warning letters or clinical holds.\n\nResult [7]: This mentions Fox Chase Cancer Center in relation to pembrolizumab for urothelial cancer, but it's from June 1, 2015, and discusses pembrolizumab as a \"promising treatment,\" not any safety issues or warning letters.\n\nResult [8]: Discusses FDA emphasizing risks of pembrolizumab in multiple myeloma, noting a 61% higher relative risk of death, but doesn't mention Fox Chase Cancer Center.\n\nResult [9]: Discusses withdrawn indications for PD-1 inhibitors in small-cell lung cancer, including pembrolizumab, but doesn't specifically mention Fox Chase Cancer Center.\n\nResult [10]: Mentions Fox Chase Cancer Center and pembrolizumab in relation to limited effect in patients with rare neuroendocrine tumors, but doesn't discuss warning letters or clinical holds.\n\nResult", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Fox Chase Cancer Center"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Fox Chase Cancer Center about clinical trial NCT06050954 for Pembrolizumab (200mg). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about Fox Chase Cancer Center's clinical trial NCT06050954 for Pembrolizumab (200mg), with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT06050954 is about:\n\nFrom result [1], I can see that NCT06050954 is titled \"A Pilot Study of Circulating Tumor...\" and is related to \"unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium.\" The study appears to be about bladder cancer (urothelial cancer). The eligibility criteria mention that subjects must be eligible for standard first-line platinum-based chemotherapy for advanced or metastatic urothelial cancer.\n\nFrom result [8], I can see that the full title is \"A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)\".\n\nHowever, I don't see any specific mention of Pembrolizumab in the trial description from result [1]. Let me check if any of the other results mention Pembrolizumab in relation to this specific trial NCT06050954.\n\nResult [2] mentions \"Researchers Find Pembrolizumab Alone Has Limited Effect in Patients With Rare Neuroendocrine Tumors\" but this appears to be a different study, not related to NCT06050954.\n\nResult [11] is about Pembrolizumab in general but doesn't mention NCT06050954 specifically.\n\nLet me check if there's any connection between NCT06050954 and Pembrolizumab in the other results:\n\nResult [3] lists clinical trials at Fox Chase but doesn't specifically mention NCT06050954 or Pembrolizumab in the excerpts provided.\n\nResult [4] mentions various trials but doesn't specifically connect NCT06050954 with Pembrolizumab.\n\nResult [5] is general information about clinical trials at Fox Chase.\n\nResult [6] is about a collaboration with Lantern Pharma on LP-184 for pancreatic cancer, not related to NCT06050954.\n\nResult [7] is general information about", "citations": [], "search_params": {"company": "Fox Chase Cancer Center", "nct_id": "NCT06050954", "drug_name": "Pembrolizumab (200mg)"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Change in standard of care,\" which indicates an administrative or operational issue rather than safety or efficacy concerns. The lack of detailed description and published results also suggests administrative or strategic reasons for the trial termination, rather than any specific safety or efficacy problems with the intervention.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:55.326947", "claude_model": "claude-3-haiku-20240307", "tokens_used": 836}}, "63": {"nct_id": "NCT06050954", "drug_name": "Pembrolizumab (400mg)", "intervention_type": "DRUG", "drug_description": "400mg Pembrolizumab every six weeks via IV infusion.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Change in standard of care.", "title": "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)", "start_date": "2023-09-30", "completion_date": "2032-01-31", "sponsor": "Fox Chase Cancer Center", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.554816", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:55.400784", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [], "has_uniprot_targets": false, "search_name": "Pembrolizumab (400mg)"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "36055895", "title": "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.", "authors": [{"name": "Yu EY", "authtype": "Author", "clusterid": ""}, {"name": "Piulats JM", "authtype": "Author", "clusterid": ""}, {"name": "Gravis G", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those that achieved disease control could prolong progression-free survival (overall survival benefit in JAVELIN may have been related to the lack of guaranteed crossover at time of progression). Of note, both of these studies showed consistency with regards to the magnitude of the PFS benefit which was \\~40% vs \\~20% at 6-months with maintenance ICI compared to BSC/placebo. Maintenance avelumab is now category 1 on the NCCN guidelines.\n\nHowever, some patients prefer prolonged chemotherapy responses and literature supports a treatment break without effecting longevity. The underlying risk resides in the selection of patients with some (currently difficult to diagnose) progressing rapidly. This trial proposes to use ctDNA to stratify chemo-responsive patients to active surveillance (i.e. a ctDNA responder referred to here as \"ctDNA-\") vs SOC maintenance pembrolizumab (ctDNA+). All patients will be treated with SOC chemotherapy and only patients with an objective (RECIST) response will be stratified.\n\nThis is a non-randomized phase 2 study with two arms based on ctDNA\n\n1. Pembrolizumab (ctDNA non-responder) maintenance therapy arm (SOC)\n2. Active surveillance arm (ctDNA responders) with serial ctDNA and crossover 1st line chemotherapy is based on physician discretion choice as described in the protocol. Patients with metastatic Urothelial Cancer are enrolled prior to initiation of SOC chemotherapy. Based on ORR (CR + PR), it is estimated that 75 patients will need to enroll onto the protocol to find 25 responders for the two arms.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Maintenance Therapy 200mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 200mg Pembrolizumab every six weeks via IV infusion.", "intervention_names": ["Drug: Pembrolizumab (200mg)"]}, {"label": "Maintenance Therapy 400mg Pembrolizumab", "type": "OTHER", "description": "Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered 400mg Pembrolizumab every six weeks via IV infusion..", "intervention_names": ["Drug: Pembrolizumab (400mg)"]}, {"label": "Active Surveillance", "type": "OTHER", "description": "Participants who are deemed ctDNA responders (reduction in ctDNA by 50% or more) on post-chemo testing will undergo active surveillance and continued serial ctDNA testing at regular intervals as defined by the study protocol. Patients will also undergo surveillance imaging as defined in the study protocol. At the time of first radiographic or ctDNA progression (to be assessed every 12 weeks in conjunction with radiographic assessment), the patient will be offered treatment with pembrolizumab.", "intervention_names": ["Diagnostic Test: Monitoring"]}], "interventions": [{"type": "DRUG", "name": "Pembrolizumab (200mg)", "description": "200mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 200mg Pembrolizumab"]}, {"type": "DRUG", "name": "Pembrolizumab (400mg)", "description": "400mg Pembrolizumab every six weeks via IV infusion.", "arm_group_labels": ["Maintenance Therapy 400mg Pembrolizumab"]}, {"type": "DIAGNOSTIC_TEST", "name": "Monitoring", "description": "active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.", "arm_group_labels": ["Active Surveillance"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Fox Chase Cancer Center+NCT06050954+terminated", "https://www.google.com/search?q=Fox Chase Cancer Center+Pembrolizumab (400mg)+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab (400mg) by Fox Chase Cancer Center. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Pembrolizumab (400mg) by Fox Chase Cancer Center.\n\nFirst, I need to identify if there are any specific FDA warning letters or clinical holds related to:\n1. Pembrolizumab (400mg)\n2. Issued to or involving Fox Chase Cancer Center\n\nLet me go through the search results systematically:\n\nResult [1]: Discusses FDA alerts about safety issues with Keytruda (pembrolizumab) and Tecentriq for urothelial cancer, but doesn't mention Fox Chase Cancer Center specifically or any 400mg dosage.\n\nResult [2]: Discusses FDA clinical holds on pembrolizumab trials for multiple myeloma (KEYNOTE-183 and KEYNOTE-185), but doesn't mention Fox Chase Cancer Center.\n\nResult [3]: Discusses FDA approval of pembrolizumab for small cell lung cancer, but doesn't mention any warning letters or clinical holds related to Fox Chase.\n\nResult [4]: General FDA cancer drug safety warnings, but no specific mention of pembrolizumab clinical holds at Fox Chase.\n\nResult [5]: Merck press release about KEYTRUDA, but no warning letters or clinical holds mentioned.\n\nResult [6]: Mentions FDA halting studies evaluating pembrolizumab for multiple myeloma, but doesn't specify Fox Chase Cancer Center.\n\nResult [7]: Mentions Fox Chase Cancer Center in relation to pembrolizumab research for urothelial cancer, but doesn't mention any warning letters or clinical holds.\n\nResult [8]: FDA approval summary for pembrolizumab, no warning letters or clinical holds mentioned.\n\nResult [9]: Discusses withdrawn indications for PD-1 inhibitors in SCLC, but doesn't mention specific warning letters to Fox Chase.\n\nResult [10]: Discusses FDA emphasizing risks of pembrolizumab in multiple myeloma, but doesn't mention Fox Chase.\n\nResult [11]: Mentions Fox Chase Cancer Center in relation to lung cancer research, but no warning letters.\n\nResult [12]: FDA approval information for pembrolizumab, no warning letters.\n\nResult [13]: Mentions Hossein Borghaei from Fox Chase Center discussing withdrawn FDA approvals for nivolumab and pembrolizumab in SCLC, but", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "Fox Chase Cancer Center"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Fox Chase Cancer Center about clinical trial NCT06050954 for Pembrolizumab (400mg). Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about Fox Chase Cancer Center's statements regarding clinical trial NCT06050954 for Pembrolizumab (400mg), with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which results are relevant to NCT06050954:\n\nResult [1] mentions NCT06050954 as \"A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)\" with Principal Investigator Benjamin Miron from Fox Chase Cancer Center.\n\nResult [3] provides more details about NCT06050954: \"A Pilot Study of Circulating Tumor DNA Adaptive...\" It mentions:\n- Drug: Pembrolizumab (200mg) - 200mg Pembrolizumab every six weeks via IV infusion\n- Drug: Pembrolizumab (400mg)\n- It's conducted at Fox Chase Cancer Center\n- The study involves patients with transitional cell carcinoma of the urothelium\n- Participants who have radiographical or ctDNA progression after 3-6 cycles of standard-of-care platinum-based chemotherapy will be offered either 200mg or 400mg Pembrolizumab every six weeks via IV infusion\n\nNow, let me check if there are any press releases, investor presentations, or public statements by Fox Chase Cancer Center specifically about this trial (NCT06050954) that discuss safety issues, adverse events, trial termination, or regulatory actions.\n\nResult [2] is a press release from Citius Pharmaceuticals, Inc. and Citius Oncology Inc. about \"promising preliminary results of an investigator-initiated phase i clinical trial of pembrolizumab (Keytruda) and LYMPHIR in cancer patients with recurrent solid tumors.\" This mentions:\n- Adverse reactions including \"increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome\"\n- Hepatotoxicity is mentioned\n- It's a different trial (not NCT06050954) as it involves LYMPHIR in combination with pembrolizumab\n\nResults [4", "citations": [], "search_params": {"company": "Fox Chase Cancer Center", "nct_id": "NCT06050954", "drug_name": "Pembrolizumab (400mg)"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Change in standard of care,\" which indicates an administrative or operational issue rather than safety or efficacy concerns. The lack of detailed description and published results also suggests administrative or strategic reasons for the trial termination, rather than any specific safety or efficacy problems with the intervention.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:55.326947", "claude_model": "claude-3-haiku-20240307", "tokens_used": 836}}, "64": {"nct_id": "NCT05489510", "drug_name": "Pulsed or continuous lighting", "intervention_type": "COMBINATION_PRODUCT", "drug_description": "The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "No participants enrolled", "title": "PXL-Platinum 330 in Eyes With Corneal Thinning Conditions", "start_date": "2023-08-15", "completion_date": "2031-12-31", "sponsor": "Vishal Jhanji", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.555277", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:48:58.768200", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Pulsed or continuous lighting"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "The primary objective of this study is to evaluate the safety and effectiveness of corneal collagen cross-linking (performed using the PXL-Platinum 330 system) for treating corneal curvature and biomechanical anomalies associated with corneal thinning conditions, e.g., progressive or non-progressive keratoconus, pellucid marginal degeneration, and treatment of patients with bacterial or fungal keratitis.", "aact_documents": [], "pubmed_results": [{"pmid": "41234920", "title": "Nitrous oxide inhalation combined with lidocaine local anesthesia on the comfort of plastic surgery outpatient procedures: a randomized, controlled, single-blind trial.", "authors": [{"name": "Su Y", "authtype": "Author", "clusterid": ""}, {"name": "Zou J", "authtype": "Author", "clusterid": ""}, {"name": "Guo J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234915", "title": "Comparative effectiveness of manual therapy and band exercises combined with high-intensity walking for pain, posture, and cardiorespiratory health in older adults: a randomised clinical trial.", "authors": [{"name": "Arnal-G\u00f3mez A", "authtype": "Author", "clusterid": ""}, {"name": "Fuentes-Aparicio L", "authtype": "Author", "clusterid": ""}, {"name": "Marqu\u00e9s-Sul\u00e9 E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41232096", "title": "Evaluating the Impact of Telehealth Exercise Prehabilitation on Cardiometabolic Health in Bariatric Surgery Candidates: Protocol for the BARI-Prehab Randomized Controlled Trial.", "authors": [{"name": "Durey BJ", "authtype": "Author", "clusterid": ""}, {"name": "Coates AM", "authtype": "Author", "clusterid": ""}, {"name": "Davison K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41231435", "title": "Evaluating Causal Effects on Time-to-Event Outcomes in an RCT in Oncology With Treatment Discontinuation.", "authors": [{"name": "Ballerini V", "authtype": "Author", "clusterid": ""}, {"name": "Bornkamp B", "authtype": "Author", "clusterid": ""}, {"name": "Mealli F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41231367", "title": "Association between daytime sleepiness and impaired expiratory lung function due to smoking in patients with mild-to-severe OSA: an observational study.", "authors": [{"name": "Sartori G", "authtype": "Author", "clusterid": ""}, {"name": "Fantin A", "authtype": "Author", "clusterid": ""}, {"name": "Ferrari M", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 system for performing corneal collagen cross-linking (CXL) for the treatment of corneal thinning disorders. The PXL Platinum 330 system is a combination product consisting of a UVA 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution) administered in conjunction with the UVA light as a photosensitizer.", "detailed_description": "The primary objective of this study is to evaluate the safety and effectiveness of corneal collagen cross-linking (performed using the PXL-Platinum 330 system) for treating corneal curvature and biomechanical anomalies associated with corneal thinning conditions, e.g., progressive or non-progressive keratoconus, pellucid marginal degeneration, and treatment of patients with bacterial or fungal keratitis.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Pulsed lighting", "type": "OTHER", "description": null, "intervention_names": ["Combination Product: Pulsed or continuous lighting"]}, {"label": "Continuous lighting", "type": "OTHER", "description": null, "intervention_names": ["Combination Product: Pulsed or continuous lighting"]}], "interventions": [{"type": "COMBINATION_PRODUCT", "name": "Pulsed or continuous lighting", "description": "The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).", "arm_group_labels": ["Continuous lighting", "Pulsed lighting"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Vishal Jhanji+NCT05489510+terminated", "https://www.google.com/search?q=Vishal Jhanji+Pulsed or continuous lighting+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pulsed or continuous lighting by Vishal Jhanji. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds related to \"Pulsed or continuous lighting by Vishal Jhanji.\" Let me go through each search result carefully.\n\nFirst, let me identify who Vishal Jhanji is from the search results:\n\nFrom result [6], I see:\n\"Effects of tear film dynamics on quality of vision.\nKoh, Shizuka; Tung, Cynthia I; Inoue, Yasushi; Jhanji, Vishal\"\n\nSo Vishal Jhanji appears to be an author/researcher in ophthalmology, specifically related to tear film dynamics and vision quality.\n\nNow, let me check if any of the search results mention FDA warning letters or clinical holds related to \"Pulsed or continuous lighting\" associated with Vishal Jhanji.\n\nResult [1]: Discusses lights and lasers with wavelengths from 400 nm to 1400 nm (retinal hazard region) being dangerous. This is general information about light hazards but doesn't mention Vishal Jhanji or any FDA warning letters/clinical holds.\n\nResult [2]: About LASIK Handbook, no mention of Vishal Jhanji or FDA warning letters.\n\nResult [3]: Contains FDA clinical review information about topical ophthalmic corticosteroid products. It mentions warnings about using these products for more than 10 days, but nothing about Vishal Jhanji or pulsed/continuous lighting.\n\nResult [4]: NYUHSL Faculty Bibliography with various ophthalmology research topics. Vishal Jhanji is not mentioned here.\n\nResult [5]: ARVO Pocket Guide 2017, no relevant information.\n\nResult [6]: Contains information about Vishal Jhanji as an author on a paper about \"Effects of tear film dynamics on quality of vision.\" However, there's no mention of FDA warning letters or clinical holds related to pulsed or continuous lighting.\n\nResult [7]: Mentions \"long-term safety concerns have yet to be established\" for gene therapy treatments, but no connection to Vishal Jhanji or lighting devices.\n\nResult [8]: Mentions FDA clearance for limited use in restricted research settings for some drugs and medical devices, but no specific connection to Vishal Jhanji or lighting devices.\n\nResult [9]: General information about World Journal of Ophthalmology, no specific relevant information.\n\nAfter reviewing all the search results, I don't see", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Vishal Jhanji mentioning clinical trial NCT05489510 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Vishal Jhanji mentioning clinical trial NCT05489510 or related drug safety issues.\n\nFirst, I need to understand what I'm looking for:\n1. SEC EDGAR 8-K filings\n2. By Vishal Jhanji (likely an individual or company representative)\n3. Mentioning clinical trial NCT05489510\n4. Or related drug safety issues\n5. Need to include filing dates, CIK numbers, and specific material events disclosed\n\nLet me go through each search result:\n\nResult [1]: This is an EDGAR Entity Landing Page for a company with CIK 1050446. It appears to be related to Strategy Inc (MSTR, STRC, STRD, STRF, STRK on Nasdaq). The page shows various filings including 8-K forms, but I don't see any mention of Vishal Jhanji, clinical trial NCT05489510, or drug safety issues. This seems to be related to a financial/cryptocurrency company.\n\nResult [2]: This is an 8-K filing for Athira Pharma, Inc. with CIK 1620463. It mentions a Phase 1 trial for ATH-1105 that enrolled 80 healthy volunteers to evaluate safety and tolerability. The study was completed in November 2024. It states \"The results of the Phase 1 trial showed that ATH-1105 demonstrated a favorable safety...\" However, I don't see any mention of Vishal Jhanji or clinical trial NCT05489510 specifically.\n\nResult [3]: This is an SEC filing (s-20250625) for a company with CIK 1583708. It appears to be related to an Annual Meeting of Stockholders held on June 25, 2025. There's no mention of clinical trials, drug safety, Vishal Jhanji, or NCT05489510.\n\nResult [4]: This is an 8-K filing for Jaguar Health, Inc. with CIK 1585608. It's dated June 30, 2025,", "citations": [], "search_params": {"company": "Vishal Jhanji", "nct_id": "NCT05489510", "start_date": "2023-08-15"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Vishal Jhanji about clinical trial NCT05489510 for Pulsed or continuous lighting. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary about external safety evidence for clinical trial NCT05489510.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Vishal Jhanji about clinical trial NCT05489510 for Pulsed or continuous lighting\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available:\n\nResult [1]: This is the ClinicalTrials.gov entry for NCT05489510, which is a study titled \"PXL-Platinum 330 in Eyes With...\" conducted by Vishal Jhanji at the University of Pittsburgh. It describes the study as a \"Prospective, double-arm, randomized single-site study\" with arms for \"pulsed or continuous lighting.\" It includes inclusion/exclusion criteria but doesn't mention any safety issues, adverse events, trial termination, or regulatory actions.\n\nResult [2]: This appears to be a PDF about a Novartis trial (CHKT288X2101) for HKT288 in patients with advanced solid tumors. It mentions that the study was terminated due to adverse events, including \"two suspected-related neurologic adverse events.\" However, this is not related to NCT05489510 or Vishal Jhanji.\n\nResult [3]: This is a YouTube video featuring Prof. Vishal Jhanji discussing biomechanics, but it doesn't appear to specifically address the NCT05489510 trial or safety issues related to it.\n\nResult [4]: This is about a Phase 2a study of Ritlecitinib for alopecia areata (EudraCT Number 2020-001509-21). It mentions adverse events but is not related to NCT05489510.\n\nResult [5]: Another YouTube video featuring Prof. Vishal Jhanji discussing corneal tomography and biomechanical assessment, but doesn't appear to specifically address the NCT05489510 trial or safety issues.\n\nResult [6]: This is an EyeWorld Weekly article from August 16, 2024, with various clinical trial updates,", "citations": [], "search_params": {"company": "Vishal Jhanji", "nct_id": "NCT05489510", "drug_name": "Pulsed or continuous lighting"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"No participants enrolled,\" indicating that the trial failed due to administrative issues, specifically an inability to enroll any participants. The detailed description does not mention any safety concerns or lack of efficacy, but rather states the primary objective was to evaluate the safety and effectiveness of the treatment. The lack of enrolled participants is the sole reason provided for the trial withdrawal, strongly suggesting an administrative failure rather than a safety or efficacy-related failure.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:48:58.766909", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1111}}, "65": {"nct_id": "NCT04987996", "drug_name": "GR-MD-02", "intervention_type": "DRUG", "drug_description": "Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study withdrawn due to lack of supply of one of the investigational agents.", "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients", "start_date": "2023-07-01", "completion_date": "2031-07-01", "sponsor": "Providence Health & Services", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.555742", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:01.546274", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "GR-MD-02"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "aact_documents": [], "pubmed_results": [{"pmid": "33837055", "title": "Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.", "authors": [{"name": "Curti BD", "authtype": "Author", "clusterid": ""}, {"name": "Koguchi Y", "authtype": "Author", "clusterid": ""}, {"name": "Leidner RS", "authtype": "Author", "clusterid": ""}]}, {"pmid": "33612037", "title": "Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis.", "authors": [{"name": "Al Attar A", "authtype": "Author", "clusterid": ""}, {"name": "Antaramian A", "authtype": "Author", "clusterid": ""}, {"name": "Noureddin M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "31812510", "title": "Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.", "authors": [{"name": "Chalasani N", "authtype": "Author", "clusterid": ""}, {"name": "Abdelmalek MF", "authtype": "Author", "clusterid": ""}, {"name": "Garcia-Tsao G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "30192782", "title": "Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.", "authors": [{"name": "Harrison SA", "authtype": "Author", "clusterid": ""}, {"name": "Dennis A", "authtype": "Author", "clusterid": ""}, {"name": "Fiore MM", "authtype": "Author", "clusterid": ""}]}, {"pmid": "28917454", "title": "A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis.", "authors": [{"name": "Ritchie S", "authtype": "Author", "clusterid": ""}, {"name": "Neal D", "authtype": "Author", "clusterid": ""}, {"name": "Shlevin H", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The purpose of this study is to test the safety \\& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.", "detailed_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "GR-MD-02 + pembrolizumab", "type": "EXPERIMENTAL", "description": "4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: GR-MD-02", "Drug: Pembrolizumab"]}, {"label": "Pembrolizumab Monotherapy", "type": "PLACEBO_COMPARATOR", "description": "4 mg/kg placebo in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "GR-MD-02", "description": "Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Patients will receive up to seventeen doses of placebo intravenously over 85 Days.", "arm_group_labels": ["Pembrolizumab Monotherapy"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab", "Pembrolizumab Monotherapy"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Providence Health & Services+NCT04987996+terminated", "https://www.google.com/search?q=Providence Health & Services+GR-MD-02+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for GR-MD-02 by Providence Health & Services. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for GR-MD-02 by Providence Health & Services.\n\nFirst, I need to identify which results might contain relevant information:\n\nResult [1]: About Galectin Therapeutics and GR-MD-02 development program. It discusses GR-MD-02 as a drug for NASH and fibrosis, but doesn't mention any FDA warning letters or clinical holds.\n\nResult [2]: FDA FOIA documents, but doesn't seem to specifically mention GR-MD-02 or Providence Health & Services.\n\nResult [3]: Galectin Therapeutics annual report mentioning GR-MD-02 clinical trials, but no FDA warning letters or clinical holds.\n\nResult [4]: About root cause analysis in healthcare, not relevant to the query.\n\nResult [5]: FDA warning letters page, but the examples shown don't mention GR-MD-02 or Providence.\n\nResult [6]: CDC guidelines, not relevant.\n\nResult [7]: Medical policy alerts, not relevant to GR-MD-02.\n\nResult [8]: NIH guidelines, not relevant.\n\nResult [9]: Galectin Therapeutics development programs, mentions GR-MD-02 in cancer immunotherapy trials with Providence Portland Medical Center, but no FDA warning letters.\n\nResult [10]: Fairfax County budget document, not relevant.\n\nResult [11]: \"FDA Warning Letter to Providence Hospital Institutional Review...\" - This seems potentially relevant as it mentions Providence Hospital and an FDA Warning Letter.\n\nResult [12]: Rhode Island Medical Journal, not relevant.\n\nResult [13]: FDA FOIA documents, but doesn't seem to specifically mention GR-MD-02.\n\nResult [14]: FDA health fraud warning letters, but no specific mention of GR-MD-02.\n\nResult [15]: Clinical trial information, but not about warning letters.\n\nLet me focus on Result [11] which specifically mentions \"FDA Warning Letter to Providence Hospital Institutional Review...\" This seems most relevant to the query about FDA warning letters related to Providence.\n\nFrom Result [11], I can see it's titled \"FDA Warning Letter to Providence Hospital Institutional Review...\" but the actual content isn't provided in the search snippet - it just shows the title repeated twice. This suggests there was a warning letter from the FDA to Providence Hospital's Institutional Review Board (IRB), but I don't have the details of what the warning letter contained", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Providence Health & Services mentioning clinical trial NCT04987996 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the task and the search results provided.\n\nI'm supposed to act as an investigator compiling external safety evidence for a specific clinical trial. I need to respond with a JSON summary containing:\n- status\n- summary\n- relevance\n- citations\n\nThe current date is Friday, November 14, 2025, 5:37 PM UTC.\n\nThe user has provided two search results:\n\n1. A PMC article (PMC10179732) about Galectin-3 Targeting Drugs for Therapeutic purposes\n2. A SEC EDGAR search page\n\nThe user's query was: \"SEC EDGAR 8-K filings by Providence Health & Services mentioning clinical trial NCT04987996 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.\"\n\nLet me analyze what information I have:\n\nFrom search result [1]:\n- This is an article about Galectin-3 (Gal3) targeting drugs\n- It mentions Gal3's role in various conditions including fibrosis, COPD, and psoriasis\n- It references a clinical trial NCT01899859 related to a Gal3 inhibitor called GR-MD-02 (which seems to be the same as GB0139 mentioned later)\n- It mentions another trial NCT05009680 for \"Hepatic impairment\" and \"NSCLC\" (Non-small cell lung cancer)\n- It discusses a study on GB0139 for COVID-19 patients\n- The article was received April 5, 2023, revised April 24, 2023, and accepted April 29, 2023\n\nFrom search result [2]:\n- This is just the SEC EDGAR search page, not actual search results\n- It doesn't contain any specific information about Providence Health & Services or clinical trial NCT04987996\n\nThe user's query was specifically about:\n- SEC EDGAR 8-K filings by Providence Health & Services\n- Mentioning clinical trial NCT04987996\n- Or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nHowever, the search results don't actually provide the requested information. Result [1] is about", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "start_date": "2023-07-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Providence Health & Services about clinical trial NCT04987996 for GR-MD-02. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about Providence Health & Services' clinical trial NCT04987996 for GR-MD-02, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which search results might contain relevant information about NCT04987996:\n\nResult [6] mentions NCT04987996: \"Study Details | NCT04987996 | GR-MD-02 + Pembrolizumab Versus...\" - This seems directly relevant.\n\nResult [8] also mentions NCT04987996: \"NCT04987996, Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute. Metastatic Melanoma|Head and Neck Squamous Cell...\"\n\nResult [10] mentions: \"Clinical Trial: NCT04987996 - My Cancer Genome\" with description: \"The purpose of this study is to test the safety & efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell...\"\n\nLet me examine these results in more detail:\n\nFrom result [6], I can see it's about \"GR-MD-02 + Pembrolizumab Versus...\" but there's not much detail provided in the snippet.\n\nFrom result [8], I can see NCT04987996 is associated with Providence Health & Services and Providence Cancer Center, Earle A. Chiles Research Institute, and is for Metastatic Melanoma and Head and Neck Squamous Cell cancer.\n\nFrom result [10], I learn that the purpose of the study is \"to test the safety & efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell...\"\n\nNow, let me check if there are any press releases, investor presentations, or public statements by Providence Health & Services about this specific trial:\n\nResult [2] contains press releases from Providence, but I don't see any specific mention of NCT04987996 or GR-MD-02 in the snippets provided. The press releases mentioned are about:\n- AI and clinical trials (11/7/2025)\n- Q3 2025 results (", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "drug_name": "GR-MD-02"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the withdrawal of the trial is \"lack of supply of one of the investigational agents.\" This indicates an administrative issue, such as a supply chain or manufacturing problem, rather than safety concerns or lack of efficacy. The detailed description does not mention any safety issues or lack of efficacy, further supporting the classification of administrative failure as the reason for the trial's withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:01.544373", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1162}}, "66": {"nct_id": "NCT04987996", "drug_name": "Pembrolizumab", "intervention_type": "DRUG", "drug_description": "Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study withdrawn due to lack of supply of one of the investigational agents.", "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients", "start_date": "2023-07-01", "completion_date": "2031-07-01", "sponsor": "Providence Health & Services", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.556213", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:01.583938", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3137343", "pref_name": "PEMBROLIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O95243", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Pembrolizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 3, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "MBD4", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "SMUG1", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "APEX1", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "MLH1", "protein_b": "MBD4", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "UHRF1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "MBD2", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TRDMT1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "SMUG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "TDG", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MBD4", "protein_b": "DNMT3B", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3B", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT3A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MBD2", "protein_b": "DNMT1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TRDMT1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "TDG", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "UHRF1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT3B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DNMT3A", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TDG", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "TRDMT1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "UHRF1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "DNMT3B", "protein_b": "DNMT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "TDG", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "DNMT1", "protein_b": "UHRF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TDG", "protein_b": "SMUG1", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.74, "clustering_coefficient": 4.37}}, "failure_enrichment": {"aact_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "aact_documents": [], "pubmed_results": [{"pmid": "41228347", "title": "Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.", "authors": [{"name": "Fedele P", "authtype": "Author", "clusterid": ""}, {"name": "Stucci SL", "authtype": "Author", "clusterid": ""}, {"name": "Landriscina M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41219635", "title": "Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis.", "authors": [{"name": "Lala M", "authtype": "Author", "clusterid": ""}, {"name": "Bardia A", "authtype": "Author", "clusterid": ""}, {"name": "Calles A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209621", "title": "Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.", "authors": [{"name": "Skoulidis F", "authtype": "Author", "clusterid": ""}, {"name": "Borghaei H", "authtype": "Author", "clusterid": ""}, {"name": "Garon EB", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206673", "title": "Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous non-small lung cancer (ETCTN 10313).", "authors": [{"name": "Villaruz LC", "authtype": "Author", "clusterid": ""}, {"name": "Schluger B", "authtype": "Author", "clusterid": ""}, {"name": "Wang H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41177680", "title": "Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.", "authors": [{"name": "Jain P", "authtype": "Author", "clusterid": ""}, {"name": "Naqvi SAA", "authtype": "Author", "clusterid": ""}, {"name": "Tripathi N", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The purpose of this study is to test the safety \\& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.", "detailed_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "GR-MD-02 + pembrolizumab", "type": "EXPERIMENTAL", "description": "4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: GR-MD-02", "Drug: Pembrolizumab"]}, {"label": "Pembrolizumab Monotherapy", "type": "PLACEBO_COMPARATOR", "description": "4 mg/kg placebo in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "GR-MD-02", "description": "Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Patients will receive up to seventeen doses of placebo intravenously over 85 Days.", "arm_group_labels": ["Pembrolizumab Monotherapy"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab", "Pembrolizumab Monotherapy"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Providence Health & Services+NCT04987996+terminated", "https://www.google.com/search?q=Providence Health & Services+Pembrolizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Pembrolizumab by Providence Health & Services. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for Pembrolizumab by Providence Health & Services\n- Specific dates, reasons, and safety issues cited\n\nFirst, I need to determine if there are any FDA warning letters or clinical holds specifically issued to \"Providence Health & Services\" regarding Pembrolizumab.\n\nLet me go through the search results to find relevant information:\n\nResult [1]: Discusses FDA warning about risk of death with pembrolizumab in multiple myeloma (MM). It mentions clinical holds on KEYNOTE-183 and KEYNOTE-185 trials, but these were Merck trials, not Providence Health & Services trials.\n\nResult [2]: Discusses FDA approval of pembrolizumab for MSI-H cancers, no warning letters or clinical holds mentioned.\n\nResult [3]: FDA alert about clinical trials KEYNOTE-183 and KEYNOTE-185 for multiple myeloma, showing increased risk of death. Again, these are Merck trials.\n\nResult [4]: Similar to [1] and [3], discussing FDA alert about pembrolizumab increasing mortality risk in multiple myeloma.\n\nResult [5]: FDA converts to full approval for KEYTRUDA for MSI-H or dMMR solid tumors. No warning letters or clinical holds mentioned.\n\nResult [6]: FDA discloses data on halted pembrolizumab myeloma trials (KEYNOTE-183 and KEYNOTE-185).\n\nResult [7]: FDA alert about decreased survival with Keytruda or Tecentriq as monotherapy for metastatic urothelial cancer.\n\nResult [8]: FDA emphasizes risks of pembrolizumab in multiple myeloma after reviewing halted trials.\n\nResult [9]: Merck's injectable version of Keytruda approved by FDA.\n\nResult [10]: FDA places clinical hold on Merck's three Keytruda multiple myeloma trials.\n\nResult [11]: Discusses FDA approval of pembrolizumab with chemotherapy drugs for endometrial cancer in June 2024.\n\nResult [12]: FDA approves neoadjuvant and adjuvant pembrolizumab for head and neck cancer.\n\nResult [13]: Mentions a new investigator-initiated study at Providence Cancer Institute evaluating pembrolizumab,", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Providence Health & Services mentioning clinical trial NCT04987996 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results provided and compile a JSON summary containing status, summary, relevance, and citations for external safety evidence related to a clinical trial.\n\nLet me examine each search result:\n\nResult [1] is from PMC (PubMed Central) with the article titled \"Development of Galectin-3 Targeting Drugs for Therapeutic...\" (PMCID: PMC10179732, PMID: 37175823). This article discusses Galectin-3 (Gal3) and its role in various diseases including fibrosis, COPD, and psoriasis. It mentions a clinical trial with a Gal3 inhibitor called GR-MD-02 (ClinicalTrials.gov Identifier: NCT01899859) that unexpectedly treated moderate to severe plaque psoriasis. It also mentions another trial with GB0139 for COVID-19 patients (NCT05009680), which is described as \"Active, not rec\" for hepatic impairment (n=54) and \"Recruiting\" for NSCLC (n=102). The article states that a pilot study with 40 COVID-19 patients treated with GB0139 plus standard of care showed some results.\n\nResult [2] appears to be a SEC EDGAR page showing company information, but it states \"No information is available for this page\" and shows no relevant data about clinical trials or safety evidence.\n\nResult [3] is a general SEC.gov search filings page that provides information about how to search for filings but doesn't contain any specific clinical trial information.\n\nResult [4] is another SEC EDGAR search page that explains the search functionality but doesn't contain specific information about the requested clinical trial.\n\nThe user query specifically asked for \"SEC EDGAR 8-K filings by Providence Health & Services mentioning clinical trial NCT04987996 or related drug safety issues.\" However, none of the search results provided contain information about:\n1. Providence Health & Services\n2. Clinical trial NCT04987996\n3. SEC Form 8-K filings related to clinical trials or drug safety\n\nThe only clinical trial identifiers mentioned in the search results are:\n- NCT01899859 (for GR-MD-02 in psoriasis treatment)\n- NCT050", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "start_date": "2023-07-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Providence Health & Services about clinical trial NCT04987996 for Pembrolizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Providence Health & Services about clinical trial NCT04987996 for Pembrolizumab\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available:\n\nResult [1]: About pembrolizumab generating responses in PMBCL, but not related to NCT04987996 or Providence Health & Services statements.\n\nResult [2]: Retrospective analysis of pembrolizumab safety data from Keynote trials, but not specific to NCT04987996 or Providence statements.\n\nResult [3]: Information about Pembrolizumab as a drug, not related to the specific trial or Providence statements.\n\nResult [4]: ClinicalTrials.gov entry for NCT04987996 - \"GR-MD-02 + Pembrolizumab Versus...\" which mentions Providence Health & Services|Providence Cancer Center as a sponsor. This confirms the trial exists and is sponsored by Providence, but doesn't provide any press releases or statements.\n\nResult [5]: About Galectin-3 targeting drugs, mentions some trials but not specifically NCT04987996 or Providence statements.\n\nResult [6] and [7]: About \"Pembrolizumab plus dinaciclib in patients with hematologic...\" but not related to NCT04987996.\n\nResult [8], [9], and [10]: All provide information about NCT04987996 trial, confirming it's a study of \"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy\" for melanoma and head and neck squamous cell cancer. Result [9] mentions \"Providence Health & Services\" as the sponsor.\n\nNow, to specifically address the query: I need to find company press releases, investor presentations, or public statements by Providence Health & Services about this trial, focusing on safety issues, adverse events, etc.\n\nAfter reviewing all the search results, I don't see any specific press releases, investor presentations, or public statements from Providence Health & Services about NCT04", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "drug_name": "Pembrolizumab"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the withdrawal of the trial is \"lack of supply of one of the investigational agents.\" This indicates an administrative issue, such as a supply chain or manufacturing problem, rather than safety concerns or lack of efficacy. The detailed description does not mention any safety issues or lack of efficacy, further supporting the classification of administrative failure as the reason for the trial's withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:01.544373", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1162}}, "67": {"nct_id": "NCT04987996", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "Patients will receive up to seventeen doses of placebo intravenously over 85 Days.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Study withdrawn due to lack of supply of one of the investigational agents.", "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients", "start_date": "2023-07-01", "completion_date": "2031-07-01", "sponsor": "Providence Health & Services", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.556692", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:01.619504", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "aact_documents": [], "pubmed_results": [{"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41233939", "title": "A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.", "authors": [{"name": "Crawford TO", "authtype": "Author", "clusterid": ""}, {"name": "Servais L", "authtype": "Author", "clusterid": ""}, {"name": "Mercuri E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "The purpose of this study is to test the safety \\& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.", "detailed_description": "Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.\n\nIn addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "GR-MD-02 + pembrolizumab", "type": "EXPERIMENTAL", "description": "4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: GR-MD-02", "Drug: Pembrolizumab"]}, {"label": "Pembrolizumab Monotherapy", "type": "PLACEBO_COMPARATOR", "description": "4 mg/kg placebo in combination with standard pembrolizumab treatment.", "intervention_names": ["Drug: Placebo", "Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "GR-MD-02", "description": "Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Patients will receive up to seventeen doses of placebo intravenously over 85 Days.", "arm_group_labels": ["Pembrolizumab Monotherapy"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.", "arm_group_labels": ["GR-MD-02 + pembrolizumab", "Pembrolizumab Monotherapy"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Providence Health & Services+NCT04987996+terminated", "https://www.google.com/search?q=Providence Health & Services+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by Providence Health & Services. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to compile a JSON summary about FDA warning letters or clinical holds for \"Placebo by Providence Health & Services.\"\n\nFirst, I need to understand what the query is asking for:\n- FDA warning letters or clinical holds related to \"Placebo by Providence Health & Services\"\n- Specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1]: Discusses FDA warning letters related to advertising and promotion, specifically about leronlimab (a drug for COVID-19 treatment). No mention of Providence Health & Services or placebo.\n\nResult [2]: Contains a PDF about an FDA Warning Letter to Providence Hospital Institutional Review Board dated January 6, 2010. This seems relevant as it mentions \"Providence Hospital IRB.\" Let me examine this more closely.\n\nFrom Result [2]:\n- It's an FDA Warning Letter to Providence Hospital Institutional Review Board\n- Inspection was conducted from October 27 through November 3, 2009\n- The letter was issued January 6, 2010\n- It cites violations of 21 CFR Part 56 (Institutional Review Boards)\n- The violations relate to IRB procedures and compliance with federal regulations\n- However, it doesn't specifically mention \"Placebo\" or clinical holds related to placebo\n\nResult [3]: Discusses compounding inspections, recalls, and actions by FDA. No specific mention of Providence Health & Services or placebo.\n\nResult [4]: Discusses FDA Warning Letters related to clinical trial oversight in general, but no specific mention of Providence Health & Services.\n\nResult [5]: Discusses accelerated drug approvals and voxelotor, but no mention of Providence Health & Services or placebo.\n\nResult [6]: Discusses an FDA Warning Letter to a corporate sponsor of a clinical trial, but doesn't specify Providence Health & Services.\n\nResult [7]: Contains a PDF about medical and pharmacy policy alerts from Providence Health Plan. It mentions FDA warnings about glatiramer but doesn't discuss warning letters to Providence or placebo-related issues.\n\nResult [8]: A retrospective analysis of FDA Warning Letters, but no specific mention of Providence Health & Services.\n\nResult [9]: General information about FDA Warning Letters for health fraud.\n\nResult [10]: General information about FDA Warning Letters.\n\nResult [11]: An Excel file query related to a warning letter dated June 10, 2", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Providence Health & Services mentioning clinical trial NCT04987996 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find information about SEC EDGAR 8-K filings by Providence Health & Services related to clinical trial NCT04987996 or drug safety issues.\n\nLet me go through each search result:\n\n1. First search result: This is about Providence Health's financial statements. It shows they provide financial reports and mentions they provided $1.9 billion in community benefit in 2024. It lists various financial statements by quarter and year. However, there's no mention of clinical trials, NCT04987996, or drug safety issues.\n\n2. Second search result: This is about the SEC's search filings page. It explains how to search for filings in the EDGAR system but doesn't contain any specific filings by Providence Health & Services related to the clinical trial in question.\n\n3. Third search result: This is an article about Galectin-3 targeting drugs. It mentions various clinical trials including NCT01899859 (a NASH clinical trial with Gal3 inhibitor GR-MD-02) and NCT05009680 (which appears to be related to hepatic impairment and NSCLC). However, it doesn't mention Providence Health & Services or NCT04987996 specifically.\n\n4. Fourth search result: This is another SEC EDGAR search page description, explaining how to use the EDGAR advanced search. It doesn't contain any specific filings related to our query.\n\nAfter reviewing all the search results, I don't see any specific information about:\n1. SEC EDGAR 8-K filings by Providence Health & Services\n2. Clinical trial NCT04987996\n3. Related drug safety issues\n\nThe search results provide general information about:\n- Providence's financial statements (but not SEC filings)\n- How to search SEC EDGAR\n- An unrelated article about Galectin-3 targeting drugs that mentions different clinical trial numbers (NCT01899859 and NCT05009680)\n\nNone of the search results contain the specific information requested in the query. There's no mention of Providence Health & Services SEC 8-K filings related to clinical trial NCT04987996 or drug safety issues.\n\nAs an investigator compiling external safety evidence, I need to", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "start_date": "2023-07-01"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Providence Health & Services about clinical trial NCT04987996 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Providence Health & Services about clinical trial NCT04987996 for Placebo\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to find relevant information about NCT04987996:\n\nResult [1] - This is about Galectin-3 Targeting Drugs, mentions some trials but doesn't specifically discuss NCT04987996.\n\nResult [2] - This is Providence press releases, but looking at the content, I don't see specific mention of NCT04987996 or safety issues related to this trial.\n\nResult [3] - This is about new studies for triple-negative breast cancer, but doesn't mention NCT04987996.\n\nResult [4] - This is Providence's Clinical Trials Directory, but doesn't provide specific details about NCT04987996.\n\nResult [5] - This is the clinicaltrials.gov page for NCT04987996. It mentions \"GR-MD-02 + Pembrolizumab Versus...\" but doesn't provide detailed safety information or trial termination reasons.\n\nResult [6] - This is the homepage of Providence Research, no specific information about NCT04987996.\n\nResult [7] - This is a MedChemExpress page about Pembrolizumab, which mentions NCT04987996 in relation to Providence Health & Services and the Earle A. Chiles Research Institute, but doesn't provide safety information.\n\nResult [8] - This is a MedChemExpress page about Belapectin (GR-MD-02), which also mentions NCT04987996 in relation to Providence Health & Services and the Earle A. Chiles Research Institute.\n\nResult [9] - This is from My Cancer Genome about NCT04987996, stating \"The purpose of this study is to test the safety & efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell...\"\n\nFrom result [5], I can see that N", "citations": [], "search_params": {"company": "Providence Health & Services", "nct_id": "NCT04987996", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason provided for the withdrawal of the trial is \"lack of supply of one of the investigational agents.\" This indicates an administrative issue, such as a supply chain or manufacturing problem, rather than safety concerns or lack of efficacy. The detailed description does not mention any safety issues or lack of efficacy, further supporting the classification of administrative failure as the reason for the trial's withdrawal.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:01.544373", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1162}}, "68": {"nct_id": "NCT04915144", "drug_name": "177Lu-DOTATOC", "intervention_type": "DRUG", "drug_description": "Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Investigator decision", "title": "177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs", "start_date": "2023-01-15", "completion_date": "2031-12-31", "sponsor": "British Columbia Cancer Agency", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.557201", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:04.410007", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "177Lu-DOTATOC"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Overall, 200 subjects will be randomized (1:1 randomization ratio) to receive standard injected activities of 177Lu-DOTATOC PRRT or personalized injection of 177Lu-DOTATOC PRRT. Randomization will be stratified for grade and primary location.\n\nScreening Phase: Subjects will be screened against the inclusion and exclusion criteria. Screening by SSR imaging will be completed to determine expression of SSR and feasibility of treatment by PRRT. Once eligibility has been confirmed they will be randomized. Subjects will undergo a physical exam, complete a medical history questionnaire, quality of life questionnaires, blood work, and a diagnostic CT.\n\nTreatment Phase: During the treatment phase, subjects will undergo 4 cycles of treatment. Each treatment cycle will be followed by 2 dosimetry SPECT/CT scans on day 1 (18 - 32 hours after treatment administration) and day 2 (64 - 80h after treatment administration) After cycle 3 quality of life questionnaires will be completed again.\n\nFollow up Phase: At the end of treatment or after discontinuation of any cause, subjects will be followed for 5 years to continue data collection for the other objectives. Objective tumour response will be assessed every 6 months by diagnostic CT according to the RECIST 1.1 criteria.", "aact_documents": [], "pubmed_results": [{"pmid": "31091247", "title": "The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE.", "authors": [{"name": "Wetz C", "authtype": "Author", "clusterid": ""}, {"name": "Genseke P", "authtype": "Author", "clusterid": ""}, {"name": "Apostolova I", "authtype": "Author", "clusterid": ""}]}, {"pmid": "29472084", "title": "Effect of image registration on 3D absorbed dose calculations in (177)Lu-DOTATOC peptide receptor radionuclide therapy.", "authors": [{"name": "Grassi E", "authtype": "Author", "clusterid": ""}, {"name": "Fioroni F", "authtype": "Author", "clusterid": ""}, {"name": "Berenato S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "27539020", "title": "The prognostic and predictive value of sstr(2)-immunohistochemistry and sstr(2)-targeted imaging in neuroendocrine tumors.", "authors": [{"name": "Brunner P", "authtype": "Author", "clusterid": ""}, {"name": "J\u00f6rg AC", "authtype": "Author", "clusterid": ""}, {"name": "Glatz K", "authtype": "Author", "clusterid": ""}]}, {"pmid": "25593116", "title": "Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.", "authors": [{"name": "Marincek N", "authtype": "Author", "clusterid": ""}, {"name": "Radojewski P", "authtype": "Author", "clusterid": ""}, {"name": "Dumont RA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "24085501", "title": "Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.", "authors": [{"name": "Romer A", "authtype": "Author", "clusterid": ""}, {"name": "Seiler D", "authtype": "Author", "clusterid": ""}, {"name": "Marincek N", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).", "detailed_description": "Overall, 200 subjects will be randomized (1:1 randomization ratio) to receive standard injected activities of 177Lu-DOTATOC PRRT or personalized injection of 177Lu-DOTATOC PRRT. Randomization will be stratified for grade and primary location.\n\nScreening Phase: Subjects will be screened against the inclusion and exclusion criteria. Screening by SSR imaging will be completed to determine expression of SSR and feasibility of treatment by PRRT. Once eligibility has been confirmed they will be randomized. Subjects will undergo a physical exam, complete a medical history questionnaire, quality of life questionnaires, blood work, and a diagnostic CT.\n\nTreatment Phase: During the treatment phase, subjects will undergo 4 cycles of treatment. Each treatment cycle will be followed by 2 dosimetry SPECT/CT scans on day 1 (18 - 32 hours after treatment administration) and day 2 (64 - 80h after treatment administration) After cycle 3 quality of life questionnaires will be completed again.\n\nFollow up Phase: At the end of treatment or after discontinuation of any cause, subjects will be followed for 5 years to continue data collection for the other objectives. Objective tumour response will be assessed every 6 months by diagnostic CT according to the RECIST 1.1 criteria.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Standard PRRT", "type": "ACTIVE_COMPARATOR", "description": "For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq \u00b1 10% as an intravenous infusion over a time of 10 to 30 minutes.", "intervention_names": ["Drug: 177Lu-DOTATOC"]}, {"label": "Personalized PRRT", "type": "EXPERIMENTAL", "description": "For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq \u00b1 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.", "intervention_names": ["Drug: 177Lu-DOTATOC"]}], "interventions": [{"type": "DRUG", "name": "177Lu-DOTATOC", "description": "Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.", "arm_group_labels": ["Personalized PRRT", "Standard PRRT"]}]}}, "company_search_urls": ["https://www.google.com/search?q=British Columbia Cancer Agency+NCT04915144+terminated", "https://www.google.com/search?q=British Columbia Cancer Agency+177Lu-DOTATOC+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for 177Lu-DOTATOC by British Columbia Cancer Agency. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there's information about FDA warning letters or clinical holds for 177Lu-DOTATOC by British Columbia Cancer Agency.\n\nThe query specifically asks for:\n1. FDA warning letters or clinical holds\n2. For 177Lu-DOTATOC\n3. By British Columbia Cancer Agency\n4. Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if any of them contain this specific information:\n\nResult [1]: About FDA receiving a 505(b)(2) NDA for lutetium Lu 177 dotatate (not DOTATOC) from Curium for SSTR-positive GEP-NETs. Mentions NETTER-1 trial data. No mention of British Columbia Cancer Agency or warning letters.\n\nResult [2]: About various FDA cancer drug safety warnings, but none specifically related to 177Lu-DOTATOC or British Columbia Cancer Agency.\n\nResult [3]: About FDA approval of lutetium Lu 177 dotatate for pediatric patients. No mention of DOTATOC or British Columbia Cancer Agency.\n\nResult [4]: General information about FDA warning letters, but no specific letter related to 177Lu-DOTATOC or British Columbia Cancer Agency.\n\nResult [5]: Post-marketing safety evaluation of Lutathera (177Lu-DOTATATE), not DOTATOC. No mention of British Columbia Cancer Agency.\n\nResult [6]: About meningiomas, not related to 177Lu-DOTATOC.\n\nResult [7]: FDA approval of lutetium Lu 177 dotatate for pediatric SSTR+ GEP-NETs. Mentions NETTER-P trial. No mention of DOTATOC or British Columbia Cancer Agency.\n\nResult [8]: General information about therapeutic applications of radiopharmaceuticals. Mentions DOTATOC briefly as \"Y-90-DOTATOC has been prepared and evaluated as a potential candidate for treatment of tumours containing somatostatin receptors\" but no FDA warning letters or clinical holds.\n\nResult [9]: PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) information, not DOTATOC.\n\nResult [10]: Prospectus for Clarity Pharmaceuticals, not relevant to the query.\n\nResult [11]:", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by British Columbia Cancer Agency mentioning clinical trial NCT04915144 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by British Columbia Cancer Agency\n- That mention clinical trial NCT04915144 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nLet me go through the search results to see if they contain relevant information:\n\nResult [1]: This is an SEC filing detail for Form 8-K from CG Oncology, Inc. (CIK: 0001991792), filed on 2025-08-08. It mentions \"Results of Operations and Financial Condition\" and \"Financial Statements and Exhibits\" but doesn't appear to be from the British Columbia Cancer Agency. It also doesn't mention NCT04915144.\n\nResult [2]: This appears to be a general SEC EDGAR search page with no specific information about British Columbia Cancer Agency filings.\n\nResult [3]: This is a 10-K filing for Celator Pharmaceuticals, Inc. It mentions \"British Columbia Cancer Agency\" in what appears to be a reference to an exhibit (Exhibit 10.9), but it doesn't seem to be a filing by the British Columbia Cancer Agency itself. It also doesn't mention NCT04915144.\n\nResult [4]: This is a Form 20-F for CureVac N.V., which doesn't appear relevant to the British Columbia Cancer Agency or NCT04915144.\n\nResult [5]: This is a Form 20-F for Novartis, which doesn't appear relevant to the British Columbia Cancer Agency or NCT04915144.\n\nResult [6]: This mentions \"THE BRITISH COLUMBIA CANCER AGENCY BRANCH\" but appears to be an exhibit (EX-4.2) from another company's filing, not a filing by the British Columbia Cancer Agency itself. It doesn't mention NCT04915144.\n\nResult [7]: This is the EDGAR search page, which doesn't contain specific filing information.\n\nResult [8]: This shows SEC EDGAR filings for \"PROVINCE OF BRITISH COLUMBIA\" (CIK: 8361", "citations": [], "search_params": {"company": "British Columbia Cancer Agency", "nct_id": "NCT04915144", "start_date": "2023-01-15"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by British Columbia Cancer Agency about clinical trial NCT04915144 for 177Lu-DOTATOC. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by British Columbia Cancer Agency regarding clinical trial NCT04915144 for 177Lu-DOTATOC, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results to see what information is available:\n\nResult [1] - ClinConnect.io page for NCT04915144:\n- This is about the trial \"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs\"\n- Launched by BRITISH COLUMBIA CANCER AGENCY on May 31, 2021\n- Current status as of November 14, 2025: \"Withdrawn\"\n- Provides eligibility criteria but no specific information about why it was withdrawn or safety issues\n\nResult [2] - ClinicalTrials.gov for NCT04529044:\n- This is a different trial (NCT04529044) about 177Lu-DOTATATE, not the one we're looking for (NCT04915144)\n- Not relevant to our query\n\nResult [3] - ClinicalTrials.gov for NCT04915144:\n- This confirms the trial details for NCT04915144\n- Shows it's a study to \"assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT\"\n- No specific information about why it was withdrawn or safety issues\n\nResult [4] - ClinicalTrials.gov for NCT01578239:\n- Different trial about 177Lu-DOTA0\n- Not relevant to our query\n\nResult [5] - MedPath page:\n- Mentions \"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs. 2021/06/07. NCT04915144. Phase 2. Withdrawn. British Columbia Cancer...\"\n- Confirms the trial was withdrawn but doesn't provide reasons\n\nResult [6", "citations": [], "search_params": {"company": "British Columbia Cancer Agency", "nct_id": "NCT04915144", "drug_name": "177Lu-DOTATOC"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The detailed description does not mention any safety concerns, adverse events, or lack of efficacy. The official reason for the trial's withdrawal is \"Investigator decision,\" which suggests administrative or operational issues rather than problems with safety or efficacy. The trial was terminated early, likely due to factors unrelated to the drug's safety or effectiveness.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:04.407592", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1258}}, "69": {"nct_id": "NCT05468359", "drug_name": "Atezolizumab", "intervention_type": "DRUG", "drug_description": "Atezolizumab intravenously, every 3 weeks, Day 1", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Temporary closure due to review of toxicity", "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients", "start_date": "2022-11-07", "completion_date": "2037-06-30", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.557693", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:08.406863", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL3707227", "pref_name": "ATEZOLIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "Q15116", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NZQ7", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Atezolizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 2, "interactions": [{"protein_a": "CD4", "protein_b": "PTPN6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LGALS9", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPN11", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LAG3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD274", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1LG2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CTLA4", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD80", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD86", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PDCD1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD86", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "LGALS9", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD86", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "LGALS9", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CD274", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "PDCD1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD86", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "LGALS9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PTPN11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "LGALS9", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "PDCD1LG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LGALS9", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "PTPN11", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "PTPN11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PTPN6", "protein_b": "CTLA4", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTPN11", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "ICOS", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD28", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1LG2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "HAVCR2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "PDCD1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "TIGIT", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CTLA4", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD274", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LAG3", "protein_b": "CD80", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "STAT3", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "TIGIT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "HAVCR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1LG2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "ICOS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "PDCD1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD80", "protein_b": "CD28", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CD274", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "ICOS", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD28", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "TIGIT", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CTLA4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "PDCD1LG2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HAVCR2", "protein_b": "CD274", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "TIGIT", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "PDCD1LG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD28", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CD274", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ICOS", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "TIGIT", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PDCD1LG2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CTLA4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD274", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "TIGIT", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CTLA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "CD274", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1", "protein_b": "PDCD1LG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "TIGIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "PDCD1LG2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD274", "protein_b": "CTLA4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "TIGIT", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PDCD1LG2", "protein_b": "CTLA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIGIT", "protein_b": "CTLA4", "combined_score": 0.922, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.38, "clustering_coefficient": 5.69}}, "failure_enrichment": {"aact_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "aact_documents": [], "pubmed_results": [{"pmid": "41208418", "title": "Efficacy and safety of atezolizumab compared to docetaxel in non-small cell lung cancer patients regardless of PD-L1 status: a systematic review and meta-analysis.", "authors": [{"name": "Li X", "authtype": "Author", "clusterid": ""}, {"name": "Zhao H", "authtype": "Author", "clusterid": ""}, {"name": "Cui Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41178454", "title": "Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.", "authors": [{"name": "Ueshima K", "authtype": "Author", "clusterid": ""}, {"name": "Tsuchiya K", "authtype": "Author", "clusterid": ""}, {"name": "Yamashita T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41154354", "title": "Effectiveness of Atezolizumab in Addition to Chemotherapy in ES-SCLC: A Retrospective Real-World Monocentric Study.", "authors": [{"name": "Pagliaro R", "authtype": "Author", "clusterid": ""}, {"name": "Vitiello F", "authtype": "Author", "clusterid": ""}, {"name": "Gilli M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41142780", "title": "On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.", "authors": [{"name": "Hattenhauer T", "authtype": "Author", "clusterid": ""}, {"name": "Mispelbaum R", "authtype": "Author", "clusterid": ""}, {"name": "Heine A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41142252", "title": "Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma.", "authors": [{"name": "Zhu Y", "authtype": "Author", "clusterid": ""}, {"name": "He C", "authtype": "Author", "clusterid": ""}, {"name": "Cao SC", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies (Part 1), and then evaluate the response rate of this combination in children, AYA with relapsed or refractory hepatocellular carcinoma (HCC) and other rare solid malignancies (Part 2).\n\nPrimary Objectives Part 1\n\n* To establish the safety associated with the administration of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors\n* To determine if sorafenib systemic exposure can be successfully targeted to an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of cycle 1 in 60% of evaluable patients, when given in combination with cyclophosphamide, bevacizumab, and atezolizumab in children and AYA with relapsed or refractory solid tumors\n\nPart 2\n\n* To evaluate the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory HCC following two cycles of therapy\n* To determine if the use of PK-guided sorafenib dosing to maintain a systemic exposure between 20 and 55 reduces the interpatient pharmacokinetic variability of sorafenib and the incidence of sorafenib- induced skin toxicities in children and AYA with relapsed or refractory HCC and other rare solid tumors\n\nParts 1 \\& 2\n\n* To determine if the combination of cyclophosphamide, PK-guided sorafenib and atezolizumab will result in increased intratumoral T-cell infiltration of CD8+C45RO+ cells between baseline and following two courses of therapy in pediatric children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n* To characterize the pharmacokinetics of atezolizumab in combination with cyclophosphamide, PK-guided sorafenib and bevacizumab in children and AYA with relapsed or refractory solid tumors\n* To assess the feasibility of performing contrast enhanced ultrasound and explore the correlation between quantitative CEUS parameters and clinical response.\n\nSecondary Objectives\n\nPart 1\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n\nPart 2\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory fibrolamellar carcinoma, desmoplastic small round cell tumor, malignant rhabdoid tumor, and other rare solid tumors following two cycles of therapy\n\nParts 1\\&2\n\n* To describe the number of children with liver tumors, initially judged unresectable at diagnosis, that can have their primary tumor resected after treatment with oral cyclophosphamide and sorafenib with intravenous bevacizumab and atezolizumab\n* To describe changes in immune cells in the peripheral blood at periodic times before and after treatment with this combination chemoimmunotherapy\n* To describe the PFS, EFS, and OS in patients treated with the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab, and atezolizumab in patients with relapsed or refractory HCC, DSRCT, MRT, FL-HCC and other rare solid tumors", "detailed_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "OTHER", "description": "All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.", "intervention_names": ["Drug: Atezolizumab", "Drug: Sorafenib", "Drug: Bevacizumab", "Drug: Cyclophosphamide"]}], "interventions": [{"type": "DRUG", "name": "Atezolizumab", "description": "Atezolizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Sorafenib", "description": "Sorafenib by mouth every 12 hours, Days 1-21", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Bevacizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Cyclophosphamide", "description": "Low-dose cyclophosphamide by mouth once daily, Days 1-21", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT05468359+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+Atezolizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Atezolizumab by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Atezolizumab by St. Jude Children's Research Hospital.\n\nFirst, I need to identify which results might contain relevant information:\n\n1. Results [1], [5], and [9] are about FDA warning letters to St. Jude Medical (which was later acquired by Abbott), but these are about medical devices (ICD leads and EP devices), not about Atezolizumab or St. Jude Children's Research Hospital.\n\n2. Results [2], [3], [6] are about FDA alerts regarding atezolizumab (Tecentriq) in combination with paclitaxel for breast cancer treatment. These mention safety concerns but are not related to St. Jude Children's Research Hospital.\n\n3. Result [4] is about FDA approval of a new formulation of atezolizumab (subcutaneous injection), not a warning letter.\n\n4. Result [7] mentions the NCI-COG Pediatric MATCH Trial which includes some safety information about selumetinib, but not atezolizumab or St. Jude Children's Research Hospital.\n\n5. Result [8] contains general FDA cancer drug safety warnings, but none specifically about atezolizumab from St. Jude Children's Research Hospital.\n\n6. Result [10] is about a clinical trial of atezolizumab, but not a warning letter.\n\n7. Result [13] is about another clinical trial involving atezolizumab, but not a warning letter.\n\n8. Result [15] mentions atezolizumab as a programmed cell death ligand 1 inhibitor, but not in relation to any warning letter from St. Jude Children's Research Hospital.\n\n9. Result [16] mentions pediatric oncology drugs but doesn't specifically address atezolizumab or St. Jude Children's Research Hospital.\n\n10. Results [11], [12], [14], and [17] don't appear to contain relevant information about FDA warning letters for atezolizumab from St. Jude Children's Research Hospital.\n\nAfter reviewing all the search results, I don't see any information about FDA warning letters or clinical holds specifically for Atezolizumab by St. Jude Children's Research Hospital. \n\nThere are several important distinctions to note", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT05468359 for Atezolizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about St. Jude Children's Research Hospital's press releases, investor presentations, or public statements regarding clinical trial NCT05468359 (which involves Atezolizumab) with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each search result:\n\n[1] This is a ClinicalTrials.gov entry for NCT05468359, which describes a phase I/II study evaluating the safety of combining atezolizumab, bevacizumab, cyclophosphamide, and sorafenib in pediatric solid tumor patients. It outlines the study objectives but doesn't provide any information about safety issues, adverse events, trial termination, or regulatory actions. It's just the study description.\n\n[2] This is St. Jude's news releases page. It contains various news items from August 2025 to March 2025, but I don't see any specific mention of NCT05468359 or safety issues related to this trial. The news items are about other clinical trials and research findings.\n\n[3] This is a Cancer Knowledgebase entry for NCT05468359, which just confirms the trial title but doesn't provide any safety information or statements from St. Jude.\n\n[4] This is St. Jude's solid tumor clinical trials page. It lists various clinical trials but doesn't specifically mention NCT05468359 or provide safety information about it.\n\n[5] This is a ClinConnect page for NCT05468359. It states that the trial is \"Suspended\" as of November 14, 2025 (which is today's date according to the prompt). This is important information! It indicates the trial status is suspended, but it doesn't explain why it was suspended or provide details about safety issues.\n\n[6] This is another clinical trial listing for NCT05468359, providing more details about the study objectives but no information about safety issues or why it might have been suspended.\n\n[7] This is St. Jude's page about the ANGIO-A trial (which appears to be NCT05468359). It describes the study but doesn't mention any", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT05468359", "drug_name": "Atezolizumab"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a review of toxicity, indicating that there were safety concerns or adverse events that led to the temporary closure of the trial. The detailed description does not mention any issues with efficacy, but rather focuses on exploratory objectives related to evaluating the immune cell infiltrates and other tumor-related markers. Therefore, the available information suggests that the trial was terminated due to safety reasons, rather than efficacy or administrative issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:08.405346", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1386}}, "70": {"nct_id": "NCT05468359", "drug_name": "Bevacizumab", "intervention_type": "DRUG", "drug_description": "Bevacizumab intravenously, every 3 weeks, Day 1", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Temporary closure due to review of toxicity", "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients", "start_date": "2022-11-07", "completion_date": "2037-06-30", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.558189", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:08.443870", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1201583", "pref_name": "BEVACIZUMAB", "targets": [{"chembl_id": null, "uniprot_id": "P31995", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P12318", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P02746", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P12314", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P02747", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Bevacizumab", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "CRP", "protein_b": "FCGR1A", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CRP", "protein_b": "FCGR3A", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CRP", "protein_b": "APCS", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CRP", "protein_b": "FCGR2A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "APCS", "protein_b": "FCGR2A", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCER1G", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCGR3A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCGR1A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "LOC102723407", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "HCK", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "LYN", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "SRC", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "SYK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "SRC", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "HCK", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "LOC102723407", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "FCGR1A", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "LYN", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "FCGR3A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "SRC", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "LOC102723407", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "HCK", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "LYN", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "FCGR1A", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "SYK", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "SRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "LOC102723407", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "LYN", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "HCK", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "SYK", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "HCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "HCK", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LOC102723407", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LYN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HCK", "protein_b": "LYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LOC102723407", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C4B", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C4A", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QC", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QA", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QB", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1S", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QC", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1S", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QA", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1R", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C4A", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C4B", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "CALR", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "VSIG4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C4B", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C4A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1S", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1QA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1QC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALR", "protein_b": "C1QC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CALR", "protein_b": "C1QA", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "VSIG4", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C4B", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C4A", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1S", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1R", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1QA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "VSIG4", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C4B", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C4A", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C1R", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C1S", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C4B", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C4A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C4A", "protein_b": "C1R", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "C4A", "protein_b": "C4B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C4B", "protein_b": "C1R", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "HCK", "combined_score": 0.727, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "FCGR1A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "IGF1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "IGF2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCER1G", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCGR3A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "FCGR1A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "HCK", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "LYN", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "FCGR2A", "protein_b": "SYK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "HCK", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "FCGR1A", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "LYN", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "FCGR3A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FCER1G", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "HCK", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "LYN", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "FCGR1A", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FCGR3A", "protein_b": "SYK", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "LYN", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "IGF2", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "HCK", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "SYK", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "IGF1", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "FCGR1A", "protein_b": "FCGR1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "HCK", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LYN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HCK", "protein_b": "LYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IGF1", "protein_b": "IGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C4B", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C4A", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QC", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QA", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1QB", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1S", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPING1", "protein_b": "C1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QC", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1S", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QA", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1R", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C4A", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C1QB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "C2", "protein_b": "C4B", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "CALR", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "VSIG4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C4B", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C4A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1S", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1QA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C1QB", "protein_b": "C1QC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALR", "protein_b": "C1QC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CALR", "protein_b": "C1QA", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "VSIG4", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C4B", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C4A", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1S", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1R", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1QC", "protein_b": "C1QA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "VSIG4", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C4B", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C4A", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C1R", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "C1QA", "protein_b": "C1S", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C4B", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C4A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "C1S", "protein_b": "C1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C4A", "protein_b": "C1R", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "C4A", "protein_b": "C4B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "C4B", "protein_b": "C1R", "combined_score": 0.991, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.54, "clustering_coefficient": 5.77}}, "failure_enrichment": {"aact_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "aact_documents": [], "pubmed_results": [{"pmid": "41230651", "title": "BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer.", "authors": [{"name": "Kopetz S", "authtype": "Author", "clusterid": ""}, {"name": "Tabernero J", "authtype": "Author", "clusterid": ""}, {"name": "\u00c9lez E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41199978", "title": "Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO-01).", "authors": [{"name": "Takakura Y", "authtype": "Author", "clusterid": ""}, {"name": "Shinozaki K", "authtype": "Author", "clusterid": ""}, {"name": "Ikeda S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41189777", "title": "Randomized study evaluating the efficacy of sustained-release dexamethasone with or without prompt laser for branch retinal vein occlusion-related macular edema.", "authors": [{"name": "Markan A", "authtype": "Author", "clusterid": ""}, {"name": "Azad SV", "authtype": "Author", "clusterid": ""}, {"name": "Takkar B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41178454", "title": "Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.", "authors": [{"name": "Ueshima K", "authtype": "Author", "clusterid": ""}, {"name": "Tsuchiya K", "authtype": "Author", "clusterid": ""}, {"name": "Yamashita T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41144065", "title": "Radiosurgery for recurrent high-grade gliomas: a critical analysis based on a retrospective single-center series.", "authors": [{"name": "Novak Filho JL", "authtype": "Author", "clusterid": ""}, {"name": "Duarte JS", "authtype": "Author", "clusterid": ""}, {"name": "Constanzo F", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies (Part 1), and then evaluate the response rate of this combination in children, AYA with relapsed or refractory hepatocellular carcinoma (HCC) and other rare solid malignancies (Part 2).\n\nPrimary Objectives Part 1\n\n* To establish the safety associated with the administration of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors\n* To determine if sorafenib systemic exposure can be successfully targeted to an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of cycle 1 in 60% of evaluable patients, when given in combination with cyclophosphamide, bevacizumab, and atezolizumab in children and AYA with relapsed or refractory solid tumors\n\nPart 2\n\n* To evaluate the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory HCC following two cycles of therapy\n* To determine if the use of PK-guided sorafenib dosing to maintain a systemic exposure between 20 and 55 reduces the interpatient pharmacokinetic variability of sorafenib and the incidence of sorafenib- induced skin toxicities in children and AYA with relapsed or refractory HCC and other rare solid tumors\n\nParts 1 \\& 2\n\n* To determine if the combination of cyclophosphamide, PK-guided sorafenib and atezolizumab will result in increased intratumoral T-cell infiltration of CD8+C45RO+ cells between baseline and following two courses of therapy in pediatric children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n* To characterize the pharmacokinetics of atezolizumab in combination with cyclophosphamide, PK-guided sorafenib and bevacizumab in children and AYA with relapsed or refractory solid tumors\n* To assess the feasibility of performing contrast enhanced ultrasound and explore the correlation between quantitative CEUS parameters and clinical response.\n\nSecondary Objectives\n\nPart 1\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n\nPart 2\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory fibrolamellar carcinoma, desmoplastic small round cell tumor, malignant rhabdoid tumor, and other rare solid tumors following two cycles of therapy\n\nParts 1\\&2\n\n* To describe the number of children with liver tumors, initially judged unresectable at diagnosis, that can have their primary tumor resected after treatment with oral cyclophosphamide and sorafenib with intravenous bevacizumab and atezolizumab\n* To describe changes in immune cells in the peripheral blood at periodic times before and after treatment with this combination chemoimmunotherapy\n* To describe the PFS, EFS, and OS in patients treated with the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab, and atezolizumab in patients with relapsed or refractory HCC, DSRCT, MRT, FL-HCC and other rare solid tumors", "detailed_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "OTHER", "description": "All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.", "intervention_names": ["Drug: Atezolizumab", "Drug: Sorafenib", "Drug: Bevacizumab", "Drug: Cyclophosphamide"]}], "interventions": [{"type": "DRUG", "name": "Atezolizumab", "description": "Atezolizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Sorafenib", "description": "Sorafenib by mouth every 12 hours, Days 1-21", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Bevacizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Cyclophosphamide", "description": "Low-dose cyclophosphamide by mouth once daily, Days 1-21", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT05468359+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+Bevacizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Bevacizumab by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds for Bevacizumab by St. Jude Children's Research Hospital. Let me go through each result carefully.\n\nResult [1]: This is about FDA giving new warnings for bevacizumab (Avastin) regarding ovarian failure, osteonecrosis of the jaw, and venous thromboembolytic events. It doesn't mention St. Jude Children's Research Hospital.\n\nResult [2]: This is about a voluntary recall of bevacizumab by AmEx Pharmacy due to a defective delivery system. It doesn't mention St. Jude Children's Research Hospital.\n\nResult [3]: This is about an FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital) regarding ICD leads. This is about a different company (St. Jude Medical, which is a medical device company) and not about bevacizumab.\n\nResult [4]: This is about bevacizumab and gastrointestinal perforations, but doesn't mention St. Jude Children's Research Hospital.\n\nResult [5]: This is about a Class II recall of bevacizumab injection due to lack of assurance of sterility. It doesn't mention St. Jude Children's Research Hospital.\n\nResult [6]: This is about recent FDA cancer drug safety warnings, but doesn't specifically mention bevacizumab or St. Jude Children's Research Hospital.\n\nResult [7]: This is an important drug warning regarding AVASTIN (bevacizumab) about tracheoesophageal fistula, but doesn't mention St. Jude Children's Research Hospital.\n\nResult [8]: This appears to be a protocol document for a study titled \"RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH...\" but the content snippet doesn't clearly indicate if it's from St. Jude Children's Research Hospital or if it's related to bevacizumab.\n\nResult [9]: This is an FDA label document for bevacizumab, but doesn't mention St. Jude Children's Research Hospital.\n\nResult [10]: This is an FDA review document, but doesn't appear to be about bevacizumab or St. Jude Children's Research Hospital.\n\nResult [11]: This is about novel adverse events of bevacizumab from the FDA's Adverse Event Reporting System, but doesn't mention St. Jude", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT05468359 for Bevacizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital\n- Specifically about clinical trial NCT05468359 for Bevacizumab\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me check if the search results contain any press releases, investor presentations, or public statements from St. Jude about this specific trial.\n\nFrom the search results:\n\n1. Result [1] is from Cancer Knowledgebase (CKB) showing trial details - NCT05468359 is suspended, but doesn't provide reasons for suspension.\n\n2. Result [2] is from clinicaltrials.gov with study overview - describes the trial as a phase I/II study evaluating safety of the combination therapy, but doesn't mention any safety issues or reasons for suspension.\n\n3. Result [3] is about bevacizumab in general from St. Jude's Together website - describes the drug, its mechanism, and possible side effects, but not specific to this trial.\n\n4. Result [4] is from ClinConnect - states the trial is \"Suspended\" as of November 14, 2025 (which is today's date according to the prompt), but doesn't provide reasons.\n\n5. Result [5] is from St. Jude's website about solid tumor clinical trials - mentions the trial but doesn't provide suspension reasons.\n\n6. Result [6] is from St. Jude's clinical trials page (ANGIO-A) - describes the trial but doesn't mention suspension or safety issues.\n\n7. Result [7] is from TrialX - provides detailed study information but no suspension reasons.\n\n8. Result [8] is from cancer.gov - brief description of the trial but no suspension information.\n\n9. Result [9] appears to be about a different trial (NCT00665990) - not relevant to our query.\n\nKey findings:\n- Multiple sources confirm the trial (NCT05468359) is suspended (Results [1], [4])\n- Result [4] specifically states \"Suspended\" with the current date (November 14, 2025)\n- None of the search results provide specific reasons for suspension\n- None", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT05468359", "drug_name": "Bevacizumab"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a review of toxicity, indicating that there were safety concerns or adverse events that led to the temporary closure of the trial. The detailed description does not mention any issues with efficacy, but rather focuses on exploratory objectives related to evaluating the immune cell infiltrates and other tumor-related markers. Therefore, the available information suggests that the trial was terminated due to safety reasons, rather than efficacy or administrative issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:08.405346", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1386}}, "71": {"nct_id": "NCT05468359", "drug_name": "Cyclophosphamide", "intervention_type": "DRUG", "drug_description": "Low-dose cyclophosphamide by mouth once daily, Days 1-21", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Temporary closure due to review of toxicity", "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients", "start_date": "2022-11-07", "completion_date": "2037-06-30", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.558735", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:08.479613", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200796", "pref_name": "CYCLOPHOSPHAMIDE", "targets": [{"chembl_id": null, "uniprot_id": "P11509", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P33260", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O75469", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P20815", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P20813", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Cyclophosphamide", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP26A1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP4A11", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP4A22", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "ENSP00000480571", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP3A5", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP3A7", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP2C18", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP1A1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CYP26B1", "protein_b": "CYP1A2", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "ENSP00000480571", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP26A1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A22", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C18", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A7", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP4A22", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP4A11", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ENSP00000480571", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP3A7", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP2C18", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP1A2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "CYP1A1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "CYP4A22", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "CYP1A2", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "CYP4A11", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "CYP1A1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "ENSP00000480571", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C18", "protein_b": "CYP3A7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ENSP00000480571", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A7", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP4A22", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "ENSP00000480571", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP4A22", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "ENSP00000480571", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP4A22", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP1A1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP4A22", "protein_b": "ENSP00000480571", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4A22", "protein_b": "CYP1A1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "ENSP00000480571", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "RXRA", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NCOR2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "XPR1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPARGC1A", "protein_b": "NCOR2", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "PPARGC1A", "protein_b": "XPR1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "PPARGC1A", "protein_b": "NR1I2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "PPARGC1A", "protein_b": "RXRA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PPARGC1A", "protein_b": "NCOA1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "NR1I2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP3A7", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "NCOR2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "EPRS1", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "XPR1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP3A4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "NCOA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "RXRA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "XPR1", "protein_b": "RXRA", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "NCOR2", "protein_b": "NCOA1", "combined_score": 0.884, "interaction_type": "physical"}, {"protein_a": "NCOR2", "protein_b": "RXRA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "RXRA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A7", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2B6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A7", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT2B7", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A10", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A6", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A8", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "UGT1A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2B6", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A7", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2B6", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A7", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2B6", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A7", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A10", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A4", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "UGT1A7", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "UGT1A8", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "UGT1A10", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "UGT1A4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "SULT2A1", "protein_b": "CYP3A4", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "SULT2A1", "protein_b": "CYP1A1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SULT2A1", "protein_b": "CYP2B6", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "ENSP00000480571", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "AOX1", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A7", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2B6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "ENSP00000480571", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A7", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2B6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "AOX1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ENSP00000480571", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A7", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "ENSP00000480571", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "AOX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "ENSP00000480571", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "ENSP00000480571", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "AOX1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP1A1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "ENSP00000480571", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "ENSP00000480571", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}], "network_features": {"avg_degree": 11.88, "clustering_coefficient": 5.94}}, "failure_enrichment": {"aact_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "aact_documents": [], "pubmed_results": [{"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41196599", "title": "Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.", "authors": [{"name": "Pasquali S", "authtype": "Author", "clusterid": ""}, {"name": "Collini P", "authtype": "Author", "clusterid": ""}, {"name": "Romagosa C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41193417", "title": "Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.", "authors": [{"name": "Lee CK", "authtype": "Author", "clusterid": ""}, {"name": "Kartikasari AER", "authtype": "Author", "clusterid": ""}, {"name": "Bound NT", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41168851", "title": "Lupus enteritis and peritonitis as a first presentation of systemic lupus erythematosus: a case report.", "authors": [{"name": "Douden BKA", "authtype": "Author", "clusterid": ""}, {"name": "Hashlamon N", "authtype": "Author", "clusterid": ""}, {"name": "Al-Zaro M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41164763", "title": "Assessing the efficacy and safety of pentoxifylline in preventing chemotherapy-induced peripheral neuropathy and mucositis in breast cancer patients.", "authors": [{"name": "Dewidar SA", "authtype": "Author", "clusterid": ""}, {"name": "Mansour NO", "authtype": "Author", "clusterid": ""}, {"name": "Hamdy O", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies (Part 1), and then evaluate the response rate of this combination in children, AYA with relapsed or refractory hepatocellular carcinoma (HCC) and other rare solid malignancies (Part 2).\n\nPrimary Objectives Part 1\n\n* To establish the safety associated with the administration of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors\n* To determine if sorafenib systemic exposure can be successfully targeted to an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of cycle 1 in 60% of evaluable patients, when given in combination with cyclophosphamide, bevacizumab, and atezolizumab in children and AYA with relapsed or refractory solid tumors\n\nPart 2\n\n* To evaluate the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory HCC following two cycles of therapy\n* To determine if the use of PK-guided sorafenib dosing to maintain a systemic exposure between 20 and 55 reduces the interpatient pharmacokinetic variability of sorafenib and the incidence of sorafenib- induced skin toxicities in children and AYA with relapsed or refractory HCC and other rare solid tumors\n\nParts 1 \\& 2\n\n* To determine if the combination of cyclophosphamide, PK-guided sorafenib and atezolizumab will result in increased intratumoral T-cell infiltration of CD8+C45RO+ cells between baseline and following two courses of therapy in pediatric children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n* To characterize the pharmacokinetics of atezolizumab in combination with cyclophosphamide, PK-guided sorafenib and bevacizumab in children and AYA with relapsed or refractory solid tumors\n* To assess the feasibility of performing contrast enhanced ultrasound and explore the correlation between quantitative CEUS parameters and clinical response.\n\nSecondary Objectives\n\nPart 1\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n\nPart 2\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory fibrolamellar carcinoma, desmoplastic small round cell tumor, malignant rhabdoid tumor, and other rare solid tumors following two cycles of therapy\n\nParts 1\\&2\n\n* To describe the number of children with liver tumors, initially judged unresectable at diagnosis, that can have their primary tumor resected after treatment with oral cyclophosphamide and sorafenib with intravenous bevacizumab and atezolizumab\n* To describe changes in immune cells in the peripheral blood at periodic times before and after treatment with this combination chemoimmunotherapy\n* To describe the PFS, EFS, and OS in patients treated with the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab, and atezolizumab in patients with relapsed or refractory HCC, DSRCT, MRT, FL-HCC and other rare solid tumors", "detailed_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "OTHER", "description": "All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.", "intervention_names": ["Drug: Atezolizumab", "Drug: Sorafenib", "Drug: Bevacizumab", "Drug: Cyclophosphamide"]}], "interventions": [{"type": "DRUG", "name": "Atezolizumab", "description": "Atezolizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Sorafenib", "description": "Sorafenib by mouth every 12 hours, Days 1-21", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Bevacizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Cyclophosphamide", "description": "Low-dose cyclophosphamide by mouth once daily, Days 1-21", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT05468359+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+Cyclophosphamide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Cyclophosphamide by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically for Cyclophosphamide by St. Jude Children's Research Hospital.\n\nLet me go through each search result to identify relevant information:\n\nResult [1]: This is about an FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital) regarding ICD leads (medical devices), not about cyclophosphamide. This is not relevant to our query.\n\nResult [2]: This discusses FDA cancer drug safety warnings for various drugs (pexidartinib, capecitabine, duvelisib, denosumab-bnht, ciltacabtagene autoleucel), but doesn't mention cyclophosphamide or St. Jude Children's Research Hospital specifically.\n\nResult [3]: This is a PDF about cyclophosphamide injection (NDA 217150). It discusses concerns about ethanol and propylene glycol content in a cyclophosphamide product, particularly for pediatric patients. It mentions that the EMA's suggested limit of exposure to propylene glycol (50 mg/kg) is easily surpassed with use of this cyclophosphamide product at pediatric dosing. The document recommends that this specific cyclophosphamide product is not indicated for use in pediatric patients. However, this doesn't appear to be specifically about St. Jude Children's Research Hospital.\n\nResult [4]: This appears to be a protocol document (AEWS1031) from the Children's Oncology Group, but the snippet doesn't provide specific information about FDA warning letters or clinical holds for cyclophosphamide at St. Jude.\n\nResult [5]: This is information about cyclophosphamide for childhood cancer patients from St. Jude Children's Research Hospital's website. It describes how cyclophosphamide works, possible side effects, and administration information. However, it doesn't mention any FDA warning letters or clinical holds.\n\nResult [6]: This is a Juno Therapeutics SEC filing that mentions St. Jude Children's Research Hospital in the context of an agreement, but doesn't discuss cyclophosphamide or FDA warning letters.\n\nResult [7]: This is the FDA label for cyclophosphamide injection. It describes warnings and precautions including myelosuppression, urinary tract and renal toxicity, and other side effects. However, it doesn't mention any", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT05468359 for Cyclophosphamide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about external safety evidence for clinical trial NCT05468359.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital\n- Specifically about clinical trial NCT05468359 for Cyclophosphamide\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available:\n\nResult [1]: This is from ClinConnect about the trial NCT05468359. It describes the trial as studying a combination of four medications (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) for pediatric solid tumor patients. It mentions the trial was launched by St. Jude Children's Research Hospital on July 19, 2022. The status is listed as \"Current as of November 14, 2025\" but doesn't specify if it's active or suspended.\n\nResult [2]: This is St. Jude's news releases page. It lists several news items but none specifically about trial NCT05468359. The news items are about other clinical trials and research findings.\n\nResult [3]: This is from Cancer Knowledgebase (CKB) showing details about NCT05468359. It explicitly states the recruitment status is \"Suspended\". This is important information related to the query.\n\nResult [4]: This is from clinicaltrials.gov with details about the trial. It describes it as a phase I/II study evaluating the safety of combining atezolizumab, bevacizumab, cyclophosphamide, and sorafenib. However, it doesn't mention the current status or any safety issues.\n\nResult [5]: This is from St. Jude's website describing the ANGIO-A trial (which is NCT05468359). It explains the purpose of the study but doesn't mention any safety issues or trial status changes.\n\nResult [6]: This is from TrialX with similar information to clinicaltrials.gov about the study design and objectives.\n\nResult [7]: This appears to be about cyclophosphamide clinical trials in general, not specifically about N", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT05468359", "drug_name": "Cyclophosphamide"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a review of toxicity, indicating that there were safety concerns or adverse events that led to the temporary closure of the trial. The detailed description does not mention any issues with efficacy, but rather focuses on exploratory objectives related to evaluating the immune cell infiltrates and other tumor-related markers. Therefore, the available information suggests that the trial was terminated due to safety reasons, rather than efficacy or administrative issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:08.405346", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1386}}, "72": {"nct_id": "NCT05468359", "drug_name": "Sorafenib", "intervention_type": "DRUG", "drug_description": "Sorafenib by mouth every 12 hours, Days 1-21", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "Temporary closure due to review of toxicity", "title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients", "start_date": "2022-11-07", "completion_date": "2037-06-30", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.559320", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:08.515362", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200485", "pref_name": "SORAFENIB TOSYLATE", "targets": [{"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 6580.0, "units": "nM"}, {"value": 3420.0, "units": "nM"}, {"value": 70600.0, "units": "nM"}, {"value": 13400.0, "units": "nM"}, {"value": 64591.0, "units": "nM"}, {"value": 4.21, "units": "nM"}, {"value": 16700.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 1463.7, "units": "nM"}, {"value": 1181.3, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 1168.43, "units": "nM"}, {"value": 1262.7, "units": "nM"}, {"value": 1508.9, "units": "nM"}, {"value": 933.9, "units": "nM"}, {"value": 46.8, "units": "nM"}, {"value": 507.5, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL259", "ic50_values": [{"value": 4480.0, "units": "nM"}], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4282", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "B2RAM5"}, {"chembl_id": "CHEMBL2185", "ic50_values": [{"value": 1800.0, "units": "nM"}], "uniprot_id": "B4DNM4"}, {"chembl_id": "CHEMBL2695", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "B4E2N6"}, {"chembl_id": "CHEMBL279", "ic50_values": [{"value": 22.0, "units": "nM"}, {"value": 12.5, "units": "nM"}, {"value": 8.5, "units": "nM"}], "uniprot_id": "A2RRS0"}, {"chembl_id": "CHEMBL3024", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "Q15153"}, {"chembl_id": "CHEMBL4296437", "ic50_values": [{"value": 1500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614039", "ic50_values": [{"value": 1600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4296473", "ic50_values": [{"value": 700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 1550.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 1384.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL400", "ic50_values": [{"value": 349.3, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL395", "ic50_values": [{"value": 214.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613979", "ic50_values": [{"value": 1954.0, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Sorafenib"}, "ppi_enrichment": {"uniprot_count": 6, "interactions": [{"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "HSP90AB1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "FOXO1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "FOXO3", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PHLPP1", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "FOXO1", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "HSP90AA1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "MTOR", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PDPK1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CDC42", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "AKT1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PDPK1", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "MTOR", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOXO3", "protein_b": "MTOR", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "FOXO3", "protein_b": "FOXO1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "FOXO3", "protein_b": "AKT1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PDPK1", "protein_b": "FOXO1", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PDPK1", "protein_b": "MTOR", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "PDPK1", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "FOXO1", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOXO1", "protein_b": "AKT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AKT1", "protein_b": "CDC42", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "INCENP", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CENPA", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "BIRC5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "KIF2C", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CCNA2", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CDCA8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "AURKB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "BUB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CDK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CENPA", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CCNA2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "KIF2C", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "BUB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CDC20", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CDK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "AURKB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "INCENP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CDCA8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "INCENP", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CENPA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CDCA8", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CCNA2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "KIF2C", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "AURKB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CDK1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "CCNA2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "KIF2C", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "CDK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "CENPA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "CDC20", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "INCENP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AURKB", "protein_b": "CDCA8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "INCENP", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "CDCA8", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "KIF2C", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "CDC20", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "CDK1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CENPA", "protein_b": "CCNA2", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "KIF2C", "protein_b": "INCENP", "combined_score": 0.899, "interaction_type": "physical"}, {"protein_a": "KIF2C", "protein_b": "CCNA2", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "KIF2C", "protein_b": "CDK1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "KIF2C", "protein_b": "CDCA8", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "KIF2C", "protein_b": "CDC20", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "INCENP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "CDCA8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "CCNA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "CDK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDCA8", "protein_b": "CCNA2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CDCA8", "protein_b": "CDK1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CDCA8", "protein_b": "INCENP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INCENP", "protein_b": "CDK1", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CDK1", "protein_b": "CCNA2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "GRB2", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "SRC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "PTK2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "TLN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "TLN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "PXN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VCL", "protein_b": "BCAR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "EGFR", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "FYN", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "GRB2", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "PTK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "TLN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "TLN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PXN", "protein_b": "BCAR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "BCAR1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "FYN", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SOS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "PTK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "GRB2", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "FYN", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "TLN2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "BCAR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLN1", "protein_b": "PTK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "BCAR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SOS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "TLN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SOS1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "BCAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "GRB2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SOS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "BCAR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "TLN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "BCAR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SOS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BCAR1", "protein_b": "TLN2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "SRC", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PECAM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PECAM1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CDH5", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "PECAM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PECAM1", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "CDC25C", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "FZR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "BUB1B", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "BUB1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "BORA", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "CCNB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "CDC20", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "PLK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "ERCC6L", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "CENPU", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "BORA", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "CDC25C", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "BUB1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "BUB1B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "FZR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCNB1", "protein_b": "PLK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CENPU", "protein_b": "BUB1", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CENPU", "protein_b": "BUB1B", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CENPU", "protein_b": "CDC20", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CENPU", "protein_b": "PLK1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CDC25C", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "ERCC6L", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "FZR1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "PLK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "BUB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1B", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "BUB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "BORA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "ERCC6L", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "CDC25C", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "FZR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "ERCC6L", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "FZR1", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CDC25C", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "BUB1", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDC25C", "protein_b": "CDC20", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "ERCC6L", "protein_b": "CDC20", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "FZR1", "combined_score": 0.937, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.32, "clustering_coefficient": 3.66}}, "failure_enrichment": {"aact_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "aact_documents": [], "pubmed_results": [{"pmid": "41232667", "title": "RhoE down-regulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma.", "authors": [{"name": "Feng J", "authtype": "Author", "clusterid": ""}, {"name": "Ye L", "authtype": "Author", "clusterid": ""}, {"name": "Chen C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41212469", "title": "Triphenylamine-Thiophene Donor-\u03c0-Acceptor Chromophores: Synthesis, Photophysical Properties, TD-DFT Analysis, and Anticancer Potential.", "authors": [{"name": "Alomari KB", "authtype": "Author", "clusterid": ""}, {"name": "Bayazeed A", "authtype": "Author", "clusterid": ""}, {"name": "Alhawiti F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41179951", "title": "Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study.", "authors": [{"name": "Liang L", "authtype": "Author", "clusterid": ""}, {"name": "Zhou J", "authtype": "Author", "clusterid": ""}, {"name": "Huang J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41169385", "title": "First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.", "authors": [{"name": "Lin Y", "authtype": "Author", "clusterid": ""}, {"name": "Liao Y", "authtype": "Author", "clusterid": ""}, {"name": "Luo B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41142780", "title": "On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.", "authors": [{"name": "Hattenhauer T", "authtype": "Author", "clusterid": ""}, {"name": "Mispelbaum R", "authtype": "Author", "clusterid": ""}, {"name": "Heine A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies (Part 1), and then evaluate the response rate of this combination in children, AYA with relapsed or refractory hepatocellular carcinoma (HCC) and other rare solid malignancies (Part 2).\n\nPrimary Objectives Part 1\n\n* To establish the safety associated with the administration of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors\n* To determine if sorafenib systemic exposure can be successfully targeted to an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of cycle 1 in 60% of evaluable patients, when given in combination with cyclophosphamide, bevacizumab, and atezolizumab in children and AYA with relapsed or refractory solid tumors\n\nPart 2\n\n* To evaluate the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory HCC following two cycles of therapy\n* To determine if the use of PK-guided sorafenib dosing to maintain a systemic exposure between 20 and 55 reduces the interpatient pharmacokinetic variability of sorafenib and the incidence of sorafenib- induced skin toxicities in children and AYA with relapsed or refractory HCC and other rare solid tumors\n\nParts 1 \\& 2\n\n* To determine if the combination of cyclophosphamide, PK-guided sorafenib and atezolizumab will result in increased intratumoral T-cell infiltration of CD8+C45RO+ cells between baseline and following two courses of therapy in pediatric children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n* To characterize the pharmacokinetics of atezolizumab in combination with cyclophosphamide, PK-guided sorafenib and bevacizumab in children and AYA with relapsed or refractory solid tumors\n* To assess the feasibility of performing contrast enhanced ultrasound and explore the correlation between quantitative CEUS parameters and clinical response.\n\nSecondary Objectives\n\nPart 1\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory solid tumors following two cycles of therapy\n\nPart 2\n\n\u2022 To describe the response rate (CR+PR) of the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab and atezolizumab in children and AYA with relapsed or refractory fibrolamellar carcinoma, desmoplastic small round cell tumor, malignant rhabdoid tumor, and other rare solid tumors following two cycles of therapy\n\nParts 1\\&2\n\n* To describe the number of children with liver tumors, initially judged unresectable at diagnosis, that can have their primary tumor resected after treatment with oral cyclophosphamide and sorafenib with intravenous bevacizumab and atezolizumab\n* To describe changes in immune cells in the peripheral blood at periodic times before and after treatment with this combination chemoimmunotherapy\n* To describe the PFS, EFS, and OS in patients treated with the combination of cyclophosphamide, PK-guided sorafenib, bevacizumab, and atezolizumab in patients with relapsed or refractory HCC, DSRCT, MRT, FL-HCC and other rare solid tumors", "detailed_description": "Exploratory Objectives (Parts 1 \\& 2)\n\n* To determine the number of HCC and FL-HCC xenografts that can be successfully established from children with relapsed or refractory HCC (enrollment on MAST with biopsy for fresh tissue required)\n* To evaluate the immune cell infiltrates in children with relapsed or refractory solid tumors before and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To evaluate the number, type, specificity, repertoire, and activity of intratumoral T cells after two cycles of therapy, compared to baseline\n* To characterize changes in tumor associated macrophages (polarization) between baseline and after two cycles of cyclophosphamide, sorafenib, bevacizumab and atezolizumab\n* To measure changes in tumor mutational burden and mutation heterogeneity\n* To explore associations between T stem cell epigenetic signatures and response to treatment\n* To explore the association between baseline CD45RO+/CD8+ T-cell infiltration and PD-L1 expression and response to treatment\n* To characterize tumor heterogeneity and microenvironment using single-cell/nuclear RNA sequencing pre- and post-treatment\n* To longitudinally assess and quantify numerous metrics of quality of life (QoL), family distress and functional impairment for patients enrolled on ANGIOA and their primary caretakers\n* To qualitatively assess patient and family physical, emotional and psychosocial experiences prior to and after receipt of therapy on ANGIOA through semi-structured interviews\n* To assess the acceptability and feasibility of capturing patient/caregiver interview data at the time of enrollment and discontinuation on ANGIOA\n* To assess the feasibility of performing quantitative multiparametric mapping sequences in patients already undergoing MRI for staging purposes and explore the correlation between quantitative enhancement and other parameters and clinical response\n\nPart 1 (safety/tolerability): Children with relapsed or refractory solid tumors with biopsy accessible and evaluable disease will be treated with two courses of oral PK-guided sorafenib (starting area under the curve (AUC) target: 20-55 ug/ml/hr), oral cyclophosphamide (50 mg/m2/dose, daily (qd) x 21 days), IV bevacizumab (15 mg/kg/dose, every (q) 21 days) and IV atezolizumab (15 mg/kg \\[max dose 1200 mg\\] q 21 days). Tumor biopsies are required before starting treatment and after course two (Section 4.1). Biopsied tissue will be used for enrollment on MAST and to evaluate changes in T-cell infiltration. Sorafenib PK will be obtained and dose adjusted to target an AUC between 20 and 55 hr\u00b7\u00b5g/mL by Day 21 of C1. Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.\n\nPart 2 (efficacy): Children and AYA with relapsed or refractory HCC will be treated with two courses of oral cyclophosphamide and sorafenib with IV bevacizumab and atezolizumab based on the RP2D from Part 1. Tumor response will be assessed after two courses according to immunologic and imaging criteria (Section 4.1). Eligible patients with Fibrolamellar Carcinoma (FL-HCC), desmoplastic small round cell tumor (DSRCT) or non-central nervous system (CNS) malignant rhabdoid tumors (MRT) will be enrolled on separate strata but target accrual will be determined by patients with HCC.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "OTHER", "description": "All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.", "intervention_names": ["Drug: Atezolizumab", "Drug: Sorafenib", "Drug: Bevacizumab", "Drug: Cyclophosphamide"]}], "interventions": [{"type": "DRUG", "name": "Atezolizumab", "description": "Atezolizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Sorafenib", "description": "Sorafenib by mouth every 12 hours, Days 1-21", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Bevacizumab intravenously, every 3 weeks, Day 1", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Cyclophosphamide", "description": "Low-dose cyclophosphamide by mouth once daily, Days 1-21", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT05468359+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+Sorafenib+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Sorafenib by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to compile a JSON summary about FDA warning letters or clinical holds for Sorafenib by St. Jude Children's Research Hospital.\n\nThe query specifically asks for:\n- FDA warning letters or clinical holds for Sorafenib\n- Related to St. Jude Children's Research Hospital\n- Specific dates, reasons, and safety issues cited\n\nLet me go through the search results to find relevant information:\n\nResult [1]: This is about an FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital) regarding ICD leads. This is not relevant to Sorafenib.\n\nResult [2]: This is a pharmacovigilance study of Sorafenib, but it doesn't mention any FDA warning letters or clinical holds related to St. Jude Children's Research Hospital.\n\nResult [3]: This discusses FDA cancer drug safety warnings, including for capecitabine, duvelisib, denosumab-bnht, ciltacabtagene autoleucel, and pexidartinib, but not Sorafenib specifically in relation to St. Jude Children's Research Hospital.\n\nResult [4]: This discusses drugs that may cause or exacerbate heart failure, but doesn't mention Sorafenib in relation to St. Jude Children's Research Hospital.\n\nResult [5]: This is a clinical trial (NCT05468359) about \"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab...\" This trial involves sorafenib and mentions St. Jude Children's Research Hospital indirectly (it's a pediatric oncology trial), but doesn't mention any FDA warning letters or clinical holds.\n\nResult [6]: This mentions eltrombopag and rosuvastatin, not Sorafenib.\n\nResult [7]: This is an FDA document about entrectinib, but it mentions Sorafenib in passing as being FDA-approved for certain treatments. It also mentions \"St. Jude Children's Research Hospital\" as a pediatric oncologist, but doesn't indicate any warning letters or clinical holds related to Sorafenib.\n\nResult [8]: This is another article about a warning letter to St. Jude Medical (not St. Jude Children's Research Hospital) regarding medical devices.\n\nResult [9]: This is about Sorafenib metabolism and mentions \"Experiments were approved by the Institutional Animal Care and Use Committees of St. Jude Children", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT05468359 for Sorafenib. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital regarding clinical trial NCT05468359 for Sorafenib, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through each search result:\n\n[1] This is from ClinConnect about the trial NCT05468359. It states that the trial is \"Suspended\" as of November 14, 2025 (which is today's date according to the prompt). It describes the trial as studying a combination of four medications (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) for children and young adults with hard-to-treat cancers. However, it doesn't provide specific details about why the trial was suspended or any safety issues.\n\n[2] This is from St. Jude's news releases page, but it doesn't seem to contain specific information about trial NCT05468359. It mentions other clinical trials and research but nothing specific to this sorafenib trial.\n\n[3] This is from ClinicalTrials.gov about the same trial NCT05468359. It provides detailed information about the trial design, objectives, and participation criteria, but doesn't mention why the trial was suspended or any specific safety issues.\n\n[4] This appears to be a PR Newswire article about FDA approvals and stock price movements, but the snippet doesn't mention anything specific about trial NCT05468359.\n\n[5] This is from Cancer Knowledgebase (CKB) and confirms that the trial NCT05468359 is \"Suspended\" with recruitment status. It provides basic trial information but no details about suspension reasons.\n\n[6] This is about sorafenib in advanced hepatocellular carcinoma, mentioning that CPIC is managed at Stanford University & St. Jude, but doesn't provide information about trial NCT05468359.\n\n[7] This is from Together by St. Jude about sorafenib as a medication for childhood cancer patients. It describes what sorafenib is, how it's used, and possible side effects, but doesn't mention trial NCT05468359", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT05468359", "drug_name": "Sorafenib"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a review of toxicity, indicating that there were safety concerns or adverse events that led to the temporary closure of the trial. The detailed description does not mention any issues with efficacy, but rather focuses on exploratory objectives related to evaluating the immune cell infiltrates and other tumor-related markers. Therefore, the available information suggests that the trial was terminated due to safety reasons, rather than efficacy or administrative issues.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:08.405346", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1386}}, "73": {"nct_id": "NCT04982354", "drug_name": "Busulfan", "intervention_type": "DRUG", "drug_description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.559941", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:10.827295", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL820", "pref_name": "BUSULFAN", "targets": [{"chembl_id": "CHEMBL614004", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614573", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614088", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614647", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614466", "ic50_values": [{"value": 92500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612798", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL220", "ic50_values": [], "uniprot_id": "A4D2E2"}, {"chembl_id": "CHEMBL226", "ic50_values": [], "uniprot_id": "A6NFY5"}, {"chembl_id": "CHEMBL251", "ic50_values": [], "uniprot_id": "B2R7E0"}, {"chembl_id": "CHEMBL256", "ic50_values": [], "uniprot_id": "A2A3P4"}, {"chembl_id": "CHEMBL612545", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL319", "ic50_values": [], "uniprot_id": "P43140"}, {"chembl_id": "CHEMBL315", "ic50_values": [], "uniprot_id": "P15823"}, {"chembl_id": "CHEMBL223", "ic50_values": [], "uniprot_id": "P25100"}, {"chembl_id": "CHEMBL1867", "ic50_values": [], "uniprot_id": "B0LPF6"}, {"chembl_id": "CHEMBL1942", "ic50_values": [], "uniprot_id": "A2RUS0"}, {"chembl_id": "CHEMBL1916", "ic50_values": [], "uniprot_id": "P18825"}, {"chembl_id": "CHEMBL213", "ic50_values": [], "uniprot_id": "B0LPE2"}, {"chembl_id": "CHEMBL210", "ic50_values": [], "uniprot_id": "B0LPE4"}, {"chembl_id": "CHEMBL246", "ic50_values": [], "uniprot_id": "P13945"}, {"chembl_id": "CHEMBL222", "ic50_values": [], "uniprot_id": "B2R707"}, {"chembl_id": "CHEMBL2622", "ic50_values": [], "uniprot_id": "P07943"}, {"chembl_id": "CHEMBL4607", "ic50_values": [], "uniprot_id": "B2R9V1"}, {"chembl_id": "CHEMBL3157", "ic50_values": [], "uniprot_id": "P30411"}, {"chembl_id": "CHEMBL1832", "ic50_values": [], "uniprot_id": "A0A0C4DG16"}, {"chembl_id": "CHEMBL218", "ic50_values": [], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL205", "ic50_values": [], "uniprot_id": "B2R7G8"}, {"chembl_id": "CHEMBL4015", "ic50_values": [], "uniprot_id": "A0AVQ3"}, {"chembl_id": "CHEMBL2414", "ic50_values": [], "uniprot_id": "P51679"}, {"chembl_id": "CHEMBL274", "ic50_values": [], "uniprot_id": "O14692"}, {"chembl_id": "CHEMBL4029", "ic50_values": [], "uniprot_id": "B2R6Q3"}, {"chembl_id": "CHEMBL2434", "ic50_values": [], "uniprot_id": "P25025"}, {"chembl_id": "CHEMBL1901", "ic50_values": [], "uniprot_id": "B2R9Z5"}, {"chembl_id": "CHEMBL221", "ic50_values": [], "uniprot_id": "A8K1V7"}, {"chembl_id": "CHEMBL230", "ic50_values": [], "uniprot_id": "A8K802"}, {"chembl_id": "CHEMBL3356", "ic50_values": [], "uniprot_id": "P05177"}, {"chembl_id": "CHEMBL5282", "ic50_values": [], "uniprot_id": "A7YAE5"}, {"chembl_id": "CHEMBL3622", "ic50_values": [], "uniprot_id": "P33259"}, {"chembl_id": "CHEMBL3397", "ic50_values": [], "uniprot_id": "P11712"}, {"chembl_id": "CHEMBL289", "ic50_values": [], "uniprot_id": "P10635"}, {"chembl_id": "CHEMBL5281", "ic50_values": [], "uniprot_id": "P05181"}, {"chembl_id": "CHEMBL340", "ic50_values": [], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL2056", "ic50_values": [], "uniprot_id": "B2RA44"}, {"chembl_id": "CHEMBL217", "ic50_values": [], "uniprot_id": "P14416"}, {"chembl_id": "CHEMBL234", "ic50_values": [], "uniprot_id": "A1A4V5"}, {"chembl_id": "CHEMBL219", "ic50_values": [], "uniprot_id": "B0M0J7"}, {"chembl_id": "CHEMBL238", "ic50_values": [], "uniprot_id": "A2RUN4"}, {"chembl_id": "CHEMBL252", "ic50_values": [], "uniprot_id": "B2R723"}, {"chembl_id": "CHEMBL206", "ic50_values": [], "uniprot_id": "Q13511"}, {"chembl_id": "CHEMBL242", "ic50_values": [], "uniprot_id": "A8K8K5"}, {"chembl_id": "CHEMBL2034", "ic50_values": [], "uniprot_id": "A0ZXF9"}, {"chembl_id": "CHEMBL3392921", "ic50_values": [], "uniprot_id": "Q91W28"}, {"chembl_id": "CHEMBL231", "ic50_values": [], "uniprot_id": "A8K047"}, {"chembl_id": "CHEMBL1941", "ic50_values": [], "uniprot_id": "B5BUP7"}, {"chembl_id": "CHEMBL402", "ic50_values": [], "uniprot_id": "B7Z3Y9"}, {"chembl_id": "CHEMBL5486", "ic50_values": [], "uniprot_id": "P15127"}, {"chembl_id": "CHEMBL1909043", "ic50_values": [], "uniprot_id": "A6XA80"}, {"chembl_id": "CHEMBL1798", "ic50_values": [], "uniprot_id": "B2R954"}, {"chembl_id": "CHEMBL4358", "ic50_values": [], "uniprot_id": "O19043"}, {"chembl_id": "CHEMBL4644", "ic50_values": [], "uniprot_id": "P41968"}, {"chembl_id": "CHEMBL259", "ic50_values": [], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4608", "ic50_values": [], "uniprot_id": "B0YJ34"}, {"chembl_id": "CHEMBL1951", "ic50_values": [], "uniprot_id": "B4DF46"}, {"chembl_id": "CHEMBL216", "ic50_values": [], "uniprot_id": "P11229"}, {"chembl_id": "CHEMBL211", "ic50_values": [], "uniprot_id": "P08172"}, {"chembl_id": "CHEMBL245", "ic50_values": [], "uniprot_id": "P20309"}, {"chembl_id": "CHEMBL1821", "ic50_values": [], "uniprot_id": "B2RPP4"}, {"chembl_id": "CHEMBL2035", "ic50_values": [], "uniprot_id": "P08912"}, {"chembl_id": "CHEMBL4777", "ic50_values": [], "uniprot_id": "B2R6H5"}, {"chembl_id": "CHEMBL4018", "ic50_values": [], "uniprot_id": "P49146"}, {"chembl_id": "CHEMBL3048", "ic50_values": [], "uniprot_id": "P70594"}, {"chembl_id": "CHEMBL3464", "ic50_values": [], "uniprot_id": "O70515"}, {"chembl_id": "CHEMBL236", "ic50_values": [], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL237", "ic50_values": [], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL233", "ic50_values": [], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL1827", "ic50_values": [], "uniprot_id": "A0AV69"}, {"chembl_id": "CHEMBL250", "ic50_values": [], "uniprot_id": "A3KMC8"}, {"chembl_id": "CHEMBL240", "ic50_values": [], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL1909044", "ic50_values": [], "uniprot_id": "Q690N0"}, {"chembl_id": "CHEMBL4074", "ic50_values": [], "uniprot_id": "O02852"}, {"chembl_id": "CHEMBL4801", "ic50_values": [], "uniprot_id": "B5MDZ1"}, {"chembl_id": "CHEMBL4071", "ic50_values": [], "uniprot_id": "P08311"}, {"chembl_id": "CHEMBL248", "ic50_values": [], "uniprot_id": "P08246"}, {"chembl_id": "CHEMBL332", "ic50_values": [], "uniprot_id": "P03956"}, {"chembl_id": "CHEMBL321", "ic50_values": [{"value": 5215.0, "units": "nM"}], "uniprot_id": "B2R7V9"}, {"chembl_id": "CHEMBL299", "ic50_values": [], "uniprot_id": "B5BU22"}, {"chembl_id": "CHEMBL3385", "ic50_values": [], "uniprot_id": "A8CZ58"}, {"chembl_id": "CHEMBL4040", "ic50_values": [], "uniprot_id": "A8CZ64"}, {"chembl_id": "CHEMBL260", "ic50_values": [], "uniprot_id": "A6ZJ92"}, {"chembl_id": "CHEMBL4445", "ic50_values": [], "uniprot_id": "A1A441"}, {"chembl_id": "CHEMBL203", "ic50_values": [], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL1841", "ic50_values": [], "uniprot_id": "B5BU57"}, {"chembl_id": "CHEMBL1824", "ic50_values": [], "uniprot_id": "B2RZG3"}, {"chembl_id": "CHEMBL258", "ic50_values": [], "uniprot_id": "D3DPP8"}, {"chembl_id": "CHEMBL3243", "ic50_values": [], "uniprot_id": "A0A0A0MT22"}, {"chembl_id": "CHEMBL273", "ic50_values": [], "uniprot_id": "P19327"}, {"chembl_id": "CHEMBL3459", "ic50_values": [], "uniprot_id": "P28564"}, {"chembl_id": "CHEMBL224", "ic50_values": [], "uniprot_id": "B2RAC5"}, {"chembl_id": "CHEMBL1833", "ic50_values": [], "uniprot_id": "B2R9D5"}, {"chembl_id": "CHEMBL225", "ic50_values": [], "uniprot_id": "B1AMW4"}, {"chembl_id": "CHEMBL5017", "ic50_values": [], "uniprot_id": "O70528"}, {"chembl_id": "CHEMBL3371", "ic50_values": [], "uniprot_id": "P50406"}, {"chembl_id": "CHEMBL228", "ic50_values": [], "uniprot_id": "P31645"}, {"chembl_id": "CHEMBL287", "ic50_values": [], "uniprot_id": "D3DRM7"}, {"chembl_id": "CHEMBL249", "ic50_values": [], "uniprot_id": "A8K150"}, {"chembl_id": "CHEMBL2327", "ic50_values": [], "uniprot_id": "A8K7I1"}, {"chembl_id": "CHEMBL3072", "ic50_values": [], "uniprot_id": "P15207"}, {"chembl_id": "CHEMBL1835", "ic50_values": [], "uniprot_id": "B4DJG6"}, {"chembl_id": "CHEMBL1868", "ic50_values": [], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL5144", "ic50_values": [], "uniprot_id": "A5JUT9"}, {"chembl_id": "CHEMBL1889", "ic50_values": [], "uniprot_id": "P37288"}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 135000.0, "units": "nM"}, {"value": 1000000.0, "units": "nM"}, {"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL613508", "ic50_values": [{"value": 25800.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612657", "ic50_values": [{"value": 24300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 36200.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Busulfan"}, "ppi_enrichment": {"uniprot_count": 108, "interactions": [{"protein_a": "CHKA", "protein_b": "CHKB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "PHOSPHO1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "ACHE", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "GPCPD1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "HSPG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "ACHE", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "DOK7", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "HSPG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "PHOSPHO1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHKB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "MAOB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "GPCPD1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHAT", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "COLQ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "PHOSPHO1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "CHKB", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "GPCPD1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DOK7", "protein_b": "COLQ", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HSPG2", "protein_b": "COLQ", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "PHOSPHO1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "CHKB", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "PHOSPHO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADORA2A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADA", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "SLC29A1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "SLC29A1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "ADORA2A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2A", "protein_b": "SLC29A1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "CNR1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "ADORA2A", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CNR1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2B", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2A", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAL", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "ADORA2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAS", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "GNAS", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "ADORA2A", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "ADORA2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADORA2A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADORA2A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1D", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1A", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "TBXA2R", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1D", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1B", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1D", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1A", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "TBXA2R", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "GNA13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1D", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "ADRA1D", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "SNTB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "UTRN", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "ADRA1D", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "SNTB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "TBXA2R", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "SNTB1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "ADRA1A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "GNA13", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ADRA1A", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TBXA2R", "protein_b": "GNA13", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNA13", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNAQ", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "ADRA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNG2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNG2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNG2", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNA13", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SEC24C", "protein_b": "ADRA2B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2C", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2C", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2C", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2C", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "ADRA2C", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2C", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ADRA2C", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "ADRA2C", "protein_b": "GNA13", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "DLG4", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "ADRB1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GCG", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "POMC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "NPPA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "DLG4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "GNAI1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ADRB2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SNX27", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GRK2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "AKAP12", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SAG", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "SAG", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "SAG", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB2", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "AKAP12", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SAG", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "UCP1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "ADRB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "FGF21", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "ADRB3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB3", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "SRC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "FGF21", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "SRC", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "ADRB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAS", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI3", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "SRC", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GNAI1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "YRDC", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "HTR1A", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SNCA", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SCRT1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC18A2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC5A2", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADCY7", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "STX1A", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC5A2", "protein_b": "ADCY7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MTUS1", "protein_b": "AGTR2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "AGTR2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "EDN1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "KNG1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "ACE2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ACE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "EDN1", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "KNG1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "ACE2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "AGTR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "KNG1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "AGTR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AGTR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "ACE", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "EDN1", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "BDKRB2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "AGT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNAQ", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "AGTR1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "BDKRB2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "BDKRB2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "BDKRB2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "BDKRB2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "BDKRB2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "BDKRB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "BDKRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "BDKRB2", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNG2", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNAS", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "ADM", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCB", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "RAMP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNAS", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "ADM", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNG2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNAS", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "ADM", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADM", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCR", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNB1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNAS", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "CALCB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "CALCB", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADM", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADM", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CALCB", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "SLC4A1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "CA2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "TCIRG1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA1", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "SLC4A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "CA2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CA2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CLCN7", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CLCN7", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBSL", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBS", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CA1", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "SLC4A4", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBS", "protein_b": "CBSL", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL13", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL7", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL8", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL5", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL8", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL7", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CXCL8", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL7", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL5", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL17", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL2", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL27", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL27", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCR4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CXCL12", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR4", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "CCR4", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "GRK3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GRK3", "protein_b": "CCR4", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL3", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CXCL12", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL5", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL3", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR1", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL2", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CXCL10", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL3", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL5", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ITIH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL3L1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL5", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CXCL10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3L1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3L1", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL3L1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL3L1", "protein_b": "CCL4", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL6", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL3", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL5", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CCL2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL8", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL12", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL12", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL12", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CCKAR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAI1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GAST", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCKAR", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNG2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNB1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAI1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAS", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCL28", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "PTK7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GAST", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCL28", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "GNB1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCK", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL28", "protein_b": "CCK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCK", "protein_b": "PTK7", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "HPGDS", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGDS", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX15", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGDS", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGDS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGDS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGS2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGDS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGES3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "ALOX5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGDS", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGES3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGDS", "protein_b": "PTGES3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "TP53", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGES", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CXCL8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "IL6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "IL6", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CXCL8", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PLA2G4A", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "PTGS2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "IL6", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "ALOX5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "PTGS2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "IL6", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2B6", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A8", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2B6", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP3A4", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2E1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A8", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2E1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP2E1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A8", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GAPDH", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "PPIG", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4A11", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "ALOX5", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C19", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C9", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4F2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP1A2", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "PPIG", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP4A11", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "ALOX5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C9", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "ALOX5", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP4A11", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "PPIG", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ALOX5", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2C19", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2C19", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ALOX5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2D6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B15", "protein_b": "CYP2D6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "CYP2D6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2D6", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "UGT1A3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A3", "protein_b": "CYP2D6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ADH1B", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "ADH1B", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A4", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A10", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTP1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTM1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "CYP2E1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "GSTP1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GSTP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP3A4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP2E1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "EPHX1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALY", "protein_b": "DRD1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "DRD1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "DRD1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "TMTC1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "DRD1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "DRD1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "DRD1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "TMTC1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "ADCYAP1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "POMC", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "NCS1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB2", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG7", "combined_score": 0.701, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG2", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "DRD3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD1", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD3", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "DRD3", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "DRD1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "BDNF", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "KLHL12", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD3", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "MAOA", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DRD2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "BDNF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TH", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SYNGR3", "protein_b": "SLC6A3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "FLOT1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "CAMK2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "TH", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SNCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "TH", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "SLC18A2", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "TH", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SNCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRB", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRB", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "KNG1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "GNA13", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "AGT", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDNRB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN2", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDNRB", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDN1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "KNG1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "GNA13", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NRIP1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SP1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SRC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA2", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA3", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "JUN", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "JUN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "MED1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SP1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "JUN", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "SRC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "FKBP5", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "STIP1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "PTGES3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "NR3C1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSPA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSPA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "STIP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "PTGES3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AB1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "PTGES3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "FKBP5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "FKBP5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FKBP5", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HRH1", "combined_score": 0.722, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "HRH1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "PLCB3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HRH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PLCB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HRH1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PLCB3", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PLCB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HRH1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "PLCB3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "TRPV1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "ATP4A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "GAST", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "GAST", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "GAST", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "HRH2", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HRH2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SQLE", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDFT1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDPS", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "INSIG1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "HMGCR", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "INSIG1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDPS", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCR", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDFT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDFT1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDPS", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "INSIG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "INSIG1", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "HMGCS2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDFT1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDPS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDPS", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDFT1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDPS", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDFT1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "HMGCS2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "SREBF2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "SREBF2", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "HMGCS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "FDFT1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "HMGCS2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "FDFT1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "HMGCS2", "protein_b": "FDFT1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "LTC4S", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "LTB4R2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR1", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "TBXA2R", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR2", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "TBXA2R", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "ALOX5AP", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTB4R2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "GNAQ", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTC4S", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "CYSLTR1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LTB4R2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CYSLTR1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5AP", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "LTB4R2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "CYSLTR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "LTB4R2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "TBXA2R", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5AP", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALOX5", "protein_b": "ALOX5AP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CTSZ", "protein_b": "MC3R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "LEP", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "POMC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "AGRP", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "MC3R", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "NPY", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "GHRL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ASIP", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "LEP", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "NPY", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "MRAP2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "GHRL", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ATP7A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "AGRP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "ASIP", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ATP7A", "protein_b": "POMC", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ASIP", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MRAP2", "protein_b": "MC5R", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "MC5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DBH", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DDC", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "COMT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "LRTOMT", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "AOC3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "ALDH2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC3", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOA", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "AOC3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DBH", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DDC", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DBH", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DDC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "COMT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOA", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOB", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "CYP2D6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "MAOB", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "AOC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DDC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DBH", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DBH", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DDC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "MAOB", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "CYP2D6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "AOC1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DBH", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DDC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "DBH", "protein_b": "DDC", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "DDC", "protein_b": "AOC1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR6", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "ARRB1", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR5", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR4", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "F2R", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "KNG1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR4", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR3", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "CHRM2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "ARRB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR4", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR5", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "CHRM2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "LPAR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "LPAR4", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "ARRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "AGTRAP", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNA15", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG12", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GRM5", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CHRM1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "NPY1R", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GHRL", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY1R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PPY", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY1R", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PYY", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY5R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNB1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY5R", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI3", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "NPY5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY5R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PRPH2", "protein_b": "NPY2R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY2R", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "POMC", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GLP1R", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "POMC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNG2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNB1", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PPY", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PYY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "POMC", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GLP1R", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "GLP1R", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "POMC", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "POMC", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "GNB1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PPY", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE6G", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE6G", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE2A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE5A", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUCY1B1", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE2A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "ITPA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "APRT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUK1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE5A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUCY1B1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUCY1B1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ALDH7A1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CCR1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PTAFR", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TLR4", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PTAFR", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ARRB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "TLR4", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "PTAFR", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "ARRB1", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "PTAFR", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TLR4", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "PTAFR", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "FPR2", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GPR135", "protein_b": "PTAFR", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "ARRB1", "protein_b": "PTAFR", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "TYK2", "protein_b": "PTAFR", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "PECAM1", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "FPR2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP8", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "GSDMD", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "IL1B", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "PYCARD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "GSDMD", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "IL1B", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP6", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP6", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "AIM2", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRC4", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "GSDMD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP8", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "GSDMD", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP8", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "GSDMD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRP1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "GSDMD", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRC4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "GSDMD", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "GSDMD", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "GSDMD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSDMD", "protein_b": "NLRP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINB4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "MMP9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "MMP9", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "MMP9", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "MMP9", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "ELANE", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPINA3", "protein_b": "ELANE", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SLPI", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "DEFA4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "SERPINA1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "DEFA4", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "DEFA4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "SLPI", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "DEFA4", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "DEFA4", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "SERPINA1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "DEFA4", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "DEFA4", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DEFA4", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLPI", "protein_b": "ELANE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPINA1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "STAT3", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "IL1B", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "IL1B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "STAT3", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP9", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP7", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "TIMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "IL1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP9", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "TIMP2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "STAT3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP9", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP9", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP3", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP9", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "MMP1", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "BSG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "MMP9", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "THBS1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "LCN2", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "CD44", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "MMP9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "TIMP3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "ELN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DMP1", "protein_b": "MMP9", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "CD44", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "MMP9", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "LCN2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCD", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCB", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PICK1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "NCF1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "MTOR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLD1", "protein_b": "PRKCA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCB", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "SDC4", "protein_b": "PRKCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PICK1", "protein_b": "PRKCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "RACK1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "RACK1", "protein_b": "PRKCB", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "FOS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "FOS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "MAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAPK3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "RPS6KA1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "PTPN7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "FOS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "FOS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "RPS6KA1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "STAT3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PEA15", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MKNK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "JUN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "JUN", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPKAPK2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ATF2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK14", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAPK14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "JUN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K6", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "DUSP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "ATF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "ATF2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "TP53", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MAP2K3", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAPKAPK3", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "JUN", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAP2K6", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAPKAPK3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "RCAN1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3R2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML6", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML5", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALM3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "NFATC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RCAN1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "RCAN1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3R2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3R2", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CB", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CB", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "CALML4", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CB", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "NFATC1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "CALML4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3CA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "CALML4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "NFATC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "CALML4", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "PPP3R2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "PPP3R2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "PTK2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LCK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SHC1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "FYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "LYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LCK", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LYN", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SHC1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "FYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SH2D1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SH2D1A", "protein_b": "LCK", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "DLG4", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LCK", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LYN", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "HSP90AA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SHC1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRG1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "HSP90AA1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SRC", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "CD44", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "ERBB4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SHC1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SRC", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "CD44", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ERBB4", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "GRB2", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "CD44", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SRC", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CD44", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "VAV1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCP2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD28", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD28", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "PTPRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD247", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "ZAP70", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "PTPRC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD28", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PTPRC", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "FYN", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "VAV1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD8A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD247", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "VAV1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD8A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SYK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD247", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "PTPRC", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "VAV1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "PTPRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "PTPRC", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "VAV1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VAV1", "protein_b": "LCK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LYN", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SPN", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "DPP4", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD22", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "SPN", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "PTPRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "SPN", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "PTPRC", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "LCK", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPP4", "protein_b": "PTPRC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD47", "protein_b": "PTPRC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LYN", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "SPN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GRM2", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GRM2", "protein_b": "HTR2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2C", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2B", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1F", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1S", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1F", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1S", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1F", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1S", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1S", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1F", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "HTR2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "CACNA1F", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CACNA1F", "protein_b": "HTR2A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNG2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNB1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "GNG2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNB1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR2A", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HTR2A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "FSHB", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "HTR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GIP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "NPPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "FSHB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GCG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "ADCYAP1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "VIP", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "POMC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "HTR7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GNAS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HTR7", "protein_b": "GNAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "VIP", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "FSHB", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "ADCYAP1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TPH1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A4", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOA", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "TPH2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "TPH2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "BDNF", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "MAOA", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR1B", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR2A", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR1B", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR1B", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR2A", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "HTR2A", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR2A", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "BDNF", "protein_b": "HTR2A", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SIGMAR1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "ERG28", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "MSMO1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SQLE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TMEM97", "protein_b": "SIGMAR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SQLE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SIGMAR1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "MSMO1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SIGMAR1", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SQLE", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SIGMAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNA4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR3", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNH6", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "HSPA5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "HSPA5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSPA5", "protein_b": "ITPR3", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "KCNA4", "protein_b": "KCNH6", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TAC1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "NTS", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TACR1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "UNC80", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC3", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "UNC80", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TACR1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "UNC80", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNAS", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "ARRB1", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "UNC80", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TACR2", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TACR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "CHKB", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TACR2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "CHKB", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "TAC3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "TBXAS1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "TBXAS1", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "TBXAS1", "protein_b": "MGAM2", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR2", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNB1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "ADCYAP1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIP", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "WASL", "protein_b": "VIPR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNB1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIPR1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNAS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNB1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ATG5", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADCYAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1B", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVP", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR2", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1B", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1B", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA14", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR1B", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "VIP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "GNA13", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVPR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AVP", "protein_b": "AVPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "AVPR2", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 10.53, "clustering_coefficient": 5.26}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41152998", "title": "Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study.", "authors": [{"name": "Alomari N", "authtype": "Author", "clusterid": ""}, {"name": "Kurdi A", "authtype": "Author", "clusterid": ""}, {"name": "Alghamdi M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41016399", "title": "Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.", "authors": [{"name": "Henderson TO", "authtype": "Author", "clusterid": ""}, {"name": "Bardwell JK", "authtype": "Author", "clusterid": ""}, {"name": "Kao PC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40949119", "title": "Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation.", "authors": [{"name": "Cao D", "authtype": "Author", "clusterid": ""}, {"name": "Qian X", "authtype": "Author", "clusterid": ""}, {"name": "Wang P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40901473", "title": "Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.", "authors": [{"name": "Wei Y", "authtype": "Author", "clusterid": ""}, {"name": "Luan S", "authtype": "Author", "clusterid": ""}, {"name": "Wang L", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+Busulfan+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Busulfan by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a JSON summary about FDA warning letters or clinical holds for Busulfan by Guenther Koehne.\n\nThe query is asking specifically for:\n- FDA warning letters or clinical holds for Busulfan\n- Related to Guenther Koehne\n- Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this information:\n\nResult [1]: This discusses dose escalation studies but doesn't mention Guenther Koehne or specific FDA warning letters for Busulfan.\n\nResult [2]: This appears to be a PDF about Waldenstr\u00f6m's Award but doesn't seem to contain information about FDA warning letters for Busulfan.\n\nResult [3]: This is an MSKCC hematology oncology report. It mentions Guenther Koehne on page 1 (listed as \"Guenther Koehne, Susan Prockop\") but doesn't discuss FDA warning letters or clinical holds for Busulfan.\n\nResult [4]: General information about cell transplantation but no specific FDA warning letters for Busulfan.\n\nResult [5]: Myeloma workshop abstracts, mentions FDA approvals but not warning letters for Busulfan.\n\nResult [6]: This is about a clinical trial \"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic...\" and mentions \"Violation: Shown when the FDA issues a Notice of Noncompliance\" but doesn't specify any actual violations, warning letters, or clinical holds related to Busulfan or Guenther Koehne. It just explains what a violation means in the context of clinical trials.\n\nResult [7]: This discusses Dr. Guenther Koehne at Miami Cancer Institute and his work with stem cell transplants, but doesn't mention any FDA warning letters or clinical holds for Busulfan specifically.\n\nAfter reviewing all the search results, I don't see any specific information about:\n1. FDA warning letters for Busulfan related to Guenther Koehne\n2. Clinical holds for Busulfan related to Guenther Koehne\n3. Specific dates, reasons, or safety issues cited in such warning letters or holds\n\nResult [6] mentions FDA Notices of Noncompliance in general terms, but doesn't provide any specific instance related to Busulfan or Guenther Koehne. Result [7]", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT04982354 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to check if any of the search results mention:\n1. Guenther Koehne as an author or related to the filing\n2. Clinical trial NCT04982354\n3. Drug safety issues\n\nLet me go through each search result:\n\nResult [1]: This is an SEC Form 8-K filing for Eagle Point Income Co Inc (CIK: 0001754836) filed on 2025-05-08. It doesn't appear to mention Guenther Koehne or clinical trial NCT04982354. It's a financial company, not a biotech/pharma company that would typically conduct clinical trials.\n\nResult [2]: This is a BioNTech SE Form 6-K filing from 2024-08-05. It mentions several clinical trials (NCT04486378, NCT05918445) but not NCT04982354. It does discuss safety data for some trials, but there's no mention of Guenther Koehne.\n\nResult [3]: This appears to be an 8-K filing for Medical Properties Trust, Inc., which is a real estate company, not a biotech/pharma company. No mention of clinical trials or Guenther Koehne.\n\nResult [4]: This is an exhibit from KYMERA THERAPEUTICS, INC. It discusses clinical trials for KT-474, KT-333, and KT-413, but doesn't mention NCT04982354 or Guenther Koehne specifically.\n\nResult [5]: Just shows an EDGAR filing index without details.\n\nResult [6]: This is a 10-K annual report for Kinnate Biopharma Inc. It discusses their clinical development programs but doesn't specifically mention NCT04982354 or Gu", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for Busulfan. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for Busulfan, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT04982354 is about based on the search results:\n\nFrom result [9] (clinicaltrials.gov):\n- Title: \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\"\n- Principal Investigator: Guenther Koehne, MD, PhD, Miami Cancer Institute at Baptist Health\n- Interventions: \n  * Drug: CPX-351\n  * Drug: Midostaurin\n  * Drug: Busulfan\n  * Drug: Melphalan\n  * Drug: Fludarabine\n  * Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor\n- Study design: It's a pilot study to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with midostaurin as induction and consolidation therapy for patients with high-risk FLT3 mutated AML, followed by CD34+-selected allogeneic stem cell transplant.\n\nFrom result [11]:\n- NCT04982354 is listed as \"Withdrawn. 1/2\"\n\nFrom result [13]:\n- Confirms it's about \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\"\n- Status: Not clearly stated in the snippet, but result [11] indicates it's \"Withdrawn\"\n\nNow, let me look for any press releases, investor presentations, or public statements by Guenther Koehne specifically about this trial, focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nResult [1] and [3] seem to be just listings of the trial without detailed information.\n\nResult [2] is about Bio-Path Holdings presenting data from a Phase 2 combination study of Prexigebersen for AML treatment, not related to NCT04982354.\n\nResult [4] is about Prexasertib, not related to", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "Busulfan"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "74": {"nct_id": "NCT04982354", "drug_name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "intervention_type": "BIOLOGICAL", "drug_description": "Allogeneic stem cell transplant infused intravenously", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.560589", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:10.865511", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "21232623", "title": "T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.", "authors": [{"name": "Jakubowski AA", "authtype": "Author", "clusterid": ""}, {"name": "Small TN", "authtype": "Author", "clusterid": ""}, {"name": "Kernan NA", "authtype": "Author", "clusterid": ""}]}, {"pmid": "10933177", "title": "Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation.", "authors": [{"name": "Ringd\u00e9n O", "authtype": "Author", "clusterid": ""}, {"name": "Remberger M", "authtype": "Author", "clusterid": ""}, {"name": "Runde V", "authtype": "Author", "clusterid": ""}]}, {"pmid": "9130690", "title": "Studies of decitabine with allogeneic progenitor cell transplantation.", "authors": [{"name": "Giralt S", "authtype": "Author", "clusterid": ""}, {"name": "Davis M", "authtype": "Author", "clusterid": ""}, {"name": "O'Brien S", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find any FDA warning letters or clinical holds related to CD34+ selected allogeneic stem cell transplants from HLA-compatible donors by Dr. Guenther Koehne.\n\nLet me go through each search result to identify relevant information:\n\nResult [1]: This discusses two FDA-approved clinical trials at Miami Cancer Institute led by Dr. Guenther Koehne for blood cancers using stem cell transplants. It mentions Dr. Koehne developed a technique to manipulate donor cells to reduce graft-versus-host disease. However, there's no mention of FDA warning letters or clinical holds.\n\nResult [2]: This is a review article about allogeneic stem cell transplant with CD34+ cell selection. It discusses risks like graft failure, GvHD, infection, etc., but doesn't mention any FDA warning letters or clinical holds related to Dr. Koehne's work.\n\nResult [3]: This discusses CMV management after stem cell transplantation, featuring Dr. Koehne. It mentions that at Miami Cancer Institute they \"frequently do CD-34-selected stem cell transplants or T-cell depleted transplants.\" However, there's no mention of FDA warning letters or clinical holds.\n\nResult [4]: This is a study about CD34-selected allogeneic HSCT for multiple myeloma at Memorial Sloan Kettering Cancer Center. It mentions the study was approved by the Institutional Review Board and the FDA, but doesn't mention any warning letters or clinical holds.\n\nResult [5]: This discusses elranatamab for multiple myeloma and mentions stem cell transplant as an exclusion criterion (must be >12 weeks before enrollment), but doesn't relate to Dr. Koehne or FDA warning letters.\n\nResult [6]: This is about a Phase II Trial of CD34+ Enriched Transplants for Myelodysplastic Syndrome, but doesn't mention Dr. Koehne or FDA warning letters.\n\nResult [7]: This appears to be an MSKCC annual report but the content provided doesn't seem relevant to the query.\n\nResult [8]: Mentions a first-in-human clinical trial utilizing CD34+ selected allografts, but doesn't mention Dr. Koehne or FDA warning letters.\n\nResult [9]: Discusses immunotherapy for multiple myeloma but doesn't mention Dr. Koehne's work or FDA warning letters.\n\nResult", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT04982354 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to check if any of the search results contain information about:\n1. Filings by someone named \"Guenther Koehne\"\n2. Clinical trial NCT04982354\n3. Drug safety issues related to this trial\n\nLet me go through each search result:\n\nResult [1]: This appears to be an SEC Form 8-K filing for \"Eagle Point Income Co Inc.\" with CIK 0001754836. Filing date is 2025-05-08. There's no mention of Guenther Koehne, NCT04982354, or any clinical trial safety issues. This seems to be a financial filing for an income company, not related to clinical trials.\n\nResult [2]: This is a BioNTech SE Form 6-K filing from 2024-08-05. It mentions several clinical trials including NCT04486378 (for CRC), NCT05918445 (for cervical cancer), but no mention of NCT04982354 or Guenther Koehne. It does contain some safety data (e.g., \"Grade 3 TRAEs in 19.7% (12/61), serious adverse events were observed in 24.6% (15/61) of patients\"), but not related to the specific trial requested.\n\nResult [3]: This appears to be an 8-K filing for Medical Properties Trust, Inc. It's a financial filing with no mention of clinical trials, Guenther Koehne, or NCT04982354.\n\nResult [4]: This is an EX-99.1 filing for Kymera Therapeutics. It mentions several clinical trials (KT-474, KT-333, KT-413) but no NCT0498235", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about clinical trial NCT04982354, specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions related to CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor.\n\nFirst, let me identify what NCT04982354 is about from the search results:\n\nFrom result [1], [4], [5], and [7], I can see that NCT04982354 is titled \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\". The sponsor is Guenther Koehne from Jazz Pharmaceuticals/Baptist Health South Florida.\n\nFrom result [4], I see that the trial status is listed as \"Withdrawn\" with phase \"1/2\".\n\nFrom result [7], it confirms that NCT04982354 is a Phase 1 trial that was withdrawn, sponsored by Guenther Koehne.\n\nNow, let me check if there's specific information about why the trial was withdrawn, any safety issues, adverse events, or regulatory actions:\n\nResult [2] mentions Dr. Guenther Koehne leading clinical trials at Miami Cancer Institute, but it doesn't specifically mention NCT04982354. It talks about two FDA-approved clinical trials, one involving \"two different drugs administered in the induction stage\" and another studying \"T-cells given after transplantation\". However, it doesn't specify if these are related to NCT04982354.\n\nResult [3] is similar to [2], mentioning FDA-approved trials led by Dr. Koehne but without specific reference to NCT04982354.\n\nResult [6] mentions Dr. Koehne discussing stem cell transplantation research, including a VBP101 (NCT04849910) trial involving CRISPR gene-editing technology, but doesn't mention NCT04982354 specifically.\n\nResult [8] mentions NCT04982354 in relation to Midostaurin (PKC412), stating it's for Acute Myeloid Leukemia with Phase 1|Phase 2 status as of 2022-07-05.\n\nResult", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "75": {"nct_id": "NCT04982354", "drug_name": "CPX-351", "intervention_type": "DRUG", "drug_description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.561166", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:10.901313", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q52KE7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P24788", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "CPX-351", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 2, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41173235", "title": "Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.", "authors": [{"name": "Palumbo FE", "authtype": "Author", "clusterid": ""}, {"name": "Vetro C", "authtype": "Author", "clusterid": ""}, {"name": "Maugeri C", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40990091", "title": "Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.", "authors": [{"name": "Guolo F", "authtype": "Author", "clusterid": ""}, {"name": "Fianchi L", "authtype": "Author", "clusterid": ""}, {"name": "Martelli MP", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40848224", "title": "Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.", "authors": [{"name": "Magee GH", "authtype": "Author", "clusterid": ""}, {"name": "Grunwald MR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40401707", "title": "A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.", "authors": [{"name": "Kadia TM", "authtype": "Author", "clusterid": ""}, {"name": "Jen WY", "authtype": "Author", "clusterid": ""}, {"name": "Bataller A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40347359", "title": "The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety.", "authors": [{"name": "Pagano L", "authtype": "Author", "clusterid": ""}, {"name": "Danesi R", "authtype": "Author", "clusterid": ""}, {"name": "Benedetti E", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+CPX-351+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CPX-351 by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds for CPX-351 by Guenther Koehne, including specific dates, reasons, and safety issues cited.\n\nLet me go through each search result to see if it contains relevant information:\n\nResult [1]: This is a review article about CPX-351 (Vyxeos) for AML treatment. It discusses efficacy and safety but doesn't mention any FDA warning letters or clinical holds. It states that CPX-351 has \"comparable safety to standard chemotherapy.\"\n\nResult [2]: This appears to be a document retrieval index from the Office of Justice Programs, not relevant to CPX-351 or FDA warnings.\n\nResult [3]: This is a SEC filing for Celator Pharmaceuticals (which developed CPX-351). It mentions clinical studies but doesn't discuss any FDA warning letters or clinical holds.\n\nResult [4]: This is an abstract book from the International Myeloma Workshop, not relevant to CPX-351 for AML.\n\nResult [5]: This is an article about Jazz subsidiary being warned over misbranding of a cancer drug. It mentions CPX-351 and states: \"These claims suggest that CPX-351... is effective for the treatment of cancer generally and newly diagnosed patients with high-risk AML...\" This suggests there was some warning related to misbranding, but it doesn't provide specific dates or details about safety issues.\n\nResult [6]: This appears to be a PhD thesis about Epstein-Barr Virus-Specific T cells, not relevant to CPX-351.\n\nResult [7]: This is an FDA document (209401Orig1s000) related to CPX-351. It mentions \"The sponsor submitted a briefing book to the FDA with a brief summary of the clinical information on CPX-351 that has been collected to date.\" This could be relevant but doesn't specifically mention warning letters or clinical holds.\n\nResult [8]: This appears to be an OCR text from NLM Digital Collections, not relevant to CPX-351 warnings.\n\nResult [9]: This is a ClinicalTrials.gov entry for a \"CPX-351 Real-World Effectiveness and Safety Study.\" It mentions post-marketing studies but doesn't discuss warning letters or clinical holds.\n\nResult [10", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Guenther Koehne\n- Mentioning clinical trial NCT04982354 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, let me understand who Guenther Koehne is based on the search results:\n\nFrom results [1], [3], [5], and [7], I can see that Guenther Koehne is:\n- A medical doctor (MD) and PhD\n- Board certified in internal medicine and medical oncology\n- Deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, part of Baptist Health South Florida\n- An internationally renowned expert in stem cell transplantation for leukemia, myelodysplastic syndrome, multiple myeloma, etc.\n- Has worked at Memorial Sloan Kettering Cancer Center\n- Has an NPI number 1679791818\n- Located in Miami, FL\n\nNow, regarding the query about SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354:\n\nLooking through the search results:\n- Result [2] is a BioNTech SE Form 6-K filed on 2024-08-05, which mentions clinical trials including NCT04486378 (CRC trial) and NCT05918445 (cervical cancer trial), but not NCT04982354.\n- Result [4] is a document from KYMERA THERAPEUTICS that mentions clinical trials (KT-474, KT-333, KT-413) but doesn't mention NCT04982354 or Guenther Koehne.\n- Result [6] is a 10-K filing but doesn't provide details in the snippet.\n- Result [8] is a filing detail but doesn't provide specifics.\n- Result [10] is a Kinnate Biopharma Inc. 10K Annual Report from March 15, 2023.\n- Result [11", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for CPX-351. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Guenther Koehne regarding clinical trial NCT04982354 for CPX-351, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT04982354 is about based on the search results:\n\nFrom result [2] and [6], NCT04982354 is titled \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\". The sponsor is Guenther Koehne from Baptist Health South Florida.\n\nFrom result [1], [2], [5], and [6], we can see that this is a trial involving FLT3 mutated Acute Myeloid Leukemia patients.\n\nFrom result [2], the interventions include:\n- Drug: CPX-351\n- Drug: Midostaurin\n- Drug: Busulfan\n- Drug: Melphalan\n- Drug: Fludarabine\n- Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor\n\nFrom result [5], I see that the trial status is listed as \"Withdrawn\" with phase \"1/2\".\n\nNow, let me look for any information about:\n1. Company press releases\n2. Investor presentations\n3. Public statements by Guenther Koehne\n4. Safety issues\n5. Adverse events\n6. Trial termination reasons\n7. Regulatory actions\n\nLooking through the search results:\n\nResult [3] and [4] are press releases from Miami Cancer Institute (where Dr. Koehne works) about clinical trials, but they don't specifically mention NCT04982354 or CPX-351. They mention two FDA-approved clinical trials but don't specify which NCT numbers they are.\n\nResult [3] states: \"While the drugs in the trial have been tested and found safe, the combination has not been tried before,\" Dr. Koehne says. \"We are hopeful that the combination of drugs will lead to complete remission.\" This suggests that Dr. Koehne has made public statements about clinical trials, but it's not clear if this refers to NCT04982354 specifically", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "CPX-351"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "76": {"nct_id": "NCT04982354", "drug_name": "Fludarabine", "intervention_type": "DRUG", "drug_description": "25 mg/m2/day x 5 doses administered intravenously", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.561751", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:10.937655", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1096882", "pref_name": "FLUDARABINE PHOSPHATE", "targets": [{"chembl_id": "CHEMBL3879801", "ic50_values": [{"value": 2000.0, "units": "nM"}, {"value": 950.0, "units": "nM"}, {"value": 150.0, "units": "nM"}, {"value": 6000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614628", "ic50_values": [{"value": 400.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL383", "ic50_values": [{"value": 90.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL385", "ic50_values": [{"value": 400.0, "units": "nM"}, {"value": 150.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614393", "ic50_values": [{"value": 600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 130.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614735", "ic50_values": [{"value": 9000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL382", "ic50_values": [{"value": 400.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL386", "ic50_values": [{"value": 3000.0, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Fludarabine"}, "ppi_enrichment": {"uniprot_count": 4, "interactions": [{"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.69, "clustering_coefficient": 2.84}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41146244", "title": "Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups.", "authors": [{"name": "Mikhaylenko N", "authtype": "Author", "clusterid": ""}, {"name": "Braun T", "authtype": "Author", "clusterid": ""}, {"name": "Timonen S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41110448", "title": "IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.", "authors": [{"name": "Xu Q", "authtype": "Author", "clusterid": ""}, {"name": "Guo Y", "authtype": "Author", "clusterid": ""}, {"name": "Gao M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41037957", "title": "Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.", "authors": [{"name": "Wang Y", "authtype": "Author", "clusterid": ""}, {"name": "Yang S", "authtype": "Author", "clusterid": ""}, {"name": "Yu Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40960310", "title": "Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.", "authors": [{"name": "Liu W", "authtype": "Author", "clusterid": ""}, {"name": "Xie T", "authtype": "Author", "clusterid": ""}, {"name": "Zhang Z", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40859744", "title": "Randomization in phase II trials: No exemption based on sample size.", "authors": [{"name": "Framke T", "authtype": "Author", "clusterid": ""}, {"name": "Beutel G", "authtype": "Author", "clusterid": ""}, {"name": "Ganser A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+Fludarabine+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Fludarabine by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Fludarabine by Guenther Koehne.\n\nFirst, I need to identify if there are any mentions of:\n1. FDA warning letters related to Fludarabine\n2. Clinical holds related to Fludarabine\n3. Any connection to a person named Guenther Koehne\n4. Specific dates, reasons, and safety issues cited\n\nLet me go through the search results one by one:\n\nResult [1]: This discusses FDA updates to fludarabine phosphate labeling in chronic lymphocytic leukemia. It mentions warnings and precautions for neurological toxicities, myelosuppression, autoimmune cytopenias, etc., but doesn't mention any specific warning letters or clinical holds, nor does it mention Guenther Koehne.\n\nResult [2]: This is about label dose escalation in general, not specifically about Fludarabine or Guenther Koehne.\n\nResult [3]: This is the DailyMed entry for Fludarabine Phosphate Injection. It mentions various safety concerns like severe CNS toxicity, autoimmune phenomena, and pulmonary toxicity, but doesn't mention any FDA warning letters or clinical holds, nor Guenther Koehne.\n\nResult [4]: This appears to be an FDA FOIA request form, not relevant to our query.\n\nResult [5]: This is an important prescribing information document for Fludarabine Phosphate. It mentions drug interactions with pentostatin and various safety concerns, but doesn't mention any warning letters, clinical holds, or Guenther Koehne.\n\nResult [6]: This is about immunotherapy for multiple myeloma, not relevant to Fludarabine.\n\nResult [7]: This mentions that \"On November 19, 2024, the Food and Drug Administration approved updated drug labeling for fludarabine phosphate (Fludarabine Phosphate Injection, Sandoz) under Project Renewal.\" This is a recent update but doesn't mention warning letters or clinical holds.\n\nResult [8]: This appears to be about lymphoma, leukemia & myeloma congress abstracts, not specifically about Fludarabine warning letters.\n\nResult [9]: Similar to [7], this mentions the November 19, 2024 FDA approval of updated drug labeling for fludarabine phosphate under Project Renew", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query asks for:\n- SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues\n- Include filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to check if any of the search results contain information about:\n1. Guenther Koehne as filer\n2. Clinical trial NCT04982354\n3. Drug safety issues related to this trial\n\nLet me go through each search result:\n\nResult [1]: This is an 8-K filing for \"Eagle Point Income Co Inc.\" (CIK: 0001754836). The filing date is 2025-05-08. This appears to be a financial company, not related to clinical trials or pharmaceuticals. No mention of Guenther Koehne, NCT04982354, or drug safety.\n\nResult [2]: This is a Form 6-K for BioNTech SE. It mentions several clinical trials including NCT04486378 (for CRC) and NCT05918445 (for cervical cancer), but not NCT04982354. It does discuss safety data for some trials, but there's no mention of Guenther Koehne. BioNTech is a pharmaceutical company, but this doesn't match the specific query.\n\nResult [3]: This appears to be an 8-K filing for Medical Properties Trust, Inc. This is a real estate company, not related to clinical trials or pharmaceuticals. No mention of Guenther Koehne or NCT04982354.\n\nResult [4]: This is an EX-99.1 filing for Kymera Therapeutics. It discusses clinical trials for KT-474, KT-333, and KT-413, but not NCT04982354. It does include some safety data (e.g., \"No DLTs, no treatment-related SAEs, no AEs leading to discontinuation\"). However, there's no mention of Guenther Koehne.\n\nResult [5]: This is", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for Fludarabine. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about external safety evidence for clinical trial NCT04982354 involving Fludarabine, with a focus on Guenther Koehne's statements.\n\nThe query asks for:\n- Company press releases\n- Investor presentations\n- Public statements by Guenther Koehne\n- Specifically about clinical trial NCT04982354 for Fludarabine\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see what information is available:\n\nResult [1]: MedChemExpress page about Fludarabine phosphate. It mentions NCT04982354 and Guenther Koehne|Jazz Pharmaceuticals for Acute Myeloid Leukemia, but doesn't provide any statements or safety information from Koehne.\n\nResult [2]: FDA document about Fludarabine Clinical BPCA. This is a clinical review document but doesn't seem to specifically address NCT04982354 or statements by Guenther Koehne.\n\nResult [3]: ClinicalTrials.gov page for NCT04982354 - \"Induction Therapy for Patients With FLT3 Mutated Acute...\" This confirms the trial exists and mentions Fludarabine as part of the treatment (25 mg/m2/day x 5 doses administered intravenously), but doesn't provide any statements by Guenther Koehne.\n\nResult [4]: ODAC meeting document from March 2023 about Polatuzumab vedotin-piiq, not related to Fludarabine or NCT04982354.\n\nResult [5]: Larvol Online Trial Tracker showing Fludarabine, Fludara, CD34+ selected allogeneic stem cell transplant with Guenther Koehne, Jazz Pharmaceuticals for Acute Myeloid Leukemia. Mentions NCT04982354 but no specific statements.\n\nResult [6]: Investing.com article about Kura Oncology presenting AML trial data at ASH meeting. This is about ziftomenib (a menin inhibitor), not Fludarabine or NCT04982354.\n\nResult [7]:", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "Fludarabine"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "77": {"nct_id": "NCT04982354", "drug_name": "Melphalan", "intervention_type": "DRUG", "drug_description": "70 mg/m2/day x 2 doses administered intravenously", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.562336", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:10.974512", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL1200863", "pref_name": "MELPHALAN HYDROCHLORIDE", "targets": [{"chembl_id": null, "uniprot_id": "P02763", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q9NS82", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q01650", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P15144", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "O75751", "ic50_values": [], "source": "uniprot_fallback"}], "has_uniprot_targets": true, "search_name": "Melphalan", "drugbank_fallback": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "ORM1", "protein_b": "SPTLC3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA3", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AMBP", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "CP", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "AHSG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SPTLC1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "HP", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "SERPINA1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ALB", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ORM1", "protein_b": "ORM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SPTLC1", "protein_b": "SPTLC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "AHSG", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA3", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "ALB", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "SERPINA1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CP", "protein_b": "HP", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "SERPINA1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "HP", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ORM2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "AHSG", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "AMBP", "protein_b": "ALB", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "HP", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ORM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "SERPINA1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "AHSG", "protein_b": "ALB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "HP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "SERPINA1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "ORM2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA3", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "ORM2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HP", "protein_b": "SERPINA1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "ORM2", "protein_b": "SERPINA1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SLC7A10", "protein_b": "SLC3A1", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "SLC7A10", "protein_b": "SLC3A2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC3A2", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC3A2", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC7A5", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC1A5", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC38A2", "protein_b": "SLC38A1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC3A2", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC7A8", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "SLC3A1", "protein_b": "SLC7A5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC38A1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC43A2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "ASNS", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC7A8", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "LLGL2", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC1A5", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC43A1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "SLC7A5", "protein_b": "SLC3A2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC43A1", "protein_b": "SLC3A2", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "SLC43A1", "protein_b": "SLC7A8", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC7A8", "protein_b": "SLC43A2", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC7A8", "protein_b": "SLC3A2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "ASNS", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "SLC43A2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "SLC3A2", "protein_b": "SLC1A5", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SLC1A5", "protein_b": "SLC38A1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "RTN4R", "protein_b": "ANPEP", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT7", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "GGT5", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "LAP3", "protein_b": "ANPEP", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT5", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT7", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "ANPEP", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "GGT6", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "CD7", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "ANPEP", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CD33", "protein_b": "FCGR3A", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT7", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "FCGR3A", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "GGT6", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "SFN", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ANPEP", "protein_b": "CD7", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CD7", "protein_b": "FCGR3A", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GGT7", "protein_b": "GGT5", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GGT7", "protein_b": "GGT6", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GGT6", "protein_b": "GGT5", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "SLC22A3", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "SLC47A1", "protein_b": "SLC22A3", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "SLC47A1", "protein_b": "SLC29A4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "SLC29A4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "EHMT2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "SLC22A3", "protein_b": "IGF2R", "combined_score": 0.906, "interaction_type": "physical"}], "network_features": {"avg_degree": 4.49, "clustering_coefficient": 2.24}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41136366", "title": "35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du My\u00e9lome (IFM) experience.", "authors": [{"name": "Moreau P", "authtype": "Author", "clusterid": ""}, {"name": "Hulin C", "authtype": "Author", "clusterid": ""}, {"name": "Talbot A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41117344", "title": "Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.", "authors": [{"name": "Rausch C", "authtype": "Author", "clusterid": ""}, {"name": "Bacher U", "authtype": "Author", "clusterid": ""}, {"name": "Rabaglio M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41065854", "title": "Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?", "authors": [{"name": "Talarico M", "authtype": "Author", "clusterid": ""}, {"name": "Barbato S", "authtype": "Author", "clusterid": ""}, {"name": "Maisnar V", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41016399", "title": "Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.", "authors": [{"name": "Henderson TO", "authtype": "Author", "clusterid": ""}, {"name": "Bardwell JK", "authtype": "Author", "clusterid": ""}, {"name": "Kao PC", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+Melphalan+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Melphalan by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a comprehensive response.\n\nThe query is asking for:\n- FDA warning letters or clinical holds for Melphalan by Guenther Koehne\n- Specific dates, reasons, and safety issues cited\n\nFirst, I need to check if there are any FDA warning letters or clinical holds related to Melphalan that are associated with someone named Guenther Koehne.\n\nLet me go through the search results:\n\nResult [1]: Discusses dose escalation trials but doesn't mention Melphalan specifically in relation to FDA warning letters or clinical holds. It mentions some adverse events in trials but nothing specific to Melphalan or Guenther Koehne.\n\nResult [2]: Appears to be a PDF about Waldenstr\u00f6m's Award but doesn't seem to contain information about FDA warning letters for Melphalan.\n\nResult [3]: Discusses immunotherapy for multiple myeloma, mentions various drugs but doesn't specifically address FDA warning letters for Melphalan or Guenther Koehne.\n\nResult [4]: About cell transplantation but doesn't mention Melphalan FDA warnings or Guenther Koehne.\n\nResult [5]: Contains information about multiple myeloma treatments, mentions melphalan in one context: \"melphalan significantly prolonged survival compared to each agent alone...\" but doesn't mention FDA warning letters or Guenther Koehne.\n\nResult [6]: About Lymphoma, Leukemia & Myeloma Congress 2025 Abstracts, mentions LP-284 but not Melphalan FDA warnings.\n\nResult [7]: Title mentions \"Dr Koehne on the Evolution of the Multiple Myeloma Treatment...\" which is relevant to the query since it mentions Guenther Koehne (though the title only says \"Koehne\"). However, the content shows \"Error: Forbidden\" and \"403: Forbidden\" so I cannot access the information.\n\nResult [8]: Mentions \"autologous stem cell transplant with high-dose melphalan\" but doesn't mention FDA warning letters or Guenther Koehne specifically.\n\nResult [9]: About drug repositioning but doesn't seem relevant to the query.\n\nNow, let me specifically look for mentions of:\n1. Melphalan\n2. FDA warning letters or clinical holds\n3. Guenther Koehne\n\nFrom result [5], I see \"melphalan significantly prolonged", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results to find SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues.\n\nLet me go through each search result to see if they contain relevant information:\n\nResult [1]: This is an SEC Form 8-K filing for Eagle Point Income Co Inc (CIK: 0001754836) filed on 2025-05-08. It doesn't appear to mention Guenther Koehne, clinical trial NCT04982354, or any drug safety issues. It's for a financial company, not a biotech/pharma company.\n\nResult [2]: This is a BioNTech SE Form 6-K filing from 2024-08-05. It mentions several clinical trials including NCT04486378 (for CRC), NCT05918445 (for cervical cancer), but doesn't mention NCT04982354 or Guenther Koehne.\n\nResult [3]: This appears to be an 8-K filing, but the content is truncated and doesn't clearly show if it mentions Guenther Koehne or NCT04982354. It seems to be related to Medical Properties Trust, which is a real estate company, not a biotech company.\n\nResult [4]: This is an EX-99.1 document from Kymera Therapeutics. It mentions several clinical trials (KT-474, KT-333, KT-413) but doesn't mention NCT04982354 or Guenther Koehne.\n\nResult [5]: Just shows an EDGAR filing index without specific content.\n\nResult [6]: This appears to be about a company that was \"a clinical-stage biotechnology company that was focused on the development and commercialization of proprietary Listeria monocytogenes, or Lm, Technology antigen delivery products.\" It mentions a Phase 3 clinical trial called AIM2CERV, but not NCT04982354 or Guenther Koehne.\n\nResults [7]-[12]: These are just filing indices or titles without clear content related to our query.\n\nAfter reviewing", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for Melphalan. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by Guenther Koehne regarding clinical trial NCT04982354 for Melphalan, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT04982354 is about based on the search results:\n\nFrom result [1], [3], [5], [7], [9]:\n- NCT04982354 is titled \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\"\n- It appears to involve melphalan (also known as Myleran)\n- Guenther Koehne is associated with this trial (mentioned in results [1], [3], [9])\n- According to result [5], the trial status is \"Withdrawn\" and it's a phase 1/2 trial\n- From result [9], the trial involves \"Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine\"\n\nNow, let me check if there are any company press releases, investor presentations, or public statements by Guenther Koehne about this specific trial:\n\nResult [1]: Just shows the trial name and Guenther Koehne's name but no specific statements.\nResult [2]: Discusses FDA withdrawal of melphalan flufenamide (Pepaxto) for multiple myeloma, but this is a different drug (melphalan flufenamide vs. melphalan) and a different indication (multiple myeloma vs. acute myeloid leukemia).\nResult [3]: Shows Guenther Koehne is associated with the trial at Baptist Health South Florida/Miami Cancer Institute, but no specific statements.\nResult [4]: Discusses the withdrawal of melphalan flufenamide (Pepaxto) approval, but again, this is a different drug.\nResult [5]: Confirms NCT04982354 is \"Withdrawn\" (phase 1/2), but doesn't provide reasons.\nResult [6]: Just shows search results for Guenther Koehne's publications.\nResult", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "Melphalan"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "78": {"nct_id": "NCT04982354", "drug_name": "Midostaurin", "intervention_type": "DRUG", "drug_description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "phase": "PHASE1/PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Could not accrue", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "start_date": "2022-07-05", "completion_date": "2032-08-01", "sponsor": "Guenther Koehne", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.562904", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:11.010346", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL608533", "pref_name": "MIDOSTAURIN", "targets": [{"chembl_id": "CHEMBL1844", "ic50_values": [{"value": 142.0, "units": "nM"}], "uniprot_id": "B5A955"}, {"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 200.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 50.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 500.0, "units": "nM"}, {"value": 50.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1974", "ic50_values": [{"value": 13.0, "units": "nM"}, {"value": 15.0, "units": "nM"}, {"value": 37.0, "units": "nM"}, {"value": 30.0, "units": "nM"}, {"value": 40.0, "units": "nM"}, {"value": 501.0, "units": "nM"}, {"value": 528.0, "units": "nM"}, {"value": 1.0, "units": "nM"}, {"value": 132.0, "units": "nM"}, {"value": 528.0, "units": "nM"}], "uniprot_id": "A0AVG9"}, {"chembl_id": "CHEMBL613835", "ic50_values": [{"value": 12.0, "units": "nM"}, {"value": 19.83, "units": "nM"}, {"value": 40.0, "units": "nM"}, {"value": 20.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613859", "ic50_values": [{"value": 180.0, "units": "nM"}, {"value": 561.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614524", "ic50_values": [{"value": 200.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 10.0, "units": "nM"}, {"value": 4.14, "units": "nM"}, {"value": 320.0, "units": "nM"}, {"value": 11.0, "units": "nM"}, {"value": 2.0, "units": "nM"}, {"value": 7.0, "units": "nM"}, {"value": 76.0, "units": "nM"}, {"value": 4.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2331044", "ic50_values": [], "uniprot_id": "E1P5H0"}, {"chembl_id": "CHEMBL1075435", "ic50_values": [{"value": 636.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366079", "ic50_values": [{"value": 1023.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075437", "ic50_values": [{"value": 2242.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612519", "ic50_values": [{"value": 1335.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614281", "ic50_values": [{"value": 5091.19, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613508", "ic50_values": [{"value": 318.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366246", "ic50_values": [{"value": 3871.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366258", "ic50_values": [{"value": 5112.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614487", "ic50_values": [{"value": 14513.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366281", "ic50_values": [{"value": 1565.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366146", "ic50_values": [{"value": 12086.2, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366118", "ic50_values": [{"value": 1164.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366312", "ic50_values": [{"value": 1329.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366135", "ic50_values": [{"value": 4055.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075432", "ic50_values": [{"value": 5667.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075436", "ic50_values": [{"value": 290.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366369", "ic50_values": [{"value": 5597.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366338", "ic50_values": [{"value": 11996.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366240", "ic50_values": [{"value": 46746.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366180", "ic50_values": [{"value": 429.23, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366367", "ic50_values": [{"value": 1261.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075438", "ic50_values": [{"value": 473.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075439", "ic50_values": [{"value": 212.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075440", "ic50_values": [{"value": 129.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075441", "ic50_values": [{"value": 525.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075442", "ic50_values": [{"value": 1300.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614516", "ic50_values": [{"value": 476.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614517", "ic50_values": [{"value": 1170.69, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366313", "ic50_values": [{"value": 2260.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075400", "ic50_values": [{"value": 348.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075429", "ic50_values": [{"value": 299.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366224", "ic50_values": [{"value": 1403.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366199", "ic50_values": [{"value": 57207.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366264", "ic50_values": [{"value": 14554.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614567", "ic50_values": [{"value": 409.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075391", "ic50_values": [{"value": 134.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366283", "ic50_values": [{"value": 13714.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075401", "ic50_values": [{"value": 21863.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075402", "ic50_values": [{"value": 1445.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075430", "ic50_values": [{"value": 2884.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075433", "ic50_values": [{"value": 1580.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614642", "ic50_values": [{"value": 119770.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614519", "ic50_values": [{"value": 331.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366195", "ic50_values": [{"value": 648.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614533", "ic50_values": [{"value": 4487.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366275", "ic50_values": [{"value": 11619.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075431", "ic50_values": [{"value": 370.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613854", "ic50_values": [{"value": 11187.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614286", "ic50_values": [{"value": 66101.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366181", "ic50_values": [{"value": 38935.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613860", "ic50_values": [{"value": 173.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366294", "ic50_values": [{"value": 145.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612566", "ic50_values": [{"value": 628.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614067", "ic50_values": [{"value": 215.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075405", "ic50_values": [{"value": 210.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366352", "ic50_values": [{"value": 3563.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366329", "ic50_values": [{"value": 9600.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366167", "ic50_values": [{"value": 18016.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614034", "ic50_values": [{"value": 323.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075434", "ic50_values": [{"value": 32103.47, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366192", "ic50_values": [{"value": 728.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075392", "ic50_values": [{"value": 321.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075406", "ic50_values": [{"value": 280.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075407", "ic50_values": [{"value": 18543.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075408", "ic50_values": [{"value": 73258.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366076", "ic50_values": [{"value": 14628.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366363", "ic50_values": [{"value": 40603.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612657", "ic50_values": [{"value": 9723.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366241", "ic50_values": [{"value": 3146.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366277", "ic50_values": [{"value": 8652.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075393", "ic50_values": [{"value": 5548.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075409", "ic50_values": [{"value": 11994.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075410", "ic50_values": [{"value": 437.19, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075411", "ic50_values": [{"value": 107.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366061", "ic50_values": [{"value": 91188.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366344", "ic50_values": [{"value": 1486.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075382", "ic50_values": [{"value": 4638.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612565", "ic50_values": [{"value": 1774.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075383", "ic50_values": [{"value": 920.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612588", "ic50_values": [{"value": 9859.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075412", "ic50_values": [{"value": 208.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075413", "ic50_values": [{"value": 932.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366360", "ic50_values": [{"value": 2016.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366174", "ic50_values": [{"value": 89273.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075384", "ic50_values": [{"value": 12097.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366253", "ic50_values": [{"value": 671.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366271", "ic50_values": [{"value": 323.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366295", "ic50_values": [{"value": 5779.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075414", "ic50_values": [{"value": 20177.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075415", "ic50_values": [{"value": 565.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075403", "ic50_values": [{"value": 18534.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075404", "ic50_values": [{"value": 15300.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075385", "ic50_values": [{"value": 120.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613102", "ic50_values": [{"value": 473.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366247", "ic50_values": [{"value": 1474.36, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614277", "ic50_values": [{"value": 565.58, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075416", "ic50_values": [{"value": 21295.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614536", "ic50_values": [{"value": 2247.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075418", "ic50_values": [{"value": 644.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613505", "ic50_values": [{"value": 2124.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614534", "ic50_values": [{"value": 368.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366115", "ic50_values": [{"value": 198.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075386", "ic50_values": [{"value": 1680.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366371", "ic50_values": [{"value": 487.41, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075394", "ic50_values": [{"value": 298.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366303", "ic50_values": [{"value": 4360.27, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366100", "ic50_values": [{"value": 181.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075419", "ic50_values": [{"value": 253.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL382", "ic50_values": [{"value": 470.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614535", "ic50_values": [{"value": 15958.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614379", "ic50_values": [{"value": 41531.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366249", "ic50_values": [{"value": 1916.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075417", "ic50_values": [{"value": 2766.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075387", "ic50_values": [{"value": 276.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366306", "ic50_values": [{"value": 587.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075395", "ic50_values": [{"value": 3214.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075396", "ic50_values": [{"value": 254.58, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366361", "ic50_values": [{"value": 1819.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366300", "ic50_values": [{"value": 42.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075421", "ic50_values": [{"value": 2898.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366237", "ic50_values": [{"value": 250.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614512", "ic50_values": [{"value": 291.5, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614514", "ic50_values": [{"value": 100.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613503", "ic50_values": [{"value": 528.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075397", "ic50_values": [{"value": 310.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075398", "ic50_values": [{"value": 2196.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075399", "ic50_values": [{"value": 2349.12, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075422", "ic50_values": [{"value": 7955.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366137", "ic50_values": [{"value": 4844.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366183", "ic50_values": [{"value": 414.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614476", "ic50_values": [{"value": 20731.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614255", "ic50_values": [{"value": 4903.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614004", "ic50_values": [{"value": 475.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366173", "ic50_values": [{"value": 925.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366317", "ic50_values": [{"value": 7586.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075423", "ic50_values": [{"value": 87.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366177", "ic50_values": [{"value": 1090.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614561", "ic50_values": [{"value": 432.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366113", "ic50_values": [{"value": 87.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366161", "ic50_values": [{"value": 331.2, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366273", "ic50_values": [{"value": 839.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366109", "ic50_values": [{"value": 1569.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366131", "ic50_values": [{"value": 10377.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613870", "ic50_values": [{"value": 3665.3, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366265", "ic50_values": [{"value": 4646.56, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366215", "ic50_values": [{"value": 1122.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366343", "ic50_values": [{"value": 5842.31, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366355", "ic50_values": [{"value": 12699.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366356", "ic50_values": [{"value": 560.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614529", "ic50_values": [{"value": 86167.92, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075425", "ic50_values": [{"value": 2734.77, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075426", "ic50_values": [{"value": 4166.29, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075427", "ic50_values": [{"value": 471.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366208", "ic50_values": [{"value": 23139.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366331", "ic50_values": [{"value": 1219.29, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614515", "ic50_values": [{"value": 119.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614069", "ic50_values": [{"value": 112.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366145", "ic50_values": [{"value": 5448.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366230", "ic50_values": [{"value": 2694.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614530", "ic50_values": [{"value": 493.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366176", "ic50_values": [{"value": 3347.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075428", "ic50_values": [{"value": 55315.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614801", "ic50_values": [{"value": 941.97, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366186", "ic50_values": [{"value": 558.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366346", "ic50_values": [{"value": 15963.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366102", "ic50_values": [{"value": 719.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612256", "ic50_values": [{"value": 39180.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075556", "ic50_values": [{"value": 4986.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366339", "ic50_values": [{"value": 30064.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366187", "ic50_values": [{"value": 3411.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612447", "ic50_values": [{"value": 611.23, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614882", "ic50_values": [{"value": 20378.74, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614913", "ic50_values": [{"value": 439.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614916", "ic50_values": [{"value": 22693.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075592", "ic50_values": [{"value": 8472.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614055", "ic50_values": [{"value": 266.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612262", "ic50_values": [{"value": 1617.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075600", "ic50_values": [{"value": 52828.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614245", "ic50_values": [{"value": 12074.77, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366272", "ic50_values": [{"value": 319.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366074", "ic50_values": [{"value": 194.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366310", "ic50_values": [{"value": 4893.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL383", "ic50_values": [{"value": 22590.13, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366104", "ic50_values": [{"value": 2703.27, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366101", "ic50_values": [{"value": 6007.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366228", "ic50_values": [{"value": 130.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075483", "ic50_values": [{"value": 26103.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366172", "ic50_values": [{"value": 35335.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366262", "ic50_values": [{"value": 174.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075504", "ic50_values": [{"value": 146137.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366225", "ic50_values": [{"value": 820.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366276", "ic50_values": [{"value": 44908.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366210", "ic50_values": [{"value": 26457.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366075", "ic50_values": [{"value": 4113.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612540", "ic50_values": [{"value": 1288.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366319", "ic50_values": [{"value": 3003.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075543", "ic50_values": [{"value": 117.08, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366068", "ic50_values": [{"value": 278.41, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612517", "ic50_values": [{"value": 577.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366341", "ic50_values": [{"value": 109035.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614917", "ic50_values": [{"value": 2970.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366314", "ic50_values": [{"value": 41487.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614919", "ic50_values": [{"value": 34809.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075593", "ic50_values": [{"value": 1168.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366143", "ic50_values": [{"value": 4788.38, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614056", "ic50_values": [{"value": 391.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366083", "ic50_values": [{"value": 20241.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075449", "ic50_values": [{"value": 1538.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366179", "ic50_values": [{"value": 1958.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075464", "ic50_values": [{"value": 337.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614826", "ic50_values": [{"value": 1793.86, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075465", "ic50_values": [{"value": 6990.41, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366219", "ic50_values": [{"value": 18239.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614586", "ic50_values": [{"value": 4431.78, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613997", "ic50_values": [{"value": 1111.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366119", "ic50_values": [{"value": 1109.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366252", "ic50_values": [{"value": 805.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614096", "ic50_values": [{"value": 7988.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366066", "ic50_values": [{"value": 17506.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614347", "ic50_values": [{"value": 164.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366286", "ic50_values": [{"value": 10016.92, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075505", "ic50_values": [{"value": 249.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366328", "ic50_values": [{"value": 8643.43, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075527", "ic50_values": [{"value": 3536.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075528", "ic50_values": [{"value": 486.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075544", "ic50_values": [{"value": 2023.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614805", "ic50_values": [{"value": 1395.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366353", "ic50_values": [{"value": 1658.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366188", "ic50_values": [{"value": 335.12, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614213", "ic50_values": [{"value": 1226.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366159", "ic50_values": [{"value": 624.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614145", "ic50_values": [{"value": 974.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614920", "ic50_values": [{"value": 1263.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075577", "ic50_values": [{"value": 399.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075594", "ic50_values": [{"value": 29286.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075595", "ic50_values": [{"value": 411.42, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366218", "ic50_values": [{"value": 413.74, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075601", "ic50_values": [{"value": 40395.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075602", "ic50_values": [{"value": 11277.94, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075450", "ic50_values": [{"value": 2075.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366111", "ic50_values": [{"value": 872.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075466", "ic50_values": [{"value": 3155.69, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614643", "ic50_values": [{"value": 180.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614587", "ic50_values": [{"value": 63845.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366348", "ic50_values": [{"value": 12528.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366190", "ic50_values": [{"value": 78363.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075484", "ic50_values": [{"value": 1144.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366072", "ic50_values": [{"value": 905.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366334", "ic50_values": [{"value": 5637.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366185", "ic50_values": [{"value": 3018.78, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366127", "ic50_values": [{"value": 6099.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366318", "ic50_values": [{"value": 1444.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075530", "ic50_values": [{"value": 230.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075531", "ic50_values": [{"value": 698.94, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366106", "ic50_values": [{"value": 1154.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366184", "ic50_values": [{"value": 706.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366105", "ic50_values": [{"value": 113826.23, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614051", "ic50_values": [{"value": 1847.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614214", "ic50_values": [{"value": 691.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614884", "ic50_values": [{"value": 4617.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075567", "ic50_values": [{"value": 24894.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614886", "ic50_values": [{"value": 406.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614923", "ic50_values": [{"value": 314.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366232", "ic50_values": [{"value": 2176.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075596", "ic50_values": [{"value": 70153.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366302", "ic50_values": [{"value": 944.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL615023", "ic50_values": [{"value": 1169.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366315", "ic50_values": [{"value": 983.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366373", "ic50_values": [{"value": 4106.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366297", "ic50_values": [{"value": 1538.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366148", "ic50_values": [{"value": 380.43, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613889", "ic50_values": [{"value": 698.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614736", "ic50_values": [{"value": 458.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075467", "ic50_values": [{"value": 19487.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366359", "ic50_values": [{"value": 8220.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366372", "ic50_values": [{"value": 66149.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613998", "ic50_values": [{"value": 262.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075485", "ic50_values": [{"value": 478.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366189", "ic50_values": [{"value": 2749.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614725", "ic50_values": [{"value": 20740.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614352", "ic50_values": [{"value": 884.12, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075510", "ic50_values": [{"value": 734.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366082", "ic50_values": [{"value": 23430.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075532", "ic50_values": [{"value": 677.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366365", "ic50_values": [{"value": 37889.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075545", "ic50_values": [{"value": 11139.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366087", "ic50_values": [{"value": 1777.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612555", "ic50_values": [{"value": 2031.5, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614660", "ic50_values": [{"value": 11109.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614628", "ic50_values": [{"value": 54813.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366170", "ic50_values": [{"value": 2943.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075578", "ic50_values": [{"value": 35399.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075579", "ic50_values": [{"value": 36200.47, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075598", "ic50_values": [{"value": 21458.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614943", "ic50_values": [{"value": 1259.11, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366098", "ic50_values": [{"value": 55317.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614247", "ic50_values": [{"value": 2681.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366069", "ic50_values": [{"value": 1223.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075444", "ic50_values": [{"value": 1076.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075452", "ic50_values": [{"value": 139.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366142", "ic50_values": [{"value": 8744.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075468", "ic50_values": [{"value": 247.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612279", "ic50_values": [{"value": 1816.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614588", "ic50_values": [{"value": 2364.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL385", "ic50_values": [{"value": 14574.68, "units": "nM"}, {"value": 10000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075486", "ic50_values": [{"value": 167.78, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075487", "ic50_values": [{"value": 312.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075488", "ic50_values": [{"value": 2592.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366311", "ic50_values": [{"value": 38311.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366236", "ic50_values": [{"value": 5000.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614353", "ic50_values": [{"value": 1198.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614354", "ic50_values": [{"value": 419.31, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614355", "ic50_values": [{"value": 36282.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075511", "ic50_values": [{"value": 767.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366351", "ic50_values": [{"value": 9792.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075533", "ic50_values": [{"value": 322.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366160", "ic50_values": [{"value": 643.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366163", "ic50_values": [{"value": 8067.78, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075546", "ic50_values": [{"value": 210.27, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366165", "ic50_values": [{"value": 612.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366370", "ic50_values": [{"value": 125376.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614949", "ic50_values": [{"value": 184.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075568", "ic50_values": [{"value": 24111.38, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075569", "ic50_values": [{"value": 54879.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366120", "ic50_values": [{"value": 109732.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075580", "ic50_values": [{"value": 15238.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613530", "ic50_values": [{"value": 4364.27, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614388", "ic50_values": [{"value": 196.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL615022", "ic50_values": [{"value": 616.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366116", "ic50_values": [{"value": 376.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366299", "ic50_values": [{"value": 2895.29, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075453", "ic50_values": [{"value": 41676.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075469", "ic50_values": [{"value": 4403.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366130", "ic50_values": [{"value": 27139.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366354", "ic50_values": [{"value": 1746.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366152", "ic50_values": [{"value": 361.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613868", "ic50_values": [{"value": 785.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612701", "ic50_values": [{"value": 402.38, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366248", "ic50_values": [{"value": 8926.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366132", "ic50_values": [{"value": 4465.13, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614356", "ic50_values": [{"value": 798.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366073", "ic50_values": [{"value": 140618.84, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366323", "ic50_values": [{"value": 38032.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075534", "ic50_values": [{"value": 443.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366077", "ic50_values": [{"value": 85124.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075547", "ic50_values": [{"value": 1638.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366169", "ic50_values": [{"value": 74477.94, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075557", "ic50_values": [{"value": 160.2, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075558", "ic50_values": [{"value": 4804.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366327", "ic50_values": [{"value": 53824.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614896", "ic50_values": [{"value": 1273.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614925", "ic50_values": [{"value": 5718.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366108", "ic50_values": [{"value": 2460.29, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366238", "ic50_values": [{"value": 45.58, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614894", "ic50_values": [{"value": 3742.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612542", "ic50_values": [{"value": 13104.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612796", "ic50_values": [{"value": 3818.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614610", "ic50_values": [{"value": 4257.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614295", "ic50_values": [{"value": 42895.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366364", "ic50_values": [{"value": 531.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366223", "ic50_values": [{"value": 32924.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366202", "ic50_values": [{"value": 7907.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075454", "ic50_values": [{"value": 84.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075455", "ic50_values": [{"value": 31505.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614580", "ic50_values": [{"value": 159.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614836", "ic50_values": [{"value": 30493.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612258", "ic50_values": [{"value": 929.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366155", "ic50_values": [{"value": 659.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366156", "ic50_values": [{"value": 94249.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614012", "ic50_values": [{"value": 820.41, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366267", "ic50_values": [{"value": 5482.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614694", "ic50_values": [{"value": 4651.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075493", "ic50_values": [{"value": 558.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366211", "ic50_values": [{"value": 4460.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366196", "ic50_values": [{"value": 4058.47, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612255", "ic50_values": [{"value": 515.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366266", "ic50_values": [{"value": 2288.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366213", "ic50_values": [{"value": 28658.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075535", "ic50_values": [{"value": 7071.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366217", "ic50_values": [{"value": 21384.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075536", "ic50_values": [{"value": 2383.84, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614197", "ic50_values": [{"value": 5326.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614931", "ic50_values": [{"value": 2703.25, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612583", "ic50_values": [{"value": 356.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614140", "ic50_values": [{"value": 538.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614899", "ic50_values": [{"value": 574.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614901", "ic50_values": [{"value": 1048.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366316", "ic50_values": [{"value": 329.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075581", "ic50_values": [{"value": 3765.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614774", "ic50_values": [{"value": 1918.93, "units": "nM"}, {"value": 29.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614361", "ic50_values": [{"value": 5248.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075604", "ic50_values": [{"value": 154215.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075605", "ic50_values": [{"value": 47373.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612799", "ic50_values": [{"value": 1006.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075606", "ic50_values": [{"value": 1782.78, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366124", "ic50_values": [{"value": 435.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075456", "ic50_values": [{"value": 1170.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366063", "ic50_values": [{"value": 879.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075457", "ic50_values": [{"value": 1530.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366291", "ic50_values": [{"value": 389.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL384", "ic50_values": [{"value": 979.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366368", "ic50_values": [{"value": 59938.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366305", "ic50_values": [{"value": 4651.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366233", "ic50_values": [{"value": 5838.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366153", "ic50_values": [{"value": 394.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614107", "ic50_values": [{"value": 329.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614721", "ic50_values": [{"value": 4229.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366070", "ic50_values": [{"value": 1834.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366362", "ic50_values": [{"value": 6377.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366227", "ic50_values": [{"value": 678.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366201", "ic50_values": [{"value": 25941.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614740", "ic50_values": [{"value": 2386.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613529", "ic50_values": [{"value": 150284.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614934", "ic50_values": [{"value": 10324.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 4665.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366235", "ic50_values": [{"value": 387.56, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075560", "ic50_values": [{"value": 14106.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366081", "ic50_values": [{"value": 128769.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075570", "ic50_values": [{"value": 239.67, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075571", "ic50_values": [{"value": 872.86, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614054", "ic50_values": [{"value": 2627.5, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614451", "ic50_values": [{"value": 773.11, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613531", "ic50_values": [{"value": 16449.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614775", "ic50_values": [{"value": 189.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366259", "ic50_values": [{"value": 248.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075607", "ic50_values": [{"value": 736.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366358", "ic50_values": [{"value": 314.3, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366097", "ic50_values": [{"value": 322.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075458", "ic50_values": [{"value": 24650.91, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075459", "ic50_values": [{"value": 37406.26, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075470", "ic50_values": [{"value": 7102.61, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075471", "ic50_values": [{"value": 2773.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613988", "ic50_values": [{"value": 60.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366287", "ic50_values": [{"value": 31963.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612264", "ic50_values": [{"value": 554.19, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366090", "ic50_values": [{"value": 7266.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366123", "ic50_values": [{"value": 56357.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075494", "ic50_values": [{"value": 1392.31, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614317", "ic50_values": [{"value": 15845.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614177", "ic50_values": [{"value": 6736.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366149", "ic50_values": [{"value": 35644.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366205", "ic50_values": [{"value": 1740.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075513", "ic50_values": [{"value": 3559.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614997", "ic50_values": [{"value": 53686.36, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075537", "ic50_values": [{"value": 108.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366340", "ic50_values": [{"value": 2156.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366263", "ic50_values": [{"value": 1402.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075561", "ic50_values": [{"value": 44411.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614241", "ic50_values": [{"value": 51755.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075573", "ic50_values": [{"value": 115065.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075574", "ic50_values": [{"value": 151728.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075582", "ic50_values": [{"value": 492.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075583", "ic50_values": [{"value": 138.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075584", "ic50_values": [{"value": 236.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366254", "ic50_values": [{"value": 123127.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL615010", "ic50_values": [{"value": 164.69, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366092", "ic50_values": [{"value": 4094.58, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075610", "ic50_values": [{"value": 369.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075611", "ic50_values": [{"value": 2359.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366206", "ic50_values": [{"value": 21296.04, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366126", "ic50_values": [{"value": 1738.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366221", "ic50_values": [{"value": 83052.84, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075472", "ic50_values": [{"value": 1640.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614582", "ic50_values": [{"value": 172.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366154", "ic50_values": [{"value": 117.41, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366136", "ic50_values": [{"value": 154.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366330", "ic50_values": [{"value": 987.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366274", "ic50_values": [{"value": 3781.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075495", "ic50_values": [{"value": 266.29, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366256", "ic50_values": [{"value": 715.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366062", "ic50_values": [{"value": 111.36, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366357", "ic50_values": [{"value": 439.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366325", "ic50_values": [{"value": 339.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366178", "ic50_values": [{"value": 1545.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075514", "ic50_values": [{"value": 414.84, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075538", "ic50_values": [{"value": 2869.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075539", "ic50_values": [{"value": 351.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075540", "ic50_values": [{"value": 2805.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366133", "ic50_values": [{"value": 39.42, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366349", "ic50_values": [{"value": 223.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366337", "ic50_values": [{"value": 1653.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366191", "ic50_values": [{"value": 1858.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614905", "ic50_values": [{"value": 247.31, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613977", "ic50_values": [{"value": 393.81, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075585", "ic50_values": [{"value": 131.7, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075586", "ic50_values": [{"value": 7249.92, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366304", "ic50_values": [{"value": 5168.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366308", "ic50_values": [{"value": 1281.4, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366193", "ic50_values": [{"value": 1391.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612815", "ic50_values": [{"value": 37009.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366307", "ic50_values": [{"value": 6498.26, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366112", "ic50_values": [{"value": 681.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614489", "ic50_values": [{"value": 52.08, "units": "nM"}, {"value": 3.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613855", "ic50_values": [{"value": 11425.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075460", "ic50_values": [{"value": 498.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614645", "ic50_values": [{"value": 2307.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614581", "ic50_values": [{"value": 178.56, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614039", "ic50_values": [{"value": 2789.23, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366229", "ic50_values": [{"value": 2302.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366239", "ic50_values": [{"value": 2307.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366335", "ic50_values": [{"value": 6257.12, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 332.74, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366242", "ic50_values": [{"value": 4791.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075496", "ic50_values": [{"value": 420.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366125", "ic50_values": [{"value": 4924.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075509", "ic50_values": [{"value": 83920.84, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075516", "ic50_values": [{"value": 29848.87, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366290", "ic50_values": [{"value": 1955.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075541", "ic50_values": [{"value": 265.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614733", "ic50_values": [{"value": 773.93, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366198", "ic50_values": [{"value": 23532.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366141", "ic50_values": [{"value": 3098.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075562", "ic50_values": [{"value": 2292.98, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614144", "ic50_values": [{"value": 1072.08, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614908", "ic50_values": [{"value": 272.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614860", "ic50_values": [{"value": 27924.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366279", "ic50_values": [{"value": 60951.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614300", "ic50_values": [{"value": 365.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366166", "ic50_values": [{"value": 1071.54, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366278", "ic50_values": [{"value": 611.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075612", "ic50_values": [{"value": 195.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366114", "ic50_values": [{"value": 262.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612250", "ic50_values": [{"value": 1185.47, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075445", "ic50_values": [{"value": 25665.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075461", "ic50_values": [{"value": 2449.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366207", "ic50_values": [{"value": 410.1, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075475", "ic50_values": [{"value": 154.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075476", "ic50_values": [{"value": 441.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366250", "ic50_values": [{"value": 9761.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614709", "ic50_values": [{"value": 92.75, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366296", "ic50_values": [{"value": 26439.5, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366140", "ic50_values": [{"value": 4225.08, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366099", "ic50_values": [{"value": 8138.3, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075497", "ic50_values": [{"value": 6599.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL400", "ic50_values": [{"value": 281.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366204", "ic50_values": [{"value": 417.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075517", "ic50_values": [{"value": 26128.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366214", "ic50_values": [{"value": 2234.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614803", "ic50_values": [{"value": 84788.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614195", "ic50_values": [{"value": 59716.36, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614135", "ic50_values": [{"value": 335.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614206", "ic50_values": [{"value": 208.95, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614208", "ic50_values": [{"value": 1569.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366320", "ic50_values": [{"value": 513.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075563", "ic50_values": [{"value": 3983.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366078", "ic50_values": [{"value": 56437.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366309", "ic50_values": [{"value": 492.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612569", "ic50_values": [{"value": 6872.31, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366293", "ic50_values": [{"value": 349.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366200", "ic50_values": [{"value": 3069.59, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614940", "ic50_values": [{"value": 654.24, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614243", "ic50_values": [{"value": 337.97, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366086", "ic50_values": [{"value": 1537.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366268", "ic50_values": [{"value": 994.34, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366245", "ic50_values": [{"value": 31334.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366071", "ic50_values": [{"value": 9306.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366326", "ic50_values": [{"value": 3232.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614036", "ic50_values": [{"value": 208.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613509", "ic50_values": [{"value": 223.39, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075446", "ic50_values": [{"value": 202.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366139", "ic50_values": [{"value": 1934.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL394", "ic50_values": [{"value": 235.68, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075477", "ic50_values": [{"value": 3207.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075478", "ic50_values": [{"value": 34944.18, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366366", "ic50_values": [{"value": 4706.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366347", "ic50_values": [{"value": 4797.89, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366257", "ic50_values": [{"value": 53824.94, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366222", "ic50_values": [{"value": 299.46, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614129", "ic50_values": [{"value": 29540.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075498", "ic50_values": [{"value": 29170.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614334", "ic50_values": [{"value": 34226.19, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366226", "ic50_values": [{"value": 5669.02, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075518", "ic50_values": [{"value": 889.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075519", "ic50_values": [{"value": 6707.71, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075542", "ic50_values": [{"value": 5072.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612440", "ic50_values": [{"value": 14353.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075552", "ic50_values": [{"value": 137.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075553", "ic50_values": [{"value": 1056.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614879", "ic50_values": [{"value": 420.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366251", "ic50_values": [{"value": 482.99, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366067", "ic50_values": [{"value": 2708.6, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075575", "ic50_values": [{"value": 1788.8, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075587", "ic50_values": [{"value": 6544.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075588", "ic50_values": [{"value": 5504.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366144", "ic50_values": [{"value": 1648.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366301", "ic50_values": [{"value": 11334.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075447", "ic50_values": [{"value": 1178.66, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612263", "ic50_values": [{"value": 334.32, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366322", "ic50_values": [{"value": 60103.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075479", "ic50_values": [{"value": 393.69, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613984", "ic50_values": [{"value": 1693.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366261", "ic50_values": [{"value": 12991.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366203", "ic50_values": [{"value": 5436.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366110", "ic50_values": [{"value": 3986.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366216", "ic50_values": [{"value": 2147.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366260", "ic50_values": [{"value": 113.45, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614335", "ic50_values": [{"value": 13036.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075499", "ic50_values": [{"value": 17463.22, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366138", "ic50_values": [{"value": 4156.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613300", "ic50_values": [{"value": 12857.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075521", "ic50_values": [{"value": 1634.92, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366333", "ic50_values": [{"value": 9372.53, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL396", "ic50_values": [{"value": 3263.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366332", "ic50_values": [{"value": 55441.48, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075554", "ic50_values": [{"value": 580.91, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366220", "ic50_values": [{"value": 2074.76, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366175", "ic50_values": [{"value": 110401.09, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366168", "ic50_values": [{"value": 795.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075564", "ic50_values": [{"value": 2864.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366298", "ic50_values": [{"value": 8403.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075576", "ic50_values": [{"value": 518.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075589", "ic50_values": [{"value": 18174.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612570", "ic50_values": [{"value": 2284.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366182", "ic50_values": [{"value": 1679.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366147", "ic50_values": [{"value": 6725.01, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366292", "ic50_values": [{"value": 560.07, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366234", "ic50_values": [{"value": 286.92, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366231", "ic50_values": [{"value": 13737.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075462", "ic50_values": [{"value": 4394.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614584", "ic50_values": [{"value": 2105.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366209", "ic50_values": [{"value": 2714.65, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075480", "ic50_values": [{"value": 3556.72, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075481", "ic50_values": [{"value": 4399.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075482", "ic50_values": [{"value": 615.85, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366091", "ic50_values": [{"value": 4510.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614066", "ic50_values": [{"value": 214.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366084", "ic50_values": [{"value": 4062.97, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075500", "ic50_values": [{"value": 726.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075501", "ic50_values": [{"value": 492.14, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614722", "ic50_values": [{"value": 147085.49, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614187", "ic50_values": [{"value": 108.03, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075522", "ic50_values": [{"value": 704.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075523", "ic50_values": [{"value": 774.83, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075524", "ic50_values": [{"value": 62.73, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614099", "ic50_values": [{"value": 12289.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614387", "ic50_values": [{"value": 423.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366342", "ic50_values": [{"value": 77485.05, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366121", "ic50_values": [{"value": 1359.15, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075555", "ic50_values": [{"value": 5517.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075565", "ic50_values": [{"value": 1544.06, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075566", "ic50_values": [{"value": 2786.33, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614912", "ic50_values": [{"value": 512.97, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366096", "ic50_values": [{"value": 353.35, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075590", "ic50_values": [{"value": 133.16, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075591", "ic50_values": [{"value": 733.37, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366089", "ic50_values": [{"value": 3175.57, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366093", "ic50_values": [{"value": 5200.55, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075448", "ic50_values": [{"value": 528.97, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366157", "ic50_values": [{"value": 172.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613888", "ic50_values": [{"value": 985.17, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075463", "ic50_values": [{"value": 3229.9, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366094", "ic50_values": [{"value": 2218.3, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366194", "ic50_values": [{"value": 1560.74, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366065", "ic50_values": [{"value": 24648.79, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075489", "ic50_values": [{"value": 753.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075490", "ic50_values": [{"value": 3715.52, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075491", "ic50_values": [{"value": 54718.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614343", "ic50_values": [{"value": 75.44, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075502", "ic50_values": [{"value": 5395.69, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075503", "ic50_values": [{"value": 1679.51, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366284", "ic50_values": [{"value": 107674.63, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366243", "ic50_values": [{"value": 18614.58, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366285", "ic50_values": [{"value": 4837.64, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2366171", "ic50_values": [{"value": 1313.82, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075525", "ic50_values": [{"value": 330.96, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1075526", "ic50_values": [{"value": 800.88, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4722", "ic50_values": [{"value": 80.0, "units": "nM"}], "uniprot_id": "E1P5F9"}, {"chembl_id": "CHEMBL279", "ic50_values": [{"value": 250.0, "units": "nM"}], "uniprot_id": "A2RRS0"}, {"chembl_id": "CHEMBL3706572", "ic50_values": [{"value": 4.7, "units": "nM"}, {"value": 262.9, "units": "nM"}, {"value": 677.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 336.51, "units": "nM"}, {"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613107", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL1936", "ic50_values": [{"value": 109.0, "units": "nM"}, {"value": 30.0, "units": "nM"}], "uniprot_id": "B5A956"}, {"chembl_id": "CHEMBL4680030", "ic50_values": [{"value": 9430.0, "units": "nM"}, {"value": 12400.0, "units": "nM"}, {"value": 7280.0, "units": "nM"}, {"value": 6020.0, "units": "nM"}], "uniprot_id": "A0A0A0MSK8"}, {"chembl_id": "CHEMBL3830", "ic50_values": [{"value": 200.0, "units": "nM"}], "uniprot_id": "Q2M2I8"}, {"chembl_id": "CHEMBL1907600", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "A1XKG3"}, {"chembl_id": "CHEMBL4937", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "P49674"}, {"chembl_id": "CHEMBL4224", "ic50_values": [{"value": 1367.0, "units": "nM"}], "uniprot_id": "B4DFW7"}, {"chembl_id": "CHEMBL4225", "ic50_values": [{"value": 2979.0, "units": "nM"}], "uniprot_id": "B1AVS9"}, {"chembl_id": "CHEMBL4226", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "D3DW59"}, {"chembl_id": "CHEMBL4203", "ic50_values": [{"value": 1555.0, "units": "nM"}], "uniprot_id": "Q9HAZ1"}, {"chembl_id": "CHEMBL2292", "ic50_values": [{"value": 886.5, "units": "nM"}], "uniprot_id": "O60769"}, {"chembl_id": "CHEMBL5543", "ic50_values": [{"value": 2035.0, "units": "nM"}], "uniprot_id": "O75258"}, {"chembl_id": "CHEMBL4376", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "B2R9V9"}, {"chembl_id": "CHEMBL4575", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "D3DT79"}, {"chembl_id": "CHEMBL1075115", "ic50_values": [{"value": 10000.0, "units": "nM"}], "uniprot_id": "A8K8F7"}, {"chembl_id": "CHEMBL262", "ic50_values": [{"value": 4636.0, "units": "nM"}], "uniprot_id": "D3DN89"}, {"chembl_id": "CHEMBL614316", "ic50_values": [{"value": 1000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL203", "ic50_values": [{"value": 3000.0, "units": "nM"}], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL4302", "ic50_values": [{"value": 68.0, "units": "nM"}], "uniprot_id": "A8K294"}, {"chembl_id": "CHEMBL5393", "ic50_values": [{"value": 4436.0, "units": "nM"}], "uniprot_id": "A0A1W3"}, {"chembl_id": "CHEMBL4296457", "ic50_values": [{"value": 8100.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2093867", "ic50_values": [{"value": 310.0, "units": "nM"}, {"value": 417.9, "units": "nM"}, {"value": 390.0, "units": "nM"}, {"value": 661.7, "units": "nM"}, {"value": 282.8, "units": "nM"}, {"value": 10000.0, "units": "nM"}], "uniprot_id": "D6W587"}], "has_uniprot_targets": true, "search_name": "Midostaurin"}, "ppi_enrichment": {"uniprot_count": 24, "interactions": [{"protein_a": "SPI1", "protein_b": "CSF1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "CSF2", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "TYROBP", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "CSF1R", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "RUNX1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TYROBP", "protein_b": "TNFSF11", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "TYROBP", "protein_b": "GRB2", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "TYROBP", "protein_b": "CSF1R", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "CSF1", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "CSF1R", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "KITLG", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "GRB2", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "CSF2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "RUNX1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "TNFSF11", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "CSF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSF1R", "protein_b": "IL34", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSF2", "protein_b": "KITLG", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CSF2", "protein_b": "RUNX1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "CSF2", "protein_b": "CSF1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CSF1", "protein_b": "KITLG", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CSF1", "protein_b": "GRB2", "combined_score": 0.785, "interaction_type": "physical"}, {"protein_a": "CSF1", "protein_b": "TNFSF11", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CSF1", "protein_b": "IL34", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "FLT3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "SPI1", "protein_b": "CEBPA", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "PIK3R1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "PIK3CA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "STAT5A", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "STAT5B", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "STAT3", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "GRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "CEBPA", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "KITLG", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT3", "protein_b": "FLT3LG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "STAT3", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "GRB2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PIK3R1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "KITLG", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "FLT3LG", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CEBPA", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "GRB2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PIK3R1", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT5A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT5B", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "FLT3LG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "KITLG", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "GRB2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "STAT5B", "protein_b": "STAT5A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "FLT3LG", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "KITLG", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "STAT5A", "protein_b": "GRB2", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "PIK3R1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FLT3LG", "protein_b": "KITLG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HERC2", "protein_b": "MYT1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "PKMYT1", "protein_b": "MYT1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "PLP1", "protein_b": "MYT1", "combined_score": 0.829, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "CCNB2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "NEDD9", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "BIRC5", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "INCENP", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "CDC20", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "PLK1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "TACC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "MYCN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "AURKA", "protein_b": "TPX2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MYCN", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "TPX2", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "BIRC5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PLK1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CCNB2", "protein_b": "TPX2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCNB2", "protein_b": "BIRC5", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CCNB2", "protein_b": "PLK1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCNB2", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "TACC3", "combined_score": 0.884, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "TPX2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "INCENP", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "BIRC5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PLK1", "protein_b": "CDC20", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TPX2", "protein_b": "TACC3", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "TPX2", "protein_b": "BIRC5", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TPX2", "protein_b": "CDC20", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "TACC3", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "CDC20", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "BIRC5", "protein_b": "INCENP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TACC3", "protein_b": "INCENP", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "TACC3", "protein_b": "CDC20", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CDC20", "protein_b": "INCENP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "SRC", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PECAM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PECAM1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CDH5", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "PECAM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "PECAM1", "protein_b": "CDH5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLEC11A", "protein_b": "KITLG", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "CLEC11A", "protein_b": "KIT", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "EGF", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "GRB2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "NRAS", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "PTPN11", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "PIK3R1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "KIT", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "KRAS", "protein_b": "PIK3CA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "GRB2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "KIT", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PTPN11", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "NRAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "PIK3R1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "KITLG", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRAS", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CXCL12", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PTPN11", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "PIK3R1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "KIT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "CXCL12", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "NRAS", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "PTPN11", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "PIK3R1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "GRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KIT", "protein_b": "KITLG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRAS", "protein_b": "GRB2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "NRAS", "protein_b": "PTPN11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NRAS", "protein_b": "PIK3R1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "PIK3R1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "PTPN11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "KITLG", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "PIK3R1", "protein_b": "PTPN11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "CALM3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "FKBP1B", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "CASQ1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "RYR2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CASQ2", "protein_b": "TRDN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "ASPH", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "TRDN", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "FKBP1B", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RYR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR3", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "JPH1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "FKBP1B", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "CASQ1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "RYR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TRDN", "protein_b": "ASPH", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "CASQ1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "ASPH", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "JPH1", "protein_b": "RYR1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "ASPH", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "RYR3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "RYR2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "CASQ1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RYR1", "protein_b": "FKBP1B", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "CASQ1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "RYR3", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RYR2", "protein_b": "FKBP1B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASQ1", "protein_b": "RYR3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CASQ1", "protein_b": "ASPH", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "ASPH", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ASPH", "protein_b": "RYR3", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "ASPH", "protein_b": "FKBP1B", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "FKBP1B", "protein_b": "RYR3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "NECAP2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "AAK1", "combined_score": 0.796, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "SGIP1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "EPS15", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "AP2M1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "AP2S1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CLTB", "protein_b": "AP2B1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "NECAP2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "AAK1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "AP2M1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "AP2S1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "REPS1", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "AP2B1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "SGIP1", "protein_b": "EPS15", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "REPS1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "NECAP2", "combined_score": 0.884, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "AP2S1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "SNAP91", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "AP2M1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "AAK1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EPS15", "protein_b": "AP2B1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "RALBP1", "protein_b": "AP2S1", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "RALBP1", "protein_b": "AAK1", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "RALBP1", "protein_b": "AP2M1", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "RALBP1", "protein_b": "REPS1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "SNAP91", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "NECAP2", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "AP2S1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "AP2B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "REPS1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "AAK1", "protein_b": "AP2M1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "NECAP2", "protein_b": "AP2S1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "NECAP2", "protein_b": "AP2M1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NECAP2", "protein_b": "AP2B1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "REPS1", "protein_b": "AP2S1", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "REPS1", "protein_b": "AP2M1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "REPS1", "protein_b": "AP2B1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SNAP91", "protein_b": "AP2M1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "SNAP91", "protein_b": "AP2B1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "AP2M1", "protein_b": "AP2B1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AP2M1", "protein_b": "AP2S1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AP2S1", "protein_b": "AP2B1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP1R1B", "protein_b": "CDK5", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CABLES1", "protein_b": "TP53", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "CABLES1", "protein_b": "CDK5", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CCND2", "protein_b": "CDK5", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "DLG4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CDK5R1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CDK5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CDK5R2", "protein_b": "CDK5", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "CDK5R1", "protein_b": "MAPT", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CDK5R1", "protein_b": "CDK5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPT", "protein_b": "DLG4", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MAPT", "protein_b": "FYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPT", "protein_b": "CDK5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DPYSL2", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CDK5", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CDK5", "protein_b": "DLG4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CDK5", "protein_b": "DPYSL2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "PER1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "NPAS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "CRY2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "CLOCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ARNTL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "CSNK1E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "PER2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "PER3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "NPAS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "CLOCK", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "PER1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "ARNTL", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "PER3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "CSNK1E", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PER2", "protein_b": "CRY2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "CSNK1E", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "GSK3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "NPAS2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "CLOCK", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "ARNTL", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "CSNK1E", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "PER3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PER1", "protein_b": "CRY2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "CSNK1E", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPAS2", "protein_b": "PER3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "NPAS2", "protein_b": "CSNK1E", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPAS2", "protein_b": "CRY2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NPAS2", "protein_b": "CLOCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NPAS2", "protein_b": "ARNTL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSNK1E", "protein_b": "PER3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CSNK1E", "protein_b": "CLOCK", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CSNK1E", "protein_b": "ARNTL", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CSNK1E", "protein_b": "CRY2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ARNTL", "protein_b": "PER3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ARNTL", "protein_b": "CLOCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARNTL", "protein_b": "CRY2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CLOCK", "protein_b": "PER3", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CLOCK", "protein_b": "CRY2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CRY2", "protein_b": "PER3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NKTR", "protein_b": "CLK1", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "CLK1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "TRA2A", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "SRPK2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "SRSF3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "SRSF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "CLK2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "CLK1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "SRSF3", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "CYCS", "protein_b": "CLK1", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "DDX23", "protein_b": "CLK1", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "DDX23", "protein_b": "SRPK2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CLK4", "protein_b": "CLK1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "CLK1", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SRSF3", "protein_b": "CLK1", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "SRSF3", "protein_b": "SRPK2", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SRSF3", "protein_b": "SRSF2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRSF2", "protein_b": "CLK1", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "SRSF2", "protein_b": "SRPK2", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "SRPK2", "protein_b": "CLK1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "RSRP1", "protein_b": "CLK3", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "RSRP1", "protein_b": "CLK2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ACIN1", "protein_b": "CLK2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SNIP1", "protein_b": "CLK2", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "SNIP1", "protein_b": "BCLAF1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "RBBP6", "protein_b": "CLK3", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "RBBP6", "protein_b": "CLK2", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "SRSF8", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "SRSF12", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "PAFAH1B3", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "CLK1", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "BCLAF1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "CLK3", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "SRSF12", "combined_score": 0.706, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "SRSF8", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "RSRP1", "protein_b": "CLK3", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "RSRP1", "protein_b": "CLK2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "SRSF8", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "CLK3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "TRA2A", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "TRA2B", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SRSF1", "protein_b": "SRSF10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TELO2", "protein_b": "CLK3", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "TELO2", "protein_b": "COQ7", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "CLK2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "SRSF8", "combined_score": 0.818, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "CLK3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "TRA2B", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "TRA2A", "protein_b": "SRSF10", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "COQ7", "protein_b": "IMMT", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "COQ7", "protein_b": "CLK3", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "SRSF8", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "CLK2", "protein_b": "CLK3", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "IMMT", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "SRSF8", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "SRSF10", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CLK3", "protein_b": "TRA2B", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "TRA2B", "protein_b": "SRSF8", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "TRA2B", "protein_b": "SRSF10", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CLK4", "protein_b": "CLK1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FAM53C", "protein_b": "DCAF7", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "FAM53C", "protein_b": "DYRK1A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "MED13L", "protein_b": "DYRK1A", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "RNF169", "protein_b": "DCAF7", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "RNF169", "protein_b": "DYRK1A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "NFATC1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "WDR26", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "RCAN1", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "FAM117B", "combined_score": 0.882, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "LIN52", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "RAD54L2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "DYRK1A", "protein_b": "DCAF7", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "FAM117B", "protein_b": "DCAF7", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "RAD54L2", "protein_b": "DCAF7", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "FAM53C", "protein_b": "DCAF7", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "FAM53C", "protein_b": "DYRK1B", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "RBL2", "protein_b": "DYRK1B", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "EP300", "protein_b": "DYRK1B", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "EP300", "protein_b": "HNF1A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "PCBD1", "protein_b": "DYRK1B", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PCBD1", "protein_b": "PCBD2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "PCBD1", "protein_b": "HNF1A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "RNF169", "protein_b": "DCAF7", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "RNF169", "protein_b": "DYRK1B", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "C10orf71", "protein_b": "DYRK1B", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PCBD2", "protein_b": "DYRK1B", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "PCBD2", "protein_b": "HNF1A", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HNF1A", "protein_b": "DYRK1B", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "DYRK1B", "protein_b": "DCAF7", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "DYRK2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "DDB1", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "ATM", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MDM2", "protein_b": "TP53", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "DDB1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "DCAF1", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "UBR5", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "DYRK2", "combined_score": 0.87, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "ATM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ATM", "protein_b": "DYRK2", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "DDB1", "protein_b": "UBR5", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "DDB1", "protein_b": "DYRK2", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "DDB1", "protein_b": "DCAF7", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "DDB1", "protein_b": "DCAF1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DYRK2", "protein_b": "DCAF7", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "DYRK2", "protein_b": "UBR5", "combined_score": 0.889, "interaction_type": "physical"}, {"protein_a": "DYRK2", "protein_b": "DCAF1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "DCAF1", "protein_b": "UBR5", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "DCAF1", "protein_b": "DCAF7", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "DYRK4", "protein_b": "DCAF7", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "DVL1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "BTRC", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "CSNK1A1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "GSK3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "AXIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "APC", "protein_b": "AXIN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "BTRC", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "DVL1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "AXIN2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "AXIN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "GSK3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CSNK1A1", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "AKT1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "FRAT1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "BTRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "DVL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "AXIN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN1", "protein_b": "GSK3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN2", "protein_b": "BTRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AXIN2", "protein_b": "DVL1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "AXIN2", "protein_b": "GSK3B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AXIN2", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "AKT1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "MAPT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "FRAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "BTRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "DVL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSK3B", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPT", "protein_b": "AKT1", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "BTRC", "protein_b": "DVL1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "BTRC", "protein_b": "CTNNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FRAT1", "protein_b": "CTNNB1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "FRAT1", "protein_b": "DVL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "DVL1", "protein_b": "AKT1", "combined_score": 0.74, "interaction_type": "physical"}, {"protein_a": "DVL1", "protein_b": "CTNNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "AKT1", "protein_b": "CTNNB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ABCF2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "SLCO1B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "NR1I2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "ABCB1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "PPIG", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP2C19", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "CYP3A4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "NR1I2", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "ABCB1", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "CYP3A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB1", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "ABCF2-2", "protein_b": "ABCB1", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP2C19", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "CYP3A4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ABCB1", "combined_score": 0.858, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "CYP3A4", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "ABCB1", "protein_b": "IGKV2D-29", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCG2", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC2A9", "protein_b": "SLC22A8", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLC2A9", "protein_b": "ABCG2", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "SLC2A9", "protein_b": "SLC22A12", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "ALB", "protein_b": "ABCG2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "ABCG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC22A1", "protein_b": "ABCC2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SLC22A1", "protein_b": "ABCG2", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCG2", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "ABCC1", "protein_b": "ABCG2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "PRKD3", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "PRKD2", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "PRKD1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "ITGAM", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "RAP1A", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "ITGB1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "RAP1B", "protein_b": "ITGB2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKD3", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKD2", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKD1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "PRKD2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "PRKD3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "PRKD1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "ITGAM", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "ITGB2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "RAP1A", "protein_b": "ITGB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "ITGAM", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "ITGB2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "ITGB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "PRKCB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "PRKCA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "PRKD2", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "PRKD3", "protein_b": "PRKD1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "PRKCB", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "PRKD2", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "PRKD1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "PRKCA", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "ITGAM", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ITGB1", "protein_b": "ITGB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ITGB2", "protein_b": "PRKD2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "ITGB2", "protein_b": "PRKD1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ITGB2", "protein_b": "ITGAM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRKD1", "protein_b": "ITGAM", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "PRKD1", "protein_b": "PRKCB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PRKD1", "protein_b": "PRKCA", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "PRKD1", "protein_b": "PRKD2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "PRKD2", "protein_b": "ITGAM", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "PRKD2", "protein_b": "PRKCB", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "PRKD2", "protein_b": "PRKCA", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}], "network_features": {"avg_degree": 5.87, "clustering_coefficient": 2.93}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41162347", "title": "Challenges in Extrapolating Healthy Volunteer Pharmacokinetics to Oncology Populations: Advocating for a Holistic Perspective.", "authors": [{"name": "Ji Y", "authtype": "Author", "clusterid": ""}, {"name": "Sechaud R", "authtype": "Author", "clusterid": ""}, {"name": "Chakraborty A", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40880701", "title": "Innovative Therapeutic Approaches in Systemic Mastocytosis: an Updated Review.", "authors": [{"name": "Soare D", "authtype": "Author", "clusterid": ""}, {"name": "Leru P", "authtype": "Author", "clusterid": ""}, {"name": "Bumbea H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40848224", "title": "Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.", "authors": [{"name": "Magee GH", "authtype": "Author", "clusterid": ""}, {"name": "Grunwald MR", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41021719", "title": "", "authors": []}, {"pmid": "40712393", "title": "Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.", "authors": [{"name": "Reiter A", "authtype": "Author", "clusterid": ""}, {"name": "Gotlib J", "authtype": "Author", "clusterid": ""}, {"name": "\u00c1lvarez-Twose I", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.", "detailed_description": null, "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Investigational Treatment", "type": "EXPERIMENTAL", "description": "Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.", "intervention_names": ["Drug: CPX-351", "Drug: Midostaurin", "Drug: Busulfan", "Drug: Melphalan", "Drug: Fludarabine", "Biological: CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor"]}], "interventions": [{"type": "DRUG", "name": "CPX-351", "description": "For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Midostaurin", "description": "The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "0.8 mg/kg/dose every six hours x 12 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Melphalan", "description": "70 mg/m2/day x 2 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "DRUG", "name": "Fludarabine", "description": "25 mg/m2/day x 5 doses administered intravenously", "arm_group_labels": ["Investigational Treatment"]}, {"type": "BIOLOGICAL", "name": "CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor", "description": "Allogeneic stem cell transplant infused intravenously", "arm_group_labels": ["Investigational Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Guenther Koehne+NCT04982354+terminated", "https://www.google.com/search?q=Guenther Koehne+Midostaurin+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Midostaurin by Guenther Koehne. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Midostaurin by Guenther Koehne.\n\nFirst, I need to understand what the query is asking for:\n- FDA warning letters or clinical holds specifically for Midostaurin\n- Related to someone named Guenther Koehne\n- Including specific dates, reasons, and safety issues cited\n\nLet me go through each search result to see if it contains relevant information:\n\nResult [1]: This is about FDA approval summary for Midostaurin for treatment of advanced conditions. It mentions warnings and precautions for embryo-fetal toxicity and pulmonary toxicity, but doesn't mention any warning letters or clinical holds, nor does it mention Guenther Koehne.\n\nResult [2]: This appears to be about Lymphoma, Leukemia & Myeloma Congress 2025 Abstracts, but the content shown is very limited and doesn't mention Midostaurin specifically in relation to warning letters or Guenther Koehne.\n\nResult [3]: This is a pharmacovigilance study of adverse events associated with gilteritinib and midostaurin. It mentions unexpected adverse events for midostaurin like neutropenic colitis, septic shock, and neutropenic sepsis, but doesn't mention any FDA warning letters or clinical holds, nor Guenther Koehne.\n\nResult [4]: This is a Novartis press release about midostaurin being granted FDA Priority Review. It doesn't mention any warning letters or clinical holds.\n\nResult [5]: This is FDA information about Midostaurin, including its approval and common adverse reactions. It doesn't mention any warning letters or clinical holds.\n\nResult [6]: This is about recent FDA cancer drug safety warnings, but focuses on CAR-T therapy and pexidartinib, not Midostaurin.\n\nResult [7]: This is a clinical policy document for Midostaurin from Ambetter Health. It doesn't mention warning letters or clinical holds.\n\nResult [8]: This appears to be an FDA approval letter for Rydapt (midostaurin) capsules, but doesn't mention warning letters or clinical holds.\n\nResult [9]: This is about FDA approval of a new combination treatment for AML involving midostaurin, but doesn't mention warning letters or clinical holds.\n\nResult [10]: This mentions \"Violation: Shown when the", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results to find SEC EDGAR 8-K filings by Guenther Koehne mentioning clinical trial NCT04982354 or related drug safety issues.\n\nFirst, I need to identify which of these search results are relevant to the query:\n\n1. The query asks for SEC EDGAR 8-K filings by Guenther Koehne\n2. Specifically mentioning clinical trial NCT04982354 or related drug safety issues\n3. Need to include filing dates, CIK number, and specific material events disclosed\n\nLet me go through each search result:\n\nResult [1]: This is an SEC Form 8-K filing for Eagle Point Income Co Inc (CIK: 0001754836) filed on 2025-05-08. This appears to be a financial company, not related to clinical trials or Guenther Koehne.\n\nResult [2]: This is a Form 6-K for BioNTech SE filed on 2024-08-05. It mentions clinical trials including NCT04486378 (for CRC) and NCT05918445 (for cervical cancer), but not NCT04982354. No mention of Guenther Koehne.\n\nResult [3]: This appears to be an 8-K filing for Medical Properties Trust, Inc., which is a real estate company, not related to clinical trials.\n\nResult [4]: This is an EX-99.1 filing for Kymera Therapeutics, Inc. It mentions clinical trials for KT-474, KT-333, and KT-413, but not NCT04982354. No mention of Guenther Koehne.\n\nResult [5]: This is just an EDGAR filing index with no clear content visible.\n\nResult [6]: This is a 10-K annual report for Kinnate Biopharma Inc. It mentions Phase 1 clinical trials for exarafenib and KIN-3248, but not NCT04982354. No mention of Guenther Koehne.\n\nResult [7]: This is just a filing detail with no clear content visible.\n\nResult [8]: This is a", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "start_date": "2022-07-05"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Guenther Koehne about clinical trial NCT04982354 for Midostaurin. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to compile external safety evidence for a specific clinical trial related to Midostaurin (PKC412). Let me analyze the search results to create a JSON summary with status, summary, relevance, and citations.\n\nFirst, I need to identify which clinical trial we're focusing on. From the search results, I can see multiple references to NCT04982354, which appears to be a trial titled \"Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia\" led by Guenther Koehne from Jazz Pharmaceuticals.\n\nLet me go through the search results to gather information about this trial:\n\nResult 1: Mentions Midostaurin (PKC412) and references NCT04982354 with Guenther Koehne|Jazz Pharmaceuticals for Acute Myeloid Leukemia.\n\nResult 2: Contains information about a Novartis trial CPKC412A2106, which is a Phase IB study for midostaurin in acute myeloid leukemia, but this doesn't appear to be the NCT04982354 trial.\n\nResult 3: Mentions \"Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin\" and NCT04982354 with Guenther Koehne, Jazz Pharmaceuticals for Acute Myeloid Leukemia.\n\nResult 4: A press release from Novartis dated Dec 6, 2015 about midostaurin improving overall survival by 23% in a Phase III study of AML patients with FLT3 mutations.\n\nResult 5: ClinicalTrials.gov entry for NCT04982354, which describes a trial where \"The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission...\"\n\nResult 6: Australian Public Assessment Report for Midostaurin (Rydapt) from Novartis Pharmaceuticals Australia.\n\nResult 7: Clin.Larvol.com entry for NCT04982354, which states: \"NCT04982354. Impact Score 3", "citations": [], "search_params": {"company": "Guenther Koehne", "nct_id": "NCT04982354", "drug_name": "Midostaurin"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial withdrawal is \"Could not accrue,\" which indicates that the trial was terminated due to enrollment issues. There is no mention of safety concerns or lack of efficacy in the provided information. Therefore, the reason for the trial failure is most likely due to administrative or operational problems in terms of patient enrollment, which aligns with the \"FAILURE_ADMINISTRATIVE\" category.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:10.826003", "claude_model": "claude-3-haiku-20240307", "tokens_used": 873}}, "79": {"nct_id": "NCT05245760", "drug_name": "Chemotherapy", "intervention_type": "DRUG", "drug_description": "Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding unavailable.", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "start_date": "2022-04-30", "completion_date": "2033-12-31", "sponsor": "Zhonglin Hao", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.563497", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:14.276692", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q92567", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8VIM0", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q96RE7", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P19875", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P20809", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Chemotherapy", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "FAM168A", "protein_b": "WWP2", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "NANOG", "protein_b": "NACC1", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "NANOG", "protein_b": "POU5F1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NANOG", "protein_b": "SOX2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POU5F1", "protein_b": "NACC1", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "POU5F1", "protein_b": "SOX2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HDAC4", "protein_b": "NACC1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NACC1", "protein_b": "SOX2", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "NACC1", "protein_b": "FBXL19", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "NACC1", "protein_b": "SCAF1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "NACC1", "protein_b": "GADD45GIP1", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CCL21", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL11", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCL5", "combined_score": 0.851, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCL11", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL21", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CCL8", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CCL11", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL11", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CCL5", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CCL5", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL11", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCR2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL11", "protein_b": "CXCR2", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL11", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL11", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL11", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL11", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CCL8", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CCL5", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "IL6R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "IL11RA", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "CNTFR", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "CNTF", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "IL11", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "IL6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "LIF", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "IL6ST", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "OSMR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OSM", "protein_b": "LIFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "IL11RA", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "IL6R", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "IL6", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "OSMR", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "IL11", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "CNTFR", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "CNTF", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "IL6ST", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LIF", "protein_b": "LIFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "CNTF", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "CNTFR", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "LIFR", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "OSMR", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "IL6", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "IL6R", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "IL6ST", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL11", "protein_b": "IL11RA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "IL6R", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "CNTFR", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "LIFR", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "CNTF", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "IL6", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "OSMR", "protein_b": "IL6ST", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "IL11RA", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "IL6", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "IL6R", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "IL6ST", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "LIFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CNTF", "protein_b": "CNTFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL6R", "protein_b": "LIFR", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "IL6R", "protein_b": "IL11RA", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "IL6R", "protein_b": "CNTFR", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "IL6R", "protein_b": "IL6ST", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL6R", "protein_b": "IL6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CNTFR", "protein_b": "IL11RA", "combined_score": 0.812, "interaction_type": "physical"}, {"protein_a": "CNTFR", "protein_b": "IL6", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CNTFR", "protein_b": "IL6ST", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CNTFR", "protein_b": "LIFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL6ST", "protein_b": "IL11RA", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "IL6ST", "protein_b": "LIFR", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL6ST", "protein_b": "IL6", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL6", "protein_b": "IL11RA", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "IL6", "protein_b": "LIFR", "combined_score": 0.956, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.19, "clustering_coefficient": 3.59}}, "failure_enrichment": {"aact_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "aact_documents": [], "pubmed_results": [{"pmid": "41236737", "title": "Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.", "authors": [{"name": "Rahimi A", "authtype": "Author", "clusterid": ""}, {"name": "Leitch M", "authtype": "Author", "clusterid": ""}, {"name": "Dogan B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41236651", "title": "Protein Lactylation Modulating Regulated Cell Death: A Novel Therapeutic Target in Neurological Diseases.", "authors": [{"name": "Long X", "authtype": "Author", "clusterid": ""}, {"name": "Sun W", "authtype": "Author", "clusterid": ""}, {"name": "Li Q", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41236620", "title": "Bispecific antibodies in metastatic castration-resistant prostate cancer: therapeutic strategies and frontier advances.", "authors": [{"name": "He JW", "authtype": "Author", "clusterid": ""}, {"name": "Li PZ", "authtype": "Author", "clusterid": ""}, {"name": "Huang ZX", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41236580", "title": "Nicotine Improves Memory Impairment in Aged Rats Through Enhanced Mitochondrial Homeostasis.", "authors": [{"name": "Ni Z", "authtype": "Author", "clusterid": ""}, {"name": "Li Y", "authtype": "Author", "clusterid": ""}, {"name": "Wang G", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41236568", "title": "Essential amino acid supplementation for pressure ulcers: pathophysiological rationale and results from a pilot study.", "authors": [{"name": "\u015awi\u0105tkiewicz M", "authtype": "Author", "clusterid": ""}, {"name": "Lejczak A", "authtype": "Author", "clusterid": ""}, {"name": "Folty\u0144ski P", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.", "detailed_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "All patient", "type": "EXPERIMENTAL", "description": "All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.", "intervention_names": ["Drug: Intravenous Tislelizumab", "Drug: Chemotherapy", "Radiation: Fractionated radiation", "Procedure: Esophagectomy"]}], "interventions": [{"type": "DRUG", "name": "Intravenous Tislelizumab", "description": "Participants will receive 200mg, every three weeks for up to 51 weeks", "arm_group_labels": ["All patient"]}, {"type": "DRUG", "name": "Chemotherapy", "description": "Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks", "arm_group_labels": ["All patient"]}, {"type": "RADIATION", "name": "Fractionated radiation", "description": "Concurrent with chemo, x5 weeks", "arm_group_labels": ["All patient"]}, {"type": "PROCEDURE", "name": "Esophagectomy", "description": "Surgical resection of cancer after chemoradiation therapy when no disease progression found.", "arm_group_labels": ["All patient"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Zhonglin Hao+NCT05245760+terminated", "https://www.google.com/search?q=Zhonglin Hao+Chemotherapy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Chemotherapy by Zhonglin Hao. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to provide a JSON summary of FDA warning letters or clinical holds for Chemotherapy by Zhonglin Hao.\n\nThe query is asking for:\n- FDA warning letters or clinical holds\n- Specifically related to \"Chemotherapy by Zhonglin Hao\"\n- Including specific dates, reasons, and safety issues cited\n\nFirst, I need to check if any of the search results mention \"Zhonglin Hao\" or a chemotherapy product associated with this person.\n\nLet me go through each search result:\n\n[1] FDA warning letters to two Chinese nonclinical testing laboratories (Mid-Link Testing Company Ltd. and Sanitation & Environmental Technology Institute of Soochow University Ltd.). These are about data quality and integrity concerns, but no mention of Zhonglin Hao or specific chemotherapy products.\n\n[2] General FDA Warning Letters page showing various companies that received warning letters, but no specific mention of Zhonglin Hao.\n\n[3] Recent FDA cancer drug safety warnings and updates, mentioning capecitabine, duvelisib, denosumab-bnht, ciltacabtagene autoleucel, and pexidartinib. No mention of Zhonglin Hao.\n\n[4] Information about single topical treatment studies, including some cancer-related trials (TOPIC trial for cervical intraepithelial neoplasia), but no mention of Zhonglin Hao.\n\n[5] Untitled Letters from FDA, listing various pharmaceutical companies but no mention of Zhonglin Hao.\n\n[6] Machine learning research, not relevant to the query.\n\n[7] Mayo Clinic Radio article about FDA cracking down on bogus cancer treatments, mentioning warning letters to 14 companies, but no specific mention of Zhonglin Hao.\n\n[8] Academic article about overall survival of resectable metastatic colon cancer, no mention of FDA warning letters or Zhonglin Hao.\n\n[9] General information about FDA Warning & Notice of Violation Letters to Pharmaceutical Companies, no specific mention of Zhonglin Hao.\n\n[10] Article about Asciminib (ABL001), an allosteric inhibitor, no mention of Zhonglin Hao or FDA warning letters.\n\n[11] Article about neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer, no mention of FDA warning letters or Zhonglin Hao.\n\nAfter reviewing all the search results, I don't see any specific mention of \"Zhonglin", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Zhonglin Hao\n- Mentioning clinical trial NCT05245760 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nThe search results provided are:\n1. A general SEC.gov search filings page\n2. The EDGAR Full Text Search page\n\nThese are just general search pages for the SEC EDGAR system, not actual search results for the specific query about Zhonglin Hao and clinical trial NCT05245760.\n\nI need to determine if there are any actual filings that match the query based on the information provided. However, the search results don't contain any specific filings - they're just the search interfaces themselves.\n\nLet me analyze what I know:\n1. The query is looking for 8-K filings (which are current reports companies file to disclose material events)\n2. By someone named \"Zhonglin Hao\" (likely an individual associated with a company)\n3. Related to clinical trial NCT05245760 or drug safety issues\n4. Need to include filing dates, CIK number, and specific material events\n\nSince the search results provided are just the SEC search interfaces and not actual search results for the query, I don't have any specific filings to report on. There's no information about whether such filings exist or not.\n\nIn this case, I should indicate that no relevant filings were found based on the search results provided, or that the search results don't contain the actual filings data needed to answer the query.\n\nLet me structure my JSON response:\n\nstatus: \"no_results\" or \"inconclusive\" since we don't have actual search results data\nsummary: A brief explanation that the provided search results are just SEC search interfaces, not actual filings data\nrelevance: How relevant the search results are to the query (in this case, not directly relevant as they don't contain the requested filings)\ncitations: The URLs provided in the search results\n\nI'll craft a response that accurately reflects the situation.\n</think>\n\n{\n  \"status\": \"no_results_found\",\n  \"summary\": \"The search results provided contain only SEC EDGAR search interface pages (SEC.gov search portal and EDGAR Full Text Search page) rather than", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "start_date": "2022-04-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Chemotherapy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the task carefully. I need to compile external safety evidence for a specific clinical trial, and respond with a JSON summary containing status, summary, relevance, and citations.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Chemotherapy\n- Focus on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT05245760 is from the search results:\n\nFrom result [5]:\nhttps://www.clinicaltrials.gov/study/NCT05245760\n\"ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer\nEsophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery.\"\n\nSo NCT05245760 is a clinical trial studying chemoradiation therapy with tislelizumab (an anti-PD-1 antibody) for esophageal/EGJ cancer.\n\nNow, I need to look for:\n1. Company press releases about this trial\n2. Investor presentations about this trial\n3. Public statements by Zhonglin Hao about this trial\n4. Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me go through the search results to see if any of them contain this information:\n\nResult [1]: About NCT05353257 (Serplulimab trial) - not relevant to NCT05245760\nResult [2]: About NCT03845296 (Rucaparib trial) - not relevant to NCT05245760\nResult [3]: About malignant pleural mesothelioma treatments - not relevant to NCT05245760\nResult [4]: About lung cancer screening in PA - not relevant to NCT05245760\nResult [5]: Describes NCT05245760 but doesn't have safety information, press releases, or statements by Zhonglin Hao\nResult [6]: German document about Tislelizumab (Tevim", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "drug_name": "Chemotherapy"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "Based on the provided information, the trial was withdrawn due to \"Funding unavailable,\" which is an administrative/operational reason for the failure of the trial. The detailed description does not mention any safety concerns or lack of efficacy, but rather states that the trial aimed to evaluate the tolerability, toxicities, progression-free survival, and overall survival of the treatment. Therefore, the most likely reason for the trial's withdrawal is the unavailability of funding, which is an administrative/operational issue.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:14.274921", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1226}}, "80": {"nct_id": "NCT05245760", "drug_name": "Esophagectomy", "intervention_type": "PROCEDURE", "drug_description": "Surgical resection of cancer after chemoradiation therapy when no disease progression found.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding unavailable.", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "start_date": "2022-04-30", "completion_date": "2033-12-31", "sponsor": "Zhonglin Hao", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.564071", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:14.313769", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "Esophagectomy"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "aact_documents": [], "pubmed_results": [{"pmid": "41219803", "title": "Effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy: a study protocol of double-center, double-blind, randomized controlled trial.", "authors": [{"name": "Wang F", "authtype": "Author", "clusterid": ""}, {"name": "Zhang H", "authtype": "Author", "clusterid": ""}, {"name": "Peng X", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41206400", "title": "ASO Visual Abstract: Predictive Value of Preoperative Cardiopulmonary Exercise Testing for Complications and Mortality After Esophagectomy: A Meta-analysis.", "authors": [{"name": "Tseng WH", "authtype": "Author", "clusterid": ""}, {"name": "Chiu CH", "authtype": "Author", "clusterid": ""}, {"name": "Chang SY", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41187776", "title": "Gastric peroral endoscopic pyloromyotomy for refractory gastroparesis following esophagectomy: results from a multicenter series.", "authors": [{"name": "Silete PJ", "authtype": "Author", "clusterid": ""}, {"name": "Houzvickova M", "authtype": "Author", "clusterid": ""}, {"name": "Degand T", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41182497", "title": "Robot-assisted (da Vinci) versus conventional esophagectomy for resectable esophageal cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.", "authors": [{"name": "Mirza W", "authtype": "Author", "clusterid": ""}, {"name": "Khan ME", "authtype": "Author", "clusterid": ""}, {"name": "Iqbal H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41163864", "title": "Adherence to CheckMate 577 Within a Community Health Care System in the First 2 Years After Approval.", "authors": [{"name": "Campbell JM", "authtype": "Author", "clusterid": ""}, {"name": "Louie BE", "authtype": "Author", "clusterid": ""}, {"name": "White PT", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.", "detailed_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "All patient", "type": "EXPERIMENTAL", "description": "All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.", "intervention_names": ["Drug: Intravenous Tislelizumab", "Drug: Chemotherapy", "Radiation: Fractionated radiation", "Procedure: Esophagectomy"]}], "interventions": [{"type": "DRUG", "name": "Intravenous Tislelizumab", "description": "Participants will receive 200mg, every three weeks for up to 51 weeks", "arm_group_labels": ["All patient"]}, {"type": "DRUG", "name": "Chemotherapy", "description": "Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks", "arm_group_labels": ["All patient"]}, {"type": "RADIATION", "name": "Fractionated radiation", "description": "Concurrent with chemo, x5 weeks", "arm_group_labels": ["All patient"]}, {"type": "PROCEDURE", "name": "Esophagectomy", "description": "Surgical resection of cancer after chemoradiation therapy when no disease progression found.", "arm_group_labels": ["All patient"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Zhonglin Hao+NCT05245760+terminated", "https://www.google.com/search?q=Zhonglin Hao+Esophagectomy+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Esophagectomy by Zhonglin Hao. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there's relevant information about FDA warning letters or clinical holds for Esophagectomy by Zhonglin Hao.\n\nThe query is asking for:\n1. FDA warning letters or clinical holds\n2. Related to \"Esophagectomy by Zhonglin Hao\"\n3. Including specific dates, reasons, and safety issues cited\n\nLet me examine each search result to see if it contains relevant information:\n\nResult [1]: This is an FDA warning letter to Novo Nordisk Inc. dated September 9, 2025. It's about misleading promotional communications regarding Wegovy, Ozempic, and Victoza (GLP-1 drugs). It discusses safety concerns related to these drugs, including risks of pancreatitis, gallbladder complications, and thyroid cancer. This is not related to esophagectomy or Zhonglin Hao.\n\nResult [2]: This is an article about recent FDA cancer drug safety warnings and updates. It mentions safety issues with various cancer drugs including duvelisib, capecitabine, denosumab-bnht, ciltacabtagene autoleucel, and pexidartinib. None of these are related to esophagectomy or Zhonglin Hao.\n\nResult [3]: This is an FDA warning letter to Hologic, Inc. dated December 18, 2024. It's about issues with a medical device called Biozorb Marker, which is used in breast cancer treatment. It discusses safety concerns related to the device, including potential interference with cancer detection, issues with radiation treatment, and infections. This is not related to esophagectomy or Zhonglin Hao.\n\nResult [4]: This is a general page about FDA warning letters with a table showing various warning letters issued to different companies for various reasons. None of the listed warning letters appear to be related to esophagectomy or Zhonglin Hao.\n\nAfter reviewing all the search results, I don't see any information about:\n- FDA warning letters related to \"Esophagectomy by Zhonglin Hao\"\n- Clinical holds related to \"Esophagectomy by Zhonglin Hao\"\n- Any specific dates, reasons, or safety issues related to this query\n\nThe search results contain information about other FDA warning letters and safety notices, but none that match the specific query about \"Esophagectomy by Zhonglin Hao.\"\n\nTherefore", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results and the query to provide a proper JSON summary.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Zhonglin Hao\n- Mentioning clinical trial NCT05245760 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nLet's examine the search results provided:\n\nResult [1] appears to be a SEC EDGAR company information page, but it shows \"No information is available for this page\" and then has empty fields for company information. It indicates \"No Filings for this company\" and no 8-K filings.\n\nResult [2] is about the EDGAR Full Text Search feature, explaining that it gives access to full text of electronic filings since 2001. It shows search filters but doesn't contain actual search results for our query.\n\nResult [3] is about the SEC's Search Filings page, describing various search tools but again doesn't contain actual search results for our specific query.\n\nNone of these search results actually contain any information about:\n1. Zhonglin Hao\n2. Clinical trial NCT05245760\n3. Any 8-K filings related to drug safety issues\n\nThe search results are just showing the SEC EDGAR search interface and general information about how to search, but they don't contain the actual results of the query we're supposed to analyze.\n\nGiven this, I need to conclude that the search did not find any relevant 8-K filings matching the query criteria. There's no evidence in the provided search results that:\n- Zhonglin Hao filed any 8-Ks with the SEC\n- There are any 8-K filings mentioning clinical trial NCT05245760\n- There are any drug safety issues related to this clinical trial disclosed in SEC filings\n\nSince the search results don't contain any actual filings data matching our query, I'll need to indicate that no relevant information was found in the JSON summary.\n\nLet me structure the JSON response:\n\nstatus: \"No relevant filings found\" (since the search results don't show any actual filings matching the query)\nsummary: A brief explanation that the search results only show EDGAR search interfaces but don't contain any actual filings matching the query criteria\nrelevance: \"Not relevant\" (since no matching filings were found)\ncitations: An empty array or", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "start_date": "2022-04-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Esophagectomy. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Zhonglin Hao\n- About clinical trial NCT05245760 for Esophagectomy\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT05245760 is from the search results:\n\nFrom result [2] and [8], I can see that NCT05245760 is titled \"ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer\". It's a study that \"aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.\" Result [8] specifically states: \"Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery.\"\n\nSo this is a trial involving tislelizumab (an anti-PD-1 antibody) for esophageal/EGJ (esophagogastric junction) cancer, not specifically for esophagectomy (which is the surgical removal of part or all of the esophagus). The trial involves chemoradiation and tislelizumab before surgery.\n\nNow, let me check if there are any press releases, investor presentations, or public statements by someone named Zhonglin Hao about this trial, particularly focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLooking through all the search results:\n\n1. Result [1]: About NCT05353257 (Serplulimab trial), not relevant to NCT05245760\n2. Result [2]: Basic info about NCT05245760, but no press releases or statements by Zhonglin Hao\n3. Result [3]: About NCT03845296 (Rucaparib trial), not relevant\n4. Result [4]: Commentary on malignant pleural mesothelioma treatments, not relevant\n5. Result [5]: About NCT00008385 (Selenium trial", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "drug_name": "Esophagectomy"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "Based on the provided information, the trial was withdrawn due to \"Funding unavailable,\" which is an administrative/operational reason for the failure of the trial. The detailed description does not mention any safety concerns or lack of efficacy, but rather states that the trial aimed to evaluate the tolerability, toxicities, progression-free survival, and overall survival of the treatment. Therefore, the most likely reason for the trial's withdrawal is the unavailability of funding, which is an administrative/operational issue.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:14.274921", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1226}}, "81": {"nct_id": "NCT05245760", "drug_name": "Fractionated radiation", "intervention_type": "RADIATION", "drug_description": "Concurrent with chemo, x5 weeks", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding unavailable.", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "start_date": "2022-04-30", "completion_date": "2033-12-31", "sponsor": "Zhonglin Hao", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.564644", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:14.350438", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "Q641K5", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q5I043", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q4U2R1", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q80SY4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q6A078", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Fractionated radiation", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [], "network_features": {"avg_degree": 0, "clustering_coefficient": 0}}, "failure_enrichment": {"aact_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "aact_documents": [], "pubmed_results": [{"pmid": "41236737", "title": "Ablative Preoperative Single-Fraction Radiation Dose Escalation Among Patients With Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.", "authors": [{"name": "Rahimi A", "authtype": "Author", "clusterid": ""}, {"name": "Leitch M", "authtype": "Author", "clusterid": ""}, {"name": "Dogan B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41234391", "title": "Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.", "authors": [{"name": "Mousavinia SM", "authtype": "Author", "clusterid": ""}, {"name": "Larti F", "authtype": "Author", "clusterid": ""}, {"name": "Ranjbar H", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41219835", "title": "Microvascular complications of type 2 diabetes with or without MASLD: the EPSOMIP study, a primary care cohort study.", "authors": [{"name": "Bergram M", "authtype": "Author", "clusterid": ""}, {"name": "Kechagias S", "authtype": "Author", "clusterid": ""}, {"name": "Iredahl F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41209341", "title": "Anterograde and trans-synaptic neurodegeneration in aquaporin-4-antibody neuromyelitis optica spectrum disorder patients with a history of transverse myelitis.", "authors": [{"name": "Jakuszyk P", "authtype": "Author", "clusterid": ""}, {"name": "Szuka\u0142o P", "authtype": "Author", "clusterid": ""}, {"name": "Kossowski B", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41198237", "title": "Preclinical Validation of [(177)Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.", "authors": [{"name": "Mortensen ACL", "authtype": "Author", "clusterid": ""}, {"name": "Mohajershojai T", "authtype": "Author", "clusterid": ""}, {"name": "Gustafsson A", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.", "detailed_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "All patient", "type": "EXPERIMENTAL", "description": "All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.", "intervention_names": ["Drug: Intravenous Tislelizumab", "Drug: Chemotherapy", "Radiation: Fractionated radiation", "Procedure: Esophagectomy"]}], "interventions": [{"type": "DRUG", "name": "Intravenous Tislelizumab", "description": "Participants will receive 200mg, every three weeks for up to 51 weeks", "arm_group_labels": ["All patient"]}, {"type": "DRUG", "name": "Chemotherapy", "description": "Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks", "arm_group_labels": ["All patient"]}, {"type": "RADIATION", "name": "Fractionated radiation", "description": "Concurrent with chemo, x5 weeks", "arm_group_labels": ["All patient"]}, {"type": "PROCEDURE", "name": "Esophagectomy", "description": "Surgical resection of cancer after chemoradiation therapy when no disease progression found.", "arm_group_labels": ["All patient"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Zhonglin Hao+NCT05245760+terminated", "https://www.google.com/search?q=Zhonglin Hao+Fractionated radiation+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Fractionated radiation by Zhonglin Hao. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and search results to compile a JSON summary about FDA warning letters or clinical holds for Fractionated radiation by Zhonglin Hao.\n\nThe query is asking for:\n- FDA warning letters or clinical holds\n- Related to \"Fractionated radiation\" \n- By a person named \"Zhonglin Hao\"\n- Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if there's any information matching this query:\n\nResult [1]: This is about Spectrum Medical Ltd receiving a warning letter from FDA on 09/29/2023. It discusses issues with their Quantum Perfusion devices being marketed with indications beyond what FDA cleared. There's no mention of \"Fractionated radiation\" or \"Zhonglin Hao\".\n\nResult [2]: This appears to be a clinical trial document (NCT04964960) about Pembrolizumab treatment. It mentions radiation therapy in the context of brain metastasis treatment, but nothing about warning letters, fractionated radiation specifically, or Zhonglin Hao.\n\nResult [3]: This is about recent FDA cancer drug safety warnings for various drugs (capecitabine, duvelisib, denosumab, ciltacabtagene autoleucel, pexidartinib). No mention of fractionated radiation or Zhonglin Hao.\n\nResult [4]: This is a general page about FDA warning letters with a table of various companies that received warning letters. I don't see any mention of \"Fractionated radiation\" or \"Zhonglin Hao\" in the visible portions.\n\nResult [5]: This is an article about radiation possibly being redundant for early-stage breast cancer patients. It mentions an FDA warning about websites selling unapproved Botox, but nothing about fractionated radiation or Zhonglin Hao.\n\nResult [6]: This appears to be a scientific article about N-Nitrosamines, not relevant to the query.\n\nResult [7]: This mentions \"FDA Issues Safety Alert for Radiation Therapy Devices\" but doesn't provide specific details in the snippet. It says \"The company recently received a letter from the FDA ordering them to stop designing, manufacturing...\" but doesn't name the company or mention Zhonglin Hao or fractionated radiation specifically.\n\nResult [8]: This is about SomaLogic publications, not relevant.\n\nResult [9]: This is about colon cancer survival, not relevant.\n\nResult [10]:", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the search results and the query to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by Zhonglin Hao\n- Mentioning clinical trial NCT05245760 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nLooking at the search results provided:\n\n1. Result [1] is just the SEC.gov search filings homepage, which explains the EDGAR system and how to search for filings.\n2. Result [2] is the EDGAR Full Text Search page, which explains how to use the advanced search feature to find filings.\n\nNeither of these search results actually contains any specific filings related to Zhonglin Hao, clinical trial NCT05245760, or any drug safety issues. These are just general search pages for the SEC EDGAR system.\n\nThe search results don't show any actual filings that match the query. There's no information about:\n- Any 8-K filings by Zhonglin Hao\n- Any mention of clinical trial NCT05245760\n- Any drug safety issues\n- Filing dates\n- CIK numbers\n- Material events disclosed\n\nSince the search results don't contain the specific information requested in the query, I need to indicate that no relevant filings were found in the provided search results.\n\nFor the JSON summary, I'll need to include:\n- status: Whether the search was successful in finding relevant information\n- summary: A brief explanation of what was found (or not found)\n- relevance: How relevant the search results are to the query\n- citations: Any specific documents or sources that were relevant (in this case, none)\n\nGiven that the search results only show the SEC search pages and not any actual filings matching the query, I'll create a JSON response indicating that no relevant filings were found in the provided search results.\n</think>\n\n{\n  \"status\": \"no_results\",\n  \"summary\": \"The provided search results only contain SEC EDGAR system search interface information and do not include any actual filings matching the query parameters. No 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues were identified in the presented search results.\",\n  \"relevance\": \"The search results are not relevant to the specific clinical trial safety investigation request as", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "start_date": "2022-04-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Fractionated radiation. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Zhonglin Hao\n- Specifically about clinical trial NCT05245760 for Fractionated radiation\n- Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nFirst, let me identify what NCT05245760 is from the search results:\n\nFrom result [4]:\nhttps://www.clinicaltrials.gov/study/NCT05245760\n\"ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer\nEsophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery.\"\n\nSo NCT05245760 is a clinical trial studying ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer.\n\nNow, the query is specifically asking for:\n1. Company press releases\n2. Investor presentations \n3. Public statements by Zhonglin Hao\n4. About this specific trial (NCT05245760)\n5. Focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me check if any of the search results contain this information:\n\nResult [1]: About NCT05353257 (a different trial studying Serplulimab)\nResult [2]: About malignant pleural mesothelioma treatments\nResult [3]: About lung cancer screening in PA populations\nResult [4]: About NCT05245760 (ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer) but only provides a brief description\nResult [5]: About multidimensional evaluation of lung cancer patients (NCT03881046)\nResult [6]: A PDF dossier about Tislelizumab (Tevimbra\u00ae) for NSCLC\nResult [7]: Information about Tislelizumab as a PD-1 inhibitor from MedChemExpress\nResult [8]: Genomic Study in Non-small Cell Lung Cancer Brain Metastasis (NCT04745715)\nResult", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "drug_name": "Fractionated radiation"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "Based on the provided information, the trial was withdrawn due to \"Funding unavailable,\" which is an administrative/operational reason for the failure of the trial. The detailed description does not mention any safety concerns or lack of efficacy, but rather states that the trial aimed to evaluate the tolerability, toxicities, progression-free survival, and overall survival of the treatment. Therefore, the most likely reason for the trial's withdrawal is the unavailability of funding, which is an administrative/operational issue.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:14.274921", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1226}}, "82": {"nct_id": "NCT05245760", "drug_name": "Intravenous Tislelizumab", "intervention_type": "DRUG", "drug_description": "Participants will receive 200mg, every three weeks for up to 51 weeks", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Funding unavailable.", "title": "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer", "start_date": "2022-04-30", "completion_date": "2033-12-31", "sponsor": "Zhonglin Hao", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.565220", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:14.390640", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL4297840", "pref_name": "TISLELIZUMAB", "targets": [], "has_uniprot_targets": false, "search_name": "Intravenous Tislelizumab"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "aact_documents": [], "pubmed_results": [{"pmid": "41179951", "title": "Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study.", "authors": [{"name": "Liang L", "authtype": "Author", "clusterid": ""}, {"name": "Zhou J", "authtype": "Author", "clusterid": ""}, {"name": "Huang J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41126100", "title": "Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.", "authors": [{"name": "Nong X", "authtype": "Author", "clusterid": ""}, {"name": "Yao Y", "authtype": "Author", "clusterid": ""}, {"name": "Xie J", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41125109", "title": "Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.", "authors": [{"name": "Chen Z", "authtype": "Author", "clusterid": ""}, {"name": "Yang F", "authtype": "Author", "clusterid": ""}, {"name": "Jiang Z", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41118318", "title": "PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.", "authors": [{"name": "Kong D", "authtype": "Author", "clusterid": ""}, {"name": "Tang Y", "authtype": "Author", "clusterid": ""}, {"name": "Zhou Y", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40889502", "title": "Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.", "authors": [{"name": "Shi G", "authtype": "Author", "clusterid": ""}, {"name": "Huang X", "authtype": "Author", "clusterid": ""}, {"name": "Li X", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.", "detailed_description": "Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "All patient", "type": "EXPERIMENTAL", "description": "All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.", "intervention_names": ["Drug: Intravenous Tislelizumab", "Drug: Chemotherapy", "Radiation: Fractionated radiation", "Procedure: Esophagectomy"]}], "interventions": [{"type": "DRUG", "name": "Intravenous Tislelizumab", "description": "Participants will receive 200mg, every three weeks for up to 51 weeks", "arm_group_labels": ["All patient"]}, {"type": "DRUG", "name": "Chemotherapy", "description": "Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks", "arm_group_labels": ["All patient"]}, {"type": "RADIATION", "name": "Fractionated radiation", "description": "Concurrent with chemo, x5 weeks", "arm_group_labels": ["All patient"]}, {"type": "PROCEDURE", "name": "Esophagectomy", "description": "Surgical resection of cancer after chemoradiation therapy when no disease progression found.", "arm_group_labels": ["All patient"]}]}}, "company_search_urls": ["https://www.google.com/search?q=Zhonglin Hao+NCT05245760+terminated", "https://www.google.com/search?q=Zhonglin Hao+Intravenous Tislelizumab+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Intravenous Tislelizumab by Zhonglin Hao. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Intravenous Tislelizumab by Zhonglin Hao.\n\nFirst, I need to understand what the query is asking for:\n- FDA warning letters or clinical holds\n- Specifically for Intravenous Tislelizumab\n- By a person named Zhonglin Hao\n- Including specific dates, reasons, and safety issues cited\n\nLet me go through the search results to see if they contain this information:\n\nResult [1]: This is about post-marketing safety concerns with Tislelizumab from NIH. It discusses adverse reactions but doesn't mention any FDA warning letters or clinical holds, nor does it mention Zhonglin Hao.\n\nResult [2]: This is the FDA label for TEVIMBRA\u00ae (tislelizumab-jsgr) injection. It describes immune-mediated adverse reactions and other safety information but doesn't mention any warning letters or clinical holds for Zhonglin Hao.\n\nResult [3]: This appears to be an FDA document about tislelizumab-jsgr risk management. It discusses adverse events but doesn't mention warning letters or clinical holds for Zhonglin Hao.\n\nResult [4] and [5]: These discuss recent FDA cancer drug safety warnings and updates, but they're about other drugs (CAR-T therapy, pexidartinib, capecitabine), not specifically about Tislelizumab warning letters for Zhonglin Hao.\n\nResult [6]: This is a PubMed abstract about long-term safety analysis of tislelizumab. It states that \"Tislelizumab's safety profile... remains consistent with previous reports\" and \"no new signals identified.\" No mention of warning letters or clinical holds.\n\nResult [7]: This discusses an FDA delay in decision for tislelizumab monotherapy for esophageal squamous cell carcinoma, citing \"site inspections could not be concluded due to COVID-19 travel restrictions in China.\" This is relevant as it mentions an FDA delay related to tislelizumab, but it doesn't mention Zhonglin Hao specifically or a warning letter.\n\nResult [8]: This is just a general page about FDA Warning Letters, not specific to tislelizumab or Zhonglin Hao.\n\nResult [9]: This mentions a December 19, 2024, FDA Warning Letter issued to Viatris", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nI need to analyze the search results provided to compile a JSON summary about external safety evidence for a specific clinical trial. The query is asking for SEC EDGAR 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues.\n\nLet me examine the search results:\n\n1. Result [1] is just the SEC.gov search filings homepage - it's a general search page with no specific information about the requested query.\n\n2. Result [2] appears to be a page about EDGAR (SEC's Electronic Data Gathering, Analysis, and Retrieval system) but shows \"No information is available for this page\" in what seems to be Korean. It has some template information about company information, CIK, EIN, etc., but no actual data for a specific company.\n\n3. Result [3] is the EDGAR Full Text Search page, which explains that the new EDGAR advanced search gives access to full text of electronic filings since 2001. It shows search filters and a table structure but no actual search results for the query.\n\nNone of these search results actually contain any specific information about:\n- Zhonglin Hao\n- Clinical trial NCT05245760\n- Any 8-K filings\n- Drug safety issues\n\nThe search results provided are just the search interfaces/templates of the SEC EDGAR system, not the actual results of the query that was performed. There's no evidence that any relevant filings were found.\n\nGiven this information, I need to create a JSON summary that accurately reflects that no relevant information was found in the provided search results.\n\nFor the JSON structure, I'll need to include:\n- status: Whether relevant information was found\n- summary: A brief explanation of what was found (or not found)\n- relevance: How relevant the findings are to the clinical trial safety evidence request\n- citations: Any relevant citations (in this case, none)\n\nSince no actual search results were provided that contain information about the requested clinical trial or filings, I'll indicate that no relevant information was found.\n</think>\n\n{\n  \"status\": \"no_evidence_found\",\n  \"summary\": \"The provided search results contain only SEC EDGAR system interface pages and search templates without any actual filings data. No 8-K filings by Zhonglin Hao mentioning clinical trial NCT05245760 or related drug safety issues", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "start_date": "2022-04-30"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Intravenous Tislelizumab. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- Company press releases, investor presentations, or public statements by Zhonglin Hao about clinical trial NCT05245760 for Intravenous Tislelizumab\n- Specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions\n\nLet me check the search results to see if they contain this information:\n\nResult [1]: This is about a phase 2 trial of tislelizumab as adjuvant therapy for rNPC (NCT05092217), not NCT05245760. It mentions a favorable safety profile but doesn't relate to the specific trial in question.\n\nResult [2]: This is about tislelizumab vs sorafenib for unresectable HCC (NCT03412773), not NCT05245760.\n\nResult [3]: This is a press release from BeiGene about tislelizumab plus chemotherapy for gastric cancer (RATIONALE 305 trial), not NCT05245760.\n\nResult [4]: This is a meta-analysis about tislelizumab for lung cancer, not specific to NCT05245760.\n\nResult [5]: This is about tislelizumab for lung cancer (a Phase III trial), but doesn't specify the NCT number and doesn't appear to be NCT05245760.\n\nResult [6]: This is a YouTube video about tislelizumab + chemotherapy for gastric cancer, not related to NCT05245760.\n\nResult [7]: This is directly about NCT05245760 - \"ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer\". It states: \"This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.\" However, it doesn't provide any details about safety issues, adverse events, trial termination, or regulatory actions. It's just a brief description of the trial's purpose.\n\nResult [8]: This mentions NCT05245760 in", "citations": [], "search_params": {"company": "Zhonglin Hao", "nct_id": "NCT05245760", "drug_name": "Intravenous Tislelizumab"}}}}, "llm_analysis": {"classification": "SAME (FAILURE_ADMINISTRATIVE)", "confidence": "high", "reasoning": "Based on the provided information, the trial was withdrawn due to \"Funding unavailable,\" which is an administrative/operational reason for the failure of the trial. The detailed description does not mention any safety concerns or lack of efficacy, but rather states that the trial aimed to evaluate the tolerability, toxicities, progression-free survival, and overall survival of the treatment. Therefore, the most likely reason for the trial's withdrawal is the unavailability of funding, which is an administrative/operational issue.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:14.274921", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1226}}, "83": {"nct_id": "NCT03863301", "drug_name": "MR-guided single dose preoperative PBI", "intervention_type": "RADIATION", "drug_description": "A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "no participants enrolled", "title": "MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer", "start_date": "2019-03-04", "completion_date": "2031-11-30", "sponsor": "UMC Utrecht", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.565803", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:17.435113", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "MR-guided single dose preoperative PBI"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "In this multi-center single arm interventional cohort study 70 patients will be treated with single dose preoperative partial breast irradiation (PBI). Breast conserving surgery will be performed 12 months following PBI to assess pathologic response. Response monitoring following PBI includes MRI (3T and 7T), liquid biopsies and biopsy of the irradiated tumor.\n\nResults from this trial can change the current treatment of patients with early stage breast cancer. The single dose PBI can be of benefit for all patients who are suitable for postoperative PBI according to current guidelines. If pathologic complete response can be accurately predicted by (one of) the abovementioned response monitoring modalities, the need for surgery will become disputable. Moreover, in patients without expected pathologic complete response, the burden of radiotherapy can be minimized from 3-4.5 weeks of radiotherapy to a single dose of radiotherapy.", "aact_documents": [], "pubmed_results": [{"pmid": "40681188", "title": "Preoperative partial breast reirradiation and repeat breast-conserving surgery in patients with recurrent breast cancer: the prospective single-arm REPEAT trial - a study protocol.", "authors": [{"name": "Civil Y", "authtype": "Author", "clusterid": ""}, {"name": "Wurfbain L", "authtype": "Author", "clusterid": ""}, {"name": "Jonker L", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37161377", "title": "Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.", "authors": [{"name": "Civil YA", "authtype": "Author", "clusterid": ""}, {"name": "Oei AL", "authtype": "Author", "clusterid": ""}, {"name": "Duvivier KM", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "This study aims to evaluate the pathologic response at 12 months after single dose preoperative partial breast irradiation in early stage breast cancer patients. Furthermore, the aim is to collect data on response monitoring. Patient-reported outcome measures and treatment-induced toxicity will be evaluated.", "detailed_description": "In this multi-center single arm interventional cohort study 70 patients will be treated with single dose preoperative partial breast irradiation (PBI). Breast conserving surgery will be performed 12 months following PBI to assess pathologic response. Response monitoring following PBI includes MRI (3T and 7T), liquid biopsies and biopsy of the irradiated tumor.\n\nResults from this trial can change the current treatment of patients with early stage breast cancer. The single dose PBI can be of benefit for all patients who are suitable for postoperative PBI according to current guidelines. If pathologic complete response can be accurately predicted by (one of) the abovementioned response monitoring modalities, the need for surgery will become disputable. Moreover, in patients without expected pathologic complete response, the burden of radiotherapy can be minimized from 3-4.5 weeks of radiotherapy to a single dose of radiotherapy.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "MR-guided single dose preoperative PBI", "type": "EXPERIMENTAL", "description": null, "intervention_names": ["Radiation: MR-guided single dose preoperative PBI"]}], "interventions": [{"type": "RADIATION", "name": "MR-guided single dose preoperative PBI", "description": "A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.", "arm_group_labels": ["MR-guided single dose preoperative PBI"]}]}}, "company_search_urls": ["https://www.google.com/search?q=UMC Utrecht+NCT03863301+terminated", "https://www.google.com/search?q=UMC Utrecht+MR-guided single dose preoperative PBI+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for MR-guided single dose preoperative PBI by UMC Utrecht. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to determine if there's any information about FDA warning letters or clinical holds for MR-guided single dose preoperative PBI (Partial Breast Irradiation) by UMC Utrecht.\n\nFirst, let's break down the query:\n- We're looking for FDA warning letters or clinical holds\n- Specifically related to \"MR-guided single dose preoperative PBI\" (Partial Breast Irradiation)\n- From UMC Utrecht (University Medical Center Utrecht)\n- Need specific dates, reasons, and safety issues cited\n\nNow, let's examine the search results to see if any contain relevant information:\n\nResult [1]: About SIOP abstracts, patient navigation programs, and some cancer treatment protocols. Mentions Utrecht in the context of \"University Medical Center Utrecht, Utrecht, the Netherlands\" but doesn't discuss FDA warning letters or clinical holds for MR-guided PBI.\n\nResult [2]: About FDA cancer drug safety warnings and updates. Mentions several FDA safety warnings for cancer drugs (pexidartinib, capecitabine, duvelisib, denosumab, ciltacabtagene autoleucel) but nothing about MR-guided PBI or UMC Utrecht.\n\nResult [3]: About the European Breast Cancer Conference. Mentions Utrecht in the context of \"University Medical Center Utrecht, Utrecht, the Netherlands\" but doesn't discuss FDA warning letters or clinical holds for MR-guided PBI.\n\nResult [4]: Netherlands Cancer Institute annual report. Mentions Utrecht but in the context of fundamental science during the pandemic and a clinical study in Shanghai about lenvatinib resistance. Nothing about FDA warning letters or clinical holds for MR-guided PBI.\n\nResult [5]: FDA Warning Letters page. This is about the general types of warning letters FDA issues, but doesn't contain specific warning letters related to MR-guided PBI or UMC Utrecht.\n\nResult [6]: About obstructive sleep apnea treatment. No relevance to the query.\n\nResult [7]: British Thoracic Society Winter Meeting. Contains general drug precautions and side effects but nothing specific to MR-guided PBI or UMC Utrecht.\n\nResult [8]: About AI in medical imaging. No relevance to the query.\n\nResult [9]: About CFTR modulator therapy. Mentions University Medical Center Utrecht in the author affiliations but is about cystic fibrosis treatment", "citations": []}, "sec_filings": {"found": true, "search_query": "SEC EDGAR 8-K filings by UMC Utrecht mentioning clinical trial NCT03863301 or related drug safety issues. Include filing dates, CIK number, and specific material events disclosed.", "summary": "<think>\nLet me analyze the query and the search results to provide a JSON summary as requested.\n\nThe query is asking for:\n- SEC EDGAR 8-K filings by UMC Utrecht\n- Specifically mentioning clinical trial NCT03863301 or related drug safety issues\n- Including filing dates, CIK number, and specific material events disclosed\n\nFirst, I need to understand what UMC Utrecht refers to. From the search results, I see:\n- Result [4] mentions \"United Microelectronics Corporation (NYSE: UMC; TWSE: 2303)\" which is a semiconductor company\n- Result [6] shows UMC's annual reports\n- Result [16] shows \"UNITED MICROELECTRONICS CORP Form 6-K Current Event Report\"\n\nHowever, \"UMC Utrecht\" typically refers to \"University Medical Center Utrecht\", which is a medical center in the Netherlands. This is different from \"United Microelectronics Corporation\" (UMC), which is a semiconductor company.\n\nLet me check if there's any mention of Utrecht or clinical trials in the search results:\n\nResult [5] mentions \"EUR Research Information Portal\" and \"von FW Thielen \u00b7 2022\" which might be related to University Medical Center Utrecht (since Utrecht is in the Netherlands), but it doesn't specifically mention NCT03863301.\n\nResult [5] does mention:\n\"from all companies involved in the R&D process of the case studies.\nSuch reports mainly included filings of financial statements that pub-\nlic companies are required to submit to the US Security and Exchange\nCommission (SEC). Publicly traded firms submit either quarterly of\nannual filings to the SEC (Forms 10-Q and 10-K, respectively).\"\n\nBut it doesn't mention UMC Utrecht specifically or the clinical trial NCT03863301.\n\nLet me check if any of the results mention NCT03863301:\n- None of the results explicitly mention NCT03863301\n- Result [5] mentions clinical trials in general but not this specific ID\n\nLet me check if any of the results mention UMC Utrecht:\n- Result [5] has \"EUR Research Information Portal\" which might be related to Utrecht (since EUR could stand for Erasmus University Rotterdam, but not Utrecht)\n", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT03863301", "start_date": "2019-03-04"}}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by UMC Utrecht about clinical trial NCT03863301 for MR-guided single dose preoperative PBI. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about UMC Utrecht's clinical trial NCT03863301 for MR-guided single dose preoperative PBI (Partial Breast Irradiation), specifically focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results to identify relevant information:\n\nResult [1]: Mentions \"The ABLATIVE trial was approved by the institutional review board of the UMC Utrecht, the Netherlands, and registered in ClinicalTrials.gov (NCT06863301).\" However, this is NCT06863301, not NCT03863301 which is the trial we're looking for.\n\nResult [2]: This is about a Novartis trial (CHKT288X2101) that was terminated due to adverse events, but it's not related to NCT03863301 or UMC Utrecht.\n\nResult [3]: Mentions \"Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. Clinical trials.gov Identifier NCT03863301.\" This is relevant as it mentions the trial ID we're looking for. It discusses MR-guided radiotherapy for breast cancer but doesn't provide specific safety information about the NCT03863301 trial.\n\nResult [4]: This is about University Medical Center Utrecht (UMCU) but doesn't mention NCT03863301 specifically or provide safety information about this trial.\n\nResult [5]: Mentions \"MRI-Guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer (Clinical trials.gov Identifier NCT03863301).\" This is directly relevant. It discusses neoadjuvant PBI and mentions some potential radiation effects: \"In an extreme case, the maximum dose measured was as high as 16.1% of the prescribed dose (64). Dose to the skin outside the treatment field was highest in patients with tumours located in the cranial part of the breast.\" However, it's not clear if this is specifically from the NCT03863301 trial or general information about this type of treatment.\n\nResult [6]: This is about mirabegron (Myrbetri", "citations": [], "search_params": {"company": "UMC Utrecht", "nct_id": "NCT03863301", "drug_name": "MR-guided single dose preoperative PBI"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The trial was withdrawn due to the official reason of \"no participants enrolled,\" which indicates an administrative failure rather than issues with safety or efficacy. The detailed description does not mention any safety concerns or lack of efficacy, but rather focuses on the potential benefits of the single dose preoperative radiotherapy approach. The trial was likely withdrawn due to enrollment challenges or other operational problems, leading to the decision not to move forward.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:17.434378", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1278}}, "84": {"nct_id": "NCT01512888", "drug_name": "Busulfan", "intervention_type": "DRUG", "drug_description": "Given intravenously (IV).", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "voluntary hold", "title": "Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants", "start_date": "2016-08-17", "completion_date": "2034-08-31", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.566411", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:20.190080", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL820", "pref_name": "BUSULFAN", "targets": [{"chembl_id": "CHEMBL614004", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614573", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614088", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614647", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614466", "ic50_values": [{"value": 92500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612798", "ic50_values": [{"value": 100000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL220", "ic50_values": [], "uniprot_id": "A4D2E2"}, {"chembl_id": "CHEMBL226", "ic50_values": [], "uniprot_id": "A6NFY5"}, {"chembl_id": "CHEMBL251", "ic50_values": [], "uniprot_id": "B2R7E0"}, {"chembl_id": "CHEMBL256", "ic50_values": [], "uniprot_id": "A2A3P4"}, {"chembl_id": "CHEMBL612545", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL319", "ic50_values": [], "uniprot_id": "P43140"}, {"chembl_id": "CHEMBL315", "ic50_values": [], "uniprot_id": "P15823"}, {"chembl_id": "CHEMBL223", "ic50_values": [], "uniprot_id": "P25100"}, {"chembl_id": "CHEMBL1867", "ic50_values": [], "uniprot_id": "B0LPF6"}, {"chembl_id": "CHEMBL1942", "ic50_values": [], "uniprot_id": "A2RUS0"}, {"chembl_id": "CHEMBL1916", "ic50_values": [], "uniprot_id": "P18825"}, {"chembl_id": "CHEMBL213", "ic50_values": [], "uniprot_id": "B0LPE2"}, {"chembl_id": "CHEMBL210", "ic50_values": [], "uniprot_id": "B0LPE4"}, {"chembl_id": "CHEMBL246", "ic50_values": [], "uniprot_id": "P13945"}, {"chembl_id": "CHEMBL222", "ic50_values": [], "uniprot_id": "B2R707"}, {"chembl_id": "CHEMBL2622", "ic50_values": [], "uniprot_id": "P07943"}, {"chembl_id": "CHEMBL4607", "ic50_values": [], "uniprot_id": "B2R9V1"}, {"chembl_id": "CHEMBL3157", "ic50_values": [], "uniprot_id": "P30411"}, {"chembl_id": "CHEMBL1832", "ic50_values": [], "uniprot_id": "A0A0C4DG16"}, {"chembl_id": "CHEMBL218", "ic50_values": [], "uniprot_id": "B2R9T4"}, {"chembl_id": "CHEMBL205", "ic50_values": [], "uniprot_id": "B2R7G8"}, {"chembl_id": "CHEMBL4015", "ic50_values": [], "uniprot_id": "A0AVQ3"}, {"chembl_id": "CHEMBL2414", "ic50_values": [], "uniprot_id": "P51679"}, {"chembl_id": "CHEMBL274", "ic50_values": [], "uniprot_id": "O14692"}, {"chembl_id": "CHEMBL4029", "ic50_values": [], "uniprot_id": "B2R6Q3"}, {"chembl_id": "CHEMBL2434", "ic50_values": [], "uniprot_id": "P25025"}, {"chembl_id": "CHEMBL1901", "ic50_values": [], "uniprot_id": "B2R9Z5"}, {"chembl_id": "CHEMBL221", "ic50_values": [], "uniprot_id": "A8K1V7"}, {"chembl_id": "CHEMBL230", "ic50_values": [], "uniprot_id": "A8K802"}, {"chembl_id": "CHEMBL3356", "ic50_values": [], "uniprot_id": "P05177"}, {"chembl_id": "CHEMBL5282", "ic50_values": [], "uniprot_id": "A7YAE5"}, {"chembl_id": "CHEMBL3622", "ic50_values": [], "uniprot_id": "P33259"}, {"chembl_id": "CHEMBL3397", "ic50_values": [], "uniprot_id": "P11712"}, {"chembl_id": "CHEMBL289", "ic50_values": [], "uniprot_id": "P10635"}, {"chembl_id": "CHEMBL5281", "ic50_values": [], "uniprot_id": "P05181"}, {"chembl_id": "CHEMBL340", "ic50_values": [], "uniprot_id": "P05184"}, {"chembl_id": "CHEMBL2056", "ic50_values": [], "uniprot_id": "B2RA44"}, {"chembl_id": "CHEMBL217", "ic50_values": [], "uniprot_id": "P14416"}, {"chembl_id": "CHEMBL234", "ic50_values": [], "uniprot_id": "A1A4V5"}, {"chembl_id": "CHEMBL219", "ic50_values": [], "uniprot_id": "B0M0J7"}, {"chembl_id": "CHEMBL238", "ic50_values": [], "uniprot_id": "A2RUN4"}, {"chembl_id": "CHEMBL252", "ic50_values": [], "uniprot_id": "B2R723"}, {"chembl_id": "CHEMBL206", "ic50_values": [], "uniprot_id": "Q13511"}, {"chembl_id": "CHEMBL242", "ic50_values": [], "uniprot_id": "A8K8K5"}, {"chembl_id": "CHEMBL2034", "ic50_values": [], "uniprot_id": "A0ZXF9"}, {"chembl_id": "CHEMBL3392921", "ic50_values": [], "uniprot_id": "Q91W28"}, {"chembl_id": "CHEMBL231", "ic50_values": [], "uniprot_id": "A8K047"}, {"chembl_id": "CHEMBL1941", "ic50_values": [], "uniprot_id": "B5BUP7"}, {"chembl_id": "CHEMBL402", "ic50_values": [], "uniprot_id": "B7Z3Y9"}, {"chembl_id": "CHEMBL5486", "ic50_values": [], "uniprot_id": "P15127"}, {"chembl_id": "CHEMBL1909043", "ic50_values": [], "uniprot_id": "A6XA80"}, {"chembl_id": "CHEMBL1798", "ic50_values": [], "uniprot_id": "B2R954"}, {"chembl_id": "CHEMBL4358", "ic50_values": [], "uniprot_id": "O19043"}, {"chembl_id": "CHEMBL4644", "ic50_values": [], "uniprot_id": "P41968"}, {"chembl_id": "CHEMBL259", "ic50_values": [], "uniprot_id": "B2RAC3"}, {"chembl_id": "CHEMBL4608", "ic50_values": [], "uniprot_id": "B0YJ34"}, {"chembl_id": "CHEMBL1951", "ic50_values": [], "uniprot_id": "B4DF46"}, {"chembl_id": "CHEMBL216", "ic50_values": [], "uniprot_id": "P11229"}, {"chembl_id": "CHEMBL211", "ic50_values": [], "uniprot_id": "P08172"}, {"chembl_id": "CHEMBL245", "ic50_values": [], "uniprot_id": "P20309"}, {"chembl_id": "CHEMBL1821", "ic50_values": [], "uniprot_id": "B2RPP4"}, {"chembl_id": "CHEMBL2035", "ic50_values": [], "uniprot_id": "P08912"}, {"chembl_id": "CHEMBL4777", "ic50_values": [], "uniprot_id": "B2R6H5"}, {"chembl_id": "CHEMBL4018", "ic50_values": [], "uniprot_id": "P49146"}, {"chembl_id": "CHEMBL3048", "ic50_values": [], "uniprot_id": "P70594"}, {"chembl_id": "CHEMBL3464", "ic50_values": [], "uniprot_id": "O70515"}, {"chembl_id": "CHEMBL236", "ic50_values": [], "uniprot_id": "B5B0B8"}, {"chembl_id": "CHEMBL237", "ic50_values": [], "uniprot_id": "E5RHC9"}, {"chembl_id": "CHEMBL233", "ic50_values": [], "uniprot_id": "B0FXJ1"}, {"chembl_id": "CHEMBL1827", "ic50_values": [], "uniprot_id": "A0AV69"}, {"chembl_id": "CHEMBL250", "ic50_values": [], "uniprot_id": "A3KMC8"}, {"chembl_id": "CHEMBL240", "ic50_values": [], "uniprot_id": "A5H1P7"}, {"chembl_id": "CHEMBL1909044", "ic50_values": [], "uniprot_id": "Q690N0"}, {"chembl_id": "CHEMBL4074", "ic50_values": [], "uniprot_id": "O02852"}, {"chembl_id": "CHEMBL4801", "ic50_values": [], "uniprot_id": "B5MDZ1"}, {"chembl_id": "CHEMBL4071", "ic50_values": [], "uniprot_id": "P08311"}, {"chembl_id": "CHEMBL248", "ic50_values": [], "uniprot_id": "P08246"}, {"chembl_id": "CHEMBL332", "ic50_values": [], "uniprot_id": "P03956"}, {"chembl_id": "CHEMBL321", "ic50_values": [{"value": 5215.0, "units": "nM"}], "uniprot_id": "B2R7V9"}, {"chembl_id": "CHEMBL299", "ic50_values": [], "uniprot_id": "B5BU22"}, {"chembl_id": "CHEMBL3385", "ic50_values": [], "uniprot_id": "A8CZ58"}, {"chembl_id": "CHEMBL4040", "ic50_values": [], "uniprot_id": "A8CZ64"}, {"chembl_id": "CHEMBL260", "ic50_values": [], "uniprot_id": "A6ZJ92"}, {"chembl_id": "CHEMBL4445", "ic50_values": [], "uniprot_id": "A1A441"}, {"chembl_id": "CHEMBL203", "ic50_values": [], "uniprot_id": "O00688"}, {"chembl_id": "CHEMBL1841", "ic50_values": [], "uniprot_id": "B5BU57"}, {"chembl_id": "CHEMBL1824", "ic50_values": [], "uniprot_id": "B2RZG3"}, {"chembl_id": "CHEMBL258", "ic50_values": [], "uniprot_id": "D3DPP8"}, {"chembl_id": "CHEMBL3243", "ic50_values": [], "uniprot_id": "A0A0A0MT22"}, {"chembl_id": "CHEMBL273", "ic50_values": [], "uniprot_id": "P19327"}, {"chembl_id": "CHEMBL3459", "ic50_values": [], "uniprot_id": "P28564"}, {"chembl_id": "CHEMBL224", "ic50_values": [], "uniprot_id": "B2RAC5"}, {"chembl_id": "CHEMBL1833", "ic50_values": [], "uniprot_id": "B2R9D5"}, {"chembl_id": "CHEMBL225", "ic50_values": [], "uniprot_id": "B1AMW4"}, {"chembl_id": "CHEMBL5017", "ic50_values": [], "uniprot_id": "O70528"}, {"chembl_id": "CHEMBL3371", "ic50_values": [], "uniprot_id": "P50406"}, {"chembl_id": "CHEMBL228", "ic50_values": [], "uniprot_id": "P31645"}, {"chembl_id": "CHEMBL287", "ic50_values": [], "uniprot_id": "D3DRM7"}, {"chembl_id": "CHEMBL249", "ic50_values": [], "uniprot_id": "A8K150"}, {"chembl_id": "CHEMBL2327", "ic50_values": [], "uniprot_id": "A8K7I1"}, {"chembl_id": "CHEMBL3072", "ic50_values": [], "uniprot_id": "P15207"}, {"chembl_id": "CHEMBL1835", "ic50_values": [], "uniprot_id": "B4DJG6"}, {"chembl_id": "CHEMBL1868", "ic50_values": [], "uniprot_id": "A3E342"}, {"chembl_id": "CHEMBL5144", "ic50_values": [], "uniprot_id": "A5JUT9"}, {"chembl_id": "CHEMBL1889", "ic50_values": [], "uniprot_id": "P37288"}, {"chembl_id": "CHEMBL6020", "ic50_values": [{"value": 135000.0, "units": "nM"}, {"value": 1000000.0, "units": "nM"}, {"value": 133000.0, "units": "nM"}], "uniprot_id": "O95342"}, {"chembl_id": "CHEMBL5748", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RMT8"}, {"chembl_id": "CHEMBL5918", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "B2RPA9"}, {"chembl_id": "CHEMBL1743128", "ic50_values": [{"value": 133000.0, "units": "nM"}], "uniprot_id": "A9Z1Z7"}, {"chembl_id": "CHEMBL613508", "ic50_values": [{"value": 25800.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612657", "ic50_values": [{"value": 24300.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 36200.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 20000.0, "units": "nM"}, {"value": 19952.62, "units": "nM"}], "uniprot_id": null}], "has_uniprot_targets": true, "search_name": "Busulfan"}, "ppi_enrichment": {"uniprot_count": 108, "interactions": [{"protein_a": "CHKA", "protein_b": "CHKB", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "PHOSPHO1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "ACHE", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "CHAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CHKA", "protein_b": "GPCPD1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "HSPG2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "APP", "protein_b": "ACHE", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "DOK7", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "HSPG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "PHOSPHO1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHKB", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "MAOB", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "GPCPD1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "CHAT", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "ACHE", "protein_b": "COLQ", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "PHOSPHO1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "CHKB", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHAT", "protein_b": "GPCPD1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DOK7", "protein_b": "COLQ", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HSPG2", "protein_b": "COLQ", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "PHOSPHO1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GPCPD1", "protein_b": "CHKB", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "PHOSPHO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADORA2A", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "ADA", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "SLC29A1", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNB1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "SLC29A1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "ADA", "protein_b": "ADORA2A", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2A", "protein_b": "SLC29A1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "CNR1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "NTRK2", "protein_b": "ADORA2A", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CNR1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2B", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADORA2A", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAL", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "ADORA2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "ADORA2B", "protein_b": "GNAS", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "GNAS", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "ADORA2A", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "ADORA2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADORA2A", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADORA2A", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "ADORA1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI3", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "KNG1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA3", "protein_b": "GNAI2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADORA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI3", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "KNG1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "ADORA1", "protein_b": "GNAI1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1B", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1D", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA1A", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "TBXA2R", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1D", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1B", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1D", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA1A", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "TBXA2R", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "GNA13", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1D", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRA1B", "protein_b": "ADRA1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "ADRA1D", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "SNTB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "SNTB2", "protein_b": "UTRN", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "ADRA1D", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "UTRN", "protein_b": "SNTB1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "TBXA2R", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "SNTB1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "ADRA1A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "ADRA1D", "protein_b": "GNA13", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "ADRA1A", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "TBXA2R", "protein_b": "GNA13", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAO1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNA13", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNAQ", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "ADRA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNG2", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNAO1", "protein_b": "GNB1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNB1", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNG2", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNG2", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNA13", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNA13", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2B", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SEC24C", "protein_b": "ADRA2B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "ADRA2B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB3", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2A", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "ADRA2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2C", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2C", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA13", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "ADRA2A", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNA12", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAQ", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2C", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "ADRA2A", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2C", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "ADRA2A", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "ADRA2C", "combined_score": 0.781, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNA13", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ADRA2A", "protein_b": "GNAQ", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ADRA2C", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ADRA2C", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "ADRA2C", "protein_b": "GNA13", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "DLG4", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "ADRB1", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GCG", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "POMC", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "NPPA", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "DLG4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "GNAI1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ADRB2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SNX27", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GRK2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "AKAP12", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SAG", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "SAG", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "SAG", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB2", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "ARRB1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "AKAP12", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SAG", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ARRB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "UCP1", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "LIPE", "protein_b": "ADRB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "FGF21", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "UCP1", "protein_b": "ADRB3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI3", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB3", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAI1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "SRC", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "ADRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADRB2", "protein_b": "GNAS", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB3", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "SRC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "ADRB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "FGF21", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "SRC", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "ADRB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI3", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAI1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ADRB3", "protein_b": "GNAS", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI3", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAI1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "ADRB1", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "SRC", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "SRC", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GNAI1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "YRDC", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "HTR1A", "combined_score": 0.788, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADRA2A", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SNCA", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SCRT1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC18A2", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC22A3", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "SLC5A2", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "ADCY7", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "SLC6A2", "protein_b": "STX1A", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC5A2", "protein_b": "ADCY7", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MTUS1", "protein_b": "AGTR2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "AGTR2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "EDN1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "KNG1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGTR1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "ACE", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "REN", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "ACE2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "ACE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "EDN1", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "KNG1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "ACE2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "AGTR2", "protein_b": "AGTR1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "KNG1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "ACE2", "protein_b": "AGTR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "BDKRB2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AGTR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "ACE", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "EDN1", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNB1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "BDKRB2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "AGT", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "GNAQ", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "BDKRB1", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "AGTR1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "BDKRB2", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "BDKRB2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGTR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "EDN1", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "BDKRB2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGTR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "KNG1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ACE", "protein_b": "AGT", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "BDKRB2", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "AGTR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "BDKRB2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "AGTR1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "BDKRB2", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "KNG1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AGTR1", "protein_b": "BDKRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "BDKRB2", "protein_b": "KNG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNG2", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "GNAS", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "ADM", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "RAMP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IAPP", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "GNAS", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCA", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "RAMP2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCB", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP3", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "RAMP1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "ADM", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNG2", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "GNAS", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "ADM", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCA", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "RAMP1", "protein_b": "CALCB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNG2", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNB1", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "GNAS", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCB", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "ADM", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CALCA", "protein_b": "CALCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADM", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CALCR", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNB1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "GNAS", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "CALCB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CALCR", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "CALCB", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADM", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CALCB", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADM", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CALCB", "protein_b": "ADM", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "GPR55", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "CNR1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FAAH", "protein_b": "MGLL", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "GPR55", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "MGLL", "protein_b": "CNR1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "CNR2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GPR55", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GPR55", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNAI1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CNR2", "protein_b": "GNB1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "CYP24A1", "protein_b": "CA1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "SLC4A1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "CA2", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "ATP6V1B1", "protein_b": "TCIRG1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA1", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "SLC4A1", "protein_b": "CA2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "SLC4A4", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "SLC9A1", "protein_b": "CA2", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CA2", "combined_score": 0.871, "interaction_type": "physical"}, {"protein_a": "TCIRG1", "protein_b": "CLCN7", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CLCN7", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBSL", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CBS", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "CA1", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CA2", "protein_b": "SLC4A4", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBS", "protein_b": "CBSL", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL13", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL7", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL8", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL11", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCL5", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL13", "protein_b": "CCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL11", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CXCL10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR2", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL8", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CCL8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL11", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL7", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CXCL8", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL7", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL5", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL4", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CCL8", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL2", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL5", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCL17", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CCL22", "protein_b": "CCR4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL2", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL27", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCR4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL17", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL27", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCR4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CXCL12", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "CCL27", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR4", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "CCR4", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "GRK3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GRK3", "protein_b": "CCR4", "combined_score": 0.756, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL3", "combined_score": 0.797, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CXCL12", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "CCR4", "protein_b": "CCL5", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL3", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR1", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL2", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CXCL10", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL3", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL5", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCL4", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ITIH4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL3L1", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL4", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL3", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL5", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCL4", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "ITIH4", "protein_b": "CCR5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3L1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR5", "protein_b": "CXCL10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CXCL10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3L1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3L1", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL4", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL10", "protein_b": "CCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL8", "protein_b": "CCL5", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3L1", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCL5", "protein_b": "CCL4", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL3L1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CCL3", "protein_b": "CCL4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL3L1", "protein_b": "CCL4", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL6", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL3", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL5", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CCL2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL8", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR2", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCL1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CX3CL1", "protein_b": "CXCR1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL6", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL12", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL5", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL2", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCR2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCL2", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL8", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL5", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "PPBP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL6", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL12", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "PPBP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL8", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR1", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "PPBP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL12", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL8", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCL5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL3", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "PPBP", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL12", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL8", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL5", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL2", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPBP", "protein_b": "CXCL12", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL12", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCL2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "CXCR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL12", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCR2", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL12", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CXCL1", "protein_b": "CXCL2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CXCL12", "protein_b": "CXCL2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CCKAR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAI1", "combined_score": 0.744, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GAST", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCKAR", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNG2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNB1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAI1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GNAS", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCL28", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "PTK7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "GAST", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "CCKAR", "protein_b": "CCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCL28", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "GNB1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "CCK", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCL28", "protein_b": "CCK", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNAI1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CCK", "protein_b": "PTK7", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "HPGDS", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGDS", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX15", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "ALOX12", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGS1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGES", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "HPGDS", "protein_b": "PTGDS", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGDS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGDS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGS2", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGDS", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "PTGES3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "ALOX5", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGDS", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "PTGES3", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGDS", "protein_b": "PTGES3", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGES", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "TP53", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGES", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CXCL8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "IL6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "IL6", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "CXCL8", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "PTGS2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PLA2G4A", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "ALOX5", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "ALOX15", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "PTGS2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CXCL8", "protein_b": "IL6", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PTGES", "protein_b": "PTGES2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PTGES2", "protein_b": "PTGS2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "ALOX5", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "PLA2G4A", "protein_b": "PTGS2", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "IL6", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "PTGS2", "protein_b": "ALOX5", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2A6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP2E1", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NAT2", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2E1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2B6", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A8", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2B6", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP3A4", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP2E1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "CYP1A2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A8", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2E1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2B6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP2E1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "UGT1A8", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP3A4", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2B6", "protein_b": "CYP1A2", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A8", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GAPDH", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP4A11", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP1A2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP2A6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT2B10", "protein_b": "CYP3A4", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A10", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A7", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP1A2", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP4A11", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT1A4", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "UGT2B7", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP3A4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CYP2A6", "protein_b": "CYP2A7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP4A11", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP4A11", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A7", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A10", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "UGT1A4", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A7", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "PPIG", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4A11", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "ALOX5", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C19", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP2C9", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP4F3", "protein_b": "CYP4F2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP1A2", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "PPIG", "combined_score": 0.845, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP4A11", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "ALOX5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "PPIG", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "EPHX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP3A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP4A11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C19", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP2C9", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP3A5", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A2", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "ALOX5", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP4A11", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "PPIG", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP1A2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP2C19", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PPIG", "protein_b": "CYP3A4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "ALOX5", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP2C19", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP4A11", "protein_b": "CYP1A2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2C19", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "ALOX5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP3A4", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C19", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "VKORC1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP4F2", "protein_b": "CYP2C9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "AOX1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP1A1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "UGT1A6", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "EPHX2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A7", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "VKORC1", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP3A4", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CYP2C9", "protein_b": "CYP2C19", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2C19", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A7", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "AOX1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP2C19", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "AOX1", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "CYP3A7", "protein_b": "CYP1A1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "VKORC1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "EPHX1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP2C19", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP1A1", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "AOX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "VKORC1", "protein_b": "EPHX1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "EPHX2", "protein_b": "EPHX1", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2D6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B15", "protein_b": "CYP2D6", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A9", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "CYP2D6", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A9", "protein_b": "UGT1A3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2D6", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2D6", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "UGT1A3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A3", "protein_b": "CYP2D6", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ADH1B", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "ADH1B", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A4", "combined_score": 0.707, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "UGT1A10", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTP1", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "GSTM1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ADH1B", "protein_b": "CYP2E1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "GSTP1", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP3A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP1A2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "CYP2E1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTM1", "protein_b": "EPHX1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A4", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "UGT1A10", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "GSTP1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "EPHX1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP3A4", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP1A2", "protein_b": "CYP2E1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP3A4", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "CYP2E1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GSTP1", "protein_b": "EPHX1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "EPHX1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "EPHX1", "protein_b": "CYP3A4", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP2E1", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP1A1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A10", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A8", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "UGT1A1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP2E1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP1A1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "CYP3A4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "CYP3A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A1", "protein_b": "UGT1A8", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A10", "protein_b": "UGT1A8", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP2E1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A4", "protein_b": "UGT1A7", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP2E1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "UGT1A7", "protein_b": "UGT1A8", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP2E1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP1A1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "UGT1A8", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "POR", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP2E1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "CYP1A1", "protein_b": "CYP3A4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP2E1", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "POR", "protein_b": "CYP3A4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CYP2E1", "protein_b": "CYP3A4", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CALY", "protein_b": "DRD1", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "DRD1", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "DRD1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "TMTC1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNB1", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "DRD1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "DRD1", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "DRD1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "TMTC1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "ADCYAP1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "POMC", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "DRD2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CNR1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADORA2A", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CNR1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD2", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "NCS1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "CNR1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ADORA2A", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "ARRB2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB1", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ARRB2", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNB1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "ADORA2A", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "CNR1", "protein_b": "GNAI1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADORA2A", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG7", "combined_score": 0.701, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB1", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNG2", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNB1", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD1", "combined_score": 0.763, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "DRD3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNB1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNAI1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB2", "protein_b": "GNG2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD1", "combined_score": 0.834, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "DRD3", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD1", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "DRD3", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNG7", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "DRD3", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "GNG7", "protein_b": "GNAI1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "DRD1", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD1", "protein_b": "BDNF", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNAI1", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "KLHL12", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "GNB3", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD3", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "GNAI1", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "GNB3", "protein_b": "DRD3", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "DRD2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD3", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "MAOA", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DRD2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD3", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "BDNF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "BDNF", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "DRD3", "protein_b": "GNAI1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TH", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "DRD2", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A3", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SYNGR3", "protein_b": "SLC6A3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "FLOT1", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "CAMK2A", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "TH", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "SNCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SLC6A3", "protein_b": "DRD2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "TH", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DRD2", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "SLC18A2", "combined_score": 0.814, "interaction_type": "physical"}, {"protein_a": "DRD2", "protein_b": "TH", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SLC18A2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "TH", "protein_b": "SNCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SLC18A2", "protein_b": "SNCA", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "EDNRB", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRB", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AGT", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "EDNRA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "KNG1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "GNA13", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "AGT", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDNRB", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRA", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN2", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDN1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "EDN3", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN2", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDN1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "EDNRB", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "AGT", "protein_b": "KNG1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDN1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "EDN2", "protein_b": "EDNRB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "KNG1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "GNA13", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "EDNRB", "protein_b": "EDN1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EDN1", "protein_b": "KNG1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NRIP1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SP1", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA1", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "NCOA3", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "SRC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA2", "combined_score": 0.754, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA1", "combined_score": 0.759, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "NCOA3", "combined_score": 0.766, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "JUN", "combined_score": 0.793, "interaction_type": "physical"}, {"protein_a": "NRIP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "JUN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "MED1", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA3", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "SP1", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "NCOA3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "MED1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA1", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "NCOA3", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "SRC", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR2", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "JUN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "SP1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR2", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "JUN", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "SRC", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "ESR1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "ESR2", "protein_b": "NCOA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "NCOA1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "SRC", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "JUN", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "SRC", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA3", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA2", "protein_b": "ESR1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "FKBP5", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "STIP1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "PTGES3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "NR3C1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSPA4", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FKBP4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSPA4", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "STIP1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOR1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "PTGES3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "NCOA2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NR3C1", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AB1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "HSP90AA1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "NCOR1", "protein_b": "NCOA1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "PTGES3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "FKBP5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "HSP90AB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "STIP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "FKBP5", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "PTGES3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STIP1", "protein_b": "HSP90AB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "FKBP5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AB1", "protein_b": "PTGES3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NCOA1", "protein_b": "NCOA2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FKBP5", "protein_b": "PTGES3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HRH1", "combined_score": 0.722, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "PLCB3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "HRH1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG2", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNB1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "PLCB3", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH1", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HRH1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PLCB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HRH1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PLCB3", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PLCB3", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HRH1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "PLCB3", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "HRH1", "protein_b": "TRPV1", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "ATP4A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ATP12A", "protein_b": "GAST", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "HRH2", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "ATP4A", "protein_b": "GAST", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "GAST", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "HDC", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GAST", "protein_b": "HRH2", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "HRH2", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "GNAL", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HRH2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF1", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SREBF2", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "SQLE", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDFT1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "FDPS", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCS1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "MVK", "protein_b": "HMGCR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "INSIG1", "combined_score": 0.955, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "SREBF2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "INSIG2", "protein_b": "HMGCR", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "INSIG1", "combined_score": 0.773, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SREBF2", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDPS", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCR", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "HMGCS1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "FDFT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDFT1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "FDPS", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "SREBF2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "INSIG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCR", "protein_b": "HMGCS2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "INSIG1", "combined_score": 0.885, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "HMGCS2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "SREBF2", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDFT1", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "HMGCS1", "protein_b": "FDPS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDPS", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "FDFT1", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "INSIG1", "protein_b": "SREBF2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDPS", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "FDFT1", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "HMGCS2", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SREBF1", "protein_b": "SREBF2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "SREBF2", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "HMGCS2", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "FDPS", "protein_b": "FDFT1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "HMGCS2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "SREBF2", "protein_b": "FDFT1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "HMGCS2", "protein_b": "FDFT1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR1", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "TBXA2R", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CYSLTR2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "CYSLTR1", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "GGT1", "protein_b": "LTC4S", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "LTB4R2", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR1", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "TBXA2R", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CYSLTR2", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "TBXA2R", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "ALOX5AP", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTB4R2", "combined_score": 0.857, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "GNAQ", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "LTC4S", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "CYSLTR2", "protein_b": "CYSLTR1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LTB4R2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CYSLTR1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TBXA2R", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5AP", "combined_score": 0.758, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "LTB4R2", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "CYSLTR1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "LTC4S", "protein_b": "ALOX5", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "LTB4R2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "TBXA2R", "combined_score": 0.75, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "CYSLTR1", "protein_b": "ALOX5AP", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALOX5", "protein_b": "ALOX5AP", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CTSZ", "protein_b": "MC3R", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "LEP", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "POMC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "AGRP", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "MC3R", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "NPY", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GHSR", "protein_b": "GHRL", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ASIP", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "LEP", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "NPY", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "MRAP2", "combined_score": 0.833, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "GHRL", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "ATP7A", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "AGRP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MC3R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "ASIP", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ATP7A", "protein_b": "POMC", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ASIP", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "LEP", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "NPY", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "POMC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "GHRL", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "AGRP", "protein_b": "MC4R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEPR", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GHRL", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "KCTD15", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "NPY", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "TMEM18", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "GNAS", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "LEP", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "FTO", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "MC4R", "protein_b": "POMC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "FTO", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "POMC", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "GHRL", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "NPY", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "LEP", "protein_b": "LEPR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "FTO", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "NPY", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "LEPR", "protein_b": "POMC", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "POMC", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "FTO", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TMEM18", "protein_b": "KCTD15", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "KCTD15", "protein_b": "FTO", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "MRAP2", "protein_b": "MC5R", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "MC5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DBH", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "DDC", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "COMT", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "LRTOMT", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "AOC3", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "ALDH2", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOB", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "AOC2", "protein_b": "MAOA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "AOC3", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "ALDH2", "protein_b": "MAOA", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "AOC3", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "COMT", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DBH", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "DDC", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "LRTOMT", "protein_b": "MAOB", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DBH", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "DDC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "COMT", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOA", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "AOC3", "protein_b": "MAOB", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "CYP2D6", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "MAOB", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "AOC1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DDC", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "DBH", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DBH", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "DDC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "MAOB", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "CYP2D6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "AOC1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DBH", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MAOB", "protein_b": "DDC", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "DBH", "protein_b": "DDC", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "DDC", "protein_b": "AOC1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR6", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "LPAR1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "ARRB1", "combined_score": 0.821, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR5", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR4", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "F2R", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "LPAR6", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "KNG1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR4", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR3", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "CHRM2", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "LPAR1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "ARRB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "CHRM2", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR4", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR3", "protein_b": "LPAR6", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "CHRM2", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR5", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR6", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "LPAR1", "protein_b": "LPAR4", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "CHRM2", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR4", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "LPAR6", "protein_b": "LPAR5", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "CHRM2", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "LPAR5", "protein_b": "LPAR4", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "LPAR4", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "KNG1", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "CHRM2", "protein_b": "ARRB1", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA15", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "AGTRAP", "combined_score": 0.715, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNA15", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNG12", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GRM5", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "CHRM1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "GNA15", "protein_b": "GNAQ", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "CHRM4", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNG2", "combined_score": 0.705, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI2", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNAI1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "GNG3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "CHRM4", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG12", "combined_score": 0.877, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG10", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "CHRM4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNG10", "combined_score": 0.726, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNAI1", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM4", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "CHRM4", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNAI1", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "GNG10", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "CHRM4", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "GNAI1", "combined_score": 0.714, "interaction_type": "physical"}, {"protein_a": "CHRM4", "protein_b": "KNG1", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG12", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM5", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GRM5", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "CHRM1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNG12", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GRM5", "combined_score": 0.929, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "CHRM5", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "CHRM3", "protein_b": "GNAQ", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG12", "combined_score": 0.776, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "KNG1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM5", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CHRM1", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GRM5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM5", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GRM5", "protein_b": "CHRM1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "CHRM5", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "GNG12", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CHRM1", "protein_b": "KNG1", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNG12", "protein_b": "CHRM5", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "CHRM5", "protein_b": "KNG1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "NPY1R", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNG2", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GHRL", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY1R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PPY", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY1R", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "PYY", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "GHRL", "protein_b": "NPY", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY5R", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY1R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNB1", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY5R", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI3", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "NPY1R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "NPY5R", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY5R", "protein_b": "PPY", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "PRPH2", "protein_b": "NPY2R", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY2R", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "NPY", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "MCHR1", "protein_b": "POMC", "combined_score": 0.847, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GLP1R", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "POMC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNG2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNB1", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "GNAI1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PPY", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "NPY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NPY2R", "protein_b": "PYY", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "NPY", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "POMC", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GLP1R", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAI1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "GLP1R", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "POMC", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "PPY", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PYY", "protein_b": "NPY", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "POMC", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GLP1R", "protein_b": "GNB1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "PPY", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "NPY", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "POMC", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "GNAI1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PPY", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "NPY", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "GNAI1", "combined_score": 0.863, "interaction_type": "physical"}, {"protein_a": "NPY", "protein_b": "PPY", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "PPY", "protein_b": "GNAI1", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GPRASP1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PNOC", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI2", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "KNG1", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PENK", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "POMC", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "OPRM1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "GNAI1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PNOC", "protein_b": "PDYN", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "OPRM1", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "GNAI2", "protein_b": "GNAI3", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "OPRM1", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "GNAI3", "protein_b": "GNAI1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "KNG1", "combined_score": 0.868, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GPRASP1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "KNG1", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "PDYN", "protein_b": "KNG1", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "POMC", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "OPRM1", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PDYN", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "PENK", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "OPRD1", "protein_b": "GNAI1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "OPRM1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GRK2", "protein_b": "ARRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "GRK5", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "GRK6", "protein_b": "ARRB2", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "OPRM1", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GRK5", "protein_b": "ARRB1", "combined_score": 0.976, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GNAI1", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PENK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "PDYN", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "OPRM1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "ARRB2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PDYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "GNAI1", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "OPRM1", "protein_b": "PENK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PENK", "protein_b": "PDYN", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE6G", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE2A", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "PDE5A", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GUK1", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "ITPA", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "HPRT1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "APRT", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "GMPR", "protein_b": "GMPS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE6G", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE2A", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "PDE5A", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "ITPA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GUK1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "GMPS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HPRT1", "protein_b": "APRT", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUCY1B1", "combined_score": 0.737, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE2A", "combined_score": 0.865, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "ITPA", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "APRT", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "GUK1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE6G", "protein_b": "PDE5A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUCY1B1", "combined_score": 0.82, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GMPS", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "APRT", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "ITPA", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDE2A", "protein_b": "PDE5A", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUCY1B1", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GMPS", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ITPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "GUK1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "APRT", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "PDE5A", "protein_b": "ALDH7A1", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "ITPA", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "APRT", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "GUK1", "protein_b": "GMPS", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "ITPA", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "APRT", "protein_b": "GMPS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GUCY1B1", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "ITPA", "protein_b": "GMPS", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "CCR1", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "PTAFR", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TLR4", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "STAT1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "PTAFR", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "ARRB1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "CCR1", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "TLR4", "combined_score": 0.725, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "PTAFR", "combined_score": 0.755, "interaction_type": "physical"}, {"protein_a": "CCR1", "protein_b": "ARRB1", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "PTAFR", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TLR4", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "STAT1", "protein_b": "TYK2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "PTAFR", "combined_score": 0.723, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "FPR2", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GPR135", "protein_b": "PTAFR", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "ARRB1", "protein_b": "PTAFR", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "TYK2", "protein_b": "PTAFR", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "PECAM1", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "PTAFR", "protein_b": "FPR2", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "CACNA1C", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "SCN5A", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNH2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNJ2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNQ1", "protein_b": "KCNE1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "CACNA1C", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE2", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNE1", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "SCN5A", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "KCNJ2", "protein_b": "KCNH2", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSPA4", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNH6", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "CACNA1C", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "HSP90AA1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "SCN5A", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KCNH2", "protein_b": "KCNE2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE3", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE1", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "KCNE2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "KCNE3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "KCNE2", "protein_b": "SCN5A", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HSPA4", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "SCN5A", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "KCNE3", "protein_b": "KCNE1", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "SCN5A", "protein_b": "KCNE1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP8", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "GSDMD", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "IL1B", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP6", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "PYCARD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MEFV", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "GSDMD", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "IL1B", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP8", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP6", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PYCARD", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP6", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "AIM2", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRC4", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "GSDMD", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP8", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "NLRP3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "GSDMD", "combined_score": 0.91, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP6", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP8", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "GSDMD", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "AIM2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRP3", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRP1", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "GSDMD", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "NLRC4", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CASP8", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "GSDMD", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRC4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AIM2", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "GSDMD", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NLRC4", "protein_b": "CASP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "GSDMD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CASP1", "protein_b": "NLRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GSDMD", "protein_b": "NLRP1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINB4", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA3", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "MMP9", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "MMP9", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "MMP9", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "MMP9", "combined_score": 0.789, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "ELANE", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "SERPINA3", "protein_b": "ELANE", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SERPINA1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "SLPI", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "DEFA4", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "BPI", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "CAMP", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "AZU1", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "PRTN3", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "LTF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MPO", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "SERPINA1", "combined_score": 0.753, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "DEFA4", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "CAMP", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "BPI", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "LTF", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "AZU1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MPO", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "DEFA4", "combined_score": 0.731, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "SLPI", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "AZU1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "BPI", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "CAMP", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "PRTN3", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "LTF", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "CAMP", "combined_score": 0.765, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "DEFA4", "combined_score": 0.855, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "BPI", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "PRTN3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AZU1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "DEFA4", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "SERPINA1", "combined_score": 0.838, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "BPI", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "CAMP", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "PRTN3", "protein_b": "ELANE", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "DEFA4", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "CAMP", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "BPI", "protein_b": "ELANE", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "DEFA4", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "CAMP", "protein_b": "ELANE", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "DEFA4", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SLPI", "protein_b": "ELANE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SERPINA1", "protein_b": "ELANE", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "STAT3", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "IL1B", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP2", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "IL1B", "combined_score": 0.745, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "STAT3", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP9", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP1", "combined_score": 0.93, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "MMP7", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "MMP2", "protein_b": "TIMP2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "IL1B", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP3", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP1", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "MMP9", "combined_score": 0.883, "interaction_type": "physical"}, {"protein_a": "MMP7", "protein_b": "TIMP2", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP3", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP3", "combined_score": 0.832, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "STAT3", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "IL1B", "protein_b": "MMP9", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP1", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP9", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "MMP3", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP9", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "MMP3", "protein_b": "MMP1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "MMP1", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "BSG", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "BSG", "protein_b": "MMP9", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "CTSG", "protein_b": "MMP9", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "THBS1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "LCN2", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP9", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TIMP1", "protein_b": "MMP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "CD44", "combined_score": 0.767, "interaction_type": "physical"}, {"protein_a": "THBS1", "protein_b": "MMP9", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "TIMP3", "combined_score": 0.923, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP1", "combined_score": 0.936, "interaction_type": "physical"}, {"protein_a": "TIMP2", "protein_b": "MMP9", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "TIMP3", "protein_b": "MMP9", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "ELN", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "MMP1", "protein_b": "MMP9", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DMP1", "protein_b": "MMP9", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "CD44", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ELN", "protein_b": "MMP9", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MMP9", "protein_b": "LCN2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCG", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCD", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCB", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PLCG1", "protein_b": "PRKCA", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PICK1", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "NCF1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "MTOR", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCB", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "PRKCG", "protein_b": "PRKCA", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "NCF1", "protein_b": "PRKCB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCB", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "PRKCD", "protein_b": "PRKCA", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "PLD1", "protein_b": "PRKCA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCB", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "MTOR", "protein_b": "PRKCA", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "SDC4", "protein_b": "PRKCA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PICK1", "protein_b": "PRKCA", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "PRKCB", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "PRKCA", "protein_b": "RACK1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "RACK1", "protein_b": "PRKCB", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB2", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ARRB1", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "FOS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK3", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "FOS", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "MAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAPK3", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "RPS6KA1", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB1", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "PTPN7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "FOS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "ARRB2", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK3", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "FOS", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB1", "combined_score": 0.875, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "ARRB2", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "FOS", "protein_b": "RPS6KA1", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "STAT3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PTPN7", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "PEA15", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "RPS6KA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MKNK1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "MAP2K2", "protein_b": "MAP2K1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "STAT3", "protein_b": "JUN", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K1", "protein_b": "JUN", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPKAPK2", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "ATF2", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAP2K3", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "MAPK14", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "DUSP1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "TP53", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK1", "protein_b": "JUN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAP2K3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TAB1", "protein_b": "MAPK14", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "JUN", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "TP53", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K6", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "DUSP1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "ATF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAP2K3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "MAPK14", "protein_b": "MAPKAPK2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "ATF2", "combined_score": 0.739, "interaction_type": "physical"}, {"protein_a": "DUSP1", "protein_b": "JUN", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "TP53", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "ATF2", "protein_b": "JUN", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "MAP2K3", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "TP53", "protein_b": "JUN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAPKAPK3", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "JUN", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAP2K3", "protein_b": "MAP2K6", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAP2K6", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "MAPKAPK2", "protein_b": "MAPKAPK3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "RCAN1", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3R2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML6", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML3", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML5", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALM3", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "CALML4", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "NFATC1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PPP3R1", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "RCAN1", "combined_score": 0.775, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CB", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "CALML6", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CALM3", "protein_b": "PPP3CA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "RCAN1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3R2", "combined_score": 0.831, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML4", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML3", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "CALML5", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CB", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CALML6", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3R2", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML4", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "CALML5", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CB", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CALML3", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3R2", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "RCAN1", "combined_score": 0.749, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "NFATC1", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "CALML4", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CB", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CALML5", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "CALML4", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "NFATC1", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CB", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "RCAN1", "protein_b": "PPP3CA", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "NFATC1", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "CALML4", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CB", "protein_b": "PPP3CA", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "PPP3R2", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "CALML4", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "PPP3CA", "protein_b": "NFATC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "CALML4", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "NFATC1", "protein_b": "PPP3R2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "CALML4", "protein_b": "PPP3R2", "combined_score": 0.827, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB3", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGF", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "ERBB2", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "DCN", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EREG", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "ERBB3", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGF", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HBEGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB2", "combined_score": 0.86, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGF", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "ERBB3", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "EREG", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGF", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB3", "combined_score": 0.856, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "ERBB2", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CDH1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGF", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "PIK3CA", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB3", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "ERBB2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GAB1", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGF", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "CBL", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB2", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "ERBB3", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PIK3CA", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB3", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGF", "combined_score": 0.859, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "ERBB2", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "PTK2", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LCK", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "LYN", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SHC1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CBL", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "FYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "GP6", "protein_b": "LYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LCK", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "LYN", "combined_score": 0.751, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SHC1", "combined_score": 0.795, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "FYN", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CAV1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "FYN", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "PTK2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SHC1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "DLG4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SH2D1A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SH2D1A", "protein_b": "LCK", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LCK", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "DLG4", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "LYN", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LCK", "combined_score": 0.746, "interaction_type": "physical"}, {"protein_a": "SHC1", "protein_b": "LYN", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "HSP90AA1", "combined_score": 0.76, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SRC", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "CD44", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "SHC1", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "NRG1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "GRB2", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGF", "protein_b": "ERBB3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "HSP90AA1", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SRC", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB3", "protein_b": "ERBB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "EGFR", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "CD44", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB2", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "ERBB4", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "CD44", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "NRG1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "HSP90AA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "EGFR", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SHC1", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "GRB2", "combined_score": 0.784, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "SRC", "combined_score": 0.791, "interaction_type": "physical"}, {"protein_a": "NRG1", "protein_b": "ERBB4", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "CD44", "combined_score": 0.779, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "ERBB4", "combined_score": 0.809, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "GRB2", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "HSP90AA1", "protein_b": "SRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "CD44", "combined_score": 0.72, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SRC", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ERBB4", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "CD44", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SRC", "protein_b": "GRB2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GRB2", "protein_b": "SHC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "VAV1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCP2", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD28", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SYK", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD247", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "ZAP70", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD8A", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD28", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "PTPRC", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "CD247", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "SYK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LCP2", "protein_b": "ZAP70", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "PTPRC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD28", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "SYK", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD8A", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "FYN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "CD247", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ZAP70", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "PTPRC", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "FYN", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "VAV1", "combined_score": 0.879, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD8A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "CD247", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD28", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "VAV1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD8A", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "SYK", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "CD247", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "PTPRC", "combined_score": 0.881, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "VAV1", "combined_score": 0.887, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "LCK", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "SYK", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CD247", "protein_b": "CD8A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "PTPRC", "combined_score": 0.772, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "CD8A", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "LCK", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "SYK", "protein_b": "VAV1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "PTPRC", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CD8A", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "VAV1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VAV1", "protein_b": "LCK", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LYN", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "SPN", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "DPP4", "combined_score": 0.774, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "CD22", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "FYN", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "PTPRC", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CD4", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "SPN", "combined_score": 0.704, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "LYN", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CD22", "protein_b": "PTPRC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "SPN", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "LGALS3", "protein_b": "PTPRC", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "LCK", "combined_score": 0.88, "interaction_type": "physical"}, {"protein_a": "PTPRCAP", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "PTPRC", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LYN", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "FYN", "protein_b": "LCK", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "DPP4", "protein_b": "PTPRC", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CD47", "protein_b": "PTPRC", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LYN", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "SPN", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "PTPRC", "protein_b": "LCK", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "LYN", "protein_b": "LCK", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GRM2", "combined_score": 0.783, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GRM2", "protein_b": "HTR2A", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2C", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2B", "combined_score": 0.891, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1F", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1S", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1F", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1S", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1F", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1S", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1S", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "CACNA1F", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "HTR2A", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "CACNA1S", "protein_b": "CACNA1F", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "CACNA1F", "protein_b": "HTR2A", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAS", "combined_score": 0.702, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2C", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "HTR2B", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNG2", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNB1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNG2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNB1", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "SLC6A4", "combined_score": 0.872, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1D", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "CACNA1C", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2A", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "HTR2C", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "HTR2B", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2C", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "GNG2", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2C", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "HTR2A", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CACNA1C", "protein_b": "CACNA1D", "combined_score": 0.981, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "CACNA1D", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNG2", "combined_score": 0.941, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNB1", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAS", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "HTR2A", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "HTR2C", "protein_b": "GNAQ", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNAS", "combined_score": 0.717, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNG2", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "HTR2A", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNB1", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "CACNA1D", "protein_b": "HTR2A", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "HTR2A", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "HTR2A", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "HTR2A", "combined_score": 0.824, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "FSHB", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "POMC", "combined_score": 0.888, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "HTR6", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "TSHB", "protein_b": "GNAS", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GIP", "combined_score": 0.9, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "NPPA", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "FSHB", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GCG", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "ADCYAP1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "VIP", "combined_score": 0.916, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "POMC", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "HTR7", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "HTR6", "protein_b": "GNAS", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "HTR7", "protein_b": "GNAS", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GNAS", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "VIP", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GIP", "protein_b": "GCG", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "POMC", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "POMC", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GCG", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "ADCYAP1", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "FSHB", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "POMC", "protein_b": "GCG", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "GCG", "protein_b": "ADCYAP1", "combined_score": 0.836, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "TPH1", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "BDNF", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "MAOA", "combined_score": 0.892, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "COMT", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "DRD4", "protein_b": "SLC6A4", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "STX1A", "protein_b": "SLC6A4", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "MAOA", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR1B", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "HTR2A", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "SLC6A4", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TPH1", "protein_b": "TPH2", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "BDNF", "combined_score": 0.922, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "TPH2", "combined_score": 0.925, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1B", "combined_score": 0.932, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "MAOA", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "COMT", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR2A", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SLC6A4", "protein_b": "HTR1A", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "BDNF", "combined_score": 0.816, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "MAOA", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR1B", "combined_score": 0.914, "interaction_type": "physical"}, {"protein_a": "HTR1A", "protein_b": "HTR2A", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR2A", "combined_score": 0.762, "interaction_type": "physical"}, {"protein_a": "TPH2", "protein_b": "HTR1B", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR1B", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "BDNF", "combined_score": 0.741, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "HTR2A", "combined_score": 0.786, "interaction_type": "physical"}, {"protein_a": "MAOA", "protein_b": "COMT", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "HTR2A", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "COMT", "protein_b": "BDNF", "combined_score": 0.919, "interaction_type": "physical"}, {"protein_a": "HTR1B", "protein_b": "HTR2A", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "BDNF", "protein_b": "HTR2A", "combined_score": 0.89, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SIGMAR1", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "ERG28", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "MSMO1", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "CYP51A1", "protein_b": "SQLE", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TMEM97", "protein_b": "SIGMAR1", "combined_score": 0.943, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SQLE", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "SIGMAR1", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "ERG28", "protein_b": "MSMO1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SIGMAR1", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "MSMO1", "protein_b": "SQLE", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "SQLE", "protein_b": "SIGMAR1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNA4", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR3", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "ITPR1", "combined_score": 0.938, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "KCNH6", "combined_score": 0.944, "interaction_type": "physical"}, {"protein_a": "SIGMAR1", "protein_b": "HSPA5", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "HSPA5", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "ITPR1", "protein_b": "ITPR3", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "HSPA5", "protein_b": "ITPR3", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "KCNA4", "protein_b": "KCNH6", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TAC1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "NTS", "combined_score": 0.843, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "TACR1", "combined_score": 0.874, "interaction_type": "physical"}, {"protein_a": "NALCN", "protein_b": "UNC80", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC3", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "UNC80", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TACR1", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NTS", "protein_b": "TAC1", "combined_score": 0.982, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "UNC80", "combined_score": 0.854, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNAS", "combined_score": 0.905, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "GNB1", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "ARRB2", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC4", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC3", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "TACR1", "protein_b": "TAC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "ARRB1", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "UNC80", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "ARRB2", "protein_b": "ARRB1", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "TACR2", "combined_score": 0.708, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC4", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "TAC1", "protein_b": "TACR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TAC3", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "CHKB", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "TAC4", "protein_b": "TACR2", "combined_score": 0.931, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "CHKB", "combined_score": 0.761, "interaction_type": "physical"}, {"protein_a": "TACR2", "protein_b": "TAC3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "CHKB", "protein_b": "TAC3", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "TBXAS1", "combined_score": 0.864, "interaction_type": "physical"}, {"protein_a": "PTGIS", "protein_b": "PTGS1", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "PTGS1", "protein_b": "TBXAS1", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "TBXAS1", "protein_b": "MGAM2", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT2", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "ANGPT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FLT1", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PDGFC", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "FGF2", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "NRP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "KDR", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "PGF", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT1", "combined_score": 0.822, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "VEGFC", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "ANGPT2", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "NRP1", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "FGF2", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PDGFC", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFD", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFC", "combined_score": 0.904, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "FLT1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "VEGFB", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "NRP1", "protein_b": "PGF", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT2", "combined_score": 0.983, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "ANGPT1", "combined_score": 0.984, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PDGFC", "combined_score": 0.989, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFC", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFB", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "PGF", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FLT1", "protein_b": "VEGFD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "ANGPT2", "combined_score": 0.743, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "PGF", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "VEGFD", "protein_b": "VEGFB", "combined_score": 0.987, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT2", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "ANGPT1", "combined_score": 0.712, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PDGFC", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "PGF", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "VEGFB", "protein_b": "VEGFC", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "VEGFC", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "PGF", "combined_score": 0.84, "interaction_type": "physical"}, {"protein_a": "ANGPT2", "protein_b": "ANGPT1", "combined_score": 0.92, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "PGF", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "PDGFC", "protein_b": "VEGFC", "combined_score": 0.876, "interaction_type": "physical"}, {"protein_a": "ANGPT1", "protein_b": "PGF", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "PGF", "protein_b": "VEGFC", "combined_score": 0.77, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR2", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIPR1", "combined_score": 0.894, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNB1", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNG2", "combined_score": 0.895, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "GNAS", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "ADCYAP1", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "SCT", "protein_b": "VIP", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "WASL", "protein_b": "VIPR1", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR2", "combined_score": 0.736, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNB1", "combined_score": 0.8, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNG2", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "VIPR1", "combined_score": 0.942, "interaction_type": "physical"}, {"protein_a": "RAMP2", "protein_b": "GNAS", "combined_score": 0.99, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNB1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIPR1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "GNAS", "combined_score": 0.994, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR2", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNG2", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNB1", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "GNAS", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ATG5", "combined_score": 0.988, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "ADCYAP1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIPR1", "protein_b": "VIP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "ADCYAP1", "combined_score": 0.901, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNAS", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "GNG2", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "VIP", "protein_b": "ADCYAP1", "combined_score": 0.732, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "ADCYAP1", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "GNAS", "protein_b": "GNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNB1", "protein_b": "ADCYAP1", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA14", "combined_score": 0.703, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNA12", "combined_score": 0.724, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1B", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA11", "protein_b": "GNAQ", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR2", "combined_score": 0.777, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1B", "combined_score": 0.896, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVP", "combined_score": 0.959, "interaction_type": "physical"}, {"protein_a": "OXT", "protein_b": "AVPR1A", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR2", "combined_score": 0.757, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNAQ", "combined_score": 0.81, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1B", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "AVPR1A", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "GNA12", "protein_b": "GNA13", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA14", "combined_score": 0.719, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "GNA13", "combined_score": 0.893, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1B", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "GNAQ", "protein_b": "AVPR1A", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA14", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "GNA13", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR1B", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVPR2", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "VIP", "combined_score": 0.997, "interaction_type": "physical"}, {"protein_a": "AVPR1A", "protein_b": "AVP", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "GNA13", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVPR2", "combined_score": 0.939, "interaction_type": "physical"}, {"protein_a": "AVPR1B", "protein_b": "AVP", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "AVP", "protein_b": "AVPR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "GNA13", "protein_b": "AVPR2", "combined_score": 0.742, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP8B1", "combined_score": 0.825, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR0B2", "combined_score": 0.866, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "FABP6", "combined_score": 0.867, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "NR1H4", "combined_score": 0.878, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCB11", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ATP8B1", "combined_score": 0.799, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "FABP6", "combined_score": 0.853, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "ABCB11", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1I2", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP8B1", "combined_score": 0.958, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "CYP7A1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "NR0B2", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCB11", "combined_score": 0.862, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCB11", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "FABP6", "combined_score": 0.835, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "ABCB11", "combined_score": 0.934, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1H4", "combined_score": 0.986, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "ABCB11", "combined_score": 0.826, "interaction_type": "physical"}, {"protein_a": "CYP8B1", "protein_b": "NR1H4", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "FABP6", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "NR1I2", "protein_b": "ABCB11", "combined_score": 0.839, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCB11", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "NR1H4", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ATP8B1", "combined_score": 0.85, "interaction_type": "physical"}, {"protein_a": "NR1H4", "protein_b": "ABCB11", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "ATP8B1", "protein_b": "ABCB11", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "CRY1", "protein_b": "ABCC2", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC2", "combined_score": 0.792, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT2B7", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "UGT1A6", "combined_score": 0.803, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "SLC22A8", "combined_score": 0.83, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC2", "combined_score": 0.842, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCG2", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCG2", "combined_score": 0.79, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC2", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "SLC22A8", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "UGT1A6", "protein_b": "ABCC2", "combined_score": 0.844, "interaction_type": "physical"}, {"protein_a": "UGT2B7", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCG2", "combined_score": 0.808, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC2", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCG2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC2", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "RDX", "protein_b": "ABCC2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC2", "protein_b": "ABCG2", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO2B1", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "ABCC3", "combined_score": 0.748, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51A", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLC51B", "combined_score": 0.802, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B3", "combined_score": 0.869, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1B1", "combined_score": 0.886, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "CYP7A1", "combined_score": 0.909, "interaction_type": "physical"}, {"protein_a": "SLC10A1", "protein_b": "SLCO1A2", "combined_score": 0.933, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC3", "combined_score": 0.769, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "ABCC3", "combined_score": 0.764, "interaction_type": "physical"}, {"protein_a": "SLCO1B1", "protein_b": "NR1I2", "combined_score": 0.852, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "ABCC3", "combined_score": 0.73, "interaction_type": "physical"}, {"protein_a": "SLCO1B3", "protein_b": "NR1I2", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "NR1I2", "combined_score": 0.718, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO1A2", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLCO2B1", "combined_score": 0.728, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "CYP7A1", "combined_score": 0.778, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51B", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "ABCC3", "protein_b": "SLC51A", "combined_score": 0.913, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "CYP7A1", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "SLC51A", "protein_b": "SLC51B", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLCO1A2", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "SLC51B", "combined_score": 0.841, "interaction_type": "physical"}, {"protein_a": "CYP7A1", "protein_b": "NR1I2", "combined_score": 0.849, "interaction_type": "physical"}, {"protein_a": "MRPS7", "protein_b": "ABCC4", "combined_score": 0.948, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "ABCC4", "combined_score": 0.771, "interaction_type": "physical"}, {"protein_a": "SLC9A3R1", "protein_b": "PDZK1", "combined_score": 0.861, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "PDZK1", "combined_score": 0.819, "interaction_type": "physical"}, {"protein_a": "SLC22A11", "protein_b": "ABCC4", "combined_score": 0.828, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A6", "combined_score": 0.798, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "ABCC4", "combined_score": 0.806, "interaction_type": "physical"}, {"protein_a": "SLC22A8", "protein_b": "SLC22A7", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "ABCC4", "combined_score": 0.805, "interaction_type": "physical"}, {"protein_a": "PDZK1", "protein_b": "SLC22A12", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "SLC22A7", "protein_b": "ABCC4", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "SLC22A12", "protein_b": "ABCC4", "combined_score": 0.768, "interaction_type": "physical"}, {"protein_a": "SLC22A6", "protein_b": "ABCC4", "combined_score": 0.734, "interaction_type": "physical"}, {"protein_a": "FABP6", "protein_b": "ABCC4", "combined_score": 0.733, "interaction_type": "physical"}, {"protein_a": "SNX27", "protein_b": "ABCC4", "combined_score": 0.799, "interaction_type": "physical"}], "network_features": {"avg_degree": 10.53, "clustering_coefficient": 5.26}}, "failure_enrichment": {"aact_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "aact_documents": [], "pubmed_results": [{"pmid": "41231348", "title": "Busulfan and melphalan (Bu-Mel) versus carboplatin, etoposide, and melphalan (CEM) conditioning regimens for autologous haematopoietic stem cell transplant in children and young adults with high-risk neuroblastoma.", "authors": [{"name": "Gupta AK", "authtype": "Author", "clusterid": ""}, {"name": "Meena JP", "authtype": "Author", "clusterid": ""}, {"name": "Bansal S", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41152998", "title": "Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study.", "authors": [{"name": "Alomari N", "authtype": "Author", "clusterid": ""}, {"name": "Kurdi A", "authtype": "Author", "clusterid": ""}, {"name": "Alghamdi M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41016399", "title": "Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.", "authors": [{"name": "Henderson TO", "authtype": "Author", "clusterid": ""}, {"name": "Bardwell JK", "authtype": "Author", "clusterid": ""}, {"name": "Kao PC", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40949119", "title": "Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation.", "authors": [{"name": "Cao D", "authtype": "Author", "clusterid": ""}, {"name": "Qian X", "authtype": "Author", "clusterid": ""}, {"name": "Wang P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "40901473", "title": "Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.", "authors": [{"name": "Wei Y", "authtype": "Author", "clusterid": ""}, {"name": "Luan S", "authtype": "Author", "clusterid": ""}, {"name": "Wang L", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.", "detailed_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "EXPERIMENTAL", "description": "Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the \u03b3c gene gene (CL20-i4-EF1\u03b1-h\u03b3c-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "intervention_names": ["Genetic: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "Drug: Busulfan", "Device: CliniMacs"]}], "interventions": [{"type": "GENETIC", "name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT", "description": "Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human \u03b3c gene.", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "Given intravenously (IV).", "arm_group_labels": ["Treatment"]}, {"type": "DEVICE", "name": "CliniMacs", "description": "Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT01512888+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+Busulfan+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Busulfan by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Busulfan by St. Jude Children's Research Hospital.\n\nFirst, I need to identify which results are relevant to:\n1. FDA warning letters related to Busulfan\n2. Clinical holds related to Busulfan\n3. Specifically from or involving St. Jude Children's Research Hospital\n\nLet's go through each search result:\n\nResult [1]: This is about an FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital), related to ICD leads (medical devices), not Busulfan. This is not relevant to our query.\n\nResult [2]: This appears to be a PDF about treosulfan (not busulfan), which is a different drug. Not relevant.\n\nResult [3]: This is about a clinical trial using busulfan/melphalan for pediatric neuroblastoma at St. Jude. It describes the busulfan dosing regimen and toxicity monitoring, but doesn't mention any FDA warning letters or clinical holds.\n\nResult [4]: This is St. Jude's patient information about busulfan for children and adolescents, listing possible side effects. No mention of FDA warning letters or clinical holds.\n\nResult [5]: This shows busulfan has an orphan drug designation for \"Preparative therapy for pediatric patients undergoing bone marrow transplantation\" from 11/25/2002, but it's noted as \"Not FDA Approved for Orphan Indication.\" No warning letters or clinical holds mentioned.\n\nResult [6]: General FDA cancer drug safety warnings, but nothing specific to busulfan or St. Jude.\n\nResult [7]: This is about gene therapy for SCID at St. Jude, which mentions busulfan as part of the treatment protocol (\"the therapy included the first use in SCID of a chemotherapy drug called busulfan\"). However, it doesn't mention any FDA warning letters or clinical holds related to busulfan.\n\nResult [8]: General review of therapies for pediatric leukemia, no specific mention of busulfan issues or FDA actions.\n\nResult [9]: Appears to be about a different drug (TEVIMBRA) and unrelated to busulfan.\n\nResult [10]: Shows busulfan has an orphan drug designation from 04/21/1994 for \"use as preparative therapy for malignancies treated with bone marrow transplantation.\" No warning letters", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT01512888 for Busulfan. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital regarding clinical trial NCT01512888 for Busulfan, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify which results are relevant to the query:\n\n1. Result [1] - CIRM page about the lentiviral gene therapy for X-linked SCID. Mentions NCT01512888 and St. Jude partnering with UCSF, but doesn't provide specific safety information or press releases.\n\n2. Result [2] - Mustang Bio 10-K filing. Contains some relevant information:\n   - Mentions MB-107 (which appears to be related to the NCT01512888 trial)\n   - In January 2021, they received FDA approval to initiate a pivotal Phase 2 trial of MB-107 for XSCID in infants under age 2\n   - In January 2022, FDA issued a clinical hold on their IND application for MB-207 (a different product for previously transplanted XSCID patients)\n   - Mentions that \"In 2022, the NIH study was suspended as a result of the study stopping rules\"\n   - This is from Mustang Bio's perspective, not directly from St. Jude\n\n3. Result [3] - ClinicalTrials.gov page for NCT01512888. Provides details about the study design, including:\n   - Monitoring for hematopoietic recovery from busulfan and severe adverse events for 42 days post gene therapy\n   - Study involves busulfan conditioning\n   - But doesn't provide specific safety outcomes or press releases\n\n4. Result [4] - Mustang Bio annual report. Contains similar information to result [2]:\n   - Mentions partnership with St. Jude on ex vivo lentiviral treatment of X-linked SCID\n   - References two Phase 1/2 clinical trials: MB-107 (multicenter trial in newly diagnosed infants sponsored by St. Jude) and MB-207 (single-center trial in previously transplanted patients sponsored by NIH)\n   - States \"In 2022, the NIH study was suspended as a result of", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT01512888", "drug_name": "Busulfan"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a voluntary hold, which suggests there were safety concerns or adverse events that led to the suspension of the study. The detailed description does not mention any lack of efficacy or administrative issues, but rather states that the study was evaluating the \"safety, feasibility and efficacy\" of the gene transfer approach. Therefore, the available evidence points to a safety-related failure as the reason for the trial suspension.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:20.188602", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1251}}, "85": {"nct_id": "NCT01512888", "drug_name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT", "intervention_type": "GENETIC", "drug_description": "Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human \u03b3c gene.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "voluntary hold", "title": "Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants", "start_date": "2016-08-17", "completion_date": "2034-08-31", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.567005", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:20.227693", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "aact_documents": [], "pubmed_results": [{"pmid": "30995372", "title": "Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.", "authors": [{"name": "Mamcarz E", "authtype": "Author", "clusterid": ""}, {"name": "Zhou S", "authtype": "Author", "clusterid": ""}, {"name": "Lockey T", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": false, "brief_summary": "SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.", "detailed_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "EXPERIMENTAL", "description": "Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the \u03b3c gene gene (CL20-i4-EF1\u03b1-h\u03b3c-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "intervention_names": ["Genetic: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "Drug: Busulfan", "Device: CliniMacs"]}], "interventions": [{"type": "GENETIC", "name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT", "description": "Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human \u03b3c gene.", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "Given intravenously (IV).", "arm_group_labels": ["Treatment"]}, {"type": "DEVICE", "name": "CliniMacs", "description": "Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT01512888+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+CL20-i4-EF1\u03b1-h\u03b3c-OPT+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CL20-i4-EF1\u03b1-h\u03b3c-OPT by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for CL20-i4-EF1\u03b1-h\u03b3c-OPT by St. Jude Children's Research Hospital.\n\nFirst, I need to identify which results are relevant to the query:\n\n1. Result [1] mentions NCT01512888 and \"A Notice of Noncompliance indicates that the FDA has determined...\" which suggests there might be an FDA warning or noncompliance notice related to this trial. The trial appears to involve \"CL20-i4-EF1\u03b1-h\u03b3c-OPT\" expressing a \u03b3c gene.\n\n2. Result [2] is about an FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital), related to ICD leads. This seems unrelated to gene therapy or CL20-i4-EF1\u03b1-h\u03b3c-OPT.\n\n3. Result [3] is about the CL20i4-EF1\u03b1-h\u03b3cOPT vector for SCID-X1 gene therapy, discussing its preclinical safety and efficacy. It doesn't mention any FDA warning letters or clinical holds.\n\n4. Result [4] is another article about an FDA warning letter to St. Jude Medical (again, not St. Jude Children's Research Hospital), related to manufacturing issues at a California plant. This is about medical devices (ICD leads), not gene therapy.\n\n5. Result [5] is a gene therapy clinical trial browser, but doesn't seem to contain specific information about FDA warnings for the CL20-i4-EF1\u03b1-h\u03b3c-OPT vector.\n\n6. Result [6] provides details about NCT01512888, \"Gene Transfer for X-Linked Severe Combined Immunodeficiency (SCID-X1)\". It mentions the CL20-i4-EF1\u03b1-h\u03b3c-OPT vector and has a note about \"Violation: Shown when the FDA issues a Notice of Noncompliance and posts the Notice of Noncompliance on its designated webpage.\"\n\n7. Result [7] mentions NCT01512888 in relation to the CL20-i4-EF1\u03b1-h\u03b3c-OPT vector, but doesn't discuss any FDA warnings.\n\n8. Result [8] mentions NCT01306019 and has a similar \"Violation\" note as in result [", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT01512888 for CL20-i4-EF1\u03b1-h\u03b3c-OPT. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital regarding clinical trial NCT01512888 (Gene Transfer for X-Linked Severe Combined Immunodeficiency).\n\nFirst, I need to identify which search results contain press releases, investor presentations, or public statements from St. Jude about this specific trial, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLooking at the search results:\n\nResult [1]: This is a ClinicalTrials.gov page describing the study details, objectives, and eligibility criteria. It's not a press release or public statement from St. Jude.\n\nResult [2]: This is from CIRM (California Institute for Regenerative Medicine) and mentions that the trial status is \"Suspended\" with a targeted enrollment of 28. This is relevant information about the trial status.\n\nResult [3]: This is from UCSF Clinical Trials and provides details about the study, including that it's a Phase 1/2 research study with St. Jude as the sponsor. It mentions the status as \"currently not accepting new patients, but might later.\"\n\nResult [4]: This is a press release from Mustang Bio (not St. Jude) dated when? The press release mentions that St. Jude published results of the lentiviral gene therapy trial in the New England Journal of Medicine. It states: \"This Phase 1/2 trial in newly diagnosed infants with XSCID continues to enroll at St. Jude, UCSF Benioff Children's Hospital and Seattle Children's Hospital.\" It also quotes Dr. Mamcarz saying \"The results have been very good thus far. We've been able to restore a full immune system pretty quickly... All of these patients were able to come off of isolation and they've returned home with immune systems that were fully functional.\" This suggests positive safety and efficacy results at the time of the press release.\n\nResult [5]: This is from Bio-protocol and mentions that human samples were obtained from the SCID-X1 clinical study (NCT01512888), which was approved by the FDA and institutional review boards at St. Jude and UCSF. It mentions 10 consecutive patients who received their stem cell product.\n\nResult [6]: This is from St. Jude's website describing the LVXSCID-ND clinical trial (which appears to", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT01512888", "drug_name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a voluntary hold, which suggests there were safety concerns or adverse events that led to the suspension of the study. The detailed description does not mention any lack of efficacy or administrative issues, but rather states that the study was evaluating the \"safety, feasibility and efficacy\" of the gene transfer approach. Therefore, the available evidence points to a safety-related failure as the reason for the trial suspension.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:20.188602", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1251}}, "86": {"nct_id": "NCT01512888", "drug_name": "CliniMacs", "intervention_type": "DEVICE", "drug_description": "Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.", "phase": "PHASE1/PHASE2", "overall_status": "SUSPENDED", "why_stopped": "voluntary hold", "title": "Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants", "start_date": "2016-08-17", "completion_date": "2034-08-31", "sponsor": "St. Jude Children's Research Hospital", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.567604", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:20.263567", "retry_count": 0}, "chembl_enrichment": {"found": false, "chembl_id": null, "targets": [], "search_name": "CliniMacs"}, "ppi_enrichment": {"uniprot_count": 0, "interactions": []}, "failure_enrichment": {"aact_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "aact_documents": [], "pubmed_results": [], "clinicaltrials_api": {"has_results": false, "brief_summary": "SCID-X1 is a genetic disorder of blood cells caused by DNA changes in a gene that is required for the normal development of the human immune system. The purpose of this study is to determine if a new method, called lentiviral gene transfer, can be used to treat SCID-X1. This method involves transferring a normal copy of the common gamma chain gene into the participant's bone marrow stem cells. The investigators want to determine if the procedure is safe, whether it can be done according to the methods they have developed, and whether the procedure will provide a normal immune system for the patient. It is hoped that this type of gene transfer may offer a new way to treat children with SCID-X1 that do not have a brother or sister who can be used as a donor for stem cell transplantation.", "detailed_description": "Bone marrow CD34+ cells will be obtained in the operating room, transduced with the lentiviral vector that contains a normal copy of the \u03b3c gene, and reinfused without any myeloreductive conditioning. Participants will be monitored for hematopoietic recovery from busulfan and for severe adverse events for 42 days post gene therapy. The primary endpoint assessing the efficacy of this approach will be T-cell immune reconstitution 52 weeks (\u00b1 4) weeks after transplantation. Continued and detailed evaluation of all aspects of immune reconstitution, protocol-related toxicity, and retroviral integration sites will also be performed. This study will evaluate the first use of a SIN lentiviral vector for the treatment of SCID-X1 and may lead to a new form of therapy that could be applied to the majority of newly diagnosed patients.\n\nOBJECTIVES\n\nAssess the safety, feasibility and efficacy of lentiviral gene transfer in newly diagnosed SCID-X1 patients transplanted with autologous CD34+ cells that have been transduced with a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT) expressing a \u03b3c gene.\n\nPrimary Objective 1: Evaluate the safety and feasibility of infusing at least 1 million transduced CD34+ cells per kilogram of body weight in SCID-X1 infants.\n\nPrimary Objective 2: Evaluate the efficacy of lentiviral gene transfer for inducing significant T-cell reconstitution 52 weeks (\u00b1 4 weeks) after transplantation. Significant reconstitution of T cells is defined as at least 2 of the following 3 criteria being present:\n\n* The development of T-cell proliferative responses to phytohemagglutinin (PHA) that are \u2265 50% the value seen in normal controls\n* \u2265 1000 autologous CD3+ T-cells/\u03bcl in the peripheral blood\n* \u2265 500 autologous CD4+ T-cells/\u03bcl in the peripheral blood\n* \u2265 200 autologous CD4+ CD45RA T-cells/\u03bcl in the peripheral blood\n\nOTHER PRE-SPECIFIED OBJECTIVES:\n\n* Correlate busulfan and its metabolite pharmacokinetics with toxicity, efficacy, engraftment of vector-transduced cells, and event-free survival and overall survival.\n* Evaluate the efficacy of busulfan dose-targeting with busulfan administration every 24 hours for a total of 2 doses in order to achieve a cumulative busulfan area under the curve of 22 mg\\*hr/L.\n* Evaluate B-cell function during longterm follow-up of protocol patients. Evaluation will include \u03b3c expression in circulating B-cells, measurement of serum IgG, IgA, and IgM concentration, measurement of antibody responses to vaccination, evaluation of IgG production after cessation of intravenous gamma globulin therapy in patients with clinical indications to discontinue IVIG.\n* Evaluate NK cell numbers in long term follow-up of protocol patients. Evaluation will include flow cytometry evaluation of NK cell numbers.\n* Determine the vector copy number and the location of vector-integration sites in sorted blood cells. Sorted T-cells, B-cells, NK cells, granulocytes and monocytes will be evaluated for vector copy number. Vector copy number in sorted T-cells will be evaluated as a potential safety measure and will be reported to the FDA if the vector copy number is greater than 5 copies per T cell in any patient at any time. Studies on sorted cells will also include deep sequencing with an automated sequencer to characterize insertion sites, and expression array analysis of T-cell clones to assay for gene expression alterations within 100 kb of the insertion sites.\n* Evaluate the overall, long-term safety of lentiviral gene transfer. This will include complete clinical evaluation of any AEs resulting from the gene transfer procedure. If any oncogenic event is seen, this evaluation will include complete molecular characterization of the tumor clone including insertion site analysis, gene expression analysis, and evaluation for the LMO2, Cdkn2a, Notch1, Cyclin D2 gene alterations.", "adverse_events": {"found": false}, "dose_info": {"found": true, "arms": [{"label": "Treatment", "type": "EXPERIMENTAL", "description": "Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the \u03b3c gene gene (CL20-i4-EF1\u03b1-h\u03b3c-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "intervention_names": ["Genetic: CL20-i4-EF1\u03b1-h\u03b3c-OPT", "Drug: Busulfan", "Device: CliniMacs"]}], "interventions": [{"type": "GENETIC", "name": "CL20-i4-EF1\u03b1-h\u03b3c-OPT", "description": "Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human \u03b3c gene.", "arm_group_labels": ["Treatment"]}, {"type": "DRUG", "name": "Busulfan", "description": "Given intravenously (IV).", "arm_group_labels": ["Treatment"]}, {"type": "DEVICE", "name": "CliniMacs", "description": "Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.", "arm_group_labels": ["Treatment"]}]}}, "company_search_urls": ["https://www.google.com/search?q=St. Jude Children's Research Hospital+NCT01512888+terminated", "https://www.google.com/search?q=St. Jude Children's Research Hospital+CliniMacs+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for CliniMacs by St. Jude Children's Research Hospital. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the query and the search results to compile a JSON summary about FDA warning letters or clinical holds for CliniMacs by St. Jude Children's Research Hospital.\n\nThe query is asking specifically about:\n- FDA warning letters or clinical holds\n- For \"CliniMacs\" \n- By \"St. Jude Children's Research Hospital\"\n- Including specific dates, reasons, and safety issues cited\n\nFirst, I need to understand what CliniMacs is. From my knowledge, CliniMacs is a cell separation system developed by Miltenyi Biotec, used for immunomagnetic cell selection in clinical applications. It's often used in cell therapy manufacturing, including for hematopoietic stem cell transplants.\n\nNow, let me go through the search results to see if there's any information about FDA warning letters or clinical holds related to CliniMacs specifically from St. Jude Children's Research Hospital.\n\nResult 1: About FDA warning letter to St. Jude Medical (not St. Jude Children's Research Hospital) regarding ICD leads (Durata and Riata). This is about a medical device company, not the children's hospital.\n\nResult 2: Another article about St. Jude Medical (the device company) getting an FDA warning letter over Durata plant. Again, this is not about St. Jude Children's Research Hospital.\n\nResult 3: Contains information about FDA news, including something about Larry Kun being named clinical director of St. Jude Children's Research Hospital, but nothing about CliniMacs or warning letters related to it.\n\nResult 4: Another article about St. Jude Medical (the device company) receiving an FDA warning letter.\n\nResult 5: FDA warning letter to Abbott (St Jude Medical Inc.) from 2017. This is about the medical device company, not the children's hospital.\n\nResult 6: Seems to be a listing of FOIA requests to FDA, nothing specific about CliniMacs or St. Jude Children's Research Hospital.\n\nResult 7: PDF of St. Jude Medical's response to a warning letter. Again, this is about the medical device company.\n\nResult 8: Another FOIA request listing, nothing specific about our query.\n\nResult 9: Article about FDA warning to St Jude Medical (the device company) over device failures.\n\nResult 10: Forum discussion about St. Jude Medical and FDA warning letters.\n\nResult 11: Article about FDA sending St", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "St. Jude Children's Research Hospital"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT01512888 for CliniMacs. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nLet me analyze the search results to find information about company press releases, investor presentations, or public statements by St. Jude Children's Research Hospital about clinical trial NCT01512888 for CliniMacs, with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFirst, let me identify what NCT01512888 is about based on the search results:\n\nFrom result [1], [3], [5], [7], [8], [9], [10], and [11], I can see that NCT01512888 is a clinical trial titled \"Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)\". It's a lentiviral gene therapy trial for infants with X-linked Severe Combined Immunodeficiency (SCID-X1).\n\nFrom result [3], I can see that the trial involves:\n- Lentiviral gene transfer using a self-inactivating lentiviral vector (CL20-i4-EF1\u03b1-h\u03b3c-OPT)\n- Autologous CD34+ cells\n- Busulfan conditioning\n\nNow, regarding CliniMacs specifically - from result [3], I can see that CliniMacs is listed under \"Interventions\" as a device. CliniMacs is likely a device used for cell processing in this trial.\n\nLet me now look for any press releases, investor presentations, or public statements by St. Jude about this trial, focusing on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nFrom result [7], I see a press release from Mustang Bio (not St. Jude directly) about St. Jude publishing results of the lentiviral gene therapy trial in the New England Journal of Medicine. This mentions:\n- It's a Phase 1/2 trial\n- It continues to enroll at St. Jude, UCSF, and Seattle Children's Hospital\n- There's a licensing partnership between St. Jude and Mustang Bio announced in Summer 2018\n- The therapy is being developed as MB-107 by Mustang\n\nFrom result [2], I see St. Jude's news releases page, but it doesn't specifically mention NCT01512888 or safety issues related to this trial.\n\nFrom result [8], I", "citations": [], "search_params": {"company": "St. Jude Children's Research Hospital", "nct_id": "NCT01512888", "drug_name": "CliniMacs"}}}}, "llm_analysis": {"classification": "FAILURE_SAFETY", "confidence": "high", "reasoning": "The trial was suspended due to a voluntary hold, which suggests there were safety concerns or adverse events that led to the suspension of the study. The detailed description does not mention any lack of efficacy or administrative issues, but rather states that the study was evaluating the \"safety, feasibility and efficacy\" of the gene transfer approach. Therefore, the available evidence points to a safety-related failure as the reason for the trial suspension.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:20.188602", "claude_model": "claude-3-haiku-20240307", "tokens_used": 1251}}, "87": {"nct_id": "NCT00546455", "drug_name": "Fenretinide", "intervention_type": "DRUG", "drug_description": "200 mg/day", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "This study was terminated due to expired drug with possibility of re-starting in the future.", "title": "A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity", "start_date": "2007-12-31", "completion_date": "2099-01-31", "sponsor": "University of California, San Diego", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.568213", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:23.541902", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": "CHEMBL7301", "pref_name": "FENRETINIDE", "targets": [{"chembl_id": "CHEMBL612545", "ic50_values": [{"value": 31850.0, "units": "nM"}, {"value": 41850.0, "units": "nM"}, {"value": 44180.0, "units": "nM"}, {"value": 2119.9, "units": "nM"}, {"value": 9489.9, "units": "nM"}, {"value": 4950.7, "units": "nM"}, {"value": 6236.5, "units": "nM"}, {"value": 5299.9, "units": "nM"}, {"value": 6694.3, "units": "nM"}, {"value": 4850.4, "units": "nM"}, {"value": 1718.0, "units": "nM"}, {"value": 1341.4, "units": "nM"}, {"value": 3242.1, "units": "nM"}, {"value": 1000.0, "units": "nM"}, {"value": 1000.0, "units": "nM"}, {"value": 5000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL387", "ic50_values": [{"value": 150.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL400", "ic50_values": [{"value": 7700.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL612518", "ic50_values": [{"value": 7500.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL390", "ic50_values": [{"value": 3600.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5141", "ic50_values": [], "uniprot_id": "B3KNI4"}, {"chembl_id": "CHEMBL614361", "ic50_values": [], "uniprot_id": null}, {"chembl_id": "CHEMBL3879801", "ic50_values": [{"value": 9000.0, "units": "nM"}, {"value": 19000.0, "units": "nM"}, {"value": 14680.0, "units": "nM"}, {"value": 12000.0, "units": "nM"}, {"value": 5000.0, "units": "nM"}, {"value": 6000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL613509", "ic50_values": [{"value": 5000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL364", "ic50_values": [{"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 10000.0, "units": "nM"}, {"value": 7943.28, "units": "nM"}, {"value": 3981.07, "units": "nM"}, {"value": 3162.28, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL614725", "ic50_values": [{"value": 7000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL2189159", "ic50_values": [{"value": 18700.0, "units": "nM"}], "uniprot_id": "A4UHF3"}, {"chembl_id": "CHEMBL1075294", "ic50_values": [{"value": 59900.0, "units": "nM"}], "uniprot_id": "P28776"}, {"chembl_id": "CHEMBL2367428", "ic50_values": [{"value": 5000.0, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL4303835", "ic50_values": [{"value": 33000.0, "units": "nM"}, {"value": 33000.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 100000.0, "units": "nM"}, {"value": 2950.0, "units": "nM"}, {"value": 2951.21, "units": "nM"}], "uniprot_id": null}, {"chembl_id": "CHEMBL5291552", "ic50_values": [{"value": 2320.0, "units": "nM"}], "uniprot_id": "Q564G4"}, {"chembl_id": "CHEMBL2021749", "ic50_values": [{"value": 100.0, "units": "nM"}], "uniprot_id": "O15121"}], "has_uniprot_targets": true, "search_name": "Fenretinide"}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "CYP26A1", "protein_b": "CYP2C8", "combined_score": 0.945, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "RDH11", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ADH6", "combined_score": 0.952, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ADH5", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ALDH1A1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "DHRS3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "LRAT", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ALDH1A3", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "RDH10", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "CYP26A1", "protein_b": "ALDH1A2", "combined_score": 0.991, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "DHRS3", "combined_score": 0.785, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "RDH11", "combined_score": 0.953, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "LRAT", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "ALDH1A1", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "ALDH1A3", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "RDH10", "protein_b": "ALDH1A2", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "ADH6", "combined_score": 0.787, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "ADH5", "combined_score": 0.794, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "ALDH1A3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "ALDH1A1", "combined_score": 0.915, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "CYP2C8", "combined_score": 0.917, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "RDH11", "combined_score": 0.949, "interaction_type": "physical"}, {"protein_a": "ALDH1A2", "protein_b": "DHRS3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ADH5", "protein_b": "ALDH1A3", "combined_score": 0.811, "interaction_type": "physical"}, {"protein_a": "ADH5", "protein_b": "ALDH1A1", "combined_score": 0.902, "interaction_type": "physical"}, {"protein_a": "ADH5", "protein_b": "LRAT", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ALDH1A1", "protein_b": "ALDH1A3", "combined_score": 0.903, "interaction_type": "physical"}, {"protein_a": "ALDH1A1", "protein_b": "ADH6", "combined_score": 0.918, "interaction_type": "physical"}, {"protein_a": "ALDH1A1", "protein_b": "CYP2C8", "combined_score": 0.924, "interaction_type": "physical"}, {"protein_a": "ALDH1A1", "protein_b": "RDH11", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "ALDH1A1", "protein_b": "DHRS3", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "ALDH1A3", "protein_b": "ADH6", "combined_score": 0.801, "interaction_type": "physical"}, {"protein_a": "ALDH1A3", "protein_b": "CYP2C8", "combined_score": 0.926, "interaction_type": "physical"}, {"protein_a": "ALDH1A3", "protein_b": "RDH11", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "ALDH1A3", "protein_b": "DHRS3", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "LRAT", "protein_b": "ADH6", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "LRAT", "protein_b": "DHRS3", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "LRAT", "protein_b": "RDH11", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "RDH11", "protein_b": "DHRS3", "combined_score": 0.729, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "CERS3", "combined_score": 0.911, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "CERS6", "combined_score": 0.928, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "CERS5", "combined_score": 0.935, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "CERS2", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SPHK1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SGMS1", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "UGCG", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "KDSR", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "SMPD2", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "CERS4", "protein_b": "DEGS1", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "SPHK1", "combined_score": 0.709, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "CERS3", "combined_score": 0.956, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "DEGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "CERS5", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "CERS2", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "CERS6", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "SGMS1", "combined_score": 0.968, "interaction_type": "physical"}, {"protein_a": "SMPD2", "protein_b": "UGCG", "combined_score": 0.973, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "CERS3", "combined_score": 0.906, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "CERS5", "combined_score": 0.94, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "CERS6", "combined_score": 0.946, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "SPHK1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "SGMS1", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "UGCG", "combined_score": 0.97, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "KDSR", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CERS2", "protein_b": "DEGS1", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "CERS5", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "CERS6", "combined_score": 0.927, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "SPHK1", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "UGCG", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "DEGS1", "combined_score": 0.965, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "KDSR", "combined_score": 0.969, "interaction_type": "physical"}, {"protein_a": "CERS3", "protein_b": "SGMS1", "combined_score": 0.975, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "DEGS1", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "CERS5", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "KDSR", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "SPHK1", "protein_b": "CERS6", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "DEGS1", "protein_b": "SGMS1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "DEGS1", "protein_b": "CERS5", "combined_score": 0.971, "interaction_type": "physical"}, {"protein_a": "DEGS1", "protein_b": "UGCG", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "DEGS1", "protein_b": "KDSR", "combined_score": 0.974, "interaction_type": "physical"}, {"protein_a": "DEGS1", "protein_b": "CERS6", "combined_score": 0.977, "interaction_type": "physical"}, {"protein_a": "CERS5", "protein_b": "CERS6", "combined_score": 0.937, "interaction_type": "physical"}, {"protein_a": "CERS5", "protein_b": "SGMS1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "CERS5", "protein_b": "UGCG", "combined_score": 0.964, "interaction_type": "physical"}, {"protein_a": "CERS5", "protein_b": "KDSR", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "SGMS1", "protein_b": "CERS6", "combined_score": 0.961, "interaction_type": "physical"}, {"protein_a": "SGMS1", "protein_b": "UGCG", "combined_score": 0.963, "interaction_type": "physical"}, {"protein_a": "UGCG", "protein_b": "CERS6", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "CERS6", "protein_b": "KDSR", "combined_score": 0.975, "interaction_type": "physical"}], "network_features": {"avg_degree": 8.09, "clustering_coefficient": 4.05}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "38530139", "title": "Fenretinide in Young Women at Genetic or Familial Risk of Breast Cancer: A Placebo-Controlled Biomarker Trial.", "authors": [{"name": "Aristarco V", "authtype": "Author", "clusterid": ""}, {"name": "Serrano D", "authtype": "Author", "clusterid": ""}, {"name": "Maisonneuve P", "authtype": "Author", "clusterid": ""}]}, {"pmid": "38470060", "title": "Growth modulatory effects of fenretinide encompass keratinocyte terminal differentiation: a favorable outcome for oral squamous cell carcinoma chemoprevention.", "authors": [{"name": "Wang D", "authtype": "Author", "clusterid": ""}, {"name": "Pei P", "authtype": "Author", "clusterid": ""}, {"name": "Shea F", "authtype": "Author", "clusterid": ""}]}, {"pmid": "37199745", "title": "Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.", "authors": [{"name": "Boulter AC", "authtype": "Author", "clusterid": ""}, {"name": "Maurer BJ", "authtype": "Author", "clusterid": ""}, {"name": "Pogue M", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36986492", "title": "Pyrazole-Enriched Cationic Nanoparticles Induced Early- and Late-Stage Apoptosis in Neuroblastoma Cells at Sub-Micromolar Concentrations.", "authors": [{"name": "Zuccari G", "authtype": "Author", "clusterid": ""}, {"name": "Zorzoli A", "authtype": "Author", "clusterid": ""}, {"name": "Marimpietri D", "authtype": "Author", "clusterid": ""}]}, {"pmid": "36913882", "title": "Examination of aminophenol-containing compounds designed as antiproliferative agents and potential atypical retinoids.", "authors": [{"name": "Chingle RM", "authtype": "Author", "clusterid": ""}, {"name": "Imai M", "authtype": "Author", "clusterid": ""}, {"name": "Altman S", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": true, "brief_summary": "Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.", "detailed_description": null, "adverse_events": {"found": true, "frequency_threshold": "0", "time_frame": "2 months", "description": "This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the adverse events.", "serious_events": [], "other_events": [], "summary": {"total_deaths": 0, "total_serious_affected": 0, "total_serious_at_risk": 0, "sae_rate": 0.0, "death_rate": 0.0, "has_safety_signal": false}}, "dose_info": {"found": true, "arms": [{"label": "A", "type": "EXPERIMENTAL", "description": "Subjects in this cohort will be given Fenretinide", "intervention_names": ["Drug: Fenretinide"]}, {"label": "B", "type": "PLACEBO_COMPARATOR", "description": "Subjects in this cohort will be given placebo.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fenretinide", "description": "200 mg/day", "arm_group_labels": ["A"]}, {"type": "DRUG", "name": "Placebo", "description": "2 capsules/day", "arm_group_labels": ["B"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of California, San Diego+NCT00546455+terminated", "https://www.google.com/search?q=University of California, San Diego+Fenretinide+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Fenretinide by University of California, San Diego. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nI need to analyze the search results to find information about FDA warning letters or clinical holds specifically for Fenretinide by University of California, San Diego. Let me go through each search result carefully.\n\nResult 1: This is about nano-fenretinide demonstrating activity in acute promyelocytic leukemia. It discusses the mechanism of action of fenretinide but doesn't mention any FDA warning letters or clinical holds related to UCSD.\n\nResult 2: This is about recent FDA cancer drug safety warnings and updates, but it mentions pexidartinib, capecitabine, duvelisib, denosumab, and ciltacabtagene autoleucel - not fenretinide.\n\nResult 3: This is about FDA warning letters in general, but the examples shown are for food safety issues, unapproved Botox products, etc. No mention of fenretinide or UCSD.\n\nResult 4: This is a PubMed article about the safety of synthetic retinoid fenretinide. It discusses adverse events like diminished dark adaptation and dermatologic disorders, but doesn't mention any FDA warning letters or clinical holds.\n\nResult 5: This appears to be an FDA FOIA request document, but it's about MenQuadfi (a Sanofi Pasteur vaccine), not fenretinide.\n\nResult 6: This is about UCSD insulin resistance clinical trials for 2025. It mentions a trial called \"Fenretinide Administered in Subjects With Obesity\" but doesn't indicate any warning letters or clinical holds. It states \"Sorry, currently not accepting new patients, but might later\" which suggests the trial is ongoing but not currently recruiting.\n\nResult 7: This is a PMC article about targeting macrophagic 17\u03b2-HSD7 by fenretinide for NAFLD treatment. No mention of FDA warnings or holds.\n\nResult 8: This is a SEC Form 20-F that mentions \"Warning Letters\" in a general context as potential regulatory actions, but doesn't specifically mention fenretinide or UCSD.\n\nResult 9: This is a ClinicalTrials.gov study details page (NCT02247531) but doesn't appear to be related to fenretinide based on the snippet provided.\n\nResult 10: This is about investigational drugs for macular degeneration, not specifically about fen", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of California, San Diego"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of California, San Diego about clinical trial NCT00546455 for Fenretinide. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to compile a JSON summary of external safety evidence for a specific clinical trial based on the search results provided. The trial in question appears to be NCT00546455, which is \"A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity\" led by University of California, San Diego.\n\nLet me analyze the search results to extract information about:\n1. Trial status\n2. Summary of findings\n3. Relevance to safety\n4. Citations\n\nFirst, let's identify the key information about the trial:\n\nFrom result [1], [4], [6], [9], and [10], I can see this is a clinical trial with registration number NCT00546455 titled \"A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity\" with University of California, San Diego as the lead sponsor.\n\nFrom result [6], it states \"This Obesity and Insulin Resistance study at UCSD ends January 2099.\" This suggests the trial is ongoing with a very distant end date, which might indicate it's either still active or the end date was set arbitrarily far in the future.\n\nFrom result [2], it mentions \"Fenretinide Administered in Subjects With Obesity - Sorry, currently not accepting new patients, but might later\" which suggests the trial is not currently recruiting but may reopen.\n\nNow, let's look for safety information:\n\nResult [3] discusses transthyretin antisense oligonucleotides and their effects on insulin sensitivity, but doesn't seem directly related to the Fenretinide trial NCT00546455.\n\nResult [5] discusses Fenretinide's effects on FGF21 in obese mice, showing it \"normalised elevated levels of FGF21 in both high-fat diet-induced obese mice and in genetically obese-diabetic Lepr db mice.\" It also mentions that \"FEN treatment also resulted in an increase in dihydroceramides\" and \"Inhibiting de novo hepatic ceramide biosynthesis may be a mechanism by which FEN can improve insulin sensitivity and glycaemia in mice.\" This provides some mechanistic safety information but is from animal studies.\n\nResult [7] states \"The synthetic retinoid, Fenretinide (FEN), inhibits", "citations": [], "search_params": {"company": "University of California, San Diego", "nct_id": "NCT00546455", "drug_name": "Fenretinide"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial suspension states that it was terminated due to \"expired drug with possibility of re-starting in the future.\" This indicates an administrative issue, likely related to the expiration of the investigational drug, rather than safety or efficacy concerns. The lack of detailed description further suggests that this was not due to any clinical issues, but rather a practical, logistical, or operational problem that led to the suspension of the trial.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:23.540052", "claude_model": "claude-3-haiku-20240307", "tokens_used": 976}}, "88": {"nct_id": "NCT00546455", "drug_name": "Placebo", "intervention_type": "DRUG", "drug_description": "2 capsules/day", "phase": "PHASE2", "overall_status": "SUSPENDED", "why_stopped": "This study was terminated due to expired drug with possibility of re-starting in the future.", "title": "A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity", "start_date": "2007-12-31", "completion_date": "2099-01-31", "sponsor": "University of California, San Diego", "enrichment_status": {"stage1_extracted": "2025-11-14T14:53:22.568827", "stage2_targets": "completed", "stage2_ppi": "completed", "stage2_failure_details": "completed", "stage3_llm_analysis": "completed", "last_updated": "2025-11-14T17:49:23.579790", "retry_count": 0}, "chembl_enrichment": {"found": true, "chembl_id": null, "targets": [{"chembl_id": null, "uniprot_id": "B3STU4", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P01574", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P00734", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "Q8GZP6", "ic50_values": [], "source": "uniprot_fallback"}, {"chembl_id": null, "uniprot_id": "P08819", "ic50_values": [], "source": "uniprot_fallback"}], "search_name": "Placebo", "drugbank_fallback": true, "has_uniprot_targets": true}, "ppi_enrichment": {"uniprot_count": 5, "interactions": [{"protein_a": "RIPK1", "protein_b": "IRF3", "combined_score": 0.78, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IRF7", "combined_score": 0.813, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR4", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TBK1", "combined_score": 0.979, "interaction_type": "physical"}, {"protein_a": "RIPK1", "protein_b": "TLR3", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TBK1", "combined_score": 0.735, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "TLR3", "combined_score": 0.747, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF7", "combined_score": 0.804, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IRF3", "combined_score": 0.848, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNL1", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNAR1", "protein_b": "IFNA1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR4", "combined_score": 0.807, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TBK1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNL1", "combined_score": 0.873, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "TLR3", "combined_score": 0.897, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF7", "combined_score": 0.967, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IRF3", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNB1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "IFNA1", "protein_b": "IFNAR2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNL1", "combined_score": 0.815, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TLR4", "combined_score": 0.907, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF7", "combined_score": 0.95, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IRF3", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "TBK1", "combined_score": 0.993, "interaction_type": "physical"}, {"protein_a": "TLR3", "protein_b": "IFNB1", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "TLR4", "combined_score": 0.957, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IFNB1", "combined_score": 0.972, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF7", "combined_score": 0.992, "interaction_type": "physical"}, {"protein_a": "TBK1", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IRF7", "combined_score": 0.782, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNAR2", "combined_score": 0.908, "interaction_type": "physical"}, {"protein_a": "IFNL1", "protein_b": "IFNB1", "combined_score": 0.962, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IRF7", "combined_score": 0.7, "interaction_type": "physical"}, {"protein_a": "IFNAR2", "protein_b": "IFNB1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF7", "combined_score": 0.898, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IRF3", "combined_score": 0.947, "interaction_type": "physical"}, {"protein_a": "TLR4", "protein_b": "IFNB1", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF7", "combined_score": 0.978, "interaction_type": "physical"}, {"protein_a": "IFNB1", "protein_b": "IRF3", "combined_score": 0.985, "interaction_type": "physical"}, {"protein_a": "IRF7", "protein_b": "IRF3", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F10", "combined_score": 0.823, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "SERPINC1", "combined_score": 0.837, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "THBD", "combined_score": 0.846, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGB", "combined_score": 0.951, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGA", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "FGG", "combined_score": 0.96, "interaction_type": "physical"}, {"protein_a": "SERPIND1", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINA5", "combined_score": 0.716, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "SERPINC1", "combined_score": 0.954, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "FGB", "protein_b": "F2", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINA5", "combined_score": 0.996, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F2R", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F5", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "SERPINC1", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "FGG", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "F10", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2", "protein_b": "THBD", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "F2R", "protein_b": "THBD", "combined_score": 0.966, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGG", "combined_score": 0.71, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "F10", "combined_score": 0.713, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "SERPINC1", "combined_score": 0.721, "interaction_type": "physical"}, {"protein_a": "SERPINA5", "protein_b": "FGA", "combined_score": 0.738, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "SERPINC1", "combined_score": 0.921, "interaction_type": "physical"}, {"protein_a": "FGG", "protein_b": "FGA", "combined_score": 0.999, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F5", "combined_score": 0.817, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "THBD", "combined_score": 0.912, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "FGA", "combined_score": 0.98, "interaction_type": "physical"}, {"protein_a": "SERPINC1", "protein_b": "F10", "combined_score": 0.998, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "THBD", "combined_score": 0.711, "interaction_type": "physical"}, {"protein_a": "F5", "protein_b": "F10", "combined_score": 0.995, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "FGA", "combined_score": 0.752, "interaction_type": "physical"}, {"protein_a": "F10", "protein_b": "THBD", "combined_score": 0.84, "interaction_type": "physical"}], "network_features": {"avg_degree": 7.09, "clustering_coefficient": 3.55}}, "failure_enrichment": {"aact_description": null, "aact_documents": [], "pubmed_results": [{"pmid": "41236500", "title": "Colchicine and cardiovascular events: An updated meta-analysis of published randomized controlled trials.", "authors": [{"name": "Xie S", "authtype": "Author", "clusterid": ""}, {"name": "Galimberti F", "authtype": "Author", "clusterid": ""}, {"name": "Olmastroni E", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41236362", "title": "Feasibility and tolerability of low-dose lithium for the treatment of agitation and abnormal motor behaviors in Frontotemporal Dementia.", "authors": [{"name": "Zide BS", "authtype": "Author", "clusterid": ""}, {"name": "Barker MS", "authtype": "Author", "clusterid": ""}, {"name": "Silverman HE", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235517", "title": "[The effect of AntiAGE-Biom probiotic on metabolic features in individuals with type 2 diabetes].", "authors": [{"name": "Shestakova EA", "authtype": "Author", "clusterid": ""}, {"name": "Nosova AV", "authtype": "Author", "clusterid": ""}, {"name": "Dzgoeva FK", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235391", "title": "Astragalus membranaceus extract reduces functional knee joint pain: a randomized, double-blinded, placebo-controlled trial.", "authors": [{"name": "Lippi L", "authtype": "Author", "clusterid": ""}, {"name": "Turco A", "authtype": "Author", "clusterid": ""}, {"name": "Rudrappa GH", "authtype": "Author", "clusterid": ""}]}, {"pmid": "41235106", "title": "Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.", "authors": [{"name": "Khrieba MO", "authtype": "Author", "clusterid": ""}, {"name": "Abdulelah FM", "authtype": "Author", "clusterid": ""}, {"name": "Alsaleh NA", "authtype": "Author", "clusterid": ""}]}], "clinicaltrials_api": {"has_results": true, "brief_summary": "Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.", "detailed_description": null, "adverse_events": {"found": true, "frequency_threshold": "0", "time_frame": "2 months", "description": "This study was terminated due to expired drug with possibility of re-starting in the future. For this reason the randomization code has not been broken and the data has not been analyzed and there is no way to report the adverse events.", "serious_events": [], "other_events": [], "summary": {"total_deaths": 0, "total_serious_affected": 0, "total_serious_at_risk": 0, "sae_rate": 0.0, "death_rate": 0.0, "has_safety_signal": false}}, "dose_info": {"found": true, "arms": [{"label": "A", "type": "EXPERIMENTAL", "description": "Subjects in this cohort will be given Fenretinide", "intervention_names": ["Drug: Fenretinide"]}, {"label": "B", "type": "PLACEBO_COMPARATOR", "description": "Subjects in this cohort will be given placebo.", "intervention_names": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fenretinide", "description": "200 mg/day", "arm_group_labels": ["A"]}, {"type": "DRUG", "name": "Placebo", "description": "2 capsules/day", "arm_group_labels": ["B"]}]}}, "company_search_urls": ["https://www.google.com/search?q=University of California, San Diego+NCT00546455+terminated", "https://www.google.com/search?q=University of California, San Diego+Placebo+clinical+trial+terminated"], "external_signals": {"fda_warnings": {"found": true, "search_query": "FDA warning letters or clinical holds for Placebo by University of California, San Diego. Include specific dates, reasons, and safety issues cited.", "summary": "<think>\nLet me analyze the search results to find information about FDA warning letters or clinical holds for Placebo by University of California, San Diego (UCSD).\n\nFirst, I'll look for any specific mentions of UCSD and placebo together in the context of FDA warning letters or clinical holds.\n\nFrom search result [1], I see information about Dr. Kang Zhang, who was the chief of eye genetics at UCSD. The article mentions:\n- Dr. Zhang was \"on leave\" after an investigation exposed how he violated human research rules\n- There was an FDA report that raised \"concerning issues\"\n- UCSD initiated at least three reviews into Zhang's projects from 2012 to 2014\n- During an eight-month suspension of enrollment in his studies, Zhang enrolled three people and injected them with a drug\n- The FDA inspection found multiple violations including:\n  * Lacking a monitoring plan for patient safety\n  * No data monitoring or quality assurance unit\n  * Failed to administer the drug 10 times to four subjects as required\n  * Missing records about 25 units of the study drug\n- The FDA warning letter described violations but \"made no mention of a harmful incident\"\n\nHowever, this doesn't specifically mention placebo-controlled trials. It seems to be about a study where an actual drug was being tested, not a placebo.\n\nLet me check other results:\n\nSearch result [2] discusses FDA warning letters in general but doesn't mention UCSD specifically.\n\nSearch result [3] is just a list of FDA warning letters but doesn't have specific information about UCSD and placebo.\n\nSearch result [4] discusses placebo-controlled trials and the FDA's approach, but doesn't mention UCSD.\n\nSearch result [5] discusses the placebo effect but doesn't mention UCSD.\n\nSearch result [6] mentions a study about warning letters issued to clinical investigators but doesn't provide specific UCSD information.\n\nSearch result [7] appears to be a request for FDA records related to University of California San Francisco (not San Diego), so not relevant.\n\nSearch result [8] mentions FDA warning letters related to clinical trials but doesn't specify UCSD.\n\nSearch result [9] is about hormone therapy, not relevant.\n\nSearch result [10] mentions a warning letter to a physician but not UCSD.\n\nSearch result [11] mentions UC San Diego in relation to FDA investigators, but states \"UC San Diego was contacted by FDA investigators but is no", "citations": []}, "sec_filings": {"found": false, "search_params": {"company": "University of California, San Diego"}, "note": "Skipped SEC search (sponsor not public company)"}, "company_disclosures": {"found": true, "search_query": "Company press releases, investor presentations, or public statements by University of California, San Diego about clinical trial NCT00546455 for Placebo. Focus on safety issues, adverse events, trial termination reasons, or regulatory actions.", "summary": "<think>\nI need to analyze the search results to find information about University of California, San Diego's press releases, investor presentations, or public statements regarding clinical trial NCT00546455 (Fenretinide for obesity) with a focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nLet me go through the search results to see what information is available:\n\nResult [1] - This is a basic listing of the clinical trial NCT00546455 from UCSD's clinical trials website. It mentions it's a Phase 2 research study with about 21 participants, but doesn't provide any safety information or statements from UCSD.\n\nResult [2] - This is about ischemic stroke clinical trials at UCSD, not related to NCT00546455.\n\nResults [3], [4], [5], [6], [7], [11] - These are scientific papers about fenretinide, its effects on obesity, insulin resistance, etc., but they don't appear to be press releases or public statements from UCSD about the clinical trial's safety.\n\nResults [8], [9], [10] - These are clinical trial listings for NCT00546455 from various clinical trial databases, but they don't contain UCSD press releases or safety statements.\n\nAfter reviewing all the search results, I don't see any company press releases, investor presentations, or public statements by University of California, San Diego specifically about clinical trial NCT00546455 that focus on safety issues, adverse events, trial termination reasons, or regulatory actions.\n\nThe search results provide:\n1. Basic trial information (NCT00546455 is a Phase 2 study of Fenretinide for obesity with about 21 participants)\n2. Scientific papers about fenretinide's mechanism of action in animal models\n3. Clinical trial listings from various databases\n\nBut there's no evidence of:\n- UCSD press releases about safety issues\n- Investor presentations discussing this trial\n- Public statements about adverse events\n- Information about trial termination (if it was terminated)\n- Regulatory actions related to this trial\n\nThe query specifically asked for \"Company press releases, investor presentations, or public statements by University of California, San Diego\" about safety issues for this trial, but the search results don't contain", "citations": [], "search_params": {"company": "University of California, San Diego", "nct_id": "NCT00546455", "drug_name": "Placebo"}}}}, "llm_analysis": {"classification": "FAILURE_ADMINISTRATIVE", "confidence": "high", "reasoning": "The official reason for the trial suspension states that it was terminated due to \"expired drug with possibility of re-starting in the future.\" This indicates an administrative issue, likely related to the expiration of the investigational drug, rather than safety or efficacy concerns. The lack of detailed description further suggests that this was not due to any clinical issues, but rather a practical, logistical, or operational problem that led to the suspension of the trial.", "verification_passed": true, "contradictions_found": [], "analysis_timestamp": "2025-11-14T17:49:23.540052", "claude_model": "claude-3-haiku-20240307", "tokens_used": 976}}}}